
<html lang="en"     class="pb-page"  data-request-id="af872d32-f8a1-47f7-8087-c575e2bafe37"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.0c00931;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-1;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Glycogen Synthase Kinase 3β: A New Gold Rush in Anti-Alzheimer’s Disease Multitarget Drug Discovery?" /></meta><meta name="dc.Creator" content="Angela  De Simone" /></meta><meta name="dc.Creator" content="Vincenzo  Tumiatti" /></meta><meta name="dc.Creator" content="Vincenza  Andrisano" /></meta><meta name="dc.Creator" content="Andrea  Milelli" /></meta><meta name="dc.Description" content="Alzheimer’s disease (AD), like other multifactorial diseases, is the result of a systemic breakdown of different physiological networks. As result, several lines of evidence suggest that it could b..." /></meta><meta name="Description" content="Alzheimer’s disease (AD), like other multifactorial diseases, is the result of a systemic breakdown of different physiological networks. As result, several lines of evidence suggest that it could b..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 21, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00931" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00931" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00931" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00931" /></link>
        
    
    

<title>Glycogen Synthase Kinase 3β: A New Gold Rush in Anti-Alzheimer’s Disease Multitarget Drug Discovery? | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00931" /></meta><meta property="og:title" content="Glycogen Synthase Kinase 3β: A New Gold Rush in Anti-Alzheimer’s Disease Multitarget Drug Discovery?" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0009.jpeg" /></meta><meta property="og:description" content="Alzheimer’s disease (AD), like other multifactorial diseases, is the result of a systemic breakdown of different physiological networks. As result, several lines of evidence suggest that it could be more efficiently tackled by molecules directed toward different dysregulated biochemical targets or pathways. In this context, the selection of targets to which the new molecules will be directed is crucial. For years, the design of such multitarget-directed ligands (MTDLs) has been based on the selection of main targets involved in the “cholinergic” and the “β-amyloid” hypothesis. Recently, there have been some reports on MTDLs targeting the glycogen synthase kinase 3β (GSK-3β) enzyme, due to its appealing properties. Indeed, this enzyme is involved in tau hyperphosphorylation, controls a multitude of CNS-specific signaling pathways, and establishes strict connections with several factors implicated in AD pathogenesis. In the present Miniperspective, we will discuss the reasons behind the development of GSK-3β-directed MTDLs and highlight some of the recent efforts to obtain these new classes of MTDLs as potential disease-modifying agents." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00931"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00931">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00931&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00931&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00931&amp;href=/doi/10.1021/acs.jmedchem.0c00931" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 1</span><span class="cit-fg-pageRange">, 26-41</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/1" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00533" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c01145" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Glycogen Synthase Kinase 3β: A New Gold Rush in Anti-Alzheimer’s Disease Multitarget Drug Discovery?</span></h1><h2 class="article_header-subtitle"><span class="hlFld-SubTitle">Miniperspective</span></h2><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Angela De Simone</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Angela De Simone</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Drug Science and Technology, University of Turin, Via Giuria 9, 10125 Torino, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Angela++De+Simone">Angela De Simone</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Vincenzo Tumiatti</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vincenzo Tumiatti</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department for Life Quality Studies, Alma Mater Studiorum-University of Bologna, Corso d’ Augusto 237, 47921 Rimini, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vincenzo++Tumiatti">Vincenzo Tumiatti</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Vincenza Andrisano</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vincenza Andrisano</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department for Life Quality Studies, Alma Mater Studiorum-University of Bologna, Corso d’ Augusto 237, 47921 Rimini, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vincenza++Andrisano">Vincenza Andrisano</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4396-1904" title="Orcid link">http://orcid.org/0000-0003-4396-1904</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Andrea Milelli</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrea Milelli</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department for Life Quality Studies, Alma Mater Studiorum-University of Bologna, Corso d’ Augusto 237, 47921 Rimini, Italy</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#b4d5dad0c6d1d59ad9ddd8d1d8d8dd87f4c1daddd6db9addc0"><span class="__cf_email__" data-cfemail="3e5f505a4c5b5f105357525b5252570d7e4b50575c5110574a">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrea++Milelli">Andrea Milelli</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2285-7403" title="Orcid link">http://orcid.org/0000-0003-2285-7403</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00931&amp;href=/doi/10.1021%2Facs.jmedchem.0c00931" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 1</span><span class="cit-pageRange">, 26–41</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 21, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 June 2020</li><li><span class="item_label"><b>Published</b> online</span>21 December 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 January 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00931" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00931</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="https://acsopenscience.org/open-access/licensing-options/"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a><span class="article_header-cc-by"><a href="https://creativecommons.org/licenses/by/4.0/"><img src="/pb-assets/images/licensesLogos/OA_Icons_cc-1612971093887.svg" alt="CC: Creative Commons" /></img><span><strong>CC: </strong>Creative Commons</span></a><a href="https://creativecommons.org/licenses/by/4.0/"><img src="/pb-assets/images/licensesLogos/OA_Icons_by-1612971093257.svg" alt="BY: Credit must be given to the creator" /></img><span><strong>BY: </strong>Credit must be given to the creator</span></a></span></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00931"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2205</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00931" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Glycogen Synthase Kinase 3β: A New Gold Rush in Anti-Alzheimer’s Disease Multitarget Drug Discovery?&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Angela&quot;,&quot;last_name&quot;:&quot;De Simone&quot;},{&quot;first_name&quot;:&quot;Vincenzo&quot;,&quot;last_name&quot;:&quot;Tumiatti&quot;},{&quot;first_name&quot;:&quot;Vincenza&quot;,&quot;last_name&quot;:&quot;Andrisano&quot;},{&quot;first_name&quot;:&quot;Andrea&quot;,&quot;last_name&quot;:&quot;Milelli&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;21&quot;,&quot;issue&quot;:&quot;1&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;26-41&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00931&quot;},&quot;abstract&quot;:&quot;Alzheimer’s disease (AD), like other multifactorial diseases, is the result of a systemic breakdown of different physiological networks. As result, several lines of evidence suggest that it could be more efficiently tackled by molecules directed toward different dysregulated biochemical targets or pathways. In this context, the selection of targets to which the new molecules will be directed is crucial. For years, the design of such multitarget-directed ligands (MTDLs) has been based on the selection of main targets involved in the “cholinergic” and the “β-amyloid” hypothesis. Recently, there have been some reports on MTDLs targeting the glycogen synthase kinase 3β (GSK-3β) enzyme, due to its appealing properties. Indeed, this enzyme is involved in tau hyperphosphorylation, controls a multitude of CNS-specific signaling pathways, and establishes strict connections with several factors implicated in AD pathogenesis. In the present Miniperspective, we will discuss the reasons behind the development of GSK-3β-di&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00931&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00931" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00931&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00931" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00931&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00931" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00931&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00931&amp;href=/doi/10.1021/acs.jmedchem.0c00931" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00931" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00931" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00931%26sid%3Dliteratum%253Aachs%26pmid%3D33346659%26genre%3Darticle%26aulast%3DDe%2BSimone%26date%3D2021%26atitle%3DGlycogen%2BSynthase%2BKinase%2B3%25CE%25B2%253A%2BA%2BNew%2BGold%2BRush%2Bin%2BAnti-Alzheimer%25E2%2580%2599s%2BDisease%2BMultitarget%2BDrug%2BDiscovery%253F%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D1%26spage%3D26%26epage%3D41%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290645" title="Aggregation">Aggregation</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292202" title="Drug discovery">Drug discovery</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/1" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/jmcmar.2021.64.issue-1/20210114/jmcmar.2021.64.issue-1.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/medium/jm0c00931_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00931&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Alzheimer’s disease (AD), like other multifactorial diseases, is the result of a systemic breakdown of different physiological networks. As result, several lines of evidence suggest that it could be more efficiently tackled by molecules directed toward different dysregulated biochemical targets or pathways. In this context, the selection of targets to which the new molecules will be directed is crucial. For years, the design of such multitarget-directed ligands (MTDLs) has been based on the selection of main targets involved in the “cholinergic” and the “β-amyloid” hypothesis. Recently, there have been some reports on MTDLs targeting the glycogen synthase kinase 3β (GSK-3β) enzyme, due to its appealing properties. Indeed, this enzyme is involved in tau hyperphosphorylation, controls a multitude of CNS-specific signaling pathways, and establishes strict connections with several factors implicated in AD pathogenesis. In the present Miniperspective, we will discuss the reasons behind the development of GSK-3β-directed MTDLs and highlight some of the recent efforts to obtain these new classes of MTDLs as potential disease-modifying agents.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22237" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22237" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3">1.1.  Multitarget Drug Discovery and Alzheimer’s Disease</h3><div class="NLM_p">The drug discovery process for complex diseases, such as neurodegenerative, proliferative, or cardiovascular ones, has found renewed hope in the multitarget drug discovery (MTDD) strategy in the past decade.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> In fact, for diseases characterized by a multifactorial nature or therapeutic resistance developments, the classic therapeutic strategy “one molecule–one target” seems no longer appropriate and exhaustive. Such diseases arise from distress in multiple but interconnected networks that cannot be contrasted by a single drug acting on a single target.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div class="NLM_p">The reasons why multitarget strategy represents an attractive, concrete, and when possible, a resolutive opportunity, rely on the possibility of taking advantage of multiple additives or synergistic pharmacodynamic activities within a single molecule.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> To this aim, a careful target combination should be pursued. Certainly, the possibility of interacting with different targets simultaneously leads to a polypharmacological drug characterized by a more effective activity profile and fewer side effects when compared to the combined use of single-targeted drugs. Of course, this also implies greater therapeutic effectiveness and delays in the development of resistance. Moreover, polypharmacology, unlike polypharmacy, is not associated with disadvantages such as lower patient compliance and the possibility of harmful drug–drug interactions.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Actually, from a pharmacokinetic point of view, the simultaneous administration of several drugs, with different pharmacokinetics, makes therapies complicated and not always applicable.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Furthermore, the clinical development of a multitarget drug (MTD) offers the opportunity to save money and time since the required clinical trials are less complicated than those requested when dealing with multiple specific drugs.</div><div class="NLM_p">However, the design of MTDs presents medicinal chemists with some challenges related to the optimization of the activity profile and physicochemical properties. In particular, MTDs are designed to obtain the same degree of <i>in vitro</i> activity for each target. Indeed, a balanced <i>in vitro</i> activity is believed to reflect the same level of target modulation also <i>in vivo</i>.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Achieving similar potency (i.e., inhibiting two targets in the same concentration range) has proven to be a challenging task in many cases. Moreover, as MTDs are in most cases designed by integrating structural elements from two or more selective ligands, they are larger and more lipophilic than most commercial drugs and, as a consequence, may suffer from poor oral absorption.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a></div><div class="NLM_p">Recently, medicinal chemists moved far away from associating MTDs only by chance. In the past years, we have witnessed the growing number of papers on the drug development process of multitarget-directed ligands (MTDLs) using different strategies and technologies to obtain multiple active compounds.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> The different MTDL strategies provide chemical entities with the ability to hit different targets or that can bind to the same target at different binding sites related to the same complex disease, in order to modulate their activities. In light of this, the possible combinations of targets to be hit are the most varied, which makes their selection a crucial step. Undoubtedly, the accurate knowledge of the pathology to which the ligands should be directed is the base for a rational target selection.</div><div class="NLM_p">Certainly, the MTDLs’ strategy suits perfectly to a complex pathology such as Alzheimer’s disease (AD) for which a resolutive treatment is still currently not available. AD represents the most common cause of dementia, with almost 50 million people worldwide living with this pathological condition. Together with its devastating effects on individuals, caregivers, and public health, AD represents also a major economic burden for national health systems.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Decades of both public and private research have shed some light on the pathogenesis of AD, but the disease is still an enigma. Indeed, a true understanding of its onset and development is far from being achieved and many theories have been elaborated over the years.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> The most advanced theory concerns the amyloid hypothesis which is supported by the observation of amyloid plaques deposition in the brain.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Other accepted theories include tau protein,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> cholinergic hypothesis,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> calcium homeostasis,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> oxidative stress,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> metal dyshomeostasis,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> inflammation,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> endoplasmic reticulum stress,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> mitochondrial disfunction,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and so on. These theories have produced many potential novel drug targets.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> However, despite massive investments and the countless number of molecules going to clinical trials every year amid enthusiastic expectations, unfortunately and disappointingly, no new drug has entered clinical practice in Europe and U.S. since memantine’s approval.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Since memantine obtained FDA approval in 2002, AD could be considered, without any doubt, the “black hole” of drug discovery, being the pathology with the highest attrition rate. Recently, in late 2019, China’s National Medical Product Administration (NMPA) has conditionally approved sodium oligomannate, a mixture of acidic linear oligosaccharides derived from marine brown algae, for the treatment of mild to moderate AD.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a> Its full mechanism is not completely known, but evidence shows that it remodels gut microbiota and induces anti-inflammatory effects.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><div class="NLM_p">On the basis of the cholinergic hypothesis and the discovery of acetylcholinesterase (AChE) inhibitors, different therapeutic strategies have emerged to delay or reverse the devastation of AD.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Despite efforts, the only commercially available therapies for AD are represented by AChE inhibitors and the NMDAR antagonist memantine. However, none of these drugs are able to mitigate neuronal loss or reverse cognitive impairments or to act as a truly disease-modifying drug.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><div class="NLM_p">It is a current belief that a single compound capable of fulfilling a scenario as intricate as that which characterizes a multifactorial disease should have a more significant impact on the course of disease progression. Since the advent of the MTDLs strategy, an increasing number of papers have been published on the discovery of anti-AD drug, and as expected, AChE has maintained its popularity as an AD-related target also in the MTDLs era. Indeed, a large part of the MTDLs strategies adopted in AD are based on the combined inhibition of AChE and another AD-relevant target.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> However, since Cavalli, Bolognesi, and co-workers brought to light the first-in-class dual β-secretase (BACE-1)/glycogen synthase kinase 3β (GSK-3β) inhibitors, the interest in developing MTDLs acting as GSK-3β inhibitors has increased.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> Undoubtedly, this is also a consequence of the growing importance of the tau hypothesis and the prominent role assumed by GSK-3β in this context.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><div id="sec1_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i4" class="anchor-spacer"></div><h4 class="article-section__title" id="_i4">1.1.1.  Tau Hypothesis</h4><div class="NLM_p">Tau is a soluble microtubule-binding protein whose main role is to stabilize microtubules in axons to direct axonal transport and cytoskeletal growth. In AD and in other tauopathies, such as frontotemporal dementia, progressive supranuclear palsy, and so on, tau becomes hyperphosphorylated and deposits in insoluble aggregates. In normal condition, tau is highly hydrophilic, while abnormal hyperphosphorylation is the most compelling cause of tau dysfunction.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Hyperphosphorylated tau and aggregates are not able to bind to tubulin and promote microtubule assembly causing their disruption.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30,31)</a> However, other alterations such as conformational changes<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> and truncation of tau<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> have also been implicated in AD pathogenesis. Several molecular mechanisms may be underlying the toxicity associated with tau including disruption of calcium homeostasis<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> and caspase activation.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Tau accumulation causes extensive damage to the transport and signaling systems, cytoskeleton, and mitochondria.</div><div class="NLM_p">Different forms of tau have been observed in AD, such as dimer/trimer and small soluble oligomers, which are not always phosphorylated, as well as filaments and neurofibrillary tangles (NFTs) that are always phosphorylated. Although NFTs are considered one of the two hallmarks of the disease, recent evidence suggests that other forms of tau may be more toxic than NFTs, such as small soluble tau oligomers.<a onclick="showRef(event, 'ref35 ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref35 ref36 ref37 ref38">(35−38)</a> This was also observed for other AD-related proteins like Aβ and α-synuclein,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> where soluble species were in fact the most toxic.<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40,41)</a> In addition, some reports even discuss a possible protective role for NFTs.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Of course, more studies are still necessary to confirm these findings.</div><div class="NLM_p">Even if tau and tangles are not specific for AD, the correlation between cognitive dysfunctions and the localization of tangles present in this neurodegenerative disorder is very strong.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Intraneuronal tangles containing hyperphosphorylated tau are a well-known hallmark of AD pathology, along with senile plaques containing extracellular amyloid-β (Aβ).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Aβ is physiologically produced even if its role in normal brain is not completely understood. However, in AD, a serious imbalance between its production and clearance leads to the formation and accumulation of oligomers, filaments, fibrils, and ultimately, plaques. Identification of the true toxic species has been tricky, but the experimental evidence now points to oligomeric and β-sheet-rich fibrillar aggregates as responsible for the toxic effects mediated by Aβ.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Aβ induces toxic effects through different mechanisms.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> For instance, Aβ accumulation in the brain leads, among others, to loss of synapses and changes in neuronal activity and synaptic transmission.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Aβ peptide has been involved also in metal-mediated oxidative stress,<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> and Aβ aggregates were able to inhibit telomerase activity both <i>in vitro</i> and <i>in vivo</i>.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></div><div class="NLM_p">Despite the uncertainty about the relative roles of Aβ and tau in AD, the stronger correlation between NFTs and memory impairment suggests the existence of a closer connection between tau pathology and neurodegenerative events than those observed with Aβ aggregates.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Moreover, since tau mutations responsible for some frontotemporal dementia were identified,<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> it was also possible to generate transgenic models showing severe tau pathology.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> This aspect is of crucial importance for the demonstration of <i>in vivo</i> pharmacodynamic effects of tau-based drugs.</div><div class="NLM_p">Different strategies can be explored in the search for anti-tau therapies, even though most approaches currently in clinical trials are immunotherapy-based.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Regarding small molecules, the two therapeutic strategies that can be followed can be summarized in (a) inhibition of hyperphosphorylated tau aggregation and (b) blockage of tau hyperphosphorylation. Although inhibition of tau aggregation appears more attractive, due to the role of tau aggregates in the development of the pathology, many challenges presented by antiaggregation approaches<a onclick="showRef(event, 'ref53 ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref53 ref54 ref55">(53−55)</a> have led to the reduction of tau hyperphosphorylation as the most suitable strategy to be pursued.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Indeed, the discovery of protein–protein interaction (PPI) modulators proved to be very difficult mainly due to the lack of a defined binding site. In particular, the interactions between proteins frequently take place over relatively large and flat surfaces. Moreover, in most cases there are unknown natural small ligands that can be used as starting point for a drug discovery campaign. Similarly, high-throughput screening (HTS) is not particularly suitable since combinatorial libraries often lack chemical scaffold adapted for discovery of PPIs modulators.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></div><div class="NLM_p">The extent of tau phosphorylation is increased in the brain of patient with AD.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> The number of characterized hyperphosphorylated sites is relatively small. Around 40 serine/threonine phosphorylation sites have been characterized.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> The phosphorylation at these sites can promote different functions regarding the enhancement of tau fibrillization,<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> the reduction of tau binding to microtubules,<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> and the prevention of tau aggregation.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></div><div class="NLM_p">Therefore, concerning the blockage of tau hyperphosphorylation, the main obstacles encountered in adopting this strategy are related to the identification of the kinase to be targeted and the selection of suitable inhibitors. Regarding possible targeted kinases, cyclin dependent kinase 5 (CDK5) and GSK-3 are the most relevant according to <i>in vitro</i> studies evaluating tau phosphorylation.<a onclick="showRef(event, 'ref60 ref49'); return false;" href="javascript:void(0);" class="ref ref60 ref49">(60,49)</a> Kinase inhibitors are employed in many clinical fields, particularly in cancer treatments.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> However, selectivity is the main problem related to the development of a kinase inhibitor, since the vast majority of these molecules bind to their target ATP-binding site.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> All of the approximately 518 kinases of the human kinome use ATP as substrate to transfer the phosphate group to different amino acids, mainly Ser, Thr, and Tyr. Therefore, the ATP-binding site contains many conserved regions and features that are essential for substrate recognition and catalysis. Most of the kinase inhibitors available are competitive with ATP for its binding site and, therefore, establish key interactions with amino acids highly conserved within all of the kinome. As consequence, such molecules suffer from low selectivity, which could be responsible for off-target toxicity. Selectivity can be enhanced in two different ways by exploiting (a) the few distinct pockets and residues located in the vicinity of the ATP binding site that are not used by ATP which characterize each kinase or (b) the highly specific substrate or allosteric sites.<a onclick="showRef(event, 'ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref63 ref64">(63,64)</a> It is clear that selective inhibitors, although they have often been characterized by lower affinity compared to ATP-competitive inhibitors, have the significant advantage of lower off-target toxicity.</div><div class="NLM_p last">Another challenge in the drug discovery process associated with CNS diseases such as AD is the overcoming of the blood–brain barrier (BBB). Molecular weight (MW), lipophilicity (log <i>P</i>), polar surface area (PSA), as well as interaction with P-glycoprotein efflux transporter (P-gp) influence the BBB penetration capacity of a molecule. Chico et al. reported that kinase inhibitor drugs tend to have higher mean values for these parameters when compared to other known CNS-penetrating compounds.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> For instance, imatinib fails a glioma trial because of its poor brain uptake due to its high MW and PSA values, which are greater than those of other BBB-penetrant drugs.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Furthermore, imatinib is also a P-gp substrate.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> On the other hand, dasatinib is characterized by higher MW and PSA compared to imatinib but does not seem to be a substrate of P-gp.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> However, it is very difficult to come up with a general rule due to the complex nature of the <i>in vivo</i> absorption and when different physicochemical characteristics have to be taken into consideration.</div></div></div><div id="sec1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">1.2.  Glycogen Synthase Kinase 3β (GSK-3β): Structure and Functions</h3><div class="NLM_p">GSK-3 is a highly conserved serine/threonine kinase ubiquitously expressed and constitutively active in unstimulated tissues. Although it was initially characterized as a cytosolic protein kinase, some nuclear functions were also reported.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> The genes encoding this kinase have been identified in every investigated eukaryotic genome. In particular, <i>GSK-3A</i> and <i>GSK-3B</i> are the two genes that encode GSK-3 in mammals. Specifically, these genes encode two proteins of 51 and 47 kDa whose domains show a very high homology (98%) but differ within their N- and C-terminal regions. Indeed, the 4 kDa difference in the protein masses is due to the presence of a glycine rich region at the N-terminal domain of the α isoform. The amino-terminal lobe is predominantly composed of β-sheets, while the C-terminal lobe is mostly α-helical. The ATP binding sites can be considered essentially identical, making remote the possibility of identifying isoform-selective inhibitors.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> However, recently significant advances in the field of isoform-selective inhibitors have been achieved by exploring small difference in the hinge region (Asp133 → Glu196 switch) to discover paralog-selective inhibitors.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> GSK-3 was first identified as the kinase that phosphorylates and inhibits glycogen synthase (GS), the rate limiting enzyme in glycogen synthesis.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Prior to GSK-3 phosphorylation, GS is prephosphorylated on a residue located at four amino acids C-terminal to the GSK-3 phosphorylation site, representing a frequent consensus sequence (S/TXXXS/T) for GSK-3 phosphorylation.<a onclick="showRef(event, 'ref73 ref74'); return false;" href="javascript:void(0);" class="ref ref73 ref74">(73,74)</a> Many other substrates are phosphorylated by GSK-3 responsible for regulating other functions such as cell growth and survival, cytoskeletal organization, immune responses, circadian rhythm, and development.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Numerous substrate proteins are functionally inhibited after being phosphorylated by this kinase.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></div><div class="NLM_p">The mechanisms responsible for controlling GSK-3 activity are very complex and depend on specific signaling pathways. Several protein kinases, such as the protein kinase B (PKB/Akt), cyclic AMP-dependent protein kinase (PKA), and atypical protein kinase C (PKC), are capable of phosphorylating and inactivating GSK-3 at the N-terminal domain site. Among these proteins, PKB/Akt is able to inactivate the kinase through phosphorylation in response to insulin.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> What turns GSK-3β into an appealing target for neurodegenerative disease is its deep implication in the Wnt-β-catenin signaling pathway, profoundly implicated in embryonic development and human homeostasis.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></div><div class="NLM_p">In this signaling pathway, Wnt blocks β-catenin phosphorylation leading to transcription of target genes. On the opposite side, phosphorylated β-catenin is recognized by ubiquitin and targeted for proteasomal degradation. The main role of GSK-3 is to keep β-catenin levels low by phosphorylating it. However, the mechanisms of GSK-3 regulation in this pathway are not completely clear.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> This signaling pathway plays a crucial role in neuronal development and in adult central nervous system (CNS) physiology.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> In particular, it regulates neurite outgrowth in adult, synapse formation and plasticity and neurogenesis.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> GSK-3 antagonizes this signaling pathway, while a pharmacological inhibition of the enzyme activates this pathway and stimulates neurogenesis.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a></div><div class="NLM_p last">The involvement of GSK-3 in different pathways clearly explains why this enzyme can be considered an important cellular nexus able to integrate several signaling systems, second messengers, and cellular stimulants.</div></div><div id="sec1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">1.3.  The Role(s) of GSK-3β in Alzheimer’s Disease</h3><div class="NLM_p">In the CNS, GSK-3β is the most abundant isoform and its expression levels are known to increase with age.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> The activity of GSK-3 is crucial for cellular signaling and to control brain functions related to development, metabolic homeostasis, neuronal growth, and differentiations, as well as cell polarity, fate, and modulation of apoptotic potential.<a onclick="showRef(event, 'ref82 ref83 ref84 ref85'); return false;" href="javascript:void(0);" class="ref ref82 ref83 ref84 ref85">(82−85)</a> GSK-3β is found to be hyperactivated in the brain of AD patients, and compelling evidence supports that it is the main tau kinase involved in AD’s pathology (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref28 ref86'); return false;" href="javascript:void(0);" class="ref ref28 ref86">(28,86)</a> As mentioned above, it is responsible for the hyperphosphorylation of tau protein, an important component of NFTs, which confers it a key role in the pathogenesis of AD.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> Indeed, the tau’s affinity for microtubule depends on its phosphorylation status and GSK-3β-mediated hyperphosphorylation leads to microtubule disassembling and NFTs formations.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> There are plenty of amino acid residues that are phosphorylation targets, and these sites are mainly close to microtubule binding domains where PPI take place. Consistently, several reports indicated that GSK-3β inhibition reduced tauopathy and degeneration <i>in vivo</i>.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/medium/jm0c00931_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Involvement of GSK-3β in AD results from many activities. The most significant are reported in this figure. GSK-3β contributes to amyloid deposition production affecting the function of presenilin 1 (PS1) and the enzymatic cleavage of APP mediated by BACE-1; senile plaques are derived from the abnormal extracellular accumulation and deposition of Aβ peptide. GSK-3β is responsible for the hyperphosphorylation of tau protein and, as consequence, NFTs formation. GSK-3β is involved in neuroinflammation promoting the production of cytokines in astrocytes and microglia.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00931&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">GSK-3β is also involved in Aβ-induced toxicity through different mechanisms.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Aβ is obtained from a series of proteolytic cleavage of amyloid precursor protein (APP), a transmembrane protein highly expressed in the brain, which undergoes two different metabolic pathways mediated by a group of secretases.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> The nonamyloidogenic pathway mediated by α-secretase leads to fragments easily degraded, while the amyloidogenic pathway, mediated by BACE-1 and γ-secretase complex, leads to the formation of Aβ peptide which accumulates in deposits in AD brain. In particular, APP is cleaved by BACE-1 producing soluble sAPPβ and a fragment, called C99, which is further cleaved by the γ-secretase complex generating APP intracellular domain and Aβ (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). GSK-3β regulates Aβ production affecting the function of presenilin 1 (PS1),<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> a component of the γ-secretase complex, and the enzymatic cleavage of APP mediated by BACE-1.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> Furthermore, NF-κB, overexpressed in AD patients, mediates GSK-3β-induced BACE-1 expression.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> To complete this loop, it has been observed that Aβ blocks Wnt-mediated GSK-3β-inhibition leading to an increase in Aβ formation and tau hyperphosphorylation.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a></div><div class="NLM_p">Further, GSK-3β is expressed in both microglia and astrocytes where it promotes production of cytokines, such as IL-1, IL-6, and TNF-α and may contribute to the development and progression of neurological disorders, such as AD, by regulating the neuroinflammation process.<a onclick="showRef(event, 'ref18 ref95 ref96'); return false;" href="javascript:void(0);" class="ref ref18 ref95 ref96">(18,95,96)</a></div><div class="NLM_p">Compelling evidence also indicates that GSK-3β plays a critical role in synaptic plasticity and memory formation.<a onclick="showRef(event, 'ref84 ref85'); return false;" href="javascript:void(0);" class="ref ref84 ref85">(84,85)</a> Indeed, GSK-3β phosphorylates and regulates the function of an impressive number of transcription factors that play critical roles in neuronal plasticity such as NF-κB,<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> heat shock factor 1 (HSF1),<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> MYC,<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> and cAMP response element-binding protein (CREB).<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Furthermore, GSK-3β is a critical regulator of the balance between long-term potentiation (LTP) and tong-term depression (LDP).<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> In particular, it has been observed that LTP induction prevented LDP via GSK-3β inhibition and that GSK-3β inhibitors blocked the induction of LTD.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a></div><div class="NLM_p last">GSK-3β also downregulates β-catenin signaling that influences synaptic size and strength. Indeed, it phosphorylates β-catenin leading to its proteasome degradation.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> Furthermore, overexpression of GSK-3β impairs the hippocampal neurogenesis in adult. GSK-3β is also involved in the degeneration of neurons due to the hyperactivation of NMDA receptors and consequent intracellular calcium accumulation. The activation of NMDA current is also modulated by Aβ oligomers leading to cell death.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a></div></div><div id="sec1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">1.4.  GSK-3β Inhibitors</h3><div class="NLM_p">Kinases represent key nodes at the intersection of multiple intracellular pathways, and deregulation of their activity has been implicated in various pathologies. For this reason, kinases have been intensively investigated as drug targets and 52 kinase inhibitors have been approved by the FDA.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> These drugs target nearly 20 different kinases, but most of them are used for the treatment of proliferative diseases.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> Recent evidence highlights that CNS protein kinases are emerging as important therapeutic targets in AD.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> GSK-3β is probably the most known kinase involved in AD. At the same time, increasing significance is being attributed to death-associated protein kinase 1 DAPK1,<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> p38α mitogen-activated protein kinase MAPK,<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> PKA, PKC, Rho-associated protein kinase 1 ROCK1,<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> and FYN<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> as targets for neurodegenerative disorders.</div><div class="NLM_p">GSK-3β inhibitors have several chemotypes and include small cations and organic compounds, both synthetic and isolated from natural sources. Lithium was the first GSK-3β inhibitor used in clinical practice to treat bipolar disorder and major depression.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> Lithium prevents Aβ-induced toxicity and tau phosphorylation both <i>in cell</i> and <i>in vivo</i> models of AD and improve cognition in transgenic mice.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> Different clinical trials have produced positive results; in patients with mild cognitive impairment (MCI), long-term treatment with lithium significantly reduced phospho-tau levels in cerebrospinal fluid and improved cognitive parameters.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> Another study conducted with microdoses of lithium for 15 months resulted in successful decrease in cognitive decline in AD patients.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a></div><div class="NLM_p">Organic GSK-3β inhibitors may be of natural or synthetic origin and, in general, are very different in structure, covering a wide range of chemical spaces. Plenty of excellent reviews have been published concerning these inhibitors, and readers are referred to them for in-depth discussions.<a onclick="showRef(event, 'ref112 ref113'); return false;" href="javascript:void(0);" class="ref ref112 ref113">(112,113)</a> On the basis of their mechanism of inhibition, they are commonly classified as ATP-competitive or non-ATP-competitive. Most inhibitors belong to the first group and act by blocking the enzyme competing with ATP for its binding site. These classes of compounds are often characterized by a very high affinity, usually in the nanomolar range of concentrations. Selectivity over other kinases represents one of the main issues associated with these compounds. Plenty of ATP-competitive inhibitors have been cocrystallized with GSK-3β and the complex structures solved by X-ray crystallography; therefore, the design of novel, highly selective ATP-competitive inhibitors may be achieved because of structure-based methodologies. Concerning ATP-competitive inhibitors, several maleimide-based inhibitors have been synthesized with a high degree of chemical diversity: linear, macrocyclic, or metal-based.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> The maleimide scaffold establishes key H-bonds with amino acids located within the hinge region; in particular, the nitrogen atom interacts with the carbonyl oxygen of Asp133, while one of the two carbonyl oxygens interacts with the backbone nitrogen of Val135 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B).<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Other ATP-competitive inhibitors are based on the structure of thiazolylureas, such as AR-A014418.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> It inhibits GSK-3β with a <i>K</i><sub>i</sub> of 38 nM, it does not inhibit related kinases, and it is able to block tau phosphorylation. Crystal structures have been obtained, and AR-A014418 binds to the hinge region via three hydrogen bond interactions (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B).<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> Paullones, such as alsterpaullone, are another interesting class of ATP-competitive inhibitors.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> The crystal structure revealed that alsterpaullone established H-bonds with Val135 while the nitro group established H-bond interactions with Lys85.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/medium/jm0c00931_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Structure of selected GSK-3β inhibitors. (B) Schematic interactions of a maleimide-based GSK-3β inhibitor and AR-A014418 within the ATP-binding site (PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1Q4L">1Q4L</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1Q5K">1Q5K</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00931&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Selectivity can be obtained with molecules that interact with specific sites of a given kinase, such as substrate binding domain or allosteric sites. Among the different compounds, tideglusib, reported in 2002 by Martinez et al.,<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> and Palinurin<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> are worth mentioning (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). In particular tideglusib showed, in a first pilot study, a satisfactory safety profile and a significant improvement in cognition compared to placebo-patients.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> However, in a phase IIb trial, although it was well tolerated, no significant improvements were detected.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> Tideglusib has been also evaluated in trials for the treatment of other conditions, such as myotonic dystrophy,<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> autism spectrum disorders,<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> and progressive supranuclear palsy.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> In particular, in a phase II study in people with congenital and childhood-onset type 1 myotonic dystrophy, tideglusib at 1000 mg dose was well tolerated and improved multiple aspects of the symptomatology, such as neuromuscular, cognitive, and autism signs.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> In a phase II trial in patients with mild-to-moderate progressive supranuclear palsy, tideglusib, at 600 or 800 mg dose, was safe and generally well tolerated but it did not show any clinical efficacy.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> Another class of irreversible non-ATP competitive inhibitors is represented by halomethyl ketone derivatives that form a covalent bond with a key Cys199 located at the entrance of the ATP binding site.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a></div><div class="NLM_p last">All the compounds classified as non-ATP competitive inhibitors usually establish weaker interactions with the enzyme, compared to ATP-competitive inhibitors, leading to a lower inhibition rate, which, in the case of GSK-3β, may be necessary to avoid toxicity. Due to GSK-3β involvement in several crucial biochemical pathways and its overactivation in pathological conditions, a weak inhibition able to bring enzymatic activity back to physiological levels may be sufficient to obtain the therapeutic effect without triggering toxic effects. Consequently, a weak to moderate inhibition of GSK-3β may be an optimal therapeutic approach. In this context, the main concerns are about the involvement of GSK-3β in glucose metabolism and in the Wnt signaling pathway. Indeed, many components of the Wnt/β-catenin pathway are involved in several cancers and GSK-3β inhibitors may be potentially oncogenic since GSK-3β suppresses tumor development.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> Indeed, this pathway affects several proto-oncoproteins, cell cycle regulators, and mediators of the epithelial to mesenchymal transition, which is critical for cancer metastasis. However, lithium has been shown to increase the level of β-catenin only in isolated cells while its long-term use in therapy has never been associated with an increased incidence of cancer.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a></div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">2.  GSK-3β-Based Multitarget Ligands</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21377" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21377" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In the past decades, anti-AD drug discovery has mainly focused on the Aβ cascade hypothesis although with disappointing results, as demonstrated by the recent failures of anti-Aβ antibody solanezumab and BACE-1 inhibitor verubecestat.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> However, other target-directed approaches have shown unsatisfactory results.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> There are many reasons for these failures. As previously discussed, a central point is represented by the fact that AD is a multifactorial disease driven by dysregulation of different but interconnected biochemical pathways. This recognition has led to a paradigmatic shift from the “one molecule–one target” to the “one molecule–multitarget” approach in drug discovery. Following this strategy, thousands of new chemical entities have been developed, called MTDLs, multitarget ligands (MTLs), hybrids or simply dirty drugs. As previously reported, without any doubt, anti-AD drug discovery is one of the main fields of application of the MTDLs design strategy.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> On the basis of the evidence pointing at GSK-3β as the functional link between Aβ and tau and due to its involvement in multiple pathways controlling crucial aspects of cell physiology, GSK-3β is gaining a lot of consideration as a drug discovery target. Indeed, promising MTDLs based on GSK-3β inhibitors are starting to appear. It is reported that a MTDL with higher possibility of success “<i>should be directed to networked targets whose connectivity has been proven</i>”,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> and GSK-3β fully satisfies this requirement representing a protein with plenty of tight connections with pathways and targets involved in AD pathogenesis. Furthermore, structural requirements necessary for GSK-3β inhibition are relatively simple and a good level of enzymatic inhibition may be achieved with low MW molecules. Herein, we will discuss some examples of GSK-3β-based MTDLs designed using the knowledge-based approach.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">2.1.  Dual GSK-3β/BACE-1 Inhibitors</h3><div class="NLM_p">In 2015, Cavalli, Bolognesi, and co-workers reported on one of the first examples of GSK-3β-based MTDLs as neuroprotective agents.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> In particular, as second target, the authors focused their attention on BACE-1. BACE-1 is a transmembrane aspartyl protease that is decisive for initiating Aβ generation that ultimately leads to the formation of Aβ plaques, one of the hallmarks of AD along with NFTs. Therefore, BACE-1’s critical role in regulating the first and rate-limiting step in Aβ production leads to the conviction that its inhibition may have a positive effect on Aβ plaques formation. Consequently, in recent years, many companies and academic laboratories have initiated programs to bring BACE-1 inhibitors into the clinic with disappointing results so far.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> Most of these BACE-1 inhibitors, such as lanabecestat, verubecestat, atabecestat, and elenbecestat, have reached late-phase clinical trials and are characterized by <i>in vitro</i> activity in the low nanomolar range.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a></div><div class="NLM_p">On the basis of several pieces of evidence reporting that Aβ and tau are crucial partners that concurrently contribute to AD,<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> the authors postulated that a molecular entity capable of concomitantly modulating targets that embody the crucial points of these two pathways may represent a true disease-modifying agent in AD therapy. Furthermore, several connections between GSK-3β and BACE-1 have been reported. For instance, (a) BACE-1 promotes Aβ formation, which in turn leads to an overactivation of GSK-3β, which consequently induces an increase in the formation of NFTs, inflammation, and cognitive impairment,<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> and (b) GSK-3β regulates the activities of secretases.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> By exploiting a ligand-based approach, the authors identified and combined the pharmacophoric features responsible for GSK-3β and BACE-1 inhibition. In particular, they recognized (a) a guanidino moiety, present in several inhibitors, able to bind to the catalytic aspartic dyad of BACE-1 and (b) a cyclic amide, present in several ATP-competitive GSK-3β inhibitors, able to provide specific H-bonds networks. These two fragments have been combined to obtain a series of dual inhibitors 6-amino-4-substituted triazinone (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> Several analogs have been synthesized, most of which are characterized by a high water solubility. Compound <b>1</b> emerged as the most promising, as it showed moderate but balanced inhibitory profile (IC<sub>50</sub>: BACE-1 = 18.03 ± 0.01 μM, GSK-3β = 14.67 ± 0.78 μM). Moreover, it is characterized by a low MW and relative structural simplicity. Compound <b>1</b> reduced Aβ production in neuroglioma cell line expressing hAPP gene harboring Swedish mutation and did not show any significant toxicity in this cell line. In addition, compound <b>1</b> showed promising anti-inflammatory properties; in fact, it induced a reduction of nitrite formation at 10 μM and iNOS induction in astrocytes and microglia cells treated with LPS together with a switch in microglia from inflammatory M1 to anti-inflammatory M2 phenotype. Neurogenic properties of compound <b>1</b> have been observed in primary rat neural stem cells. Furthermore, pharmacokinetic analyses in mice showed that compound <b>1</b> had good oral bioavailability and BBB penetration. Indeed, after oral administration (10 mg/kg) <i>C</i><sub>max</sub> in plasma after 30 min was 665 ng/mL while 30 min after oral administration compound <b>1</b> reached the concentration of 0.613 ng/mL in 1 mL of brain homogenate.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/medium/jm0c00931_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Design strategy leading to the discovery of dual GSK-3β/BACE-1 inhibitor <b>1</b>. Triazinones were obtained combining structural features responsible for GSK-3β and BACE-1 inhibition, a cyclic amide and a guanidino moiety, respectively. Compound <b>1</b> is the most interesting of the series with an IC<sub>50</sub> in the micromolar range against both proteins.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00931&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">2.2.  Dual GSK-3β/Tau Aggregation Inhibitors</h3><div class="NLM_p">As previously discussed, GSK-3β is responsible for the hyperphosphorylation of tau protein increasing its propensity to aggregate leading to neuronal death. Bolognesi and co-workers designed a series of 5-arylidene-2,4-thiazolidinedione able to interfere in two crucial points of the tau network: (a) reduction of tau hyperphosphorylation and (b) inhibition of tau aggregation processes.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> The design strategy started with the observation that a five-member heterocycle is a common feature in different biologically active compounds, including both GSK-3β and tau aggregation inhibitors. For instance, tideglusib is a pentacyclic thiadiazolidinedione while thiohydantoin, hydantoin, and rhodanine are effective scaffolds to inhibit tau aggregation.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> However, the authors decided to explore the 2,4-thiazolidinedione fragment, which was never used before as GSK-3β or tau aggregation inhibitor, and to decorate it with an (hetero)aromatic moiety in position 5. Indeed, previous studies reported that the introduction of a 5-arylidene substituent in a series of 2-iminothiazolidin-4-one improved affinity and, more importantly, selectivity toward GSK-3β since such large substituents are not able to fit in similar regions of homologous kinases.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> Therefore, the substituent in position 5 has a double role: (a) it increases the volume and the interactions of the molecule with the aim of inducing selectivity toward other kinases since ATP binding pocket in GSK-3β is larger than its homologous counterparts,<a onclick="showRef(event, 'ref135 ref136'); return false;" href="javascript:void(0);" class="ref ref135 ref136">(135,136)</a> and (b) its planarity and aromaticity are crucial for the interaction with the tau fibrils (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Among the different molecules synthesized, compounds <b>2</b> and <b>3</b> emerged as favorable lead compounds. In fact, they (a) selectively inhibited GSK-3β in an ATP-competitive manner, with an IC<sub>50</sub> in the low micromolar range (4.93 ± 0.66 μM for <b>2</b> and 0.89 ± 0.21 μM for <b>3</b>), (b) showed PAMPA-BBB permeability, (c) were found to be not toxic in primary cultures of cerebellar granule neurons and human hepatoma cell line up to 50 μM, and (d) protect neuroblastoma SH-SY5Y cells from toxic insults induced by okaic acid. Compounds <b>2</b> and <b>3</b> have been evaluated for their ability to inhibit the aggregation of AcPHF6, a short peptide (<sub>306</sub>VQIVYK<sub>311</sub>) localized in the microtubule-binding moiety of tau protein that undergoes spontaneous fibrillation and has been proposed as a suitable model for screening of antiaggregants.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> Most importantly, compounds <b>2</b> and <b>3</b> inhibited the aggregation of AcPHF6 peptide (50 μM) at a concentration of 10 μM by stabilizing the peptide in a less fibrillogenic conformation.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/medium/jm0c00931_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Design of dual GSK-3β/tau aggregation inhibitors. The 5-arylidene-2,4-thiazolidinedione has been designed taking into consideration that a five-member heterocycle is a moiety present in both GSK-3β and tau aggregation inhibitors and that a planar substituent in position 5 may increase both the selectivity toward GSK-3β and the interactions with the tau fibrils.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00931&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">2.3.  Dual GSK-3β/AChE Inhibitors</h3><div class="NLM_p">AChE is the enzyme responsible for the degradation of acetylcholine because of its catalytic site, and it is the target of one of the two classes of drugs currently available for AD treatment, although only as palliative. Several studies pointed out that AChE is also responsible for Aβ fibrils aggregation because of a secondary site located at the entrance of the enzymatic gorge, called peripheral anionic site (PAS).<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> Therefore, blocking AChE may result in a double benefit: (a) improve cognition and (b) prevent the formation of Aβ plaques. During the rise of the MTDD design strategy, thousands of ligands, endowed with AChE inhibitory activity, have been coupled with a second pharmacophore to provide an additional biological activity such as inhibition of Aβ formation or aggregation, scavenging activity toward ROS and metal chelating properties. Most of these ligands were based on the structure of AChE inhibitor tacrine.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> In 2018, Sun and co-workers speculated that compounds able to simultaneously inhibit GSK-3β and AChE may represent suitable anti-AD agents due to their ability to interfere with NFTs and Aβ plaques formations.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> Hence, they reported the first class of dual GSK-3β/AChE inhibitors starting from the structure of tacrine, as AChE inhibitor, and a pyridothiazole as GSK-3β inhibitor <b>4</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). The design of this new class of compounds was based on the observation that the carbonyl oxygen of compound <b>4</b><a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> establishes critical H-bonds with the Lys85 while the primary amide and the methoxy group are located in the solvent exposed site and, therefore, may be used as point to link the AChE binding fragment, namely, tacrine. Compound <b>5</b> showed good inhibitory activity against AChE and GSK-3β (IC<sub>50</sub>: AChE = 6.4 ± 0.3 nM, GSK-3β = 66 ± 6.2 nM) and self-induced Aβ aggregation (inhibitory rate 46% at 20 μM). Furthermore, it inhibited tau phosphorylation at Ser396 at 10 μM in mouse neuroblastoma N2a-Tau cells. In <i>in vivo</i> studies, compound <b>5</b> at 15 mg/kg ameliorated the cognitive disorders in scopolamine-treated ICR mice. Most importantly, compound <b>5</b>, contrary to tacrine, did not show any signs of hepatotoxicity, as confirmed by the reduction of alanine aminotransferase (ALT) and aspartate aminotransferase (AST).<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/medium/jm0c00931_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Design of dual GSK-3β/AChE inhibitors <b>5</b> and <b>6</b>. Tacrine has been extensively used to develop MTDLs by linking a structure responsible for inducing a second biological effect. In the cases reported in the figure, GSK-3β inhibitor <b>4</b> has been coupled to tacrine to obtain compound <b>5</b> by taking advantage of the amide in <b>4</b> localized in solvent-exposed portion of the molecule. In the second example, to obtain compound <b>6</b>, the structure of valmerin has been used as GSK-3β binding-fragment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00931&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">A second example of dual GSK-3β/AChE inhibitors appeared in 2019.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> In this investigation, tacrine and valmerin, a GSK-3β binding fragment, were linked through a triazole. Valmerin contains the tetrahydropyrido[1,2-<i>a</i>]isoindolone core and inhibits GSK-3β in the nanomolar range.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> Several analogs were synthesized, and compound <b>6</b> emerged as the most interesting since it showed a good inhibition profile (IC<sub>50</sub>: GSK-3β = 7 nM, AChE = 9.5 ± 0.4 nM) and low toxicity in different cell lines, including SH-SY5Y, and it was predicted to cross the BBB (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">2.4.  Dual GSK-3β/Adenosine Kinase Inhibitors</h3><div class="NLM_p">Brogi and co-workers reported the first example of dual GSK-3β/adenosine kinase (AK) inhibitors as neuroprotective agents.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> Indeed, AK, as well as GSK-3β, is involved in oxidative stress modulation. In particular, AK phosphorylates nucleoside adenosine and displays protective effects reducing ROS levels by enhancing the activity of antioxidant enzymes, such as superoxide dismutase and glutathione peroxidase.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> Analyzing the structure of hAK inhibitors, such as NSD438<a onclick="showRef(event, 'ref145 ref146'); return false;" href="javascript:void(0);" class="ref ref145 ref146">(145,146)</a> and GSK-3β allosteric inhibitors, such as VP0.7<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> along with compound <b>7</b>,<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> the authors designed and synthesized compound <b>8</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>)<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> able to inhibit GSK-3β but, unfortunately, with no activity on hAK at concentration lower than 50 μM. Starting from compound <b>8</b>, through ring contractions and groups replacement, the authors designed new benzoxazinones capable, in theory, of inhibiting both targets. Compound <b>9</b> was the most interesting of the series with an inhibitory profile in the micromolar range with no toxic effects in neuroblastoma cell line IMR 32 and capable of counteracting ROS formation.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/medium/jm0c00931_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Design of dual GSK-3β/AK inhibitors. Compound <b>9</b>, able to bind to both GSK-3β and hAK in the micromolar range of concentrations, has been obtained through a series of modifications of compound <b>8</b>, developed by the same authors, that fails to bind to hAK.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00931&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">2.5.  GSK-3β Inhibitor/Metal Chelator</h3><div class="NLM_p">Shi and co-workers focused their attention on metal dyshomeostasis.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> Changes in the transition metals, zinc, copper, and iron have been shown to affect the molecular mechanisms of the disease.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> High concentrations of metals have been found in Aβ plaques and were held responsible for accelerating the formation of Aβ oligomers.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> It was also reported that copper is able to contribute to ROS formation<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> and oxidative stress was reported to affect tau protein phosphorylation and to significantly increase GSK-3β activity.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> To design this new class of multifunctional agents targeting GSK-3β and metal dyshomeostasis, the authors considered the structure of the GSK-3β inhibitor seen in compound <b>10</b>.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> The authors took into consideration the <i>N</i>-(pyridin-2-yl)cyclopropanecarboxamide, able to establish favorable interactions with the hinge region of GSK-3β (i.e., H-bonds with Val135), and replaced the pyrrolopyridinone with a substituted pyridine ring (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> An amine and an aromatic group were introduced as pyridine substituents aiming to establish additional interactions with GSK-3β and to chelate metals. Compound <b>11</b> was found to be a highly active GSK-3β inhibitor (IC<sub>50</sub> = 49 ± 3.2 nM) chelating Al<sup>3+</sup> and Cu<sup>2+</sup>, efficiently inhibiting Cu<sup>2+</sup>-induced Aβ<sub>1–42</sub> (40 μM) aggregation at 20 μM, inducing disaggregation of Cu<sup>2+</sup>-induced Aβ<sub>1–42</sub> aggregation and inhibiting ROS formations. Furthermore, compound <b>11</b> did not induce toxic effects in neuroblastoma SH-SY5Y cell lines, blocked Aβ-induced tau hyperphosphorylation at Ser396, and protected cells against toxicity induced by H<sub>2</sub>O<sub>2</sub> (150 μM) at 10 μM.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/medium/jm0c00931_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Design of dual GSK-3β inhibitors/metal chelators. The <i>N</i>-(pyridin-2-yl)cyclopropanecarboxamide, able to establish favorable interactions with GSK-3β, has been coupled with a substituted aminopyridine responsible for metal chelation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00931&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">2.6.  Dual GSK-3β/Histone Deacetylase Inhibitors</h3><div class="NLM_p">In 2019, we focused our attention on histone deacetylases (HDACs), a prominent epigenetic target, and in particular on their role in neurodegeneration and its connections with GSK-3β.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> HDACs, together with the action of histone acetyltransferase, modulate both gene expressions and the functions of several non-histone proteins, such as tau, α-tubulin, and Hsp90. Due to the involvement of HDACs in neurodevelopment, memory formation, and cognitive processes, HDACs inhibitors (HDACIs) have been suggested as innovative agents for the treatment of neurodegenerative disorders such as AD.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> Although HDACIs have been used in clinical practice as anticancer agents, vorinostat, the prototype of HDACIs, has recently entered phase I clinical trial for AD. HDACIs have long been used to develop successfully MTDLs as antiproliferative agents. Only very recently, some examples of multiple drugs based on of HDACIs appeared in the literature.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> We planned to design a class of dual GSK-3β/HDACs inhibitors based on the strict connections existing between these two classes of enzymes; namely, (a) neurotoxic effects of HDAC1 depends on GSK-3β activity, and the block of such activity prevents HDAC1-induced cell death in cerebellar granule neurons, (b) GSK-3β and HDAC6 are found in the same protein complex where GSK-3β phosphorylates HDAC6, enhancing its activity (i.e., tau phosphorylation), and (c) combined inhibition of GSK-3β and HDACs induced synergistic neuroprotective effects compared to single-drugs combination treatment.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> To design this class of compounds, we combined in a single chemical entity the pharmacophoric groups responsible for binding to GSK-3β and HDACs. The HDACs pharmacophoric model is well-known and comprised a zinc binding group, able to chelate the Zn<sup>2+</sup> ion located in HDACs active site, a linker, and a CAP group, usually an aromatic surface that interacts with the external surface of the enzyme. We choose a hydroxamic acid as zinc binding group and a phthalimide as CAP group, known to interact with the ATP-binding site of GSK-3β (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). From the <i>in vitro</i> evaluation against GSK-3β, HDAC1, and HDAC6, compound <b>12</b> emerged as the most interesting of the series. Compound <b>12</b> induced an increase in histone H3 and α-tubulin acetylation and blocked copper-induced tau hyperphosphorylation. In the latter case, the effect was more marked than that obtained with the combination of vorinostat and a pure GSK-3β inhibitor. Furthermore, it was shown to be nontoxic and protective against H<sub>2</sub>O<sub>2</sub> and 6-OHDA stimuli in SH-SY5Y and in CGN cell lines, promoting neurogenesis and showing immunomodulatory effects.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/medium/jm0c00931_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Design of dual GSK-3β/HDACs inhibitors. The phthalimide moiety, which interacts with the ATP-binding site of GSK-3β, and an hydroxamic acid, which chelates the Zn<sup>2+</sup> located in the HDAC active site, were linked through an alkylthiourea chain.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00931&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">3.  Conclusions and Future Perspectives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73452" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73452" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The rise of polypharmacology and MTDLs strategy has revolutionized the design-paradigms well established in the medicinal chemistry community. Since the seminal papers by Morphy and Rankovic<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> and Melchiorre and collaborators,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> we have witnessed an unprecedented explosion in the design of MTDLs directed toward neurodegenerative disorders, especially AD. However, on the basis of the most popular theories pursued by scientists to shed light on AD pharmacotherapy, the designed MTDLs were mainly centered on AChE and Aβ (both production and aggregation) inhibitors. Recently, some reports regarding MTDLs based on the tau hypothesis started to appear. This was mainly, but not only, because the Aβ theory, considered for years the cornerstone of AD, had disappointing results so far.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> Among the potential anti-tau targets, GSK-3β has been considered a primary focus due to its function as a link between tau and Aβ.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> Moreover, GSK-3β is a kinase critical in a multitude of CNS-specific signaling pathways and takes roles not only in tau- and Aβ-mediated toxicities but also in oxidative stress, inflammation, memory formation, and synaptic plasticity.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Consequently, several studies have reported that GSK-3β inhibitors had efficiently antagonized neurodegeneration in different cell lines and <i>in vivo</i> models, some of which reach clinical trials.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Furthermore, GSK-3β is networked with several other factors involved in AD, such as BACE-1, HDACs, etc.<a onclick="showRef(event, 'ref27 ref153'); return false;" href="javascript:void(0);" class="ref ref27 ref153">(27,153)</a> These important and confirmed connections make GSK-3β a key target for the design of more successful MTDLs even when characterized by lower affinity when compared to high-affinity single target-directed drugs.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div class="NLM_p">In this context, GSK-3β is a particularly appropriate target since (a) structure-based design strategies may be applied to design MTDLs given the availability of several X-ray solved protein–ligand structures, (b) the pharmacophoric model, at least for ATP-binding site inhibitors, is relatively simple and good inhibition levels may be achieved with high ligand efficiency leading, therefore, to more drug-like MTDLs, (c) strict kinase selectivity is not an absolute requirement since other kinases, such as CDK5 and protein-kinase A, are involved in tau phosphorylation and in critical CNS-signaling pathways,<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> and (d) “soft” inhibition is required to obtain therapeutic effects and reduce the side ones. The latter point is very important since it is challenging to obtain high affinity target(s) while maintaining at the same time the structural requirements in terms of physical chemical characteristics. Higher GSK-3β activity is observed in neuropathological conditions, and approximately 20–25% inhibition is sufficient to produce therapeutic efficacy in CNS diseases.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> Therefore, IC<sub>50</sub> in the low micromolar range of concentrations should be enough to obtain the desired pharmacological effects. Luckily, these levels of inhibition are not sufficient to impact other signaling pathways or target, such β-catenin, that may be responsible for side effects. This is confirmed by the long-used drug lithium whose employment is not associated with increased levels of tumorigenesis.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a></div><div class="NLM_p last">On the basis of these considerations and on the above-reported examples of GSK-3β-directed MTDLs, we strongly support that GSK-3β could be used to design MTDLs with innovative mechanisms of actions. As briefly shown in this Miniperspective, the few examples of GSK-3β-based MTDLs are very promising in terms of anti-AD effects, toxicity, and physical chemical properties. As discussed, the design of MTDLs poses some challenges but we believe that the examples herein reported may induce a shift from an AChE-centric to a tau-centric paradigm leading to a new “gold rush” in the design of anti-AD MTDLs.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00931" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55556" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55556" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrea Milelli</span> - <span class="hlFld-Affiliation affiliation">Department
for Life Quality Studies, Alma Mater Studiorum-University
of Bologna, Corso d’ Augusto 237, 47921 Rimini, Italy</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2285-7403" title="Orcid link">http://orcid.org/0000-0003-2285-7403</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#84e5eae0f6e1e5aae9ede8e1e8e8edb7c4f1eaede6ebaaedf0"><span class="__cf_email__" data-cfemail="f6979892849397d89b9f9a939a9a9fc5b683989f9499d89f82">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Angela De Simone</span> - <span class="hlFld-Affiliation affiliation">Department
of Drug Science and Technology, University
of Turin, Via Giuria 9, 10125 Torino, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vincenzo Tumiatti</span> - <span class="hlFld-Affiliation affiliation">Department
for Life Quality Studies, Alma Mater Studiorum-University
of Bologna, Corso d’ Augusto 237, 47921 Rimini, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vincenza Andrisano</span> - <span class="hlFld-Affiliation affiliation">Department
for Life Quality Studies, Alma Mater Studiorum-University
of Bologna, Corso d’ Augusto 237, 47921 Rimini, Italy</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4396-1904" title="Orcid link">http://orcid.org/0000-0003-4396-1904</a></span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56742" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56742" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Angela De Simone</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00931&amp;id=BIO-d7e1316-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Angela De Simone</b> graduated in Chemistry and Pharmaceutical Technologies from the University of Bologna in 2006 and received her Ph.D. in Pharmaceutical Sciences in 2010 from the same institution under the supervision of Prof. Vincenza Andrisano. From 2011 to 2012 she had a position as postdoc-junior at Italian Institute of Technology. In 2015–2016 she spent 6 months as a visiting researcher at Ludwig Maxmilians University of Munich, Germany, under the supervision of Prof. Wanner. Currently, she is Associate Professor at the University of Turin. Her main research lines focus on the development of analytical methods for the investigation of protein–protein or ligand–protein interactions involved in AD.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Vincenzo Tumiatti</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00931&amp;id=BIO-d7e1321-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Vincenzo Tumiatti</b> obtained his degree in Medicinal Chemistry in 1986. In 1991–1992, he was a Visiting Scientist in the University of Frankfurt/M working in collaboration with Profs. G. Dannhardt, G. Lambrecht, and E. Mutschler. Since 2005, he has been Full Professor in the Department for Life Quality Studies of the University of Bologna, Campus of Rimini. His main current scientific activity focuses on the design and synthesis of new MTDLs against AD and cancer.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Vincenza Andrisano</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00931&amp;id=BIO-d7e1326-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Vincenza Andrisano</b> is Full Professor in Medicinal Chemistry at the Department for the Quality of Life, University of Bologna. As part of her postdoctoral training, she spent two years as a research assistant at the Sydney University Australia (Department of Biochemistry), and she has been a visiting professor at McGill University, Division de Pharmacocinétique, Department D’Oncologie, Montréal, Canada, and at the Department of Pharmacology Georgetown University Medical Center Washington, DC, U.S. She has published more than 224 papers in peer-reviewed scientific journals (HI = 51, Scopus). Vincenza Andrisano’s research lines cover the area of Alzheimer’s disease drug discovery: structural characterization of protein targets and their post-translational modification, binding properties by biochromatography, and characterization of the ligand/target and peptide/protein/enzyme interactions by surface plasmon resonance, mass spectrometry, and circular dichroism.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Andrea Milelli</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00931&amp;id=BIO-d7e1331-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Andrea Milelli</b> received his Master’s degree in Chemistry and Pharmaceutical Technologies from the University of Bologna followed by a Ph.D. in Pharmaceutical Sciences in 2009. He spent a research period at Aarhus University, Denmark, working under the supervision of Prof. Karl Anker Jørgensen, and in 2016, he was Visiting Scientist at Konstanz University, Germany. Currently, he is Associate Professor at the University of Bologna. His current research focuses on the development of small molecules with potential applications in neurodegenerative diseases and cancer.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41108" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41108" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work has been supported by the University of Bologna and FFABR. The authors deeply acknowledge Dr. Claudia Seidl for invaluable support. We apologize to all the authors whose excellent works have not been reported due to space limitations.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AChE</td><td class="NLM_def"><p class="first last">acetylcholinesterase</p></td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">Alzheimer’s disease</p></td></tr><tr><td class="NLM_term">AK</td><td class="NLM_def"><p class="first last">adenosine kinase</p></td></tr><tr><td class="NLM_term">APP</td><td class="NLM_def"><p class="first last">amyloid precursor protein</p></td></tr><tr><td class="NLM_term">Aβ</td><td class="NLM_def"><p class="first last">β-amyloid</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">BACE-1</td><td class="NLM_def"><p class="first last">β-secretase</p></td></tr><tr><td class="NLM_term">CDK5</td><td class="NLM_def"><p class="first last">cyclin dependent kinase 5</p></td></tr><tr><td class="NLM_term">CREB</td><td class="NLM_def"><p class="first last">cAMP response element-binding protein</p></td></tr><tr><td class="NLM_term">DAPK1</td><td class="NLM_def"><p class="first last">death-associated protein kinase 1</p></td></tr><tr><td class="NLM_term">GS</td><td class="NLM_def"><p class="first last">glycogen synthase</p></td></tr><tr><td class="NLM_term">GSK-3β</td><td class="NLM_def"><p class="first last">glycogen synthase kinase 3β</p></td></tr><tr><td class="NLM_term">HDAC</td><td class="NLM_def"><p class="first last">histone deacetylase</p></td></tr><tr><td class="NLM_term">HSF1</td><td class="NLM_def"><p class="first last">heat shock factor 1</p></td></tr><tr><td class="NLM_term">Hsp90</td><td class="NLM_def"><p class="first last">heat shock protein 90</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high throughput screening</p></td></tr><tr><td class="NLM_term">LTP</td><td class="NLM_def"><p class="first last">long-term potentiation</p></td></tr><tr><td class="NLM_term">LTD</td><td class="NLM_def"><p class="first last">long-term depression</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">p38α mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">MTD</td><td class="NLM_def"><p class="first last">multitarget drug</p></td></tr><tr><td class="NLM_term">MCI</td><td class="NLM_def"><p class="first last">mild cognitive impairment</p></td></tr><tr><td class="NLM_term">MTDL</td><td class="NLM_def"><p class="first last">multitarget-directed ligand</p></td></tr><tr><td class="NLM_term">MW</td><td class="NLM_def"><p class="first last">molecular weight</p></td></tr><tr><td class="NLM_term">NMPA</td><td class="NLM_def"><p class="first last">China’s National Medical Product Administration</p></td></tr><tr><td class="NLM_term">NFT</td><td class="NLM_def"><p class="first last">neurofibrillary tangle</p></td></tr><tr><td class="NLM_term">PAS</td><td class="NLM_def"><p class="first last">peripheral anionic site</p></td></tr><tr><td class="NLM_term">PKA</td><td class="NLM_def"><p class="first last">cyclic AMP-dependent protein kinase</p></td></tr><tr><td class="NLM_term">PKB/Akt</td><td class="NLM_def"><p class="first last">protein kinase B</p></td></tr><tr><td class="NLM_term">PKC</td><td class="NLM_def"><p class="first last">atypical protein kinase C</p></td></tr><tr><td class="NLM_term">PPI</td><td class="NLM_def"><p class="first last">protein–protein interaction</p></td></tr><tr><td class="NLM_term">PS1</td><td class="NLM_def"><p class="first last">presenilin 1</p></td></tr><tr><td class="NLM_term">ROCK1</td><td class="NLM_def"><p class="first last">Rho-associated protein kinase 1</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54411" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54411" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 156 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popovic-Nikolic, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uliassi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">A perspective on multi-target drug discovery and design for complex diseases</span>. <i>Clin Transl Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">3</span>, <span class="refDoi"> DOI: 10.1186/s40169-017-0181-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1186%2Fs40169-017-0181-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=29340951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BC1MvhsVaiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=3&author=R.+R.+Ramsayauthor=M.+R.+Popovic-Nikolicauthor=K.+Nikolicauthor=E.+Uliassiauthor=M.+L.+Bolognesi&title=A+perspective+on+multi-target+drug+discovery+and+design+for+complex+diseases&doi=10.1186%2Fs40169-017-0181-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">A perspective on multi-target drug discovery and design for complex diseases</span></div><div class="casAuthors">Ramsay Rona R; Popovic-Nikolic Marija R; Nikolic Katarina; Uliassi Elisa; Bolognesi Maria Laura</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and translational medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3</span>
        ISSN:<span class="NLM_cas:issn">2001-1326</span>.
    </div><div class="casAbstract">Diseases of infection, of neurodegeneration (such as Alzheimer's and Parkinson's diseases), and of malignancy (cancers) have complex and varied causative factors.  Modern drug discovery has the power to identify potential modulators for multiple targets from millions of compounds.  Computational approaches allow the determination of the association of each compound with its target before chemical synthesis and biological testing is done.  These approaches depend on the prior identification of clinically and biologically validated targets.  This Perspective will focus on the molecular and computational approaches that underpin drug design by medicinal chemists to promote understanding and collaboration with clinical scientists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJhSGsWpifCZcXNb62YGmbfW6udTcc2eYPOU47qi4dULntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvhsVaiug%253D%253D&md5=5b05a73a3bbc955c77b9b2df93deb946</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1186%2Fs40169-017-0181-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40169-017-0181-2%26sid%3Dliteratum%253Aachs%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26aulast%3DPopovic-Nikolic%26aufirst%3DM.%2BR.%26aulast%3DNikolic%26aufirst%3DK.%26aulast%3DUliassi%26aufirst%3DE.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DA%2520perspective%2520on%2520multi-target%2520drug%2520discovery%2520and%2520design%2520for%2520complex%2520diseases%26jtitle%3DClin%2520Transl%2520Med.%26date%3D2018%26volume%3D7%26spage%3D3%26doi%3D10.1186%2Fs40169-017-0181-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">Harnessing polypharmacology with medicinal chemistry</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00039</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00039" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVWjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=273-275&author=M.+L.+Bolognesi&title=Harnessing+polypharmacology+with+medicinal+chemistry&doi=10.1021%2Facsmedchemlett.9b00039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Harnessing Polypharmacology with Medicinal Chemistry</span></div><div class="casAuthors">Bolognesi, Maria Laura</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">273-275</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polypharmacol. has expanded enormously over the last ten years, with several multitarget drugs (MTDs) already in the market.  This Viewpoint provides a basis for a discussion about the crit. need to develop MTDs in a more rationale and conscious way.  A checklist to maximize success in polypharmacol. is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4yXxJ_uU72bVg90H21EOLACvtfcHk0li3BPGckkQhaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVWjt7g%253D&md5=28a8cc47ae2966a2ecd8a411adfb1ef5</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00039%26sid%3Dliteratum%253Aachs%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DHarnessing%2520polypharmacology%2520with%2520medicinal%2520chemistry%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D273%26epage%3D275%26doi%3D10.1021%2Facsmedchemlett.9b00039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designed multiple ligands. An emerging drug discovery paradigm</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6523</span>– <span class="NLM_lpage">6543</span>, <span class="refDoi"> DOI: 10.1021/jm058225d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+multiple+ligands.+An+emerging+drug+discovery+paradigm&doi=10.1021%2Fjm058225d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0li3BPGckkQhaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520multiple%2520ligands.%2520An%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543%26doi%3D10.1021%2Fjm058225d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. U.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology - foe or friend?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8955</span>– <span class="NLM_lpage">5971</span>, <span class="refDoi"> DOI: 10.1021/jm400856t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400856t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8955-5971&author=J.+U.+Peters&title=Polypharmacology+-+foe+or+friend%3F&doi=10.1021%2Fjm400856t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology - Foe or Friend?</span></div><div class="casAuthors">Peters, Jens-Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8955-8971</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Polypharmacol. describes the activity of compds. at multiple targets.  Current research focuses on two aspects of polypharmacol.: (1) unintended polypharmacol. can lead to adverse effects; (2) polypharmacol. across several disease-relevant targets can improve therapeutic efficacy, prevent drug resistance, or reduce therapeutic-target-related adverse effects.  This perspective reviews these interconnected aspects of polypharmacol.  The first part discusses the relevance of polypharmacol. for the safety of drugs, the mitigation of safety risks, and methods to identify polypharmacol. compds. early in the drug discovery process.  The second part discusses the advantages of polypharmacol. in the treatment of multigenic diseases and infections, and opportunities for drug discovery and drug repurposing.  This perspective aims to provide a balanced view on polypharmacol., which can compromise the safety of drugs, but can also confer superior efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5vnFGPfTnGLVg90H21EOLACvtfcHk0lh3UHauUUzkzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO&md5=f4aeb6efddd4bfdf4e94656303323cba</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm400856t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400856t%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.%2BU.%26atitle%3DPolypharmacology%2520-%2520foe%2520or%2520friend%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8955%26epage%3D5971%26doi%3D10.1021%2Fjm400856t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minarini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumiatti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recanatini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melchiorre, C.</span></span> <span> </span><span class="NLM_article-title">Multi-target-directed ligands to combat neurodegenerative diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">372</span>, <span class="refDoi"> DOI: 10.1021/jm7009364</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7009364" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsl2qsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=347-372&author=A.+Cavalliauthor=M.+L.+Bolognesiauthor=A.+Minariniauthor=M.+Rosiniauthor=V.+Tumiattiauthor=M.+Recanatiniauthor=C.+Melchiorre&title=Multi-target-directed+ligands+to+combat+neurodegenerative+diseases&doi=10.1021%2Fjm7009364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target-Directed Ligands to Combat Neurodegenerative Diseases</span></div><div class="casAuthors">Cavalli, Andrea; Bolognesi, Maria Laura; Minarini, Anna; Rosini, Michela; Tumiatti, Vincenzo; Recanatini, Maurizio; Melchiorre, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">347-372</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The authors review the investigations reported in the past decade that illustrate the ability of medicinal chemists to design multi-target-directed ligands (MTDLs) to confront neurodegenerative diseases.  The authors briefly illustrate the multifactorial nature of these diseases before discussing the possible development of MTDLs in light of the known mol. bases of the main neurodegenerative pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYY0I0UHEir7Vg90H21EOLACvtfcHk0lh3UHauUUzkzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsl2qsbk%253D&md5=c682235151489316d043cf97f78e56f3</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fjm7009364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7009364%26sid%3Dliteratum%253Aachs%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DMinarini%26aufirst%3DA.%26aulast%3DRosini%26aufirst%3DM.%26aulast%3DTumiatti%26aufirst%3DV.%26aulast%3DRecanatini%26aufirst%3DM.%26aulast%3DMelchiorre%26aufirst%3DC.%26atitle%3DMulti-target-directed%2520ligands%2520to%2520combat%2520neurodegenerative%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D347%26epage%3D372%26doi%3D10.1021%2Fjm7009364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designing multiple ligands - medicinal chemistry strategies and challenges</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.2174/138161209787315594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.2174%2F138161209787315594" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=19199984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvVSns70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=587-600&author=R.+Morphyauthor=Z.+Rankovic&title=Designing+multiple+ligands+-+medicinal+chemistry+strategies+and+challenges&doi=10.2174%2F138161209787315594"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Designing multiple ligands - medicinal chemistry strategies and challenges</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">587-600</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  It has been widely recognized over the recent years that parallel modulation of multiple biol. targets can be beneficial for treatment of diseases with complex etiologies such as cancer asthma, and psychiatric disease.  In this article, current strategies for the generation of ligands with a specific multi-target profile (designed multiple ligands or DMLs) are described and a no. of illustrative example are given.  Designing multiple ligands is frequently a challenging endeavor for medicinal chemists, with the need to appropriately balance affinity for 2 or more targets while obtaining physicochem. and pharmacokinetic properties that are consistent with the administration of an oral drug.  Given that the properties of DMLs are influenced to a large extent by the proteomic superfamily to which the targets belong and the lead generation strategy that is pursued, an early assessment of the feasibility of any given DML project is essential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUo6NjoK5D-LVg90H21EOLACvtfcHk0lh3UHauUUzkzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvVSns70%253D&md5=fa34039be6e9c3b489f530fc74fd0346</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2174%2F138161209787315594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161209787315594%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigning%2520multiple%2520ligands%2520-%2520medicinal%2520chemistry%2520strategies%2520and%2520challenges%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2009%26volume%3D15%26spage%3D587%26epage%3D600%26doi%3D10.2174%2F138161209787315594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">The physicochemical challenges of designing multiple ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">4961</span>– <span class="NLM_lpage">4970</span>, <span class="refDoi"> DOI: 10.1021/jm0603015</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0603015" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFejtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4961-4970&author=R.+Morphyauthor=Z.+Rankovic&title=The+physicochemical+challenges+of+designing+multiple+ligands&doi=10.1021%2Fjm0603015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The Physicochemical Challenges of Designing Multiple Ligands</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4961-4970</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Compds. designed to bind more than one target can provide a therapeutic benefit relative to highly target-selective ligands.  The physicochem. properties of designed multiple ligands were found to be less druglike than those for preclin. compds. in general.  These properties are controlled by the superfamily to which the targets belong and the lead discovery strategy that was followed.  The properties for peptide G-protein-coupled receptor (GPCR) ligands were the least favorable for oral delivery, whereas transporter, monoamine GPCR, and oxidase ligands were the most druglike.  The lead discovery strategy, framework combination or screening, exerts a profound influence on the property values.  Combining the frameworks from two selective ligands often results in large, complex dual ligands, but druglike ligands can be achieved if the degree of framework overlap is maximized and the size of the selective ligands minimized.  For some target combinations, a screening approach may provide a route to smaller, less complex leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonGHbXyxgv4LVg90H21EOLACvtfcHk0lh0zNLXFDcKhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFejtL4%253D&md5=c7a227848516d0aa58ed037a582943fe</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm0603015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0603015%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DThe%2520physicochemical%2520challenges%2520of%2520designing%2520multiple%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4961%26epage%3D4970%26doi%3D10.1021%2Fjm0603015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Fragments, network biology and designing multiple ligands</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">156</span>– <span class="NLM_lpage">160</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2006.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.drudis.2006.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=17275736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtleisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=156-160&author=R.+Morphyauthor=Z.+Rankovic&title=Fragments%2C+network+biology+and+designing+multiple+ligands&doi=10.1016%2Fj.drudis.2006.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Fragments, network biology and designing multiple ligands</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3&4</span>),
    <span class="NLM_cas:pages">156-160</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Modulating multiple protein targets simultaneously can be beneficial for treating complex diseases.  The redundancy that exists within biol. networks means that modulating single proteins might not be sufficient to produce the desired efficacy while, at the same time, minimizing adverse effects.  Designing multi-target drugs can be challenging for medicinal chemists, with current lead-discovery strategies often producing large, complex mols. with low ligand efficiency and poor oral bioavailability.  Paradoxically, analyses of the relationship between the selectivity of biol. active compds. and their mol. size suggest that promiscuous compds. should typically be smaller than target-selective compds.  A fragment-based approach to multi-target drug discovery could lead to a new generation of compds. with improved physicochem. and pharmacokinetic properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXRYwI33BCNLVg90H21EOLACvtfcHk0lh0zNLXFDcKhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtleisbs%253D&md5=64a3c7e8c3280db166dda799a77d689a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2006.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2006.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFragments%252C%2520network%2520biology%2520and%2520designing%2520multiple%2520ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26spage%3D156%26epage%3D160%26doi%3D10.1016%2Fj.drudis.2006.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology by design: A medicinal chemist’s perspective on multitargeting compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">420</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=420-444&author=E.+Proschakauthor=H.+Starkauthor=D.+Merk&title=Polypharmacology+by+design%3A+A+medicinal+chemist%E2%80%99s+perspective+on+multitargeting+compounds&doi=10.1021%2Facs.jmedchem.8b00760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds</span></div><div class="casAuthors">Proschak, Ewgenij; Stark, Holger; Merk, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">420-444</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multitargeting compds. comprising activity on more than a single biol. target have gained remarkable relevance in drug discovery owing to the complexity of multifactorial diseases such as cancer, inflammation, or the metabolic syndrome.  Polypharmacol. drug profiles can produce additive or synergistic effects while reducing side effects and significantly contribute to the high therapeutic success of indispensable drugs such as aspirin.  While their identification has long been the result of serendipity, medicinal chem. now tends to design polypharmacol.  Modern in vitro pharmacol. methods and chem. probes allow a systematic search for rational target combinations and recent innovations in computational technologies, crystallog., or fragment-based design equip multitarget compd. development with valuable tools.  In this Perspective, we analyze the relevance of multiple ligands in drug discovery and the versatile toolbox to design polypharmacol.  We conclude that despite some characteristic challenges remaining unresolved, designed polypharmacol. holds enormous potential to secure future therapeutic innovation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOEwJSxWw3vbVg90H21EOLACvtfcHk0lh0zNLXFDcKhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE&md5=6dc4b8e1c4777372396626140a302663</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00760%26sid%3Dliteratum%253Aachs%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DMerk%26aufirst%3DD.%26atitle%3DPolypharmacology%2520by%2520design%253A%2520A%2520medicinal%2520chemist%25E2%2580%2599s%2520perspective%2520on%2520multitargeting%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D420%26epage%3D444%26doi%3D10.1021%2Facs.jmedchem.8b00760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MareŠová, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolejs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohelska, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, L. K.</span></span> <span> </span><span class="NLM_article-title">Cost of treatment and care for people with Alzheimer’s disease: A Meta- Analysis</span>. <i>Curr. Alzheimer Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1245</span>– <span class="NLM_lpage">1253</span>, <span class="refDoi"> DOI: 10.2174/1567205017666200102144640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.2174%2F1567205017666200102144640" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2020&pages=1245-1253&author=P.+Mare%C5%A0ov%C3%A1author=J.+Dolejsauthor=H.+Mohelskaauthor=L.+K.+Bryan&title=Cost+of+treatment+and+care+for+people+with+Alzheimer%E2%80%99s+disease%3A+A+Meta-+Analysis&doi=10.2174%2F1567205017666200102144640"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F1567205017666200102144640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1567205017666200102144640%26sid%3Dliteratum%253Aachs%26aulast%3DMare%25C5%25A0ov%25C3%25A1%26aufirst%3DP.%26aulast%3DDolejs%26aufirst%3DJ.%26aulast%3DMohelska%26aufirst%3DH.%26aulast%3DBryan%26aufirst%3DL.%2BK.%26atitle%3DCost%2520of%2520treatment%2520and%2520care%2520for%2520people%2520with%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520A%2520Meta-%2520Analysis%26jtitle%3DCurr.%2520Alzheimer%2520Res.%26date%3D2020%26volume%3D16%26spage%3D1245%26epage%3D1253%26doi%3D10.2174%2F1567205017666200102144640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J. S.</span></span> <span> </span><span class="NLM_article-title">History and progress of hypotheses and clinical trials for Alzheimer’s disease</span>. <i>Signal Transduct Target Ther</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">29</span>, <span class="refDoi"> DOI: 10.1038/s41392-019-0063-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2Fs41392-019-0063-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=31637009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BB3MjgtlSrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&pages=29&author=P.+P.+Liuauthor=Y.+Xieauthor=X.+Y.+Mengauthor=J.+S.+Kang&title=History+and+progress+of+hypotheses+and+clinical+trials+for+Alzheimer%E2%80%99s+disease&doi=10.1038%2Fs41392-019-0063-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">History and progress of hypotheses and clinical trials for Alzheimer's disease</span></div><div class="casAuthors">Liu Pei-Pei; Xie Yi; Meng Xiao-Yan; Kang Jian-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Signal transduction and targeted therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">29</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive memory loss along with neuropsychiatric symptoms and a decline in activities of daily life.  Its main pathological features are cerebral atrophy, amyloid plaques, and neurofibrillary tangles in the brains of patients.  There are various descriptive hypotheses regarding the causes of AD, including the cholinergic hypothesis, amyloid hypothesis, tau propagation hypothesis, mitochondrial cascade hypothesis, calcium homeostasis hypothesis, neurovascular hypothesis, inflammatory hypothesis, metal ion hypothesis, and lymphatic system hypothesis.  However, the ultimate etiology of AD remains obscure.  In this review, we discuss the main hypotheses of AD and related clinical trials.  Wealthy puzzles and lessons have made it possible to develop explanatory theories and identify potential strategies for therapeutic interventions for AD.  The combination of hypometabolism and autophagy deficiency is likely to be a causative factor for AD.  We further propose that fluoxetine, a selective serotonin reuptake inhibitor, has the potential to treat AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQyv72FvQh8PUg6wdEZmT2rfW6udTcc2eYNk8fa5Ca9mbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjgtlSrug%253D%253D&md5=78392550d619092b1bdc7b2744bfeaaa</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fs41392-019-0063-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41392-019-0063-8%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%2BP.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DMeng%26aufirst%3DX.%2BY.%26aulast%3DKang%26aufirst%3DJ.%2BS.%26atitle%3DHistory%2520and%2520progress%2520of%2520hypotheses%2520and%2520clinical%2520trials%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DSignal%2520Transduct%2520Target%2520Ther%26date%3D2019%26volume%3D4%26spage%3D29%26doi%3D10.1038%2Fs41392-019-0063-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Selkoe, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, J.</span></span> <span> </span><span class="NLM_article-title">The amyloid hypothesis of Alzheimer’s disease at 25 years</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">595</span>– <span class="NLM_lpage">608</span>, <span class="refDoi"> DOI: 10.15252/emmm.201606210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.15252%2Femmm.201606210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=27025652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC28XltVOhtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=595-608&author=D.+J.+Selkoeauthor=J.+Hardy&title=The+amyloid+hypothesis+of+Alzheimer%E2%80%99s+disease+at+25+years&doi=10.15252%2Femmm.201606210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The amyloid hypothesis of Alzheimer's disease at 25 years</span></div><div class="casAuthors">Selkoe, Dennis J.; Hardy, John</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">595-608</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Despite continuing debate about the amyloid β-protein or Aβ hypothesis, new lines of evidence from labs. and clinics worldwide support the concept that an imbalance between prodn. and clearance of Aβ42 and related Aβ peptides is a very early, often initiating factor in Alzheimer's disease AD.  Confirmation that presenilin is the catalytic site of γ-secretase has provided a linchpin: all dominant mutations causing early-onset AD occur either in the substrate amyloid precursor protein, APP or the protease presenilin of the reaction that generates Aβ.  Duplication of the wild-type APP gene in Down's syndrome leads to Aβ deposits in the teens, followed by microgliosis, astrocytosis, and neurofibrillary tangles typical of AD.  Apolipoprotein E4, which predisposes to AD in > 40% of cases, has been found to impair Aβ clearance from the brain.  Sol. oligomers of Aβ42 isolated from AD patients' brains can decrease synapse no., inhibit long-term potentiation, and enhance long-term synaptic depression in rodent hippocampus, and injecting them into healthy rats impairs memory.  The human oligomers also induce hyperphosphorylation of tau at AD-relevant epitopes and cause neuritic dystrophy in cultured neurons.  Crossing human APP with human tau transgenic mice enhances tau-pos. neurotoxicity.  In humans, new studies show that low cerebrospinal fluid CSF Aβ42 and amyloid-PET positivity precede other AD manifestations by many years.  Most importantly, recent trials of three different Aβ antibodies solanezumab, crenezumab, and aducanumab have suggested a slowing of cognitive decline in post hoc analyses of mild AD subjects.  Although many factors contribute to AD pathogenesis, Aβ dyshomeostasis has emerged as the most extensively validated and compelling therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyGo1qmyvVtbVg90H21EOLACvtfcHk0lgE1m_3lHh61Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltVOhtL8%253D&md5=b7a2003ba5d341f5eef5c7e9454235ce</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.15252%2Femmm.201606210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Femmm.201606210%26sid%3Dliteratum%253Aachs%26aulast%3DSelkoe%26aufirst%3DD.%2BJ.%26aulast%3DHardy%26aufirst%3DJ.%26atitle%3DThe%2520amyloid%2520hypothesis%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%2520at%252025%2520years%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2016%26volume%3D8%26spage%3D595%26epage%3D608%26doi%3D10.15252%2Femmm.201606210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span> <span> </span><span class="NLM_article-title">New insights into the pathogenesis of Alzheimer’s disease</span>. <i>Front Neurol</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1312</span>, <span class="refDoi"> DOI: 10.3389/fneur.2019.01312</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.3389%2Ffneur.2019.01312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=31998208" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=1312&author=L.+Fanauthor=C.+Maoauthor=X.+Huauthor=S.+Zhangauthor=Z.+Yangauthor=Z.+Huauthor=H.+Sunauthor=Y.+Fanauthor=Y.+Dongauthor=J.+Yangauthor=C.+Shiauthor=Y.+Xu&title=New+insights+into+the+pathogenesis+of+Alzheimer%E2%80%99s+disease&doi=10.3389%2Ffneur.2019.01312"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.3389%2Ffneur.2019.01312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffneur.2019.01312%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DL.%26aulast%3DMao%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DY.%26atitle%3DNew%2520insights%2520into%2520the%2520pathogenesis%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DFront%2520Neurol%26date%3D2020%26volume%3D10%26spage%3D1312%26doi%3D10.3389%2Ffneur.2019.01312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, A. J.</span></span> <span> </span><span class="NLM_article-title">Selective loss of central cholinergic neurons in Alzheimer’s disease</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>308</i></span>,  <span class="NLM_fpage">1403</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(76)91936-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2FS0140-6736%2876%2991936-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=1976&pages=1403&author=P.+Daviesauthor=A.+J.+Maloney&title=Selective+loss+of+central+cholinergic+neurons+in+Alzheimer%E2%80%99s+disease&doi=10.1016%2FS0140-6736%2876%2991936-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2876%2991936-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252876%252991936-X%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DP.%26aulast%3DMaloney%26aufirst%3DA.%2BJ.%26atitle%3DSelective%2520loss%2520of%2520central%2520cholinergic%2520neurons%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DLancet%26date%3D1976%26volume%3D308%26spage%3D1403%26doi%3D10.1016%2FS0140-6736%2876%2991936-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tong, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, K. H.</span></span> <span> </span><span class="NLM_article-title">Calcium signaling in Alzheimer’s disease & therapies</span>. <i>Biochim. Biophys. Acta, Mol. Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>1865</i></span>,  <span class="NLM_fpage">1745</span>– <span class="NLM_lpage">1760</span>, <span class="refDoi"> DOI: 10.1016/j.bbamcr.2018.07.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.bbamcr.2018.07.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=30059692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVGjt77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1865&publication_year=2018&pages=1745-1760&author=B.+C.+Tongauthor=A.+J.+Wuauthor=M.+Liauthor=K.+H.+Cheung&title=Calcium+signaling+in+Alzheimer%E2%80%99s+disease+%26+therapies&doi=10.1016%2Fj.bbamcr.2018.07.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Calcium signaling in Alzheimer's disease & therapies</span></div><div class="casAuthors">Tong, Benjamin Chun-Kit; Wu, Aston Jiaxi; Li, Min; Cheung, King-Ho</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">1865</span>
        (<span class="NLM_cas:issue">11_Part_B</span>),
    <span class="NLM_cas:pages">1745-1760</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is the most common type of dementia and is characterized by the accumulation of amyloid (Aβ) plaques and neurofibrillary tangles in the brain.  Much attention has been given to develop AD treatments based on the amyloid cascade hypothesis; however, none of these drugs had good efficacy at improving cognitive functions in AD patients suggesting that Aβ might not be the disease origin.  Thus, there are urgent needs for the development of new therapies that target on the proximal cause of AD.  Cellular calcium (Ca2+) signals regulate important facets of neuronal physiol.  An increasing body of evidence suggests that age-related dysregulation of neuronal Ca2+ homeostasis may play a proximal role in the pathogenesis of AD as disrupted Ca2+ could induce synaptic deficits and promote the accumulation of Aβ plaques and neurofibrillary tangles.  Given that Ca2+ disruption is ubiquitously involved in all AD pathologies, it is likely that using chem. agents or small mols. specific to Ca2+ channels or handling proteins on the plasma membrane and membranes of intracellular organelles to correct neuronal Ca2+ dysregulation could open up a new approach to AD prevention and treatment.  This review summarizes current knowledge on the mol. mechanisms linking Ca2+ dysregulation with AD pathologies and discusses the possibility of correcting neuronal Ca2+ disruption as a therapeutic approach for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEJK32o3x9WbVg90H21EOLACvtfcHk0lgE1m_3lHh61Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVGjt77L&md5=99d76eeda35ebcddb0e88c2a7763821c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2018.07.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2018.07.018%26sid%3Dliteratum%253Aachs%26aulast%3DTong%26aufirst%3DB.%2BC.%26aulast%3DWu%26aufirst%3DA.%2BJ.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DCheung%26aufirst%3DK.%2BH.%26atitle%3DCalcium%2520signaling%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520%2526%2520therapies%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Res.%26date%3D2018%26volume%3D1865%26spage%3D1745%26epage%3D1760%26doi%3D10.1016%2Fj.bbamcr.2018.07.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butterfield, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halliwell, B.</span></span> <span> </span><span class="NLM_article-title">Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">148</span>– <span class="NLM_lpage">160</span>, <span class="refDoi"> DOI: 10.1038/s41583-019-0132-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2Fs41583-019-0132-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=30737462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmsVyms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=148-160&author=D.+A.+Butterfieldauthor=B.+Halliwell&title=Oxidative+stress%2C+dysfunctional+glucose+metabolism+and+Alzheimer+disease&doi=10.1038%2Fs41583-019-0132-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease</span></div><div class="casAuthors">Butterfield, D. Allan; Halliwell, Barry</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">148-160</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Alzheimer disease (AD) is a major cause of age-related dementia.  We do not fully understand AD etiol. and pathogenesis, but oxidative damage is a key component.  The brain mostly uses glucose for energy, but in AD and amnestic mild cognitive impairment glucose metab. is dramatically decreased, probably owing, at least in part, to oxidative damage to enzymes involved in glycolysis, the tricarboxylic acid cycle and ATP biosynthesis.  Consequently, ATP-requiring processes for cognitive function are impaired, and synaptic dysfunction and neuronal death result, with ensuing thinning of key brain areas.  We summarize current research on the interplay and sequence of these processes and suggest potential pharmacol. interventions to retard AD progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob7mdept4G1LVg90H21EOLACvtfcHk0lgP9u2MS_LxXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmsVyms7s%253D&md5=d0a1863fd4aaa5f55263c0b055412f9d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fs41583-019-0132-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41583-019-0132-6%26sid%3Dliteratum%253Aachs%26aulast%3DButterfield%26aufirst%3DD.%2BA.%26aulast%3DHalliwell%26aufirst%3DB.%26atitle%3DOxidative%2520stress%252C%2520dysfunctional%2520glucose%2520metabolism%2520and%2520Alzheimer%2520disease%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2019%26volume%3D20%26spage%3D148%26epage%3D160%26doi%3D10.1038%2Fs41583-019-0132-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonda, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. A.</span></span> <span> </span><span class="NLM_article-title">Role of metal dyshomeostasis in Alzheimer’s disease</span>. <i>Metallomics</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">270</span>, <span class="refDoi"> DOI: 10.1039/c0mt00074d</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1039%2Fc0mt00074d" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=21298161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksVGlsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=267-270&author=D.+J.+Bondaauthor=H.+G.+Leeauthor=J.+A.+Blairauthor=X.+Zhuauthor=G.+Perryauthor=M.+A.+Smith&title=Role+of+metal+dyshomeostasis+in+Alzheimer%E2%80%99s+disease&doi=10.1039%2Fc0mt00074d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Role of metal dyshomeostasis in Alzheimer's disease</span></div><div class="casAuthors">Bonda, David J.; Lee, Hyoung-gon; Blair, Jeffrey A.; Zhu, Xiongwei; Perry, George; Smith, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Metallomics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">267-270</span>CODEN:
                <span class="NLM_cas:coden">METAJS</span>;
        ISSN:<span class="NLM_cas:issn">1756-591X</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Despite serving a crucial purpose in neurobiol. function, transition metals play a sinister part in the aging brain, where the abnormal accumulation and distribution of reactive iron, copper, and zinc elicit oxidative stress and macromol. damage that impedes cellular function.  Alzheimer's disease (AD), an age-related neurodegenerative condition, presents marked accumulations of oxidative stress-induced damage, and increasing evidence points to aberrant transition metal homeostasis as a crit. factor in its pathogenesis.  Amyloid-β oligomerization and fibrillation, considered by many to be the pptg. factor underlying AD onset and development, is also induced by abnormal transition metal activity.  We here elaborate on the roles of iron, copper, and zinc in AD and describe the therapeutic implications they present.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiug6uC3OgKbVg90H21EOLACvtfcHk0lgP9u2MS_LxXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksVGlsbo%253D&md5=97a8ae421b09da255aa0ee37fe366aee</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1039%2Fc0mt00074d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc0mt00074d%26sid%3Dliteratum%253Aachs%26aulast%3DBonda%26aufirst%3DD.%2BJ.%26aulast%3DLee%26aufirst%3DH.%2BG.%26aulast%3DBlair%26aufirst%3DJ.%2BA.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DPerry%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DM.%2BA.%26atitle%3DRole%2520of%2520metal%2520dyshomeostasis%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DMetallomics%26date%3D2011%26volume%3D3%26spage%3D267%26epage%3D270%26doi%3D10.1039%2Fc0mt00074d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinney, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bemiller, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murtishaw, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leisgang, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salazar, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, B. T.</span></span> <span> </span><span class="NLM_article-title">Inflammation as a central mechanism in Alzheimer’s disease</span>. <i>Alzheimers Dement (N Y)</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">575</span>– <span class="NLM_lpage">590</span>, <span class="refDoi"> DOI: 10.1016/j.trci.2018.06.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.trci.2018.06.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=30406177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BB3cvnvVSltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=575-590&author=J.+W.+Kinneyauthor=S.+M.+Bemillerauthor=A.+S.+Murtishawauthor=A.+M.+Leisgangauthor=A.+M.+Salazarauthor=B.+T.+Lamb&title=Inflammation+as+a+central+mechanism+in+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.trci.2018.06.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammation as a central mechanism in Alzheimer's disease</span></div><div class="casAuthors">Kinney Jefferson W; Murtishaw Andrew S; Leisgang Amanda M; Salazar Arnold M; Bemiller Shane M; Lamb Bruce T</div><div class="citationInfo"><span class="NLM_cas:title">Alzheimer's & dementia (New York, N. Y.)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">575-590</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is characterized by cognitive decline and the presence of two core pathologies, amyloid β plaques and neurofibrillary tangles.  Over the last decade, the presence of a sustained immune response in the brain has emerged as a third core pathology in AD.  The sustained activation of the brain's resident macrophages (microglia) and other immune cells has been demonstrated to exacerbate both amyloid and tau pathology and may serve as a link in the pathogenesis of the disorder.  In the following review, we provide an overview of inflammation in AD and a detailed coverage of a number of microglia-related signaling mechanisms that have been implicated in AD.  Additional information on microglia signaling and a number of cytokines in AD are also reviewed.  We also review the potential connection of risk factors for AD and how they may be related to inflammatory mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR0qVKieHI_a-dfST00W0BcfW6udTcc2eZMYVtw0eqm2Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvnvVSltA%253D%253D&md5=cf1cea8f5c84010fd13daebab3094edf</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.trci.2018.06.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.trci.2018.06.014%26sid%3Dliteratum%253Aachs%26aulast%3DKinney%26aufirst%3DJ.%2BW.%26aulast%3DBemiller%26aufirst%3DS.%2BM.%26aulast%3DMurtishaw%26aufirst%3DA.%2BS.%26aulast%3DLeisgang%26aufirst%3DA.%2BM.%26aulast%3DSalazar%26aufirst%3DA.%2BM.%26aulast%3DLamb%26aufirst%3DB.%2BT.%26atitle%3DInflammation%2520as%2520a%2520central%2520mechanism%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DAlzheimers%2520Dement%2520%2528N%2520Y%2529%26date%3D2018%26volume%3D4%26spage%3D575%26epage%3D590%26doi%3D10.1016%2Fj.trci.2018.06.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerakis, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hetz, C.</span></span> <span> </span><span class="NLM_article-title">Emerging roles of ER stress in the etiology and pathogenesis of Alzheimer’s disease</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">995</span>– <span class="NLM_lpage">1011</span>, <span class="refDoi"> DOI: 10.1111/febs.14332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1111%2Ffebs.14332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=29148236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOntL7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2018&pages=995-1011&author=Y.+Gerakisauthor=C.+Hetz&title=Emerging+roles+of+ER+stress+in+the+etiology+and+pathogenesis+of+Alzheimer%E2%80%99s+disease&doi=10.1111%2Ffebs.14332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging roles of ER stress in the etiology and pathogenesis of Alzheimer's disease</span></div><div class="casAuthors">Gerakis, Yannis; Hetz, Claudio</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">995-1011</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by synaptic dysfunction and accumulation of abnormal aggregates formed by amyloid-β peptides or phosphorylated tau proteins.  Accumulating evidence suggests that alterations in the buffering capacity of the proteostasis network are a salient feature of AD.  The endoplasmic reticulum (ER) is the main compartment involved in protein folding and secretion and is drastically affected in AD neurons.  ER stress triggers the activation of the unfolded protein response (UPR), a signal transduction pathway that enforces adaptive programs to recover homeostasis or trigger apoptosis of irreversibly damaged cells.  Exptl. manipulation of specific UPR signaling modules in preclin. models of AD has revealed a key role of this pathway in regulating protein misfolding and neurodegeneration.  Recent studies suggest that the UPR also influences synaptic plasticity and memory through ER stress-independent mechanisms.  Consequently, targeting of the UPR in AD is emerging as an interesting therapeutic approach to modify the two pillars of AD, protein misfolding and synaptic failure.  Here, we review the functional role of ER stress signaling in AD, discussing the complex involvement of the pathway in controlling neuronal survival, the amyloid cascade, neurodegeneration and synaptic function.  Recent intervention efforts to target the UPR with pharmacol. and gene therapy strategies are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKjpOIPTqPM7Vg90H21EOLACvtfcHk0lhaN6xpfXN7Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOntL7J&md5=c626a50b7010a4e07215026ecb2cc87c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1111%2Ffebs.14332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Ffebs.14332%26sid%3Dliteratum%253Aachs%26aulast%3DGerakis%26aufirst%3DY.%26aulast%3DHetz%26aufirst%3DC.%26atitle%3DEmerging%2520roles%2520of%2520ER%2520stress%2520in%2520the%2520etiology%2520and%2520pathogenesis%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DFEBS%2520J.%26date%3D2018%26volume%3D285%26spage%3D995%26epage%3D1011%26doi%3D10.1111%2Ffebs.14332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swerdlow, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, S. M.</span></span> <span> </span><span class="NLM_article-title">The Alzheimer’s disease mitochondrial cascade hypothesis: Progress and perspectives</span>. <i>Biochim. Biophys. Acta, Mol. Basis Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1842</i></span>,  <span class="NLM_fpage">1219</span>– <span class="NLM_lpage">1231</span>, <span class="refDoi"> DOI: 10.1016/j.bbadis.2013.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.bbadis.2013.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=24071439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFOgu7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1842&publication_year=2014&pages=1219-1231&author=R.+H.+Swerdlowauthor=J.+M.+Burnsauthor=S.+M.+Khan&title=The+Alzheimer%E2%80%99s+disease+mitochondrial+cascade+hypothesis%3A+Progress+and+perspectives&doi=10.1016%2Fj.bbadis.2013.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The Alzheimer's disease mitochondrial cascade hypothesis: Progress and perspectives</span></div><div class="casAuthors">Swerdlow, Russell H.; Burns, Jeffrey M.; Khan, Shaharyar M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Basis of Disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1842</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1219-1231</span>CODEN:
                <span class="NLM_cas:coden">BBADEX</span>;
        ISSN:<span class="NLM_cas:issn">0925-4439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  Ten years ago we first proposed the Alzheimer's disease (AD) mitochondrial cascade hypothesis.  This hypothesis maintains that gene inheritance defines an individual's baseline mitochondrial function; inherited and environmental factors det. rates at which mitochondrial function changes over time; and baseline mitochondrial function and mitochondrial change rates influence AD chronol.  Our hypothesis unequivocally states in sporadic, late-onset AD, mitochondrial function affects amyloid precursor protein (APP) expression, APP processing, or beta amyloid (Aβ) accumulation and argues if an amyloid cascade truly exists, mitochondrial function triggers it.  We now review the state of the mitochondrial cascade hypothesis, and discuss it in the context of recent AD biomarker studies, diagnostic criteria, and clin. trials.  Our hypothesis predicts that biomarker changes reflect brain aging, new AD definitions clin. stage brain aging, and removing brain Aβ at any point will marginally impact cognitive trajectories.  Our hypothesis, therefore, offers unique perspective into what sporadic, late-onset AD is and how to best treat it.  This article is part of a Special Issue entitled: Misfolded Proteins, Mitochondrial Dysfunction, and Neurodegenerative Diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnl0OsMeI8rbVg90H21EOLACvtfcHk0lhaN6xpfXN7Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFOgu7zI&md5=fe6deed8b82bdf9eff21850be7b1ffe3</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bbadis.2013.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbadis.2013.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DSwerdlow%26aufirst%3DR.%2BH.%26aulast%3DBurns%26aufirst%3DJ.%2BM.%26aulast%3DKhan%26aufirst%3DS.%2BM.%26atitle%3DThe%2520Alzheimer%25E2%2580%2599s%2520disease%2520mitochondrial%2520cascade%2520hypothesis%253A%2520Progress%2520and%2520perspectives%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Basis%2520Dis.%26date%3D2014%26volume%3D1842%26spage%3D1219%26epage%3D1231%26doi%3D10.1016%2Fj.bbadis.2013.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabbagh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, K.</span></span> <span> </span><span class="NLM_article-title">Alzheimer’s disease drug development pipeline: 2020</span>. <i>Alzheimers Dement (N Y)</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">e12050</span> <span class="refDoi"> DOI: 10.1002/trc2.12050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1002%2Ftrc2.12050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=32695874" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2020&author=J.+Cummingsauthor=G.+Leeauthor=A.+Ritterauthor=M.+Sabbaghauthor=K.+Zhong&title=Alzheimer%E2%80%99s+disease+drug+development+pipeline%3A+2020&doi=10.1002%2Ftrc2.12050"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Ftrc2.12050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Ftrc2.12050%26sid%3Dliteratum%253Aachs%26aulast%3DCummings%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DG.%26aulast%3DRitter%26aufirst%3DA.%26aulast%3DSabbagh%26aufirst%3DM.%26aulast%3DZhong%26aufirst%3DK.%26atitle%3DAlzheimer%25E2%2580%2599s%2520disease%2520drug%2520development%2520pipeline%253A%25202020%26jtitle%3DAlzheimers%2520Dement%2520%2528N%2520Y%2529%26date%3D2020%26volume%3D6%26doi%3D10.1002%2Ftrc2.12050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Syed, Y. Y.</span></span> <span> </span><span class="NLM_article-title">Sodium Oligomannate: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1007/s40265-020-01268-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1007%2Fs40265-020-01268-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=32020555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BB38%252FotlKlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=441-444&author=Y.+Y.+Syed&title=Sodium+Oligomannate%3A+First+Approval&doi=10.1007%2Fs40265-020-01268-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Sodium Oligomannate: First Approval</span></div><div class="casAuthors">Syed Yahiya Y</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">441-444</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sodium oligomannate ((®); GV-971) is a marine algae-derived oral oligosaccharide being developed by Shanghai Green Valley Pharmaceuticals for the treatment of Alzheimer's disease (AD).  Sodium oligomannate received its first approval in November 2019 in China for the treatment of mild to moderate AD to improve cognitive function.  This article summarizes the milestones in the development of sodium oligomannate leading to this first approval for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbpElibNSrFNFxYDaSSP8XfW6udTcc2eZbaXr-87y4Zbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38%252FotlKlsg%253D%253D&md5=1c672e61641ea74da9583fd4305b9fbf</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1007%2Fs40265-020-01268-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-020-01268-1%26sid%3Dliteratum%253Aachs%26aulast%3DSyed%26aufirst%3DY.%2BY.%26atitle%3DSodium%2520Oligomannate%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2020%26volume%3D80%26spage%3D441%26epage%3D444%26doi%3D10.1007%2Fs40265-020-01268-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Citron, M.</span></span> <span> </span><span class="NLM_article-title">Alzheimer’s disease: Strategies for disease modification</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">398</span>, <span class="refDoi"> DOI: 10.1038/nrd2896</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2Fnrd2896" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=20431570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsVWjsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=387-398&author=M.+Citron&title=Alzheimer%E2%80%99s+disease%3A+Strategies+for+disease+modification&doi=10.1038%2Fnrd2896"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Alzheimer's disease: strategies for disease modification</span></div><div class="casAuthors">Citron, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">387-398</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease is the largest unmet medical need in neurol.  Current drugs improve symptoms, but do not have profound disease-modifying effects.  However, in recent years, several approaches aimed at inhibiting disease progression have advanced to clin. trials.  Among these, strategies targeting the prodn. and clearance of the amyloid-β peptide - a cardinal feature of Alzheimer's disease that is thought to be important in disease pathogenesis - are the most advanced.  Approaches aimed at modulating the abnormal aggregation of tau filaments (another key feature of the disease), and those targeting metabolic dysfunction, are also being evaluated in the clinic.  This article discusses recent progress with each of these strategies, with a focus on anti-amyloid strategies, highlighting the lessons learned and the challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeM0fsdJQ-z7Vg90H21EOLACvtfcHk0lhaN6xpfXN7Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsVWjsrw%253D&md5=281ba27137d2a1fa173d5dde1dcbe772</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnrd2896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2896%26sid%3Dliteratum%253Aachs%26aulast%3DCitron%26aufirst%3DM.%26atitle%3DAlzheimer%25E2%2580%2599s%2520disease%253A%2520Strategies%2520for%2520disease%2520modification%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D387%26epage%3D398%26doi%3D10.1038%2Fnrd2896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grossberg, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tariot, P. N.</span></span> <span> </span><span class="NLM_article-title">Present algorithms and future treatments for Alzheimer’s disease</span>. <i>J. Alzheimer's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">1157</span>– <span class="NLM_lpage">1171</span>, <span class="refDoi"> DOI: 10.3233/JAD-180903</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.3233%2FJAD-180903" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=30741683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BB3cfht1altA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2019&pages=1157-1171&author=G.+T.+Grossbergauthor=G.+Tongauthor=A.+D.+Burkeauthor=P.+N.+Tariot&title=Present+algorithms+and+future+treatments+for+Alzheimer%E2%80%99s+disease&doi=10.3233%2FJAD-180903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Present Algorithms and Future Treatments for Alzheimer's Disease</span></div><div class="casAuthors">Grossberg George T; Tong Gary; Burke Anna D; Tariot Pierre N</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's disease : JAD</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1157-1171</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">An estimated 47 million people live with Alzheimer's disease (AD) and other forms of dementia worldwide.  Although no disease-modifying treatments are currently available for AD, earlier diagnosis and proper management of the disease could have considerable impact on patient and caregiver quality of life and functioning.  Drugs currently approved for AD treat the cognitive, behavioral, and functional symptoms of the disease and consist of three cholinesterase inhibitors (ChEIs) and the N-methyl-D-aspartate receptor antagonist memantine.  Treatment of patients with mild to moderate AD is generally initiated with a ChEI.  Patients who show progression of symptoms while on ChEI monotherapy may be switched to another ChEI and/or memantine can be added to the treatment regimen.  In recent years, putative disease-modifying therapies have emerged that aim to slow the progression of AD instead of only addressing its symptoms.  However, many therapies have failed in clinical trials in patients with established AD, suggesting that, once developed, disease-modifying agents may need to be deployed earlier in the course of illness.  The goal of this narrative literature review is to discuss present treatment algorithms and potential future therapies in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRzz6tULPklxXELvajU9pjPfW6udTcc2eYiE_1BKAECq7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfht1altA%253D%253D&md5=c390932b1dff6314af37252a58c5799e</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.3233%2FJAD-180903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-180903%26sid%3Dliteratum%253Aachs%26aulast%3DGrossberg%26aufirst%3DG.%2BT.%26aulast%3DTong%26aufirst%3DG.%26aulast%3DBurke%26aufirst%3DA.%2BD.%26aulast%3DTariot%26aufirst%3DP.%2BN.%26atitle%3DPresent%2520algorithms%2520and%2520future%2520treatments%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Alzheimer%2527s%2520Dis.%26date%3D2019%26volume%3D67%26spage%3D1157%26epage%3D1171%26doi%3D10.3233%2FJAD-180903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">Multi-target design strategies for the improved treatment of Alzheimer’s disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">228</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.ejmech.2019.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=31103902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvVGnsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2019&pages=228-247&author=P.+Zhangauthor=S.+Xuauthor=Z.+Zhuauthor=J.+Xu&title=Multi-target+design+strategies+for+the+improved+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.ejmech.2019.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target design strategies for the improved treatment of Alzheimer's disease</span></div><div class="casAuthors">Zhang, Pengfei; Xu, Shengtao; Zhu, Zheying; Xu, Jinyi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">228-247</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) is a multifactorial syndrome resulting in profound misery and poses a substantial burden on human health, economy, and society throughout the world.  Based on the numerous AD-related targets in the disease network, multi-target design strategy is a crucial direction to seek for enhanced therapy, and multi-target drugs have the ability to regulate more targets than single-target drugs, affecting the disease network with more potency.  Herein, we highlight nine major targets assocd. with AD, which are acetylcholine esterase (AChE), beta-site amyloid precursor protein cleaving enzyme 1 (β-secretase, BACE-1), glycogen synthase kinase 3 beta (GSK-3β), monoamine oxidases (MAOs), metal ions in the brain, N-methyl-D-aspartate (NMDA) receptor, 5-hydroxytryptamine (5-HT) receptors, the third subtype of histamine receptor (H3 receptor), and phosphodiesterases (PDEs), and their resp. relationship to the disease network.  Furthermore, eleven multi-target design strategies classified by the involvement of AChE and related promising compds. for improved therapy of AD in recent years are described based on the nine major targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRXynXSn84-bVg90H21EOLACvtfcHk0lib2I5cZGVXMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvVGnsb8%253D&md5=86555914b4ef65fae2d38caedb87f1aa</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DMulti-target%2520design%2520strategies%2520for%2520the%2520improved%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D176%26spage%3D228%26epage%3D247%26doi%3D10.1016%2Fj.ejmech.2019.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Simone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armirotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertozzi, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrisano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Castillo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massenzio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polito, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatino, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottegoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the first dual BACE-1/GSK-3β fragment hits against Alzheimer’s disease</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1665</span>– <span class="NLM_lpage">1682</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.5b00121</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.5b00121" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFKkt73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1665-1682&author=F.+Pratiauthor=A.+De+Simoneauthor=A.+Armirottiauthor=M.+Summaauthor=D.+Pizziraniauthor=R.+Scarpelliauthor=S.+M.+Bertozziauthor=D.+I.+Perezauthor=V.+Andrisanoauthor=A.+Perez-Castilloauthor=B.+Montiauthor=F.+Massenzioauthor=L.+Politoauthor=M.+Racchiauthor=P.+Sabatinoauthor=G.+Bottegoniauthor=A.+Martinezauthor=A.+Cavalliauthor=M.+L.+Bolognesi&title=3%2C4-Dihydro-1%2C3%2C5-triazin-2%281H%29-ones+as+the+first+dual+BACE-1%2FGSK-3%CE%B2+fragment+hits+against+Alzheimer%E2%80%99s+disease&doi=10.1021%2Facschemneuro.5b00121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the First Dual BACE-1/GSK-3β Fragment Hits against Alzheimer's Disease</span></div><div class="casAuthors">Prati, Federica; De Simone, Angela; Armirotti, Andrea; Summa, Maria; Pizzirani, Daniela; Scarpelli, Rita; Bertozzi, Sine Mandrup; Perez, Daniel I.; Andrisano, Vincenza; Perez-Castillo, Ana; Monti, Barbara; Massenzio, Francesca; Polito, Letizia; Racchi, Marco; Sabatino, Piera; Bottegoni, Giovanni; Martinez, Ana; Cavalli, Andrea; Bolognesi, Maria L.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1665-1682</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">One of the main obstacles toward the discovery of effective anti-Alzheimer drugs is the multifactorial nature of its etiopathol.  Therefore, the use of multitarget-directed ligands has emerged as particularly suitable.  Such ligands, able to modulate different neurodegenerative pathways, for example, amyloid and tau cascades, as well as cognitive and neurogenic functions, are fostered to come.  In this respect, we report herein on the first class of BACE-1/GSK-3β dual inhibitors based on a 3,4-dihydro-1,3,5-triazin-2(1H)-one skeleton, whose hit compd. 1 showed interesting properties in a preliminary investigation.  Notably, compd. 2, endowed with well-balanced potencies against the two isolated enzymes (IC50 of 16 and 7 μM against BACE-1 and GSK-3β, resp.), displayed effective neuroprotective and neurogenic activities and no neurotoxicity in cell-based assays.  It also showed good brain permeability in a pharmacokinetic assessment in mice.  Overall, triazinone derivs., thanks to the simultaneous modulation of multiple points of the diseased network, might emerge as suitable candidates to be tested in in vivo Alzheimer's disease models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9gpkNszZOQ7Vg90H21EOLACvtfcHk0lib2I5cZGVXMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFKkt73O&md5=5d02342f3164a73e41eb17c4f87fb4fa</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.5b00121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.5b00121%26sid%3Dliteratum%253Aachs%26aulast%3DPrati%26aufirst%3DF.%26aulast%3DDe%2BSimone%26aufirst%3DA.%26aulast%3DArmirotti%26aufirst%3DA.%26aulast%3DSumma%26aufirst%3DM.%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DScarpelli%26aufirst%3DR.%26aulast%3DBertozzi%26aufirst%3DS.%2BM.%26aulast%3DPerez%26aufirst%3DD.%2BI.%26aulast%3DAndrisano%26aufirst%3DV.%26aulast%3DPerez-Castillo%26aufirst%3DA.%26aulast%3DMonti%26aufirst%3DB.%26aulast%3DMassenzio%26aufirst%3DF.%26aulast%3DPolito%26aufirst%3DL.%26aulast%3DRacchi%26aufirst%3DM.%26aulast%3DSabatino%26aufirst%3DP.%26aulast%3DBottegoni%26aufirst%3DG.%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3D3%252C4-Dihydro-1%252C3%252C5-triazin-2%25281H%2529-ones%2520as%2520the%2520first%2520dual%2520BACE-1%252FGSK-3%25CE%25B2%2520fragment%2520hits%2520against%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2015%26volume%3D6%26spage%3D1665%26epage%3D1682%26doi%3D10.1021%2Facschemneuro.5b00121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Simone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisignano, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armirotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrisano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Castillo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massenzio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polito, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favia, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottegoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span> <span> </span><span class="NLM_article-title">Multitarget drug discovery for Alzheimer’s disease: Triazinones as BACE-1 and GSK-3β inhibitors</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1578</span>– <span class="NLM_lpage">1582</span>, <span class="refDoi"> DOI: 10.1002/anie.201410456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1002%2Fanie.201410456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVyhtrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=1578-1582&author=F.+Pratiauthor=A.+De+Simoneauthor=P.+Bisignanoauthor=A.+Armirottiauthor=M.+Summaauthor=D.+Pizziraniauthor=R.+Scarpelliauthor=D.+I.+Perezauthor=V.+Andrisanoauthor=A.+Perez-Castilloauthor=B.+Montiauthor=F.+Massenzioauthor=L.+Politoauthor=M.+Racchiauthor=A.+D.+Faviaauthor=G.+Bottegoniauthor=A.+Martinezauthor=M.+L.+Bolognesiauthor=A.+Cavalli&title=Multitarget+drug+discovery+for+Alzheimer%E2%80%99s+disease%3A+Triazinones+as+BACE-1+and+GSK-3%CE%B2+inhibitors&doi=10.1002%2Fanie.201410456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Multitarget Drug Discovery for Alzheimer's Disease: Triazinones as BACE-1 and GSK-3β Inhibitors</span></div><div class="casAuthors">Prati, Federica; De Simone, Angela; Bisignano, Paola; Armirotti, Andrea; Summa, Maria; Pizzirani, Daniela; Scarpelli, Rita; Perez, Daniel I.; Andrisano, Vincenza; Perez-Castillo, Ana; Monti, Barbara; Massenzio, Francesca; Polito, Letizia; Racchi, Marco; Favia, Angelo D.; Bottegoni, Giovanni; Martinez, Ana; Bolognesi, Maria Laura; Cavalli, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1578-1582</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Cumulative evidence strongly supports that the amyloid and tau hypotheses are not mutually exclusive, but concomitantly contribute to neurodegeneration in Alzheimer's disease (AD).  Thus, the development of multitarget drugs which are involved in both pathways might represent a promising therapeutic strategy.  Accordingly, reported here in is the discovery of 6-amino-4-phenyl-3,4-dihydro-1,3,5-triazin-2(1H)-ones as the first class of mols. able to simultaneously modulate BACE-1 and GSK-3β.  Notably, one triazinone showed well-balanced in vitro potencies against the two enzymes (IC50 of (18.03±0.01) μM and (14.67±0.78) μM for BACE-1 and GSK-3β, resp.).  In cell-based assays, it displayed effective neuroprotective and neurogenic activities and no neurotoxicity.  It also showed good brain permeability in a preliminary pharmacokinetic assessment in mice.  Overall, triazinones might represent a promising starting point towards high quality lead compds. with an AD-modifying potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr709_eEcKrqrVg90H21EOLACvtfcHk0lgLsro4CLYVCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVyhtrjE&md5=9d372688168ec28086c92d557a1ed708</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fanie.201410456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201410456%26sid%3Dliteratum%253Aachs%26aulast%3DPrati%26aufirst%3DF.%26aulast%3DDe%2BSimone%26aufirst%3DA.%26aulast%3DBisignano%26aufirst%3DP.%26aulast%3DArmirotti%26aufirst%3DA.%26aulast%3DSumma%26aufirst%3DM.%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DScarpelli%26aufirst%3DR.%26aulast%3DPerez%26aufirst%3DD.%2BI.%26aulast%3DAndrisano%26aufirst%3DV.%26aulast%3DPerez-Castillo%26aufirst%3DA.%26aulast%3DMonti%26aufirst%3DB.%26aulast%3DMassenzio%26aufirst%3DF.%26aulast%3DPolito%26aufirst%3DL.%26aulast%3DRacchi%26aufirst%3DM.%26aulast%3DFavia%26aufirst%3DA.%2BD.%26aulast%3DBottegoni%26aufirst%3DG.%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DCavalli%26aufirst%3DA.%26atitle%3DMultitarget%2520drug%2520discovery%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520Triazinones%2520as%2520BACE-1%2520and%2520GSK-3%25CE%25B2%2520inhibitors%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D1578%26epage%3D1582%26doi%3D10.1002%2Fanie.201410456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lauretti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dincer, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Praticò, D.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3 signaling in Alzheimer’s disease</span>. <i>Biochim. Biophys. Acta, Mol. Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>1867</i></span>,  <span class="NLM_fpage">118664</span>, <span class="refDoi"> DOI: 10.1016/j.bbamcr.2020.118664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.bbamcr.2020.118664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=32006534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlCgt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1867&publication_year=2020&pages=118664&author=E.+Laurettiauthor=O.+Dincerauthor=D.+Pratic%C3%B2&title=Glycogen+synthase+kinase-3+signaling+in+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.bbamcr.2020.118664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase-3 signaling in Alzheimer's disease</span></div><div class="casAuthors">Lauretti, Elisabetta; Dincer, Ozlem; Pratico, Domenico</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">1867</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">118664</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) is the most common form of neurodegenerative disorder with dementia, accounting for approx. 70% of the all cases.  Currently, 5.8 million people in the U.  S. are living with AD and by 2050 this no. is expected to double resulting in a significant socio-economic burden.  Despite intensive research, the exact mechanisms that trigger AD are still not known and at the present there is no cure for it.  In recent years, many signaling pathways assocd. with AD neuropathol. have been explored as possible candidate targets for the treatment of this condition including glycogen synthase kinase-3β (GSK3-β).  GSK3-β is considered a key player in AD pathophysiol. since dysregulation of this kinase influences all the major hallmarks of the disease including: tau phosphorylation, amyloid-β prodn., memory, neurogenesis and synaptic function.  The present review summarizes the current understanding of the GSK3-β neurobiol. with particular emphasis on its effects on specific signaling pathways assocd. with AD pathophysiol.  Moreover, it discusses the feasibility of targeting GSK3-β for AD treatment and provides a summary of the current research effort to develop GSK3-β inhibitors in preclin. and clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMz18wal6wnbVg90H21EOLACvtfcHk0lgLsro4CLYVCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlCgt70%253D&md5=22881b36df641d995ec30e34737660ca</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2020.118664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2020.118664%26sid%3Dliteratum%253Aachs%26aulast%3DLauretti%26aufirst%3DE.%26aulast%3DDincer%26aufirst%3DO.%26aulast%3DPratic%25C3%25B2%26aufirst%3DD.%26atitle%3DGlycogen%2520synthase%2520kinase-3%2520signaling%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Res.%26date%3D2020%26volume%3D1867%26spage%3D118664%26doi%3D10.1016%2Fj.bbamcr.2020.118664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grundke-Iqbal, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tung, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinlan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisniewski, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binder, L. I.</span></span> <span> </span><span class="NLM_article-title">Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">4913</span>– <span class="NLM_lpage">4917</span>, <span class="refDoi"> DOI: 10.1073/pnas.83.13.4913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1073%2Fpnas.83.13.4913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=3088567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADyaL28XksFyqtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1986&pages=4913-4917&author=I.+Grundke-Iqbalauthor=K.+Iqbalauthor=Y.+C.+Tungauthor=M.+Quinlanauthor=H.+M.+Wisniewskiauthor=L.+I.+Binder&title=Abnormal+phosphorylation+of+the+microtubule-associated+protein+tau+%28tau%29+in+Alzheimer+cytoskeletal+pathology&doi=10.1073%2Fpnas.83.13.4913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Abnormal phosphorylation of the microtubule-associated protein τ (tau) in Alzheimer cytoskeletal pathology</span></div><div class="casAuthors">Grundke-Iqbal, Inge; Iqbal, Khalid; Tung, Yunn Chyn; Quinlan, Maureen; Wisniewski, Henryk M.; Binder, Lester I.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4913-17</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">A monoclonal antibody to the microtubule-assocd. protein τ (tau) labeled some neurofibrillary tangles and plaque neurites, the 2 major locations of paired-helical filaments (PHF), in Alzheimer disease brain.  The antibody also labeled isolated PHF that had been repeatedly washed with SDS.  Dephosphorylation of the tissue sections with alk. phosphatase prior to immunolabeling dramatically increased the no. of tangles and plaques recognized by the antibody.  The plaque core amyloid was not stained in either dephosphorylated or nondephosphorylated tissue sections.  On immunoblots PHF polypeptides were labeled readily only when dephosphorylated.  In contrast, a com. available monoclonal antibody to a phosphorylated epitope of neurofilaments that labeled the tangles and the plaque neurites in tissue did not label any PHF polypeptides on immunoblots.  The PHF polypeptides, labeled with the monoclonal antibody to τ, electrophoresed with those polypeptides recognized by antibodies to isolated PHF.  The antibody to τ labeled microtubules from normal human brains assembled in vitro but identically treated Alzheimer brain prepns. had to be dephosphorylated to be completely recognized by this antibody.  These findings suggest that τ in Alzheimer brain is an abnormally phosphorylated protein component of PHF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcyxbsq2aXprVg90H21EOLACvtfcHk0lgLsro4CLYVCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XksFyqtrg%253D&md5=3ac88b7002e26c53c54e71a3a91471ba</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.83.13.4913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.83.13.4913%26sid%3Dliteratum%253Aachs%26aulast%3DGrundke-Iqbal%26aufirst%3DI.%26aulast%3DIqbal%26aufirst%3DK.%26aulast%3DTung%26aufirst%3DY.%2BC.%26aulast%3DQuinlan%26aufirst%3DM.%26aulast%3DWisniewski%26aufirst%3DH.%2BM.%26aulast%3DBinder%26aufirst%3DL.%2BI.%26atitle%3DAbnormal%2520phosphorylation%2520of%2520the%2520microtubule-associated%2520protein%2520tau%2520%2528tau%2529%2520in%2520Alzheimer%2520cytoskeletal%2520pathology%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1986%26volume%3D83%26spage%3D4913%26epage%3D4917%26doi%3D10.1073%2Fpnas.83.13.4913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaidi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundke-Iqbal, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, K.</span></span> <span> </span><span class="NLM_article-title">Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">6923</span>– <span class="NLM_lpage">6928</span>, <span class="refDoi"> DOI: 10.1073/pnas.121119298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1073%2Fpnas.121119298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=11381127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD3MXksVOrsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=6923-6928&author=A.+Alonsoauthor=T.+Zaidiauthor=M.+Novakauthor=I.+Grundke-Iqbalauthor=K.+Iqbal&title=Hyperphosphorylation+induces+self-assembly+of+tau+into+tangles+of+paired+helical+filaments%2Fstraight+filaments&doi=10.1073%2Fpnas.121119298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Hyperphosphorylation induces self-assembly of τ into tangles of paired helical filaments/straight filaments</span></div><div class="casAuthors">Alonso, Alejandra Del C.; Zaidi, Tanweer; Novak, Michal; Grundke-Iqbal, Inge; Iqbal, Khalid</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">6923-6928</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The microtubule-assocd. protein τ is a family of six isoforms that becomes abnormally hyperphosphorylated and accumulates in the form of paired helical filaments (PHF) in the brains of patients with Alzheimer's disease (AD) and patients with several other tauopathies.  Here, we show that the abnormally hyperphosphorylated τ from AD brain cytosol (AD P-τ) self-aggregates into PHF-like structures on incubation at pH 6.9 under reducing conditions at 35° during 90 min.  In vitro dephosphorylation, but not deglycosylation, of AD P-τ inhibits its self-assocn. into PHF.  Furthermore, hyperphosphorylation induces self-assembly of each of the six τ isoforms into tangles of PHF and straight filaments, and the microtubule binding domains/repeats region in the absence of the rest of the mol. can also self-assemble into PHF.  Thus, it appears that τ self-assembles by assocn. of the microtubule binding domains/repeats and that the abnormal hyperphosphorylation promotes the self-assembly of τ into tangles of PHF and straight filaments by neutralizing the inhibitory basic charges of the flanking regions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotRjItZ2IrZrVg90H21EOLACvtfcHk0ljc8hLfrPmrlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXksVOrsL8%253D&md5=358aed40bd36b81cb3bc1f8f5bc4bfed</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1073%2Fpnas.121119298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.121119298%26sid%3Dliteratum%253Aachs%26aulast%3DAlonso%26aufirst%3DA.%26aulast%3DZaidi%26aufirst%3DT.%26aulast%3DNovak%26aufirst%3DM.%26aulast%3DGrundke-Iqbal%26aufirst%3DI.%26aulast%3DIqbal%26aufirst%3DK.%26atitle%3DHyperphosphorylation%2520induces%2520self-assembly%2520of%2520tau%2520into%2520tangles%2520of%2520paired%2520helical%2520filaments%252Fstraight%2520filaments%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2001%26volume%3D98%26spage%3D6923%26epage%3D6928%26doi%3D10.1073%2Fpnas.121119298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morozova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ElIdrissi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleiman, F. E.</span></span> <span> </span><span class="NLM_article-title">Hyperphosphorylation of tau associates with changes in its function beyond microtubule stability</span>. <i>Front. Cell. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">338</span>, <span class="refDoi"> DOI: 10.3389/fncel.2018.00338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.3389%2Ffncel.2018.00338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=30356756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFyjt7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=338&author=A.+D.+Alonsoauthor=L.+S.+Cohenauthor=C.+Corboauthor=V.+Morozovaauthor=A.+ElIdrissiauthor=G.+Phillipsauthor=F.+E.+Kleiman&title=Hyperphosphorylation+of+tau+associates+with+changes+in+its+function+beyond+microtubule+stability&doi=10.3389%2Ffncel.2018.00338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Hyperphosphorylation of tau associates with changes in its function beyond microtubule stability</span></div><div class="casAuthors">Alonso, Alejandra D.; Cohen, Leah S.; Corbo, Christopher; Morozova, Viktoriya; ElIdrissi, Abdeslem; Phillips, Greg; Kleiman, Frida E.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Cellular Neuroscience</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">338</span>CODEN:
                <span class="NLM_cas:coden">FCNRAH</span>;
        ISSN:<span class="NLM_cas:issn">1662-5102</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Tau is a neuronal microtubule assocd. protein whose main biol. functions are to promote microtubule self-assembly by tubulin and to stabilize those already formed.  Tau also plays an important role as an axonal microtubule protein.  Tau is an amazing protein that plays a key role in cognitive processes, however, deposits of abnormal forms of tau are assocd. with several neurodegenerative diseases, including Alzheimer disease (AD), the most prevalent, and Chronic Traumatic Encephalopathy (CTE) and Traumatic Brain Injury (TBI), the most recently assocd. to abnormal tau.  Tau post-translational modifications (PTMs) are responsible for its gain of toxic function.  Alonso et al. were the first to show that the pathol. tau isolated from AD brains has prion-like properties and can transfer its toxic function to the normal mol.  Furthermore, we reported that the pathol. changes are assocd. with tau phosphorylation at Ser199 and 262 and Thr212 and 231.  This pathol. version of tau induces subcellular mislocalization in cultured cells and neurons, and translocates into the nucleus or accumulated in the perinuclear region of cells.  We have generated a transgenic mouse model that expresses pathol. human tau (PH-Tau) in neurons at two different concns. (4% and 14% of the total endogenous tau).  In this model, PH-Tau causes cognitive decline by at least two different mechanisms: one that involves the cytoskeleton with axonal disruption (at high concn.), and another in which the apparent neuronal morphol. is not grossly affected, but the synaptic terminals are altered (at lower concn.).  We will discuss the putative involvement of tau in proteostasis under these conditions.  Understanding tau's biol. activity on and off the microtubules will help shed light to the mechanism of neurodegeneration and of normal neuronal function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPUEgtgX4MvrVg90H21EOLACvtfcHk0ljc8hLfrPmrlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFyjt7zK&md5=a898fe9a035a5b9e45afcc2ed5095bff</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.3389%2Ffncel.2018.00338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffncel.2018.00338%26sid%3Dliteratum%253Aachs%26aulast%3DAlonso%26aufirst%3DA.%2BD.%26aulast%3DCohen%26aufirst%3DL.%2BS.%26aulast%3DCorbo%26aufirst%3DC.%26aulast%3DMorozova%26aufirst%3DV.%26aulast%3DElIdrissi%26aufirst%3DA.%26aulast%3DPhillips%26aufirst%3DG.%26aulast%3DKleiman%26aufirst%3DF.%2BE.%26atitle%3DHyperphosphorylation%2520of%2520tau%2520associates%2520with%2520changes%2520in%2520its%2520function%2520beyond%2520microtubule%2520stability%26jtitle%3DFront.%2520Cell.%2520Neurosci.%26date%3D2018%26volume%3D12%26spage%3D338%26doi%3D10.3389%2Ffncel.2018.00338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jicha, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otvos, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, P.</span></span> <span> </span><span class="NLM_article-title">A conformation- and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer’s disease</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">2087</span>– <span class="NLM_lpage">2095</span>, <span class="refDoi"> DOI: 10.1046/j.1471-4159.1997.69052087.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1046%2Fj.1471-4159.1997.69052087.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=9349554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADyaK2sXmvVKktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=1997&pages=2087-2095&author=G.+A.+Jichaauthor=E.+Laneauthor=I.+Vincentauthor=L.+Otvosauthor=R.+Hoffmannauthor=P.+Davies&title=A+conformation-+and+phosphorylation-dependent+antibody+recognizing+the+paired+helical+filaments+of+Alzheimer%E2%80%99s+disease&doi=10.1046%2Fj.1471-4159.1997.69052087.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">A conformation- and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer's disease</span></div><div class="casAuthors">Jicha, Gregory A.; Lane, Eric; Vincent, Inez; Otvos, Laszlo, Jr.; Hoffmann, Ralf; Davies, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2087-2095</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Lippincott-Raven</span>)
        </div><div class="casAbstract">Hyperphosphorylated tau (PHF-tau) is the major constituent of paired helical filaments (PHFs) from Alzheimer's disease (AD) brains.  This conclusion has been based largely on the creation and characterization of monoclonal antibodies raised against PHFs, which can be classified in three categories: (a) those recognizing unmodified primary sequences of tau, (b) those recognizing phosphorylation-dependent epitopes on tau, and (c) those recognizing conformation-dependent epitopes on tau.  Recent studies have suggested that the antibodies recognizing primary sequence and phosphorylation-dependent epitopes on tau are unable to distinguish between normal adult biopsy tau and PHF-tau.  We now present evidence for a new fourth class of monoclonal antibodies recognizing conformation-dependent phosphoepitopes on tau, typified by TG-3, a monoclonal antibody raised to PHFs from AD brain homogenates.  Studies using a series of deletional tau mutants, site-directed tau mutants, and synthetic peptides enable the precise epitope mapping of TG-3.  Addnl. studies demonstrate that TG-3 reacts with neonatal mouse tau and PHF-tau but does not recognize adult mouse tau or tau derived from normal human autopsy or biopsy tissue.  Further investigation reveals that TG-3 recognizes a unique conformation of tau found almost exclusively in PHFs from AD brains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfjT9MtA9FrbVg90H21EOLACvtfcHk0ljc8hLfrPmrlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmvVKktrc%253D&md5=6668245383d37d5d5d2272033aa40e4f</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.1997.69052087.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.1997.69052087.x%26sid%3Dliteratum%253Aachs%26aulast%3DJicha%26aufirst%3DG.%2BA.%26aulast%3DLane%26aufirst%3DE.%26aulast%3DVincent%26aufirst%3DI.%26aulast%3DOtvos%26aufirst%3DL.%26aulast%3DHoffmann%26aufirst%3DR.%26aulast%3DDavies%26aufirst%3DP.%26atitle%3DA%2520conformation-%2520and%2520phosphorylation-dependent%2520antibody%2520recognizing%2520the%2520paired%2520helical%2520filaments%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Neurochem.%26date%3D1997%26volume%3D69%26spage%3D2087%26epage%3D2095%26doi%3D10.1046%2Fj.1471-4159.1997.69052087.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gamblin, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zambrano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagalwar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillozet, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Sierra, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaPointe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binder, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cryns, V. L.</span></span> <span> </span><span class="NLM_article-title">Caspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer’s disease</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">10032</span>– <span class="NLM_lpage">10037</span>, <span class="refDoi"> DOI: 10.1073/pnas.1630428100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1073%2Fpnas.1630428100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=12888622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvVeisrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=10032-10037&author=T.+C.+Gamblinauthor=F.+Chenauthor=A.+Zambranoauthor=A.+Abrahaauthor=S.+Lagalwarauthor=A.+L.+Guillozetauthor=M.+Luauthor=Y.+Fuauthor=F.+Garcia-Sierraauthor=N.+LaPointeauthor=R.+Millerauthor=R.+W.+Berryauthor=L.+I.+Binderauthor=V.+L.+Cryns&title=Caspase+cleavage+of+tau%3A+Linking+amyloid+and+neurofibrillary+tangles+in+Alzheimer%E2%80%99s+disease&doi=10.1073%2Fpnas.1630428100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Caspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer's disease</span></div><div class="casAuthors">Gamblin, T. Chris; Chen, Feng; Zambrano, Angara; Abraha, Aida; Lagalwar, Sarita; Guillozet, Angela L.; Lu, Meiling; Fu, Yifan; Garcia-Sierra, Francisco; LaPointe, Nichole; Miller, Richard; Berry, Robert W.; Binder, Lester I.; Cryns, Vincent L.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">10032-10037</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The principal pathol. features of Alzheimer's disease (AD) are extracellular amyloid plaques and intracellular neurofibrillary tangles, the latter composed of the microtubule-binding protein tau assembled into paired helical and straight filaments.  Recent studies suggest that these pathol. entities may be functionally linked, although the mechanisms by which amyloid deposition promotes pathol. tau filament assembly are poorly understood.  Here, we report that tau is proteolyzed by multiple caspases at a highly conserved aspartate residue (Asp421) in its C terminus in vitro and in neurons treated with amyloid-β (Aβ) (1-42) peptide.  Tau is rapidly cleaved at Asp421 in Aβ-treated neurons (within 2 h), and its proteolysis appears to precede the nuclear events of apoptosis.  We also demonstrate that caspase cleavage of tau generates a truncated protein that lacks its C-terminal 20 amino acids and assembles more rapidly and more extensively into tau filaments in vitro than wild-type tau.  Using a monoclonal antibody that specifically recognizes tau truncated at Asp421, we show that tau is proteolytically cleaved at this site in the fibrillar pathologies of AD brain.  Taken together, our results suggest a novel mechanism linking amyloid deposition and neurofibrillary tangles in AD: Aβ peptides promote pathol. tau filament assembly in neurons by triggering caspase cleavage of tau and generating a proteolytic product with enhanced polymn. kinetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTQ2uuzOCOcLVg90H21EOLACvtfcHk0ljExdavmX-XBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvVeisrc%253D&md5=0b11eb04bfa16794ef3e207e88fd4a35</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1630428100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1630428100%26sid%3Dliteratum%253Aachs%26aulast%3DGamblin%26aufirst%3DT.%2BC.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DZambrano%26aufirst%3DA.%26aulast%3DAbraha%26aufirst%3DA.%26aulast%3DLagalwar%26aufirst%3DS.%26aulast%3DGuillozet%26aufirst%3DA.%2BL.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DFu%26aufirst%3DY.%26aulast%3DGarcia-Sierra%26aufirst%3DF.%26aulast%3DLaPointe%26aufirst%3DN.%26aulast%3DMiller%26aufirst%3DR.%26aulast%3DBerry%26aufirst%3DR.%2BW.%26aulast%3DBinder%26aufirst%3DL.%2BI.%26aulast%3DCryns%26aufirst%3DV.%2BL.%26atitle%3DCaspase%2520cleavage%2520of%2520tau%253A%2520Linking%2520amyloid%2520and%2520neurofibrillary%2520tangles%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2003%26volume%3D100%26spage%3D10032%26epage%3D10037%26doi%3D10.1073%2Fpnas.1630428100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Magi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castaldo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macrì, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiolino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matteucci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastioli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gratteri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amoroso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lariccia, V.</span></span> <span> </span><span class="NLM_article-title">Intracellular calcium dysregulation: Implications for Alzheimer’s disease</span>. <i>BioMed Res. Int.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2016</i></span>,  <span class="NLM_fpage">6701324</span>, <span class="refDoi"> DOI: 10.1155/2016/6701324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1155%2F2016%2F6701324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=27340665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BC2s7js1WltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2016&publication_year=2016&pages=6701324&author=S.+Magiauthor=P.+Castaldoauthor=M.+L.+Macr%C3%ACauthor=M.+Maiolinoauthor=A.+Matteucciauthor=G.+Bastioliauthor=S.+Gratteriauthor=S.+Amorosoauthor=V.+Lariccia&title=Intracellular+calcium+dysregulation%3A+Implications+for+Alzheimer%E2%80%99s+disease&doi=10.1155%2F2016%2F6701324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular Calcium Dysregulation: Implications for Alzheimer's Disease</span></div><div class="casAuthors">Magi Simona; Castaldo Pasqualina; Macri Maria Loredana; Maiolino Marta; Matteucci Alessandra; Bastioli Guendalina; Amoroso Salvatore; Lariccia Vincenzo; Gratteri Santo</div><div class="citationInfo"><span class="NLM_cas:title">BioMed research international</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2016</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6701324</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Alzheimer's Disease (AD) is a neurodegenerative disorder characterized by progressive neuronal loss.  AD is associated with aberrant processing of the amyloid precursor protein, which leads to the deposition of amyloid-β plaques within the brain.  Together with plaques deposition, the hyperphosphorylation of the microtubules associated protein tau and the formation of intraneuronal neurofibrillary tangles are a typical neuropathological feature in AD brains.  Cellular dysfunctions involving specific subcellular compartments, such as mitochondria and endoplasmic reticulum (ER), are emerging as crucial players in the pathogenesis of AD, as well as increased oxidative stress and dysregulation of calcium homeostasis.  Specifically, dysregulation of intracellular calcium homeostasis has been suggested as a common proximal cause of neural dysfunction in AD.  Aberrant calcium signaling has been considered a phenomenon mainly related to the dysfunction of intracellular calcium stores, which can occur in both neuronal and nonneuronal cells.  This review reports the most recent findings on cellular mechanisms involved in the pathogenesis of AD, with main focus on the control of calcium homeostasis at both cytosolic and mitochondrial level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRyi3EPEOXNOUwlCcfExbvbfW6udTcc2eYszTGsV56zULntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7js1WltA%253D%253D&md5=962cd2ab1a8d825fe85291003880edf9</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1155%2F2016%2F6701324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2016%252F6701324%26sid%3Dliteratum%253Aachs%26aulast%3DMagi%26aufirst%3DS.%26aulast%3DCastaldo%26aufirst%3DP.%26aulast%3DMacr%25C3%25AC%26aufirst%3DM.%2BL.%26aulast%3DMaiolino%26aufirst%3DM.%26aulast%3DMatteucci%26aufirst%3DA.%26aulast%3DBastioli%26aufirst%3DG.%26aulast%3DGratteri%26aufirst%3DS.%26aulast%3DAmoroso%26aufirst%3DS.%26aulast%3DLariccia%26aufirst%3DV.%26atitle%3DIntracellular%2520calcium%2520dysregulation%253A%2520Implications%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DBioMed%2520Res.%2520Int.%26date%3D2016%26volume%3D2016%26spage%3D6701324%26doi%3D10.1155%2F2016%2F6701324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spires-Jones, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoothoff, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Calignon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, B. T.</span></span> <span> </span><span class="NLM_article-title">Tau pathophysiology in neurodegeneration: A tangled issue</span>. <i>Trends Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">150</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1016/j.tins.2008.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.tins.2008.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=19162340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFOns70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2009&pages=150-159&author=T.+L.+Spires-Jonesauthor=W.+H.+Stoothoffauthor=A.+de+Calignonauthor=P.+B.+Jonesauthor=B.+T.+Hyman&title=Tau+pathophysiology+in+neurodegeneration%3A+A+tangled+issue&doi=10.1016%2Fj.tins.2008.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Tau pathophysiology in neurodegeneration: a tangled issue</span></div><div class="casAuthors">Spires-Jones, Tara L.; Stoothoff, William H.; de Calignon, Alix; Jones, Phillip B.; Hyman, Bradley T.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Neurosciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">150-159</span>CODEN:
                <span class="NLM_cas:coden">TNSCDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-2236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Neurodegenerative tauopathies are marked by their common pathol. feature of aggregates formed of hyperphosphorylated tau protein, which are assocd. with synapse and neuronal loss.  Changes in tau conformation result in both loss of normal function and gain of fibrillogenicity that leads to aggregation.  Here, we discuss the pathophysiol. of tau and emerging evidence of how changes in this protein might ultimately lead to neuronal death.  In particular, based on recent evidence, we propose that a non-apoptotic caspase-assocd. form of death is occurring in tauopathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfJH0otFZPurVg90H21EOLACvtfcHk0ljFBr-nsV6BUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFOns70%253D&md5=2de93205966e73aaa20a2010d55a59f6</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.tins.2008.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tins.2008.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DSpires-Jones%26aufirst%3DT.%2BL.%26aulast%3DStoothoff%26aufirst%3DW.%2BH.%26aulast%3Dde%2BCalignon%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DP.%2BB.%26aulast%3DHyman%26aufirst%3DB.%2BT.%26atitle%3DTau%2520pathophysiology%2520in%2520neurodegeneration%253A%2520A%2520tangled%2520issue%26jtitle%3DTrends%2520Neurosci.%26date%3D2009%26volume%3D32%26spage%3D150%26epage%3D159%26doi%3D10.1016%2Fj.tins.2008.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ash, P. E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maziuk, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballance, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boudeau, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdullatif, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlando, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrucelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikezu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolozin, B.</span></span> <span> </span><span class="NLM_article-title">TIA1 regulates the generation and response to toxic tau oligomers</span>. <i>Acta Neuropathol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">259</span>– <span class="NLM_lpage">277</span>, <span class="refDoi"> DOI: 10.1007/s00401-018-1937-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1007%2Fs00401-018-1937-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=30465259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlCmtLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2019&pages=259-277&author=L.+Jiangauthor=P.+E.+A.+Ashauthor=B.+F.+Maziukauthor=H.+I.+Ballanceauthor=S.+Boudeauauthor=A.+A.+Abdullatifauthor=M.+Orlandoauthor=L.+Petrucelliauthor=T.+Ikezuauthor=B.+Wolozin&title=TIA1+regulates+the+generation+and+response+to+toxic+tau+oligomers&doi=10.1007%2Fs00401-018-1937-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">TIA1 regulates the generation and response to toxic tau oligomers</span></div><div class="casAuthors">Jiang, Lulu; Ash, Peter E. A.; Maziuk, Brandon F.; Ballance, Heather I.; Boudeau, Samantha; Abdullatif, Ali Al; Orlando, Marcello; Petrucelli, Leonard; Ikezu, Tsuneya; Wolozin, Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Neuropathologica</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">259-277</span>CODEN:
                <span class="NLM_cas:coden">ANPTAL</span>;
        ISSN:<span class="NLM_cas:issn">0001-6322</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">RNA binding proteins (RBPs) are strongly linked to the pathophysiol. of motor neuron diseases.  Recent studies show that RBPs, such as TIA1, also contribute to the pathophysiol. of tauopathy.  RBPs co-localize with tau pathol., and redn. of TIA1 protects against tau-mediated neurodegeneration.  The mechanism through which TIA1 redn. protects against tauopathy, and whether TIA1 modulates the propagation of tau, are unknown.  Previous studies indicate that the protective effect of TIA1 depletion correlates with both the redn. of oligomeric tau and the redn. of pathol. TIA1 pos. tau inclusions.  In the current report, we used a novel tau propagation approach to test whether TIA1 is required for producing toxic tau oligomers and whether TIA1 redn. would provide protection against the spread of these oligomers.  The approach used young PS19 P301S tau mice at an age at which neurodegeneration would normally not yet occur and seeding oligomeric or fibrillar tau by injection into hippocampal CA1 region.  We find that propagation of exogenous tau oligomers (but not fibrils) across the brain drives neurodegeneration in this model.  We demonstrate that TIA1 redn. essentially brackets the pathophysiol. of tau, being required for the prodn. of tau oligomers, as well as regulating the response of neurons to propagated toxic tau oligomers.  These results indicate that RNA binding proteins modulate the pathophysiol. of tau at multiple levels and provide insights into possible therapeutic approaches to reduce the spread of neurodegeneration in tauopathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1CgtEBal-g7Vg90H21EOLACvtfcHk0ljFBr-nsV6BUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlCmtLjF&md5=ee7ea3652391188cc212876ecca80c2e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1007%2Fs00401-018-1937-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00401-018-1937-5%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DAsh%26aufirst%3DP.%2BE.%2BA.%26aulast%3DMaziuk%26aufirst%3DB.%2BF.%26aulast%3DBallance%26aufirst%3DH.%2BI.%26aulast%3DBoudeau%26aufirst%3DS.%26aulast%3DAbdullatif%26aufirst%3DA.%2BA.%26aulast%3DOrlando%26aufirst%3DM.%26aulast%3DPetrucelli%26aufirst%3DL.%26aulast%3DIkezu%26aufirst%3DT.%26aulast%3DWolozin%26aufirst%3DB.%26atitle%3DTIA1%2520regulates%2520the%2520generation%2520and%2520response%2520to%2520toxic%2520tau%2520oligomers%26jtitle%3DActa%2520Neuropathol.%26date%3D2019%26volume%3D137%26spage%3D259%26epage%3D277%26doi%3D10.1007%2Fs00401-018-1937-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kopeikina, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spires-Jones, T. L.</span></span> <span> </span><span class="NLM_article-title">Soluble forms of tau are toxic in Alzheimer’s disease</span>. <i>Transl. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.2478/s13380-012-0032-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.2478%2Fs13380-012-0032-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=23029602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BC2sris1Sntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=223-233&author=K.+J.+Kopeikinaauthor=B.+T.+Hymanauthor=T.+L.+Spires-Jones&title=Soluble+forms+of+tau+are+toxic+in+Alzheimer%E2%80%99s+disease&doi=10.2478%2Fs13380-012-0032-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble forms of tau are toxic in Alzheimer's disease</span></div><div class="casAuthors">Kopeikina Katherine J; Hyman Bradley T; Spires-Jones Tara L</div><div class="citationInfo"><span class="NLM_cas:title">Translational neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">223-233</span>
        ISSN:<span class="NLM_cas:issn">2081-3856</span>.
    </div><div class="casAbstract">Accumulation of neurofibrillary tangles (NFT), intracellular inclusions of fibrillar forms of tau, is a hallmark of Alzheimer Disease.  NFT have been considered causative of neuronal death, however, recent evidence challenges this idea.  Other species of tau, such as soluble misfolded, hyperphosphorylated, and mislocalized forms, are now being implicated as toxic.  Here we review the data supporting soluble tau as toxic to neurons and synapses in the brain and the implications of these data for development of therapeutic strategies for Alzheimer's disease and other tauopathies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSGcnTbQFS8PHWEEzDrymxmfW6udTcc2eYq4JVBxXWNrbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sris1Sntw%253D%253D&md5=4536d9d10f37dc659ba09d309a41152c</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.2478%2Fs13380-012-0032-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2478%252Fs13380-012-0032-y%26sid%3Dliteratum%253Aachs%26aulast%3DKopeikina%26aufirst%3DK.%2BJ.%26aulast%3DHyman%26aufirst%3DB.%2BT.%26aulast%3DSpires-Jones%26aufirst%3DT.%2BL.%26atitle%3DSoluble%2520forms%2520of%2520tau%2520are%2520toxic%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DTransl.%2520Neurosci.%26date%3D2012%26volume%3D3%26spage%3D223%26epage%3D233%26doi%3D10.2478%2Fs13380-012-0032-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jaworski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kügler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Leuven, F.</span></span> <span> </span><span class="NLM_article-title">Modeling of tau-mediated synaptic and neuronal degeneration in Alzheimer’s disease</span>. <i>Int. J. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_fpage">573138</span>, <span class="refDoi"> DOI: 10.4061/2010/573138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.4061%2F2010%2F573138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=20862366" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&pages=573138&author=T.+Jaworskiauthor=S.+K%C3%BCglerauthor=F.+Van+Leuven&title=Modeling+of+tau-mediated+synaptic+and+neuronal+degeneration+in+Alzheimer%E2%80%99s+disease&doi=10.4061%2F2010%2F573138"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.4061%2F2010%2F573138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4061%252F2010%252F573138%26sid%3Dliteratum%253Aachs%26aulast%3DJaworski%26aufirst%3DT.%26aulast%3DK%25C3%25BCgler%26aufirst%3DS.%26aulast%3DVan%2BLeuven%26aufirst%3DF.%26atitle%3DModeling%2520of%2520tau-mediated%2520synaptic%2520and%2520neuronal%2520degeneration%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DInt.%2520J.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2010%26spage%3D573138%26doi%3D10.4061%2F2010%2F573138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Twohig, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, H. M.</span></span> <span> </span><span class="NLM_article-title">α-synuclein in the pathophysiology of Alzheimer’s disease</span>. <i>Mol. Neurodegener.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">23</span>, <span class="refDoi"> DOI: 10.1186/s13024-019-0320-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1186%2Fs13024-019-0320-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=31186026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BB3M3lsVGksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=23&author=D.+Twohigauthor=H.+M.+Nielsen&title=%CE%B1-synuclein+in+the+pathophysiology+of+Alzheimer%E2%80%99s+disease&doi=10.1186%2Fs13024-019-0320-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">α-synuclein in the pathophysiology of Alzheimer's disease</span></div><div class="casAuthors">Twohig Daniel; Nielsen Henrietta M</div><div class="citationInfo"><span class="NLM_cas:title">Molecular neurodegeneration</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Alzheimer's disease (AD) afflicted brain is neuropathologically defined by extracellular amyloid-β (Aβ) plaques and intraneuronal neurofibrillary tangles composed of hyperphosphorylated tau protein.  However, accumulating evidence suggests that the presynaptic protein α-synuclein (αSyn), mainly associated with synucleinopathies like Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA), is involved in the pathophysiology of AD.  Lewy-related pathology (LRP), primarily comprised of αSyn, is present in a majority of autopsied AD brains, and higher levels of αSyn in the cerebrospinal fluid (CSF) of patients with mild cognitive impairment (MCI) and AD have been linked to cognitive decline.  Recent studies also suggest that the asymptomatic accumulation of Aβ plaques is associated with higher CSF αSyn levels in subjects at risk of sporadic AD and in individuals carrying autosomal dominant AD mutations.  Experimental evidence has further linked αSyn mainly to tau hyperphosphorylation, but also to the pathological actions of Aβ and the APOEε4 allele, the latter being a major genetic risk factor for both AD and DLB.  In this review, we provide a summary of the current evidence proposing an involvement of αSyn either as an active or passive player in the pathophysiological ensemble of AD, and furthermore describe in detail the current knowledge of αSyn structure and inferred function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJvFbWKSujKyO2kE7krGOBfW6udTcc2eYHYtgg_7Jxe7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3lsVGksA%253D%253D&md5=3dd826d6335e986ef9f4959ea82c0f64</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1186%2Fs13024-019-0320-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13024-019-0320-x%26sid%3Dliteratum%253Aachs%26aulast%3DTwohig%26aufirst%3DD.%26aulast%3DNielsen%26aufirst%3DH.%2BM.%26atitle%3D%25CE%25B1-synuclein%2520in%2520the%2520pathophysiology%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DMol.%2520Neurodegener.%26date%3D2019%26volume%3D14%26spage%3D23%26doi%3D10.1186%2Fs13024-019-0320-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sengupta, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilson, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayed, R.</span></span> <span> </span><span class="NLM_article-title">The role of amyloid-β oligomers in toxicity, propagation, and immunotherapy</span>. <i>EBioMedicine</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">42</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.1016/j.ebiom.2016.03.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.ebiom.2016.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=27211547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FisVKisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=42-49&author=U.+Senguptaauthor=A.+N.+Nilsonauthor=R.+Kayed&title=The+role+of+amyloid-%CE%B2+oligomers+in+toxicity%2C+propagation%2C+and+immunotherapy&doi=10.1016%2Fj.ebiom.2016.03.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy</span></div><div class="casAuthors">Sengupta Urmi; Nilson Ashley N; Kayed Rakez</div><div class="citationInfo"><span class="NLM_cas:title">EBioMedicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">42-49</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The incidence of Alzheimer's disease (AD) is growing every day and finding an effective treatment is becoming more vital.  Amyloid-β (Aβ) has been the focus of research for several decades.  The recent shift in the Aβ cascade hypothesis from all Aβ to small soluble oligomeric intermediates is directing the search for therapeutics towards the toxic mediators of the disease.  Targeting the most toxic oligomers may prove to be an effective treatment by preventing their spread.  Specific targeting of oligomers has been shown to protect cognition in rodent models.  Additionally, the heterogeneity of research on Aβ oligomers may seem contradictory until size and conformation are taken into account.  In this review, we will discuss Aβ oligomers and their toxicity in relation to size and conformation as well as their influence on inflammation and the potential of Aβ oligomer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmiQSE8_179zslzEEsg76ufW6udTcc2eYHYtgg_7Jxe7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FisVKisA%253D%253D&md5=5b2a9f3283846038e653cca6731fa90f</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.ebiom.2016.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ebiom.2016.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DSengupta%26aufirst%3DU.%26aulast%3DNilson%26aufirst%3DA.%2BN.%26aulast%3DKayed%26aufirst%3DR.%26atitle%3DThe%2520role%2520of%2520amyloid-%25CE%25B2%2520oligomers%2520in%2520toxicity%252C%2520propagation%252C%2520and%2520immunotherapy%26jtitle%3DEBioMedicine%26date%3D2016%26volume%3D6%26spage%3D42%26epage%3D49%26doi%3D10.1016%2Fj.ebiom.2016.03.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bousset, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otzen, D. E.</span></span> <span> </span><span class="NLM_article-title">α-synuclein oligomers and fibrils: A spectrum of species, a spectrum of toxicities</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">522</span>– <span class="NLM_lpage">534</span>, <span class="refDoi"> DOI: 10.1111/jnc.14808</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1111%2Fjnc.14808" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=31254394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFSgsrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2019&pages=522-534&author=P.+Alamauthor=L.+Boussetauthor=R.+Melkiauthor=D.+E.+Otzen&title=%CE%B1-synuclein+oligomers+and+fibrils%3A+A+spectrum+of+species%2C+a+spectrum+of+toxicities&doi=10.1111%2Fjnc.14808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">α-synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities</span></div><div class="casAuthors">Alam, Parvez; Bousset, Luc; Melki, Ronald; Otzen, Daniel E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">522-534</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  This review article provides an overview of the different species that α-synuclein aggregates can populate.  It also attempts to reconcile conflicting views regarding the cytotoxic roles of oligomers vs. fibrils. α-synuclein, while highly dynamic in the monomeric state, can access a large no. of different assembly states.  Depending on assembly conditions, these states can interconvert over different timescales.  The fibrillar state is the most thermodynamically favored due to the many stabilizing interactions formed between each monomeric unit, but different fibrillar types form at different rates.  The end distribution is likely to reflect kinetic partitioning as much as thermodn. equilibra.  In addn., metastable oligomeric species, some of which are on-pathway and others off-pathway, can be populated for remarkably long periods of time.  Chem. modifications (phosphorylation, oxidn., covalent links to ligands, etc.) perturb these phys. interconversions and invariably destabilize the fibrillar state, leading to small prefibrillar assemblies which can coalesce into amorphous states.  Both oligomeric and fibrillar species have been shown to be cytotoxic although firm conclusions require very careful evaluation of particle concns. and is complicated by the great variety and heterogeneity of different exptl. obsd. states.  The mechanistic relationship between oligomers and fibrils remains to be clarified, both in terms of assembly of oligomers into fibrils and potential dissoln. of fibrils into oligomers.  While oligomers are possibly implicated in the collapse of neuronal homeostasis, the fibrillar state(s) appears to be the most efficient at propagating itself both in vitro and in vivo, pointing to crit. roles for multiple different aggregate species in the progression of Parkinson's disease ().</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq19WdmbXPwT7Vg90H21EOLACvtfcHk0lh_M8WTAgVpQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFSgsrnF&md5=8e80c1d5f545bb95f162791356ad7e35</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1111%2Fjnc.14808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjnc.14808%26sid%3Dliteratum%253Aachs%26aulast%3DAlam%26aufirst%3DP.%26aulast%3DBousset%26aufirst%3DL.%26aulast%3DMelki%26aufirst%3DR.%26aulast%3DOtzen%26aufirst%3DD.%2BE.%26atitle%3D%25CE%25B1-synuclein%2520oligomers%2520and%2520fibrils%253A%2520A%2520spectrum%2520of%2520species%252C%2520a%2520spectrum%2520of%2520toxicities%26jtitle%3DJ.%2520Neurochem.%26date%3D2019%26volume%3D150%26spage%3D522%26epage%3D534%26doi%3D10.1111%2Fjnc.14808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thal, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rüb, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Günzel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zedlick, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schober, R.</span></span> <span> </span><span class="NLM_article-title">Alzheimer-related tau-pathology in the perforant path target zone and in the hippocampal stratum oriens and radiatum correlates with onset and degree of dementia</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">98</span>– <span class="NLM_lpage">110</span>, <span class="refDoi"> DOI: 10.1006/exnr.2000.7380</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1006%2Fexnr.2000.7380" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10785448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD3cXislCntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2000&pages=98-110&author=D.+R.+Thalauthor=M.+Holzerauthor=U.+R%C3%BCbauthor=G.+Waldmannauthor=S.+G%C3%BCnzelauthor=D.+Zedlickauthor=R.+Schober&title=Alzheimer-related+tau-pathology+in+the+perforant+path+target+zone+and+in+the+hippocampal+stratum+oriens+and+radiatum+correlates+with+onset+and+degree+of+dementia&doi=10.1006%2Fexnr.2000.7380"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Alzheimer-related τ-pathology in the perforant path target zone and in the hippocampal stratum oriens and radiatum correlates with onset and degree of dementia</span></div><div class="casAuthors">Thal, Dietmar Rudolf; Holzer, Max; Rub, Udo; Waldmann, Guido; Gunzel, Steffen; Zedlick, Dyrk; Schober, Ralf</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">98-110</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Abnormal phosphorylation of the τ-protein is regarded as a crucial step in the formation of neurofibrillary tangles in the neuronal cell body and neuropil threads in dendrites.  The authors studied the effects of τ-pathol. on the clin. expression of dementia in 106 autopsy cases in the entorhinal region, the hippocampal stratum oriens, the stratum radiatum, and the perforant path target zone.  The first cytoskeletal lesions were located in the perikarya and dendrites of the pre-α cells of the transentorhinal and entorhinal region.  Next, abnormally phosphorylated τ-protein (PHF-τ) was found in the neuropil of the CA1-subiculum region.  Thereafter, the stratum radiatum and stratum oriens began to be involved in PHF-τ pathol. in Braak stage II.  In the Braak stages IV and V, the stratum radiatum was completely involved, the stratum oriens increasingly so.  Beginning in Braak stage III, cases having PHF-τ pathol. in the perforant path target zone of the outer mol. layer of the dentate gyrus were noted.  The increase of this pathol. with ever greater involvement on the part of the entorhinohippocampal circuit correlated not only with the Braak stages and with the neurochem. detd. hippocampal content of PHF-τ but also with the degree of dementia as defined by the clin. dementia rating (CDR) scale.  The affection of the stratum oriens in combination with PHF-τ pathol. in the stratum radiatum and in the outer mol. layer of the dentate gyrus was encountered almost exclusively in demented individuals (CDR 1-3).  Thus, axonal PHF-τ pathol. in hippocampal pathways is presumably crit. for the clin. expression of dementia and may constitute an anatomical substrate of clin. verifiable memory dysfunction in Alzheimer's disease.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7MnZIS60L_LVg90H21EOLACvtfcHk0lh_M8WTAgVpQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXislCntr4%253D&md5=d01e074dd528ef1dbcce4f08a9abe7f4</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1006%2Fexnr.2000.7380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fexnr.2000.7380%26sid%3Dliteratum%253Aachs%26aulast%3DThal%26aufirst%3DD.%2BR.%26aulast%3DHolzer%26aufirst%3DM.%26aulast%3DR%25C3%25BCb%26aufirst%3DU.%26aulast%3DWaldmann%26aufirst%3DG.%26aulast%3DG%25C3%25BCnzel%26aufirst%3DS.%26aulast%3DZedlick%26aufirst%3DD.%26aulast%3DSchober%26aufirst%3DR.%26atitle%3DAlzheimer-related%2520tau-pathology%2520in%2520the%2520perforant%2520path%2520target%2520zone%2520and%2520in%2520the%2520hippocampal%2520stratum%2520oriens%2520and%2520radiatum%2520correlates%2520with%2520onset%2520and%2520degree%2520of%2520dementia%26jtitle%3DExp.%2520Neurol.%26date%3D2000%26volume%3D163%26spage%3D98%26epage%3D110%26doi%3D10.1006%2Fexnr.2000.7380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goedert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klug, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowther, R. A.</span></span> <span> </span><span class="NLM_article-title">Tau protein, the paired helical filament and Alzheimer’s disease</span>. <i>J. Alzheimer's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">207</span>, <span class="refDoi"> DOI: 10.3233/JAD-2006-9S323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.3233%2FJAD-2006-9S323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=16914859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD28XotFKktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2006&pages=195-207&author=M.+Goedertauthor=A.+Klugauthor=R.+A.+Crowther&title=Tau+protein%2C+the+paired+helical+filament+and+Alzheimer%E2%80%99s+disease&doi=10.3233%2FJAD-2006-9S323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Tau protein, the paired helical filament and Alzheimer's disease</span></div><div class="casAuthors">Goedert, Michel; Klug, Aaron; Crowther, R. Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">Suppl. 3</span>),
    <span class="NLM_cas:pages">195-207</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">A review.  In 1906, Alzheimer described the clin. and neuropathol. characteristics of the disease that was subsequently named after him.  Although the paired helical filament was identified as the major component of the neurofibrillary pathol. of Alzheimer's disease in 1963, its mol. compn. was only uncovered in the 1980s.  In 1988, work at the MRC Lab. of Mol. Biol. in Cambridge (UK) provided direct proof that tau protein is an integral component of the paired helical filament.  The paper highlighted here [Goedert M., Wischik C.M., Crowther R.A., Walker J.E. and Klug A. (1988) Cloning and sequencing of a core protein of the paired helical filament of Alzheimer disease: Identification as the microtubule-assocd. protein tau. Proc. Natl. Acad. Sci. USA 85, 4051-4055] also reported the first sequence of a human tau isoform and paved the way for the identification of the six brain tau isoforms that are expressed by alternative mRNA splicing from a single gene.  By the early 1990s, it was clear that tau protein is the major component of the paired helical filament and that the latter is made of all six tau isoforms, each full-length and hyperphosphorylated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGray90MZn-vsrVg90H21EOLACvtfcHk0liJv1UQ3o-PBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotFKktb8%253D&md5=771b173ae0abf27ecca786094c932931</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.3233%2FJAD-2006-9S323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-2006-9S323%26sid%3Dliteratum%253Aachs%26aulast%3DGoedert%26aufirst%3DM.%26aulast%3DKlug%26aufirst%3DA.%26aulast%3DCrowther%26aufirst%3DR.%2BA.%26atitle%3DTau%2520protein%252C%2520the%2520paired%2520helical%2520filament%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Alzheimer%2527s%2520Dis.%26date%3D2006%26volume%3D9%26spage%3D195%26epage%3D207%26doi%3D10.3233%2FJAD-2006-9S323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knowles, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vendruscolo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobson, C. M.</span></span> <span> </span><span class="NLM_article-title">The amyloid state and its association with protein misfolding diseases</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">384</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.1038/nrm3810</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2Fnrm3810" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=24854788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosV2lurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=384-396&author=T.+P.+Knowlesauthor=M.+Vendruscoloauthor=C.+M.+Dobson&title=The+amyloid+state+and+its+association+with+protein+misfolding+diseases&doi=10.1038%2Fnrm3810"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">The amyloid state and its association with protein misfolding diseases</span></div><div class="casAuthors">Knowles, Tuomas P. J.; Vendruscolo, Michele; Dobson, Christopher M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">384-396</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The phenomenon of protein aggregation and amyloid formation has become the subject of rapidly increasing research activities across a wide range of scientific disciplines.  Such activities have been stimulated by the assocn. of amyloid deposition with a range of debilitating medical disorders, from Alzheimer's disease to type II diabetes, many of which are major threats to human health and welfare in the modern world.  It has become clear, however, that the ability to form the amyloid state is more general than previously imagined, and that its study can provide unique insights into the nature of the functional forms of peptides and proteins, as well as understanding the means by which protein homeostasis can be maintained and protein metastasis avoided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryuIN_Qt8Fa7Vg90H21EOLACvtfcHk0liJv1UQ3o-PBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosV2lurk%253D&md5=68e2e4d963646f1daca50ab3288f5a37</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnrm3810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3810%26sid%3Dliteratum%253Aachs%26aulast%3DKnowles%26aufirst%3DT.%2BP.%26aulast%3DVendruscolo%26aufirst%3DM.%26aulast%3DDobson%26aufirst%3DC.%2BM.%26atitle%3DThe%2520amyloid%2520state%2520and%2520its%2520association%2520with%2520protein%2520misfolding%2520diseases%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2014%26volume%3D15%26spage%3D384%26epage%3D396%26doi%3D10.1038%2Fnrm3810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajasekhar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakrabarti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindaraju, T.</span></span> <span> </span><span class="NLM_article-title">Function and toxicity of amyloid beta and recent therapeutic interventions targeting amyloid beta in Alzheimer’s disease</span>. <i>Chem. Commun. (Cambridge, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">13434</span>– <span class="NLM_lpage">13450</span>, <span class="refDoi"> DOI: 10.1039/C5CC05264E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1039%2FC5CC05264E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=26247608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1KmtbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=13434-13450&author=K.+Rajasekharauthor=M.+Chakrabartiauthor=T.+Govindaraju&title=Function+and+toxicity+of+amyloid+beta+and+recent+therapeutic+interventions+targeting+amyloid+beta+in+Alzheimer%E2%80%99s+disease&doi=10.1039%2FC5CC05264E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Function and toxicity of amyloid beta and recent therapeutic interventions targeting amyloid beta in Alzheimer's disease</span></div><div class="casAuthors">Rajasekhar, K.; Chakrabarti, Malabika; Govindaraju, T.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">70</span>),
    <span class="NLM_cas:pages">13434-13450</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Amyloidogenesis has been implicated in a broad spectrum of diseases in which amyloid protein is invariably misfolded and deposited in cells and organs.  Alzheimer's disease is one of the most devastating ailments among amyloidogenesis induced dementia.  The amyloid beta (Aβ) peptide derived from amyloid precursor protein (APP) is misfolded and deposited as plaques in the brain, which are said to be the hallmark of Alzheimer's disease.  In normal brains physiol. concn. of the Aβ peptide has been indicated to be involved in modulating neurogenesis and synaptic plasticity.  However, excess Aβ prodn., its aggregation and deposition deleteriously affect a large no. of biol. important pathways leading to neuronal cell death.  Targeting Aβ prodn., Aβ aggregation or its clearance from the brain has been an active area of research for preventing or curing AD.  Our Feature Article intends to detail the aggregation mechanism, the physiol. role of the Aβ peptide, elaborate its toxic effects, and outline the different classes of mols. designed in the last two years to inhibit amyloidogenic APP processing, Aβ oligomerization or fibrillogenesis and to modulate different pathways for active clearance of Aβ from the brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTO9UD6e6Hh7Vg90H21EOLACvtfcHk0liJv1UQ3o-PBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1KmtbzP&md5=8a7b765f1d2f7bdda5c3f8bbba831452</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1039%2FC5CC05264E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5CC05264E%26sid%3Dliteratum%253Aachs%26aulast%3DRajasekhar%26aufirst%3DK.%26aulast%3DChakrabarti%26aufirst%3DM.%26aulast%3DGovindaraju%26aufirst%3DT.%26atitle%3DFunction%2520and%2520toxicity%2520of%2520amyloid%2520beta%2520and%2520recent%2520therapeutic%2520interventions%2520targeting%2520amyloid%2520beta%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DChem.%2520Commun.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D2015%26volume%3D51%26spage%3D13434%26epage%3D13450%26doi%3D10.1039%2FC5CC05264E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Canter, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, L. H.</span></span> <span> </span><span class="NLM_article-title">The road to restoring neural circuits for the treatment of Alzheimer’s disease</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>539</i></span>,  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1038/nature20412</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2Fnature20412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=27830780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BC2snkslKhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=539&publication_year=2016&pages=187-196&author=R.+G.+Canterauthor=J.+Penneyauthor=L.+H.+Tsai&title=The+road+to+restoring+neural+circuits+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1038%2Fnature20412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The road to restoring neural circuits for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Canter Rebecca G; Penney Jay; Tsai Li-Huei; Tsai Li-Huei</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">539</span>
        (<span class="NLM_cas:issue">7628</span>),
    <span class="NLM_cas:pages">187-196</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Alzheimer's disease is a progressive loss of memory and cognition, for which there is no cure.  Although genetic studies initially suggested a primary role for amyloid-in Alzheimer's disease, treatment strategies targeted at reducing amyloid-have failed to reverse cognitive symptoms.  These clinical findings suggest that cognitive decline is the result of a complex pathophysiology and that targeting amyloid-alone may not be sufficient to treat Alzheimer's disease.  Instead, a broad outlook on neural-circuit-damaging processes may yield insights into new therapeutic strategies for curing memory loss in the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHFxchnTOjw90Q2ypr7jHkfW6udTcc2ea17MIduCyi07ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2snkslKhtg%253D%253D&md5=508cffcf1281908d3f030c7a14468109</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fnature20412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature20412%26sid%3Dliteratum%253Aachs%26aulast%3DCanter%26aufirst%3DR.%2BG.%26aulast%3DPenney%26aufirst%3DJ.%26aulast%3DTsai%26aufirst%3DL.%2BH.%26atitle%3DThe%2520road%2520to%2520restoring%2520neural%2520circuits%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNature%26date%3D2016%26volume%3D539%26spage%3D187%26epage%3D196%26doi%3D10.1038%2Fnature20412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheignon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefont-Rousselot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hureau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collin, F.</span></span> <span> </span><span class="NLM_article-title">Oxidative stress and the amyloid beta peptide in Alzheimer’s disease</span>. <i>Redox Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">450</span>– <span class="NLM_lpage">464</span>, <span class="refDoi"> DOI: 10.1016/j.redox.2017.10.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.redox.2017.10.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=29080524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslans73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=450-464&author=C.+Cheignonauthor=M.+Tomasauthor=D.+Bonnefont-Rousselotauthor=P.+Fallerauthor=C.+Hureauauthor=F.+Collin&title=Oxidative+stress+and+the+amyloid+beta+peptide+in+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.redox.2017.10.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative stress and the amyloid beta peptide in Alzheimer's disease</span></div><div class="casAuthors">Cheignon, C.; Tomas, M.; Bonnefont-Rousselot, D.; Faller, P.; Hureau, C.; Collin, F.</div><div class="citationInfo"><span class="NLM_cas:title">Redox Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">450-464</span>CODEN:
                <span class="NLM_cas:coden">RBEIB3</span>;
        ISSN:<span class="NLM_cas:issn">2213-2317</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Oxidative stress is known to play an important role in the pathogenesis of a no. of diseases.  In particular, it is linked to the etiol. of Alzheimer's disease (AD), an age-related neurodegenerative disease and the most common cause of dementia in the elderly.  Histopathol. hallmarks of AD are intracellular neurofibrillary tangles and extracellular formation of senile plaques composed of the amyloid-beta peptide (Aβ) in aggregated form along with metal-ions such as copper, iron or zinc.  Redox active metal ions, as for example copper, can catalyze the prodn. of Reactive Oxygen Species (ROS) when bound to the amyloid-β (Aβ).  The ROS thus produced, in particular the hydroxyl radical which is the most reactive one, may contribute to oxidative damage on both the Aβ peptide itself and on surrounding mol. (proteins, lipids, ...).  This review highlights the existing link between oxidative stress and AD, and the consequences towards the Aβ peptide and surrounding mols. in terms of oxidative damage.  In addn., the implication of metal ions in AD, their interaction with the Aβ peptide and redox properties leading to ROS prodn. are discussed, along with both in vitro and in vivo oxidn. of the Aβ peptide, at the mol. level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAsJM-PSPjNrVg90H21EOLACvtfcHk0lgxIPxEGfrigQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslans73L&md5=f61600ab9e355cd49838961d26de5c4f</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.redox.2017.10.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.redox.2017.10.014%26sid%3Dliteratum%253Aachs%26aulast%3DCheignon%26aufirst%3DC.%26aulast%3DTomas%26aufirst%3DM.%26aulast%3DBonnefont-Rousselot%26aufirst%3DD.%26aulast%3DFaller%26aufirst%3DP.%26aulast%3DHureau%26aufirst%3DC.%26aulast%3DCollin%26aufirst%3DF.%26atitle%3DOxidative%2520stress%2520and%2520the%2520amyloid%2520beta%2520peptide%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DRedox%2520Biol.%26date%3D2018%26volume%3D14%26spage%3D450%26epage%3D464%26doi%3D10.1016%2Fj.redox.2017.10.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, X.</span></span> <span> </span><span class="NLM_article-title">New insights in amyloid beta interactions with human telomerase</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">1213</span>– <span class="NLM_lpage">1219</span>, <span class="refDoi"> DOI: 10.1021/ja511030s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja511030s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltVWrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=1213-1219&author=J.+Wangauthor=C.+Zhaoauthor=A.+Zhaoauthor=M.+Liauthor=J.+Renauthor=X.+Qu&title=New+insights+in+amyloid+beta+interactions+with+human+telomerase&doi=10.1021%2Fja511030s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">New Insights in Amyloid Beta Interactions with Human Telomerase</span></div><div class="casAuthors">Wang, Jiasi; Zhao, Chuanqi; Zhao, Andong; Li, Meng; Ren, Jinsong; Qu, Xiaogang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1213-1219</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">It is well-known that aging is the most risk factor for Alzheimer's disease (AD).  Recent studies have demonstrated that human telomerase is assocd. with pathol. mechanisms of AD.  In view of the central role of telomere and telomerase in the aging process, herein we found that the aggregated form Aβ (Aβ1-40 and Aβ1-42), not Aβ monomer, could inhibit telomerase activity both in vitro and in living cells.  The β-sheet structures were essential for Aβ-induced telomerase inhibition.  Further studies indicated Aβ oligomers inhibited telomerase activity through binding to DNA·RNA hybrid formed by telomeric DNA and the RNA template of telomerase, then blocking telomerase elongation of telomeric DNA.  We also identified that intracellular Aβ localized at telomere, and induced cell senescence and telomere shortening.  These results indicate that Aβ oligomers can be potential natural inhibitors of telomerase and that inhibition of telomerase activity may be one of the factors for Aβ-induced cytotoxicity.  Our work may offer a new clue to a better understanding of aging and AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpotcUOPckUfLVg90H21EOLACvtfcHk0lgxIPxEGfrigQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltVWrtg%253D%253D&md5=1d867014e443b42d27ae739137909ecc</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fja511030s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja511030s%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DQu%26aufirst%3DX.%26atitle%3DNew%2520insights%2520in%2520amyloid%2520beta%2520interactions%2520with%2520human%2520telomerase%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26spage%3D1213%26epage%3D1219%26doi%3D10.1021%2Fja511030s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brunden, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojanowski, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, V. M.</span></span> <span> </span><span class="NLM_article-title">Advances in tau-focused drug discovery for Alzheimer’s disease and related tauopathies</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">783</span>– <span class="NLM_lpage">793</span>, <span class="refDoi"> DOI: 10.1038/nrd2959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2Fnrd2959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=19794442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2kurrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=783-793&author=K.+R.+Brundenauthor=J.+Q.+Trojanowskiauthor=V.+M.+Lee&title=Advances+in+tau-focused+drug+discovery+for+Alzheimer%E2%80%99s+disease+and+related+tauopathies&doi=10.1038%2Fnrd2959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies</span></div><div class="casAuthors">Brunden, Kurt R.; Trojanowski, John Q.; Lee, Virginia M.-Y.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">783-793</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Neuronal inclusions comprised of the microtubule-assocd. protein tau are found in numerous neurodegenerative diseases, commonly known as tauopathies.  In Alzheimer's disease - the most prevalent tauopathy - misfolded tau is probably a key pathol. agent.  The recent failure of amyloid-β-targeted therapeutics in Phase III clin. trials suggests that it is timely and prudent to consider alternative drug discovery strategies for Alzheimer's disease.  Here, we focus on strategies directed at reducing misfolded tau and compensating for the loss of normal tau function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeWhB7oau9ALVg90H21EOLACvtfcHk0lgxIPxEGfrigQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2kurrN&md5=6178c6f0e9a83c31a0e7f9dd8dae79d8</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fnrd2959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2959%26sid%3Dliteratum%253Aachs%26aulast%3DBrunden%26aufirst%3DK.%2BR.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26aulast%3DLee%26aufirst%3DV.%2BM.%26atitle%3DAdvances%2520in%2520tau-focused%2520drug%2520discovery%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%2520and%2520related%2520tauopathies%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D783%26epage%3D793%26doi%3D10.1038%2Fnrd2959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hutton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lendon, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froelich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houlden, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickering-Brown, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraverty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grover, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lincoln, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Graaff, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wauters, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Baren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillebrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joosse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowotny, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojanowski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lannfelt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neystat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dark, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tannenberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodd, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schofield, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreadis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snowden, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craufurd, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neary, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oostra, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goate, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Swieten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heutink, P.</span></span> <span> </span><span class="NLM_article-title">Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>393</i></span>,  <span class="NLM_fpage">702</span>– <span class="NLM_lpage">705</span>, <span class="refDoi"> DOI: 10.1038/31508</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2F31508" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=9641683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADyaK1cXktVyqsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=393&publication_year=1998&pages=702-705&author=M.+Huttonauthor=C.+L.+Lendonauthor=P.+Rizzuauthor=M.+Bakerauthor=S.+Froelichauthor=H.+Houldenauthor=S.+Pickering-Brownauthor=S.+Chakravertyauthor=A.+Isaacsauthor=A.+Groverauthor=J.+Hackettauthor=J.+Adamsonauthor=S.+Lincolnauthor=D.+Dicksonauthor=P.+Daviesauthor=R.+C.+Petersenauthor=M.+Stevensauthor=E.+de+Graaffauthor=E.+Wautersauthor=J.+van+Barenauthor=M.+Hillebrandauthor=M.+Joosseauthor=J.+M.+Kwonauthor=P.+Nowotnyauthor=L.+K.+Cheauthor=J.+Nortonauthor=J.+C.+Morrisauthor=L.+A.+Reedauthor=J.+Trojanowskiauthor=H.+Basunauthor=L.+Lannfeltauthor=M.+Neystatauthor=S.+Fahnauthor=F.+Darkauthor=T.+Tannenbergauthor=P.+R.+Doddauthor=N.+Haywardauthor=J.+B.+Kwokauthor=P.+R.+Schofieldauthor=A.+Andreadisauthor=J.+Snowdenauthor=D.+Craufurdauthor=D.+Nearyauthor=F.+Owenauthor=B.+A.+Oostraauthor=J.+Hardyauthor=A.+Goateauthor=J.+van+Swietenauthor=D.+Mannauthor=T.+Lynchauthor=P.+Heutink&title=Association+of+missense+and+5%E2%80%B2-splice-site+mutations+in+tau+with+the+inherited+dementia+FTDP-17&doi=10.1038%2F31508"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17</span></div><div class="casAuthors">Hutton, Mike; Lendon, Corinne L.; Rizzu, Patrizia; Baker, Matt; Froelich, Susanne; Houlden, Henry; Pickering-Brown, Stuart; Chakraverty, Sumi; Isaacs, Adrian; Grover, Andrew; Hackett, Jennifer; Adamson, Jennifer; Lincoln, Sarah; Dickson, Dennis; Davies, Peter; Petersen, Ronald C.; Stevens, Martijn; de Graaff, Esther; Wauters, Erwin; van Baren, Jeltje; Hillebrand, Marcel; Joosse, Marijke; Kwon, Jennifer M.; Nowotny, Petra; Che, Lien Kuei; Norton, Joanne; Morris, John C.; Reed, Lee A.; Trojanowski, John; Basun, Hans; Lannfelt, Lars; Neystat, Michael; Fahn, Stanley; Dark, Francis; Tannenberg, Tony; Dodd, Peter R.; Hayward, Nick; Kwok, John B. J.; Schofield, Peter R.; Andreadis, Athena; Snowden, Julie; Craufurd, David; Neary, David; Owen, Frank; Oostra, Ben A.; Hardy, John; Goate, Alison; van Swieten, John; Mann, David; Lynch, Timothy; Heutink, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">393</span>
        (<span class="NLM_cas:issue">6686</span>),
    <span class="NLM_cas:pages">702-705</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Thirteen families have been described with an autosomal dominantly inherited dementia named frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), historically termed Pick's disease.  Most FTDP-17 cases show neuronal and/or glial inclusions that stain pos. with antibodies raised against the microtubule-assocd. protein Tau, although the Tau pathol. varies considerably in both its quantity (or severity) and characteristics.  Previous studies have mapped the FTDP-17 locus to a 2-centimorgan region on chromosome 17q21.11; the tau gene also lies within this region.  We have now sequenced tau in FTDP-17 families and identified three missense mutations (G272V, P301L and R406W) and three mutations in the 5' splice site of exon 10.  The splice-site mutations all destabilize a potential stem-loop structure which is probably involved in regulating the alternative splicing of exon 10.  This causes more frequent usage of the 5' splice site an increased proportion of tau transcripts that include exon 10.  The increase in exon 10+ mRNA will increase the proportion of Tau contg. four microtubule-binding repeats, which is consistent with the neuropathol. described in several families with FTDP-17.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmDAkDTiFru7Vg90H21EOLACvtfcHk0liOusU60aXxeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXktVyqsr0%253D&md5=8ec0725fa99708a52022b404dc97a72f</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2F31508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F31508%26sid%3Dliteratum%253Aachs%26aulast%3DHutton%26aufirst%3DM.%26aulast%3DLendon%26aufirst%3DC.%2BL.%26aulast%3DRizzu%26aufirst%3DP.%26aulast%3DBaker%26aufirst%3DM.%26aulast%3DFroelich%26aufirst%3DS.%26aulast%3DHoulden%26aufirst%3DH.%26aulast%3DPickering-Brown%26aufirst%3DS.%26aulast%3DChakraverty%26aufirst%3DS.%26aulast%3DIsaacs%26aufirst%3DA.%26aulast%3DGrover%26aufirst%3DA.%26aulast%3DHackett%26aufirst%3DJ.%26aulast%3DAdamson%26aufirst%3DJ.%26aulast%3DLincoln%26aufirst%3DS.%26aulast%3DDickson%26aufirst%3DD.%26aulast%3DDavies%26aufirst%3DP.%26aulast%3DPetersen%26aufirst%3DR.%2BC.%26aulast%3DStevens%26aufirst%3DM.%26aulast%3Dde%2BGraaff%26aufirst%3DE.%26aulast%3DWauters%26aufirst%3DE.%26aulast%3Dvan%2BBaren%26aufirst%3DJ.%26aulast%3DHillebrand%26aufirst%3DM.%26aulast%3DJoosse%26aufirst%3DM.%26aulast%3DKwon%26aufirst%3DJ.%2BM.%26aulast%3DNowotny%26aufirst%3DP.%26aulast%3DChe%26aufirst%3DL.%2BK.%26aulast%3DNorton%26aufirst%3DJ.%26aulast%3DMorris%26aufirst%3DJ.%2BC.%26aulast%3DReed%26aufirst%3DL.%2BA.%26aulast%3DTrojanowski%26aufirst%3DJ.%26aulast%3DBasun%26aufirst%3DH.%26aulast%3DLannfelt%26aufirst%3DL.%26aulast%3DNeystat%26aufirst%3DM.%26aulast%3DFahn%26aufirst%3DS.%26aulast%3DDark%26aufirst%3DF.%26aulast%3DTannenberg%26aufirst%3DT.%26aulast%3DDodd%26aufirst%3DP.%2BR.%26aulast%3DHayward%26aufirst%3DN.%26aulast%3DKwok%26aufirst%3DJ.%2BB.%26aulast%3DSchofield%26aufirst%3DP.%2BR.%26aulast%3DAndreadis%26aufirst%3DA.%26aulast%3DSnowden%26aufirst%3DJ.%26aulast%3DCraufurd%26aufirst%3DD.%26aulast%3DNeary%26aufirst%3DD.%26aulast%3DOwen%26aufirst%3DF.%26aulast%3DOostra%26aufirst%3DB.%2BA.%26aulast%3DHardy%26aufirst%3DJ.%26aulast%3DGoate%26aufirst%3DA.%26aulast%3Dvan%2BSwieten%26aufirst%3DJ.%26aulast%3DMann%26aufirst%3DD.%26aulast%3DLynch%26aufirst%3DT.%26aulast%3DHeutink%26aufirst%3DP.%26atitle%3DAssociation%2520of%2520missense%2520and%25205%25E2%2580%25B2-splice-site%2520mutations%2520in%2520tau%2520with%2520the%2520inherited%2520dementia%2520FTDP-17%26jtitle%3DNature%26date%3D1998%26volume%3D393%26spage%3D702%26epage%3D705%26doi%3D10.1038%2F31508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brion, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heraud, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, K.</span></span> <span> </span><span class="NLM_article-title">Modulation of tau pathology in tau transgenic models</span>. <i>Biochem. Soc. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">996</span>– <span class="NLM_lpage">1000</span>, <span class="refDoi"> DOI: 10.1042/BST0380996</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1042%2FBST0380996" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=20658992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlyls7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=996-1000&author=J.+P.+Brionauthor=K.+Andoauthor=C.+Heraudauthor=K.+Leroy&title=Modulation+of+tau+pathology+in+tau+transgenic+models&doi=10.1042%2FBST0380996"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of tau pathology in tau transgenic models</span></div><div class="casAuthors">Brion, Jean-Pierre; Ando, Kunie; Heraud, Celine; Leroy, Karelle</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">996-1000</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  NFTs (neurofibrillary tangles) in Alzheimer's disease and in tauopathies are hallmark neuropathol. lesions whose relationship with neuronal dysfunction, neuronal death and with other lesions [such as Aβ (amyloid β-peptide) pathol.] are still imperfectly understood.  Many transgenic mice overexpressing wild-type or mutant tau proteins have been generated to investigate the physiopathol. of tauopathies.  Most of the mice overexpressing wild-type tau do not develop NFTs, but can develop a severe axonopathy, whereas overexpression of mutant tau leads to NFT formation, synaptic loss and neuronal death in several models.  The assocn. between neuronal death and NFTs has, however, been challenged in some models showing a dissocn. between tau aggregation and tau toxicity.  Cross-breeding of mice developing NFTs with mice developing Aβ deposits increases NFT pathol., highlighting the relationship between tau and amyloid pathol.  On the other hand, tau expression seems to be necessary for expression of a pathol. phenotype assocd. with amyloid pathol.  These findings suggest that there is a bilateral cross-talk between Aβ and tau pathol.  These observations are discussed by the presentation of some relevant models developed recently.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrl_dl5emyJlLVg90H21EOLACvtfcHk0liOusU60aXxeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlyls7s%253D&md5=62f579a4e36ca8169802eb415ddf54a7</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1042%2FBST0380996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST0380996%26sid%3Dliteratum%253Aachs%26aulast%3DBrion%26aufirst%3DJ.%2BP.%26aulast%3DAndo%26aufirst%3DK.%26aulast%3DHeraud%26aufirst%3DC.%26aulast%3DLeroy%26aufirst%3DK.%26atitle%3DModulation%2520of%2520tau%2520pathology%2520in%2520tau%2520transgenic%2520models%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2010%26volume%3D38%26spage%3D996%26epage%3D1000%26doi%3D10.1042%2FBST0380996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Congdon, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigurdsson, E. M.</span></span> <span> </span><span class="NLM_article-title">Tau-targeting therapies for Alzheimer disease</span>. <i>Nat. Rev. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">399</span>– <span class="NLM_lpage">415</span>, <span class="refDoi"> DOI: 10.1038/s41582-018-0013-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2Fs41582-018-0013-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=29895964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFaks73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=399-415&author=E.+E.+Congdonauthor=E.+M.+Sigurdsson&title=Tau-targeting+therapies+for+Alzheimer+disease&doi=10.1038%2Fs41582-018-0013-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Tau-targeting therapies for Alzheimer disease</span></div><div class="casAuthors">Congdon, Erin E.; Sigurdsson, Einar M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neurology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">399-415</span>CODEN:
                <span class="NLM_cas:coden">NRNACP</span>;
        ISSN:<span class="NLM_cas:issn">1759-4758</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Alzheimer disease (AD) is the most common form of dementia.  Pathol., AD is characterized by amyloid plaques and neurofibrillary tangles in the brain, with assocd. loss of synapses and neurons, resulting in cognitive deficits and eventually dementia.  Amyloid-β (Aβ) peptide and tau protein are the primary components of the plaques and tangles, resp.  In the decades since Aβ and tau were identified, development of therapies for AD has primarily focused on Aβ, but tau has received more attention in recent years, in part because of the failure of various Aβ-targeting treatments in clin. trials.  In this article, we review the current status of tau-targeting therapies for AD.  Initially, potential anti-tau therapies were based mainly on inhibition of kinases or tau aggregation, or on stabilization of microtubules, but most of these approaches have been discontinued because of toxicity and/or lack of efficacy.  Currently, the majority of tau-targeting therapies in clin. trials are immunotherapies, which have shown promise in numerous preclin. studies.  Given that tau pathol. correlates better with cognitive impairments than do Aβ lesions, targeting of tau is expected to be more effective than Aβ clearance once the clin. symptoms are evident.  With future improvements in diagnostics, these two hallmarks of the disease might be targeted prophylactically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT0IYIr5ElmbVg90H21EOLACvtfcHk0ljfJNRpt9IFCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFaks73M&md5=d26350964814206ce4860b7256c9d6a0</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fs41582-018-0013-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41582-018-0013-z%26sid%3Dliteratum%253Aachs%26aulast%3DCongdon%26aufirst%3DE.%2BE.%26aulast%3DSigurdsson%26aufirst%3DE.%2BM.%26atitle%3DTau-targeting%2520therapies%2520for%2520Alzheimer%2520disease%26jtitle%3DNat.%2520Rev.%2520Neurol.%26date%3D2018%26volume%3D14%26spage%3D399%26epage%3D415%26doi%3D10.1038%2Fs41582-018-0013-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bulic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickhardt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandelkow, E.</span></span> <span> </span><span class="NLM_article-title">Progress and developments in tau aggregation inhibitors for Alzheimer disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4135</span>– <span class="NLM_lpage">4155</span>, <span class="refDoi"> DOI: 10.1021/jm3017317</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3017317" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktVCks7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4135-4155&author=B.+Bulicauthor=M.+Pickhardtauthor=E.+Mandelkow&title=Progress+and+developments+in+tau+aggregation+inhibitors+for+Alzheimer+disease&doi=10.1021%2Fjm3017317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Progress and Developments in Tau Aggregation Inhibitors for Alzheimer Disease</span></div><div class="casAuthors">Bulic, Bruno; Pickhardt, Marcus; Mandelkow, Eckhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4135-4155</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pharmacol. approaches directed toward Alzheimer disease are diversifying in parallel with a growing no. of promising targets.  Investigations on the microtubule-assocd. protein tau yielded innovative targets backed by recent findings about the central role of tau in numerous neurodegenerative diseases.  In this review, we summarize the recent evolution in the development of nonpeptidic small mols. tau aggregation inhibitors (TAGIs) and their advancement toward clin. trials.  The compds. are classified according to their chem. structures, providing correlative insights into their pharmacol.  Overall, shared structure-activity traits are emerging, as well as specific binding modes related to their ability to engage in hydrogen bonding.  Medicinal chem. efforts on TAGIs together with encouraging in vivo data argue for successful translation to the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-MCCWng61lLVg90H21EOLACvtfcHk0ljfJNRpt9IFCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktVCks7w%253D&md5=35aa968d078ff044e0d353fca4f13e42</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fjm3017317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3017317%26sid%3Dliteratum%253Aachs%26aulast%3DBulic%26aufirst%3DB.%26aulast%3DPickhardt%26aufirst%3DM.%26aulast%3DMandelkow%26aufirst%3DE.%26atitle%3DProgress%2520and%2520developments%2520in%2520tau%2520aggregation%2520inhibitors%2520for%2520Alzheimer%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4135%26epage%3D4155%26doi%3D10.1021%2Fjm3017317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ballatore, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunden, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojanowski, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huryn, D. M.</span></span> <span> </span><span class="NLM_article-title">Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">317</span>– <span class="NLM_lpage">330</span>, <span class="refDoi"> DOI: 10.2174/156802611794072605</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.2174%2F156802611794072605" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=21320060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslahsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=317-330&author=C.+Ballatoreauthor=K.+R.+Brundenauthor=J.+Q.+Trojanowskiauthor=V.+M.+Leeauthor=A.+B.+Smithauthor=D.+M.+Huryn&title=Modulation+of+protein-protein+interactions+as+a+therapeutic+strategy+for+the+treatment+of+neurodegenerative+tauopathies&doi=10.2174%2F156802611794072605"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies</span></div><div class="casAuthors">Ballatore, C.; Brunden, K. R.; Trojanowski, J. Q.; Lee, V. M.-Y.; Smith, A. B., III; Huryn, D. M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">317-330</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The recognition that malfunction of the microtubule (MT) assocd. protein tau is likely to play a defining role in the onset and/or progression of a no. of neurodegenerative diseases, including Alzheimer's disease, has resulted in the initiation of drug discovery programs that target this protein.  Tau is an endogenous MT-stabilizing agent that is highly expressed in the axons of neurons.  The MT-stabilizing function of tau is essential for the axonal transport of proteins, neurotransmitters and other cellular constituents.  Under pathol. conditions, tau misfolding and aggregation results in axonal transport deficits that appear to have deleterious consequences for the affected neurons, leading to synapse dysfunction and, ultimately, neuronal loss.  This review focuses on both progress and unresolved issues surrounding the development of novel therapeutics for the treatment of neurodegenerative tauopathies, which are based on (A) MT-stabilizing agents to compensate for the loss of normal tau function and (B) small mol. inhibitors of tau aggregation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRv3v9WR9uIrVg90H21EOLACvtfcHk0ljfJNRpt9IFCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslahsLk%253D&md5=b35d6ff9dac27b56e59f1e2fd5b8fafd</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.2174%2F156802611794072605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611794072605%26sid%3Dliteratum%253Aachs%26aulast%3DBallatore%26aufirst%3DC.%26aulast%3DBrunden%26aufirst%3DK.%2BR.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26aulast%3DLee%26aufirst%3DV.%2BM.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DHuryn%26aufirst%3DD.%2BM.%26atitle%3DModulation%2520of%2520protein-protein%2520interactions%2520as%2520a%2520therapeutic%2520strategy%2520for%2520the%2520treatment%2520of%2520neurodegenerative%2520tauopathies%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D317%26epage%3D330%26doi%3D10.2174%2F156802611794072605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mabonga, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kappo, A. P.</span></span> <span> </span><span class="NLM_article-title">Protein-protein interaction modulators: Advances, successes and remaining challenges</span>. <i>Biophys. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">559</span>– <span class="NLM_lpage">581</span>, <span class="refDoi"> DOI: 10.1007/s12551-019-00570-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1007%2Fs12551-019-00570-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=31301019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtl2rsb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=559-581&author=L.+Mabongaauthor=A.+P.+Kappo&title=Protein-protein+interaction+modulators%3A+Advances%2C+successes+and+remaining+challenges&doi=10.1007%2Fs12551-019-00570-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Protein-protein interaction modulators: advances, successes and remaining challenges</span></div><div class="casAuthors">Mabonga, Lloyd; Kappo, Abidemi Paul</div><div class="citationInfo"><span class="NLM_cas:title">Biophysical Reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">559-581</span>CODEN:
                <span class="NLM_cas:coden">BRIECG</span>;
        ISSN:<span class="NLM_cas:issn">1867-2450</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Modulating disease-relevant protein-protein interactions (PPIs) using small-mol. inhibitors is a quite indispensable diagnostic and therapeutic strategy in averting pathophysiol. cues and disease progression.  Over the years, targeting intracellular PPIs as drug design targets has been a challenging task owing to their highly dynamic and expansive interfacial areas (flat, featureless and relatively large).  However, advances in PPI-focused drug discovery technol. have been reported and a few drugs are already on the market, with some potential drug-like candidates already in clin. trials.  In this article, we review the advances, successes and remaining challenges in the application of small mols. as valuable PPI modulators in disease diagnosis and therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKCN2e4SrXuLVg90H21EOLACvtfcHk0ljfJNRpt9IFCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtl2rsb3J&md5=02c2c9b4b9d1ccb279c76c21776bb2ec</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1007%2Fs12551-019-00570-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12551-019-00570-x%26sid%3Dliteratum%253Aachs%26aulast%3DMabonga%26aufirst%3DL.%26aulast%3DKappo%26aufirst%3DA.%2BP.%26atitle%3DProtein-protein%2520interaction%2520modulators%253A%2520Advances%252C%2520successes%2520and%2520remaining%2520challenges%26jtitle%3DBiophys.%2520Rev.%26date%3D2019%26volume%3D11%26spage%3D559%26epage%3D581%26doi%3D10.1007%2Fs12551-019-00570-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsuo, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billingsley, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van deVoorde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojanowski, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, V. M.</span></span> <span> </span><span class="NLM_article-title">Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer’s disease paired helical filament tau</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">989</span>– <span class="NLM_lpage">1002</span>, <span class="refDoi"> DOI: 10.1016/0896-6273(94)90264-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2F0896-6273%2894%2990264-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=7946342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADyaK2MXitVOgt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1994&pages=989-1002&author=E.+S.+Matsuoauthor=R.+W.+Shinauthor=M.+L.+Billingsleyauthor=A.+Van+deVoordeauthor=M.+O%E2%80%99Connorauthor=J.+Q.+Trojanowskiauthor=V.+M.+Lee&title=Biopsy-derived+adult+human+brain+tau+is+phosphorylated+at+many+of+the+same+sites+as+Alzheimer%E2%80%99s+disease+paired+helical+filament+tau&doi=10.1016%2F0896-6273%2894%2990264-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau</span></div><div class="casAuthors">Matsuo, Eriko S.; Shin, Ryong-Woon; Billingsley, Melvin L.; Van deVoorde, Andre; O'Connor, Michael; Trojanowski, John Q.; Lee, Virginia M.-Y.</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">989-1002</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Tau from Alzheimer's disease (AD) paired helical filaments (PHF-tau) is phosphorylated at sites not found in autopsy-derived adult tau from normal human brains, and this suggested that PHF-tau is abnormally phosphorylated.  To explore this hypothesis, the authors examd. human adult tau from brain biopsies and demonstrated that biopsy-derived tau is phosphorylated at most sites thought to be abnormally phosphorylated in PHF-tau.  These sites also were phosphorylated in autopsy-derived human fetal tau and rapidly processed rat tau.  The hypophosphorylation of autopsy-derived adult human tau is due to rapid dephosphorylation postmortem, and protein phosphatases 2A (PP2A) and 2B (PP2B) in human brain biopsies dephosphorylate tau in a site-specific manner.  The down-regulation of phosphatases (i.e, PP2A and PP2B) in the AD brain could lead to the generation of maximally phosphorylated PHF-tau that does not bind microtubules and aggregates as PHFs in neurofibrillary tangles and dystrophic neurites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryVEroJQtKMbVg90H21EOLACvtfcHk0ljcUgwfW4qY0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXitVOgt7o%253D&md5=9316d037d89f85f75008bef2789dde77</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2F0896-6273%2894%2990264-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0896-6273%252894%252990264-X%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuo%26aufirst%3DE.%2BS.%26aulast%3DShin%26aufirst%3DR.%2BW.%26aulast%3DBillingsley%26aufirst%3DM.%2BL.%26aulast%3DVan%2BdeVoorde%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26aulast%3DLee%26aufirst%3DV.%2BM.%26atitle%3DBiopsy-derived%2520adult%2520human%2520brain%2520tau%2520is%2520phosphorylated%2520at%2520many%2520of%2520the%2520same%2520sites%2520as%2520Alzheimer%25E2%2580%2599s%2520disease%2520paired%2520helical%2520filament%2520tau%26jtitle%3DNeuron%26date%3D1994%26volume%3D13%26spage%3D989%26epage%3D1002%26doi%3D10.1016%2F0896-6273%2894%2990264-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundke-Iqbal, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, K.</span></span> <span> </span><span class="NLM_article-title">Alzheimer’s disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">783</span>– <span class="NLM_lpage">787</span>, <span class="refDoi"> DOI: 10.1038/nm0796-783</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2Fnm0796-783" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=8673924" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADyaK28XjvF2isr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1996&pages=783-787&author=A.+C.+Alonsoauthor=I.+Grundke-Iqbalauthor=K.+Iqbal&title=Alzheimer%E2%80%99s+disease+hyperphosphorylated+tau+sequesters+normal+tau+into+tangles+of+filaments+and+disassembles+microtubules&doi=10.1038%2Fnm0796-783"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules</span></div><div class="casAuthors">Alonso, Alejandra delC.; Grundke-Iqbal, Inge; Iqbal, Khalid</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">783-787</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">Microtubule-assocd. protein tau becomes abnormally hyperphosphorylated in Alzheimer's disease (AD) and accumulates as tangles of paired helical filaments in neurons undergoing degeneration.  The authors now show that in soln., normal tau assocs. with the AD hyperphosphorylated tau (AD P-tau) in a nonsaturable fashion, forming large tangles of filaments 3.3 nm in diam.  These tangles, which are not detected in identically treated normal tau or AD P-tau alone, are made up of filaments several microns in length and are labeled with tau antibodies.  Dephosphorylation with alk. phosphatase abolishes the ability of AD P-tau to aggregate with normal tau and prevents tangle formation.  AD P-tau disassembles microtubules assembled from normal tau and tubulin.  These data provide insight into how the hyperphosphorylation of tau might lead to the formation of the neurofibrillary tangles and the degeneration of the affected neurons in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoubdLxKdTTmLVg90H21EOLACvtfcHk0ljcUgwfW4qY0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjvF2isr0%253D&md5=c49e7b62bcb15f24084cedbd86ef438c</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fnm0796-783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0796-783%26sid%3Dliteratum%253Aachs%26aulast%3DAlonso%26aufirst%3DA.%2BC.%26aulast%3DGrundke-Iqbal%26aufirst%3DI.%26aulast%3DIqbal%26aufirst%3DK.%26atitle%3DAlzheimer%25E2%2580%2599s%2520disease%2520hyperphosphorylated%2520tau%2520sequesters%2520normal%2520tau%2520into%2520tangles%2520of%2520filaments%2520and%2520disassembles%2520microtubules%26jtitle%3DNat.%2520Med.%26date%3D1996%26volume%3D2%26spage%3D783%26epage%3D787%26doi%3D10.1038%2Fnm0796-783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sengupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundke-Iqbal, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, K.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of tau at both thr 231 and Ser. 262 is required for maximal inhibition of its binding to microtubules</span>. <i>Arch. Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>357</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1006/abbi.1998.0813</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1006%2Fabbi.1998.0813" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=9735171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADyaK1cXmtFyjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=1998&pages=299-309&author=A.+Senguptaauthor=J.+Kabatauthor=M.+Novakauthor=Q.+Wuauthor=I.+Grundke-Iqbalauthor=K.+Iqbal&title=Phosphorylation+of+tau+at+both+thr+231+and+Ser.+262+is+required+for+maximal+inhibition+of+its+binding+to+microtubules&doi=10.1006%2Fabbi.1998.0813"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules</span></div><div class="casAuthors">Sengupta, Amitabha; Kabat, Juraj; Novak, Michal; Wu, Qiongli; Grundke-Iqbal, Inge; Iqbal, Khalid</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">299-309</span>CODEN:
                <span class="NLM_cas:coden">ABBIA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-9861</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The paired helical filaments (PHFs) found in Alzheimer's disease (AD) brains are composed primarily of the microtubule-assocd. protein tau.  PHF-tau is in a hyperphosphorylated state and is unable to promote microtubule assembly.  We investigated whether the inhibition of tau is binding to microtubules is increased when tau is phosphorylated by different kinases in combination with GSK-3.  We found that when tau was first phosphorylated by A-kinase, C-kinase, cdk5, or CaM kinase II and then by GSK-3, its binding to microtubules was inhibited by 45, 61, 78, and 79%, resp.  Further, the kinase combinations cdk5/GSK-3 and CaM kinase II/GSK-3 rapidly phosphorylated the sites Thr 231 and Ser 235.  When these sites were individually replaced by Ala and the phosphorylation expts. repeated, tau binding to microtubules was inhibited by 54 and 71%, resp.  By comparison, when Ser 262 was replaced by Ala, tau binding to microtubules was inhibited by only 8% after phosphorylation by CaM kinase II.  From these observations we est. that the phosphorylation of Thr 231, Ser 235, and Ser 262 contributes ∼26, ∼9, and ∼33%, resp., of the overall inhibition of tau binding to microtubules.  Together, our results indicate that the binding of tau to microtubules is controlled by the phosphorylation of several sites, among which are Thr 231, Ser 235, and Ser 262.  (c) 1998 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwvML27B25WbVg90H21EOLACvtfcHk0ljcUgwfW4qY0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmtFyjtbo%253D&md5=e807d59160bb4455368978560e5f3561</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1006%2Fabbi.1998.0813&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fabbi.1998.0813%26sid%3Dliteratum%253Aachs%26aulast%3DSengupta%26aufirst%3DA.%26aulast%3DKabat%26aufirst%3DJ.%26aulast%3DNovak%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DQ.%26aulast%3DGrundke-Iqbal%26aufirst%3DI.%26aulast%3DIqbal%26aufirst%3DK.%26atitle%3DPhosphorylation%2520of%2520tau%2520at%2520both%2520thr%2520231%2520and%2520Ser.%2520262%2520is%2520required%2520for%2520maximal%2520inhibition%2520of%2520its%2520binding%2520to%2520microtubules%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D1998%26volume%3D357%26spage%3D299%26epage%3D309%26doi%3D10.1006%2Fabbi.1998.0813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biernat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Bergen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandelkow, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandelkow, E. M.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">3549</span>– <span class="NLM_lpage">3558</span>, <span class="refDoi"> DOI: 10.1021/bi981874p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi981874p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADyaK1MXhsVyhsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1999&pages=3549-3558&author=A.+Schneiderauthor=J.+Biernatauthor=M.+von+Bergenauthor=E.+Mandelkowauthor=E.+M.+Mandelkow&title=Phosphorylation+that+detaches+tau+protein+from+microtubules+%28Ser262%2C+Ser214%29+also+protects+it+against+aggregation+into+Alzheimer+paired+helical+filaments&doi=10.1021%2Fbi981874p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments</span></div><div class="casAuthors">Schneider, A.; Biernat, J.; von Bergen, M.; Mandelkow, E.; Mandelkow, E.-M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3549-3558</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">One of the hallmarks of Alzheimer's disease is the abnormal state of the microtubule-assocd. protein tau in neurons.  It is both highly phosphorylated and aggregated into paired helical filaments, and it is commonly assumed that the hyperphosphorylation of tau causes its detachment from microtubules and promotes its assembly into PHFs.  The authors have studied the relation between the phosphorylation of tau by several kinases (MARK, PKA, MAPK, GSK3) and its assembly into PHFs.  The proline-directed kinases MAPK and GSK3 are known to phosphorylate most Ser-Pro or Thr-Pro motifs in the regions flanking the repeat domain of tau: they induce the reaction with several antibodies diagnostic of Alzheimer PHFs, but this type of phosphorylation has only a weak effect on tau-microtubule interactions and on PHF assembly.  By contrast, MARK and PKA phosphorylate several sites within the repeats (notably the KXGS motifs including Ser262, Ser324, and Ser356, plus Ser320); in addn. PKA phosphorylates some sites in the flanking domains, notably Ser214.  This type of phosphorylation strongly reduces tau's affinity for microtubules, and at the same time inhibits tau's assembly into PHFs.  Thus, contrary to expectations, the phosphorylation that detaches tau from microtubules does not prime it for PHF assembly, but rather inhibits it.  Likewise, although the phosphorylation sites on Ser-Pro or Thr-Pro motifs are the most prominent ones on Alzheimer PHFs (by antibody labeling), they are only weakly inhibitory to PHF assembly.  This implies that the hyperphosphorylation of tau in Alzheimer's disease is not directly responsible for the pathol. aggregation into PHFs; on the contrary, phosphorylation protects tau against aggregation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpR_mr0wtSK4bVg90H21EOLACvtfcHk0lguso9RyG8BjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhsVyhsbk%253D&md5=3403b22fdd0e690bae38d7262c016e96</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fbi981874p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi981874p%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DA.%26aulast%3DBiernat%26aufirst%3DJ.%26aulast%3Dvon%2BBergen%26aufirst%3DM.%26aulast%3DMandelkow%26aufirst%3DE.%26aulast%3DMandelkow%26aufirst%3DE.%2BM.%26atitle%3DPhosphorylation%2520that%2520detaches%2520tau%2520protein%2520from%2520microtubules%2520%2528Ser262%252C%2520Ser214%2529%2520also%2520protects%2520it%2520against%2520aggregation%2520into%2520Alzheimer%2520paired%2520helical%2520filaments%26jtitle%3DBiochemistry%26date%3D1999%26volume%3D38%26spage%3D3549%26epage%3D3558%26doi%3D10.1021%2Fbi981874p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanger, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, W.</span></span> <span> </span><span class="NLM_article-title">Tau phosphorylation: The therapeutic challenge for neurodegenerative disease</span>. <i>Trends Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">119</span>, <span class="refDoi"> DOI: 10.1016/j.molmed.2009.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.molmed.2009.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=19246243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjt1ahu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=112-119&author=D.+P.+Hangerauthor=B.+H.+Andertonauthor=W.+Noble&title=Tau+phosphorylation%3A+The+therapeutic+challenge+for+neurodegenerative+disease&doi=10.1016%2Fj.molmed.2009.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Tau phosphorylation: the therapeutic challenge for neurodegenerative disease</span></div><div class="casAuthors">Hanger, Diane P.; Anderton, Brian H.; Noble, Wendy</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">112-119</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The microtubule-assocd. protein tau is integral to the pathogenesis of Alzheimer's disease (AD), as well as several related disorders, termed tauopathies, in which tau is deposited in affected brain regions.  In the tauopathies, pathol. tau is in an elevated state of phosphorylation and is aberrantly cleaved.  It also exhibits abnormal conformations and becomes aggregated, resulting in neurofibrillary tau pathol.  Recent evidence suggests that relatively early disease-assocd. changes in sol. tau proteins, including phosphorylation, are involved in the induction of neuronal death.  Here, we summarize recent developments that suggest new therapeutic strategies to prevent or reduce the progression of pathol. in the tauopathies.  A list of tau phosphorylation sites identified in the tauopathies and in controls accompanies this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8l3EQ3bznVLVg90H21EOLACvtfcHk0lguso9RyG8BjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjt1ahu7w%253D&md5=116159eeaae25800a22b687f36df70e2</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2009.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2009.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DHanger%26aufirst%3DD.%2BP.%26aulast%3DAnderton%26aufirst%3DB.%2BH.%26aulast%3DNoble%26aufirst%3DW.%26atitle%3DTau%2520phosphorylation%253A%2520The%2520therapeutic%2520challenge%2520for%2520neurodegenerative%2520disease%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2009%26volume%3D15%26spage%3D112%26epage%3D119%26doi%3D10.1016%2Fj.molmed.2009.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Kinase inhibitors: The road ahead</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1038/nrd.2018.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2Fnrd.2018.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=29545548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1cXks12ktbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=353-377&author=F.+M.+Fergusonauthor=N.+S.+Gray&title=Kinase+inhibitors%3A+The+road+ahead&doi=10.1038%2Fnrd.2018.21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase inhibitors: the road ahead</span></div><div class="casAuthors">Ferguson, Fleur M.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">353-377</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinase signaling pathways have been successfully targeted to inhibit proliferation and angiogenesis for cancer therapy.  However, kinase deregulation has been firmly demonstrated to play an essential role in virtually all major disease areas.  Kinase inhibitor drug discovery programs have recently broadened their focus to include an expanded range of kinase targets and therapeutic areas.  In this Review, we provide an overview of the novel targets, biol. processes and disease areas that kinase-targeting small mols. are being developed against, highlight the assocd. challenges and assess the strategies and technologies that are enabling efficient generation of highly optimized kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZPospb1TP7Vg90H21EOLACvtfcHk0lguso9RyG8BjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXks12ktbg%253D&md5=34e42911d8a70301905460c3507e737a</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.21%26sid%3Dliteratum%253Aachs%26aulast%3DFerguson%26aufirst%3DF.%2BM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DKinase%2520inhibitors%253A%2520The%2520road%2520ahead%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26spage%3D353%26epage%3D377%26doi%3D10.1038%2Fnrd.2018.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghoreschi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">Selectivity and therapeutic inhibition of kinases: To be or not to be?</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">356</span>– <span class="NLM_lpage">360</span>, <span class="refDoi"> DOI: 10.1038/ni.1701</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2Fni.1701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=19295632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtlyms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=356-360&author=K.+Ghoreschiauthor=A.+Laurenceauthor=J.+J.+O%E2%80%99Shea&title=Selectivity+and+therapeutic+inhibition+of+kinases%3A+To+be+or+not+to+be%3F&doi=10.1038%2Fni.1701"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Selectivity and therapeutic inhibition of kinases: to be or not to be?</span></div><div class="casAuthors">Ghoreschi, Kamran; Laurence, Arian; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">356-360</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Protein kinases, which serve crit. functions in signaling pathways in all cells, are popular therapeutic targets.  At present, eight kinase inhibitors have been approved in the United States, each of which shows nanomolar potency.  Although the initial goal was to generate inhibitors with a high degree of selectivity, recent experience has revealed that many of these approved compds. target more than one kinase.  Surprisingly, this promiscuity is less problematic than one would have imagined; indeed, it opens new therapeutic opportunities.  In this Perspective, we discuss the present status of Janus kinase inhibitors-a new class of immunosuppressive drugs-and the advantages and disadvantages of selectively inhibiting this class of kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrU0w6t4jgqirVg90H21EOLACvtfcHk0lgLgOGyHtAmIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtlyms78%253D&md5=64dd47e897181d00e5dce6be3bc5db6e</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fni.1701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.1701%26sid%3Dliteratum%253Aachs%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DSelectivity%2520and%2520therapeutic%2520inhibition%2520of%2520kinases%253A%2520To%2520be%2520or%2520not%2520to%2520be%253F%26jtitle%3DNat.%2520Immunol.%26date%3D2009%26volume%3D10%26spage%3D356%26epage%3D360%26doi%3D10.1038%2Fni.1701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. G.</span></span> <span> </span><span class="NLM_article-title">Recent advances in designing substrate-competitive protein kinase inhibitors</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2875</span>– <span class="NLM_lpage">2882</span>, <span class="refDoi"> DOI: 10.2174/138161212800672697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.2174%2F138161212800672697" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=22571656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFaltr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=2875-2882&author=K.+C.+Hanauthor=S.+Y.+Kimauthor=E.+G.+Yang&title=Recent+advances+in+designing+substrate-competitive+protein+kinase+inhibitors&doi=10.2174%2F138161212800672697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in designing substrate-competitive protein kinase inhibitors</span></div><div class="casAuthors">Han, Ki-Cheol; Kim, So Yeon; Yang, Eun Gyeong</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2875-2882</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases play central roles in cellular signaling pathways and their abnormal phosphorylation activity is inseparably linked with various human diseases.  Therefore, modulation of kinase activity using potent inhibitors is an attractive strategy for the treatment of human disease.  While most protein kinase inhibitors in clin. development are mainly targeted to the highly conserved ATP-binding sites and thus likely promiscuously inhibit multiple kinases, including kinases unrelated to diseases, protein substrate-competitive inhibitors are more selective and expected to be promising therapeutic agents.  Most substrate-competitive inhibitors mimic peptides derived from substrate proteins, or from inhibitory domains within kinases or inhibitor proteins.  In addn., bisubstrate inhibitors are generated by conjugating substrate-competitive peptide inhibitors to ATP-competitive inhibitors to improve affinity and selectivity.  Although structural information on protein kinases provides invaluable guidance in designing substrate-competitive inhibitors, other strategies including bioinformatics, computational modeling, and high-throughput screening are often employed for developing specific substrate-competitive kinase inhibitors.  Here, the authors focus on recent advances in the design and discovery of substrate-competitive inhibitors of protein kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGAqU2Rh64l7Vg90H21EOLACvtfcHk0lgLgOGyHtAmIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFaltr8%253D&md5=841afc2c63bb0d956ba9d5c4caef3cb6</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.2174%2F138161212800672697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161212800672697%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DK.%2BC.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DYang%26aufirst%3DE.%2BG.%26atitle%3DRecent%2520advances%2520in%2520designing%2520substrate-competitive%2520protein%2520kinase%2520inhibitors%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2012%26volume%3D18%26spage%3D2875%26epage%3D2882%26doi%3D10.2174%2F138161212800672697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">New promise and opportunities for allosteric kinase inhibitors</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">13764</span>– <span class="NLM_lpage">13776</span>, <span class="refDoi"> DOI: 10.1002/anie.201914525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1002%2Fanie.201914525" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmt1Giurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2020&pages=13764-13776&author=X.+Luauthor=J.+B.+Smaillauthor=K.+Ding&title=New+promise+and+opportunities+for+allosteric+kinase+inhibitors&doi=10.1002%2Fanie.201914525"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">New Promise and Opportunities for Allosteric Kinase Inhibitors</span></div><div class="casAuthors">Lu, Xiaoyun; Smaill, Jeff B.; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">13764-13776</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Drugs that function through allosteric inhibition of kinase signaling represent a promising approach for the targeted discovery of therapeutics.  The majority of developed allosteric kinase inhibitors are characterized as type III and IV inhibitors that show good kinome selectivity but generally lack the subtype selectivity of same kinase family.  Recently allosteric inhibitors have been developed that bind outside the catalytic kinase domain with high selectivity for specific kinase subtypes.  Allosteric inhibitors that bind to the pseudokinase domain of pseudokinase or the extracellular domain of receptor tyrosine kinases are reviewed.  We also review recent developments in the field of allosteric kinase inhibitors including examples of proteolysis targeting chimeras, and highlight the unique binding modes for each type of inhibitors and address future opportunities in this area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIeFGyjfBKrLVg90H21EOLACvtfcHk0lgLgOGyHtAmIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmt1Giurw%253D&md5=27959fdb1a96202db7ca65b2a8e19bc7</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1002%2Fanie.201914525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201914525%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DNew%2520promise%2520and%2520opportunities%2520for%2520allosteric%2520kinase%2520inhibitors%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2020%26volume%3D59%26spage%3D13764%26epage%3D13776%26doi%3D10.1002%2Fanie.201914525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chico, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eldik, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span> <span> </span><span class="NLM_article-title">Targeting protein kinases in central nervous system disorders</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">892</span>– <span class="NLM_lpage">909</span>, <span class="refDoi"> DOI: 10.1038/nrd2999</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2Fnrd2999" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=19876042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCjtrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=892-909&author=L.+K.+Chicoauthor=L.+J.+Van+Eldikauthor=D.+M.+Watterson&title=Targeting+protein+kinases+in+central+nervous+system+disorders&doi=10.1038%2Fnrd2999"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting protein kinases in central nervous system disorders</span></div><div class="casAuthors">Chico, Laura K.; Van Eldik, Linda J.; Watterson, D. Martin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">892-909</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Protein kinases are a growing drug target class in disorders in peripheral tissues, but the development of kinase-targeted therapies for central nervous system (CNS) diseases remains a challenge, largely owing to issues assocd. specifically with CNS drug discovery.  However, several candidate therapeutics that target CNS protein kinases are now in various stages of preclin. and clin. development.  We review candidate compds. and discuss selected CNS protein kinases that are emerging as important therapeutic targets.  In addn., we analyze trends in small-mol. properties that correlate with key challenges in CNS drug discovery, such as blood-brain barrier penetrance and cytochrome P 450-mediated metab., and discuss the potential of future approaches that will integrate mol.-fragment expansion with pharmacoinformatics to address these challenges.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzQo2JmuPNlrVg90H21EOLACvtfcHk0lgLgOGyHtAmIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCjtrzO&md5=4dc1f6b7542e59c99f91525d37c49973</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fnrd2999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2999%26sid%3Dliteratum%253Aachs%26aulast%3DChico%26aufirst%3DL.%2BK.%26aulast%3DVan%2BEldik%26aufirst%3DL.%2BJ.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26atitle%3DTargeting%2520protein%2520kinases%2520in%2520central%2520nervous%2520system%2520disorders%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D892%26epage%3D909%26doi%3D10.1038%2Fnrd2999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wen, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yung, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamborn, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahia, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrey, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raizer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cloughesy, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junck, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiff, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieberman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fine, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robins, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeAngelis, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groves, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puduvalli, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrad, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldape, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letvak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egorin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capdeville, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murgo, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiles, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prados, M. D.</span></span> <span> </span><span class="NLM_article-title">Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American brain tumor consortium study 99–08</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">4899</span>– <span class="NLM_lpage">4907</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-06-0773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1158%2F1078-0432.CCR-06-0773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=16914578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD28XotFKgt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=4899-4907&author=P.+Y.+Wenauthor=W.+K.+Yungauthor=K.+R.+Lambornauthor=P.+L.+Dahiaauthor=Y.+Wangauthor=B.+Pengauthor=L.+E.+Abreyauthor=J.+Raizerauthor=T.+F.+Cloughesyauthor=K.+Finkauthor=M.+Gilbertauthor=S.+Changauthor=L.+Junckauthor=D.+Schiffauthor=F.+Liebermanauthor=H.+A.+Fineauthor=M.+Mehtaauthor=H.+I.+Robinsauthor=L.+M.+DeAngelisauthor=M.+D.+Grovesauthor=V.+K.+Puduvalliauthor=V.+Levinauthor=C.+Conradauthor=E.+A.+Maherauthor=K.+Aldapeauthor=M.+Hayesauthor=L.+Letvakauthor=M.+J.+Egorinauthor=R.+Capdevilleauthor=R.+Kaplanauthor=A.+J.+Murgoauthor=C.+Stilesauthor=M.+D.+Prados&title=Phase+I%2FII+study+of+imatinib+mesylate+for+recurrent+malignant+gliomas%3A+North+American+brain+tumor+consortium+study+99%E2%80%9308&doi=10.1158%2F1078-0432.CCR-06-0773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08</span></div><div class="casAuthors">Wen, Patrick Y.; Yung, W. K. Alfred; Lamborn, Kathleen R.; Dahia, Patricia L.; Wang, Yanfeng; Peng, Bin; Abrey, Lauren E.; Raizer, Jeffrey; Cloughesy, Timothy F.; Fink, Karen; Gilbert, Mark; Chang, Susan; Junck, Larry; Schiff, David; Lieberman, Frank; Fine, Howard A.; Mehta, Minesh; Robins, H. Ian; DeAngelis, Lisa M.; Groves, Morris D.; Puduvalli, Vinay K.; Levin, Victor; Conrad, Charles; Maher, Elizabeth A.; Aldape, Kenneth; Hayes, Michael; Letvak, Laurie; Egorin, Merrill J.; Capdeville, Renaud; Kaplan, Richard; Murgo, Anthony J.; Stiles, Charles; Prados, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4899-4907</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Phase I: To det. the max. tolerated doses, toxicities, and pharmacokinetics of imatinib mesylate (Gleevec) in patients with malignant gliomas taking enzyme-inducing antiepileptic drugs (EIAED) or not taking EIAED.  Phase II: To det. the therapeutic efficacy of imatinib.  Exptl. Design: Phase I component used an inter-patient dose escalation scheme.  End points of the phase II component were 6-mo progression-free survival and response.  RESULTS: Fifty patients enrolled in the phase I component (27 EIAED and 23 non-EIAED).  The max. tolerated dose for non-EIAED patients was 800 mg/d.  Dose-limiting toxicities were neutropenia, rash, and elevated alanine aminotransferase.  EIAED patients received up to 1200 mg/d imatinib without developing dose-limiting toxicity.  Plasma exposure of imatinib was reduced by ∼68% in EIAED patients compared with non-EIAED patients.  Fifty-five non-EIAED patients (34 glioblastoma multiforme and 21 anaplastic glioma) enrolled in the phase II component.  Patients initially received 800 mg/d imatinib; 15 anaplastic glioma patients received 600 mg/d after hemorrhages were obsd.  There were 2 partial response and 6 stable disease among glioblastoma multiforme patients and 0 partial response and 5 stable disease among anaplastic glioma patients.  Six-month progression-free survival was 3% for glioblastoma multiforme and 10% for anaplastic glioma patients.  Five phase II patients developed intratumoral hemorrhages.  CONCLUSIONS: Single-agent imatinib has minimal activity in malignant gliomas.  CYP3A4 inducers, such as EIAEDs, substantially decreased plasma exposure of imatinib and should be avoided in patients receiving imatinib for chronic myelogenous leukemia and gastrointestinal stromal tumors.  The evaluation of the activity of combination regimens incorporating imatinib is under way in phase II trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAxZrLJjINsLVg90H21EOLACvtfcHk0lis_cAqWLczvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotFKgt70%253D&md5=6776f269d0c46042919c98b17db03214</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-0773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-0773%26sid%3Dliteratum%253Aachs%26aulast%3DWen%26aufirst%3DP.%2BY.%26aulast%3DYung%26aufirst%3DW.%2BK.%26aulast%3DLamborn%26aufirst%3DK.%2BR.%26aulast%3DDahia%26aufirst%3DP.%2BL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DAbrey%26aufirst%3DL.%2BE.%26aulast%3DRaizer%26aufirst%3DJ.%26aulast%3DCloughesy%26aufirst%3DT.%2BF.%26aulast%3DFink%26aufirst%3DK.%26aulast%3DGilbert%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DS.%26aulast%3DJunck%26aufirst%3DL.%26aulast%3DSchiff%26aufirst%3DD.%26aulast%3DLieberman%26aufirst%3DF.%26aulast%3DFine%26aufirst%3DH.%2BA.%26aulast%3DMehta%26aufirst%3DM.%26aulast%3DRobins%26aufirst%3DH.%2BI.%26aulast%3DDeAngelis%26aufirst%3DL.%2BM.%26aulast%3DGroves%26aufirst%3DM.%2BD.%26aulast%3DPuduvalli%26aufirst%3DV.%2BK.%26aulast%3DLevin%26aufirst%3DV.%26aulast%3DConrad%26aufirst%3DC.%26aulast%3DMaher%26aufirst%3DE.%2BA.%26aulast%3DAldape%26aufirst%3DK.%26aulast%3DHayes%26aufirst%3DM.%26aulast%3DLetvak%26aufirst%3DL.%26aulast%3DEgorin%26aufirst%3DM.%2BJ.%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DKaplan%26aufirst%3DR.%26aulast%3DMurgo%26aufirst%3DA.%2BJ.%26aulast%3DStiles%26aufirst%3DC.%26aulast%3DPrados%26aufirst%3DM.%2BD.%26atitle%3DPhase%2520I%252FII%2520study%2520of%2520imatinib%2520mesylate%2520for%2520recurrent%2520malignant%2520gliomas%253A%2520North%2520American%2520brain%2520tumor%2520consortium%2520study%252099%25E2%2580%259308%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D4899%26epage%3D4907%26doi%3D10.1158%2F1078-0432.CCR-06-0773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marbach, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemaire, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmquist, W. F.</span></span> <span> </span><span class="NLM_article-title">Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>304</i></span>,  <span class="NLM_fpage">1085</span>– <span class="NLM_lpage">1092</span>, <span class="refDoi"> DOI: 10.1124/jpet.102.045260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1124%2Fjpet.102.045260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=12604685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit1eisrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2003&pages=1085-1092&author=H.+Daiauthor=P.+Marbachauthor=M.+Lemaireauthor=M.+Hayesauthor=W.+F.+Elmquist&title=Distribution+of+STI-571+to+the+brain+is+limited+by+P-glycoprotein-mediated+efflux&doi=10.1124%2Fjpet.102.045260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux</span></div><div class="casAuthors">Dai, Haiqing; Marbach, Peter; Lemaire, Michel; Hayes, Michael; Elmquist, William F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1085-1092</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The adequate distribution of STI-571 (Gleevec) to the central nervous system (CNS) is crit. for its effective use in CNS tumors.  P-glycoprotein-mediated efflux in the blood-brain barrier may play a role in the CNS delivery of this drug.  Whether STI-571 is a substrate of P-glycoprotein was detd. by examg. the directional flux of [14C]STI-571 in parental and MDR1-transfected Madin-Darby canine kidney (MDCK) II epithelial cell monolayers.  The basolateral-to-apical flux of STI-571 was 39-fold greater than the apical-to-basolateral flux in the MDR1-transfected cells and 8-fold greater in the parental cell monolayers.  This difference in directional flux was significantly reduced by a specific P-glycoprotein inhibitor (2R)-anti-5-{3-[4-(10,11-difluoromethanodibenzo- suber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline trihydrochloride (LY335979).  The role of P-glycoprotein in the CNS distribution of STI-571 was examd. in vivo, using wild-type and mdr1a/b (-/-) knockout mice that were orally administered 25 mg/kg [14C]STI-571.  In the wild-type mice, the brain-to-plasma STI-571 concn. ratio at all time points was low (1-3%); however, there was an 11-fold greater brain partitioning of STI-571 at 1 h postdose in the mdr1a/b (-/-) mice compared with the wild-type mice.  When 12.5 mg/kg STI-571 was given i.v., the brain-to-plasma ratio of STI-571 in the mdr1a/b (-/-) mice was approx. 7-fold greater than that of wild-type mice up to 120 min postdose.  These data indicate that STI-571 is a substrate of P-glycoprotein, and that the inhibition of P-glycoprotein affects the transport of STI-571 across MDCKII monolayers.  Moreover, P-glycoprotein plays an important role in limiting the distribution of STI-571 to the CNS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF6vLgl-LGObVg90H21EOLACvtfcHk0lis_cAqWLczvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit1eisrs%253D&md5=c4f1082f27454e16635d768ce337ce7f</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1124%2Fjpet.102.045260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.102.045260%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DH.%26aulast%3DMarbach%26aufirst%3DP.%26aulast%3DLemaire%26aufirst%3DM.%26aulast%3DHayes%26aufirst%3DM.%26aulast%3DElmquist%26aufirst%3DW.%2BF.%26atitle%3DDistribution%2520of%2520STI-571%2520to%2520the%2520brain%2520is%2520limited%2520by%2520P-glycoprotein-mediated%2520efflux%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2003%26volume%3D304%26spage%3D1085%26epage%3D1092%26doi%3D10.1124%2Fjpet.102.045260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porkka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koskenvesa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundán, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimpiläinen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustjoki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smykla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brethon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccersley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hjorth-Hansen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Höglund, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klamova, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knutsen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffoux, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruber, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brito-Babapulle, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dombret, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duarte, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elonen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paquette, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwaan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F. Y.</span></span> <span> </span><span class="NLM_article-title">Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">1005</span>– <span class="NLM_lpage">1012</span>, <span class="refDoi"> DOI: 10.1182/blood-2008-02-140665</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1182%2Fblood-2008-02-140665" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=18477770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpvVOksL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2008&pages=1005-1012&author=K.+Porkkaauthor=P.+Koskenvesaauthor=T.+Lund%C3%A1nauthor=J.+Rimpil%C3%A4inenauthor=S.+Mustjokiauthor=R.+Smyklaauthor=R.+Wildauthor=R.+Luoauthor=M.+Arnanauthor=B.+Brethonauthor=L.+Eccersleyauthor=H.+Hjorth-Hansenauthor=M.+H%C3%B6glundauthor=H.+Klamovaauthor=H.+Knutsenauthor=S.+Parikhauthor=E.+Raffouxauthor=F.+Gruberauthor=F.+Brito-Babapulleauthor=H.+Dombretauthor=R.+F.+Duarteauthor=E.+Elonenauthor=R.+Paquetteauthor=C.+M.+Zwaanauthor=F.+Y.+Lee&title=Dasatinib+crosses+the+blood-brain+barrier+and+is+an+efficient+therapy+for+central+nervous+system+Philadelphia+chromosome-positive+leukemia&doi=10.1182%2Fblood-2008-02-140665"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system philadelphia chromosome-positive leukemia</span></div><div class="casAuthors">Porkka, Kimmo; Koskenvesa, Perttu; Lundan, Tuija; Rimpilainen, Johanna; Mustjoki, Satu; Smykla, Richard; Wild, Robert; Luo, Roger; Arnan, Montserrat; Brethon, Benoit; Eccersley, Lydia; Hjorth-Hansen, Henrik; Hoglund, Martin; Klamova, Hana; Knutsen, Havar; Parikh, Suhag; Raffoux, Emmanuel; Gruber, Franz; Brito-Babapulle, Finella; Dombret, Herve; Duarte, Rafael F.; Elonen, Erkki; Paquette, Ron; Zwaan, C. Michel; Lee, Francis Y. F.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1005-1012</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Although imatinib, a BCR-ABL tyrosine kinase inhibitor, is used to treat acute Philadelphia chromosome-pos. (Ph+) leukemia, it does not prevent central nervous system (CNS) relapses resulting from poor drug penetration through the blood-brain barrier.  Imatinib and dasatinib (a dual-specific SRC/BCR-ABL kinase inhibitor) were compared in a preclin. mouse model of intracranial Ph+ leukemia.  Clin. dasatinib treatment in patients with CNS Ph+ leukemia was assessed.  In preclin. studies, dasatinib increased survival, whereas imatinib failed to inhibit intracranial tumor growth.  Stabilization and regression of CNS disease were achieved with continued dasatinib administration.  The drug also demonstrated substantial activity in 11 adult and pediatric patients with CNS Ph+ leukemia.  Eleven evaluable patients had clin. significant, long-lasting responses, which were complete in 7 patients.  In 3 addnl. patients, isolated CNS relapse occurred during dasatinib therapy; and in 2 of them, it was caused by expansion of a BCR-ABL-mutated dasatinib-resistant clone, implying selection pressure exerted by the compd. in the CNS.  Dasatinib has promising therapeutic potential in managing intracranial leukemic disease and substantial clin. activity in patients who experience CNS relapse while on imatinib therapy.  This study is registered at ClinicalTrials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc65cpne9-fbVg90H21EOLACvtfcHk0ljK2KYUD4L7dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpvVOksL0%253D&md5=2edc2781403f7d921ec732db2e9cd560</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-02-140665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-02-140665%26sid%3Dliteratum%253Aachs%26aulast%3DPorkka%26aufirst%3DK.%26aulast%3DKoskenvesa%26aufirst%3DP.%26aulast%3DLund%25C3%25A1n%26aufirst%3DT.%26aulast%3DRimpil%25C3%25A4inen%26aufirst%3DJ.%26aulast%3DMustjoki%26aufirst%3DS.%26aulast%3DSmykla%26aufirst%3DR.%26aulast%3DWild%26aufirst%3DR.%26aulast%3DLuo%26aufirst%3DR.%26aulast%3DArnan%26aufirst%3DM.%26aulast%3DBrethon%26aufirst%3DB.%26aulast%3DEccersley%26aufirst%3DL.%26aulast%3DHjorth-Hansen%26aufirst%3DH.%26aulast%3DH%25C3%25B6glund%26aufirst%3DM.%26aulast%3DKlamova%26aufirst%3DH.%26aulast%3DKnutsen%26aufirst%3DH.%26aulast%3DParikh%26aufirst%3DS.%26aulast%3DRaffoux%26aufirst%3DE.%26aulast%3DGruber%26aufirst%3DF.%26aulast%3DBrito-Babapulle%26aufirst%3DF.%26aulast%3DDombret%26aufirst%3DH.%26aulast%3DDuarte%26aufirst%3DR.%2BF.%26aulast%3DElonen%26aufirst%3DE.%26aulast%3DPaquette%26aufirst%3DR.%26aulast%3DZwaan%26aufirst%3DC.%2BM.%26aulast%3DLee%26aufirst%3DF.%2BY.%26atitle%3DDasatinib%2520crosses%2520the%2520blood-brain%2520barrier%2520and%2520is%2520an%2520efficient%2520therapy%2520for%2520central%2520nervous%2520system%2520Philadelphia%2520chromosome-positive%2520leukemia%26jtitle%3DBlood%26date%3D2008%26volume%3D112%26spage%3D1005%26epage%3D1012%26doi%3D10.1182%2Fblood-2008-02-140665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, P. S.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3 and alternative splicing</span>. <i>Wiley Interdiscip Rev. RNA</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e1501</span> <span class="refDoi"> DOI: 10.1002/wrna.1501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1002%2Fwrna.1501" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=30118183" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&author=X.+Liuauthor=P.+S.+Klein&title=Glycogen+synthase+kinase-3+and+alternative+splicing&doi=10.1002%2Fwrna.1501"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1002%2Fwrna.1501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fwrna.1501%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DKlein%26aufirst%3DP.%2BS.%26atitle%3DGlycogen%2520synthase%2520kinase-3%2520and%2520alternative%2520splicing%26jtitle%3DWiley%2520Interdiscip%2520Rev.%2520RNA%26date%3D2018%26volume%3D9%26doi%3D10.1002%2Fwrna.1501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arden, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viars, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vestergaard, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Møller, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodgett, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, O.</span></span> <span> </span><span class="NLM_article-title">Chromosomal mapping and mutational analysis of the coding region of the glycogen synthase kinase-3alpha and beta isoforms in patients with NIDDM</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">940</span>– <span class="NLM_lpage">946</span>, <span class="refDoi"> DOI: 10.1007/s001250050771</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1007%2Fs001250050771" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=9267989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADyaK2sXltV2kt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=940-946&author=L.+Hansenauthor=K.+C.+Ardenauthor=S.+B.+Rasmussenauthor=C.+S.+Viarsauthor=H.+Vestergaardauthor=T.+Hansenauthor=A.+M.+M%C3%B8llerauthor=J.+R.+Woodgettauthor=O.+Pedersen&title=Chromosomal+mapping+and+mutational+analysis+of+the+coding+region+of+the+glycogen+synthase+kinase-3alpha+and+beta+isoforms+in+patients+with+NIDDM&doi=10.1007%2Fs001250050771"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Chromosomal mapping and mutational analysis of the coding region of the glycogen synthase kinase-3α and β isoforms in patients with NIDDM</span></div><div class="casAuthors">Hansen, L.; Arden, K. C.; Rasmussen, S. B.; Viars, C. S.; Vestergaard, H.; Hansen, T.; Moller, A. M.; Woodgett, J. R.; Pedersen, O.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetologia</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">940-946</span>CODEN:
                <span class="NLM_cas:coden">DBTGAJ</span>;
        ISSN:<span class="NLM_cas:issn">0012-186X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Activation of glycogen synthesis in skeletal muscle in response to insulin results from the combined inactivation of glycogen synthase kinase-3 (GSK-3) and activation of the protein phosphatase-1, changing the ratio between the inactive phosphorylated state of the glycogen synthase to the active dephosphorylated state.  In a search for genetic defects responsible for the decreased insulin stimulated glycogen synthesis seen in patients with non-insulin-dependent diabetes mellitus (NIDDM) and their glucose-tolerant first-degree relatives the authors performed mutational anal. of the coding region of the 2 isoforms of GSK-3α and GSK-3β in 72 NIDDM patients and 12 control subjects.  No structural changes were detected apart from a few silent mutations.  Mapping of the GSK-3α to chromosome 19q13.1-13.2 and the GSK-3β to chromosome 3q13.3-q21 outside known genetic loci linked to NIDDM further makes it unlikely that these genes are involved in the pathogenesis of common forms of NIDDM [Diabetologia (1997), 40: 940-946].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaPb_ulal5Z7Vg90H21EOLACvtfcHk0ljK2KYUD4L7dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXltV2kt7g%253D&md5=c6a2aa87dba5e73148b16a6999ca5e3d</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1007%2Fs001250050771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs001250050771%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DL.%26aulast%3DArden%26aufirst%3DK.%2BC.%26aulast%3DRasmussen%26aufirst%3DS.%2BB.%26aulast%3DViars%26aufirst%3DC.%2BS.%26aulast%3DVestergaard%26aufirst%3DH.%26aulast%3DHansen%26aufirst%3DT.%26aulast%3DM%25C3%25B8ller%26aufirst%3DA.%2BM.%26aulast%3DWoodgett%26aufirst%3DJ.%2BR.%26aulast%3DPedersen%26aufirst%3DO.%26atitle%3DChromosomal%2520mapping%2520and%2520mutational%2520analysis%2520of%2520the%2520coding%2520region%2520of%2520the%2520glycogen%2520synthase%2520kinase-3alpha%2520and%2520beta%2520isoforms%2520in%2520patients%2520with%2520NIDDM%26jtitle%3DDiabetologia%26date%3D1997%26volume%3D40%26spage%3D940%26epage%3D946%26doi%3D10.1007%2Fs001250050771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benajiba, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weïwer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacher, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gale, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puissant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Back, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pikman, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galinsky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeAngelo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robers, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machleidt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermine, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakshminarasimhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemann, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scolnick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegmaier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holson, E. B.</span></span> <span> </span><span class="NLM_article-title">Exploiting an Asp-Glu “switch” in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">eaam8460</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aam8460</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1126%2Fscitranslmed.aam8460" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=29515000" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=eaam8460&author=F.+F.+Wagnerauthor=L.+Benajibaauthor=A.+J.+Campbellauthor=M.+We%C3%AFwerauthor=J.+R.+Sacherauthor=J.+P.+Galeauthor=L.+Rossauthor=A.+Puissantauthor=G.+Alexeauthor=A.+Conwayauthor=M.+Backauthor=Y.+Pikmanauthor=I.+Galinskyauthor=D.+J.+DeAngeloauthor=R.+M.+Stoneauthor=T.+Kayaauthor=X.+Shiauthor=M.+B.+Robersauthor=T.+Machleidtauthor=J.+Wilkinsonauthor=O.+Hermineauthor=A.+Kungauthor=A.+J.+Steinauthor=D.+Lakshminarasimhanauthor=M.+T.+Hemannauthor=E.+Scolnickauthor=Y.+L.+Zhangauthor=J.+Q.+Panauthor=K.+Stegmaierauthor=E.+B.+Holson&title=Exploiting+an+Asp-Glu+%E2%80%9Cswitch%E2%80%9D+in+glycogen+synthase+kinase+3+to+design+paralog-selective+inhibitors+for+use+in+acute+myeloid+leukemia&doi=10.1126%2Fscitranslmed.aam8460"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aam8460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aam8460%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DF.%2BF.%26aulast%3DBenajiba%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DA.%2BJ.%26aulast%3DWe%25C3%25AFwer%26aufirst%3DM.%26aulast%3DSacher%26aufirst%3DJ.%2BR.%26aulast%3DGale%26aufirst%3DJ.%2BP.%26aulast%3DRoss%26aufirst%3DL.%26aulast%3DPuissant%26aufirst%3DA.%26aulast%3DAlexe%26aufirst%3DG.%26aulast%3DConway%26aufirst%3DA.%26aulast%3DBack%26aufirst%3DM.%26aulast%3DPikman%26aufirst%3DY.%26aulast%3DGalinsky%26aufirst%3DI.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DKaya%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DRobers%26aufirst%3DM.%2BB.%26aulast%3DMachleidt%26aufirst%3DT.%26aulast%3DWilkinson%26aufirst%3DJ.%26aulast%3DHermine%26aufirst%3DO.%26aulast%3DKung%26aufirst%3DA.%26aulast%3DStein%26aufirst%3DA.%2BJ.%26aulast%3DLakshminarasimhan%26aufirst%3DD.%26aulast%3DHemann%26aufirst%3DM.%2BT.%26aulast%3DScolnick%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DY.%2BL.%26aulast%3DPan%26aufirst%3DJ.%2BQ.%26aulast%3DStegmaier%26aufirst%3DK.%26aulast%3DHolson%26aufirst%3DE.%2BB.%26atitle%3DExploiting%2520an%2520Asp-Glu%2520%25E2%2580%259Cswitch%25E2%2580%259D%2520in%2520glycogen%2520synthase%2520kinase%25203%2520to%2520design%2520paralog-selective%2520inhibitors%2520for%2520use%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2018%26volume%3D10%26spage%3Deaam8460%26doi%3D10.1126%2Fscitranslmed.aam8460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doble, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodgett, J. R.</span></span> <span> </span><span class="NLM_article-title">GSK-3: Tricks of the trade for a multi-tasking kinase</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">1175</span>– <span class="NLM_lpage">1186</span>, <span class="refDoi"> DOI: 10.1242/jcs.00384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1242%2Fjcs.00384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=12615961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD3sXivFWhtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2003&pages=1175-1186&author=B.+W.+Dobleauthor=J.+R.+Woodgett&title=GSK-3%3A+Tricks+of+the+trade+for+a+multi-tasking+kinase&doi=10.1242%2Fjcs.00384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">GSK-3: Tricks of the trade for a multi-tasking kinase</span></div><div class="casAuthors">Doble, Bradley W.; Woodgett, James R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1175-1186</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  Glycogen synthase kinase-3 (GSK-3) is a multifunctional serine/threonine kinase found in all eukaryotes.  The enzyme is a key regulator of numerous signaling pathways, including cellular responses to Wnt, receptor tyrosine kinases, and G-protein-coupled receptors and is involved in a wide range of cellular processes, ranging from glycogen metab. to cell cycle regulation and proliferation.  GSK-3 is unusual in that it is normally active in cells and is primarily regulated through inhibition of its activity.  Another peculiarity compared with other protein kinases is its preference for primed substrates, i.e., substrates previously phosphorylated by another kinase.  Several recent advances have improved the understanding of GSK-3 regulation in multiple pathways.  These include the soln. of the crystal structure of GSK-3, which has provided insight into GSK-3's penchant for primed substrates and the regulation of GSK-3 by serine phosphorylation, and findings related to the involvement of GSK-3 in the Wnt/β-catenin and Hedgehog pathways.  Finally, since increased GSK-3 activity may be linked to pathol. in diseases such as Alzheimer's disease and non-insulin-dependent diabetes mellitus, several new GSK-3 inhibitors, such as the aloisines, the paullones and the maleimides, have been developed.  Although they are just starting to be characterized in cell culture expts., these new inhibitors hold promise as therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7SGJVebXiRLVg90H21EOLACvtfcHk0ljQJ0J-FxY_bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXivFWhtbc%253D&md5=fb267e44a019d584b6cac5881e8ed1a9</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1242%2Fjcs.00384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.00384%26sid%3Dliteratum%253Aachs%26aulast%3DDoble%26aufirst%3DB.%2BW.%26aulast%3DWoodgett%26aufirst%3DJ.%2BR.%26atitle%3DGSK-3%253A%2520Tricks%2520of%2520the%2520trade%2520for%2520a%2520multi-tasking%2520kinase%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2003%26volume%3D116%26spage%3D1175%26epage%3D1186%26doi%3D10.1242%2Fjcs.00384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frame, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biondi, R. M.</span></span> <span> </span><span class="NLM_article-title">A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1321</span>– <span class="NLM_lpage">1327</span>, <span class="refDoi"> DOI: 10.1016/S1097-2765(01)00253-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2FS1097-2765%2801%2900253-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=11430833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkvVejsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=1321-1327&author=S.+Frameauthor=P.+Cohenauthor=R.+M.+Biondi&title=A+common+phosphate+binding+site+explains+the+unique+substrate+specificity+of+GSK3+and+its+inactivation+by+phosphorylation&doi=10.1016%2FS1097-2765%2801%2900253-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation</span></div><div class="casAuthors">Frame, Sheelagh; Cohen, Philip; Biondi, Ricardo M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1321-1327</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The inhibition of GSK3 is required for the stimulation of glycogen and protein synthesis by insulin and the specification of cell fate during development.  Here, we demonstrate that the insulin-induced inhibition of GSK3 and its unique substrate specificity are explained by the existence of a phosphate binding site in which Arg-96 is crit.  Thus, mutation of Arg-96 abolishes the phosphorylation of "primed" glycogen synthase as well as inhibition by PKB-mediated phosphorylation of Ser-9.  Hence, the phosphorylated N terminus acts as a pseudosubstrate, occupying the same phosphate binding site used by primed substrates.  Significantly, this mutation does not affect phosphorylation of "non-primed" substrates in the Wnt-signaling pathway (Axin and β-catenin), suggesting new approaches to design more selective GSK3 inhibitors for the treatment of diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp8FVqjCg77LVg90H21EOLACvtfcHk0ljQJ0J-FxY_bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkvVejsr4%253D&md5=994d36975d1db73b52ab8a01be39175a</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2801%2900253-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252801%252900253-2%26sid%3Dliteratum%253Aachs%26aulast%3DFrame%26aufirst%3DS.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DBiondi%26aufirst%3DR.%2BM.%26atitle%3DA%2520common%2520phosphate%2520binding%2520site%2520explains%2520the%2520unique%2520substrate%2520specificity%2520of%2520GSK3%2520and%2520its%2520inactivation%2520by%2520phosphorylation%26jtitle%3DMol.%2520Cell%26date%3D2001%26volume%3D7%26spage%3D1321%26epage%3D1327%26doi%3D10.1016%2FS1097-2765%2801%2900253-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gumbiner, B. M.</span></span> <span> </span><span class="NLM_article-title">Regulation of protein stability by GSK3 mediated phosphorylation</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">4032</span>– <span class="NLM_lpage">4039</span>, <span class="refDoi"> DOI: 10.4161/cc.8.24.10111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.4161%2Fcc.8.24.10111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=19923896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC3cXotlWru7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=4032-4039&author=C.+Xuauthor=N.+G.+Kimauthor=B.+M.+Gumbiner&title=Regulation+of+protein+stability+by+GSK3+mediated+phosphorylation&doi=10.4161%2Fcc.8.24.10111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of protein stability by GSK3 mediated phosphorylation</span></div><div class="casAuthors">Xu, Chong; Kim, Nam-Gyun; Gumbiner, Barry M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4032-4039</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  Glycogen synthase kinase-3 (GSK3) plays important roles in numerous signaling pathways that regulate a variety of cellular processes including cell proliferation, differentiation, apoptosis and embryonic development.  In the canonical Wnt signaling pathway, GSK3 phosphorylation mediates proteasomal targeting and degrdn. of β-catenin via the destruction complex.  We recently reported a biochem. screen that discovered multiple addnl. protein substrates whose stability is regulated by Wnt signaling and/or GSK3 and these have important implications for Wnt/GSK3 regulation of different cellular processes.  In this article, we also present a bio-informatics based screen for proteins whose stability may be controlled by GSK3 and β-Trcp, the SCF E3 ubiquitin ligase that is responsible for β-catenin degrdn. in the Wnt signaling pathway.  Furthermore, we review various GSK3 regulated proteolysis substrates described in the literature.  We propose that GSK3 phosphorylation dependent proteolysis is a widespread mechanism that the cell employs to regulate a variety of cell processes in response to signals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLdvp6WfBWKrVg90H21EOLACvtfcHk0ljQJ0J-FxY_bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXotlWru7g%253D&md5=8d89a41f58e318bf45ede52d6ecba030</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.4161%2Fcc.8.24.10111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.8.24.10111%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DN.%2BG.%26aulast%3DGumbiner%26aufirst%3DB.%2BM.%26atitle%3DRegulation%2520of%2520protein%2520stability%2520by%2520GSK3%2520mediated%2520phosphorylation%26jtitle%3DCell%2520Cycle%26date%3D2009%26volume%3D8%26spage%3D4032%26epage%3D4039%26doi%3D10.4161%2Fcc.8.24.10111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beurel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grieco, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jope, R. S.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2014.11.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.pharmthera.2014.11.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=25435019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVeisr7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2015&pages=114-131&author=E.+Beurelauthor=S.+F.+Griecoauthor=R.+S.+Jope&title=Glycogen+synthase+kinase-3+%28GSK3%29%3A+Regulation%2C+actions%2C+and+diseases&doi=10.1016%2Fj.pharmthera.2014.11.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases</span></div><div class="casAuthors">Beurel, Eleonore; Grieco, Steven F.; Jope, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">114-131</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Glycogen synthase kinase-3 (GSK3) may be the busiest kinase in most cells, with over 100 known substrates to deal with.  How does GSK3 maintain control to selectively phosphorylate each substrate, and why was it evolutionarily favorable for GSK3 to assume such a large responsibility.  GSK3 must be particularly adaptable for incorporating new substrates into its repertoire, and we discuss the distinct properties of GSK3 that may contribute to its capacity to fulfill its roles in multiple signaling pathways.  The mechanisms regulating GSK3 (predominantly post-translational modifications, substrate priming, cellular trafficking, protein complexes) have been reviewed previously, so here we focus on newly identified complexities in these mechanisms, how each of these regulatory mechanism contributes to the ability of GSK3 to select which substrates to phosphorylate, and how these mechanisms may have contributed to its adaptability as new substrates evolved.  The current understanding of the mechanisms regulating GSK3 is reviewed, as are emerging topics in the actions of GSK3, particularly its interactions with receptors and receptor-coupled signal transduction events, and differential actions and regulation of the two GSK3 isoforms, GSK3α and GSK3β.  Another remarkable characteristic of GSK3 is its involvement in many prevalent disorders, including psychiatric and neurol. diseases, inflammatory diseases, cancer, and others.  We address the feasibility of targeting GSK3 therapeutically, and provide an update of its involvement in the etiol. and treatment of several disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonota4sOu8PbVg90H21EOLACvtfcHk0liBVgfQVjJE0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVeisr7J&md5=a6c54e0331492b0b61a9d67b1f07575d</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2014.11.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2014.11.016%26sid%3Dliteratum%253Aachs%26aulast%3DBeurel%26aufirst%3DE.%26aulast%3DGrieco%26aufirst%3DS.%2BF.%26aulast%3DJope%26aufirst%3DR.%2BS.%26atitle%3DGlycogen%2520synthase%2520kinase-3%2520%2528GSK3%2529%253A%2520Regulation%252C%2520actions%252C%2520and%2520diseases%26jtitle%3DPharmacol.%2520Ther.%26date%3D2015%26volume%3D148%26spage%3D114%26epage%3D131%26doi%3D10.1016%2Fj.pharmthera.2014.11.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alessi, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andjelkovich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemmings, B. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">785</span>– <span class="NLM_lpage">789</span>, <span class="refDoi"> DOI: 10.1038/378785a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2F378785a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=8524413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADyaK28XltFWj" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=1995&pages=785-789&author=D.+A.+Crossauthor=D.+R.+Alessiauthor=P.+Cohenauthor=M.+Andjelkovichauthor=B.+A.+Hemmings&title=Inhibition+of+glycogen+synthase+kinase-3+by+insulin+mediated+by+protein+kinase+B&doi=10.1038%2F378785a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B</span></div><div class="casAuthors">Cross, Darren A. E.; Alessi, Dario R.; Cohen, Philip; Andjelkovich, Mirjana; Hemmings, Brian A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">6559</span>),
    <span class="NLM_cas:pages">785-9</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Agents which prevent the activation of both MAP kinase-activated protein kinase-1 and p70S6k by insulin in vivo do not block the phosphorylation and inhibition of glycogen synthase kinase-3 (GSK3) in L6 myotubes.  Another insulin-stimulated protein kinase inactivates GSK3 under these conditions, and the authors demonstrate that it is the product of the proto-oncogene protein kinase B (PKB, also known as Akt/RAC).  Like the inhibition of GSK3, the activation of PKB is prevented by inhibitors of phosphatidylinositol 3-kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKh6GNVgGhFbVg90H21EOLACvtfcHk0liBVgfQVjJE0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XltFWj&md5=56723cab1f5412b4e55aca875989d1fa</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1038%2F378785a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F378785a0%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DAndjelkovich%26aufirst%3DM.%26aulast%3DHemmings%26aufirst%3DB.%2BA.%26atitle%3DInhibition%2520of%2520glycogen%2520synthase%2520kinase-3%2520by%2520insulin%2520mediated%2520by%2520protein%2520kinase%2520B%26jtitle%3DNature%26date%3D1995%26volume%3D378%26spage%3D785%26epage%3D789%26doi%3D10.1038%2F378785a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span> <span> </span><span class="NLM_article-title">Wnt/beta-catenin signaling: Components, mechanisms, and diseases</span>. <i>Dev. Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/j.devcel.2009.06.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.devcel.2009.06.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=19619488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsV2msb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=9-26&author=B.+T.+MacDonaldauthor=K.+Tamaiauthor=X.+He&title=Wnt%2Fbeta-catenin+signaling%3A+Components%2C+mechanisms%2C+and+diseases&doi=10.1016%2Fj.devcel.2009.06.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Wnt/β-catenin signaling: components, mechanisms, and diseases</span></div><div class="casAuthors">MacDonald, Bryan T.; Tamai, Keiko; He, Xi</div><div class="citationInfo"><span class="NLM_cas:title">Developmental Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-26</span>CODEN:
                <span class="NLM_cas:coden">DCEEBE</span>;
        ISSN:<span class="NLM_cas:issn">1534-5807</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Signaling by the Wnt family of secreted glycolipoproteins via the transcriptional coactivator β-catenin controls embryonic development and adult homeostasis.  Here we review recent progress in this so-called canonical Wnt signaling pathway.  We discuss Wnt ligands, agonists, and antagonists, and their interactions with Wnt receptors.  We also dissect crit. events that regulate β-catenin stability, from Wnt receptors to the cytoplasmic β-catenin destruction complex, and nuclear machinery that mediates β-catenin-dependent transcription.  Finally, we highlight some key aspects of Wnt/β-catenin signaling in human diseases including congenital malformations, cancer, and osteoporosis, and discuss potential therapeutic implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNap4TpxXFWbVg90H21EOLACvtfcHk0liBVgfQVjJE0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsV2msb8%253D&md5=25e1a7dd5c3aca54a1cfc7993fd5bb43</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.devcel.2009.06.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.devcel.2009.06.016%26sid%3Dliteratum%253Aachs%26aulast%3DMacDonald%26aufirst%3DB.%2BT.%26aulast%3DTamai%26aufirst%3DK.%26aulast%3DHe%26aufirst%3DX.%26atitle%3DWnt%252Fbeta-catenin%2520signaling%253A%2520Components%252C%2520mechanisms%252C%2520and%2520diseases%26jtitle%3DDev.%2520Cell%26date%3D2009%26volume%3D17%26spage%3D9%26epage%3D26%26doi%3D10.1016%2Fj.devcel.2009.06.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Metcalfe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bienz, M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of GSK3 by wnt signalling--two contrasting models</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">3537</span>– <span class="NLM_lpage">3544</span>, <span class="refDoi"> DOI: 10.1242/jcs.091991</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1242%2Fjcs.091991" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=22083140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1OrtrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2011&pages=3537-3544&author=C.+Metcalfeauthor=M.+Bienz&title=Inhibition+of+GSK3+by+wnt+signalling%2D%2Dtwo+contrasting+models&doi=10.1242%2Fjcs.091991"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of GSK3 by Wnt signaling - two contrasting models</span></div><div class="casAuthors">Metcalfe, Ciara; Bienz, Mariann</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3537-3544</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  The key read-out of Wnt signaling is a change in the transcriptional profile of the cell, which is driven by β-catenin.  β-Catenin levels are normally kept low by a phosphorylation event that is mediated by glycogen synthase kinase-3 (GSK3, α- and β-isoforms), which targets β-catenin for ubiquitination and proteasomal degrdn.  Wnt blocks this phosphorylation event, thereby allowing β-catenin to accumulate and to co-activate transcription in the nucleus.  Exactly how Wnt inhibits GSK3 activity toward β-catenin is unclear and has been the focus of intensive research.  Recent studies on the role of conserved PPPSPxS motifs in the cytoplasmic tail of low-d. lipoprotein receptor-related protein (LRP, isoforms 5 and 6) culminated in a biochem. model: Wnt induces the phosphorylation of LRP6 PPPSPxS motifs, which consequently access the catalytic pocket of GSK3 as pseudo-substrates, thus directly blocking its activity against β-catenin.  A distinct cell-biol. model was proposed more recently: Wnt proteins induce the uptake of GSK3 into multivesicular bodies (MVBs), an event that sequesters the enzyme away from newly synthesized β-catenin substrate in the cytoplasm, thus blocking its phosphorylation.  This new model is based on intriguing observations, but also challenges a body of existing evidence, so will require further exptl. consolidation.  The authors discuss whether the 2 models apply to different modes of Wnt signaling: acute vs. chronic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq7IOjo03EtrVg90H21EOLACvtfcHk0liBVgfQVjJE0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1OrtrrL&md5=5ee874619c533fe30b143204d0c77437</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1242%2Fjcs.091991&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.091991%26sid%3Dliteratum%253Aachs%26aulast%3DMetcalfe%26aufirst%3DC.%26aulast%3DBienz%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520GSK3%2520by%2520wnt%2520signalling--two%2520contrasting%2520models%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2011%26volume%3D124%26spage%3D3537%26epage%3D3544%26doi%3D10.1242%2Fjcs.091991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valvezan, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, P. S.</span></span> <span> </span><span class="NLM_article-title">GSK-3 and wnt signaling in neurogenesis and bipolar disorder</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2012.00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.3389%2Ffnmol.2012.00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=22319467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Kks7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2012&pages=1&author=A.+J.+Valvezanauthor=P.+S.+Klein&title=GSK-3+and+wnt+signaling+in+neurogenesis+and+bipolar+disorder&doi=10.3389%2Ffnmol.2012.00001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">GSK-3 and Wnt signaling in neurogenesis and bipolar disorder</span></div><div class="casAuthors">Valvezan, Alexander J.; Klein, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">Jan.</span>),
    <span class="NLM_cas:pages">1</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  The canonical Wnt signaling pathway is crit. for development of the mammalian central nervous system and regulates diverse processes throughout adulthood, including adult neurogenesis.  Glycogen synthase kinase-3 (GSK-3) antagonizes the canonical Wnt pathway and therefore also plays a central role in neural development and adult neurogenesis.  Lithium, the first line of therapy for bipolar disorder, inhibits GSK-3, activates Wnt signaling and stimulates adult neurogenesis, which may be important for its therapeutic effects.  GSK-3 also regulates other crit. signaling pathways which may contribute to the therapeutic effects of lithium, including growth factor/neurotrophin signaling downstream of Akt.  Here we will review the roles of GSK-3 in CNS development and adult neurogenesis, with a focus on the canonical Wnt pathway.  We will also discuss the validation of GSK-3 as the relevant target of lithium and the mechanisms downstream of GSK-3 that influence mammalian behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrye-OzONjfJbVg90H21EOLACvtfcHk0liDDIZzMiub3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Kks7g%253D&md5=126a406fd1623765a65f8d0ab5d9df84</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2012.00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2012.00001%26sid%3Dliteratum%253Aachs%26aulast%3DValvezan%26aufirst%3DA.%2BJ.%26aulast%3DKlein%26aufirst%3DP.%2BS.%26atitle%3DGSK-3%2520and%2520wnt%2520signaling%2520in%2520neurogenesis%2520and%2520bipolar%2520disorder%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2012%26volume%3D5%26spage%3D1%26doi%3D10.3389%2Ffnmol.2012.00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salcedo-Tello, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz-Matamoros, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arias, C.</span></span> <span> </span><span class="NLM_article-title">GSK3 function in the brain during development, neuronal plasticity, and neurodegeneration</span>. <i>Int. J. Alzheimer's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2011</i></span>,  <span class="NLM_fpage">189728</span>, <span class="refDoi"> DOI: 10.4061/2011/189728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.4061%2F2011%2F189728" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=21660241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BC3Mrpt1alsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=189728&author=P.+Salcedo-Telloauthor=A.+Ortiz-Matamorosauthor=C.+Arias&title=GSK3+function+in+the+brain+during+development%2C+neuronal+plasticity%2C+and+neurodegeneration&doi=10.4061%2F2011%2F189728"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">GSK3 Function in the Brain during Development, Neuronal Plasticity, and Neurodegeneration</span></div><div class="casAuthors">Salcedo-Tello Pamela; Ortiz-Matamoros Abril; Arias Clorinda</div><div class="citationInfo"><span class="NLM_cas:title">International journal of Alzheimer's disease</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2011</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">189728</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">GSK3 has diverse functions, including an important role in brain pathology.  In this paper, we address the primary functions of GSK3 in development and neuroplasticity, which appear to be interrelated and to mediate age-associated neurological diseases.  Specifically, GSK3 plays a pivotal role in controlling neuronal progenitor proliferation and establishment of neuronal polarity during development, and the upstream and downstream signals modulating neuronal GSK3 function affect cytoskeletal reorganization and neuroplasticity throughout the lifespan.  Modulation of GSK3 in brain areas subserving cognitive function has become a major focus for treating neuropsychiatric and neurodegenerative diseases.  As a crucial node that mediates a variety of neuronal processes, GSK3 is proposed to be a therapeutic target for restoration of synaptic functioning and cognition, particularly in Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTSWpsFFc4A4BKDYG3bNImrfW6udTcc2eYXty-XMtZLVLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mrpt1alsQ%253D%253D&md5=817cf22bd2735fe4d1c6249959a690ef</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.4061%2F2011%2F189728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4061%252F2011%252F189728%26sid%3Dliteratum%253Aachs%26aulast%3DSalcedo-Tello%26aufirst%3DP.%26aulast%3DOrtiz-Matamoros%26aufirst%3DA.%26aulast%3DArias%26aufirst%3DC.%26atitle%3DGSK3%2520function%2520in%2520the%2520brain%2520during%2520development%252C%2520neuronal%2520plasticity%252C%2520and%2520neurodegeneration%26jtitle%3DInt.%2520J.%2520Alzheimer%2527s%2520Dis.%26date%3D2011%26volume%3D2011%26spage%3D189728%26doi%3D10.4061%2F2011%2F189728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joo, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cha, C. I.</span></span> <span> </span><span class="NLM_article-title">Age-related changes in glycogen synthase kinase 3beta (GSK3beta) immunoreactivity in the central nervous system of rats</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>409</i></span>,  <span class="NLM_fpage">134</span>– <span class="NLM_lpage">139</span>, <span class="refDoi"> DOI: 10.1016/j.neulet.2006.09.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.neulet.2006.09.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=17046157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFerurjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=409&publication_year=2006&pages=134-139&author=S.+J.+Leeauthor=Y.+H.+Chungauthor=K.+M.+Jooauthor=H.+C.+Limauthor=G.+S.+Jeonauthor=D.+Kimauthor=W.+B.+Leeauthor=Y.+S.+Kimauthor=C.+I.+Cha&title=Age-related+changes+in+glycogen+synthase+kinase+3beta+%28GSK3beta%29+immunoreactivity+in+the+central+nervous+system+of+rats&doi=10.1016%2Fj.neulet.2006.09.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Age-related changes in glycogen synthase kinase 3β (GSK3β) immunoreactivity in the central nervous system of rats</span></div><div class="casAuthors">Lee, Soo Joo; Chung, Yoon Hee; Joo, Kyeung Min; Lim, Heon Chang; Jeon, Gye Sun; Kim, Daejin; Lee, Won Bok; Kim, Yong Sik; Cha, Choong Ik</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">409</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">134-139</span>CODEN:
                <span class="NLM_cas:coden">NELED5</span>;
        ISSN:<span class="NLM_cas:issn">0304-3940</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Although glycogen synthase kinase 3β (GSK3β) is emerging as a prominent drug target in the treatment of neurodegenerative diseases such as Alzheimer's disease (AD) and stroke, very little is known about age-related changes in GSK3β expression and GSK3β phosphorylation.  Therefore, we examd. age-related changes in immunoreactivities for GSK3β and phosphorylated GSK3β (pGSK3β) in the central nervous system.  In aged rats, there were significant increases in GSK3β immunoreactivity in the cell bodies and processes of pyramidal cells in most cortical regions.  GSK3β immunoreactivity was also significantly increased in the pyramidal layer of CA1-3 regions, and the granule cell layer of dentate gyrus.  Age-related increases were prominent in lateral septal nuclei, compared to the medial septal nuclei.  Interestingly, both GSK3β and pGSK3β was increased in the prefrontal cortex, while GSK3β and pGSK3β was differentially localized in the cerebellar cortex.  The first demonstration of age-related alterations in immunoreactivities for GSK3β and pGSK3β in the basal forebrain area and cholinergic projection targets may provide useful data for investigating the pathogenesis of age-related neurodegenerative diseases including AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCfWv5OuCta7Vg90H21EOLACvtfcHk0liDDIZzMiub3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFerurjO&md5=3593884bff31c615b4a0bccb9299600e</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.neulet.2006.09.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neulet.2006.09.026%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DChung%26aufirst%3DY.%2BH.%26aulast%3DJoo%26aufirst%3DK.%2BM.%26aulast%3DLim%26aufirst%3DH.%2BC.%26aulast%3DJeon%26aufirst%3DG.%2BS.%26aulast%3DKim%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DW.%2BB.%26aulast%3DKim%26aufirst%3DY.%2BS.%26aulast%3DCha%26aufirst%3DC.%2BI.%26atitle%3DAge-related%2520changes%2520in%2520glycogen%2520synthase%2520kinase%25203beta%2520%2528GSK3beta%2529%2520immunoreactivity%2520in%2520the%2520central%2520nervous%2520system%2520of%2520rats%26jtitle%3DNeurosci.%2520Lett.%26date%3D2006%26volume%3D409%26spage%3D134%26epage%3D139%26doi%3D10.1016%2Fj.neulet.2006.09.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span> <span> </span><span class="NLM_article-title">The role of GSK3beta in the development of the central nervous system</span>. <i>Front. Biol. (Beijing, China)</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">212</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1007/s11515-012-1222-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1007%2Fs11515-012-1222-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=25688261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsFGit7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=212-220&author=J.+Luo&title=The+role+of+GSK3beta+in+the+development+of+the+central+nervous+system&doi=10.1007%2Fs11515-012-1222-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">The role of GSK3beta in the development of the central nervous system</span></div><div class="casAuthors">Luo, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Biology (Beijing, China)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">212-220</span>CODEN:
                <span class="NLM_cas:coden">FBRIA3</span>;
        ISSN:<span class="NLM_cas:issn">1674-7984</span>.
    
            (<span class="NLM_cas:orgname">Higher Education Press</span>)
        </div><div class="casAbstract">A review.  Glycogen synthase kinase 3β (GSK3β) is a multifunctional serine/threonine kinase.  It is particularly abundant in the developing central nervous system (CNS).  Since GSK3β has diverse substrates ranging from metabolic/signaling proteins and structural proteins to transcription factors, it is involved in many developmental events in the immature brain, such as neurogenesis, neuronal migration, differentiation and survival.  The activity of GSK3β is developmentally regulated and is affected by various environmental/cellular insults, such as deprivation of nutrients/trophic factors, oxidative stress and endoplasmic reticulum stress.  Abnormalities in GSK3β activity may disrupt CNS development.  Therefore, GSK3β is a crit. signaling protein that regulates brain development.  It may also det. neuronal susceptibility to damages caused by various environmental insults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDh9aAoCAcXbVg90H21EOLACvtfcHk0lh3jJ9botRZlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsFGit7o%253D&md5=e508714d47c9f85da04c30c8a74c33d9</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1007%2Fs11515-012-1222-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11515-012-1222-2%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DJ.%26atitle%3DThe%2520role%2520of%2520GSK3beta%2520in%2520the%2520development%2520of%2520the%2520central%2520nervous%2520system%26jtitle%3DFront.%2520Biol.%2520%2528Beijing%252C%2520China%2529%26date%3D2012%26volume%3D7%26spage%3D212%26epage%3D220%26doi%3D10.1007%2Fs11515-012-1222-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hur, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F. Q.</span></span> <span> </span><span class="NLM_article-title">GSK3 signalling in neural development</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">539</span>– <span class="NLM_lpage">551</span>, <span class="refDoi"> DOI: 10.1038/nrn2870</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2Fnrn2870" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=20648061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptVGisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=539-551&author=E.+M.+Hurauthor=F.+Q.+Zhou&title=GSK3+signalling+in+neural+development&doi=10.1038%2Fnrn2870"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">GSK3 signaling in neural development</span></div><div class="casAuthors">Hur, Eun-Mi; Zhou, Feng-Quan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">539-551</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Recent evidence suggests that glycogen synthase kinase-3 (GSK3) proteins and their upstream and downstream regulators have key roles in many fundamental processes during neurodevelopment.  Disruption of GSK3 signaling adversely affects brain development and is assocd. with several neurodevelopmental disorders.  Here, the authors discuss the mechanisms by which GSK3 activity is regulated in the nervous system and provide an overview of the recent advances in the understanding of how GSK3 signaling controls neurogenesis, neuronal polarization, and axon growth during brain development.  These recent advances suggest that GSK3 is a crucial node that mediates various cellular processes that are controlled by multiple signaling mols., e.g., disrupted in schizophrenia 1 (DISC1), partitioning defective homolog 3 (PAR3), PAR6, and Wnt proteins, that regulate neurodevelopment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiOzmiQawg1rVg90H21EOLACvtfcHk0ljhGxPvnp5kfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptVGisro%253D&md5=7ad4651b8fd5a97028df1a57be2c4b38</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2Fnrn2870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn2870%26sid%3Dliteratum%253Aachs%26aulast%3DHur%26aufirst%3DE.%2BM.%26aulast%3DZhou%26aufirst%3DF.%2BQ.%26atitle%3DGSK3%2520signalling%2520in%2520neural%2520development%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2010%26volume%3D11%26spage%3D539%26epage%3D551%26doi%3D10.1038%2Fnrn2870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jaworski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banach-Kasper, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gralec, K.</span></span> <span> </span><span class="NLM_article-title">GSK-3 at the intersection of neuronal plasticity and neurodegeneration</span>. <i>Neural Plast.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>2019</i></span>,  <span class="NLM_fpage">4209475</span>, <span class="refDoi"> DOI: 10.1155/2019/4209475</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1155%2F2019%2F4209475" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=31191636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BB3M3mtVWmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2019&publication_year=2019&pages=4209475&author=T.+Jaworskiauthor=E.+Banach-Kasperauthor=K.+Gralec&title=GSK-3+at+the+intersection+of+neuronal+plasticity+and+neurodegeneration&doi=10.1155%2F2019%2F4209475"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">GSK-3β at the Intersection of Neuronal Plasticity and Neurodegeneration</span></div><div class="casAuthors">Jaworski Tomasz; Banach-Kasper Ewa; Gralec Katarzyna</div><div class="citationInfo"><span class="NLM_cas:title">Neural plasticity</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">2019</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4209475</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In neurons, Glycogen Synthase Kinase-3β (GSK-3β) has been shown to regulate various critical processes underlying structural and functional synaptic plasticity.  Mouse models with neuron-selective expression or deletion of GSK-3β present behavioral and cognitive abnormalities, positioning this protein kinase as a key signaling molecule in normal brain functioning.  Furthermore, mouse models with defective GSK-3β activity display distinct structural and behavioral abnormalities, which model some aspects of different neurological and neuropsychiatric disorders.  Equalizing GSK-3β activity in these mouse models by genetic or pharmacological interventions is able to rescue some of these abnormalities.  Thus, GSK-3β is a relevant therapeutic target for the treatment of many brain disorders.  Here, we provide an overview of how GSK-3β is regulated in physiological synaptic plasticity and how aberrant GSK-3β activity contributes to the development of dysfunctional synaptic plasticity in neuropsychiatric and neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQMWTmz72EpP7ZpSb_XWfMrfW6udTcc2eZi6pvSvrfYWrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3mtVWmtg%253D%253D&md5=0b0c558757f5d282532f9b894d51910a</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1155%2F2019%2F4209475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2019%252F4209475%26sid%3Dliteratum%253Aachs%26aulast%3DJaworski%26aufirst%3DT.%26aulast%3DBanach-Kasper%26aufirst%3DE.%26aulast%3DGralec%26aufirst%3DK.%26atitle%3DGSK-3%2520at%2520the%2520intersection%2520of%2520neuronal%2520plasticity%2520and%2520neurodegeneration%26jtitle%3DNeural%2520Plast.%26date%3D2019%26volume%3D2019%26spage%3D4209475%26doi%3D10.1155%2F2019%2F4209475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giese, K. P.</span></span> <span> </span><span class="NLM_article-title">GSK-3: A key player in neurodegeneration and memory</span>. <i>IUBMB Life</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">516</span>– <span class="NLM_lpage">521</span>, <span class="refDoi"> DOI: 10.1002/iub.187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1002%2Fiub.187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=19391164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFCgsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2009&pages=516-521&author=K.+P.+Giese&title=GSK-3%3A+A+key+player+in+neurodegeneration+and+memory&doi=10.1002%2Fiub.187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">GSK-3: a key player in neurodegeneration and memory</span></div><div class="casAuthors">Giese, Karl Peter</div><div class="citationInfo"><span class="NLM_cas:title">IUBMB Life</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">516-521</span>CODEN:
                <span class="NLM_cas:coden">IULIF8</span>;
        ISSN:<span class="NLM_cas:issn">1521-6543</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Inc.</span>)
        </div><div class="casAbstract">A review.  Abnormalities in mol. signalling have been implicated in neurodegeneration.  It is emerging that glycogen synthase kinase-3 (GSK-3) is a key signalling mol. that induces neurodegeneration and deficits in memory formation related to Alzheimer's disease (AD).  Early stages of AD are assocd. with deficits in memory formation before neuronal cell death is detectable.  Recent studies in rodents have suggested that these impairments in memory formation might result from increased GSK-3 signalling, because enhanced GSK-3 activity impairs hippocampal memory formation.  GSK-3 activity blocks synaptic long-term potentiation and induces long-term depression.  Furthermore, increased GSK-3 signalling is likely to be a key contributor to the formation of the pathol. hallmarks in AD, neurofibrillary tangles (NFTs) and amyloid plaques.  Recent studies with mouse models have indicated that GSK-3, but not cyclin-dependent kinase 5, is crit. for hyperphosphorylation of the cytoskeletal protein tau, which is the prerequisite for NFT formation in AD.  Furthermore, increased GSK-3 signalling in AD mice causes abnormal processing of the amyloid precursor protein so that amyloid peptide prodn. augments and neurotoxicity is induced.  Taken together, the current evidences suggest that increased GSK-3 signalling may be responsible for the deficits in memory formation in early stages of AD and neurodegeneration in later stages of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfGAuMfcOC_bVg90H21EOLACvtfcHk0ljhGxPvnp5kfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFCgsLk%253D&md5=eb868c3ad7371c3a7a07ccbf1648fe98</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1002%2Fiub.187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fiub.187%26sid%3Dliteratum%253Aachs%26aulast%3DGiese%26aufirst%3DK.%2BP.%26atitle%3DGSK-3%253A%2520A%2520key%2520player%2520in%2520neurodegeneration%2520and%2520memory%26jtitle%3DIUBMB%2520Life%26date%3D2009%26volume%3D61%26spage%3D516%26epage%3D521%26doi%3D10.1002%2Fiub.187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Llorens-Martín, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurado, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernández, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avila, J.</span></span> <span> </span><span class="NLM_article-title">GSK-3β, a pivotal kinase in Alzheimer disease</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">46</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2014.00046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.3389%2Ffnmol.2014.00046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=24904272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVaqs7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=46&author=M.+Llorens-Mart%C3%ADnauthor=J.+Juradoauthor=F.+Hern%C3%A1ndezauthor=J.+Avila&title=GSK-3%CE%B2%2C+a+pivotal+kinase+in+Alzheimer+disease&doi=10.3389%2Ffnmol.2014.00046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">GSK-3β, a pivotal kinase in Alzheimer disease</span></div><div class="casAuthors">Llorens-Martin, Maria; Jurado, Jeronimo; Hernandez, Felix; Avila, Jesus</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46/1-46/11, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Alzheimer disease (AD) is the most common form of age-related dementia.  The etiol. of AD is considered to be multifactorial as only a negligible percentage of cases have a familial or genetic origin.  Glycogen synthase kinase-3 (GSK-3) is regarded as a crit. mol. link between the two histopathol. hallmarks of the disease, namely senile plaques and neurofibrillary tangles.  In this review, we summarize current data regarding the involvement of this kinase in several aspects of AD development and progression, as well as key observations highlighting GSK-3 as one of the most relevant targets for AD treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-u6YWBRA8XLVg90H21EOLACvtfcHk0ljhGxPvnp5kfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVaqs7fM&md5=7ea2969c4a89644aebb73701cf7b7d60</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2014.00046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2014.00046%26sid%3Dliteratum%253Aachs%26aulast%3DLlorens-Mart%25C3%25ADn%26aufirst%3DM.%26aulast%3DJurado%26aufirst%3DJ.%26aulast%3DHern%25C3%25A1ndez%26aufirst%3DF.%26aulast%3DAvila%26aufirst%3DJ.%26atitle%3DGSK-3%25CE%25B2%252C%2520a%2520pivotal%2520kinase%2520in%2520Alzheimer%2520disease%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2014%26volume%3D7%26spage%3D46%26doi%3D10.3389%2Ffnmol.2014.00046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanger, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodgett, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brion, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, B. H.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3 induces Alzheimer’s disease-like phosphorylation of tau: Generation of paired helical filament epitopes and neuronal localisation of the kinase</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">62</span>, <span class="refDoi"> DOI: 10.1016/0304-3940(92)90774-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2F0304-3940%2892%2990774-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1336152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADyaK3sXpvFGksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=1992&pages=58-62&author=D.+P.+Hangerauthor=K.+Hughesauthor=J.+R.+Woodgettauthor=J.+P.+Brionauthor=B.+H.+Anderton&title=Glycogen+synthase+kinase-3+induces+Alzheimer%E2%80%99s+disease-like+phosphorylation+of+tau%3A+Generation+of+paired+helical+filament+epitopes+and+neuronal+localisation+of+the+kinase&doi=10.1016%2F0304-3940%2892%2990774-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau:  generation of paired helical filament epitopes and neuronal localization of the kinase</span></div><div class="casAuthors">Hanger, Diane P.; Hughes, Kenneth; Woodgett, James R.; Brion, Jean Pierre; Anderton, Brian H.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience Letters</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-62</span>CODEN:
                <span class="NLM_cas:coden">NELED5</span>;
        ISSN:<span class="NLM_cas:issn">0304-3940</span>.
    </div><div class="casAbstract">Glycogen synthase kinase-3 (GSK-3) reduced the mobility of human tau on SDS-PAGE, prevented binding of the monoclonal antibody (mAb) Tau. 1, and induced binding of the mAb 8D8.  Recombinant tau phosphorylated by GSK-3 aligned on SDS-PAGE with the abnormally phosphorylated tau (PHF-tau) assocd. with the paired helical filaments in Alzheimer's disease brain.  Phosphorylated serine396 (numbering of the largest human brain tau isoform) was identified as a binding site on tau for mAb 8D8.  The localization of GSK-3 within granular structures in pyramidal cells indicates that GSK-3α and GSK-3β may have a role in the prodn. of PHF-tau in Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOM1_KaxlV9LVg90H21EOLACvtfcHk0lixvMkSRRl2pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXpvFGksg%253D%253D&md5=88d0a3271ce167362ce8b363bae5dbf4</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2F0304-3940%2892%2990774-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0304-3940%252892%252990774-2%26sid%3Dliteratum%253Aachs%26aulast%3DHanger%26aufirst%3DD.%2BP.%26aulast%3DHughes%26aufirst%3DK.%26aulast%3DWoodgett%26aufirst%3DJ.%2BR.%26aulast%3DBrion%26aufirst%3DJ.%2BP.%26aulast%3DAnderton%26aufirst%3DB.%2BH.%26atitle%3DGlycogen%2520synthase%2520kinase-3%2520induces%2520Alzheimer%25E2%2580%2599s%2520disease-like%2520phosphorylation%2520of%2520tau%253A%2520Generation%2520of%2520paired%2520helical%2520filament%2520epitopes%2520and%2520neuronal%2520localisation%2520of%2520the%2520kinase%26jtitle%3DNeurosci.%2520Lett.%26date%3D1992%26volume%3D147%26spage%3D58%26epage%3D62%26doi%3D10.1016%2F0304-3940%2892%2990774-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Medina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wandosell, F. G.</span></span> <span> </span><span class="NLM_article-title">Modulation of GSK-3 as a therapeutic strategy on tau pathologies</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">24</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2011.00024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.3389%2Ffnmol.2011.00024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=22007157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC38XovVOr" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=24&author=M.+Medinaauthor=J.+J.+Garridoauthor=F.+G.+Wandosell&title=Modulation+of+GSK-3+as+a+therapeutic+strategy+on+tau+pathologies&doi=10.3389%2Ffnmol.2011.00024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of GSK-3 as a therapeutic strategy on tau pathologies</span></div><div class="casAuthors">Medina, Miguel; Garrido, Juan Jose; Wandosell, Francisco G.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">Oct.</span>),
    <span class="NLM_cas:pages">24</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Glycogen synthase kinase-3 (GSK-3) is ubiquitously expressed and unusually active in resting, non-stimulated cells.  In mammals, at least three proteins (α, β1, and β2), generated from two different genes, gsk-3α and gsk-3β, are widely expressed at both the RNA and protein levels although some tissues show preferential expression of some of the three proteins.  Control of GSK-3 activity occurs by complex mechanisms that depend on specific signaling pathways, often controlling the inhibition of the kinase activity.  GSK-3 appears to integrate different signaling pathways from a wide selection of cellular stimuli.  The unique position of GSK-3 in modulating the function of a diverse series of proteins and its assocn. with a wide variety of human disorders has attracted significant attention as a therapeutic target and as a means to understand the mol. basis of brain disorders.  Different neurodegenerative diseases including frontotemporal dementia, progressive supranuclear palsy, and Alzheimer's disease, present prominent tau pathol. such as tau hyperphosphorylation and aggregation and are collectively referred to as tauopathies.  GSK-3 has also been assocd. to different neuropsychiatric disorders, like schizophrenia and bipolar disorder.  GSK-3β is the major kinase to phosphorylate tau both in vitro and in vivo and has been proposed as a target for therapeutic intervention.  The first therapeutic strategy to modulate GSK-3 activity was the direct inhibition of its kinase activity.  This review will focus on the signaling pathways involved in the control of GSK-3 activity and its pathol. deregulation.  We will highlight different alternatives of GSK-3 modulation including the direct pharmacol. inhibition as compared to the modulation by upstream regulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozOpI-IGncc7Vg90H21EOLACvtfcHk0lixvMkSRRl2pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovVOr&md5=ba4d1b446707beabb6db326ec3d6b951</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2011.00024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2011.00024%26sid%3Dliteratum%253Aachs%26aulast%3DMedina%26aufirst%3DM.%26aulast%3DGarrido%26aufirst%3DJ.%2BJ.%26aulast%3DWandosell%26aufirst%3DF.%2BG.%26atitle%3DModulation%2520of%2520GSK-3%2520as%2520a%2520therapeutic%2520strategy%2520on%2520tau%2520pathologies%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2011%26volume%3D4%26spage%3D24%26doi%3D10.3389%2Ffnmol.2011.00024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaworski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Leuven, F.</span></span> <span> </span><span class="NLM_article-title">GSK3 and Alzheimer’s disease: Facts and fiction...</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">17</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2011.00017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.3389%2Ffnmol.2011.00017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=21904524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC38XovVKr" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=17&author=A.+Kremerauthor=J.+V.+Louisauthor=T.+Jaworskiauthor=F.+Van+Leuven&title=GSK3+and+Alzheimer%E2%80%99s+disease%3A+Facts+and+fiction...&doi=10.3389%2Ffnmol.2011.00017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">GSK3 and Alzheimer's disease: facts and fiction</span></div><div class="casAuthors">Kremer, Anna; Louis, Justin V.; Jaworski, Tomasz; Van Leuven, Fred</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">Aug.</span>),
    <span class="NLM_cas:pages">17</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  The physiol. functions and pathol. roles of the Glycogen synthase kinase-type 3 (GSK3) kinases in peripheral and central systems are diverse and complex, and therefore hard to unravel in mol. detail in vivo.  Our assignment to review and discuss available data to clarify the actual position of these kinases in the pathol. of Alzheimer's dementia (AD) was both ambitious and easy.  On the one hand, numerous studies are available in isolated, recombinant, or cell-based systems, which have resulted in very diverse data-sets that are hardly informative for the brain in vivo.  At the other extreme, reliable, and relevant models for the role of GSK3 in CNS are rare, if not lacking.  Moreover, (too) many in vivo studies used Li+ as "specific" inhibitor of GSK3, which is factually not valid because lithium ions are neither specific nor potent inhibitors of GSK3 in vivo.  More specific pharmacol. inhibitors of GSK3 have met with considerable problems, and are reviewed by others in this issue or elsewhere.  We conc. here on AD-related aspects of GSK3 in brain in vivo, mainly studied in transgenic mice and highlight some of the more important issues, among many remaining: activation of GSK3 by amyloid, phosphorylation of protein tau, effects on or interference with synaptic activity, differentiation between both GSK3 isoforms.  These relate directly to brain function, and brain dysfunction in AD, and are to be resolved if we want to understand the mol. pathol. of this dreadful disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkyOq4ZInd37Vg90H21EOLACvtfcHk0lixvMkSRRl2pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovVKr&md5=ca9888444963da083e23df3c17a51521</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2011.00017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2011.00017%26sid%3Dliteratum%253Aachs%26aulast%3DKremer%26aufirst%3DA.%26aulast%3DLouis%26aufirst%3DJ.%2BV.%26aulast%3DJaworski%26aufirst%3DT.%26aulast%3DVan%2BLeuven%26aufirst%3DF.%26atitle%3DGSK3%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520Facts%2520and%2520fiction...%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2011%26volume%3D4%26spage%3D17%26doi%3D10.3389%2Ffnmol.2011.00017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melcher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H. E.</span></span> <span> </span><span class="NLM_article-title">Amyloid beta: Structure, biology and structure-based therapeutic development</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1205</span>– <span class="NLM_lpage">1235</span>, <span class="refDoi"> DOI: 10.1038/aps.2017.28</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2Faps.2017.28" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=28713158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVektLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2017&pages=1205-1235&author=G.+F.+Chenauthor=T.+H.+Xuauthor=Y.+Yanauthor=Y.+R.+Zhouauthor=Y.+Jiangauthor=K.+Melcherauthor=H.+E.+Xu&title=Amyloid+beta%3A+Structure%2C+biology+and+structure-based+therapeutic+development&doi=10.1038%2Faps.2017.28"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Amyloid beta: structure, biology and structure-based therapeutic development</span></div><div class="casAuthors">Chen, Guo-fang; Xu, Ting-hai; Yan, Yan; Zhou, Yu-ren; Jiang, Yi; Melcher, Karsten; Xu, H. Eric</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1205-1235</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Amyloid beta peptide (Aβ) is produced through the proteolytic processing of a transmembrane protein, amyloid precursor protein (APP), by β- and γ-secretases.  Aβ accumulation in the brain is proposed to be an early toxic event in the pathogenesis of Alzheimer's disease, which is the most common form of dementia assocd. with plaques and tangles in the brain.  Currently, it is unclear what the physiol. and pathol. forms of Aβ are and by what mechanism Aβ causes dementia.  Moreover, there are no efficient drugs to stop or reverse the progression of Alzheimer's disease.  In this paper, we review the structures, biol. functions, and neurotoxicity role of Aβ.  We also discuss the potential receptors that interact with Aβ and mediate Aβ intake, clearance, and metab.  Addnl., we summarize the therapeutic developments and recent advances of different strategies for treating Alzheimer's disease.  Finally, we will report on the progress in searching for novel, potentially effective agents as well as selected promising strategies for the treatment of Alzheimer's disease.  These prospects include agents acting on Aβ, its receptors and tau protein, such as small mols., vaccines and antibodies against Aβ; inhibitors or modulators of β- and γ-secretase; Aβ-degrading proteases; tau protein inhibitors and vaccines; amyloid dyes and microRNAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC9Hw1Lo4LXbVg90H21EOLACvtfcHk0lixvMkSRRl2pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVektLbM&md5=b29b9899f56ebeecf5bce2cd80b04d2a</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1038%2Faps.2017.28&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2017.28%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DG.%2BF.%26aulast%3DXu%26aufirst%3DT.%2BH.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.%2BR.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DMelcher%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DH.%2BE.%26atitle%3DAmyloid%2520beta%253A%2520Structure%252C%2520biology%2520and%2520structure-based%2520therapeutic%2520development%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2017%26volume%3D38%26spage%3D1205%26epage%3D1235%26doi%3D10.1038%2Faps.2017.28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uemura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuzuya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimozono, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoyagi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimohama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, A.</span></span> <span> </span><span class="NLM_article-title">GSK3beta activity modifies the localization and function of presenilin 1</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>282</i></span>,  <span class="NLM_fpage">15823</span>– <span class="NLM_lpage">15832</span>, <span class="refDoi"> DOI: 10.1074/jbc.M610708200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1074%2Fjbc.M610708200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=17389597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltl2ns7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=15823-15832&author=K.+Uemuraauthor=A.+Kuzuyaauthor=Y.+Shimozonoauthor=N.+Aoyagiauthor=K.+Andoauthor=S.+Shimohamaauthor=A.+Kinoshita&title=GSK3beta+activity+modifies+the+localization+and+function+of+presenilin+1&doi=10.1074%2Fjbc.M610708200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">GSK3β Activity Modifies the Localization and Function of Presenilin 1</span></div><div class="casAuthors">Uemura, Kengo; Kuzuya, Akira; Shimozono, Yoshiharu; Aoyagi, Nobuhisa; Ando, Koichi; Shimohama, Shun; Kinoshita, Ayae</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">15823-15832</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Presenilin 1, a causative gene product of familial Alzheimer disease, has been reported to be localized mainly in the endoplasmic reticulum and Golgi membranes.  However, endogenous Presenilin 1 also localizes at the plasma membrane as a biol. active mol.  Presenilin 1 interacts with N-cadherin/β-catenin to form a trimeric complex at the synaptic site through its loop domain, whose serine residues (serine 353 and 357) can be phosphorylated by glycogen synthase kinase 3β.  Here, we demonstrate that cell-surface expression of Presenilin 1/γ-secretase is enhanced by N-cadherin-based cell-cell contact.  Phys. interaction between Presenilin 1 and N-cadherin/β-catenin plays an important role in this process.  Glycogen synthase kinase 3β-mediated phosphorylation of Presenilin 1 reduces its binding to N-cadherin, thereby down-regulating its cell-surface expression.  Moreover, redn. of the Presenilin 1·N-cadherin·β-catenin complex formation leads to an impaired activation of contact-mediated phosphatidylinositol 3-kinase/Akt cell survival signaling.  Furthermore, phosphorylation of Presenilin 1 hinders ε-cleavage of N-cadherin, whereas ε-cleavage of APP remained unchanged.  This is the first report that clarifies the regulatory mechanism of Presenilin 1/γ-secretase with respect to its subcellular distribution and its differential substrate cleavage.  Because the cleavage of various membrane proteins by Presenilin 1/γ-cleavage is involved in cellular signaling, glycogen synthase kinase 3β-mediated phosphorylation of Presenilin 1 should be deeply assocd. with signaling functions.  Our findings indicate that the abnormal activation of glycogen synthase kinase 3β can reduce neuronal viability and synaptic plasticity via modulating Presenilin 1/N-cadherin/β-catenin interaction and thus have important implications in the pathophysiol. of Alzheimer disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvgbs5a8_hL7Vg90H21EOLACvtfcHk0liwIlJRVXizPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltl2ns7Y%253D&md5=196ac5747507f94a668eec0766e763d1</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M610708200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M610708200%26sid%3Dliteratum%253Aachs%26aulast%3DUemura%26aufirst%3DK.%26aulast%3DKuzuya%26aufirst%3DA.%26aulast%3DShimozono%26aufirst%3DY.%26aulast%3DAoyagi%26aufirst%3DN.%26aulast%3DAndo%26aufirst%3DK.%26aulast%3DShimohama%26aufirst%3DS.%26aulast%3DKinoshita%26aufirst%3DA.%26atitle%3DGSK3beta%2520activity%2520modifies%2520the%2520localization%2520and%2520function%2520of%2520presenilin%25201%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D15823%26epage%3D15832%26doi%3D10.1074%2Fjbc.M610708200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ly, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodgett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, W.</span></span> <span> </span><span class="NLM_article-title">Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">224</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.1172/JCI64516</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1172%2FJCI64516" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=23202730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsFGntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2013&pages=224-235&author=P.+T.+Lyauthor=Y.+Wuauthor=H.+Zouauthor=R.+Wangauthor=W.+Zhouauthor=A.+Kinoshitaauthor=M.+Zhangauthor=Y.+Yangauthor=F.+Caiauthor=J.+Woodgettauthor=W.+Song&title=Inhibition+of+GSK3%CE%B2-mediated+BACE1+expression+reduces+Alzheimer-associated+phenotypes&doi=10.1172%2FJCI64516"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes</span></div><div class="casAuthors">Ly, Philip T. T.; Wu, Yili; Zou, Haiyan; Wang, Ruitao; Zhou, Weihui; Kinoshita, Ayae; Zhang, Mingming; Yang, Yi; Cai, Fang; Woodgett, James; Song, Weihong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">224-235</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Deposition of amyloid β protein (Aβ) to form neuritic plaques in the brain is the pathol. hallmark of Alzheimer's disease (AD).  Aβ is generated from sequential cleavages of the β-amyloid precursor protein (APP) by the β- and γ-secretases, and β-site APP-cleaving enzyme 1 (BACE1) is the β-secretase essential for Aβ generation.  Previous studies have indicated that glycogen synthase kinase 3 (GSK3) may play a role in APP processing by modulating γ-secretase activity, thereby facilitating Aβ prodn.  There are 2 highly conserved isoforms of GSK3: GSK3α and GSK3β.  We now report that specific inhibition of GSK3β, but not GSK3α, reduced BACE1-mediated cleavage of APP and Aβ prodn. by decreasing BACE1 gene transcription and expression.  The regulation of BACE1 gene expression by GSK3β was dependent on NF-κB signaling.  Inhibition of GSK3 signaling markedly reduced Aβ deposition and neuritic plaque formation, and rescued memory deficits in the double transgenic AD model mice.  These data provide evidence for regulation of BACE1 expression and AD pathogenesis by GSK3β and that inhibition of GSK3 signaling can reduce Aβ neuropathol. and alleviate memory deficits in AD model mice.  Our study suggests that interventions that specifically target the β-isoform of GSK3 may be a safe and effective approach for treating AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpvC5m1dwxRLVg90H21EOLACvtfcHk0liwIlJRVXizPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsFGntw%253D%253D&md5=560fdf1e8199e9f7bc15294d1f8cc712</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1172%2FJCI64516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI64516%26sid%3Dliteratum%253Aachs%26aulast%3DLy%26aufirst%3DP.%2BT.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DKinoshita%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DF.%26aulast%3DWoodgett%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DW.%26atitle%3DInhibition%2520of%2520GSK3%25CE%25B2-mediated%2520BACE1%2520expression%2520reduces%2520Alzheimer-associated%2520phenotypes%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2013%26volume%3D123%26spage%3D224%26epage%3D235%26doi%3D10.1172%2FJCI64516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tone, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, W.</span></span> <span> </span><span class="NLM_article-title">Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer’s disease</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1017/S1461145711000149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1017%2FS1461145711000149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=21329555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC38XksValsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2012&pages=77-90&author=C.+H.+Chenauthor=W.+Zhouauthor=S.+Liuauthor=Y.+Dengauthor=F.+Caiauthor=M.+Toneauthor=Y.+Toneauthor=Y.+Tongauthor=W.+Song&title=Increased+NF-%CE%BAB+signalling+up-regulates+BACE1+expression+and+its+therapeutic+potential+in+Alzheimer%E2%80%99s+disease&doi=10.1017%2FS1461145711000149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease</span></div><div class="casAuthors">Chen, Chia-Hsiung; Zhou, Weihui; Liu, Shengchun; Deng, Yu; Cai, Fang; Tone, Masahide; Tone, Yukiko; Tong, Yigang; Song, Weihong</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-90</span>CODEN:
                <span class="NLM_cas:coden">IJNUFB</span>;
        ISSN:<span class="NLM_cas:issn">1461-1457</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">Elevated levels of β-site APP cleaving enzyme 1 (BACE1) were found in the brain of some sporadic Alzheimer's disease (AD) patients; however, the underlying mechanism is unknown.  BACE1 cleaves β-amyloid precursor protein (APP) to generate amyloid β protein (Aβ), a central component of neuritic plaques in AD brains.  Nuclear factor-kappa B (NF-κB) signalling plays an important role in gene regulation and is implicated in inflammation, oxidative stress and apoptosis.  In this report we found that both BACE1 and NF-κB p65 levels were significantly increased in the brains of AD patients.  Two functional NF-κB-binding elements were identified in the human BACE1 promoter region.  We found that NF-κB p65 expression resulted in increased BACE1 promoter activity and BACE1 transcription, while disruption of NF-κB p65 decreased BACE1 gene expression in p65 knockout (RelA-knockout) cells.  In addn., NF-κB p65 expression leads to up-regulated β-secretase cleavage and Aβ prodn., while non-steroidal anti-inflammatory drugs (NSAIDs) inhibited BACE1 transcriptional activation induced by strong NF-κB activator tumor necrosis factor-alpha (TNF-α).  Taken together, our results clearly demonstrate that NF-κB signalling facilitates BACE1 gene expression and APP processing, and increased BACE1 expression mediated by NF-κB signalling in the brain could be one of the novel mol. mechanisms underlying the development of AD in some sporadic cases.  Furthermore, NSAIDs could block the inflammation-induced BACE1 transcription and Aβ prodn.  Our study suggests that inhibition of NF-κB-mediated BACE1 expression may be a valuable drug target for AD therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ1hkA7XSgYLVg90H21EOLACvtfcHk0liwIlJRVXizPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksValsbk%253D&md5=ccbec29126abde16c207a8960edec470</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1017%2FS1461145711000149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1461145711000149%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DF.%26aulast%3DTone%26aufirst%3DM.%26aulast%3DTone%26aufirst%3DY.%26aulast%3DTong%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DW.%26atitle%3DIncreased%2520NF-%25CE%25BAB%2520signalling%2520up-regulates%2520BACE1%2520expression%2520and%2520its%2520therapeutic%2520potential%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2012%26volume%3D15%26spage%3D77%26epage%3D90%26doi%3D10.1017%2FS1461145711000149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Magdesian, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendes, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saraiva, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juliano, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juliano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Abreu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, S. T.</span></span> <span> </span><span class="NLM_article-title">Amyloid-beta binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt/beta-catenin signaling</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">9359</span>– <span class="NLM_lpage">9368</span>, <span class="refDoi"> DOI: 10.1074/jbc.M707108200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1074%2Fjbc.M707108200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=18234671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjslyqs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=9359-9368&author=M.+H.+Magdesianauthor=M.+M.+Carvalhoauthor=F.+A.+Mendesauthor=L.+M.+Saraivaauthor=M.+A.+Julianoauthor=L.+Julianoauthor=J.+Garcia-Abreuauthor=S.+T.+Ferreira&title=Amyloid-beta+binds+to+the+extracellular+cysteine-rich+domain+of+Frizzled+and+inhibits+Wnt%2Fbeta-catenin+signaling&doi=10.1074%2Fjbc.M707108200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Amyloid-β Binds to the Extracellular Cysteine-rich Domain of Frizzled and Inhibits Wnt/β-Catenin Signaling</span></div><div class="casAuthors">Magdesian, Margaret H.; Carvalho, Milena M. V. F.; Mendes, Fabio A.; Saraiva, Leonardo M.; Juliano, Maria A.; Juliano, Luiz; Garcia-Abreu, Jose; Ferreira, Sergio T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">9359-9368</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The amyloid-β peptide (Aβ) plays a major role in neuronal dysfunction and neurotoxicity in Alzheimer disease.  However, the signal transduction mechanisms involved in Aβ-induced neuronal dysfunction remain to be fully elucidated.  A major current unknown is the identity of the protein receptor(s) involved in neuronal Aβ binding.  Using phage display of peptide libraries, we have identified a no. of peptides that bind Aβ and are homologous to neuronal receptors putatively involved in Aβ interactions.  We report here on a cysteine-linked cyclic heptapeptide (denominated cSP5) that binds Aβ with high affinity and is homologous to the extracellular cysteine-rich domain of several members of the Frizzled (Fz) family of Wnt receptors.  Based on this homol., we investigated the interaction between Aβ and Fz.  The results show that Aβ binds to the Fz cysteine-rich domain at or in close proximity to the Wnt-binding site and inhibits the canonical Wnt signaling pathway.  Interestingly, the cSP5 peptide completely blocks Aβ binding to Fz and prevents inhibition of Wnt signaling.  These results indicate that the Aβ-binding site in Fz is homologous to cSP5 and that this is a relevant target for Aβ-instigated neurotoxicity.  Furthermore, they suggest that blocking the interaction of Aβ with Fz might lead to novel therapeutic approaches to prevent neuronal dysfunction in Alzheimer disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe760qxDg897Vg90H21EOLACvtfcHk0lhKvNNUJacI3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjslyqs7w%253D&md5=1c65d7e97f51ce92b10d82cfa25073da</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M707108200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M707108200%26sid%3Dliteratum%253Aachs%26aulast%3DMagdesian%26aufirst%3DM.%2BH.%26aulast%3DCarvalho%26aufirst%3DM.%2BM.%26aulast%3DMendes%26aufirst%3DF.%2BA.%26aulast%3DSaraiva%26aufirst%3DL.%2BM.%26aulast%3DJuliano%26aufirst%3DM.%2BA.%26aulast%3DJuliano%26aufirst%3DL.%26aulast%3DGarcia-Abreu%26aufirst%3DJ.%26aulast%3DFerreira%26aufirst%3DS.%2BT.%26atitle%3DAmyloid-beta%2520binds%2520to%2520the%2520extracellular%2520cysteine-rich%2520domain%2520of%2520Frizzled%2520and%2520inhibits%2520Wnt%252Fbeta-catenin%2520signaling%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D9359%26epage%3D9368%26doi%3D10.1074%2Fjbc.M707108200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spangenberg, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, K. N.</span></span> <span> </span><span class="NLM_article-title">Inflammation in Alzheimer’s disease: Lessons learned from microglia-depletion models</span>. <i>Brain, Behav., Immun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1016/j.bbi.2016.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.bbi.2016.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=27395435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFKkur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2017&pages=1-11&author=E.+E.+Spangenbergauthor=K.+N.+Green&title=Inflammation+in+Alzheimer%E2%80%99s+disease%3A+Lessons+learned+from+microglia-depletion+models&doi=10.1016%2Fj.bbi.2016.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammation in Alzheimer's disease: Lessons learned from microglia-depletion models</span></div><div class="casAuthors">Spangenberg, Elizabeth E.; Green, Kim N.</div><div class="citationInfo"><span class="NLM_cas:title">Brain, Behavior, and Immunity</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-11</span>CODEN:
                <span class="NLM_cas:coden">BBIMEW</span>;
        ISSN:<span class="NLM_cas:issn">0889-1591</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Microglia are the primary immune cell of the brain and function to protect the central nervous system (CNS) from injury and invading pathogens.  In the homeostatic brain, microglia serve to support neuronal health through synaptic pruning, promoting normal brain connectivity and development, and through release of neurotrophic factors, providing support for CNS integrity.  However, recent evidence indicates that the homeostatic functioning of these cells is lost in neurodegenerative disease, including Alzheimer's disease (AD), ultimately contributing to a chronic neuroinflammatory environment in the brain.  Importantly, the development of compds. and genetic models to ablate the microglial compartment has emerged as effective tools to further our understanding of microglial function in AD.  Use of these models has identified roles of microglia in several pathol. facets of AD, including tau propagation, synaptic stripping, neuronal loss, and cognitive decline.  Although culminating evidence utilizing these microglial ablation models reports an absence of CNS-endogenous and peripheral myeloid cell involvement in Aβ phagocytosis, recent data indicates that targeting microglia-evoked neuroinflammation in AD may be essential for potential therapeutics.  Therefore, identifying altered signaling pathways in the microglia-devoid brain may assist with the development of effective inflammation-based therapies in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpnkdakB1rHrVg90H21EOLACvtfcHk0lhKvNNUJacI3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFKkur%252FI&md5=05af777f48592b90bbee6df13e1dcf3f</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2Fj.bbi.2016.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbi.2016.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DSpangenberg%26aufirst%3DE.%2BE.%26aulast%3DGreen%26aufirst%3DK.%2BN.%26atitle%3DInflammation%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520Lessons%2520learned%2520from%2520microglia-depletion%2520models%26jtitle%3DBrain%252C%2520Behav.%252C%2520Immun.%26date%3D2017%26volume%3D61%26spage%3D1%26epage%3D11%26doi%3D10.1016%2Fj.bbi.2016.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Green, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, Y. M.</span></span> <span> </span><span class="NLM_article-title">GSK-3 mediates the release of IL-1β, TNF-α and IL-10 from cortical glia</span>. <i>Neurochem. Int.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">666</span>– <span class="NLM_lpage">671</span>, <span class="refDoi"> DOI: 10.1016/j.neuint.2012.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.neuint.2012.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=22796213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsV2qur%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2012&pages=666-671&author=H.+F.+Greenauthor=Y.+M.+Nolan&title=GSK-3+mediates+the+release+of+IL-1%CE%B2%2C+TNF-%CE%B1+and+IL-10+from+cortical+glia&doi=10.1016%2Fj.neuint.2012.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">GSK-3 mediates the release of IL-1β, TNF-α and IL-10 from cortical glia</span></div><div class="casAuthors">Green, Holly F.; Nolan, Yvonne M.</div><div class="citationInfo"><span class="NLM_cas:title">Neurochemistry International</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">666-671</span>CODEN:
                <span class="NLM_cas:coden">NEUIDS</span>;
        ISSN:<span class="NLM_cas:issn">0197-0186</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Neuroinflammation has been shown to contribute to neurodegenerative and psychiatric disorders such as Alzheimer's disease and major depression due to the inappropriate release of pro-inflammatory cytokines from activated microglia.  The precise mol. events that mediate cytokine release from glia remain unknown but we suggest that the serine/threonine kinase glycogen synthase kinase-3 (GSK-3) may be involved.  The aim of this study therefore was to investigate the effect of lipopolysaccharide (LPS) on expression and activity of the GSK-3β isoform in glia, and to assess if GSK-3 mediates the LPS-induced change in inflammatory cytokine levels in culture medium from rat glial-enriched cortical cultures.  GSK-3β was expressed in microglia and astrocytes, and stimulation of these cultures with LPS induced an increase in GSK-3β expression and activity, and in pro-inflammatory cytokine levels in culture media.  We show that GSK-3 inhibition using a small mol. inhibitor SB216763 or the mood stabilizer lithium chloride reduced the LPS-induced elevated levels of pro-inflammatory cytokines present in culture media from rat glial-enriched cortical cultures.  These results demonstrate a role for GSK-3 as a modulator of inflammatory cytokine levels in the brain, and contribute to a mechanistic insight into neurol. disorders in which neuroinflammation is a characteristic feature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8OgZoGE-b97Vg90H21EOLACvtfcHk0lhKvNNUJacI3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsV2qur%252FK&md5=3f04cb3cc247a5f779c9a7bb194b8af3</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2Fj.neuint.2012.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuint.2012.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DGreen%26aufirst%3DH.%2BF.%26aulast%3DNolan%26aufirst%3DY.%2BM.%26atitle%3DGSK-3%2520mediates%2520the%2520release%2520of%2520IL-1%25CE%25B2%252C%2520TNF-%25CE%25B1%2520and%2520IL-10%2520from%2520cortical%2520glia%26jtitle%3DNeurochem.%2520Int.%26date%3D2012%26volume%3D61%26spage%3D666%26epage%3D671%26doi%3D10.1016%2Fj.neuint.2012.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinbrecher, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cogswell, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, A. S.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase 3beta functions to specify gene-specific, NF-kappaB-dependent transcription</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">8444</span>– <span class="NLM_lpage">8455</span>, <span class="refDoi"> DOI: 10.1128/MCB.25.19.8444-8455.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1128%2FMCB.25.19.8444-8455.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=16166627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVKqsLnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2005&pages=8444-8455&author=K.+A.+Steinbrecherauthor=W.+Wilsonauthor=P.+C.+Cogswellauthor=A.+S.+Baldwin&title=Glycogen+synthase+kinase+3beta+functions+to+specify+gene-specific%2C+NF-kappaB-dependent+transcription&doi=10.1128%2FMCB.25.19.8444-8455.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase 3β functions to specify gene-specific, NF-κB-dependent transcription</span></div><div class="casAuthors">Steinbrecher, Kris A.; Wilson, Willie, III; Cogswell, Patricia C.; Baldwin, Albert S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8444-8455</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Loss of glycogen synthase kinase 3β (GSK-3β) in mice results in embryonic lethality via hepatocyte apoptosis.  Consistent with this result, cells from these mice have diminished nuclear factor κB (NF-κB) activity, implying a functional role for GSK-3β in regulating NF-κB.  Here, the authors have explored mechanisms by which GSK-3β may control NF-κB function.  Cytokine-induced IκB kinase activity and subsequent phosphorylation of IκBα, p105, and p65 are not affected by the absence of GSK-3β activity.  Furthermore, nuclear accumulation of p65 following tumor necrosis factor treatment is unaffected by the loss of GSK-3β.  However, NF-κB DNA binding activity is reduced in GSK-3β null cells and in cells treated with a pharmacol. inhibitor of GSK-3.  Expression of certain NF-κB-regulated genes, such as IκBα and macrophage inflammatory protein 2, is minimally affected by the absence of GSK-3β.  Conversely, the authors have identified a subset of NF-κB-regulated genes, including those for interleukin-6 and monocyte chemoattractant protein 1, that require GSK-3β for efficient expression.  Efficient localization of p65 to the promoter regions of the interleukin-6 and monocyte chemoattractant protein 1 genes following tumor necrosis factor alpha treatment requires GSK-3β.  Therefore, GSK-3β has profound effects on transcription in a gene-specific manner through a mechanism involving control of promoter-specific recruitment of NF-κB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeCUceQlkidrVg90H21EOLACvtfcHk0liD5rSPmnfK1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVKqsLnF&md5=f27038f11633983692d6a198f8bc5d98</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1128%2FMCB.25.19.8444-8455.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.25.19.8444-8455.2005%26sid%3Dliteratum%253Aachs%26aulast%3DSteinbrecher%26aufirst%3DK.%2BA.%26aulast%3DWilson%26aufirst%3DW.%26aulast%3DCogswell%26aufirst%3DP.%2BC.%26aulast%3DBaldwin%26aufirst%3DA.%2BS.%26atitle%3DGlycogen%2520synthase%2520kinase%25203beta%2520functions%2520to%2520specify%2520gene-specific%252C%2520NF-kappaB-dependent%2520transcription%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2005%26volume%3D25%26spage%3D8444%26epage%3D8455%26doi%3D10.1128%2FMCB.25.19.8444-8455.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xavier, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercier, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLoughlin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodgett, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ovsenek, N.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase 3beta negatively regulates both DNA-binding and transcriptional activities of heat shock factor 1</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">29147</span>– <span class="NLM_lpage">29152</span>, <span class="refDoi"> DOI: 10.1074/jbc.M002169200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1074%2Fjbc.M002169200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10856293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD3cXms1Cqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=29147-29152&author=I.+J.+Xavierauthor=P.+A.+Mercierauthor=C.+M.+McLoughlinauthor=A.+Aliauthor=J.+R.+Woodgettauthor=N.+Ovsenek&title=Glycogen+synthase+kinase+3beta+negatively+regulates+both+DNA-binding+and+transcriptional+activities+of+heat+shock+factor+1&doi=10.1074%2Fjbc.M002169200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase 3β negatively regulates both DNA-binding and transcriptional activities of heat shock factor 1</span></div><div class="casAuthors">Xavier, Ilungo J.; Mercier, Phillipe A.; McLoughlin, Christine M.; Ali, Adnan; Woodgett, James R.; Ovsenek, Nick</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">29147-29152</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Stress activation of heat shock factor (HSF1) involves the conversion of repressed monomers to DNA-binding homotrimers with increased transcriptional capacity and results in transcriptional up-regulation of the heat shock protein (hsp) gene family.  Cells tightly control the activity of HSF1 through interactions with hsp90 chaperone complexes and through integration into a no. of different signaling cascades.  A no. of studies have shown that HSF1 transcriptional activity is neg. regulated by constitutive phosphorylation in the regulatory domain by glycogen synthase kinase (GSK3) isoforms α/β.  However, previous studies have not examd. the ability of GSK3 to regulate the DNA-binding activity of native HSF1 in vivo under heat shock conditions.  Here we show that GSK3β inhibits both DNA-binding and transcriptional activities of HSF1 in heat-shocked cells.  Specific inhibition of GSK3 increased the levels of DNA binding and transcription after heat shock and delayed the attenuation of HSF1 during recovery.  In contrast, the overexpression of GSK3β resulted in significant redn. in heat-induced HSF1 activities.  These results confirm the role of GSK3β as a neg. regulator of HSF1 transcription in cells during heat shock and demonstrate for the first time that GSK3β functions to repress DNA binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqa4pyU8oLnNrVg90H21EOLACvtfcHk0liD5rSPmnfK1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXms1Cqtbk%253D&md5=0532574b9c26b7186ed43c25170c3314</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M002169200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M002169200%26sid%3Dliteratum%253Aachs%26aulast%3DXavier%26aufirst%3DI.%2BJ.%26aulast%3DMercier%26aufirst%3DP.%2BA.%26aulast%3DMcLoughlin%26aufirst%3DC.%2BM.%26aulast%3DAli%26aufirst%3DA.%26aulast%3DWoodgett%26aufirst%3DJ.%2BR.%26aulast%3DOvsenek%26aufirst%3DN.%26atitle%3DGlycogen%2520synthase%2520kinase%25203beta%2520negatively%2520regulates%2520both%2520DNA-binding%2520and%2520transcriptional%2520activities%2520of%2520heat%2520shock%2520factor%25201%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D29147%26epage%3D29152%26doi%3D10.1074%2Fjbc.M002169200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hann, S. R.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">51606</span>– <span class="NLM_lpage">51612</span>, <span class="refDoi"> DOI: 10.1074/jbc.M310722200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1074%2Fjbc.M310722200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=14563837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpslOgsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=51606-51612&author=M.+A.+Gregoryauthor=Y.+Qiauthor=S.+R.+Hann&title=Phosphorylation+by+glycogen+synthase+kinase-3+controls+c-myc+proteolysis+and+subnuclear+localization&doi=10.1074%2Fjbc.M310722200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation by Glycogen Synthase Kinase-3 Controls c-Myc Proteolysis and Subnuclear Localization</span></div><div class="casAuthors">Gregory, Mark A.; Qi, Ying; Hann, Stephen R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">51606-51612</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The c-Myc protein is a transcription factor that is a central regulator of cell growth and proliferation.  Thr-58 is a major phosphorylation site in c-Myc and is a mutational hot spot in Burkitt's and other aggressive human lymphomas, indicating that Thr-58 phosphorylation restricts the oncogenic potential of c-Myc.  Mutation of Thr-58 is also assocd. with increased c-Myc protein stability.  Here we show that inhibition of glycogen synthase kinase-3 (GSK-3) activity with lithium increases c-Myc stability and inhibits phosphorylation of c-Myc specifically at Thr-58 in vivo.  Conversely, overexpression of GSK-3α or GSK-3β enhances Thr-58 phosphorylation and ubiquitination of c-Myc.  Together, these observations suggest that phosphorylation of Thr-58 mediated by GSK-3 facilitates c-Myc rapid proteolysis by the ubiquitin pathway.  Furthermore, we demonstrate that GSK-3 binds c-Myc in vivo and in vitro and that GSK-3 colocalizes with c-Myc in the nucleus, strongly arguing that GSK-3 is the c-Myc Thr-58 kinase.  We found that c-MycS, which lacks the N-terminal 100 amino acids of c-Myc, is unable to bind GSK-3; however, mutation of Ser-62, the priming phosphorylation site necessary for Thr-58 phosphorylation, does not disrupt GSK-3 binding.  Finally, we show that Thr-58 phosphorylation alters the subnuclear localization of c-Myc, enhancing its localization to discrete nuclear bodies together with GSK-3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6Dzcw8D5CHrVg90H21EOLACvtfcHk0liD5rSPmnfK1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpslOgsrg%253D&md5=f2386608b12050118c5b0594b3468b8a</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M310722200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M310722200%26sid%3Dliteratum%253Aachs%26aulast%3DGregory%26aufirst%3DM.%2BA.%26aulast%3DQi%26aufirst%3DY.%26aulast%3DHann%26aufirst%3DS.%2BR.%26atitle%3DPhosphorylation%2520by%2520glycogen%2520synthase%2520kinase-3%2520controls%2520c-myc%2520proteolysis%2520and%2520subnuclear%2520localization%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D51606%26epage%3D51612%26doi%3D10.1074%2Fjbc.M310722200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grimes, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jope, R. S.</span></span> <span> </span><span class="NLM_article-title">CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1219</span>– <span class="NLM_lpage">1232</span>, <span class="refDoi"> DOI: 10.1046/j.1471-4159.2001.00495.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1046%2Fj.1471-4159.2001.00495.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=11579131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnt12isr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2001&pages=1219-1232&author=C.+A.+Grimesauthor=R.+S.+Jope&title=CREB+DNA+binding+activity+is+inhibited+by+glycogen+synthase+kinase-3+beta+and+facilitated+by+lithium&doi=10.1046%2Fj.1471-4159.2001.00495.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">CREB DNA binding activity is inhibited by glycogen synthase kinase-3β and facilitated by lithium</span></div><div class="casAuthors">Grimes, Carol A.; Jope, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1219-1232</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">The regulatory influences of glycogen synthase kinase-3β (GSK3β) and lithium on the activity of cAMP response element binding protein (CREB) were examd. in human neuroblastoma SH-SY5Y cells.  Activation of Akt (protein kinase B) with serum-increased phospho-serine-9-GSK3β (the inactive form of the enzyme), inhibited GSK3β activity, and increased CREB DNA binding activity.  Inhibition of GSK3β by another paradigm, treatment with the selective inhibitor lithium, also increased CREB DNA binding activity.  The inhibitory regulation of CREB DNA binding activity by GSK3β also was evident in differentiated SH-SY5Y cells, indicating that this regulatory interaction is maintained in nonproliferating cells.  These results demonstrate that inhibition of GSK3β by serine-9 phosphorylation or directly by lithium increases CREB activation.  Conversely, overexpression of active GSK3β to 3.5-fold the normal levels completely blocked increases in CREB DNA binding activity induced by epidermal growth factor, insulin-like growth factor-1, forskolin, and cAMP.  The inhibitory effects due to overexpressed GSK3β were reversed by treatment with lithium and with another GSK3β inhibitor, sodium valproate.  Overall, these results demonstrate that GSK3β inhibits, and lithium enhances, CREB activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHQYoVSZwN7rVg90H21EOLACvtfcHk0lin4TiNbaGlOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnt12isr0%253D&md5=e7a16d91216e2b1c7f81fc0d747a9e69</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.2001.00495.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.2001.00495.x%26sid%3Dliteratum%253Aachs%26aulast%3DGrimes%26aufirst%3DC.%2BA.%26aulast%3DJope%26aufirst%3DR.%2BS.%26atitle%3DCREB%2520DNA%2520binding%2520activity%2520is%2520inhibited%2520by%2520glycogen%2520synthase%2520kinase-3%2520beta%2520and%2520facilitated%2520by%2520lithium%26jtitle%3DJ.%2520Neurochem.%26date%3D2001%26volume%3D78%26spage%3D1219%26epage%3D1232%26doi%3D10.1046%2Fj.1471-4159.2001.00495.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hooper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markevich, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plattner, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Killick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schofield, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenblum, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bliss, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avila, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giese, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephenson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovestone, S.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3 inhibition is integral to long-term potentiation</span>. <i>Eur. J. Neurosci</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1111/j.1460-9568.2006.05245.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1111%2Fj.1460-9568.2006.05245.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=17241269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BD2s7is1Clsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=81-86&author=C.+Hooperauthor=V.+Markevichauthor=F.+Plattnerauthor=R.+Killickauthor=E.+Schofieldauthor=T.+Engelauthor=F.+Hernandezauthor=B.+Andertonauthor=K.+Rosenblumauthor=T.+Blissauthor=S.+F.+Cookeauthor=J.+Avilaauthor=J.+J.+Lucasauthor=K.+P.+Gieseauthor=J.+Stephensonauthor=S.+Lovestone&title=Glycogen+synthase+kinase-3+inhibition+is+integral+to+long-term+potentiation&doi=10.1111%2Fj.1460-9568.2006.05245.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase-3 inhibition is integral to long-term potentiation</span></div><div class="casAuthors">Hooper Claudie; Markevich Vladimir; Plattner Florian; Killick Richard; Schofield Emma; Engel Tobias; Hernandez Felix; Anderton Brian; Rosenblum Kobi; Bliss Tim; Cooke Sam F; Avila Jesus; Lucas Jose J; Giese Karl Peter; Stephenson John; Lovestone Simon</div><div class="citationInfo"><span class="NLM_cas:title">The European journal of neuroscience</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">81-6</span>
        ISSN:<span class="NLM_cas:issn">0953-816X</span>.
    </div><div class="casAbstract">Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase regulating diverse cellular functions including metabolism, transcription and cell survival.  Numerous intracellular signalling pathways converge on GSK-3 and regulate its activity via inhibitory serine-phosphorylation.  Recently, GSK-3 has been involved in learning and memory and in neurodegeneration.  Here, we present evidence that implicates GSK-3 in synaptic plasticity.  We show that phosphorylation at the inhibitory Ser9 site on GSK-3beta is increased upon induction of long-term potentiation (LTP) in both hippocampal subregions CA1 and the dentate gyrus (DG) in vivo.  The increase in inhibitory GSK-3beta phosphorylation is robust and persists for at least one hour postinduction.  Furthermore, we find that LTP is impaired in transgenic mice conditionally overexpressing GSK-3beta.  The LTP deficits can be attenuated/rescued by chronic treatment with lithium, a GSK-3 inhibitor.  These results suggest that the inhibition of GSK-3 facilitates the induction of LTP and this might explain some of the negative effects of GSK-3 on learning and memory.  It follows that this role of GSK-3beta in LTP might underlie some of the cognitive dysfunction in diseases where GSK-3 dysfunction has been implicated, including Alzheimer's and other dementias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTXsmmxOKDKocScOqQTSkOffW6udTcc2ebUwMJNe-FiNrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s7is1Clsw%253D%253D&md5=f3ba7589dc57ada4966512aeb9c8279d</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1111%2Fj.1460-9568.2006.05245.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1460-9568.2006.05245.x%26sid%3Dliteratum%253Aachs%26aulast%3DHooper%26aufirst%3DC.%26aulast%3DMarkevich%26aufirst%3DV.%26aulast%3DPlattner%26aufirst%3DF.%26aulast%3DKillick%26aufirst%3DR.%26aulast%3DSchofield%26aufirst%3DE.%26aulast%3DEngel%26aufirst%3DT.%26aulast%3DHernandez%26aufirst%3DF.%26aulast%3DAnderton%26aufirst%3DB.%26aulast%3DRosenblum%26aufirst%3DK.%26aulast%3DBliss%26aufirst%3DT.%26aulast%3DCooke%26aufirst%3DS.%2BF.%26aulast%3DAvila%26aufirst%3DJ.%26aulast%3DLucas%26aufirst%3DJ.%2BJ.%26aulast%3DGiese%26aufirst%3DK.%2BP.%26aulast%3DStephenson%26aufirst%3DJ.%26aulast%3DLovestone%26aufirst%3DS.%26atitle%3DGlycogen%2520synthase%2520kinase-3%2520inhibition%2520is%2520integral%2520to%2520long-term%2520potentiation%26jtitle%3DEur.%2520J.%2520Neurosci%26date%3D2007%26volume%3D25%26spage%3D81%26epage%3D86%26doi%3D10.1111%2Fj.1460-9568.2006.05245.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, G.</span></span> <span> </span><span class="NLM_article-title">Modulation of GSK-3β/β-catenin signaling contributes to learning and memory impairment in a rat model of depression</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">858</span>– <span class="NLM_lpage">870</span>, <span class="refDoi"> DOI: 10.1093/ijnp/pyy040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1093%2Fijnp%2Fpyy040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=29688389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmvVyqur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2018&pages=858-870&author=J.+Huiauthor=J.+Zhangauthor=M.+Puauthor=X.+Zhouauthor=L.+Dongauthor=X.+Maoauthor=G.+Shiauthor=J.+Zouauthor=J.+Wuauthor=D.+Jiangauthor=G.+Xi&title=Modulation+of+GSK-3%CE%B2%2F%CE%B2-catenin+signaling+contributes+to+learning+and+memory+impairment+in+a+rat+model+of+depression&doi=10.1093%2Fijnp%2Fpyy040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of GSK-3β/β-catenin signaling contributes to learning and memory impairment in a rat model of depression</span></div><div class="casAuthors">Hui, Jiaojie; Zhang, Jianping; Pu, Mengjia; Zhou, Xingliang; Dong, Liang; Mao, Xuqiang; Shi, Guofeng; Zou, Jian; Wu, Jingjing; Jiang, Dongmei; Xi, Guangjun</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">858-870</span>CODEN:
                <span class="NLM_cas:coden">IJNUFB</span>;
        ISSN:<span class="NLM_cas:issn">1461-1457</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: It is widely accepted that cognitive processes, such as learning and memory, are affected in depression, but the mol. mechanisms underlying the interactions of these 2 disorders are not clearly understood.  Recently, glycogen synthase kinase-3 beta (GSK-3β)/β-catenin signaling was shown to play an important role in the regulation of learning and memory.  Methods: The present study used a rat model of depression, chronic unpredictable stress, to det. whether hippocampal GSK-3β/β-catenin signaling was involved in learning and memory alterations.  Results: Our results demonstrated that chronic unpredictable stress had a dramatic influence on spatial cognitive performance in the Morris water maze task and reduced the phosphorylation of Ser9 of GSK-3β as well as the total and nuclear levels of β-catenin in the hippocampus.  Inhibition of GSK3β by SB216763 significantly ameliorated the cognitive deficits induced by chronic unpredictable stress, while overexpression of GSK3β by AAV-mediated gene transfer significantly decreased cognitive performance in adult rats.  In addn., chronic unpredictable stress exposure increased the expression of the canonical Wnt antagonist Dkk-1.  Furthermore, chronic administration of corticosterone significantly increased Dkk-1 expression, decreased the phosphorylation of Ser9 of GSK-3β, and resulted in the impairment of hippocampal learning and memory.  Conclusions: Our results indicate that impairment of learning and memory in response to chronic unpredictable stress may be attributed to the dysfunction of GSK-3β/β-catenin signaling mediated by increased glucocorticoid signaling via Dkk-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZTdJOX6mbGbVg90H21EOLACvtfcHk0lin4TiNbaGlOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmvVyqur0%253D&md5=b66563325561d33206d654c9e5142188</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1093%2Fijnp%2Fpyy040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fijnp%252Fpyy040%26sid%3Dliteratum%253Aachs%26aulast%3DHui%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DPu%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DDong%26aufirst%3DL.%26aulast%3DMao%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DG.%26aulast%3DZou%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DD.%26aulast%3DXi%26aufirst%3DG.%26atitle%3DModulation%2520of%2520GSK-3%25CE%25B2%252F%25CE%25B2-catenin%2520signaling%2520contributes%2520to%2520learning%2520and%2520memory%2520impairment%2520in%2520a%2520rat%2520model%2520of%2520depression%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2018%26volume%3D21%26spage%3D858%26epage%3D870%26doi%3D10.1093%2Fijnp%2Fpyy040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Z.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase 3 regulates N-methyl-D-aspartate receptor channel trafficking and function in cortical neurons</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1124/mol.107.034942</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1124%2Fmol.107.034942" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=17400762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsVyjs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=40-51&author=P.+Chenauthor=Z.+Guauthor=W.+Liuauthor=Z.+Yan&title=Glycogen+synthase+kinase+3+regulates+N-methyl-D-aspartate+receptor+channel+trafficking+and+function+in+cortical+neurons&doi=10.1124%2Fmol.107.034942"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase 3 regulates N-methyl-D-aspartate receptor channel trafficking and function in cortical neurons</span></div><div class="casAuthors">Chen, Paul; Gu, Zhenglin; Liu, Wenhua; Yan, Zhen</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">40-51</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Emerging evidence has suggested that glycogen synthase kinase 3 (GSK-3) is a key regulatory kinase involved in a plethora of processes in the nervous system, including neuronal development, mood stabilization, and neurodegeneration.  However, the cellular mechanisms underlying the actions of GSK-3 remain to be identified.  In this study, we examd. the impact of GSK-3 on the N-methyl-D-aspartate (NMDA) receptor channel, a central player involved in cognitive and emotional processes.  We found that application of various structurally different GSK-3 inhibitors caused a long-lasting redn. of NMDA receptor-mediated ionic and synaptic current in cortical pyramidal neurons.  Cellular knockdown of GSK-3β in neuronal cultures with a small interfering RNA led to smaller NMDA receptor current and loss of its regulation by GSK-3 inhibitors.  The NR2B subunit-contg. NMDA receptor was the primary target of GSK-3, but the GSK-3 modulation of NMDAR current did not involve the motor protein kinesin superfamily member 17-based transport of NR2B-contg. vesicles along microtubules.  Combined electrophysiol., immunocytochem., and biochem. evidence indicated that GSK-3 inhibitors induced the down-regulation of NMDAR current through increasing the Rab5-mediated and PSD-95-regulated NMDAR internalization in a clathrin/dynamin-dependent manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAsbFOh2O_vbVg90H21EOLACvtfcHk0liwNPHU03edyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsVyjs7c%253D&md5=40421b2ca753a3e573909d432e18e3ea</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1124%2Fmol.107.034942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.107.034942%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DP.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DYan%26aufirst%3DZ.%26atitle%3DGlycogen%2520synthase%2520kinase%25203%2520regulates%2520N-methyl-D-aspartate%2520receptor%2520channel%2520trafficking%2520and%2520function%2520in%2520cortical%2520neurons%26jtitle%3DMol.%2520Pharmacol.%26date%3D2007%26volume%3D72%26spage%3D40%26epage%3D51%26doi%3D10.1124%2Fmol.107.034942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.</span></span> <span> </span><span class="NLM_article-title">Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>152</i></span>,  <span class="NLM_fpage">104609</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2019.104609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.phrs.2019.104609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=31862477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisV2ktbrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2020&pages=104609&author=R.+Roskoski&title=Properties+of+FDA-approved+small+molecule+protein+kinase+inhibitors%3A+A+2020+update&doi=10.1016%2Fj.phrs.2019.104609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update</span></div><div class="casAuthors">Roskoski, Robert Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104609</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Because genetic alterations including mutations, overexpression, translocations, and dysregulation of protein kinases are involved in the pathogenesis of many illnesses, this enzyme family is currently the subject of many drug discovery programs in the pharmaceutical industry.  The US FDA approved four small mol. protein kinase antagonists in 2019; these include entrectinib, erdafitinib, pexidartinib, and fedratinib.  Entrectinib binds to TRKA/B/C and ROS1 and is prescribed for the treatment of solid tumors with NTRK fusion proteins and for ROS1-postive non-small cell lung cancers.  Erdafitinib inhibits fibroblast growth factor receptors 1-4 and is used in the treatment of urothelial bladder cancers.  Pexidartinib is a CSF1R antagonist that is prescribed for the treatment of tenosynovial giant cell tumors.  Fedratinib blocks JAK2 and is used in the treatment of myelofibrosis.  Overall, the US FDA has approved 52 small mol. protein kinase inhibitors, nearly all of which are orally effective with the exceptions of temsirolimus (which is given i.v.) and netarsudil (an eye drop).  Of the 52 approved drugs, eleven inhibit protein-serine/threonine protein kinases, two are directed against dual specificity protein kinases, eleven target non-receptor protein-tyrosine kinases, and 28 block receptor protein-tyrosine kinases.  The data indicate that 46 of these drugs are used in the treatment of neoplastic diseases (eight against non-solid tumors such as leukemias and 41 against solid tumors including breast and lung cancers; some drugs are used against both tumor types).  Eight drugs are employed in the treatment of non-malignancies: fedratinib, myelofibrosis; ruxolitinib, myelofibrosis and polycythemia vera; fostamatinib, chronic immune thrombocytopenia; baricitinib, rheumatoid arthritis; sirolimus, renal graft vs. host disease; nintedanib, idiopathic pulmonary fibrosis; netarsudil, glaucoma; and tofacitinib, rheumatoid arthritis, Crohn disease, and ulcerative colitis.  Moreover, sirolimus and ibrutinib are used for the treatment of both neoplastic and non-neoplastic diseases.  Entrectinib and larotrectinib are tissue-agnostic anti-cancer small mol. protein kinase inhibitors.  These drugs are prescribed for the treatment of any solid cancer harboring NTRK1/2/3 fusion proteins regardless of the organ, tissue, anatomical location, or histol. type.  Of the 52 approved drugs, seventeen are used in the treatment of more than one disease.  Imatinib, for example, is approved for the treatment of eight disparate disorders.  The most common drug targets of the approved pharmaceuticals include BCR-Abl, B-Raf, vascular endothelial growth factor receptors (VEGFR), epidermal growth factor receptors (EGFR), and ALK.  Most of the approved small mol. protein kinase antagonists (49) bind to the protein kinase domain and six of them bind covalently.  In contrast, everolimus, temsirolimus, and sirolimus are larger mols. (MW ≈ 1000) that bind to FK506 binding protein-12 (FKBP-12) to generate a complex that inhibits the mammalian target of rapamycin (mTOR) protein kinase complex.  This review presents the physicochem. properties of all of the FDA-approved small mol. protein kinase inhibitors.  Twenty-two of the 52 drugs have mol. wts. greater than 500, exceeding a Lipinski rule of five criterion.  Excluding the macrolides (everolimus, sirolimus, temsirolimus), the av. mol. wt. of the approved drugs is 480 with a range of 306 (ruxolitinib) to 615 (trametinib).  More than half of the antagonists (29) have lipophilic efficiency values of less than five while the recommended optima range from 5 to 10.  One of the troublesome problems with both targeted and cytotoxic drugs in the treatment of malignant diseases is the near universal development of resistance to every therapeutic modality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRgMvsJqanSLVg90H21EOLACvtfcHk0liwNPHU03edyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisV2ktbrE&md5=7753f0e8c04a145e15b09b3e55e09cde</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2019.104609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2019.104609%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DProperties%2520of%2520FDA-approved%2520small%2520molecule%2520protein%2520kinase%2520inhibitors%253A%2520A%25202020%2520update%26jtitle%3DPharmacol.%2520Res.%26date%3D2020%26volume%3D152%26spage%3D104609%26doi%3D10.1016%2Fj.phrs.2019.104609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, J. P.</span></span> <span> </span><span class="NLM_article-title">DAPK1: A novel pathology and treatment target for Alzheimer’s disease</span>. <i>Mol. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2838</span>– <span class="NLM_lpage">2844</span>, <span class="refDoi"> DOI: 10.1007/s12035-018-1242-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1007%2Fs12035-018-1242-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=30062675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVWrurnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2019&pages=2838-2844&author=L.+Z.+Xuauthor=B.+Q.+Liauthor=J.+P.+Jia&title=DAPK1%3A+A+novel+pathology+and+treatment+target+for+Alzheimer%E2%80%99s+disease&doi=10.1007%2Fs12035-018-1242-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">DAPK1: a Novel Pathology and Treatment Target for Alzheimer's Disease</span></div><div class="casAuthors">Xu, Ling-zhi; Li, Bing-qiu; Jia, Jian-ping</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Neurobiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2838-2844</span>CODEN:
                <span class="NLM_cas:coden">MONBEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-7648</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) is the most common neurodegenerative disease and seriously damages the health of elderly population.  Clin. drug research targeting at classic pathol. hallmarks, such as amyloid-β (Aβ) and tau protein, failed to achieve effective cognitive improvement, suggesting that the pathogenesis of AD is much complicated, and there are still other unknown and undetd. important factors.  Death-assocd. protein kinase 1 (DAPK1) is a calcium/calmodulin-dependent serine/threonine kinase that plays an important role in various neuronal injury models.  Mounting evidence has demonstrated that DAPK1 variants are assocd. with AD risk.  The activation of DAPK1 is also involved in AD-related neurodegeneration in the brain.  Exploring the roles of DAPK1 in AD might help us understand the pathogenic mechanisms and find a novel promising therapeutic target in AD.  Therefore, in this review, we comprehensively summary the main progress of DAPK1 in the AD studies from genetic risk, neuropathol. process, and clin. potential implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovHMU9i6Hha7Vg90H21EOLACvtfcHk0liwNPHU03edyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVWrurnI&md5=59f867741be4079125dc272a7e1e76fd</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1007%2Fs12035-018-1242-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12035-018-1242-2%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DL.%2BZ.%26aulast%3DLi%26aufirst%3DB.%2BQ.%26aulast%3DJia%26aufirst%3DJ.%2BP.%26atitle%3DDAPK1%253A%2520A%2520novel%2520pathology%2520and%2520treatment%2520target%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DMol.%2520Neurobiol.%26date%3D2019%26volume%3D56%26spage%3D2838%26epage%3D2844%26doi%3D10.1007%2Fs12035-018-1242-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N. J.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the inhibition of p38 MAPK as a potential strategy for the treatment of Alzheimer’s disease</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1287</span>, <span class="refDoi"> DOI: 10.3390/molecules22081287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.3390%2Fmolecules22081287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=28767069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Cls77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=1287&author=J.+K.+Leeauthor=N.+J.+Kim&title=Recent+advances+in+the+inhibition+of+p38+MAPK+as+a+potential+strategy+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.3390%2Fmolecules22081287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the inhibition of p38 MAPK as a potential strategy for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Lee, Jong Kil; Kim, Nam-Jung</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1287/1-1287/23</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">P38 mitogen-activated protein kinase (MAPK) is a crucial target for chronic inflammatory diseases.  Alzheimer's disease (AD) is characterized by the presence of amyloid plaques and neurofibrillary tangles in the brain, as well as neurodegeneration, and there is no known cure.  Recent studies on the underlying biol. of AD in cellular and animal models have indicated that p38 MAPK is capable of orchestrating diverse events related to AD, such as tau phosphorylation, neurotoxicity, neuroinflammation and synaptic dysfunction.  Thus, the inhibition of p38 MAPK is considered a promising strategy for the treatment of AD.  In this review, we summarize recent advances in the targeting of p38 MAPK as a potential strategy for the treatment of AD and envision possibilities of p38 MAPK inhibitors as a fundamental therapeutics for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1NNXguBzPobVg90H21EOLACvtfcHk0liwNPHU03edyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Cls77P&md5=9aa70ca6361ea8e5e3bf789fd5df58be</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.3390%2Fmolecules22081287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules22081287%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BK.%26aulast%3DKim%26aufirst%3DN.%2BJ.%26atitle%3DRecent%2520advances%2520in%2520the%2520inhibition%2520of%2520p38%2520MAPK%2520as%2520a%2520potential%2520strategy%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DMolecules%26date%3D2017%26volume%3D22%26spage%3D1287%26doi%3D10.3390%2Fmolecules22081287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentry, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rush, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troncoso, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thambisetty, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montine, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herskowitz, J. H.</span></span> <span> </span><span class="NLM_article-title">Rho-associated protein kinase 1 (ROCK1) is increased in Alzheimer’s disease and ROCK1 depletion reduces amyloid-β levels in brain</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">531</span>, <span class="refDoi"> DOI: 10.1111/jnc.13688</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1111%2Fjnc.13688" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=27246255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVyntLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2016&pages=525-531&author=B.+W.+Hendersonauthor=E.+G.+Gentryauthor=T.+Rushauthor=J.+C.+Troncosoauthor=M.+Thambisettyauthor=T.+J.+Montineauthor=J.+H.+Herskowitz&title=Rho-associated+protein+kinase+1+%28ROCK1%29+is+increased+in+Alzheimer%E2%80%99s+disease+and+ROCK1+depletion+reduces+amyloid-%CE%B2+levels+in+brain&doi=10.1111%2Fjnc.13688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Rho-associated protein kinase 1 (ROCK1) is increased in Alzheimer's disease and ROCK1 depletion reduces amyloid-β levels in brain</span></div><div class="casAuthors">Henderson, Benjamin W.; Gentry, Erik G.; Rush, Travis; Troncoso, Juan C.; Thambisetty, Madhav; Montine, Thomas J.; Herskowitz, Jeremy H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">525-531</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is the leading cause of dementia and mitigating amyloid-β (Aβ) levels may serve as a rational therapeutic avenue to slow AD progression.  Pharmacol. inhibition of the Rho-assocd. protein kinases (ROCK1 and ROCK2) is proposed to curb Aβ levels, and mechanisms that underlie ROCK2's effects on Aβ prodn. are defined.  How ROCK1 affects Aβ generation remains a crit. barrier.  Here, we report that ROCK1 protein levels were elevated in mild cognitive impairment due to AD (MCI) and AD brains compared to controls.  Aβ42 oligomers marginally increased ROCK1 and ROCK2 protein levels in neurons but strongly induced phosphorylation of Lim kinase 1 (LIMK1), suggesting that Aβ42 activates ROCKs.  RNAi depletion of ROCK1 or ROCK2 suppressed endogenous Aβ40 prodn. in neurons, and Aβ40 levels were reduced in brains of ROCK1 heterozygous knock-out mice compared to wild-type littermate controls.  ROCK1 knockdown decreased amyloid precursor protein (APP), and treatment with bafilomycin accumulated APP levels in neurons depleted of ROCK1.  These observations suggest that redn. of ROCK1 diminishes Aβ levels by enhancing APP protein degrdn.  Collectively, these findings support the hypothesis that both ROCK1 and ROCK2 are therapeutic targets to combat Aβ prodn. in AD.  Mitigating amyloid-β (Aβ) levels is a rational strategy for Alzheimer's disease (AD) treatment, however, therapeutic targets with clin. available drugs are lacking.  We hypothesize that Aβ accumulation in mild cognitive impairment because of AD (MCI) and AD activates the RhoA/ROCK pathway which in turn fuels prodn. of Aβ.  Escalation of this cycle over the course of many years may contribute to the buildup of amyloid pathol. in MCI and/or AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqojJcfZXda27Vg90H21EOLACvtfcHk0lg0voKrTg2J-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVyntLvN&md5=07493d821f9384878f455b62d7836778</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1111%2Fjnc.13688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjnc.13688%26sid%3Dliteratum%253Aachs%26aulast%3DHenderson%26aufirst%3DB.%2BW.%26aulast%3DGentry%26aufirst%3DE.%2BG.%26aulast%3DRush%26aufirst%3DT.%26aulast%3DTroncoso%26aufirst%3DJ.%2BC.%26aulast%3DThambisetty%26aufirst%3DM.%26aulast%3DMontine%26aufirst%3DT.%2BJ.%26aulast%3DHerskowitz%26aufirst%3DJ.%2BH.%26atitle%3DRho-associated%2520protein%2520kinase%25201%2520%2528ROCK1%2529%2520is%2520increased%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520and%2520ROCK1%2520depletion%2520reduces%2520amyloid-%25CE%25B2%2520levels%2520in%2520brain%26jtitle%3DJ.%2520Neurochem.%26date%3D2016%26volume%3D138%26spage%3D525%26epage%3D531%26doi%3D10.1111%2Fjnc.13688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nygaard, H. B.</span></span> <span> </span><span class="NLM_article-title">Targeting Fyn kinase in Alzheimer’s disease</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">369</span>– <span class="NLM_lpage">376</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2017.06.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.biopsych.2017.06.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=28709498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFGmt7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2018&pages=369-376&author=H.+B.+Nygaard&title=Targeting+Fyn+kinase+in+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.biopsych.2017.06.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Fyn Kinase in Alzheimer's Disease</span></div><div class="casAuthors">Nygaard, Haakon B.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">369-376</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The past decade has brought tremendous progress in unraveling the pathophysiol. of Alzheimer's disease (AD).  While increasingly sophisticated immunotherapy targeting sol. and aggregated brain amyloid-beta (Aβ) continues to dominate clin. research in AD, a deeper understanding of Aβ physiol. has led to the recognition of distinct neuronal signaling pathways linking Aβ to synaptotoxicity and neurodegeneration and to new targets for therapeutic intervention.  Identifying specific signaling pathways involving Aβ has allowed for the development of more precise therapeutic interventions targeting the most relevant mol. mechanisms leading to AD.  In this review, I highlight the discovery of cellular prion protein as a high-affinity receptor for Aβ oligomers, and the downstream signaling pathway elucidated to date, converging on nonreceptor tyrosine kinase Fyn.  I discuss preclin. studies targeting Fyn as a therapeutic intervention in AD and our recent experience with the safety, tolerability, and cerebrospinal fluid penetration of the Src family kinase inhibitor saracatinib in patients with AD.  Fyn is an attractive target for AD therapeutics, not only based on its activation by Aβ via cellular prion protein but also due to its known interaction with tau, uniquely linking the two key pathologies in AD.  Fyn is also a challenging target, with broad expression throughout the body and significant homol. with other members of the Src family kinases, which may lead to unintended off-target effects.  A phase 2a proof-of-concept clin. trial in patients with AD is currently under way, providing crit. first data on the potential effectiveness of targeting Fyn in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDCIJXCt9gzbVg90H21EOLACvtfcHk0lg0voKrTg2J-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFGmt7jF&md5=55d32bcf85535a8bc303114a8f42e42d</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2017.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2017.06.004%26sid%3Dliteratum%253Aachs%26aulast%3DNygaard%26aufirst%3DH.%2BB.%26atitle%3DTargeting%2520Fyn%2520kinase%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DBiol.%2520Psychiatry%26date%3D2018%26volume%3D83%26spage%3D369%26epage%3D376%26doi%3D10.1016%2Fj.biopsych.2017.06.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tondo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergink, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grof, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewitka, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Licht, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manchia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller-Oerlinghausen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simhandl, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldessarini, R. J.</span></span> <span> </span><span class="NLM_article-title">Clinical use of lithium salts: Guide for users and prescribers</span>. <i>Int. J. Bipolar Disord.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">16</span>, <span class="refDoi"> DOI: 10.1186/s40345-019-0151-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1186%2Fs40345-019-0151-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=31328245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BB3MzpsF2hsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=16&author=L.+Tondoauthor=M.+Aldaauthor=M.+Bauerauthor=V.+Berginkauthor=P.+Grofauthor=T.+Hajekauthor=U.+Lewitkaauthor=R.+W.+Lichtauthor=M.+Manchiaauthor=B.+M%C3%BCller-Oerlinghausenauthor=R.+E.+Nielsenauthor=M.+Seloauthor=C.+Simhandlauthor=R.+J.+Baldessarini&title=Clinical+use+of+lithium+salts%3A+Guide+for+users+and+prescribers&doi=10.1186%2Fs40345-019-0151-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical use of lithium salts: guide for users and prescribers</span></div><div class="casAuthors">Tondo Leonardo; Baldessarini Ross J; Tondo Leonardo; Baldessarini Ross J; Tondo Leonardo; Alda Martin; Hajek Tomas; Bauer Michael; Lewitka Ute; Bergink Veerle; Bergink Veerle; Grof Paul; Licht Rasmus W; Nielsen Rene E; Licht Rasmus W; Nielsen Rene E; Manchia Mirko; Manchia Mirko; Muller-Oerlinghausen Bruno; Selo Marylou; Simhandl Christian</div><div class="citationInfo"><span class="NLM_cas:title">International journal of bipolar disorders</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16</span>
        ISSN:<span class="NLM_cas:issn">2194-7511</span>.
    </div><div class="casAbstract">BACKGROUND:  Lithium has been used clinically for 70 years, mainly to treat bipolar disorder.  Competing treatments and exaggerated impressions about complexity and risks of lithium treatment have led to its declining use in some countries, encouraging this update about its safe clinical use.  We conducted a nonsystematic review of recent research reports and developed consensus among international experts on the use of lithium to treat major mood disorders, aiming for a simple but authoritative guide for patients and prescribers.  MAIN TEXT:  We summarized recommendations concerning safe clinical use of lithium salts to treat major mood disorders, including indications, dosing, clinical monitoring, adverse effects and use in specific circumstances including during pregnancy and for the elderly.  CONCLUSIONS:  Lithium continues as the standard and most extensively evaluated treatment for bipolar disorder, especially for long-term prophylaxis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRrqOwhPXN7GUH3Rlp_k91zfW6udTcc2ebTEmj4kNaeZLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MzpsF2hsA%253D%253D&md5=02de55b07286d06c5e5bee44e1a9fdfe</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1186%2Fs40345-019-0151-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40345-019-0151-2%26sid%3Dliteratum%253Aachs%26aulast%3DTondo%26aufirst%3DL.%26aulast%3DAlda%26aufirst%3DM.%26aulast%3DBauer%26aufirst%3DM.%26aulast%3DBergink%26aufirst%3DV.%26aulast%3DGrof%26aufirst%3DP.%26aulast%3DHajek%26aufirst%3DT.%26aulast%3DLewitka%26aufirst%3DU.%26aulast%3DLicht%26aufirst%3DR.%2BW.%26aulast%3DManchia%26aufirst%3DM.%26aulast%3DM%25C3%25BCller-Oerlinghausen%26aufirst%3DB.%26aulast%3DNielsen%26aufirst%3DR.%2BE.%26aulast%3DSelo%26aufirst%3DM.%26aulast%3DSimhandl%26aufirst%3DC.%26aulast%3DBaldessarini%26aufirst%3DR.%2BJ.%26atitle%3DClinical%2520use%2520of%2520lithium%2520salts%253A%2520Guide%2520for%2520users%2520and%2520prescribers%26jtitle%3DInt.%2520J.%2520Bipolar%2520Disord.%26date%3D2019%26volume%3D7%26spage%3D16%26doi%3D10.1186%2Fs40345-019-0151-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Forlenza, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De-Paula, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diniz, B. S.</span></span> <span> </span><span class="NLM_article-title">Neuroprotective effects of lithium: Implications for the treatment of Alzheimer’s disease and related neurodegenerative disorders</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1021/cn5000309</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn5000309" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmvF2nur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=443-450&author=O.+V.+Forlenzaauthor=V.+J.+De-Paulaauthor=B.+S.+Diniz&title=Neuroprotective+effects+of+lithium%3A+Implications+for+the+treatment+of+Alzheimer%E2%80%99s+disease+and+related+neurodegenerative+disorders&doi=10.1021%2Fcn5000309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroprotective Effects of Lithium: Implications for the Treatment of Alzheimer's Disease and Related Neurodegenerative Disorders</span></div><div class="casAuthors">Forlenza, O. V.; De-Paula, V. J. R.; Diniz, B. S. O.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">443-450</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Lithium is a well-established therapeutic option for the acute and long-term management of bipolar disorder and major depression.  More recently, based on findings from translational research, lithium has also been regarded as a neuroprotective agent and a candidate drug for disease-modification in certain neurodegenerative disorders, namely, Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and, more recently, Parkinson's disease (PD).  The putative neuroprotective effects of lithium rely on the fact that it modulates several homeostatic mechanisms involved in neurotrophic response, autophagy, oxidative stress, inflammation, and mitochondrial function.  Such a wide range of intracellular responses may be secondary to two key effects, i.e., the inhibition of glycogen synthase kinase-3 beta (GSK-3β) and inositol monophosphatase (IMP) by lithium.  In the present review, we revisit the neurobiol. properties of lithium in light of the available evidence of its neurotrophic and neuroprotective properties, and discuss the rationale for its use in the treatment and prevention of neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZTodicRKytrVg90H21EOLACvtfcHk0lgloDDz3oM8SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmvF2nur4%253D&md5=d9920f0dda84aa3bcfc5bb8666a52448</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1021%2Fcn5000309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn5000309%26sid%3Dliteratum%253Aachs%26aulast%3DForlenza%26aufirst%3DO.%2BV.%26aulast%3DDe-Paula%26aufirst%3DV.%2BJ.%26aulast%3DDiniz%26aufirst%3DB.%2BS.%26atitle%3DNeuroprotective%2520effects%2520of%2520lithium%253A%2520Implications%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%2520and%2520related%2520neurodegenerative%2520disorders%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2014%26volume%3D5%26spage%3D443%26epage%3D450%26doi%3D10.1021%2Fcn5000309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nunes, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viel, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buck, H. S.</span></span> <span> </span><span class="NLM_article-title">Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer’s disease</span>. <i>Curr. Alzheimer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">104</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.2174/1567205011310010014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.2174%2F1567205011310010014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=22746245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFelsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=104-107&author=M.+A.+Nunesauthor=T.+A.+Vielauthor=H.+S.+Buck&title=Microdose+lithium+treatment+stabilized+cognitive+impairment+in+patients+with+Alzheimer%E2%80%99s+disease&doi=10.2174%2F1567205011310010014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease</span></div><div class="casAuthors">Nunes, Marielza Andrade; Viel, Tania Araujo; Buck, Hudson Sousa</div><div class="citationInfo"><span class="NLM_cas:title">Current Alzheimer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">104-107</span>CODEN:
                <span class="NLM_cas:coden">CARUBY</span>;
        ISSN:<span class="NLM_cas:issn">1567-2050</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A lower incidence of dementia in bipolar patients treated with lithium has been described.  This metal inhibits the phosphorylation of glycogen-synthase-kinase 3-α and β, which are related to amyloid precursor protein processing and tau hyperphosphorylation in pathol. conditions, resp.  Following the same rationale, a group just found that lithium has disease-modifying properties in amnestic mild cognitive impairment with potential clin. implications for the prevention of Alzheimer's Disease (AD) when a dose ranging from 150 to 600 mg is used.  As lithium is highly toxic in regular doses, our group evaluated the effect of a microdose of 300μg, administered once daily on AD patients for 15 mo.  In the evaluation phase, the treated group showed no decreased performance in the mini-mental state examn. test, in opposition to the lower scores obsd. for the control group during the treatment, with significant differences starting three months after the beginning of the treatment, and increasing progressively.  This data suggests the efficacy of a microdose lithium treatment in preventing cognitive loss, reinforcing its therapeutic potential to treat AD using very low doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouXJgwK8Wwu7Vg90H21EOLACvtfcHk0lgloDDz3oM8SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFelsrY%253D&md5=a4892edfba3411511adea4e09cd27d32</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.2174%2F1567205011310010014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1567205011310010014%26sid%3Dliteratum%253Aachs%26aulast%3DNunes%26aufirst%3DM.%2BA.%26aulast%3DViel%26aufirst%3DT.%2BA.%26aulast%3DBuck%26aufirst%3DH.%2BS.%26atitle%3DMicrodose%2520lithium%2520treatment%2520stabilized%2520cognitive%2520impairment%2520in%2520patients%2520with%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DCurr.%2520Alzheimer%2520Res.%26date%3D2013%26volume%3D10%26spage%3D104%26epage%3D107%26doi%3D10.2174%2F1567205011310010014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo Monte, F.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibitors of GSK-3: Structural insights and their application to Alzheimer’s disease models</span>. <i>Int. J. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2012</i></span>,  <span class="NLM_fpage">381029</span>, <span class="refDoi"> DOI: 10.1155/2012/381029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1155%2F2012%2F381029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=22888461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BC38fpvVKmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2012&publication_year=2012&pages=381029&author=T.+Kramerauthor=B.+Schmidtauthor=F.+Lo+Monte&title=Small-molecule+inhibitors+of+GSK-3%3A+Structural+insights+and+their+application+to+Alzheimer%E2%80%99s+disease+models&doi=10.1155%2F2012%2F381029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Inhibitors of GSK-3: Structural Insights and Their Application to Alzheimer's Disease Models</span></div><div class="casAuthors">Kramer Thomas; Schmidt Boris; Lo Monte Fabio</div><div class="citationInfo"><span class="NLM_cas:title">International journal of Alzheimer's disease</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2012</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">381029</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The world health organization (WHO) estimated that 18 million people are struck by Alzheimer's disease (AD).  The USA, France, Germany, and other countries launched major programmes targeting the identification of risk factors, the improvement of caretaking, and fundamental research aiming to postpone the onset of AD.  The glycogen synthase kinase 3 (GSK-3) is implicated in multiple cellular processes and has been linked to the pathogenesis of several diseases including diabetes mellitus, cancer, and AD.  Inhibition of GSK-3 leads to neuroprotective effects, decreased β-amyloid production, and a reduction in tau hyperphosphorylation, which are all associated with AD.  Various classes of small molecule GSK-3 inhibitors have been published in patents and original publications.  Herein, we present a comprehensive summary of small molecules reported to interact with GSK-3.  We illustrate the interactions of the inhibitors with the active site.  Furthermore, we refer to the biological characterisation in terms of activity and selectivity for GSK-3, elucidate in vivo studies and pre-/clinical trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRgN9KQeV4e1yA3UY9EwTNrfW6udTcc2eYznon4bqEeG7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38fpvVKmug%253D%253D&md5=100844ec1c85bbf465eeecb27559066d</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1155%2F2012%2F381029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2012%252F381029%26sid%3Dliteratum%253Aachs%26aulast%3DKramer%26aufirst%3DT.%26aulast%3DSchmidt%26aufirst%3DB.%26aulast%3DLo%2BMonte%26aufirst%3DF.%26atitle%3DSmall-molecule%2520inhibitors%2520of%2520GSK-3%253A%2520Structural%2520insights%2520and%2520their%2520application%2520to%2520Alzheimer%25E2%2580%2599s%2520disease%2520models%26jtitle%3DInt.%2520J.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2012%26volume%3D2012%26spage%3D381029%26doi%3D10.1155%2F2012%2F381029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakesh, K. P.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship (SAR) studies of synthetic glycogen synthase kinase-3β inhibitors: A critical review</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">448</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.12.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.ejmech.2018.12.073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=30616053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkvVGgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2019&pages=448-470&author=M.+Xuauthor=S.+L.+Wangauthor=L.+Zhuauthor=P.+Y.+Wuauthor=W.+B.+Daiauthor=K.+P.+Rakesh&title=Structure-activity+relationship+%28SAR%29+studies+of+synthetic+glycogen+synthase+kinase-3%CE%B2+inhibitors%3A+A+critical+review&doi=10.1016%2Fj.ejmech.2018.12.073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationship (SAR) studies of synthetic glycogen synthase kinase-3β inhibitors: A critical review</span></div><div class="casAuthors">Xu, M.; Wang, S. L.; Zhu, L.; Wu, P. Y.; Dai, W. B.; Rakesh, K. P.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">448-470</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Glycogen Synthase Kinase-3 (GSK-3) is a constitutively dynamic, omnipresent serine/threonine protein kinase regularly called as a "multi-tasking kinase" due to its pliable function in diverse signaling pathways.  It exists in two isoforms i.e., GSK-3α and GSK-3β.  Inhibition of GSK-3 may be useful in curing various diseases such as Alzheimer's disease, type II diabetes, mood disorders, cancers, chronic inflammatory agents, stroke, bipolar disorders and so on, but the approach poses significant challenges.  Lithium was the first GSK-3β inhibitor to be used for therapeutic outcome and has been effectively used for many years.  In recent years, a large no. of structurally diverse potent GSK-3β inhibitors are reported.  The present review focuses on the recent developments in the area of medicinal chem. to explore the diverse chem. structures of potent GSK-3β inhibitors and also describes its structure-activity relationships (SAR) and mol. binding interactions of favorable applicability in various diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp72bJHjANYA7Vg90H21EOLACvtfcHk0ljcz44HT1oGIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkvVGgug%253D%253D&md5=3ee6633bf8aea71b4eec73979f2f39c9</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.12.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.12.073%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DS.%2BL.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DP.%2BY.%26aulast%3DDai%26aufirst%3DW.%2BB.%26aulast%3DRakesh%26aufirst%3DK.%2BP.%26atitle%3DStructure-activity%2520relationship%2520%2528SAR%2529%2520studies%2520of%2520synthetic%2520glycogen%2520synthase%2520kinase-3%25CE%25B2%2520inhibitors%253A%2520A%2520critical%2520review%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D164%26spage%3D448%26epage%3D470%26doi%3D10.1016%2Fj.ejmech.2018.12.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thieffine, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristiani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valsasina, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalisz, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flocco, M.</span></span> <span> </span><span class="NLM_article-title">Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>333</i></span>,  <span class="NLM_fpage">393</span>– <span class="NLM_lpage">407</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2003.08.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.jmb.2003.08.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=14529625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD3sXns1KrtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=333&publication_year=2003&pages=393-407&author=J.+A.+Bertrandauthor=S.+Thieffineauthor=A.+Vulpettiauthor=C.+Cristianiauthor=B.+Valsasinaauthor=S.+Knappauthor=H.+M.+Kaliszauthor=M.+Flocco&title=Structural+characterization+of+the+GSK-3beta+active+site+using+selective+and+non-selective+ATP-mimetic+inhibitors&doi=10.1016%2Fj.jmb.2003.08.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Characterization of the GSK-3β Active Site Using Selective and Non-selective ATP-mimetic Inhibitors</span></div><div class="casAuthors">Bertrand, J. A.; Thieffine, S.; Vulpetti, A.; Cristiani, C.; Valsasina, B.; Knapp, S.; Kalisz, H. M.; Flocco, M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">333</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">393-407</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">GSK-3β is a regulatory serine/threonine kinase with a plethora of cellular targets.  Consequently, selective small mol. inhibitors of GSK-3β may have a variety of therapeutic uses including the treatment of neurodegenerative diseases, type II diabetes and cancer.  In order to characterize the active site of GSK-3β, we detd. crystal structures of unphosphorylated GSK-3β in complex with selective and non-selective ATP-mimetic inhibitors.  Anal. of the inhibitors' interactions with GSK-3β in the structures reveals how the enzyme can accommodate a no. of diverse mol. scaffolds.  In addn., a conserved water mol. near Thr138 is identified that can serve a functional role in inhibitor binding.  Finally, a comparison of the interactions made by selective and non-selective inhibitors highlights residues on the edge of the ATP binding-site that can be used to obtain inhibitor selectivity.  Information gained from these structures provides a promising route for the design of second-generation GSK-3β inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1bMYOQCSrdrVg90H21EOLACvtfcHk0ljcz44HT1oGIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXns1KrtLY%253D&md5=788fcb4dfa754e16e529c468014f44ab</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2003.08.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2003.08.031%26sid%3Dliteratum%253Aachs%26aulast%3DBertrand%26aufirst%3DJ.%2BA.%26aulast%3DThieffine%26aufirst%3DS.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DCristiani%26aufirst%3DC.%26aulast%3DValsasina%26aufirst%3DB.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DKalisz%26aufirst%3DH.%2BM.%26aulast%3DFlocco%26aufirst%3DM.%26atitle%3DStructural%2520characterization%2520of%2520the%2520GSK-3beta%2520active%2520site%2520using%2520selective%2520and%2520non-selective%2520ATP-mimetic%2520inhibitors%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2003%26volume%3D333%26spage%3D393%26epage%3D407%26doi%3D10.1016%2Fj.jmb.2003.08.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ormö, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radesäter, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jerning, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markgren, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgegård, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nylöf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giménez-Cassina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernández, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Díaz-Nido, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avila, J.</span></span> <span> </span><span class="NLM_article-title">Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">45937</span>– <span class="NLM_lpage">45945</span>, <span class="refDoi"> DOI: 10.1074/jbc.M306268200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1074%2Fjbc.M306268200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=12928438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosl2itL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=45937-45945&author=R.+Bhatauthor=Y.+Xueauthor=S.+Bergauthor=S.+Hellbergauthor=M.+Orm%C3%B6author=Y.+Nilssonauthor=A.+C.+Rades%C3%A4terauthor=E.+Jerningauthor=P.+O.+Markgrenauthor=T.+Borgeg%C3%A5rdauthor=M.+Nyl%C3%B6fauthor=A.+Gim%C3%A9nez-Cassinaauthor=F.+Hern%C3%A1ndezauthor=J.+J.+Lucasauthor=J.+D%C3%ADaz-Nidoauthor=J.+Avila&title=Structural+insights+and+biological+effects+of+glycogen+synthase+kinase+3-specific+inhibitor+AR-A014418&doi=10.1074%2Fjbc.M306268200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Insights and Biological Effects of Glycogen Synthase Kinase 3-specific Inhibitor AR-A014418</span></div><div class="casAuthors">Bhat, Ratan; Xue, Yafeng; Berg, Stefan; Hellberg, Sven; Ormoe, Mats; Nilsson, Yvonne; Radesaeter, Ann-Cathrin; Jerning, Eva; Markgren, Per-Olof; Borgegard, Thomas; Nyloef, Martin; Gimenez-Cassina, Alfredo; Hernandez, Felix; Lucas, Jose J.; Diaz-Nido, Javier; Avila, Jesus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">45937-45945</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Glycogen synthase kinase 3 (GSK3) is a serine/threonine kinase that has been implicated in pathol. conditions such as diabetes and Alzheimer's disease.  We report the characterization of a GSK3 inhibitor, AR-A014418, which inhibits GSK3 (IC50 = 104±27 nM), in an ATP-competitive manner (Ki = 38 nM).  AR-A014418 does not significantly inhibit cdk2 or cdk5 (IC50 > 100 μM) or 26 other kinases demonstrating high specificity for GSK3.  We report the co-crystn. of AR-A014418 with the GSK3β protein and provide a description of the interactions within the ATP pocket, as well as an understanding of the structural basis for the selectivity of AR-A014418.  AR-A014418 inhibits tau phosphorylation at a GSK3-specific site (Ser-396) in cells stably expressing human four-repeat tau protein.  AR-A014418 protects N2A neuroblastoma cells against cell death mediated by inhibition of the phosphatidylinositol 3-kinase/protein kinase B survival pathway.  Furthermore, AR-A014418 inhibits neurodegeneration mediated by β-amyloid peptide in hippocampal slices.  AR-A014418 may thus have important applications as a tool to elucidate the role of GSK3 in cellular signaling and possibly in Alzheimer's disease.  AR-A014418 is the first compd. of a family of specific inhibitors of GSK3 that does not significantly inhibit closely related kinases such as cdk2 or cdk5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVw7LgEHct0LVg90H21EOLACvtfcHk0ljcz44HT1oGIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosl2itL0%253D&md5=c52e13ab3dfdcef165620714c3181860</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M306268200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M306268200%26sid%3Dliteratum%253Aachs%26aulast%3DBhat%26aufirst%3DR.%26aulast%3DXue%26aufirst%3DY.%26aulast%3DBerg%26aufirst%3DS.%26aulast%3DHellberg%26aufirst%3DS.%26aulast%3DOrm%25C3%25B6%26aufirst%3DM.%26aulast%3DNilsson%26aufirst%3DY.%26aulast%3DRades%25C3%25A4ter%26aufirst%3DA.%2BC.%26aulast%3DJerning%26aufirst%3DE.%26aulast%3DMarkgren%26aufirst%3DP.%2BO.%26aulast%3DBorgeg%25C3%25A5rd%26aufirst%3DT.%26aulast%3DNyl%25C3%25B6f%26aufirst%3DM.%26aulast%3DGim%25C3%25A9nez-Cassina%26aufirst%3DA.%26aulast%3DHern%25C3%25A1ndez%26aufirst%3DF.%26aulast%3DLucas%26aufirst%3DJ.%2BJ.%26aulast%3DD%25C3%25ADaz-Nido%26aufirst%3DJ.%26aulast%3DAvila%26aufirst%3DJ.%26atitle%3DStructural%2520insights%2520and%2520biological%2520effects%2520of%2520glycogen%2520synthase%2520kinase%25203-specific%2520inhibitor%2520AR-A014418%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D45937%26epage%3D45945%26doi%3D10.1074%2Fjbc.M306268200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leost, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Link, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biernat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandelkow, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bibb, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greengard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaharevitz, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gussio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senderowicz, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sausville, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunick, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span> <span> </span><span class="NLM_article-title">Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25</span>. <i>Eur. J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>267</i></span>,  <span class="NLM_fpage">5983</span>– <span class="NLM_lpage">5994</span>, <span class="refDoi"> DOI: 10.1046/j.1432-1327.2000.01673.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1046%2Fj.1432-1327.2000.01673.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10998059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnt1Smtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=2000&pages=5983-5994&author=M.+Leostauthor=C.+Schultzauthor=A.+Linkauthor=Y.+Z.+Wuauthor=J.+Biernatauthor=E.+M.+Mandelkowauthor=J.+A.+Bibbauthor=G.+L.+Snyderauthor=P.+Greengardauthor=D.+W.+Zaharevitzauthor=R.+Gussioauthor=A.+M.+Senderowiczauthor=E.+A.+Sausvilleauthor=C.+Kunickauthor=L.+Meijer&title=Paullones+are+potent+inhibitors+of+glycogen+synthase+kinase-3beta+and+cyclin-dependent+kinase+5%2Fp25&doi=10.1046%2Fj.1432-1327.2000.01673.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Paullones are potent inhibitors of glycogen synthase kinase-3β and cyclin-dependent kinase 5/p25</span></div><div class="casAuthors">Leost, Maryse; Schultz, Christiane; Link, Andreas; Wu, Yong-Zhong; Biernat, Jacek; Mandelkow, Eva-Maria; Bibb, James A.; Snyder, Gretchen L.; Greengard, Paul; Zaharevitz, Daniel W.; Gussio, Rick; Senderowicz, Adrian M.; Sausville, Edward A.; Kunick, Conrad; Meijer, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5983-5994</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">Paullones constitute a new family of benzazepinones with promising antitumor properties.  They were recently described as potent, ATP-competitive, inhibitors of the cell cycle regulating cyclin-dependent kinases (CDKs).  We here report that paullones also act as very potent inhibitors of glycogen synthase kinase-3β u(GSuK-3β) (IC50·4-80 nm) and the neuronal CDK5/p25 (IC50:20-200 nM).  These two enzymes are responsible for most of the hyperphosphorylation of the microtubule-binding protein lau, a feature obsd. in the brains of patients with Alzheimer's disease and other neurodegenerative 'taupathies'.  Alsterpaullone, the most active paullone, was demonstrated to act by competing with ATP for binding to GSK-3β.  Alsterpaullone inhibits the phosphorylation of tau in vivo at sites which are typically phosphorylated by GSK-3β in Alzheimer's disease.  Alsterpaullone also inhibits the CDK5/p25-dependent phosphorylation of DARPP-32 in mouse striatum slices in vitro.  This dual specificity of paullones may turn these compds. into very useful tools for the study and possibly treatment of neurodegenerative and proliferative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkzLsn0FFzNLVg90H21EOLACvtfcHk0liYMW6Nxl525g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnt1Smtro%253D&md5=7a9ab4b55ac18653eb74246ace20754a</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1046%2Fj.1432-1327.2000.01673.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1432-1327.2000.01673.x%26sid%3Dliteratum%253Aachs%26aulast%3DLeost%26aufirst%3DM.%26aulast%3DSchultz%26aufirst%3DC.%26aulast%3DLink%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DY.%2BZ.%26aulast%3DBiernat%26aufirst%3DJ.%26aulast%3DMandelkow%26aufirst%3DE.%2BM.%26aulast%3DBibb%26aufirst%3DJ.%2BA.%26aulast%3DSnyder%26aufirst%3DG.%2BL.%26aulast%3DGreengard%26aufirst%3DP.%26aulast%3DZaharevitz%26aufirst%3DD.%2BW.%26aulast%3DGussio%26aufirst%3DR.%26aulast%3DSenderowicz%26aufirst%3DA.%2BM.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DKunick%26aufirst%3DC.%26aulast%3DMeijer%26aufirst%3DL.%26atitle%3DPaullones%2520are%2520potent%2520inhibitors%2520of%2520glycogen%2520synthase%2520kinase-3beta%2520and%2520cyclin-dependent%2520kinase%25205%252Fp25%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D2000%26volume%3D267%26spage%3D5983%26epage%3D5994%26doi%3D10.1046%2Fj.1432-1327.2000.01673.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, F. J.</span></span> <span> </span><span class="NLM_article-title">First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1292</span>– <span class="NLM_lpage">1299</span>, <span class="refDoi"> DOI: 10.1021/jm011020u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm011020u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtFCgu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=1292-1299&author=A.+Martinezauthor=M.+Alonsoauthor=A.+Castroauthor=C.+P%C3%A9rezauthor=F.+J.+Moreno&title=First+non-ATP+competitive+glycogen+synthase+kinase+3+beta+%28GSK-3beta%29+inhibitors%3A+Thiadiazolidinones+%28TDZD%29+as+potential+drugs+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1021%2Fjm011020u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">First Non-ATP Competitive Glycogen Synthase Kinase 3β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease</span></div><div class="casAuthors">Martinez, Ana; Alonso, Mercedes; Castro, Ana; Perez, Concepcion; Moreno, Francisco J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1292-1299</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glycogen synthase kinase 3β (GSK-3β) has a central role in Alzheimer's disease (AD).  Selective inhibitors which avoid τ hyperphosphorylation may represent an effective therapeutic approach to the pharmacotherapy of AD and other neurodegenerative disorders.  The synthesis, biol. evaluation, and SAR of some thiadiazolidinones (TDZD) as the first non-ATP competitive inhibitor of GSK-3β.  Their synthesis is based on the reactivity of sulfenyl chlorides.  In GSK-3β assays, TDZD derivs. showed IC50 values in the micromolar range, whereas in other protein kinase assays they were devoid of any inhibitory activity.  SAR studies allowed the identification of the key structural features.  Finally, a possible enzymic binding mode is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofQZkRe2BHh7Vg90H21EOLACvtfcHk0liYMW6Nxl525g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtFCgu70%253D&md5=a364133d1035bee183c58ad30ac140f8</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Fjm011020u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm011020u%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DAlonso%26aufirst%3DM.%26aulast%3DCastro%26aufirst%3DA.%26aulast%3DP%25C3%25A9rez%26aufirst%3DC.%26aulast%3DMoreno%26aufirst%3DF.%2BJ.%26atitle%3DFirst%2520non-ATP%2520competitive%2520glycogen%2520synthase%2520kinase%25203%2520beta%2520%2528GSK-3beta%2529%2520inhibitors%253A%2520Thiadiazolidinones%2520%2528TDZD%2529%2520as%2520potential%2520drugs%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D1292%26epage%3D1299%26doi%3D10.1021%2Fjm011020u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bidon-Chanal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuertes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luque, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, M.</span></span> <span> </span><span class="NLM_article-title">Evidence for a new binding mode to GSK-3: Allosteric regulation by the marine compound palinurin</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">479</span>– <span class="NLM_lpage">489</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2012.12.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.ejmech.2012.12.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=23354070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtVelsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2013&pages=479-489&author=A.+Bidon-Chanalauthor=A.+Fuertesauthor=D.+Alonsoauthor=D.+I.+P%C3%A9rezauthor=A.+Mart%C3%ADnezauthor=F.+J.+Luqueauthor=M.+Medina&title=Evidence+for+a+new+binding+mode+to+GSK-3%3A+Allosteric+regulation+by+the+marine+compound+palinurin&doi=10.1016%2Fj.ejmech.2012.12.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for a new binding mode to GSK-3: Allosteric regulation by the marine compound palinurin</span></div><div class="casAuthors">Bidon-Chanal, Axel; Fuertes, Ana; Alonso, Diana; Perez, Daniel I.; Martinez, Ana; Luque, F. Javier; Medina, Miguel</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">479-489</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Glycogen synthase kinase 3β (GSK-3β) is widely recognized as a relevant player in the pathogenesis of several highly prevalent disorders such as Alzheimer's disease, mood disorders, diabetes and cancer.  Therefore, this enzyme constitutes a highly attractive therapeutic target for the development of selective inhibitors as new promising drugs for the treatment of these pathologies.  The authors describe here the isolation and biochem. characterization of the marine natural sesquiterpene palinurin as a GSK-3β inhibitor.  Exptl. studies performed for characterizing the inhibitory mechanism indicate that GSK-3β inhibition by palinurin cannot be competed out by ATP nor peptide substrate.  Mol. modeling techniques have enabled the authors to propose an unconventional binding mode to GSK-3β.  Moreover, mol. dynamics simulations have identified an allosteric mechanism by which binding of palinurin leads to GSK-3β inhibition.  The inhibitory activities detd. for a series of structurally related analogs support the proposed binding mode of palinurin, which is the first compd. described to target this allosteric site.  The results offer new opportunities for designing and developing selective inhibitors with novel mechanisms of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpXmrBhA5ub7Vg90H21EOLACvtfcHk0liYMW6Nxl525g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtVelsrY%253D&md5=e9005c12a4f6897a91c3ee56e83b5f2d</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.12.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.12.014%26sid%3Dliteratum%253Aachs%26aulast%3DBidon-Chanal%26aufirst%3DA.%26aulast%3DFuertes%26aufirst%3DA.%26aulast%3DAlonso%26aufirst%3DD.%26aulast%3DP%25C3%25A9rez%26aufirst%3DD.%2BI.%26aulast%3DMart%25C3%25ADnez%26aufirst%3DA.%26aulast%3DLuque%26aufirst%3DF.%2BJ.%26aulast%3DMedina%26aufirst%3DM.%26atitle%3DEvidence%2520for%2520a%2520new%2520binding%2520mode%2520to%2520GSK-3%253A%2520Allosteric%2520regulation%2520by%2520the%2520marine%2520compound%2520palinurin%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D60%26spage%3D479%26epage%3D489%26doi%3D10.1016%2Fj.ejmech.2012.12.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">del Ser, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinwachs, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gertz, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrés, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gómez-Carrillo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vericat, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redondo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">León, T.</span></span> <span> </span><span class="NLM_article-title">Treatment of Alzheimer’s disease with the GSK-3 inhibitor tideglusib: A pilot study</span>. <i>J. Alzheimer's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">215</span>, <span class="refDoi"> DOI: 10.3233/JAD-2012-120805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.3233%2FJAD-2012-120805" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=205-215&author=T.+del+Serauthor=K.+C.+Steinwachsauthor=H.+J.+Gertzauthor=M.+V.+Andr%C3%A9sauthor=B.+G%C3%B3mez-Carrilloauthor=M.+Medinaauthor=J.+A.+Vericatauthor=P.+Redondoauthor=D.+Fleetauthor=T.+Le%C3%B3n&title=Treatment+of+Alzheimer%E2%80%99s+disease+with+the+GSK-3+inhibitor+tideglusib%3A+A+pilot+study&doi=10.3233%2FJAD-2012-120805"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.3233%2FJAD-2012-120805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-2012-120805%26sid%3Dliteratum%253Aachs%26aulast%3Ddel%2BSer%26aufirst%3DT.%26aulast%3DSteinwachs%26aufirst%3DK.%2BC.%26aulast%3DGertz%26aufirst%3DH.%2BJ.%26aulast%3DAndr%25C3%25A9s%26aufirst%3DM.%2BV.%26aulast%3DG%25C3%25B3mez-Carrillo%26aufirst%3DB.%26aulast%3DMedina%26aufirst%3DM.%26aulast%3DVericat%26aufirst%3DJ.%2BA.%26aulast%3DRedondo%26aufirst%3DP.%26aulast%3DFleet%26aufirst%3DD.%26aulast%3DLe%25C3%25B3n%26aufirst%3DT.%26atitle%3DTreatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%2520with%2520the%2520GSK-3%2520inhibitor%2520tideglusib%253A%2520A%2520pilot%2520study%26jtitle%3DJ.%2520Alzheimer%2527s%2520Dis.%26date%3D2012%26volume%3D33%26spage%3D205%26epage%3D215%26doi%3D10.3233%2FJAD-2012-120805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovestone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hüll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinne, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huppertz, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrés, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gómez-Carrillo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">León, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">del Ser, T.</span></span> <span> </span><span class="NLM_article-title">A phase II trial of tideglusib in Alzheimer’s disease</span>. <i>J. Alzheimer's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.3233/JAD-141959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.3233%2FJAD-141959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=25537011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjslOltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2015&pages=75-88&author=S.+Lovestoneauthor=M.+Boadaauthor=B.+Duboisauthor=M.+H%C3%BCllauthor=J.+O.+Rinneauthor=H.+J.+Huppertzauthor=M.+Caleroauthor=M.+V.+Andr%C3%A9sauthor=B.+G%C3%B3mez-Carrilloauthor=T.+Le%C3%B3nauthor=T.+del+Ser&title=A+phase+II+trial+of+tideglusib+in+Alzheimer%E2%80%99s+disease&doi=10.3233%2FJAD-141959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase II Trial of Tideglusib in Alzheimer's Disease</span></div><div class="casAuthors">Lovestone, Simon; Boada, Merce; Dubois, Bruno; Huell, Michael; Rinne, Juha O.; Huppertz, Hans-Juergen; Calero, Miguel; Andres, Maria V.; Gomez-Carrillo, Belen; Leon, Teresa; del Ser, Teodoro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-88</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">Background: The ARGO study was a phase II, double-blind, placebo controlled, four parallel arm trial of tideglusib in Alzheimer's disease (AD).  Objective: To prove the clin. efficacy of an inhibitor of glycogen synthase kinase-3 (GSK-3), in AD.  Methods: Mild to moderate (Mini-Mental State Examn. (MMSE) score, 14-26) AD patients on cholinesterase inhibitor and/or memantine treatment were administered tideglusib or placebo for 26 wk.  The ADAS-cog15 was the primary efficacy measure; function, cognition, behavior, and quality of life were assessed as secondary measures; cerebral atrophy in MRI and the levels of tau, amyloid-β, and BACE1 in cerebrospinal fluid (CSF) were exploratory endpoints.  Results: 306 AD patients were randomized to active (1000 mg QD: n = 86, 1000 mg QOD: n = 90, and 500 mg QD: n = 50) or placebo (n = 85) in 55 sites in four European countries.  There were no statistically significant differences between either active and placebo arms in the efficacy variables.  However, BACE1 in CSF significantly decreased with treatment in a small subgroup of patients.  Participants with mild AD in the 500 mg QD group showed significant responses on ADAS-cog15, MMSE, and word fluency.  Diarrhea (14-18% in active, 11% placebo) and dose-dependent, mild to moderate, and fully reversible transaminase increase (9-16% in active, 3.5% placebo) were the most frequent adverse events.  Conclusions: Short term (26 wk) tideglusib was acceptably safe but produced no clin. benefit in this trial.  However, given the non-linear dose response, esp. in mildly affected patients, further dose finding studies in early disease stages and for longer duration are warranted to examine GSK-3 inhibition in AD patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGru-ZlfznWkUbVg90H21EOLACvtfcHk0lhIU2e72ItExw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjslOltb8%253D&md5=7a342ad28ad2cfbbc3dc768849fb73ef</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.3233%2FJAD-141959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-141959%26sid%3Dliteratum%253Aachs%26aulast%3DLovestone%26aufirst%3DS.%26aulast%3DBoada%26aufirst%3DM.%26aulast%3DDubois%26aufirst%3DB.%26aulast%3DH%25C3%25BCll%26aufirst%3DM.%26aulast%3DRinne%26aufirst%3DJ.%2BO.%26aulast%3DHuppertz%26aufirst%3DH.%2BJ.%26aulast%3DCalero%26aufirst%3DM.%26aulast%3DAndr%25C3%25A9s%26aufirst%3DM.%2BV.%26aulast%3DG%25C3%25B3mez-Carrillo%26aufirst%3DB.%26aulast%3DLe%25C3%25B3n%26aufirst%3DT.%26aulast%3Ddel%2BSer%26aufirst%3DT.%26atitle%3DA%2520phase%2520II%2520trial%2520of%2520tideglusib%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Alzheimer%2527s%2520Dis.%26date%3D2015%26volume%3D45%26spage%3D75%26epage%3D88%26doi%3D10.3233%2FJAD-141959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><a href="https://clinicaltrials.gov/ct2/show/NCT03692312" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03692312</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03692312."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><a href="https://clinicaltrials.gov/ct2/show/NCT02586935?term=tideglusib’draw=2&amp;rank=2&amp;rank=2" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02586935?term=tideglusib'draw=2&rank=2&rank=2</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02586935%3Fterm%3Dtideglusib%27draw%3D2%26rank%3D2%26rank%3D2."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tolosa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litvan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Höglinger, G. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrés, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gómez-Carrillo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">León, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Ser, T.</span></span> <span> </span><span class="NLM_article-title">A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy</span>. <i>Mov. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">470</span>– <span class="NLM_lpage">478</span>, <span class="refDoi"> DOI: 10.1002/mds.25824</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1002%2Fmds.25824" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=24532007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvFSmtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2014&pages=470-478&author=E.+Tolosaauthor=I.+Litvanauthor=G.+U.+H%C3%B6glingerauthor=D.+Burnauthor=A.+Leesauthor=M.+V.+Andr%C3%A9sauthor=B.+G%C3%B3mez-Carrilloauthor=T.+Le%C3%B3nauthor=T.+Del+Ser&title=A+phase+2+trial+of+the+GSK-3+inhibitor+tideglusib+in+progressive+supranuclear+palsy&doi=10.1002%2Fmds.25824"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy</span></div><div class="casAuthors">Tolosa, Eduardo; Litvan, Irene; Hoeglinger, Guenter U.; Burn, David; Lees, Andrew; Andres, Maria V.; Gomez-Carrillo, Belen; Leon, Teresa; del Ser, Teodoro</div><div class="citationInfo"><span class="NLM_cas:title">Movement Disorders</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">470-478</span>CODEN:
                <span class="NLM_cas:coden">MOVDEA</span>;
        ISSN:<span class="NLM_cas:issn">0885-3185</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">It is believed that glycogen synthase kinase-3 (GSK-3) hyperphosphorylates tau protein in progressive supranuclear palsy (PSP).  The Tau Restoration on PSP (TAUROS) study was a double-blind, placebo-controlled, randomized trial to assess the efficacy, safety, and tolerability of tideglusib, a GSK-3 inhibitor, as potential treatment for PSP.  The study enrolled 146 PSP patients with mild-to-moderate disease who were randomized to receive once-daily 600 mg tideglusib, 800 mg tideglusib, or placebo (ratio, 2:2:1) administered orally over 52 wk.  The primary endpoint was the change from baseline to week 52 on the PSP rating scale.  Secondary endpoints were safety and tolerability of tideglusib, changes in motor function (the Timed Up and Go Test), cognition (Dementia Rating Scale-2, Frontal Assessment Battery, verbal fluency), apathy (Starkstein scale), activities of daily living (Schwab and England scale; Unified Parkinson's Disease Rating Scale, part II), quality of life (EuroQol), and Global Clin. Assessment.  Brain atrophy on magnetic resonance imaging and several biomarkers in plasma and cerebrospinal fluid also were examd.  No significant differences were detected in the primary or secondary endpoints at week 52 between placebo and either dose of tideglusib.  Tideglusib was safe, with the exception of some asymptomatic, transient, and reversible transaminase elevations (mainly alanine aminotransferase) in 9% of patients, and diarrhea in 13% of patients.  Tideglusib was generally well tolerated but it did not show clin. efficacy in patients with mild-to-moderate PSP. © 2014 International Parkinson and Movement Disorder Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgJLeCmPA9ULVg90H21EOLACvtfcHk0lhIU2e72ItExw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvFSmtL8%253D&md5=4b7899d99427a60b8edae580355a740d</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1002%2Fmds.25824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.25824%26sid%3Dliteratum%253Aachs%26aulast%3DTolosa%26aufirst%3DE.%26aulast%3DLitvan%26aufirst%3DI.%26aulast%3DH%25C3%25B6glinger%26aufirst%3DG.%2BU.%26aulast%3DBurn%26aufirst%3DD.%26aulast%3DLees%26aufirst%3DA.%26aulast%3DAndr%25C3%25A9s%26aufirst%3DM.%2BV.%26aulast%3DG%25C3%25B3mez-Carrillo%26aufirst%3DB.%26aulast%3DLe%25C3%25B3n%26aufirst%3DT.%26aulast%3DDel%2BSer%26aufirst%3DT.%26atitle%3DA%2520phase%25202%2520trial%2520of%2520the%2520GSK-3%2520inhibitor%2520tideglusib%2520in%2520progressive%2520supranuclear%2520palsy%26jtitle%3DMov.%2520Disord.%26date%3D2014%26volume%3D29%26spage%3D470%26epage%3D478%26doi%3D10.1002%2Fmds.25824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horrigan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snape, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolenko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMorn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaroshinsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Della Pasqua, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oosterholt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lochmüller, H.</span></span> <span> </span><span class="NLM_article-title">A phase 2 study of AMO-02 (Tideglusib) in congenital and childhood-onset myotonic dystrophy type 1 (DM1)</span>. <i>Pediatr Neurol</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1016/j.pediatrneurol.2020.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.pediatrneurol.2020.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=32942085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BB3s%252FgtVyisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2020&pages=84-93&author=J.+Horriganauthor=T.+B.+Gomesauthor=M.+Snapeauthor=N.+Nikolenkoauthor=A.+McMornauthor=S.+Evansauthor=A.+Yaroshinskyauthor=O.+Della+Pasquaauthor=S.+Oosterholtauthor=H.+Lochm%C3%BCller&title=A+phase+2+study+of+AMO-02+%28Tideglusib%29+in+congenital+and+childhood-onset+myotonic+dystrophy+type+1+%28DM1%29&doi=10.1016%2Fj.pediatrneurol.2020.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase 2 Study of AMO-02 (Tideglusib) in Congenital and Childhood-Onset Myotonic Dystrophy Type 1 (DM1)</span></div><div class="casAuthors">Horrigan Joseph; Gomes Tiago Bernardino; Snape Mike; McMorn Alison; Evans Stuart; Nikolenko Nikoletta; Yaroshinsky Alex; Della Pasqua Oscar; Oosterholt Sean; Lochmuller Hanns</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric neurology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">84-93</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  GSK3β is an intracellular regulatory kinase that is dysregulated in multiple tissues in type 1 myotonic dystrophy, a rare neuromuscular disorder that manifests at any age.  AMO-02 (tideglusib) inhibits GSK3β activity in preclinical models of type 1 myotonic dystrophy and promotes cellular maturation as well as normalizes aberrant molecular and behavioral phenotypes.  This phase 2 study assessed the pharmacokinetics, safety and tolerability, and preliminary efficacy of AMO-02 in adolescents and adults with congenital and childhood-onset type 1 myotonic dystrophy.  METHODS:  Sixteen subjects (aged 13 to 34 years) with congenital and childhood-onset type 1 myotonic dystrophy received 12 weeks of single-blind fixed-dose oral treatment with either 400 mg (n = 8) or 1000 mg (n = 8) AMO-02 (NCT02858908).  Blood samples were obtained for pharmacokinetic assessment.  Safety assessments, such as laboratory tests and electrocardiograms, as well as efficacy assessments of syndromal, cognitive, and muscular functioning, were obtained.  RESULTS:  AMO-02 plasma concentrations conformed to a two-compartment model with first-order absorption and elimination, and dose-dependent increases in exposure (area under the curve) were observed.  AMO-02 was generally safe and well-tolerated.  No early discontinuations due to adverse events or dose adjustments of AMO-02 occurred.  The majority of subjects manifested clinical improvement in their central nervous system and neuromuscular symptoms after 12 weeks of treatment compared with the placebo baseline, with a larger response noted at the 1000 mg/day dose level.  AMO-02 exposure (cumulative area under the curve) was significantly correlated (P < 0.01) with change from baseline on several key efficacy assessments.  CONCLUSION:  AMO-02 has favorable pharmacokinetic and clinical risk/benefit profiles meriting further study as a potential treatment for congenital and childhood-onset type 1 myotonic dystrophy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRo1-Ytzv0sx-Lt9HypzAgQfW6udTcc2eZTKkhjrrn_A7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3s%252FgtVyisQ%253D%253D&md5=74db89ffb71eb1fc21a6989770b194ef</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.pediatrneurol.2020.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pediatrneurol.2020.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DHorrigan%26aufirst%3DJ.%26aulast%3DGomes%26aufirst%3DT.%2BB.%26aulast%3DSnape%26aufirst%3DM.%26aulast%3DNikolenko%26aufirst%3DN.%26aulast%3DMcMorn%26aufirst%3DA.%26aulast%3DEvans%26aufirst%3DS.%26aulast%3DYaroshinsky%26aufirst%3DA.%26aulast%3DDella%2BPasqua%26aufirst%3DO.%26aulast%3DOosterholt%26aufirst%3DS.%26aulast%3DLochm%25C3%25BCller%26aufirst%3DH.%26atitle%3DA%2520phase%25202%2520study%2520of%2520AMO-02%2520%2528Tideglusib%2529%2520in%2520congenital%2520and%2520childhood-onset%2520myotonic%2520dystrophy%2520type%25201%2520%2528DM1%2529%26jtitle%3DPediatr%2520Neurol%26date%3D2020%26volume%3D112%26spage%3D84%26epage%3D93%26doi%3D10.1016%2Fj.pediatrneurol.2020.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palomo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soteras, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campillo, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span> <span> </span><span class="NLM_article-title">Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">8461</span>– <span class="NLM_lpage">8470</span>, <span class="refDoi"> DOI: 10.1021/jm200996g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200996g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVWms7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8461-8470&author=V.+Palomoauthor=I.+Soterasauthor=D.+I.+Perezauthor=C.+Perezauthor=C.+Gilauthor=N.+E.+Campilloauthor=A.+Martinez&title=Exploring+the+binding+sites+of+glycogen+synthase+kinase+3.+Identification+and+characterization+of+allosteric+modulation+cavities&doi=10.1021%2Fjm200996g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring the Binding Sites of Glycogen Synthase Kinase 3. Identification and Characterization of Allosteric Modulation Cavities</span></div><div class="casAuthors">Palomo, Valle; Soteras, Ignacio; Perez, Daniel I.; Perez, Concepcion; Gil, Carmen; Campillo, Nuria Eugenia; Martinez, Ana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8461-8470</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glycogen synthase kinase 3 (GSK-3) is an important drug target for human severe unmet diseases.  Discovery and/or design of allosteric kinase modulators are gaining importance in this field not only for the increased selectivity of this kind of compds. but also for the subtle modulation of the target.  This last point is of utmost importance for the GSK-3 inhibition as a therapeutic approach.  GSK-3 activity is completely necessary for life, and only the aberrant overactivity found in the pathologies should be inhibited with its inhibitors treatment.  We performed here a search for the druggable sites on the enzyme using the fpocket algorithm with the aim to provide allosteric potential binding sites on it and new clues for further drug discoveries.  Moreover, our results allowed us to det. the binding sites of different GSK-3 ATP noncompetitive inhibitors, such as manzamine A and the new small mol. VP 0.7, providing evidence for potential allosteric inhibition of GSK-3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9YWCNrZPfb7Vg90H21EOLACvtfcHk0liMH_gC8eJtMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVWms7zI&md5=087cfee46fb46b531abcacb46317d122</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1021%2Fjm200996g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200996g%26sid%3Dliteratum%253Aachs%26aulast%3DPalomo%26aufirst%3DV.%26aulast%3DSoteras%26aufirst%3DI.%26aulast%3DPerez%26aufirst%3DD.%2BI.%26aulast%3DPerez%26aufirst%3DC.%26aulast%3DGil%26aufirst%3DC.%26aulast%3DCampillo%26aufirst%3DN.%2BE.%26aulast%3DMartinez%26aufirst%3DA.%26atitle%3DExploring%2520the%2520binding%2520sites%2520of%2520glycogen%2520synthase%2520kinase%25203.%2520Identification%2520and%2520characterization%2520of%2520allosteric%2520modulation%2520cavities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8461%26epage%3D8470%26doi%3D10.1021%2Fjm200996g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duda, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akula, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steelman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martelli, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocco, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Candido, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Libra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montalto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gizak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakus, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCubrey, J. A.</span></span> <span> </span><span class="NLM_article-title">Targeting GSK3 and associated signaling pathways involved in cancer</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1110</span>, <span class="refDoi"> DOI: 10.3390/cells9051110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.3390%2Fcells9051110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BB3cXis1Sku7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=1110&author=P.+Dudaauthor=S.+M.+Akulaauthor=S.+L.+Abramsauthor=L.+S.+Steelmanauthor=A.+M.+Martelliauthor=L.+Coccoauthor=S.+Rattiauthor=S.+Candidoauthor=M.+Libraauthor=G.+Montaltoauthor=M.+Cervelloauthor=A.+Gizakauthor=D.+Rakusauthor=J.+A.+McCubrey&title=Targeting+GSK3+and+associated+signaling+pathways+involved+in+cancer&doi=10.3390%2Fcells9051110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting GSK3 and associated signaling pathways involved in cancer</span></div><div class="casAuthors">Duda, Przemyslaw; Akula, Shaw M.; Abrams, Stephen L.; Steelman, Linda S.; Martelli, Alberto M.; Cocco, Lucio; Ratti, Stefano; Candido, Saverio; Libra, Massimo; Montalto, Giuseppe; Cervello, Melchiorre; Gizak, Agnieszka; Rakus, Dariusz; McCubrey, James A.</div><div class="citationInfo"><span class="NLM_cas:title">Cells</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1110</span>CODEN:
                <span class="NLM_cas:coden">CELLC6</span>;
        ISSN:<span class="NLM_cas:issn">2073-4409</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Glycogen synthase kinase 3 (GSK-3) is a serine/threonine (S/T) protein kinase.  Although GSK-3 originally was identified to have functions in regulation of glycogen synthase, it was subsequently detd. to have roles in multiple normal biochem. processes as well as various disease conditions.  GSK-3 is sometimes referred to as a moonlighting protein due to the multiple substrates and processes which it controls.  Frequently, when GSK-3 phosphorylates proteins, they are targeted for degrdn.  GSK-3 is often considered a component of the PI3K/PTEN/AKT/GSK-3/mTORC1 pathway as GSK-3 is frequently phosphorylated by AKT which regulates its inactivation.  AKT is often active in human cancer and hence, GSK-3 is often inactivated.  Moreover, GSK-3 also interacts with WNT/β-catenin signaling and β-catenin and other proteins in this pathway are targets of GSK-3.  GSK-3 can modify NF-κB activity which is often expressed at high levels in cancer cells.  Multiple pharmaceutical companies developed small mol. inhibitors to suppress GSK-3 activity.  In addn., various natural products will modify GSK-3 activity.  This review will focus on the effects of small mol. inhibitors and natural products on GSK-3 activity and provide examples where these compds. were effective in suppressing cancer growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmtCdaBstHubVg90H21EOLACvtfcHk0liMH_gC8eJtMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXis1Sku7jK&md5=52d9fc10c3720bf3bbd37ba51511754d</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.3390%2Fcells9051110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells9051110%26sid%3Dliteratum%253Aachs%26aulast%3DDuda%26aufirst%3DP.%26aulast%3DAkula%26aufirst%3DS.%2BM.%26aulast%3DAbrams%26aufirst%3DS.%2BL.%26aulast%3DSteelman%26aufirst%3DL.%2BS.%26aulast%3DMartelli%26aufirst%3DA.%2BM.%26aulast%3DCocco%26aufirst%3DL.%26aulast%3DRatti%26aufirst%3DS.%26aulast%3DCandido%26aufirst%3DS.%26aulast%3DLibra%26aufirst%3DM.%26aulast%3DMontalto%26aufirst%3DG.%26aulast%3DCervello%26aufirst%3DM.%26aulast%3DGizak%26aufirst%3DA.%26aulast%3DRakus%26aufirst%3DD.%26aulast%3DMcCubrey%26aufirst%3DJ.%2BA.%26atitle%3DTargeting%2520GSK3%2520and%2520associated%2520signaling%2520pathways%2520involved%2520in%2520cancer%26jtitle%3DCells%26date%3D2020%26volume%3D9%26spage%3D1110%26doi%3D10.3390%2Fcells9051110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Makin, S.</span></span> <span> </span><span class="NLM_article-title">The amyloid hypothesis on trial</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>559</i></span>,  <span class="NLM_fpage">S4</span>– <span class="NLM_lpage">S7</span>, <span class="refDoi"> DOI: 10.1038/d41586-018-05719-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2Fd41586-018-05719-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=30046080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtl2jt7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=559&publication_year=2018&pages=S4-S7&author=S.+Makin&title=The+amyloid+hypothesis+on+trial&doi=10.1038%2Fd41586-018-05719-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">The amyloid hypothesis on trial</span></div><div class="casAuthors">Makin, Simon</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">559</span>
        (<span class="NLM_cas:issue">7715</span>),
    <span class="NLM_cas:pages">S4-S7</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">As the development of treatments for Alzheimer's disease continues to stumble, is it time for researchers to broaden their list of the condition's potential causes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYpIAatE5SYbVg90H21EOLACvtfcHk0lhVbQ5Puy5ttw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtl2jt7zI&md5=83ae788246ed27a5a8b93b6bc20d8803</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1038%2Fd41586-018-05719-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fd41586-018-05719-4%26sid%3Dliteratum%253Aachs%26aulast%3DMakin%26aufirst%3DS.%26atitle%3DThe%2520amyloid%2520hypothesis%2520on%2520trial%26jtitle%3DNature%26date%3D2018%26volume%3D559%26spage%3DS4%26epage%3DS7%26doi%3D10.1038%2Fd41586-018-05719-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hargreaves, R. J.</span></span> <span> </span><span class="NLM_article-title">“It ain't over 'til it's over” (a) -the search for treatments and cures for Alzheimer’s disease</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">862</span>– <span class="NLM_lpage">866</span>, <span class="refDoi"> DOI: 10.1021/ml300359g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300359g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFygtLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=862-866&author=R.+J.+Hargreaves&title=%E2%80%9CIt+ain%27t+over+%27til+it%27s+over%E2%80%9D+%28a%29+-the+search+for+treatments+and+cures+for+Alzheimer%E2%80%99s+disease&doi=10.1021%2Fml300359g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">"It Ain't Over 'til It's Over"a-The Search for Treatments and Cures for Alzheimer's Disease</span></div><div class="casAuthors">Hargreaves, Richard J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">862-866</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In the neuro-science landscape, there is no condition with higher unmet medical and societal need than Alzheimer's disease (AD).  There are significant opportunities to improve upon symptomatic treatments in AD, and as yet, there are no treatments to modify (slow, stop, or prevent) underlying disease progression.  Our goals are to discover new symptomatic AD therapies with improved efficacy and longevity; to complete definitive studies that refute or prove the amyloid hypothesis, potentially opening multiple avenues to new therapeutic modalities; and to initiate tests of novel mechanisms that can prevent tau pathol. and neurodegeneration.  It's a crit. time in the testing of novel AD therapeutics-let's hope we succeed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ6SVDrZ3RkrVg90H21EOLACvtfcHk0lhVbQ5Puy5ttw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFygtLnM&md5=0062f7f6ff1c79cbef8b013bda0425e5</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1021%2Fml300359g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300359g%26sid%3Dliteratum%253Aachs%26aulast%3DHargreaves%26aufirst%3DR.%2BJ.%26atitle%3D%25E2%2580%259CIt%2520ain%2527t%2520over%2520%2527til%2520it%2527s%2520over%25E2%2580%259D%2520%2528a%2529%2520-the%2520search%2520for%2520treatments%2520and%2520cures%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D862%26epage%3D866%26doi%3D10.1021%2Fml300359g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottegoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span> <span> </span><span class="NLM_article-title">BACE-1 inhibitors: From recent single-target molecules to multitarget compounds for Alzheimer’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">619</span>– <span class="NLM_lpage">637</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00393</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00393" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1eks7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=619-637&author=F.+Pratiauthor=G.+Bottegoniauthor=M.+L.+Bolognesiauthor=A.+Cavalli&title=BACE-1+inhibitors%3A+From+recent+single-target+molecules+to+multitarget+compounds+for+Alzheimer%E2%80%99s+disease&doi=10.1021%2Facs.jmedchem.7b00393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">BACE-1 Inhibitors: From Recent Single-Target Molecules to Multitarget Compounds for Alzheimer's Disease</span></div><div class="casAuthors">Prati, Federica; Bottegoni, Giovanni; Bolognesi, Maria Laura; Cavalli, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">619-637</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The amyloid hypothesis has long been the central dogma in drug discovery for Alzheimer's disease (AD), leading to many small-mol. and biol. drug candidates.  One major target has been the β-site amyloid-precursor-protein-cleaving enzyme 1 (BACE-1), with many big pharma companies expending great resources in the search for BACE-1 inhibitors.  The lack of efficacy of verubecestat in mild-to-moderate AD raises important questions about the timing of intervention with BACE-1 inhibitors, and anti-amyloid therapies in general, in AD treatment.  It also suggests new possibilities for discovering BACE-1-targeted compds. with more complex mechanisms of actions and improved efficacy.  Herein, the authors review the major advances in BACE-1 drug discovery, from single-target small mol. inhibitors to multitarget compds.  The authors discuss these compds. as innovative tools for better understanding the complexity of AD and for identifying efficacious drug candidates to treat this devastating disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqIKti01PzWrVg90H21EOLACvtfcHk0lhVbQ5Puy5ttw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1eks7nO&md5=a30fe7a54f34206355c6380eb9eacbe4</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00393%26sid%3Dliteratum%253Aachs%26aulast%3DPrati%26aufirst%3DF.%26aulast%3DBottegoni%26aufirst%3DG.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DCavalli%26aufirst%3DA.%26atitle%3DBACE-1%2520inhibitors%253A%2520From%2520recent%2520single-target%2520molecules%2520to%2520multitarget%2520compounds%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D619%26epage%3D637%26doi%3D10.1021%2Facs.jmedchem.7b00393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mullard, A.</span></span> <span> </span><span class="NLM_article-title">BACE inhibitor bust in Alzheimer trial</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">155</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.43</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2Fnrd.2017.43" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlslentL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=155&author=A.+Mullard&title=BACE+inhibitor+bust+in+Alzheimer+trial&doi=10.1038%2Fnrd.2017.43"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">New plaque psoriasis approval carries suicide warning</span></div><div class="casAuthors">Mullard, Asher</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">155</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorrFVcqAa99rVg90H21EOLACvtfcHk0lhVbQ5Puy5ttw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlslentL4%253D&md5=057ed2ef8ae29db922708b84a51482f2</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.43&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.43%26sid%3Dliteratum%253Aachs%26aulast%3DMullard%26aufirst%3DA.%26atitle%3DBACE%2520inhibitor%2520bust%2520in%2520Alzheimer%2520trial%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D155%26doi%3D10.1038%2Fnrd.2017.43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ittner, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Götz, J.</span></span> <span> </span><span class="NLM_article-title">Amyloid-β and tau--a toxic pas de deux in Alzheimer’s disease</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1038/nrn2967</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2Fnrn2967" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=67-72&author=L.+M.+Ittnerauthor=J.+G%C3%B6tz&title=Amyloid-%CE%B2+and+tau%2D%2Da+toxic+pas+de+deux+in+Alzheimer%E2%80%99s+disease&doi=10.1038%2Fnrn2967"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1038%2Fnrn2967&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn2967%26sid%3Dliteratum%253Aachs%26aulast%3DIttner%26aufirst%3DL.%2BM.%26aulast%3DG%25C3%25B6tz%26aufirst%3DJ.%26atitle%3DAmyloid-%25CE%25B2%2520and%2520tau--a%2520toxic%2520pas%2520de%2520deux%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2011%26volume%3D12%26spage%3D67%26epage%3D72%26doi%3D10.1038%2Fnrn2967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Terwel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muyllaert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewachter, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borghgraef, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devijver, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Leuven, F.</span></span> <span> </span><span class="NLM_article-title">Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">786</span>– <span class="NLM_lpage">798</span>, <span class="refDoi"> DOI: 10.2353/ajpath.2008.070904</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.2353%2Fajpath.2008.070904" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=18258852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktVKgsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2008&pages=786-798&author=D.+Terwelauthor=D.+Muyllaertauthor=I.+Dewachterauthor=P.+Borghgraefauthor=S.+Croesauthor=H.+Devijverauthor=F.+Van+Leuven&title=Amyloid+activates+GSK-3beta+to+aggravate+neuronal+tauopathy+in+bigenic+mice&doi=10.2353%2Fajpath.2008.070904"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Amyloid activates GSK-3β to aggravate neuronal tauopathy in bigenic mice</span></div><div class="casAuthors">Terwel, Dick; Muyllaert, David; Dewachter, Ilse; Borghgraef, Peter; Croes, Sophie; Devijver, Herman; Van Leuven, Fred</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">786-798</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">The hypothesis that amyloid pathol. precedes and induces the tau pathol. of Alzheimer's disease is exptl. supported here through the identification of GSK-3 isoenzymes as a major link in the signaling pathway from amyloid to tau pathol.  This study compares two novel bigenic mouse models: APP-V717I × Tau-P301L mice with combined amyloid and tau pathol. and GSK-3β × Tau-P301L mice with tauopathy only.  Extensive and remarkable parallels were obsd. between these strains including (1) aggravation of tauopathy with highly fibrillar tangles in the hippocampus and cortex; (2) prolonged survival correlated to alleviated brainstem tauopathy; (3) development of severe cognitive and behavioral defects in young adults before the onset of amyloid deposition or tauopathy; and (4) presence of pathol. phospho-epitopes of tau, including the characteristic GSK-3β motif at S396/S404.  Both GSK-3 isoenzymes were activated in the brain of parental APP-V717I amyloid mice, even at a young age when cognitive and behavioral defects are evident but before amyloid deposition.  The data indicate that amyloid induces tauopathy through activation of GSK-3 and suggest a role for the kinase in maintaining the functional integrity of adult neurons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0Q4WlwJ0AZrVg90H21EOLACvtfcHk0lh_wPYw9Ii_Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktVKgsrk%253D&md5=734b1ec316392574d4624734bb80a2e3</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.2353%2Fajpath.2008.070904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2353%252Fajpath.2008.070904%26sid%3Dliteratum%253Aachs%26aulast%3DTerwel%26aufirst%3DD.%26aulast%3DMuyllaert%26aufirst%3DD.%26aulast%3DDewachter%26aufirst%3DI.%26aulast%3DBorghgraef%26aufirst%3DP.%26aulast%3DCroes%26aufirst%3DS.%26aulast%3DDevijver%26aufirst%3DH.%26aulast%3DVan%2BLeuven%26aufirst%3DF.%26atitle%3DAmyloid%2520activates%2520GSK-3beta%2520to%2520aggravate%2520neuronal%2520tauopathy%2520in%2520bigenic%2520mice%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2008%26volume%3D172%26spage%3D786%26epage%3D798%26doi%3D10.2353%2Fajpath.2008.070904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gandini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedesco, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Gonzalez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campillo, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaldivar-Diez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccheri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petralla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moda, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legname, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">Tau-centric multitarget approach for Alzheimer’s disease: Development of first-in-class dual Glycogen synthase kinase 3β and Tau-aggregation inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7640</span>– <span class="NLM_lpage">7656</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00610</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00610" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVChu7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7640-7656&author=A.+Gandiniauthor=M.+Bartoliniauthor=D.+Tedescoauthor=L.+Martinez-Gonzalezauthor=C.+Rocaauthor=N.+E.+Campilloauthor=J.+Zaldivar-Diezauthor=C.+Perezauthor=G.+Zuccheriauthor=A.+Mitiauthor=A.+Feoliauthor=S.+Castellanoauthor=S.+Petrallaauthor=B.+Montiauthor=M.+Rossiauthor=F.+Modaauthor=G.+Legnameauthor=A.+Martinezauthor=M.+L.+Bolognesi&title=Tau-centric+multitarget+approach+for+Alzheimer%E2%80%99s+disease%3A+Development+of+first-in-class+dual+Glycogen+synthase+kinase+3%CE%B2+and+Tau-aggregation+inhibitors&doi=10.1021%2Facs.jmedchem.8b00610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Tau-Centric Multitarget Approach for Alzheimer's Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors</span></div><div class="casAuthors">Gandini, Annachiara; Bartolini, Manuela; Tedesco, Daniele; Martinez-Gonzalez, Loreto; Roca, Carlos; Campillo, Nuria E.; Zaldivar-Diez, Josefa; Perez, Concepcion; Zuccheri, Giampaolo; Miti, Andrea; Feoli, Alessandra; Castellano, Sabrina; Petralla, Sabrina; Monti, Barbara; Rossi, Martina; Moda, Fabio; Legname, Giuseppe; Martinez, Ana; Bolognesi, Maria Laura</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7640-7656</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several findings propose the altered tau protein network as an important target for Alzheimer's disease (AD).  Particularly, two points of pharmacol. intervention can be envisaged: inhibition of phosphorylating tau kinase GSK-3β and tau aggregation process.  On the basis of this consideration and on the authors' interest in multitarget paradigms in AD, the authors report on the discovery of 2,4-thiazolidinedione derivs. endowed with such a profile. 28 and 30 displayed micromolar IC50 values toward GSK-3β, together with the capacity of inhibiting AcPHF6 aggregation of 60% and 80% at 10 μM, resp.  In addn., they showed PAMPA-BBB permeability, together with a suitable cellular safety profile. 30 also displayed inhibition of both K18 and full-length tau aggregations.  Finally, both compds. were able to improve cell viability in an okadaic acid-induced neurodegeneration cell model.  To the best of the authors' knowledge, 28 and 30 are the first balanced, nontoxic, dual-acting compds. hitting tau cascade at two different hubs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6bQV6XoAhyrVg90H21EOLACvtfcHk0lh_wPYw9Ii_Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVChu7%252FL&md5=34b7e2f2556f3e96c768dd87fb3f0e6d</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00610%26sid%3Dliteratum%253Aachs%26aulast%3DGandini%26aufirst%3DA.%26aulast%3DBartolini%26aufirst%3DM.%26aulast%3DTedesco%26aufirst%3DD.%26aulast%3DMartinez-Gonzalez%26aufirst%3DL.%26aulast%3DRoca%26aufirst%3DC.%26aulast%3DCampillo%26aufirst%3DN.%2BE.%26aulast%3DZaldivar-Diez%26aufirst%3DJ.%26aulast%3DPerez%26aufirst%3DC.%26aulast%3DZuccheri%26aufirst%3DG.%26aulast%3DMiti%26aufirst%3DA.%26aulast%3DFeoli%26aufirst%3DA.%26aulast%3DCastellano%26aufirst%3DS.%26aulast%3DPetralla%26aufirst%3DS.%26aulast%3DMonti%26aufirst%3DB.%26aulast%3DRossi%26aufirst%3DM.%26aulast%3DModa%26aufirst%3DF.%26aulast%3DLegname%26aufirst%3DG.%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DTau-centric%2520multitarget%2520approach%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520Development%2520of%2520first-in-class%2520dual%2520Glycogen%2520synthase%2520kinase%25203%25CE%25B2%2520and%2520Tau-aggregation%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7640%26epage%3D7656%26doi%3D10.1021%2Facs.jmedchem.8b00610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bulic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickhardt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khlistunova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biernat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandelkow, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandelkow, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldmann, H.</span></span> <span> </span><span class="NLM_article-title">Rhodanine-based tau aggregation inhibitors in cell models of tauopathy</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">9215</span>– <span class="NLM_lpage">9219</span>, <span class="refDoi"> DOI: 10.1002/anie.200704051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1002%2Fanie.200704051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BD2sjjtlSltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=9215-9219&author=B.+Bulicauthor=M.+Pickhardtauthor=I.+Khlistunovaauthor=J.+Biernatauthor=E.+M.+Mandelkowauthor=E.+Mandelkowauthor=H.+Waldmann&title=Rhodanine-based+tau+aggregation+inhibitors+in+cell+models+of+tauopathy&doi=10.1002%2Fanie.200704051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Rhodanine-based tau aggregation inhibitors in cell models of tauopathy</span></div><div class="casAuthors">Bulic Bruno; Pickhardt Marcus; Khlistunova Inna; Biernat Jacek; Mandelkow Eva-Maria; Mandelkow Eckhard; Waldmann Herbert</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie (International ed. in English)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">9215-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcScsfK7C2PCgf6xYuD7tu2XfW6udTcc2eZKVu2u8KGnn7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sjjtlSltg%253D%253D&md5=9948b3054bae5ce9e52d0ce3d4635788</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1002%2Fanie.200704051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200704051%26sid%3Dliteratum%253Aachs%26aulast%3DBulic%26aufirst%3DB.%26aulast%3DPickhardt%26aufirst%3DM.%26aulast%3DKhlistunova%26aufirst%3DI.%26aulast%3DBiernat%26aufirst%3DJ.%26aulast%3DMandelkow%26aufirst%3DE.%2BM.%26aulast%3DMandelkow%26aufirst%3DE.%26aulast%3DWaldmann%26aufirst%3DH.%26atitle%3DRhodanine-based%2520tau%2520aggregation%2520inhibitors%2520in%2520cell%2520models%2520of%2520tauopathy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2007%26volume%3D46%26spage%3D9215%26epage%3D9219%26doi%3D10.1002%2Fanie.200704051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arfeen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborti, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharatam, P. V.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of 5-benzylidene-2-iminothiazolidin-4-ones as selective GSK-3β inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">736</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.04.075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.ejmech.2016.04.075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=27423119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtF2hs7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2016&pages=727-736&author=M.+Arfeenauthor=S.+Bhagatauthor=R.+Patelauthor=S.+Prasadauthor=I.+Royauthor=A.+K.+Chakrabortiauthor=P.+V.+Bharatam&title=Design%2C+synthesis+and+biological+evaluation+of+5-benzylidene-2-iminothiazolidin-4-ones+as+selective+GSK-3%CE%B2+inhibitors&doi=10.1016%2Fj.ejmech.2016.04.075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of 5-benzylidene-2-iminothiazolidin-4-ones as selective GSK-3β inhibitors</span></div><div class="casAuthors">Arfeen, Minhajul; Bhagat, Shweta; Patel, Rahul; Prasad, Shivcharan; Roy, Ipsita; Chakraborti, Asit K.; Bharatam, Prasad V.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">727-736</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In this work, iminothiazolidin-4-one derivs. were explored as selective GSK-3β inhibitors.  Mol. docking anal. was carried to design a series of compds., which were synthesized using substituted thioureas, Et chloroacetate and benzaldehydes.  Out of the twenty five compds. synthesized during this work, the in vitro evaluation against GSK-3 led to the identification of nine compds. with activity in lower nano-molar range (2-85 nM).  Further, in vitro evaluation against CDK-2 showed five compds. to be selective towards GSK-3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquv-FRHRtwRbVg90H21EOLACvtfcHk0ljbcnPZjutg8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtF2hs7vJ&md5=fae12d7afdb57bf8512a0f8fbe481056</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.04.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.04.075%26sid%3Dliteratum%253Aachs%26aulast%3DArfeen%26aufirst%3DM.%26aulast%3DBhagat%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DR.%26aulast%3DPrasad%26aufirst%3DS.%26aulast%3DRoy%26aufirst%3DI.%26aulast%3DChakraborti%26aufirst%3DA.%2BK.%26aulast%3DBharatam%26aufirst%3DP.%2BV.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%25205-benzylidene-2-iminothiazolidin-4-ones%2520as%2520selective%2520GSK-3%25CE%25B2%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D121%26spage%3D727%26epage%3D736%26doi%3D10.1016%2Fj.ejmech.2016.04.075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaisina, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petukhov, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blond, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidhu, A.</span></span> <span> </span><span class="NLM_article-title">Highly potent and specific GSK-3beta inhibitors that block tau phosphorylation and decrease alpha-synuclein protein expression in a cellular model of Parkinson’s disease</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">256</span>– <span class="NLM_lpage">266</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200500039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1002%2Fcmdc.200500039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=16892358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvFyjur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=256-266&author=A.+P.+Kozikowskiauthor=I.+N.+Gaisinaauthor=P.+A.+Petukhovauthor=J.+Sridharauthor=L.+T.+Kingauthor=S.+Y.+Blondauthor=T.+Dukaauthor=M.+Rusnakauthor=A.+Sidhu&title=Highly+potent+and+specific+GSK-3beta+inhibitors+that+block+tau+phosphorylation+and+decrease+alpha-synuclein+protein+expression+in+a+cellular+model+of+Parkinson%E2%80%99s+disease&doi=10.1002%2Fcmdc.200500039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Highly potent and specific GSK-3β inhibitors that block tau phosphorylation and decrease α-synuclein protein expression in a cellular model of Parkinson's disease</span></div><div class="casAuthors">Kozikowski, Alan P.; Gaisina, Irina N.; Petukhov, Pavel A.; Sridhar, Jayalakshmi; King, LaShaunda T.; Blond, Sylvie Y.; Duka, Tetyana; Rusnak, Milan; Sidhu, Anita</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">256-266</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Research by Klein and co-workers suggests that the inhibition of GSK-3β by small mols. may offer an important strategy in the treatment of a no. of central nervous system (CNS) disorders including Alzheimer's disease, Parkinson's disease, and bipolar disorders.  Based on results from kinase-screening assays that identified a staurosporine analog as a modest inhibitor of GSK-3β, a series of 3-indolyl-4-indazolylmaleimides was prepd. for study in both enzymic and cell-based assays.  Most strikingly, whereas we identified ligands having poor to high potency for GSK-3β inhibition, only ligands with a Ki value of less than 8 nM, namely maleimides 18 and 22, were found to inhibit Tau phosphorylation at a GSK-3β-specific site (Ser 396/404).  Accordingly, maleimides 18 and 22 may protect neuronal cells against cell death by decreasing the level of α-Syn protein expression.  We conclude that the GSK-3β inhibitors described herein offer promise in defending cells against MPP+-induced neurotoxicity and that such compds. will be valuable to explore in animal models of Parkinson's disease as well as in other Tau-related neurodegenerative disease states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX5jA9WqgoU7Vg90H21EOLACvtfcHk0ljbcnPZjutg8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvFyjur4%253D&md5=8fbe6e281c054141c7e85aaa31eeac7b</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200500039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200500039%26sid%3Dliteratum%253Aachs%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DGaisina%26aufirst%3DI.%2BN.%26aulast%3DPetukhov%26aufirst%3DP.%2BA.%26aulast%3DSridhar%26aufirst%3DJ.%26aulast%3DKing%26aufirst%3DL.%2BT.%26aulast%3DBlond%26aufirst%3DS.%2BY.%26aulast%3DDuka%26aufirst%3DT.%26aulast%3DRusnak%26aufirst%3DM.%26aulast%3DSidhu%26aufirst%3DA.%26atitle%3DHighly%2520potent%2520and%2520specific%2520GSK-3beta%2520inhibitors%2520that%2520block%2520tau%2520phosphorylation%2520and%2520decrease%2520alpha-synuclein%2520protein%2520expression%2520in%2520a%2520cellular%2520model%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DChemMedChem%26date%3D2006%26volume%3D1%26spage%3D256%26epage%3D266%26doi%3D10.1002%2Fcmdc.200500039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Northfield, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craik, D. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of tau aggregation using a naturally-occurring cyclic peptide scaffold</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">342</span>– <span class="NLM_lpage">349</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.01.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.ejmech.2016.01.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=26807864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtl2ntLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2016&pages=342-349&author=C.+K.+Wangauthor=S.+E.+Northfieldauthor=Y.+H.+Huangauthor=M.+C.+Ramosauthor=D.+J.+Craik&title=Inhibition+of+tau+aggregation+using+a+naturally-occurring+cyclic+peptide+scaffold&doi=10.1016%2Fj.ejmech.2016.01.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of tau aggregation using a naturally-occurring cyclic peptide scaffold</span></div><div class="casAuthors">Wang, Conan K.; Northfield, Susan E.; Huang, Yen-Hua; Ramos, Mariana C.; Craik, David J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">342-349</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Disulfide-rich macrocyclic peptides are emerging as versatile scaffolds for the development of stable biochem. tools.  This potential is due to the combination of their structural stability and range of bioactivities.  Here, we explored the activity of these peptides on fibril growth of the hexapeptide Ac-VQIVYK-NH2 (AcPHF6), which is a tau-derived peptide that has been widely used to understand the pathol. mechanism of numerous tauopathies, including Alzheimer's disease.  Of the cyclic peptides tested, SFTI-1 and kB1 showed an inherent ability to inhibit AcPHF6 fibril formation.  Using an end-capping strategy and combining it with a mol. grafting approach, we demonstrated that SFTI-1 could be used as a starting point to design more potent fibril inhibitors.  We further identified chem. and structural features of SFTI-1 and its analogs that underpin their inhibitory activity.  The ability to inhibit fibril growth using the strategy employed herein supports the 'steric zipper' model of AcPHF6 fibril formation and shows that naturally-occurring cyclic peptides have potential as drug leads or mol. probes for understanding fibril formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8EceNHBR-sbVg90H21EOLACvtfcHk0ljpqXLuF1fxNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtl2ntLk%253D&md5=3e649c3437e072ab206fc739d3d95bd2</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.01.006%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%2BK.%26aulast%3DNorthfield%26aufirst%3DS.%2BE.%26aulast%3DHuang%26aufirst%3DY.%2BH.%26aulast%3DRamos%26aufirst%3DM.%2BC.%26aulast%3DCraik%26aufirst%3DD.%2BJ.%26atitle%3DInhibition%2520of%2520tau%2520aggregation%2520using%2520a%2520naturally-occurring%2520cyclic%2520peptide%2520scaffold%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D109%26spage%3D342%26epage%3D349%26doi%3D10.1016%2Fj.ejmech.2016.01.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Inestrosa, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderón, F.</span></span> <span> </span><span class="NLM_article-title">Acetylcholinesterase is a senile plaque component that promotes assembly of amyloid beta-peptide into Alzheimer’s filaments</span>. <i>Mol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">359</span>– <span class="NLM_lpage">361</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=9154226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADyaK2s3pvVyisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1996&pages=359-361&author=N.+C.+Inestrosaauthor=A.+Alvarezauthor=F.+Calder%C3%B3n&title=Acetylcholinesterase+is+a+senile+plaque+component+that+promotes+assembly+of+amyloid+beta-peptide+into+Alzheimer%E2%80%99s+filaments"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Acetylcholinesterase is a senile plaque component that promotes assembly of amyloid beta-peptide into Alzheimer's filaments</span></div><div class="casAuthors">Inestrosa N C; Alvarez A; Calderon F</div><div class="citationInfo"><span class="NLM_cas:title">Molecular psychiatry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">359-61</span>
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTv6bPd99LAEbZpSb_XWfMrfW6udTcc2eZ7vfeVvPQ1prntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s3pvVyisg%253D%253D&md5=dfddb14f33e0950f8b5a8d0719ef79a5</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DInestrosa%26aufirst%3DN.%2BC.%26aulast%3DAlvarez%26aufirst%3DA.%26aulast%3DCalder%25C3%25B3n%26aufirst%3DF.%26atitle%3DAcetylcholinesterase%2520is%2520a%2520senile%2520plaque%2520component%2520that%2520promotes%2520assembly%2520of%2520amyloid%2520beta-peptide%2520into%2520Alzheimer%25E2%2580%2599s%2520filaments%26jtitle%3DMol.%2520Psychiatry%26date%3D1996%26volume%3D1%26spage%3D359%26epage%3D361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Simone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ticchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrisano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumiatti, V.</span></span> <span> </span><span class="NLM_article-title">Tacrine-based multifunctional agents in Alzheimer’s disease: An old story in continuous development</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3522</span>– <span class="NLM_lpage">3546</span>, <span class="refDoi"> DOI: 10.2174/0929867324666170309123920</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.2174%2F0929867324666170309123920" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=28294041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGgtrnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=3522-3546&author=A.+Milelliauthor=A.+De+Simoneauthor=N.+Ticchiauthor=H.+H.+Chenauthor=N.+Betariauthor=V.+Andrisanoauthor=V.+Tumiatti&title=Tacrine-based+multifunctional+agents+in+Alzheimer%E2%80%99s+disease%3A+An+old+story+in+continuous+development&doi=10.2174%2F0929867324666170309123920"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Tacrine-based Multifunctional Agents in Alzheimer's Disease: An Old Story in Continuous Development.bdintg.</span></div><div class="casAuthors">Milelli, Andrea; De Simone, Angela; Ticchi, Nicole; Chen, Huan H.; Betari, Nibal; Andrisano, Vincenza; Tumiatti, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">3522-3546</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: The design of multifunctional agents represents one of the most active research field in medicinal chem.  In particular, tacrine, a well known Acetylcholinesterase inhibitor, is one of the most used starting point to develop multifunctional ligands and hundreds of papers report about these new agents.  This is the third review of a series concerning tacrine based multifunctional ligands; in particular, in the present, we will summarize and discuss the most intriguing examples of tacrine-based multifunctional agents published since 2013 until 2016. </P><P> Methods: We analyzed the bibliog. databases for peer-reviewed publications concerning tacrine-based multifunctional agents possessing biol. actions that go beyond the simple "cholinergic" blockage.  These papers have been subdivided according to their biol. activities.  Since this is the third review of a series, we took into considerations only the papers appeared since 2013 until 2016.  Results: In this review, we have analyzed more than 33 papers.  All the reported compds. retain good inhibitory activity towards acetyl- and butyryl-cholinesterase.  The other biol. activities concern mostly inhibition of a. β-amyloid aggregation, b. β-secretase, c. monoamino oxidases, modulation of β; and ROS and metal chelation.  Conclusion: The anal. of the current literature reported in this review confirm the importance of tacrine as scaffold to develop multifunctional agents potentially usefull to contrast Alzheimer's disease.  Furthermore, the compds. herein reported showed very intriguing biol. activities that could be used as starting point to develop new compds. even more interesting and, hopefully, clin. usefull to contrast Alzheimer's Disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZimowwL4q_7Vg90H21EOLACvtfcHk0ljpqXLuF1fxNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGgtrnM&md5=2a6f856526a08139bca151c647733f95</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.2174%2F0929867324666170309123920&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867324666170309123920%26sid%3Dliteratum%253Aachs%26aulast%3DMilelli%26aufirst%3DA.%26aulast%3DDe%2BSimone%26aufirst%3DA.%26aulast%3DTicchi%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DH.%2BH.%26aulast%3DBetari%26aufirst%3DN.%26aulast%3DAndrisano%26aufirst%3DV.%26aulast%3DTumiatti%26aufirst%3DV.%26atitle%3DTacrine-based%2520multifunctional%2520agents%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520An%2520old%2520story%2520in%2520continuous%2520development%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2017%26volume%3D24%26spage%3D3522%26epage%3D3546%26doi%3D10.2174%2F0929867324666170309123920" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. P.</span></span> <span> </span><span class="NLM_article-title">Dual GSK-3β/AChE inhibitors as a new strategy for multitargeting anti-Alzheimer’s disease drug discovery</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisF2gtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=171-176&author=X.+Y.+Jiangauthor=T.+K.+Chenauthor=J.+T.+Zhouauthor=S.+Y.+Heauthor=H.+Y.+Yangauthor=Y.+Chenauthor=W.+Quauthor=F.+Fengauthor=H.+P.+Sun&title=Dual+GSK-3%CE%B2%2FAChE+inhibitors+as+a+new+strategy+for+multitargeting+anti-Alzheimer%E2%80%99s+disease+drug+discovery&doi=10.1021%2Facsmedchemlett.7b00463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Dual GSK-3β/AChE Inhibitors as a New Strategy for Multitargeting Anti-Alzheimer's Disease Drug Discovery</span></div><div class="casAuthors">Jiang, Xue-Yang; Chen, Ting-Kai; Zhou, Jun-Ting; He, Si-Yu; Yang, Hong-Yu; Chen, Yao; Qu, Wei; Feng, Feng; Sun, Hao-Peng</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">171-176</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Designing multitarget-directed ligands (MTDLs) is considered to be a promising approach to address complex and multifactorial maladies such as Alzheimer's disease (AD).  The concurrent inhibition of the two crucial AD targets, glycogen synthase kinase-3β (GSK-3β) and human acetylcholinesterase (hAChE), might represent a breakthrough in the quest for clin. efficacy.  Thus, a novel family of GSK-3β/AChE dual-target inhibitors was designed and synthesized.  Among these hybrids, I showed the most promising profile as a nanomolar inhibitor on both hAChE (IC50 = 6.5 nM) and hGSK-3β kinase activity (IC50 = 66 nM).  It also showed good inhibitory effect on β-amyloid self-aggregation (inhibitory rate = 46%) at 20 μM.  Western blot anal. revealed that compd. I inhibited hyperphosphorylation of tau protein in mouse neuroblastoma N2a-Tau cells.  In vivo studies confirmed that I significantly ameliorated the cognitive disorders in scopolamine-treated ICR mice and less hepatotoxicity than tacrine.  This study provides new leads for assessment of GSK-3β and AChE pathway dual inhibition as a promising strategy for AD treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq103h9q_6uaLVg90H21EOLACvtfcHk0ljpqXLuF1fxNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisF2gtrY%253D&md5=8858bb4cbc503c79896ccbc00fb23153</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00463%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DX.%2BY.%26aulast%3DChen%26aufirst%3DT.%2BK.%26aulast%3DZhou%26aufirst%3DJ.%2BT.%26aulast%3DHe%26aufirst%3DS.%2BY.%26aulast%3DYang%26aufirst%3DH.%2BY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DQu%26aufirst%3DW.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DH.%2BP.%26atitle%3DDual%2520GSK-3%25CE%25B2%252FAChE%2520inhibitors%2520as%2520a%2520new%2520strategy%2520for%2520multitargeting%2520anti-Alzheimer%25E2%2580%2599s%2520disease%2520drug%2520discovery%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D171%26epage%3D176%26doi%3D10.1021%2Facsmedchemlett.7b00463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sivaprakasam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civiello, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacutin-Porte, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kish, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pokross, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szapiel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newitt, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nophsker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubowchik, G. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of new acylaminopyridines as GSK-3 inhibitors by a structure guided in-depth exploration of chemical space around a pyrrolopyridinone core</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1856</span>– <span class="NLM_lpage">1863</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.03.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.bmcl.2015.03.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=25845281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVKrsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1856-1863&author=P.+Sivaprakasamauthor=X.+Hanauthor=R.+L.+Civielloauthor=S.+Jacutin-Porteauthor=K.+Kishauthor=M.+Pokrossauthor=H.+A.+Lewisauthor=N.+Ahmedauthor=N.+Szapielauthor=J.+A.+Newittauthor=E.+T.+Baldwinauthor=H.+Xiaoauthor=C.+M.+Krauseauthor=H.+Parkauthor=M.+Nophskerauthor=J.+S.+Lippyauthor=C.+R.+Burtonauthor=D.+R.+Langleyauthor=J.+E.+Macorauthor=G.+M.+Dubowchik&title=Discovery+of+new+acylaminopyridines+as+GSK-3+inhibitors+by+a+structure+guided+in-depth+exploration+of+chemical+space+around+a+pyrrolopyridinone+core&doi=10.1016%2Fj.bmcl.2015.03.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of new acylaminopyridines as GSK-3 inhibitors by a structure guided in-depth exploration of chemical space around a pyrrolopyridinone core</span></div><div class="casAuthors">Sivaprakasam, Prasanna; Han, Xiaojun; Civiello, Rita L.; Jacutin-Porte, Swanee; Kish, Kevin; Pokross, Matt; Lewis, Hal A.; Ahmed, Nazia; Szapiel, Nicolas; Newitt, John A.; Baldwin, Eric T.; Xiao, Hong; Krause, Carol M.; Park, Hyunsoo; Nophsker, Michelle; Lippy, Jonathan S.; Burton, Catherine R.; Langley, David R.; Macor, John E.; Dubowchik, Gene M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1856-1863</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Glycogen synthase kinase-3 (GSK-3) has been proposed to play a crucial role in the pathogenesis of many diseases including cancer, stroke, bipolar disorders, diabetes and neurodegenerative diseases.  GSK-3 inhibition has been a major area of pharmaceutical interest over the last two decades.  A plethora of reports appeared recently on selective inhibitors and their co-crystal structures in GSK-3β.  We identified several series of promising new GSK-3β inhibitors from a coherent design around a pyrrolopyridinone core structure.  A systematic exploration of the chem. space around the central spacer led to potent single digit and sub-nanomolar GSK-3β inhibitors.  When dosed orally in a transgenic mouse model of Alzheimer's disease (AD), an exemplary compd. showed significant lowering of Tau phosphorylation at one of the GSK-3 phosphorylating sites, Ser396.  X-ray crystallog. greatly aided in validating the binding hypotheses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTULEgiCtJ_bVg90H21EOLACvtfcHk0ljpPryriRYeVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVKrsro%253D&md5=207523726b69167ee5318f90b2822af0</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.03.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.03.046%26sid%3Dliteratum%253Aachs%26aulast%3DSivaprakasam%26aufirst%3DP.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DCiviello%26aufirst%3DR.%2BL.%26aulast%3DJacutin-Porte%26aufirst%3DS.%26aulast%3DKish%26aufirst%3DK.%26aulast%3DPokross%26aufirst%3DM.%26aulast%3DLewis%26aufirst%3DH.%2BA.%26aulast%3DAhmed%26aufirst%3DN.%26aulast%3DSzapiel%26aufirst%3DN.%26aulast%3DNewitt%26aufirst%3DJ.%2BA.%26aulast%3DBaldwin%26aufirst%3DE.%2BT.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DKrause%26aufirst%3DC.%2BM.%26aulast%3DPark%26aufirst%3DH.%26aulast%3DNophsker%26aufirst%3DM.%26aulast%3DLippy%26aufirst%3DJ.%2BS.%26aulast%3DBurton%26aufirst%3DC.%2BR.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DDubowchik%26aufirst%3DG.%2BM.%26atitle%3DDiscovery%2520of%2520new%2520acylaminopyridines%2520as%2520GSK-3%2520inhibitors%2520by%2520a%2520structure%2520guided%2520in-depth%2520exploration%2520of%2520chemical%2520space%2520around%2520a%2520pyrrolopyridinone%2520core%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D1856%26epage%3D1863%26doi%3D10.1016%2Fj.bmcl.2015.03.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oukoloff, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coquelle, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naldi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Guevel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bach, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josselin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruchaud, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denora, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacobazzi, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sussman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buron, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colletier, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Routier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renard, P. Y.</span></span> <span> </span><span class="NLM_article-title">Design, biological evaluation and X-ray crystallography of nanomolar multifunctional ligands targeting simultaneously acetylcholinesterase and glycogen synthase kinase-3</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.12.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.ejmech.2018.12.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=30798053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjs1Ghsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2019&pages=58-77&author=K.+Oukoloffauthor=N.+Coquelleauthor=M.+Bartoliniauthor=M.+Naldiauthor=R.+Le+Guevelauthor=S.+Bachauthor=B.+Josselinauthor=S.+Ruchaudauthor=M.+Cattoauthor=L.+Pisaniauthor=N.+Denoraauthor=R.+M.+Iacobazziauthor=I.+Silmanauthor=J.+L.+Sussmanauthor=F.+Buronauthor=J.+P.+Colletierauthor=L.+Jeanauthor=S.+Routierauthor=P.+Y.+Renard&title=Design%2C+biological+evaluation+and+X-ray+crystallography+of+nanomolar+multifunctional+ligands+targeting+simultaneously+acetylcholinesterase+and+glycogen+synthase+kinase-3&doi=10.1016%2Fj.ejmech.2018.12.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Design, biological evaluation and X-ray crystallography of nanomolar multifunctional ligands targeting simultaneously acetylcholinesterase and glycogen synthase kinase-3</span></div><div class="casAuthors">Oukoloff, Killian; Coquelle, Nicolas; Bartolini, Manuela; Naldi, Marina; Le Guevel, Remy; Bach, Stephane; Josselin, Beatrice; Ruchaud, Sandrine; Catto, Marco; Pisani, Leonardo; Denora, Nunzio; Iacobazzi, Rosa Maria; Silman, Israel; Sussman, Joel L.; Buron, Frederic; Colletier, Jacques-Philippe; Jean, Ludovic; Routier, Sylvain; Renard, Pierre-Yves</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">58-77</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Two scaffolds, targeting AChE (tacrine) and GSK-3α/β (valmerin) simultaneously, were assembled, using copper(I)-catalyzed azide alkyne cycloaddn. (CuAAC), to generate a new series of multifunctional ligands.  A series of eight multi-target directed ligands (MTDLs) was synthesized and evaluated in-vitro and in cell cultures.  Mol. docking studies, together with the crystal structures of three MTDL/TcAChE complexes, with three tacrine-valmerin hybrids allowed designing an appropriate linker contg. a 1,2,3-triazole moiety whose incorporation preserved and even increased, the original inhibitory potencies of the two selected pharmacophores toward the two targets.  Most of the new derivs. exhibited nanomolar affinity for both targets and the most potent compd. of the series displayed inhibitory potencies of 9.5 nM for human acetylcholinesterase (hAChE) and 7 nM for GSK-3α/β.  These novel dual MTDLs was served as suitable leads for further development, since, in the micromolar range, they exhibited low cytotoxicity on a panel of representative human cell lines including the human neuroblastoma cell line SH-SY5Y.  Moreover, these tacrine-valmerin hybrids displayed a good ability to penetrate the blood-brain barrier (BBB) without interacting with efflux pumps such as P-gp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAKk4Uw7lCIbVg90H21EOLACvtfcHk0ljpPryriRYeVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjs1Ghsrw%253D&md5=50fe860fee4331dde495b905772f5ad8</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.12.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.12.063%26sid%3Dliteratum%253Aachs%26aulast%3DOukoloff%26aufirst%3DK.%26aulast%3DCoquelle%26aufirst%3DN.%26aulast%3DBartolini%26aufirst%3DM.%26aulast%3DNaldi%26aufirst%3DM.%26aulast%3DLe%2BGuevel%26aufirst%3DR.%26aulast%3DBach%26aufirst%3DS.%26aulast%3DJosselin%26aufirst%3DB.%26aulast%3DRuchaud%26aufirst%3DS.%26aulast%3DCatto%26aufirst%3DM.%26aulast%3DPisani%26aufirst%3DL.%26aulast%3DDenora%26aufirst%3DN.%26aulast%3DIacobazzi%26aufirst%3DR.%2BM.%26aulast%3DSilman%26aufirst%3DI.%26aulast%3DSussman%26aufirst%3DJ.%2BL.%26aulast%3DBuron%26aufirst%3DF.%26aulast%3DColletier%26aufirst%3DJ.%2BP.%26aulast%3DJean%26aufirst%3DL.%26aulast%3DRoutier%26aufirst%3DS.%26aulast%3DRenard%26aufirst%3DP.%2BY.%26atitle%3DDesign%252C%2520biological%2520evaluation%2520and%2520X-ray%2520crystallography%2520of%2520nanomolar%2520multifunctional%2520ligands%2520targeting%2520simultaneously%2520acetylcholinesterase%2520and%2520glycogen%2520synthase%2520kinase-3%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D168%26spage%3D58%26epage%3D77%26doi%3D10.1016%2Fj.ejmech.2018.12.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boulahjar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozach, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guguen-Guillouzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Guevel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akssira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillaumet, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Routier, S.</span></span> <span> </span><span class="NLM_article-title">Advances in tetrahydropyrido[1,2-a]isoindolone (valmerins) series: Potent glycogen synthase kinase 3 and cyclin dependent kinase 5 inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">274</span>– <span class="NLM_lpage">287</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.06.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.ejmech.2015.06.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=26142492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlCqsbrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2015&pages=274-287&author=R.+Boulahjarauthor=A.+Ouachauthor=S.+Bourgauthor=P.+Bonnetauthor=O.+Lozachauthor=L.+Meijerauthor=C.+Guguen-Guillouzoauthor=R.+Le+Guevelauthor=S.+Lazarauthor=M.+Akssiraauthor=Y.+Troinauthor=G.+Guillaumetauthor=S.+Routier&title=Advances+in+tetrahydropyrido%5B1%2C2-a%5Disoindolone+%28valmerins%29+series%3A+Potent+glycogen+synthase+kinase+3+and+cyclin+dependent+kinase+5+inhibitors&doi=10.1016%2Fj.ejmech.2015.06.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in tetrahydropyrido[1,2-a]isoindolone (valmerins) series: Potent glycogen synthase kinase 3 and cyclin dependent kinase 5 inhibitors</span></div><div class="casAuthors">Boulahjar, Rajaa; Ouach, Aziz; Bourg, Stephane; Bonnet, Pascal; Lozach, Olivier; Meijer, Laurent; Guguen-Guillouzo, Christiane; Le Guevel, Remy; Lazar, Said; Akssira, Mohamed; Troin, Yves; Guillaumet, Gerald; Routier, Sylvain</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">274-287</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">An efficient synthetic strategy was developed to modulate the structure of the tetrahydropyridine isoindolone (Valmerin) skeleton.  A library of more than 30 novel final structures was generated.  Biol. activities on CDK5 and GSK3 as well as cellular effects on cancer cell lines were measured for each novel compd.  Addnl. docking studies were performed to support medicinal chem. efforts.  A strong GSK3/CDK5 dual inhibitor (I, IC50 GSK3/CDK5 32/84 nM) was obtained.  A set of highly selective GSK3 inhibitors was synthesized by fine-tuning structural modifications (II, IC50 GSK3/CDK5 32/320 nM).  Antiproliferative effects on cells were correlated with the in vitro kinase activities and the best effects were obtained with lung and colon cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNKc6ssVA1k7Vg90H21EOLACvtfcHk0lj-Rm32IobOMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlCqsbrK&md5=5385782f450d6914ddc149004d5facce</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.06.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.06.046%26sid%3Dliteratum%253Aachs%26aulast%3DBoulahjar%26aufirst%3DR.%26aulast%3DOuach%26aufirst%3DA.%26aulast%3DBourg%26aufirst%3DS.%26aulast%3DBonnet%26aufirst%3DP.%26aulast%3DLozach%26aufirst%3DO.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DGuguen-Guillouzo%26aufirst%3DC.%26aulast%3DLe%2BGuevel%26aufirst%3DR.%26aulast%3DLazar%26aufirst%3DS.%26aulast%3DAkssira%26aufirst%3DM.%26aulast%3DTroin%26aufirst%3DY.%26aulast%3DGuillaumet%26aufirst%3DG.%26aulast%3DRoutier%26aufirst%3DS.%26atitle%3DAdvances%2520in%2520tetrahydropyrido%255B1%252C2-a%255Disoindolone%2520%2528valmerins%2529%2520series%253A%2520Potent%2520glycogen%2520synthase%2520kinase%25203%2520and%2520cyclin%2520dependent%2520kinase%25205%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D101%26spage%3D274%26epage%3D287%26doi%3D10.1016%2Fj.ejmech.2015.06.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brogi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramunno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chemi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecorelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pambianchi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galatello, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compagnoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Focher, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biamonti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valacchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campiani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brindisi, M.</span></span> <span> </span><span class="NLM_article-title">First dual AK/GSK-3β inhibitors endowed with antioxidant properties as multifunctional, potential neuroprotective agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">438</span>– <span class="NLM_lpage">457</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.06.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.ejmech.2017.06.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=28689095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFChurvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2017&pages=438-457&author=S.+Brogiauthor=A.+Ramunnoauthor=L.+Saviauthor=G.+Chemiauthor=G.+Alfanoauthor=A.+Pecorelliauthor=E.+Pambianchiauthor=P.+Galatelloauthor=G.+Compagnoniauthor=F.+Focherauthor=G.+Biamontiauthor=G.+Valacchiauthor=S.+Butiniauthor=S.+Gemmaauthor=G.+Campianiauthor=M.+Brindisi&title=First+dual+AK%2FGSK-3%CE%B2+inhibitors+endowed+with+antioxidant+properties+as+multifunctional%2C+potential+neuroprotective+agents&doi=10.1016%2Fj.ejmech.2017.06.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">First dual AK/GSK-3β inhibitors endowed with antioxidant properties as multifunctional, potential neuroprotective agents</span></div><div class="casAuthors">Brogi, Simone; Ramunno, Anna; Savi, Lida; Chemi, Giulia; Alfano, Gloria; Pecorelli, Alessandra; Pambianchi, Erika; Galatello, Paola; Compagnoni, Giulia; Focher, Federico; Biamonti, Giuseppe; Valacchi, Giuseppe; Butini, Stefania; Gemma, Sandra; Campiani, Giuseppe; Brindisi, Margherita</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">438-457</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The manuscript deals with the design, synthesis and biol. evaluation of novel benzoxazinone- and indole-based compds. as multifunctional neuroprotective agents.  These compds. inhibit human adenosine kinase (hAK) and human glycogen synthase kinase 3 beta (hGSK-3β) enzymes.  In silico hints drove the synthesis of appropriately decorated benzoxazinones I (R1 = Ph, 1-naphthyl, 2-naphthyl; R2 = CH2C6H5, 4-ClC6H4CH2, 4-O2NC6H4CH2, etc.; X = H, F, morpholin-1-yl; Y = H; XY = OCH2O; Z = H, O) and indoles II (R1 = 4-H3CC6H4, 1-naphthyl; R2 = CH3, N(Et)2) and biochem. anal. revealed their behavior as allosteric inhibitors of hGSK-3β.  For hit III and compds. I (R1 = 1-naphthyl; R2 = 4-FC6H4CH2; X = Y = H; Z = O), I (R1 = 1-naphthyl; R2 = CH2C6H5; XY = OCH2O; Z = O) and II (R1 = 1-naphthyl; R2 = CH3) the potential antioxidant profile was assessed in human neuroblastoma cell lines (IMR 32), by evaluating the protective effect of selected compds. against H2O2 cytotoxicity and reactive oxygen species (ROS) prodn.  Results showed a strong efficacy of the tested compds., even at the lower doses, in counteracting the induced oxidative stress (50 μM of H2O2) and in preventing ROS formation.  In addn., the tested compds. did not show any cytotoxic effect detd. by the LDH release, at the concn. range analyzed (from 0.1 to 50 μM).  This study allowed the identification of compd. I (R1 = 1-naphthyl; R2 = CH2C6H5; XY = OCH2O; Z = O), as the first dual hAK/hGSK-3β inhibitor reported to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrno6lxql7c_7Vg90H21EOLACvtfcHk0lj-Rm32IobOMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFChurvO&md5=1ea9d5251ac6d10f173c170e7c749b4b</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.06.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.06.017%26sid%3Dliteratum%253Aachs%26aulast%3DBrogi%26aufirst%3DS.%26aulast%3DRamunno%26aufirst%3DA.%26aulast%3DSavi%26aufirst%3DL.%26aulast%3DChemi%26aufirst%3DG.%26aulast%3DAlfano%26aufirst%3DG.%26aulast%3DPecorelli%26aufirst%3DA.%26aulast%3DPambianchi%26aufirst%3DE.%26aulast%3DGalatello%26aufirst%3DP.%26aulast%3DCompagnoni%26aufirst%3DG.%26aulast%3DFocher%26aufirst%3DF.%26aulast%3DBiamonti%26aufirst%3DG.%26aulast%3DValacchi%26aufirst%3DG.%26aulast%3DButini%26aufirst%3DS.%26aulast%3DGemma%26aufirst%3DS.%26aulast%3DCampiani%26aufirst%3DG.%26aulast%3DBrindisi%26aufirst%3DM.%26atitle%3DFirst%2520dual%2520AK%252FGSK-3%25CE%25B2%2520inhibitors%2520endowed%2520with%2520antioxidant%2520properties%2520as%2520multifunctional%252C%2520potential%2520neuroprotective%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D138%26spage%3D438%26epage%3D457%26doi%3D10.1016%2Fj.ejmech.2017.06.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Savi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brindisi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Pietra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novellino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lossani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Focher, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavella, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campiani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, S.</span></span> <span> </span><span class="NLM_article-title">Site-directed mutagenesis of key residues unveiled a novel allosteric site on human adenosine kinase for Pyrrolobenzoxa(thia)zepinone non-nucleoside inhibitors</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.1111/cbdd.12630</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1111%2Fcbdd.12630" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=26242695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFWlsLfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2016&pages=112-120&author=L.+Saviauthor=M.+Brindisiauthor=G.+Alfanoauthor=S.+Butiniauthor=V.+La+Pietraauthor=E.+Novellinoauthor=L.+Marinelliauthor=A.+Lossaniauthor=F.+Focherauthor=C.+Cavellaauthor=G.+Campianiauthor=S.+Gemma&title=Site-directed+mutagenesis+of+key+residues+unveiled+a+novel+allosteric+site+on+human+adenosine+kinase+for+Pyrrolobenzoxa%28thia%29zepinone+non-nucleoside+inhibitors&doi=10.1111%2Fcbdd.12630"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Site-directed Mutagenesis of Key Residues Unveiled a Novel Allosteric Site on Human Adenosine Kinase for Pyrrolobenzoxa(thia)zepinone Non-Nucleoside Inhibitors</span></div><div class="casAuthors">Savi, Lida; Brindisi, Margherita; Alfano, Gloria; Butini, Stefania; La Pietra, Valeria; Novellino, Ettore; Marinelli, Luciana; Lossani, Andrea; Focher, Federico; Cavella, Caterina; Campiani, Giuseppe; Gemma, Sandra</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">112-120</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Most nucleoside kinases, besides the catalytic domain, feature an allosteric domain which modulates their activity.  Generally, non-substrate analogs, interacting with allosteric sites, represent a major opportunity for developing more selective and safer therapeutics.  We recently developed a series of non-nucleoside non-competitive inhibitors of human adenosine kinase (hAK), based on a pyrrolobenzoxa(thia)zepinone scaffold.  Based on computational anal., we hypothesized the existence of a novel allosteric site on hAK, topog. distinct from the catalytic site.  In this study, we have adopted a multidisciplinary approach including mol. modeling, biochem. studies, and site-directed mutagenesis to validate our hypothesis.  Based on a three-dimensional model of interaction between hAK and our mols., we designed, cloned, and expressed specific, single and double point mutants of hAK (Q74A, Q78A, H107A, K341A, F338A, and Q74A-F338A).  Kinetic characterization of recombinant enzymes indicated that these mutations did not affect enzyme functioning; conversely, mutated enzymes are endowed with reduced susceptibility to our non-nucleoside inhibitors, while maintaining comparable affinity for nucleoside inhibitors to the wild-type enzyme.  This study represents the first characterization and validation of a novel allosteric site in hAK and may pave the way to the development of novel selective and potent non-nucleoside inhibitors of hAK endowed with therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxKNxAhKk_jrVg90H21EOLACvtfcHk0lhe_3mDAjIqag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFWlsLfM&md5=b2ef5d8ee0a05b6c29b69d1df321df02</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.12630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.12630%26sid%3Dliteratum%253Aachs%26aulast%3DSavi%26aufirst%3DL.%26aulast%3DBrindisi%26aufirst%3DM.%26aulast%3DAlfano%26aufirst%3DG.%26aulast%3DButini%26aufirst%3DS.%26aulast%3DLa%2BPietra%26aufirst%3DV.%26aulast%3DNovellino%26aufirst%3DE.%26aulast%3DMarinelli%26aufirst%3DL.%26aulast%3DLossani%26aufirst%3DA.%26aulast%3DFocher%26aufirst%3DF.%26aulast%3DCavella%26aufirst%3DC.%26aulast%3DCampiani%26aufirst%3DG.%26aulast%3DGemma%26aufirst%3DS.%26atitle%3DSite-directed%2520mutagenesis%2520of%2520key%2520residues%2520unveiled%2520a%2520novel%2520allosteric%2520site%2520on%2520human%2520adenosine%2520kinase%2520for%2520Pyrrolobenzoxa%2528thia%2529zepinone%2520non-nucleoside%2520inhibitors%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2016%26volume%3D87%26spage%3D112%26epage%3D120%26doi%3D10.1111%2Fcbdd.12630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brindisi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borrelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lossani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponte, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maga, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Pietra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorini, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamponi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campiani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zisterer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathwani, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sartini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Motta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Da Settimo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novellino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Focher, F.</span></span> <span> </span><span class="NLM_article-title">Non-nucleoside inhibitors of human adenosine kinase: Synthesis, molecular modeling, and biological studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1401</span>– <span class="NLM_lpage">1420</span>, <span class="refDoi"> DOI: 10.1021/jm101438u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101438u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFeisLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1401-1420&author=S.+Butiniauthor=S.+Gemmaauthor=M.+Brindisiauthor=G.+Borrelliauthor=A.+Lossaniauthor=A.+M.+Ponteauthor=A.+Tortiauthor=G.+Magaauthor=L.+Marinelliauthor=V.+La+Pietraauthor=I.+Fioriniauthor=S.+Lamponiauthor=G.+Campianiauthor=D.+M.+Zistererauthor=S.+M.+Nathwaniauthor=S.+Sartiniauthor=C.+La+Mottaauthor=F.+Da+Settimoauthor=E.+Novellinoauthor=F.+Focher&title=Non-nucleoside+inhibitors+of+human+adenosine+kinase%3A+Synthesis%2C+molecular+modeling%2C+and+biological+studies&doi=10.1021%2Fjm101438u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Non-nucleoside inhibitors of human adenosine kinase: synthesis, molecular modeling, and biological studies</span></div><div class="casAuthors">Butini, Stefania; Gemma, Sandra; Brindisi, Margherita; Borrelli, Giuseppe; Lossani, Andrea; Ponte, Anna Maria; Torti, Andrea; Maga, Giovanni; Marinelli, Luciana; La Pietra, Valeria; Fiorini, Isabella; Lamponi, Stefania; Campiani, Giuseppe; Zisterer, Daniela M.; Nathwani, Seema-Maria; Sartini, Stefania; La Motta, Concettina; Da Settimo, Federico; Novellino, Ettore; Focher, Federico</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1401-1420</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Adenosine kinase (AK) catalyzes the phosphorylation of adenosine (Ado) to AMP by means of a kinetic mechanism in which the two substrates Ado and ATP bind the enzyme in a binary and/or ternary complex, with distinct protein conformations.  Most of the described inhibitors have Ado-like structural motifs and are nonselective, and some of them (e.g., the tubercidine-like ligands) are characterized by a toxic profile.  Here, human AK (hAK) was cloned and expressed, and a search for novel non-substrate-like inhibitors was carried out.  The efforts to widen the structural diversity of AK inhibitors led to the identification of novel non-nucleoside, noncompetitive allosteric modulators I (X, Y = O, S; R1 = H, Et; R2 = Ph, 2-ClC6H4, 4-Me3SiC≡CC6H4, 2,6-Cl2C6H3, 2-pyridyl, 2-pyrimidyl, 2-imidazolyl, etc.) characterized by a unique mol. scaffold.  Among the pyrrolobenzoxa(thia)zepinones developed, I (X = O; Y = S; R1 = Et; R2 = Ph) was identified as a non-nucleoside prototype hAK inhibitor.  This compd. has proapoptotic efficacy, slight inhibition of short-term RNA synthesis, and cytostatic activity on tumor cell lines while showing low cytotoxicity and no significant adverse effects on short-term DNA synthesis in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprrF751kg487Vg90H21EOLACvtfcHk0lhe_3mDAjIqag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFeisLg%253D&md5=ef3868f031a50a451dd7ea1cd8505361</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1021%2Fjm101438u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101438u%26sid%3Dliteratum%253Aachs%26aulast%3DButini%26aufirst%3DS.%26aulast%3DGemma%26aufirst%3DS.%26aulast%3DBrindisi%26aufirst%3DM.%26aulast%3DBorrelli%26aufirst%3DG.%26aulast%3DLossani%26aufirst%3DA.%26aulast%3DPonte%26aufirst%3DA.%2BM.%26aulast%3DTorti%26aufirst%3DA.%26aulast%3DMaga%26aufirst%3DG.%26aulast%3DMarinelli%26aufirst%3DL.%26aulast%3DLa%2BPietra%26aufirst%3DV.%26aulast%3DFiorini%26aufirst%3DI.%26aulast%3DLamponi%26aufirst%3DS.%26aulast%3DCampiani%26aufirst%3DG.%26aulast%3DZisterer%26aufirst%3DD.%2BM.%26aulast%3DNathwani%26aufirst%3DS.%2BM.%26aulast%3DSartini%26aufirst%3DS.%26aulast%3DLa%2BMotta%26aufirst%3DC.%26aulast%3DDa%2BSettimo%26aufirst%3DF.%26aulast%3DNovellino%26aufirst%3DE.%26aulast%3DFocher%26aufirst%3DF.%26atitle%3DNon-nucleoside%2520inhibitors%2520of%2520human%2520adenosine%2520kinase%253A%2520Synthesis%252C%2520molecular%2520modeling%252C%2520and%2520biological%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1401%26epage%3D1420%26doi%3D10.1021%2Fjm101438u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, Y.</span></span> <span> </span><span class="NLM_article-title">Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">5639</span>– <span class="NLM_lpage">5643</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.10.078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.bmcl.2014.10.078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=25467150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVylu7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=5639-5643&author=P.+Zhangauthor=S.+Liauthor=Y.+Gaoauthor=W.+Luauthor=K.+Huangauthor=D.+Yeauthor=X.+Liauthor=Y.+Chu&title=Novel+benzothiazinones+%28BTOs%29+as+allosteric+modulator+or+substrate+competitive+inhibitor+of+glycogen+synthase+kinase+3%CE%B2+%28GSK-3%CE%B2%29+with+cellular+activity+of+promoting+glucose+uptake&doi=10.1016%2Fj.bmcl.2014.10.078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake</span></div><div class="casAuthors">Zhang, Peng; Li, Shufen; Gao, Yang; Lu, Wenbo; Huang, Ke; Ye, Deyong; Li, Xi; Chu, Yong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5639-5643</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Glycogen synthase kinase 3β (GSK-3β) plays a key role in insulin metabolizing pathway and therefore inhibition of the enzyme might provide an important therapeutic approach for treatment of insulin resistance and type 2 diabetes.  Recently, discovery of ATP noncompetitive inhibitors is gaining importance not only due to their generally increased selectivity but also for the potentially subtle modulation of the target.  These kinds of compds. include allosteric modulators and substrate competitive inhibitors.  Here we reported two benzothiazinone compds. (BTO), named BTO-5h (IC50 = 8 μM) and BTO-5s (IC50 = 10 μM) as novel allosteric modulator and substrate competitive inhibitor of GSK-3β, resp.  Their different action modes were proved by kinetic expts.  Furthermore, BTO-5s was selected to check the kinases profile and showed little or even no activity to a panel of ten protein kinases at 100 μM, indicating it has good selectivity.  Docking studies were performed to give suggesting binding modes which can well explain their impacts on the enzyme.  Moreover, cell expts. displayed both compds. reduced the phosphorylation level of glycogen synthase in an intact cell, and greatly enhanced the glucose uptake in both HpG2 and 3T3-L1 cells.  All of these results suggested BTO-5s and BTO-5h maybe have potentially therapeutic value for anti-diabetes.  The results also offer a new scaffold for designing and developing selective inhibitors with novel mechanisms of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV3DIlOnazo7Vg90H21EOLACvtfcHk0lhe_3mDAjIqag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVylu7%252FL&md5=9dbd90f264f80c8aabae85c5237c01bd</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.10.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.10.078%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DK.%26aulast%3DYe%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DChu%26aufirst%3DY.%26atitle%3DNovel%2520benzothiazinones%2520%2528BTOs%2529%2520as%2520allosteric%2520modulator%2520or%2520substrate%2520competitive%2520inhibitor%2520of%2520glycogen%2520synthase%2520kinase%25203%25CE%25B2%2520%2528GSK-3%25CE%25B2%2529%2520with%2520cellular%2520activity%2520of%2520promoting%2520glucose%2520uptake%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D5639%26epage%3D5643%26doi%3D10.1016%2Fj.bmcl.2014.10.078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of novel GSK-3β inhibitors as multifunctional agents against Alzheimer’s disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">211</span>– <span class="NLM_lpage">225</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.ejmech.2019.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=30772605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjt1Wit7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2019&pages=211-225&author=X.+L.+Shiauthor=J.+D.+Wuauthor=P.+Liuauthor=Z.+P.+Liu&title=Synthesis+and+evaluation+of+novel+GSK-3%CE%B2+inhibitors+as+multifunctional+agents+against+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.ejmech.2019.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of novel GSK-3β inhibitors as multifunctional agents against Alzheimer's disease</span></div><div class="casAuthors">Shi, Xiao-Long; Wu, Jing-De; Liu, Ping; Liu, Zhao-Peng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">211-225</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">To target the multi-facets of Alzheimer's disease (AD), a series of novel GSK-3β inhibitors contg. the 2,3-diaminopyridine moiety I [R = H, Ph, 4-Me-2-thienyl, etc.], II [R = H, 4-Ph, 4-(4-ClC6H4), etc.] and III [R = H, Ph, 4-MeC6H4, 4-Me-2-thienyl, 4-pyridinyl] were designed and synthesized.  The amide derivs. I [R = H, Ph, 4-Me-2-thienyl, etc.] showed moderate potency against GSK-3β with weak Cu2+, Zn2+ and Al3+ chelating ability.  The imine derivs. II [R = H, 5-Ph, 5-(4-pyridinyl)] were potent GSK-3β inhibitors and selective Cu2+and Al3+ chelators.  The 1,2-diamine derivs. III [R = H, Ph, 4-MeC6H4, 4-Me-2-thienyl, 4-pyridinyl] were strong metal-chelators, but decreased or lost their GSK-3β inhibitory potency.  In-vitro, compds. II [R = H, 5-Ph, 5-(4-pyridinyl)] esp. compd. II [R = 5-Ph] exhibited good Cu2+-induced Aβ aggregation inhibition, Cu2+-Aβ complex disaggregation, ROS formation inhibition and antioxidant activities.  In cells, compds. II [R = H, 5-Ph, 5-(4-pyridinyl)] inhibited tau protein phosphorylation and protect neuro cells against Cu2+-Aβ1-42 and H2O2-induced cell damage.  Furthermore, compd. II [R = 5-Ph] was predicted to have the ability to pass the BBB with drug likeness properties.  Therefore, compd. II [R = 5-Ph] might be a good lead for the development of novel GSK-3β inhibitors targeting multi-facets of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_ELITXD4x-bVg90H21EOLACvtfcHk0lhBvNRzovTS6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjt1Wit7s%253D&md5=e3bfb7dd073058e731546b83774696f1</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DX.%2BL.%26aulast%3DWu%26aufirst%3DJ.%2BD.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DZ.%2BP.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520novel%2520GSK-3%25CE%25B2%2520inhibitors%2520as%2520multifunctional%2520agents%2520against%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D167%26spage%3D211%26epage%3D225%26doi%3D10.1016%2Fj.ejmech.2019.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. Z.</span></span> <span> </span><span class="NLM_article-title">Current understanding of metal ions in the pathogenesis of Alzheimer’s disease</span>. <i>Transl. Neurodegener.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">10</span>, <span class="refDoi"> DOI: 10.1186/s40035-020-00189-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1186%2Fs40035-020-00189-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=32266063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BB38zivVSrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=10&author=L.+Wangauthor=Y.+L.+Yinauthor=X.+Z.+Liuauthor=P.+Shenauthor=Y.+G.+Zhengauthor=X.+R.+Lanauthor=C.+B.+Luauthor=J.+Z.+Wang&title=Current+understanding+of+metal+ions+in+the+pathogenesis+of+Alzheimer%E2%80%99s+disease&doi=10.1186%2Fs40035-020-00189-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Current understanding of metal ions in the pathogenesis of Alzheimer's disease</span></div><div class="casAuthors">Wang Lu; Yin Ya-Ling; Liu Xin-Zi; Shen Peng; Zheng Yan-Ge; Lan Xin-Rui; Lu Cheng-Biao; Wang Jian-Zhi</div><div class="citationInfo"><span class="NLM_cas:title">Translational neurodegeneration</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10</span>
        ISSN:<span class="NLM_cas:issn">2047-9158</span>.
    </div><div class="casAbstract">Background:  The homeostasis of metal ions, such as iron, copper, zinc and calcium, in the brain is crucial for maintaining normal physiological functions.  Studies have shown that imbalance of these metal ions in the brain is closely related to the onset and progression of Alzheimer's disease (AD), the most common neurodegenerative disorder in the elderly.  Main body:  Erroneous deposition/distribution of the metal ions in different brain regions induces oxidative stress.  The metal ions imbalance and oxidative stress together or independently promote amyloid-β (Aβ) overproduction by activating β- or γ-secretases and inhibiting α-secretase, it also causes tau hyperphosphorylation by activating protein kinases, such as glycogen synthase kinase-3β (GSK-3β), cyclin-dependent protein kinase-5 (CDK5), mitogen-activated protein kinases (MAPKs), etc., and inhibiting protein phosphatase 2A (PP2A).  The metal ions imbalances can also directly or indirectly disrupt organelles, causing endoplasmic reticulum (ER) stress; mitochondrial and autophagic dysfunctions, which can cause or aggravate Aβ and tau aggregation/accumulation, and impair synaptic functions.  Even worse, the metal ions imbalance-induced alterations can reversely exacerbate metal ions misdistribution and deposition.  The vicious cycles between metal ions imbalances and Aβ/tau abnormalities will eventually lead to a chronic neurodegeneration and cognitive deficits, such as seen in AD patients.  Conclusion:  The metal ions imbalance induces Aβ and tau pathologies by directly or indirectly affecting multiple cellular/subcellular pathways, and the disrupted homeostasis can reversely aggravate the abnormalities of metal ions transportation/deposition.  Therefore, adjusting metal balance by supplementing or chelating the metal ions may be potential in ameliorating AD pathologies, which provides new research directions for AD treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSz7VnJ4vRr7b7NkxioyDXTfW6udTcc2ebyc0SlvWJmX7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38zivVSrsQ%253D%253D&md5=5e609526d780b09dd908be0390148907</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1186%2Fs40035-020-00189-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40035-020-00189-z%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYin%26aufirst%3DY.%2BL.%26aulast%3DLiu%26aufirst%3DX.%2BZ.%26aulast%3DShen%26aufirst%3DP.%26aulast%3DZheng%26aufirst%3DY.%2BG.%26aulast%3DLan%26aufirst%3DX.%2BR.%26aulast%3DLu%26aufirst%3DC.%2BB.%26aulast%3DWang%26aufirst%3DJ.%2BZ.%26atitle%3DCurrent%2520understanding%2520of%2520metal%2520ions%2520in%2520the%2520pathogenesis%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DTransl.%2520Neurodegener.%26date%3D2020%26volume%3D9%26spage%3D10%26doi%3D10.1186%2Fs40035-020-00189-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cristóvão, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, C. M.</span></span> <span> </span><span class="NLM_article-title">Metals and neuronal metal binding proteins implicated in Alzheimer’s disease</span>. <i>Oxid. Med. Cell. Longevity</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2016</i></span>,  <span class="NLM_fpage">9812178</span>, <span class="refDoi"> DOI: 10.1155/2016/9812178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1155%2F2016%2F9812178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=26881049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BC28jhtVOksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2016&publication_year=2016&pages=9812178&author=J.+S.+Crist%C3%B3v%C3%A3oauthor=R.+Santosauthor=C.+M.+Gomes&title=Metals+and+neuronal+metal+binding+proteins+implicated+in+Alzheimer%E2%80%99s+disease&doi=10.1155%2F2016%2F9812178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Metals and Neuronal Metal Binding Proteins Implicated in Alzheimer's Disease</span></div><div class="casAuthors">Cristovao Joana S; Gomes Claudio M; Santos Renata</div><div class="citationInfo"><span class="NLM_cas:title">Oxidative medicine and cellular longevity</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2016</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9812178</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Alzheimer's disease (AD) is the most prevalent age-related dementia affecting millions of people worldwide.  Its main pathological hallmark feature is the formation of insoluble protein deposits of amyloid-β and hyperphosphorylated tau protein into extracellular plaques and intracellular neurofibrillary tangles, respectively.  Many of the mechanistic details of this process remain unknown, but a well-established consequence of protein aggregation is synapse dysfunction and neuronal loss in the AD brain.  Different pathways including mitochondrial dysfunction, oxidative stress, inflammation, and metal metabolism have been suggested to be implicated in this process.  In particular, a body of evidence suggests that neuronal metal ions such as copper, zinc, and iron play important roles in brain function in health and disease states and altered homeostasis and distribution as a common feature across different neurodegenerative diseases and aging.  In this focused review, we overview neuronal proteins that are involved in AD and whose metal binding properties may underlie important biochemical and regulatory processes occurring in the brain during the AD pathophysiological process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRRFS7HBs9MUudfST00W0BcfW6udTcc2ebyc0SlvWJmX7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jhtVOksg%253D%253D&md5=cb60acf31e00254b550a419d450f97e9</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1155%2F2016%2F9812178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2016%252F9812178%26sid%3Dliteratum%253Aachs%26aulast%3DCrist%25C3%25B3v%25C3%25A3o%26aufirst%3DJ.%2BS.%26aulast%3DSantos%26aufirst%3DR.%26aulast%3DGomes%26aufirst%3DC.%2BM.%26atitle%3DMetals%2520and%2520neuronal%2520metal%2520binding%2520proteins%2520implicated%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DOxid.%2520Med.%2520Cell.%2520Longevity%26date%3D2016%26volume%3D2016%26spage%3D9812178%26doi%3D10.1155%2F2016%2F9812178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuajungco, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atwood, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartshorn, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyndall, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokes, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopold, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Multhaup, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpa, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moir, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glabe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowden, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masters, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlie, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanzi, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bush, A. I.</span></span> <span> </span><span class="NLM_article-title">Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>274</i></span>,  <span class="NLM_fpage">37111</span>– <span class="NLM_lpage">37116</span>, <span class="refDoi"> DOI: 10.1074/jbc.274.52.37111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1074%2Fjbc.274.52.37111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10601271" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD3cXpsFSi" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=37111-37116&author=X.+Huangauthor=M.+P.+Cuajungcoauthor=C.+S.+Atwoodauthor=M.+A.+Hartshornauthor=J.+D.+Tyndallauthor=G.+R.+Hansonauthor=K.+C.+Stokesauthor=M.+Leopoldauthor=G.+Multhaupauthor=L.+E.+Goldsteinauthor=R.+C.+Scarpaauthor=A.+J.+Saundersauthor=J.+Limauthor=R.+D.+Moirauthor=C.+Glabeauthor=E.+F.+Bowdenauthor=C.+L.+Mastersauthor=D.+P.+Fairlieauthor=R.+E.+Tanziauthor=A.+I.+Bush&title=Cu%28II%29+potentiation+of+alzheimer+abeta+neurotoxicity.+Correlation+with+cell-free+hydrogen+peroxide+production+and+metal+reduction&doi=10.1074%2Fjbc.274.52.37111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Cu(II) potentiation of Alzheimer Aβ neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction</span></div><div class="casAuthors">Huang, Xudong; Cuajungco, Math P.; Atwood, Craig S.; Hartshorn, Mariana A.; Tyndall, Joel D. A.; Hanson, Graeme R.; Stokes, Karen C.; Leopold, Michael; Multhaup, Gerd; Goldstein, Lee E.; Scarpa, Richard C.; Saunders, Aleister J.; Lim, James; Moir, Robert D.; Glahe, Charles; Bowden, Edmond F.; Masters, Colin L.; Fairlie, David P.; Tanzi, Rudolph E.; Bush, Ashley I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">274</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">37111-37116</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Oxidative stress markers as well as high concns. of copper are found in the vicinity of Aβ amyloid deposits in Alzheimer's disease.  The neurotoxicity of Aβ in cell culture has been linked to H2O2 generation by an unknown mechanism.  We now report that Cu(II) markedly potentiates the neurotoxicity exhibited by Aβ in cell culture.  The potentiation of toxicity is greatest for Aβ1-42 > Aβ1-40 » mouse/rat Aβ1-40, corresponding to their relative capacities to reduce Cu(II) to Cu(I), form H2O2 in cell-free assays and to exhibit amyloid pathol.  The copper complex of Aβ1-42 has a highly pos. formal redn. potential (≈+500-550 mV vs. Ag/AgCl) characteristic of strongly reducing cuproproteins.  These findings suggest that certain redox active metal ions may be important in exacerbating and perhaps facilitating Aβ-mediated oxidative damage in Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB0QS7aV67c7Vg90H21EOLACvtfcHk0lhcC8d3WetPtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXpsFSi&md5=dcd0d9e8ebf8fc3550a356111e07eee7</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1074%2Fjbc.274.52.37111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.274.52.37111%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DCuajungco%26aufirst%3DM.%2BP.%26aulast%3DAtwood%26aufirst%3DC.%2BS.%26aulast%3DHartshorn%26aufirst%3DM.%2BA.%26aulast%3DTyndall%26aufirst%3DJ.%2BD.%26aulast%3DHanson%26aufirst%3DG.%2BR.%26aulast%3DStokes%26aufirst%3DK.%2BC.%26aulast%3DLeopold%26aufirst%3DM.%26aulast%3DMulthaup%26aufirst%3DG.%26aulast%3DGoldstein%26aufirst%3DL.%2BE.%26aulast%3DScarpa%26aufirst%3DR.%2BC.%26aulast%3DSaunders%26aufirst%3DA.%2BJ.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DMoir%26aufirst%3DR.%2BD.%26aulast%3DGlabe%26aufirst%3DC.%26aulast%3DBowden%26aufirst%3DE.%2BF.%26aulast%3DMasters%26aufirst%3DC.%2BL.%26aulast%3DFairlie%26aufirst%3DD.%2BP.%26aulast%3DTanzi%26aufirst%3DR.%2BE.%26aulast%3DBush%26aufirst%3DA.%2BI.%26atitle%3DCu%2528II%2529%2520potentiation%2520of%2520alzheimer%2520abeta%2520neurotoxicity.%2520Correlation%2520with%2520cell-free%2520hydrogen%2520peroxide%2520production%2520and%2520metal%2520reduction%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D37111%26epage%3D37116%26doi%3D10.1074%2Fjbc.274.52.37111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alavi Naini, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soussi-Yanicostas, N.</span></span> <span> </span><span class="NLM_article-title">Tau hyperphosphorylation and oxidative stress, a critical vicious circle in neurodegenerative tauopathies?</span>. <i>Oxid. Med. Cell. Longevity</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>,  <span class="NLM_fpage">151979</span>, <span class="refDoi"> DOI: 10.1155/2015/151979</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1155%2F2015%2F151979" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=26576216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BC28vjvVantA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=151979&author=S.+M.+Alavi+Nainiauthor=N.+Soussi-Yanicostas&title=Tau+hyperphosphorylation+and+oxidative+stress%2C+a+critical+vicious+circle+in+neurodegenerative+tauopathies%3F&doi=10.1155%2F2015%2F151979"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Tau Hyperphosphorylation and Oxidative Stress, a Critical Vicious Circle in Neurodegenerative Tauopathies?</span></div><div class="casAuthors">Alavi Naini Seyedeh Maryam; Soussi-Yanicostas Nadia</div><div class="citationInfo"><span class="NLM_cas:title">Oxidative medicine and cellular longevity</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2015</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">151979</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Hyperphosphorylation and aggregation of the microtubule-associated protein tau in brain, are pathological hallmarks of a large family of neurodegenerative disorders, named tauopathies, which include Alzheimer's disease.  It has been shown that increased phosphorylation of tau destabilizes tau-microtubule interactions, leading to microtubule instability, transport defects along microtubules, and ultimately neuronal death.  However, although mutations of the MAPT gene have been detected in familial early-onset tauopathies, causative events in the more frequent sporadic late-onset forms and relationships between tau hyperphosphorylation and neurodegeneration remain largely elusive.  Oxidative stress is a further pathological hallmark of tauopathies, but its precise role in the disease process is poorly understood.  Another open question is the source of reactive oxygen species, which induce oxidative stress in brain neurons.  Mitochondria have been classically viewed as a major source for oxidative stress, but microglial cells were recently identified as reactive oxygen species producers in tauopathies.  Here we review the complex relationships between tau pathology and oxidative stress, placing emphasis on (i) tau protein function, (ii) origin and consequences of reactive oxygen species production, and (iii) links between tau phosphorylation and oxidative stress.  Further, we go on to discuss the hypothesis that tau hyperphosphorylation and oxidative stress are two key components of a vicious circle, crucial in neurodegenerative tauopathies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcROas30ElPsHlMGsG_HTXYFfW6udTcc2eYKZBcnscnce7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28vjvVantA%253D%253D&md5=ba6fa445008d606ebb146fad41bbe68d</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1155%2F2015%2F151979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F151979%26sid%3Dliteratum%253Aachs%26aulast%3DAlavi%2BNaini%26aufirst%3DS.%2BM.%26aulast%3DSoussi-Yanicostas%26aufirst%3DN.%26atitle%3DTau%2520hyperphosphorylation%2520and%2520oxidative%2520stress%252C%2520a%2520critical%2520vicious%2520circle%2520in%2520neurodegenerative%2520tauopathies%253F%26jtitle%3DOxid.%2520Med.%2520Cell.%2520Longevity%26date%3D2015%26volume%3D2015%26spage%3D151979%26doi%3D10.1155%2F2015%2F151979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Simone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Pietra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petragnani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniele, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietrobono, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petralla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casadei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frabetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russomanno, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novellino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montanari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumiatti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballerini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebbioso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altucci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrisano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milelli, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of the first-in-class GSK-3β/HDAC dual inhibitor as disease-modifying agent to combat Alzheimer’s disease</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">469</span>– <span class="NLM_lpage">474</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00507</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00507" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVSqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=469-474&author=A.+De+Simoneauthor=V.+La+Pietraauthor=N.+Betariauthor=N.+Petragnaniauthor=M.+Conteauthor=S.+Danieleauthor=D.+Pietrobonoauthor=C.+Martiniauthor=S.+Petrallaauthor=R.+Casadeiauthor=L.+Davaniauthor=F.+Frabettiauthor=P.+Russomannoauthor=E.+Novellinoauthor=S.+Montanariauthor=V.+Tumiattiauthor=P.+Balleriniauthor=F.+Sarnoauthor=A.+Nebbiosoauthor=L.+Altucciauthor=B.+Montiauthor=V.+Andrisanoauthor=A.+Milelli&title=Discovery+of+the+first-in-class+GSK-3%CE%B2%2FHDAC+dual+inhibitor+as+disease-modifying+agent+to+combat+Alzheimer%E2%80%99s+disease&doi=10.1021%2Facsmedchemlett.8b00507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease</span></div><div class="casAuthors">De Simone, Angela; La Pietra, Valeria; Betari, Nibal; Petragnani, Nicola; Conte, Mariarosaria; Daniele, Simona; Pietrobono, Deborah; Martini, Claudia; Petralla, Sabrina; Casadei, Raffaella; Davani, Lara; Frabetti, Flavia; Russomanno, Pasquale; Novellino, Ettore; Montanari, Serena; Tumiatti, Vincenzo; Ballerini, Patrizia; Sarno, Federica; Nebbioso, Angela; Altucci, Lucia; Monti, Barbara; Andrisano, Vincenza; Milelli, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">469-474</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several evidence pointed out the role of epigenetics in Alzheimer's disease (AD) revealing strictly relationships between epigenetic and "classical" AD targets.  Based on the reported connection among histone deacetylases (HDACs) and glycogen synthase kinase 3β (GSK-3β), herein we present the discovery and the biochem. characterization of the first-in-class hit compd. able to exert promising anti-AD effects by modulating the targeted proteins in the low micromolar range of concn.  Compd. 11 induces an increase in histone acetylation and a redn. of tau phosphorylation.  It is nontoxic and protective against H2O2 and 6-OHDA stimuli in SH-SY5Y and in CGN cell lines, resp.  Moreover, it promotes neurogenesis and displays immunomodulatory effects.  Compd. 11 shows no lethality in a wt-zebrafish model (<100 μM) and high water soly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFpd6rQuX3jrVg90H21EOLACvtfcHk0lhcC8d3WetPtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVSqtbs%253D&md5=c57168700a73c70eafa747add137cac1</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00507%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSimone%26aufirst%3DA.%26aulast%3DLa%2BPietra%26aufirst%3DV.%26aulast%3DBetari%26aufirst%3DN.%26aulast%3DPetragnani%26aufirst%3DN.%26aulast%3DConte%26aufirst%3DM.%26aulast%3DDaniele%26aufirst%3DS.%26aulast%3DPietrobono%26aufirst%3DD.%26aulast%3DMartini%26aufirst%3DC.%26aulast%3DPetralla%26aufirst%3DS.%26aulast%3DCasadei%26aufirst%3DR.%26aulast%3DDavani%26aufirst%3DL.%26aulast%3DFrabetti%26aufirst%3DF.%26aulast%3DRussomanno%26aufirst%3DP.%26aulast%3DNovellino%26aufirst%3DE.%26aulast%3DMontanari%26aufirst%3DS.%26aulast%3DTumiatti%26aufirst%3DV.%26aulast%3DBallerini%26aufirst%3DP.%26aulast%3DSarno%26aufirst%3DF.%26aulast%3DNebbioso%26aufirst%3DA.%26aulast%3DAltucci%26aufirst%3DL.%26aulast%3DMonti%26aufirst%3DB.%26aulast%3DAndrisano%26aufirst%3DV.%26aulast%3DMilelli%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520the%2520first-in-class%2520GSK-3%25CE%25B2%252FHDAC%2520dual%2520inhibitor%2520as%2520disease-modifying%2520agent%2520to%2520combat%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D469%26epage%3D474%26doi%3D10.1021%2Facsmedchemlett.8b00507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z. F.</span></span> <span> </span><span class="NLM_article-title">Targeting HDACs: A promising therapy for Alzheimer’s disease</span>. <i>Oxid. Med. Cell. Longevity</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2011</i></span>,  <span class="NLM_fpage">143269</span>, <span class="refDoi"> DOI: 10.1155/2011/143269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1155%2F2011%2F143269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=21941604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BC3MflvVWitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=143269&author=K.+Xuauthor=X.+L.+Daiauthor=H.+C.+Huangauthor=Z.+F.+Jiang&title=Targeting+HDACs%3A+A+promising+therapy+for+Alzheimer%E2%80%99s+disease&doi=10.1155%2F2011%2F143269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting HDACs: a promising therapy for Alzheimer's disease</span></div><div class="casAuthors">Xu Ke; Dai Xue-Ling; Huang Han-Chang; Jiang Zhao-Feng</div><div class="citationInfo"><span class="NLM_cas:title">Oxidative medicine and cellular longevity</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2011</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">143269</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Epigenetic modifications like DNA methylation and histone acetylation play an important role in a wide range of brain disorders.  Histone deacetylases (HDACs) regulate the homeostasis of histone acetylation.  Histone deacetylase inhibitors, which initially were used as anticancer drugs, are recently suggested to act as neuroprotectors by enhancing synaptic plasticity and learning and memory in a wide range of neurodegenerative and psychiatric disorders, such as Alzheimer's disease (AD) and Parkinson's disease (PD).  To reveal the physiological roles of HDACs may provide us with a new perspective to understand the mechanism of AD and to develop selective HDAC inhibitors.  This paper focuses on the recent research progresses of HDAC proteins and their inhibitors on the roles of the treatment for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTRVYQlbx4kqny-c-E1v-fmfW6udTcc2eZjcpY1YRnifbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MflvVWitA%253D%253D&md5=0f0bed71a4778db8838e676d9e2e81f7</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1155%2F2011%2F143269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2011%252F143269%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DK.%26aulast%3DDai%26aufirst%3DX.%2BL.%26aulast%3DHuang%26aufirst%3DH.%2BC.%26aulast%3DJiang%26aufirst%3DZ.%2BF.%26atitle%3DTargeting%2520HDACs%253A%2520A%2520promising%2520therapy%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DOxid.%2520Med.%2520Cell.%2520Longevity%26date%3D2011%26volume%3D2011%26spage%3D143269%26doi%3D10.1155%2F2011%2F143269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Simone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milelli, A.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase inhibitors as multitarget ligands: New players in Alzheimer’s disease drug discovery?</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1067</span>– <span class="NLM_lpage">1073</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201900174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1002%2Fcmdc.201900174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=30958639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1MXos1Wiurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=1067-1073&author=A.+De+Simoneauthor=A.+Milelli&title=Histone+Deacetylase+inhibitors+as+multitarget+ligands%3A+New+players+in+Alzheimer%E2%80%99s+disease+drug+discovery%3F&doi=10.1002%2Fcmdc.201900174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors as multitarget ligands: new players in Alzheimer's disease drug discovery?</span></div><div class="casAuthors">De Simone, Angela; Milelli, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1067-1073</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase inhibitors (HDACIs) are responsible for controlling gene expression by modulating the acetylation status of histone proteins.  Furthermore, they modulate the activity of cytoplasmic non-histone proteins.  Due to the involvement of HDACs in neurodevelopment, memory formation, and cognitive processes, HDACIs have been suggested as innovative agents for the treatment of neurodegenerative disorders such as Alzheimer's disease (AD).  Given their mechanisms of action and the complex nature of AD, HDACIs have been proposed for the design of novel multitarget ligands (MTLs).  To this aim, the fragment responsible for HDAC inhibition has been coupled with other structures that are able to provide addnl. biol. actions, such as antioxidant activity or the inhibition of phosphodiesterase 5, transglutaminase 2, and glycogen synthase kinase 3β.  Herein we discuss recent efforts to design HDACI-based MTLs as potential disease-modifying entities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotgFDwLEiUt7Vg90H21EOLACvtfcHk0lj9QwqByaFXvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXos1Wiurc%253D&md5=191fca2c9334551a52be5c13bf71cf90</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201900174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201900174%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSimone%26aufirst%3DA.%26aulast%3DMilelli%26aufirst%3DA.%26atitle%3DHistone%2520Deacetylase%2520inhibitors%2520as%2520multitarget%2520ligands%253A%2520New%2520players%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520drug%2520discovery%253F%26jtitle%3DChemMedChem%26date%3D2019%26volume%3D14%26spage%3D1067%26epage%3D1073%26doi%3D10.1002%2Fcmdc.201900174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eldar-Finkelman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span> <span> </span><span class="NLM_article-title">GSK-3 inhibitors: Preclinical and clinical focus on CNS</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">32</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2011.00032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.3389%2Ffnmol.2011.00032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=22065134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC38XovVyg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=32&author=H.+Eldar-Finkelmanauthor=A.+Martinez&title=GSK-3+inhibitors%3A+Preclinical+and+clinical+focus+on+CNS&doi=10.3389%2Ffnmol.2011.00032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">GSK-3 inhibitors: preclinical and clinical focus on CNS</span></div><div class="casAuthors">Eldar-Finkelman, Hagit; Martinez, Ana</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">Oct.</span>),
    <span class="NLM_cas:pages">32</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Inhibiting glycogen synthase kinase-3 (GSK-3) activity via pharmacol. intervention has become an important strategy for treating neurodegenerative and psychiatric disorders.  The known GSK-3 inhibitors are of diverse chemotypes and mechanisms of action and include compds. isolated from natural sources, cations, synthetic small-mol. ATP-competitive inhibitors, non-ATP-competitive inhibitors, and substrate-competitive inhibitors.  Here we describe the variety of GSK-3 inhibitors with a specific emphasis on their biol. activities in neurons and neurol. disorders.  We further highlight our current progress in the development of non-ATP-competitive inhibitors of GSK-3.  The available data raise the hope that one or more of these drug design approaches will prove successful at stabilizing or even reversing the aberrant neuropathol. and cognitive deficits of certain central nervous system disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh6s366QUVnLVg90H21EOLACvtfcHk0lj9QwqByaFXvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovVyg&md5=d497efe2ec600fc16f10260cd53d7103</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2011.00032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2011.00032%26sid%3Dliteratum%253Aachs%26aulast%3DEldar-Finkelman%26aufirst%3DH.%26aulast%3DMartinez%26aufirst%3DA.%26atitle%3DGSK-3%2520inhibitors%253A%2520Preclinical%2520and%2520clinical%2520focus%2520on%2520CNS%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2011%26volume%3D4%26spage%3D32%26doi%3D10.3389%2Ffnmol.2011.00032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenwu  Liu</span>, <span class="hlFld-ContribAuthor ">Xin  Liu</span>, <span class="hlFld-ContribAuthor ">Liting  Tian</span>, <span class="hlFld-ContribAuthor ">Yaping  Gao</span>, <span class="hlFld-ContribAuthor ">Wenjie  Liu</span>, <span class="hlFld-ContribAuthor ">Huanhua  Chen</span>, <span class="hlFld-ContribAuthor ">Xiaowen  Jiang</span>, <span class="hlFld-ContribAuthor ">Zihua  Xu</span>, <span class="hlFld-ContribAuthor ">Huaiwei  Ding</span>, <span class="hlFld-ContribAuthor ">Qingchun  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>222 </em>, 113554. <a href="https://doi.org/10.1016/j.ejmech.2021.113554" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113554</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113554%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bharmine%252Bderivatives%252Bas%252Bpotent%252BGSK-3%2525CE%2525B2%25252FDYRK1A%252Bdual%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252BAlzheimer%252527s%252Bdisease%26aulast%3DLiu%26aufirst%3DWenwu%26date%3D2021%26volume%3D222%26spage%3D113554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/medium/jm0c00931_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00931&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/medium/jm0c00931_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Involvement of GSK-3β in AD results from many activities. The most significant are reported in this figure. GSK-3β contributes to amyloid deposition production affecting the function of presenilin 1 (PS1) and the enzymatic cleavage of APP mediated by BACE-1; senile plaques are derived from the abnormal extracellular accumulation and deposition of Aβ peptide. GSK-3β is responsible for the hyperphosphorylation of tau protein and, as consequence, NFTs formation. GSK-3β is involved in neuroinflammation promoting the production of cytokines in astrocytes and microglia.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00931&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/medium/jm0c00931_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Structure of selected GSK-3β inhibitors. (B) Schematic interactions of a maleimide-based GSK-3β inhibitor and AR-A014418 within the ATP-binding site (PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1Q4L">1Q4L</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1Q5K">1Q5K</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00931&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/medium/jm0c00931_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Design strategy leading to the discovery of dual GSK-3β/BACE-1 inhibitor <b>1</b>. Triazinones were obtained combining structural features responsible for GSK-3β and BACE-1 inhibition, a cyclic amide and a guanidino moiety, respectively. Compound <b>1</b> is the most interesting of the series with an IC<sub>50</sub> in the micromolar range against both proteins.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00931&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/medium/jm0c00931_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Design of dual GSK-3β/tau aggregation inhibitors. The 5-arylidene-2,4-thiazolidinedione has been designed taking into consideration that a five-member heterocycle is a moiety present in both GSK-3β and tau aggregation inhibitors and that a planar substituent in position 5 may increase both the selectivity toward GSK-3β and the interactions with the tau fibrils.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00931&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/medium/jm0c00931_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Design of dual GSK-3β/AChE inhibitors <b>5</b> and <b>6</b>. Tacrine has been extensively used to develop MTDLs by linking a structure responsible for inducing a second biological effect. In the cases reported in the figure, GSK-3β inhibitor <b>4</b> has been coupled to tacrine to obtain compound <b>5</b> by taking advantage of the amide in <b>4</b> localized in solvent-exposed portion of the molecule. In the second example, to obtain compound <b>6</b>, the structure of valmerin has been used as GSK-3β binding-fragment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00931&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/medium/jm0c00931_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Design of dual GSK-3β/AK inhibitors. Compound <b>9</b>, able to bind to both GSK-3β and hAK in the micromolar range of concentrations, has been obtained through a series of modifications of compound <b>8</b>, developed by the same authors, that fails to bind to hAK.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00931&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/medium/jm0c00931_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Design of dual GSK-3β inhibitors/metal chelators. The <i>N</i>-(pyridin-2-yl)cyclopropanecarboxamide, able to establish favorable interactions with GSK-3β, has been coupled with a substituted aminopyridine responsible for metal chelation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00931&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/medium/jm0c00931_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Design of dual GSK-3β/HDACs inhibitors. The phthalimide moiety, which interacts with the ATP-binding site of GSK-3β, and an hydroxamic acid, which chelates the Zn<sup>2+</sup> located in the HDAC active site, were linked through an alkylthiourea chain.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c00931/20210216/images/large/jm0c00931_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00931&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i22">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04505" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04505" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 156 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popovic-Nikolic, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uliassi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">A perspective on multi-target drug discovery and design for complex diseases</span>. <i>Clin Transl Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">3</span>, <span class="refDoi"> DOI: 10.1186/s40169-017-0181-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1186%2Fs40169-017-0181-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=29340951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BC1MvhsVaiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=3&author=R.+R.+Ramsayauthor=M.+R.+Popovic-Nikolicauthor=K.+Nikolicauthor=E.+Uliassiauthor=M.+L.+Bolognesi&title=A+perspective+on+multi-target+drug+discovery+and+design+for+complex+diseases&doi=10.1186%2Fs40169-017-0181-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">A perspective on multi-target drug discovery and design for complex diseases</span></div><div class="casAuthors">Ramsay Rona R; Popovic-Nikolic Marija R; Nikolic Katarina; Uliassi Elisa; Bolognesi Maria Laura</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and translational medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3</span>
        ISSN:<span class="NLM_cas:issn">2001-1326</span>.
    </div><div class="casAbstract">Diseases of infection, of neurodegeneration (such as Alzheimer's and Parkinson's diseases), and of malignancy (cancers) have complex and varied causative factors.  Modern drug discovery has the power to identify potential modulators for multiple targets from millions of compounds.  Computational approaches allow the determination of the association of each compound with its target before chemical synthesis and biological testing is done.  These approaches depend on the prior identification of clinically and biologically validated targets.  This Perspective will focus on the molecular and computational approaches that underpin drug design by medicinal chemists to promote understanding and collaboration with clinical scientists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJhSGsWpifCZcXNb62YGmbfW6udTcc2eaixIptv2_OL7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvhsVaiug%253D%253D&md5=5b05a73a3bbc955c77b9b2df93deb946</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1186%2Fs40169-017-0181-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40169-017-0181-2%26sid%3Dliteratum%253Aachs%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26aulast%3DPopovic-Nikolic%26aufirst%3DM.%2BR.%26aulast%3DNikolic%26aufirst%3DK.%26aulast%3DUliassi%26aufirst%3DE.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DA%2520perspective%2520on%2520multi-target%2520drug%2520discovery%2520and%2520design%2520for%2520complex%2520diseases%26jtitle%3DClin%2520Transl%2520Med.%26date%3D2018%26volume%3D7%26spage%3D3%26doi%3D10.1186%2Fs40169-017-0181-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">Harnessing polypharmacology with medicinal chemistry</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00039</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00039" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVWjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=273-275&author=M.+L.+Bolognesi&title=Harnessing+polypharmacology+with+medicinal+chemistry&doi=10.1021%2Facsmedchemlett.9b00039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Harnessing Polypharmacology with Medicinal Chemistry</span></div><div class="casAuthors">Bolognesi, Maria Laura</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">273-275</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polypharmacol. has expanded enormously over the last ten years, with several multitarget drugs (MTDs) already in the market.  This Viewpoint provides a basis for a discussion about the crit. need to develop MTDs in a more rationale and conscious way.  A checklist to maximize success in polypharmacol. is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4yXxJ_uU72bVg90H21EOLACvtfcHk0ljQ1pJM554qSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVWjt7g%253D&md5=28a8cc47ae2966a2ecd8a411adfb1ef5</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00039%26sid%3Dliteratum%253Aachs%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DHarnessing%2520polypharmacology%2520with%2520medicinal%2520chemistry%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D273%26epage%3D275%26doi%3D10.1021%2Facsmedchemlett.9b00039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designed multiple ligands. An emerging drug discovery paradigm</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6523</span>– <span class="NLM_lpage">6543</span>, <span class="refDoi"> DOI: 10.1021/jm058225d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+multiple+ligands.+An+emerging+drug+discovery+paradigm&doi=10.1021%2Fjm058225d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0ljQ1pJM554qSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520multiple%2520ligands.%2520An%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543%26doi%3D10.1021%2Fjm058225d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. U.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology - foe or friend?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8955</span>– <span class="NLM_lpage">5971</span>, <span class="refDoi"> DOI: 10.1021/jm400856t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400856t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8955-5971&author=J.+U.+Peters&title=Polypharmacology+-+foe+or+friend%3F&doi=10.1021%2Fjm400856t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology - Foe or Friend?</span></div><div class="casAuthors">Peters, Jens-Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8955-8971</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Polypharmacol. describes the activity of compds. at multiple targets.  Current research focuses on two aspects of polypharmacol.: (1) unintended polypharmacol. can lead to adverse effects; (2) polypharmacol. across several disease-relevant targets can improve therapeutic efficacy, prevent drug resistance, or reduce therapeutic-target-related adverse effects.  This perspective reviews these interconnected aspects of polypharmacol.  The first part discusses the relevance of polypharmacol. for the safety of drugs, the mitigation of safety risks, and methods to identify polypharmacol. compds. early in the drug discovery process.  The second part discusses the advantages of polypharmacol. in the treatment of multigenic diseases and infections, and opportunities for drug discovery and drug repurposing.  This perspective aims to provide a balanced view on polypharmacol., which can compromise the safety of drugs, but can also confer superior efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5vnFGPfTnGLVg90H21EOLACvtfcHk0ljQ1pJM554qSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO&md5=f4aeb6efddd4bfdf4e94656303323cba</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm400856t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400856t%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.%2BU.%26atitle%3DPolypharmacology%2520-%2520foe%2520or%2520friend%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8955%26epage%3D5971%26doi%3D10.1021%2Fjm400856t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minarini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumiatti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recanatini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melchiorre, C.</span></span> <span> </span><span class="NLM_article-title">Multi-target-directed ligands to combat neurodegenerative diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">372</span>, <span class="refDoi"> DOI: 10.1021/jm7009364</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7009364" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsl2qsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=347-372&author=A.+Cavalliauthor=M.+L.+Bolognesiauthor=A.+Minariniauthor=M.+Rosiniauthor=V.+Tumiattiauthor=M.+Recanatiniauthor=C.+Melchiorre&title=Multi-target-directed+ligands+to+combat+neurodegenerative+diseases&doi=10.1021%2Fjm7009364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target-Directed Ligands to Combat Neurodegenerative Diseases</span></div><div class="casAuthors">Cavalli, Andrea; Bolognesi, Maria Laura; Minarini, Anna; Rosini, Michela; Tumiatti, Vincenzo; Recanatini, Maurizio; Melchiorre, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">347-372</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The authors review the investigations reported in the past decade that illustrate the ability of medicinal chemists to design multi-target-directed ligands (MTDLs) to confront neurodegenerative diseases.  The authors briefly illustrate the multifactorial nature of these diseases before discussing the possible development of MTDLs in light of the known mol. bases of the main neurodegenerative pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYY0I0UHEir7Vg90H21EOLACvtfcHk0lhCsO59Hzxt1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsl2qsbk%253D&md5=c682235151489316d043cf97f78e56f3</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fjm7009364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7009364%26sid%3Dliteratum%253Aachs%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DMinarini%26aufirst%3DA.%26aulast%3DRosini%26aufirst%3DM.%26aulast%3DTumiatti%26aufirst%3DV.%26aulast%3DRecanatini%26aufirst%3DM.%26aulast%3DMelchiorre%26aufirst%3DC.%26atitle%3DMulti-target-directed%2520ligands%2520to%2520combat%2520neurodegenerative%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D347%26epage%3D372%26doi%3D10.1021%2Fjm7009364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designing multiple ligands - medicinal chemistry strategies and challenges</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.2174/138161209787315594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.2174%2F138161209787315594" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=19199984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvVSns70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=587-600&author=R.+Morphyauthor=Z.+Rankovic&title=Designing+multiple+ligands+-+medicinal+chemistry+strategies+and+challenges&doi=10.2174%2F138161209787315594"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Designing multiple ligands - medicinal chemistry strategies and challenges</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">587-600</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  It has been widely recognized over the recent years that parallel modulation of multiple biol. targets can be beneficial for treatment of diseases with complex etiologies such as cancer asthma, and psychiatric disease.  In this article, current strategies for the generation of ligands with a specific multi-target profile (designed multiple ligands or DMLs) are described and a no. of illustrative example are given.  Designing multiple ligands is frequently a challenging endeavor for medicinal chemists, with the need to appropriately balance affinity for 2 or more targets while obtaining physicochem. and pharmacokinetic properties that are consistent with the administration of an oral drug.  Given that the properties of DMLs are influenced to a large extent by the proteomic superfamily to which the targets belong and the lead generation strategy that is pursued, an early assessment of the feasibility of any given DML project is essential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUo6NjoK5D-LVg90H21EOLACvtfcHk0lhCsO59Hzxt1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvVSns70%253D&md5=fa34039be6e9c3b489f530fc74fd0346</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2174%2F138161209787315594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161209787315594%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigning%2520multiple%2520ligands%2520-%2520medicinal%2520chemistry%2520strategies%2520and%2520challenges%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2009%26volume%3D15%26spage%3D587%26epage%3D600%26doi%3D10.2174%2F138161209787315594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">The physicochemical challenges of designing multiple ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">4961</span>– <span class="NLM_lpage">4970</span>, <span class="refDoi"> DOI: 10.1021/jm0603015</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0603015" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFejtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4961-4970&author=R.+Morphyauthor=Z.+Rankovic&title=The+physicochemical+challenges+of+designing+multiple+ligands&doi=10.1021%2Fjm0603015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The Physicochemical Challenges of Designing Multiple Ligands</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4961-4970</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Compds. designed to bind more than one target can provide a therapeutic benefit relative to highly target-selective ligands.  The physicochem. properties of designed multiple ligands were found to be less druglike than those for preclin. compds. in general.  These properties are controlled by the superfamily to which the targets belong and the lead discovery strategy that was followed.  The properties for peptide G-protein-coupled receptor (GPCR) ligands were the least favorable for oral delivery, whereas transporter, monoamine GPCR, and oxidase ligands were the most druglike.  The lead discovery strategy, framework combination or screening, exerts a profound influence on the property values.  Combining the frameworks from two selective ligands often results in large, complex dual ligands, but druglike ligands can be achieved if the degree of framework overlap is maximized and the size of the selective ligands minimized.  For some target combinations, a screening approach may provide a route to smaller, less complex leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonGHbXyxgv4LVg90H21EOLACvtfcHk0lhCsO59Hzxt1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFejtL4%253D&md5=c7a227848516d0aa58ed037a582943fe</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm0603015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0603015%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DThe%2520physicochemical%2520challenges%2520of%2520designing%2520multiple%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4961%26epage%3D4970%26doi%3D10.1021%2Fjm0603015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Fragments, network biology and designing multiple ligands</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">156</span>– <span class="NLM_lpage">160</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2006.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.drudis.2006.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=17275736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtleisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=156-160&author=R.+Morphyauthor=Z.+Rankovic&title=Fragments%2C+network+biology+and+designing+multiple+ligands&doi=10.1016%2Fj.drudis.2006.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Fragments, network biology and designing multiple ligands</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3&4</span>),
    <span class="NLM_cas:pages">156-160</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Modulating multiple protein targets simultaneously can be beneficial for treating complex diseases.  The redundancy that exists within biol. networks means that modulating single proteins might not be sufficient to produce the desired efficacy while, at the same time, minimizing adverse effects.  Designing multi-target drugs can be challenging for medicinal chemists, with current lead-discovery strategies often producing large, complex mols. with low ligand efficiency and poor oral bioavailability.  Paradoxically, analyses of the relationship between the selectivity of biol. active compds. and their mol. size suggest that promiscuous compds. should typically be smaller than target-selective compds.  A fragment-based approach to multi-target drug discovery could lead to a new generation of compds. with improved physicochem. and pharmacokinetic properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXRYwI33BCNLVg90H21EOLACvtfcHk0lipCaYIBwqX3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtleisbs%253D&md5=64a3c7e8c3280db166dda799a77d689a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2006.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2006.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFragments%252C%2520network%2520biology%2520and%2520designing%2520multiple%2520ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26spage%3D156%26epage%3D160%26doi%3D10.1016%2Fj.drudis.2006.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology by design: A medicinal chemist’s perspective on multitargeting compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">420</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=420-444&author=E.+Proschakauthor=H.+Starkauthor=D.+Merk&title=Polypharmacology+by+design%3A+A+medicinal+chemist%E2%80%99s+perspective+on+multitargeting+compounds&doi=10.1021%2Facs.jmedchem.8b00760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds</span></div><div class="casAuthors">Proschak, Ewgenij; Stark, Holger; Merk, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">420-444</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multitargeting compds. comprising activity on more than a single biol. target have gained remarkable relevance in drug discovery owing to the complexity of multifactorial diseases such as cancer, inflammation, or the metabolic syndrome.  Polypharmacol. drug profiles can produce additive or synergistic effects while reducing side effects and significantly contribute to the high therapeutic success of indispensable drugs such as aspirin.  While their identification has long been the result of serendipity, medicinal chem. now tends to design polypharmacol.  Modern in vitro pharmacol. methods and chem. probes allow a systematic search for rational target combinations and recent innovations in computational technologies, crystallog., or fragment-based design equip multitarget compd. development with valuable tools.  In this Perspective, we analyze the relevance of multiple ligands in drug discovery and the versatile toolbox to design polypharmacol.  We conclude that despite some characteristic challenges remaining unresolved, designed polypharmacol. holds enormous potential to secure future therapeutic innovation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOEwJSxWw3vbVg90H21EOLACvtfcHk0lipCaYIBwqX3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE&md5=6dc4b8e1c4777372396626140a302663</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00760%26sid%3Dliteratum%253Aachs%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DMerk%26aufirst%3DD.%26atitle%3DPolypharmacology%2520by%2520design%253A%2520A%2520medicinal%2520chemist%25E2%2580%2599s%2520perspective%2520on%2520multitargeting%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D420%26epage%3D444%26doi%3D10.1021%2Facs.jmedchem.8b00760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MareŠová, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolejs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohelska, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, L. K.</span></span> <span> </span><span class="NLM_article-title">Cost of treatment and care for people with Alzheimer’s disease: A Meta- Analysis</span>. <i>Curr. Alzheimer Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1245</span>– <span class="NLM_lpage">1253</span>, <span class="refDoi"> DOI: 10.2174/1567205017666200102144640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.2174%2F1567205017666200102144640" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2020&pages=1245-1253&author=P.+Mare%C5%A0ov%C3%A1author=J.+Dolejsauthor=H.+Mohelskaauthor=L.+K.+Bryan&title=Cost+of+treatment+and+care+for+people+with+Alzheimer%E2%80%99s+disease%3A+A+Meta-+Analysis&doi=10.2174%2F1567205017666200102144640"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F1567205017666200102144640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1567205017666200102144640%26sid%3Dliteratum%253Aachs%26aulast%3DMare%25C5%25A0ov%25C3%25A1%26aufirst%3DP.%26aulast%3DDolejs%26aufirst%3DJ.%26aulast%3DMohelska%26aufirst%3DH.%26aulast%3DBryan%26aufirst%3DL.%2BK.%26atitle%3DCost%2520of%2520treatment%2520and%2520care%2520for%2520people%2520with%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520A%2520Meta-%2520Analysis%26jtitle%3DCurr.%2520Alzheimer%2520Res.%26date%3D2020%26volume%3D16%26spage%3D1245%26epage%3D1253%26doi%3D10.2174%2F1567205017666200102144640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J. S.</span></span> <span> </span><span class="NLM_article-title">History and progress of hypotheses and clinical trials for Alzheimer’s disease</span>. <i>Signal Transduct Target Ther</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">29</span>, <span class="refDoi"> DOI: 10.1038/s41392-019-0063-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2Fs41392-019-0063-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=31637009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BB3MjgtlSrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&pages=29&author=P.+P.+Liuauthor=Y.+Xieauthor=X.+Y.+Mengauthor=J.+S.+Kang&title=History+and+progress+of+hypotheses+and+clinical+trials+for+Alzheimer%E2%80%99s+disease&doi=10.1038%2Fs41392-019-0063-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">History and progress of hypotheses and clinical trials for Alzheimer's disease</span></div><div class="casAuthors">Liu Pei-Pei; Xie Yi; Meng Xiao-Yan; Kang Jian-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Signal transduction and targeted therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">29</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive memory loss along with neuropsychiatric symptoms and a decline in activities of daily life.  Its main pathological features are cerebral atrophy, amyloid plaques, and neurofibrillary tangles in the brains of patients.  There are various descriptive hypotheses regarding the causes of AD, including the cholinergic hypothesis, amyloid hypothesis, tau propagation hypothesis, mitochondrial cascade hypothesis, calcium homeostasis hypothesis, neurovascular hypothesis, inflammatory hypothesis, metal ion hypothesis, and lymphatic system hypothesis.  However, the ultimate etiology of AD remains obscure.  In this review, we discuss the main hypotheses of AD and related clinical trials.  Wealthy puzzles and lessons have made it possible to develop explanatory theories and identify potential strategies for therapeutic interventions for AD.  The combination of hypometabolism and autophagy deficiency is likely to be a causative factor for AD.  We further propose that fluoxetine, a selective serotonin reuptake inhibitor, has the potential to treat AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQyv72FvQh8PUg6wdEZmT2rfW6udTcc2ea0uya8KcVqo7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjgtlSrug%253D%253D&md5=78392550d619092b1bdc7b2744bfeaaa</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fs41392-019-0063-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41392-019-0063-8%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%2BP.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DMeng%26aufirst%3DX.%2BY.%26aulast%3DKang%26aufirst%3DJ.%2BS.%26atitle%3DHistory%2520and%2520progress%2520of%2520hypotheses%2520and%2520clinical%2520trials%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DSignal%2520Transduct%2520Target%2520Ther%26date%3D2019%26volume%3D4%26spage%3D29%26doi%3D10.1038%2Fs41392-019-0063-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Selkoe, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, J.</span></span> <span> </span><span class="NLM_article-title">The amyloid hypothesis of Alzheimer’s disease at 25 years</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">595</span>– <span class="NLM_lpage">608</span>, <span class="refDoi"> DOI: 10.15252/emmm.201606210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.15252%2Femmm.201606210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=27025652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC28XltVOhtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=595-608&author=D.+J.+Selkoeauthor=J.+Hardy&title=The+amyloid+hypothesis+of+Alzheimer%E2%80%99s+disease+at+25+years&doi=10.15252%2Femmm.201606210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The amyloid hypothesis of Alzheimer's disease at 25 years</span></div><div class="casAuthors">Selkoe, Dennis J.; Hardy, John</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">595-608</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Despite continuing debate about the amyloid β-protein or Aβ hypothesis, new lines of evidence from labs. and clinics worldwide support the concept that an imbalance between prodn. and clearance of Aβ42 and related Aβ peptides is a very early, often initiating factor in Alzheimer's disease AD.  Confirmation that presenilin is the catalytic site of γ-secretase has provided a linchpin: all dominant mutations causing early-onset AD occur either in the substrate amyloid precursor protein, APP or the protease presenilin of the reaction that generates Aβ.  Duplication of the wild-type APP gene in Down's syndrome leads to Aβ deposits in the teens, followed by microgliosis, astrocytosis, and neurofibrillary tangles typical of AD.  Apolipoprotein E4, which predisposes to AD in > 40% of cases, has been found to impair Aβ clearance from the brain.  Sol. oligomers of Aβ42 isolated from AD patients' brains can decrease synapse no., inhibit long-term potentiation, and enhance long-term synaptic depression in rodent hippocampus, and injecting them into healthy rats impairs memory.  The human oligomers also induce hyperphosphorylation of tau at AD-relevant epitopes and cause neuritic dystrophy in cultured neurons.  Crossing human APP with human tau transgenic mice enhances tau-pos. neurotoxicity.  In humans, new studies show that low cerebrospinal fluid CSF Aβ42 and amyloid-PET positivity precede other AD manifestations by many years.  Most importantly, recent trials of three different Aβ antibodies solanezumab, crenezumab, and aducanumab have suggested a slowing of cognitive decline in post hoc analyses of mild AD subjects.  Although many factors contribute to AD pathogenesis, Aβ dyshomeostasis has emerged as the most extensively validated and compelling therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyGo1qmyvVtbVg90H21EOLACvtfcHk0liIsPW_xzYWJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltVOhtL8%253D&md5=b7a2003ba5d341f5eef5c7e9454235ce</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.15252%2Femmm.201606210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Femmm.201606210%26sid%3Dliteratum%253Aachs%26aulast%3DSelkoe%26aufirst%3DD.%2BJ.%26aulast%3DHardy%26aufirst%3DJ.%26atitle%3DThe%2520amyloid%2520hypothesis%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%2520at%252025%2520years%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2016%26volume%3D8%26spage%3D595%26epage%3D608%26doi%3D10.15252%2Femmm.201606210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span> <span> </span><span class="NLM_article-title">New insights into the pathogenesis of Alzheimer’s disease</span>. <i>Front Neurol</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1312</span>, <span class="refDoi"> DOI: 10.3389/fneur.2019.01312</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.3389%2Ffneur.2019.01312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=31998208" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=1312&author=L.+Fanauthor=C.+Maoauthor=X.+Huauthor=S.+Zhangauthor=Z.+Yangauthor=Z.+Huauthor=H.+Sunauthor=Y.+Fanauthor=Y.+Dongauthor=J.+Yangauthor=C.+Shiauthor=Y.+Xu&title=New+insights+into+the+pathogenesis+of+Alzheimer%E2%80%99s+disease&doi=10.3389%2Ffneur.2019.01312"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.3389%2Ffneur.2019.01312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffneur.2019.01312%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DL.%26aulast%3DMao%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DY.%26atitle%3DNew%2520insights%2520into%2520the%2520pathogenesis%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DFront%2520Neurol%26date%3D2020%26volume%3D10%26spage%3D1312%26doi%3D10.3389%2Ffneur.2019.01312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, A. J.</span></span> <span> </span><span class="NLM_article-title">Selective loss of central cholinergic neurons in Alzheimer’s disease</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>308</i></span>,  <span class="NLM_fpage">1403</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(76)91936-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2FS0140-6736%2876%2991936-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=1976&pages=1403&author=P.+Daviesauthor=A.+J.+Maloney&title=Selective+loss+of+central+cholinergic+neurons+in+Alzheimer%E2%80%99s+disease&doi=10.1016%2FS0140-6736%2876%2991936-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2876%2991936-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252876%252991936-X%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DP.%26aulast%3DMaloney%26aufirst%3DA.%2BJ.%26atitle%3DSelective%2520loss%2520of%2520central%2520cholinergic%2520neurons%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DLancet%26date%3D1976%26volume%3D308%26spage%3D1403%26doi%3D10.1016%2FS0140-6736%2876%2991936-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tong, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, K. H.</span></span> <span> </span><span class="NLM_article-title">Calcium signaling in Alzheimer’s disease & therapies</span>. <i>Biochim. Biophys. Acta, Mol. Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>1865</i></span>,  <span class="NLM_fpage">1745</span>– <span class="NLM_lpage">1760</span>, <span class="refDoi"> DOI: 10.1016/j.bbamcr.2018.07.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.bbamcr.2018.07.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=30059692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVGjt77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1865&publication_year=2018&pages=1745-1760&author=B.+C.+Tongauthor=A.+J.+Wuauthor=M.+Liauthor=K.+H.+Cheung&title=Calcium+signaling+in+Alzheimer%E2%80%99s+disease+%26+therapies&doi=10.1016%2Fj.bbamcr.2018.07.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Calcium signaling in Alzheimer's disease & therapies</span></div><div class="casAuthors">Tong, Benjamin Chun-Kit; Wu, Aston Jiaxi; Li, Min; Cheung, King-Ho</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">1865</span>
        (<span class="NLM_cas:issue">11_Part_B</span>),
    <span class="NLM_cas:pages">1745-1760</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is the most common type of dementia and is characterized by the accumulation of amyloid (Aβ) plaques and neurofibrillary tangles in the brain.  Much attention has been given to develop AD treatments based on the amyloid cascade hypothesis; however, none of these drugs had good efficacy at improving cognitive functions in AD patients suggesting that Aβ might not be the disease origin.  Thus, there are urgent needs for the development of new therapies that target on the proximal cause of AD.  Cellular calcium (Ca2+) signals regulate important facets of neuronal physiol.  An increasing body of evidence suggests that age-related dysregulation of neuronal Ca2+ homeostasis may play a proximal role in the pathogenesis of AD as disrupted Ca2+ could induce synaptic deficits and promote the accumulation of Aβ plaques and neurofibrillary tangles.  Given that Ca2+ disruption is ubiquitously involved in all AD pathologies, it is likely that using chem. agents or small mols. specific to Ca2+ channels or handling proteins on the plasma membrane and membranes of intracellular organelles to correct neuronal Ca2+ dysregulation could open up a new approach to AD prevention and treatment.  This review summarizes current knowledge on the mol. mechanisms linking Ca2+ dysregulation with AD pathologies and discusses the possibility of correcting neuronal Ca2+ disruption as a therapeutic approach for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEJK32o3x9WbVg90H21EOLACvtfcHk0liIsPW_xzYWJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVGjt77L&md5=99d76eeda35ebcddb0e88c2a7763821c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2018.07.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2018.07.018%26sid%3Dliteratum%253Aachs%26aulast%3DTong%26aufirst%3DB.%2BC.%26aulast%3DWu%26aufirst%3DA.%2BJ.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DCheung%26aufirst%3DK.%2BH.%26atitle%3DCalcium%2520signaling%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520%2526%2520therapies%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Res.%26date%3D2018%26volume%3D1865%26spage%3D1745%26epage%3D1760%26doi%3D10.1016%2Fj.bbamcr.2018.07.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butterfield, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halliwell, B.</span></span> <span> </span><span class="NLM_article-title">Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">148</span>– <span class="NLM_lpage">160</span>, <span class="refDoi"> DOI: 10.1038/s41583-019-0132-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2Fs41583-019-0132-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=30737462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmsVyms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=148-160&author=D.+A.+Butterfieldauthor=B.+Halliwell&title=Oxidative+stress%2C+dysfunctional+glucose+metabolism+and+Alzheimer+disease&doi=10.1038%2Fs41583-019-0132-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease</span></div><div class="casAuthors">Butterfield, D. Allan; Halliwell, Barry</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">148-160</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Alzheimer disease (AD) is a major cause of age-related dementia.  We do not fully understand AD etiol. and pathogenesis, but oxidative damage is a key component.  The brain mostly uses glucose for energy, but in AD and amnestic mild cognitive impairment glucose metab. is dramatically decreased, probably owing, at least in part, to oxidative damage to enzymes involved in glycolysis, the tricarboxylic acid cycle and ATP biosynthesis.  Consequently, ATP-requiring processes for cognitive function are impaired, and synaptic dysfunction and neuronal death result, with ensuing thinning of key brain areas.  We summarize current research on the interplay and sequence of these processes and suggest potential pharmacol. interventions to retard AD progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob7mdept4G1LVg90H21EOLACvtfcHk0liIsPW_xzYWJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmsVyms7s%253D&md5=d0a1863fd4aaa5f55263c0b055412f9d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fs41583-019-0132-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41583-019-0132-6%26sid%3Dliteratum%253Aachs%26aulast%3DButterfield%26aufirst%3DD.%2BA.%26aulast%3DHalliwell%26aufirst%3DB.%26atitle%3DOxidative%2520stress%252C%2520dysfunctional%2520glucose%2520metabolism%2520and%2520Alzheimer%2520disease%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2019%26volume%3D20%26spage%3D148%26epage%3D160%26doi%3D10.1038%2Fs41583-019-0132-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonda, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. A.</span></span> <span> </span><span class="NLM_article-title">Role of metal dyshomeostasis in Alzheimer’s disease</span>. <i>Metallomics</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">270</span>, <span class="refDoi"> DOI: 10.1039/c0mt00074d</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1039%2Fc0mt00074d" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=21298161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksVGlsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=267-270&author=D.+J.+Bondaauthor=H.+G.+Leeauthor=J.+A.+Blairauthor=X.+Zhuauthor=G.+Perryauthor=M.+A.+Smith&title=Role+of+metal+dyshomeostasis+in+Alzheimer%E2%80%99s+disease&doi=10.1039%2Fc0mt00074d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Role of metal dyshomeostasis in Alzheimer's disease</span></div><div class="casAuthors">Bonda, David J.; Lee, Hyoung-gon; Blair, Jeffrey A.; Zhu, Xiongwei; Perry, George; Smith, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Metallomics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">267-270</span>CODEN:
                <span class="NLM_cas:coden">METAJS</span>;
        ISSN:<span class="NLM_cas:issn">1756-591X</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Despite serving a crucial purpose in neurobiol. function, transition metals play a sinister part in the aging brain, where the abnormal accumulation and distribution of reactive iron, copper, and zinc elicit oxidative stress and macromol. damage that impedes cellular function.  Alzheimer's disease (AD), an age-related neurodegenerative condition, presents marked accumulations of oxidative stress-induced damage, and increasing evidence points to aberrant transition metal homeostasis as a crit. factor in its pathogenesis.  Amyloid-β oligomerization and fibrillation, considered by many to be the pptg. factor underlying AD onset and development, is also induced by abnormal transition metal activity.  We here elaborate on the roles of iron, copper, and zinc in AD and describe the therapeutic implications they present.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiug6uC3OgKbVg90H21EOLACvtfcHk0lj7rzPRT5TESg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksVGlsbo%253D&md5=97a8ae421b09da255aa0ee37fe366aee</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1039%2Fc0mt00074d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc0mt00074d%26sid%3Dliteratum%253Aachs%26aulast%3DBonda%26aufirst%3DD.%2BJ.%26aulast%3DLee%26aufirst%3DH.%2BG.%26aulast%3DBlair%26aufirst%3DJ.%2BA.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DPerry%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DM.%2BA.%26atitle%3DRole%2520of%2520metal%2520dyshomeostasis%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DMetallomics%26date%3D2011%26volume%3D3%26spage%3D267%26epage%3D270%26doi%3D10.1039%2Fc0mt00074d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinney, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bemiller, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murtishaw, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leisgang, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salazar, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, B. T.</span></span> <span> </span><span class="NLM_article-title">Inflammation as a central mechanism in Alzheimer’s disease</span>. <i>Alzheimers Dement (N Y)</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">575</span>– <span class="NLM_lpage">590</span>, <span class="refDoi"> DOI: 10.1016/j.trci.2018.06.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.trci.2018.06.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=30406177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BB3cvnvVSltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=575-590&author=J.+W.+Kinneyauthor=S.+M.+Bemillerauthor=A.+S.+Murtishawauthor=A.+M.+Leisgangauthor=A.+M.+Salazarauthor=B.+T.+Lamb&title=Inflammation+as+a+central+mechanism+in+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.trci.2018.06.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammation as a central mechanism in Alzheimer's disease</span></div><div class="casAuthors">Kinney Jefferson W; Murtishaw Andrew S; Leisgang Amanda M; Salazar Arnold M; Bemiller Shane M; Lamb Bruce T</div><div class="citationInfo"><span class="NLM_cas:title">Alzheimer's & dementia (New York, N. Y.)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">575-590</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is characterized by cognitive decline and the presence of two core pathologies, amyloid β plaques and neurofibrillary tangles.  Over the last decade, the presence of a sustained immune response in the brain has emerged as a third core pathology in AD.  The sustained activation of the brain's resident macrophages (microglia) and other immune cells has been demonstrated to exacerbate both amyloid and tau pathology and may serve as a link in the pathogenesis of the disorder.  In the following review, we provide an overview of inflammation in AD and a detailed coverage of a number of microglia-related signaling mechanisms that have been implicated in AD.  Additional information on microglia signaling and a number of cytokines in AD are also reviewed.  We also review the potential connection of risk factors for AD and how they may be related to inflammatory mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR0qVKieHI_a-dfST00W0BcfW6udTcc2eYPM2zCfbWporntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvnvVSltA%253D%253D&md5=cf1cea8f5c84010fd13daebab3094edf</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.trci.2018.06.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.trci.2018.06.014%26sid%3Dliteratum%253Aachs%26aulast%3DKinney%26aufirst%3DJ.%2BW.%26aulast%3DBemiller%26aufirst%3DS.%2BM.%26aulast%3DMurtishaw%26aufirst%3DA.%2BS.%26aulast%3DLeisgang%26aufirst%3DA.%2BM.%26aulast%3DSalazar%26aufirst%3DA.%2BM.%26aulast%3DLamb%26aufirst%3DB.%2BT.%26atitle%3DInflammation%2520as%2520a%2520central%2520mechanism%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DAlzheimers%2520Dement%2520%2528N%2520Y%2529%26date%3D2018%26volume%3D4%26spage%3D575%26epage%3D590%26doi%3D10.1016%2Fj.trci.2018.06.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerakis, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hetz, C.</span></span> <span> </span><span class="NLM_article-title">Emerging roles of ER stress in the etiology and pathogenesis of Alzheimer’s disease</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">995</span>– <span class="NLM_lpage">1011</span>, <span class="refDoi"> DOI: 10.1111/febs.14332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1111%2Ffebs.14332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=29148236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOntL7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2018&pages=995-1011&author=Y.+Gerakisauthor=C.+Hetz&title=Emerging+roles+of+ER+stress+in+the+etiology+and+pathogenesis+of+Alzheimer%E2%80%99s+disease&doi=10.1111%2Ffebs.14332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging roles of ER stress in the etiology and pathogenesis of Alzheimer's disease</span></div><div class="casAuthors">Gerakis, Yannis; Hetz, Claudio</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">995-1011</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by synaptic dysfunction and accumulation of abnormal aggregates formed by amyloid-β peptides or phosphorylated tau proteins.  Accumulating evidence suggests that alterations in the buffering capacity of the proteostasis network are a salient feature of AD.  The endoplasmic reticulum (ER) is the main compartment involved in protein folding and secretion and is drastically affected in AD neurons.  ER stress triggers the activation of the unfolded protein response (UPR), a signal transduction pathway that enforces adaptive programs to recover homeostasis or trigger apoptosis of irreversibly damaged cells.  Exptl. manipulation of specific UPR signaling modules in preclin. models of AD has revealed a key role of this pathway in regulating protein misfolding and neurodegeneration.  Recent studies suggest that the UPR also influences synaptic plasticity and memory through ER stress-independent mechanisms.  Consequently, targeting of the UPR in AD is emerging as an interesting therapeutic approach to modify the two pillars of AD, protein misfolding and synaptic failure.  Here, we review the functional role of ER stress signaling in AD, discussing the complex involvement of the pathway in controlling neuronal survival, the amyloid cascade, neurodegeneration and synaptic function.  Recent intervention efforts to target the UPR with pharmacol. and gene therapy strategies are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKjpOIPTqPM7Vg90H21EOLACvtfcHk0lj7rzPRT5TESg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOntL7J&md5=c626a50b7010a4e07215026ecb2cc87c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1111%2Ffebs.14332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Ffebs.14332%26sid%3Dliteratum%253Aachs%26aulast%3DGerakis%26aufirst%3DY.%26aulast%3DHetz%26aufirst%3DC.%26atitle%3DEmerging%2520roles%2520of%2520ER%2520stress%2520in%2520the%2520etiology%2520and%2520pathogenesis%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DFEBS%2520J.%26date%3D2018%26volume%3D285%26spage%3D995%26epage%3D1011%26doi%3D10.1111%2Ffebs.14332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swerdlow, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, S. M.</span></span> <span> </span><span class="NLM_article-title">The Alzheimer’s disease mitochondrial cascade hypothesis: Progress and perspectives</span>. <i>Biochim. Biophys. Acta, Mol. Basis Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1842</i></span>,  <span class="NLM_fpage">1219</span>– <span class="NLM_lpage">1231</span>, <span class="refDoi"> DOI: 10.1016/j.bbadis.2013.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.bbadis.2013.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=24071439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFOgu7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1842&publication_year=2014&pages=1219-1231&author=R.+H.+Swerdlowauthor=J.+M.+Burnsauthor=S.+M.+Khan&title=The+Alzheimer%E2%80%99s+disease+mitochondrial+cascade+hypothesis%3A+Progress+and+perspectives&doi=10.1016%2Fj.bbadis.2013.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The Alzheimer's disease mitochondrial cascade hypothesis: Progress and perspectives</span></div><div class="casAuthors">Swerdlow, Russell H.; Burns, Jeffrey M.; Khan, Shaharyar M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Basis of Disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1842</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1219-1231</span>CODEN:
                <span class="NLM_cas:coden">BBADEX</span>;
        ISSN:<span class="NLM_cas:issn">0925-4439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  Ten years ago we first proposed the Alzheimer's disease (AD) mitochondrial cascade hypothesis.  This hypothesis maintains that gene inheritance defines an individual's baseline mitochondrial function; inherited and environmental factors det. rates at which mitochondrial function changes over time; and baseline mitochondrial function and mitochondrial change rates influence AD chronol.  Our hypothesis unequivocally states in sporadic, late-onset AD, mitochondrial function affects amyloid precursor protein (APP) expression, APP processing, or beta amyloid (Aβ) accumulation and argues if an amyloid cascade truly exists, mitochondrial function triggers it.  We now review the state of the mitochondrial cascade hypothesis, and discuss it in the context of recent AD biomarker studies, diagnostic criteria, and clin. trials.  Our hypothesis predicts that biomarker changes reflect brain aging, new AD definitions clin. stage brain aging, and removing brain Aβ at any point will marginally impact cognitive trajectories.  Our hypothesis, therefore, offers unique perspective into what sporadic, late-onset AD is and how to best treat it.  This article is part of a Special Issue entitled: Misfolded Proteins, Mitochondrial Dysfunction, and Neurodegenerative Diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnl0OsMeI8rbVg90H21EOLACvtfcHk0lj7rzPRT5TESg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFOgu7zI&md5=fe6deed8b82bdf9eff21850be7b1ffe3</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bbadis.2013.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbadis.2013.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DSwerdlow%26aufirst%3DR.%2BH.%26aulast%3DBurns%26aufirst%3DJ.%2BM.%26aulast%3DKhan%26aufirst%3DS.%2BM.%26atitle%3DThe%2520Alzheimer%25E2%2580%2599s%2520disease%2520mitochondrial%2520cascade%2520hypothesis%253A%2520Progress%2520and%2520perspectives%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Basis%2520Dis.%26date%3D2014%26volume%3D1842%26spage%3D1219%26epage%3D1231%26doi%3D10.1016%2Fj.bbadis.2013.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabbagh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, K.</span></span> <span> </span><span class="NLM_article-title">Alzheimer’s disease drug development pipeline: 2020</span>. <i>Alzheimers Dement (N Y)</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">e12050</span> <span class="refDoi"> DOI: 10.1002/trc2.12050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1002%2Ftrc2.12050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=32695874" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2020&author=J.+Cummingsauthor=G.+Leeauthor=A.+Ritterauthor=M.+Sabbaghauthor=K.+Zhong&title=Alzheimer%E2%80%99s+disease+drug+development+pipeline%3A+2020&doi=10.1002%2Ftrc2.12050"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Ftrc2.12050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Ftrc2.12050%26sid%3Dliteratum%253Aachs%26aulast%3DCummings%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DG.%26aulast%3DRitter%26aufirst%3DA.%26aulast%3DSabbagh%26aufirst%3DM.%26aulast%3DZhong%26aufirst%3DK.%26atitle%3DAlzheimer%25E2%2580%2599s%2520disease%2520drug%2520development%2520pipeline%253A%25202020%26jtitle%3DAlzheimers%2520Dement%2520%2528N%2520Y%2529%26date%3D2020%26volume%3D6%26doi%3D10.1002%2Ftrc2.12050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Syed, Y. Y.</span></span> <span> </span><span class="NLM_article-title">Sodium Oligomannate: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1007/s40265-020-01268-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1007%2Fs40265-020-01268-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=32020555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BB38%252FotlKlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=441-444&author=Y.+Y.+Syed&title=Sodium+Oligomannate%3A+First+Approval&doi=10.1007%2Fs40265-020-01268-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Sodium Oligomannate: First Approval</span></div><div class="casAuthors">Syed Yahiya Y</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">441-444</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sodium oligomannate ((®); GV-971) is a marine algae-derived oral oligosaccharide being developed by Shanghai Green Valley Pharmaceuticals for the treatment of Alzheimer's disease (AD).  Sodium oligomannate received its first approval in November 2019 in China for the treatment of mild to moderate AD to improve cognitive function.  This article summarizes the milestones in the development of sodium oligomannate leading to this first approval for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbpElibNSrFNFxYDaSSP8XfW6udTcc2eZ-SIynJRJNaLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38%252FotlKlsg%253D%253D&md5=1c672e61641ea74da9583fd4305b9fbf</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1007%2Fs40265-020-01268-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-020-01268-1%26sid%3Dliteratum%253Aachs%26aulast%3DSyed%26aufirst%3DY.%2BY.%26atitle%3DSodium%2520Oligomannate%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2020%26volume%3D80%26spage%3D441%26epage%3D444%26doi%3D10.1007%2Fs40265-020-01268-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Citron, M.</span></span> <span> </span><span class="NLM_article-title">Alzheimer’s disease: Strategies for disease modification</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">398</span>, <span class="refDoi"> DOI: 10.1038/nrd2896</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2Fnrd2896" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=20431570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsVWjsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=387-398&author=M.+Citron&title=Alzheimer%E2%80%99s+disease%3A+Strategies+for+disease+modification&doi=10.1038%2Fnrd2896"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Alzheimer's disease: strategies for disease modification</span></div><div class="casAuthors">Citron, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">387-398</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease is the largest unmet medical need in neurol.  Current drugs improve symptoms, but do not have profound disease-modifying effects.  However, in recent years, several approaches aimed at inhibiting disease progression have advanced to clin. trials.  Among these, strategies targeting the prodn. and clearance of the amyloid-β peptide - a cardinal feature of Alzheimer's disease that is thought to be important in disease pathogenesis - are the most advanced.  Approaches aimed at modulating the abnormal aggregation of tau filaments (another key feature of the disease), and those targeting metabolic dysfunction, are also being evaluated in the clinic.  This article discusses recent progress with each of these strategies, with a focus on anti-amyloid strategies, highlighting the lessons learned and the challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeM0fsdJQ-z7Vg90H21EOLACvtfcHk0ljpcrU7y11ypw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsVWjsrw%253D&md5=281ba27137d2a1fa173d5dde1dcbe772</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnrd2896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2896%26sid%3Dliteratum%253Aachs%26aulast%3DCitron%26aufirst%3DM.%26atitle%3DAlzheimer%25E2%2580%2599s%2520disease%253A%2520Strategies%2520for%2520disease%2520modification%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D387%26epage%3D398%26doi%3D10.1038%2Fnrd2896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grossberg, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tariot, P. N.</span></span> <span> </span><span class="NLM_article-title">Present algorithms and future treatments for Alzheimer’s disease</span>. <i>J. Alzheimer's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">1157</span>– <span class="NLM_lpage">1171</span>, <span class="refDoi"> DOI: 10.3233/JAD-180903</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.3233%2FJAD-180903" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=30741683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BB3cfht1altA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2019&pages=1157-1171&author=G.+T.+Grossbergauthor=G.+Tongauthor=A.+D.+Burkeauthor=P.+N.+Tariot&title=Present+algorithms+and+future+treatments+for+Alzheimer%E2%80%99s+disease&doi=10.3233%2FJAD-180903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Present Algorithms and Future Treatments for Alzheimer's Disease</span></div><div class="casAuthors">Grossberg George T; Tong Gary; Burke Anna D; Tariot Pierre N</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's disease : JAD</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1157-1171</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">An estimated 47 million people live with Alzheimer's disease (AD) and other forms of dementia worldwide.  Although no disease-modifying treatments are currently available for AD, earlier diagnosis and proper management of the disease could have considerable impact on patient and caregiver quality of life and functioning.  Drugs currently approved for AD treat the cognitive, behavioral, and functional symptoms of the disease and consist of three cholinesterase inhibitors (ChEIs) and the N-methyl-D-aspartate receptor antagonist memantine.  Treatment of patients with mild to moderate AD is generally initiated with a ChEI.  Patients who show progression of symptoms while on ChEI monotherapy may be switched to another ChEI and/or memantine can be added to the treatment regimen.  In recent years, putative disease-modifying therapies have emerged that aim to slow the progression of AD instead of only addressing its symptoms.  However, many therapies have failed in clinical trials in patients with established AD, suggesting that, once developed, disease-modifying agents may need to be deployed earlier in the course of illness.  The goal of this narrative literature review is to discuss present treatment algorithms and potential future therapies in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRzz6tULPklxXELvajU9pjPfW6udTcc2eZ-SIynJRJNaLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfht1altA%253D%253D&md5=c390932b1dff6314af37252a58c5799e</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.3233%2FJAD-180903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-180903%26sid%3Dliteratum%253Aachs%26aulast%3DGrossberg%26aufirst%3DG.%2BT.%26aulast%3DTong%26aufirst%3DG.%26aulast%3DBurke%26aufirst%3DA.%2BD.%26aulast%3DTariot%26aufirst%3DP.%2BN.%26atitle%3DPresent%2520algorithms%2520and%2520future%2520treatments%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Alzheimer%2527s%2520Dis.%26date%3D2019%26volume%3D67%26spage%3D1157%26epage%3D1171%26doi%3D10.3233%2FJAD-180903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">Multi-target design strategies for the improved treatment of Alzheimer’s disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">228</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.ejmech.2019.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=31103902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvVGnsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2019&pages=228-247&author=P.+Zhangauthor=S.+Xuauthor=Z.+Zhuauthor=J.+Xu&title=Multi-target+design+strategies+for+the+improved+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.ejmech.2019.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target design strategies for the improved treatment of Alzheimer's disease</span></div><div class="casAuthors">Zhang, Pengfei; Xu, Shengtao; Zhu, Zheying; Xu, Jinyi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">228-247</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) is a multifactorial syndrome resulting in profound misery and poses a substantial burden on human health, economy, and society throughout the world.  Based on the numerous AD-related targets in the disease network, multi-target design strategy is a crucial direction to seek for enhanced therapy, and multi-target drugs have the ability to regulate more targets than single-target drugs, affecting the disease network with more potency.  Herein, we highlight nine major targets assocd. with AD, which are acetylcholine esterase (AChE), beta-site amyloid precursor protein cleaving enzyme 1 (β-secretase, BACE-1), glycogen synthase kinase 3 beta (GSK-3β), monoamine oxidases (MAOs), metal ions in the brain, N-methyl-D-aspartate (NMDA) receptor, 5-hydroxytryptamine (5-HT) receptors, the third subtype of histamine receptor (H3 receptor), and phosphodiesterases (PDEs), and their resp. relationship to the disease network.  Furthermore, eleven multi-target design strategies classified by the involvement of AChE and related promising compds. for improved therapy of AD in recent years are described based on the nine major targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRXynXSn84-bVg90H21EOLACvtfcHk0liNMl2jralb-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvVGnsb8%253D&md5=86555914b4ef65fae2d38caedb87f1aa</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DMulti-target%2520design%2520strategies%2520for%2520the%2520improved%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D176%26spage%3D228%26epage%3D247%26doi%3D10.1016%2Fj.ejmech.2019.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Simone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armirotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertozzi, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrisano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Castillo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massenzio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polito, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatino, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottegoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the first dual BACE-1/GSK-3β fragment hits against Alzheimer’s disease</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1665</span>– <span class="NLM_lpage">1682</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.5b00121</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.5b00121" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFKkt73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1665-1682&author=F.+Pratiauthor=A.+De+Simoneauthor=A.+Armirottiauthor=M.+Summaauthor=D.+Pizziraniauthor=R.+Scarpelliauthor=S.+M.+Bertozziauthor=D.+I.+Perezauthor=V.+Andrisanoauthor=A.+Perez-Castilloauthor=B.+Montiauthor=F.+Massenzioauthor=L.+Politoauthor=M.+Racchiauthor=P.+Sabatinoauthor=G.+Bottegoniauthor=A.+Martinezauthor=A.+Cavalliauthor=M.+L.+Bolognesi&title=3%2C4-Dihydro-1%2C3%2C5-triazin-2%281H%29-ones+as+the+first+dual+BACE-1%2FGSK-3%CE%B2+fragment+hits+against+Alzheimer%E2%80%99s+disease&doi=10.1021%2Facschemneuro.5b00121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the First Dual BACE-1/GSK-3β Fragment Hits against Alzheimer's Disease</span></div><div class="casAuthors">Prati, Federica; De Simone, Angela; Armirotti, Andrea; Summa, Maria; Pizzirani, Daniela; Scarpelli, Rita; Bertozzi, Sine Mandrup; Perez, Daniel I.; Andrisano, Vincenza; Perez-Castillo, Ana; Monti, Barbara; Massenzio, Francesca; Polito, Letizia; Racchi, Marco; Sabatino, Piera; Bottegoni, Giovanni; Martinez, Ana; Cavalli, Andrea; Bolognesi, Maria L.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1665-1682</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">One of the main obstacles toward the discovery of effective anti-Alzheimer drugs is the multifactorial nature of its etiopathol.  Therefore, the use of multitarget-directed ligands has emerged as particularly suitable.  Such ligands, able to modulate different neurodegenerative pathways, for example, amyloid and tau cascades, as well as cognitive and neurogenic functions, are fostered to come.  In this respect, we report herein on the first class of BACE-1/GSK-3β dual inhibitors based on a 3,4-dihydro-1,3,5-triazin-2(1H)-one skeleton, whose hit compd. 1 showed interesting properties in a preliminary investigation.  Notably, compd. 2, endowed with well-balanced potencies against the two isolated enzymes (IC50 of 16 and 7 μM against BACE-1 and GSK-3β, resp.), displayed effective neuroprotective and neurogenic activities and no neurotoxicity in cell-based assays.  It also showed good brain permeability in a pharmacokinetic assessment in mice.  Overall, triazinone derivs., thanks to the simultaneous modulation of multiple points of the diseased network, might emerge as suitable candidates to be tested in in vivo Alzheimer's disease models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9gpkNszZOQ7Vg90H21EOLACvtfcHk0lhs0jrOfY3YGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFKkt73O&md5=5d02342f3164a73e41eb17c4f87fb4fa</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.5b00121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.5b00121%26sid%3Dliteratum%253Aachs%26aulast%3DPrati%26aufirst%3DF.%26aulast%3DDe%2BSimone%26aufirst%3DA.%26aulast%3DArmirotti%26aufirst%3DA.%26aulast%3DSumma%26aufirst%3DM.%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DScarpelli%26aufirst%3DR.%26aulast%3DBertozzi%26aufirst%3DS.%2BM.%26aulast%3DPerez%26aufirst%3DD.%2BI.%26aulast%3DAndrisano%26aufirst%3DV.%26aulast%3DPerez-Castillo%26aufirst%3DA.%26aulast%3DMonti%26aufirst%3DB.%26aulast%3DMassenzio%26aufirst%3DF.%26aulast%3DPolito%26aufirst%3DL.%26aulast%3DRacchi%26aufirst%3DM.%26aulast%3DSabatino%26aufirst%3DP.%26aulast%3DBottegoni%26aufirst%3DG.%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3D3%252C4-Dihydro-1%252C3%252C5-triazin-2%25281H%2529-ones%2520as%2520the%2520first%2520dual%2520BACE-1%252FGSK-3%25CE%25B2%2520fragment%2520hits%2520against%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2015%26volume%3D6%26spage%3D1665%26epage%3D1682%26doi%3D10.1021%2Facschemneuro.5b00121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Simone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisignano, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armirotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrisano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Castillo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massenzio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polito, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favia, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottegoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span> <span> </span><span class="NLM_article-title">Multitarget drug discovery for Alzheimer’s disease: Triazinones as BACE-1 and GSK-3β inhibitors</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1578</span>– <span class="NLM_lpage">1582</span>, <span class="refDoi"> DOI: 10.1002/anie.201410456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1002%2Fanie.201410456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVyhtrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=1578-1582&author=F.+Pratiauthor=A.+De+Simoneauthor=P.+Bisignanoauthor=A.+Armirottiauthor=M.+Summaauthor=D.+Pizziraniauthor=R.+Scarpelliauthor=D.+I.+Perezauthor=V.+Andrisanoauthor=A.+Perez-Castilloauthor=B.+Montiauthor=F.+Massenzioauthor=L.+Politoauthor=M.+Racchiauthor=A.+D.+Faviaauthor=G.+Bottegoniauthor=A.+Martinezauthor=M.+L.+Bolognesiauthor=A.+Cavalli&title=Multitarget+drug+discovery+for+Alzheimer%E2%80%99s+disease%3A+Triazinones+as+BACE-1+and+GSK-3%CE%B2+inhibitors&doi=10.1002%2Fanie.201410456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Multitarget Drug Discovery for Alzheimer's Disease: Triazinones as BACE-1 and GSK-3β Inhibitors</span></div><div class="casAuthors">Prati, Federica; De Simone, Angela; Bisignano, Paola; Armirotti, Andrea; Summa, Maria; Pizzirani, Daniela; Scarpelli, Rita; Perez, Daniel I.; Andrisano, Vincenza; Perez-Castillo, Ana; Monti, Barbara; Massenzio, Francesca; Polito, Letizia; Racchi, Marco; Favia, Angelo D.; Bottegoni, Giovanni; Martinez, Ana; Bolognesi, Maria Laura; Cavalli, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1578-1582</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Cumulative evidence strongly supports that the amyloid and tau hypotheses are not mutually exclusive, but concomitantly contribute to neurodegeneration in Alzheimer's disease (AD).  Thus, the development of multitarget drugs which are involved in both pathways might represent a promising therapeutic strategy.  Accordingly, reported here in is the discovery of 6-amino-4-phenyl-3,4-dihydro-1,3,5-triazin-2(1H)-ones as the first class of mols. able to simultaneously modulate BACE-1 and GSK-3β.  Notably, one triazinone showed well-balanced in vitro potencies against the two enzymes (IC50 of (18.03±0.01) μM and (14.67±0.78) μM for BACE-1 and GSK-3β, resp.).  In cell-based assays, it displayed effective neuroprotective and neurogenic activities and no neurotoxicity.  It also showed good brain permeability in a preliminary pharmacokinetic assessment in mice.  Overall, triazinones might represent a promising starting point towards high quality lead compds. with an AD-modifying potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr709_eEcKrqrVg90H21EOLACvtfcHk0ljiFs7Pwl0d2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVyhtrjE&md5=9d372688168ec28086c92d557a1ed708</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fanie.201410456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201410456%26sid%3Dliteratum%253Aachs%26aulast%3DPrati%26aufirst%3DF.%26aulast%3DDe%2BSimone%26aufirst%3DA.%26aulast%3DBisignano%26aufirst%3DP.%26aulast%3DArmirotti%26aufirst%3DA.%26aulast%3DSumma%26aufirst%3DM.%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DScarpelli%26aufirst%3DR.%26aulast%3DPerez%26aufirst%3DD.%2BI.%26aulast%3DAndrisano%26aufirst%3DV.%26aulast%3DPerez-Castillo%26aufirst%3DA.%26aulast%3DMonti%26aufirst%3DB.%26aulast%3DMassenzio%26aufirst%3DF.%26aulast%3DPolito%26aufirst%3DL.%26aulast%3DRacchi%26aufirst%3DM.%26aulast%3DFavia%26aufirst%3DA.%2BD.%26aulast%3DBottegoni%26aufirst%3DG.%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DCavalli%26aufirst%3DA.%26atitle%3DMultitarget%2520drug%2520discovery%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520Triazinones%2520as%2520BACE-1%2520and%2520GSK-3%25CE%25B2%2520inhibitors%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D1578%26epage%3D1582%26doi%3D10.1002%2Fanie.201410456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lauretti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dincer, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Praticò, D.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3 signaling in Alzheimer’s disease</span>. <i>Biochim. Biophys. Acta, Mol. Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>1867</i></span>,  <span class="NLM_fpage">118664</span>, <span class="refDoi"> DOI: 10.1016/j.bbamcr.2020.118664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.bbamcr.2020.118664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=32006534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlCgt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1867&publication_year=2020&pages=118664&author=E.+Laurettiauthor=O.+Dincerauthor=D.+Pratic%C3%B2&title=Glycogen+synthase+kinase-3+signaling+in+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.bbamcr.2020.118664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase-3 signaling in Alzheimer's disease</span></div><div class="casAuthors">Lauretti, Elisabetta; Dincer, Ozlem; Pratico, Domenico</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">1867</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">118664</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) is the most common form of neurodegenerative disorder with dementia, accounting for approx. 70% of the all cases.  Currently, 5.8 million people in the U.  S. are living with AD and by 2050 this no. is expected to double resulting in a significant socio-economic burden.  Despite intensive research, the exact mechanisms that trigger AD are still not known and at the present there is no cure for it.  In recent years, many signaling pathways assocd. with AD neuropathol. have been explored as possible candidate targets for the treatment of this condition including glycogen synthase kinase-3β (GSK3-β).  GSK3-β is considered a key player in AD pathophysiol. since dysregulation of this kinase influences all the major hallmarks of the disease including: tau phosphorylation, amyloid-β prodn., memory, neurogenesis and synaptic function.  The present review summarizes the current understanding of the GSK3-β neurobiol. with particular emphasis on its effects on specific signaling pathways assocd. with AD pathophysiol.  Moreover, it discusses the feasibility of targeting GSK3-β for AD treatment and provides a summary of the current research effort to develop GSK3-β inhibitors in preclin. and clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMz18wal6wnbVg90H21EOLACvtfcHk0ljiFs7Pwl0d2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlCgt70%253D&md5=22881b36df641d995ec30e34737660ca</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2020.118664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2020.118664%26sid%3Dliteratum%253Aachs%26aulast%3DLauretti%26aufirst%3DE.%26aulast%3DDincer%26aufirst%3DO.%26aulast%3DPratic%25C3%25B2%26aufirst%3DD.%26atitle%3DGlycogen%2520synthase%2520kinase-3%2520signaling%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Res.%26date%3D2020%26volume%3D1867%26spage%3D118664%26doi%3D10.1016%2Fj.bbamcr.2020.118664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grundke-Iqbal, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tung, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinlan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisniewski, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binder, L. I.</span></span> <span> </span><span class="NLM_article-title">Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">4913</span>– <span class="NLM_lpage">4917</span>, <span class="refDoi"> DOI: 10.1073/pnas.83.13.4913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1073%2Fpnas.83.13.4913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=3088567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADyaL28XksFyqtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1986&pages=4913-4917&author=I.+Grundke-Iqbalauthor=K.+Iqbalauthor=Y.+C.+Tungauthor=M.+Quinlanauthor=H.+M.+Wisniewskiauthor=L.+I.+Binder&title=Abnormal+phosphorylation+of+the+microtubule-associated+protein+tau+%28tau%29+in+Alzheimer+cytoskeletal+pathology&doi=10.1073%2Fpnas.83.13.4913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Abnormal phosphorylation of the microtubule-associated protein τ (tau) in Alzheimer cytoskeletal pathology</span></div><div class="casAuthors">Grundke-Iqbal, Inge; Iqbal, Khalid; Tung, Yunn Chyn; Quinlan, Maureen; Wisniewski, Henryk M.; Binder, Lester I.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4913-17</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">A monoclonal antibody to the microtubule-assocd. protein τ (tau) labeled some neurofibrillary tangles and plaque neurites, the 2 major locations of paired-helical filaments (PHF), in Alzheimer disease brain.  The antibody also labeled isolated PHF that had been repeatedly washed with SDS.  Dephosphorylation of the tissue sections with alk. phosphatase prior to immunolabeling dramatically increased the no. of tangles and plaques recognized by the antibody.  The plaque core amyloid was not stained in either dephosphorylated or nondephosphorylated tissue sections.  On immunoblots PHF polypeptides were labeled readily only when dephosphorylated.  In contrast, a com. available monoclonal antibody to a phosphorylated epitope of neurofilaments that labeled the tangles and the plaque neurites in tissue did not label any PHF polypeptides on immunoblots.  The PHF polypeptides, labeled with the monoclonal antibody to τ, electrophoresed with those polypeptides recognized by antibodies to isolated PHF.  The antibody to τ labeled microtubules from normal human brains assembled in vitro but identically treated Alzheimer brain prepns. had to be dephosphorylated to be completely recognized by this antibody.  These findings suggest that τ in Alzheimer brain is an abnormally phosphorylated protein component of PHF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcyxbsq2aXprVg90H21EOLACvtfcHk0ljiFs7Pwl0d2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XksFyqtrg%253D&md5=3ac88b7002e26c53c54e71a3a91471ba</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.83.13.4913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.83.13.4913%26sid%3Dliteratum%253Aachs%26aulast%3DGrundke-Iqbal%26aufirst%3DI.%26aulast%3DIqbal%26aufirst%3DK.%26aulast%3DTung%26aufirst%3DY.%2BC.%26aulast%3DQuinlan%26aufirst%3DM.%26aulast%3DWisniewski%26aufirst%3DH.%2BM.%26aulast%3DBinder%26aufirst%3DL.%2BI.%26atitle%3DAbnormal%2520phosphorylation%2520of%2520the%2520microtubule-associated%2520protein%2520tau%2520%2528tau%2529%2520in%2520Alzheimer%2520cytoskeletal%2520pathology%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1986%26volume%3D83%26spage%3D4913%26epage%3D4917%26doi%3D10.1073%2Fpnas.83.13.4913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaidi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundke-Iqbal, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, K.</span></span> <span> </span><span class="NLM_article-title">Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">6923</span>– <span class="NLM_lpage">6928</span>, <span class="refDoi"> DOI: 10.1073/pnas.121119298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1073%2Fpnas.121119298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=11381127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD3MXksVOrsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=6923-6928&author=A.+Alonsoauthor=T.+Zaidiauthor=M.+Novakauthor=I.+Grundke-Iqbalauthor=K.+Iqbal&title=Hyperphosphorylation+induces+self-assembly+of+tau+into+tangles+of+paired+helical+filaments%2Fstraight+filaments&doi=10.1073%2Fpnas.121119298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Hyperphosphorylation induces self-assembly of τ into tangles of paired helical filaments/straight filaments</span></div><div class="casAuthors">Alonso, Alejandra Del C.; Zaidi, Tanweer; Novak, Michal; Grundke-Iqbal, Inge; Iqbal, Khalid</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">6923-6928</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The microtubule-assocd. protein τ is a family of six isoforms that becomes abnormally hyperphosphorylated and accumulates in the form of paired helical filaments (PHF) in the brains of patients with Alzheimer's disease (AD) and patients with several other tauopathies.  Here, we show that the abnormally hyperphosphorylated τ from AD brain cytosol (AD P-τ) self-aggregates into PHF-like structures on incubation at pH 6.9 under reducing conditions at 35° during 90 min.  In vitro dephosphorylation, but not deglycosylation, of AD P-τ inhibits its self-assocn. into PHF.  Furthermore, hyperphosphorylation induces self-assembly of each of the six τ isoforms into tangles of PHF and straight filaments, and the microtubule binding domains/repeats region in the absence of the rest of the mol. can also self-assemble into PHF.  Thus, it appears that τ self-assembles by assocn. of the microtubule binding domains/repeats and that the abnormal hyperphosphorylation promotes the self-assembly of τ into tangles of PHF and straight filaments by neutralizing the inhibitory basic charges of the flanking regions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotRjItZ2IrZrVg90H21EOLACvtfcHk0lg7gtP1xULkiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXksVOrsL8%253D&md5=358aed40bd36b81cb3bc1f8f5bc4bfed</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1073%2Fpnas.121119298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.121119298%26sid%3Dliteratum%253Aachs%26aulast%3DAlonso%26aufirst%3DA.%26aulast%3DZaidi%26aufirst%3DT.%26aulast%3DNovak%26aufirst%3DM.%26aulast%3DGrundke-Iqbal%26aufirst%3DI.%26aulast%3DIqbal%26aufirst%3DK.%26atitle%3DHyperphosphorylation%2520induces%2520self-assembly%2520of%2520tau%2520into%2520tangles%2520of%2520paired%2520helical%2520filaments%252Fstraight%2520filaments%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2001%26volume%3D98%26spage%3D6923%26epage%3D6928%26doi%3D10.1073%2Fpnas.121119298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morozova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ElIdrissi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleiman, F. E.</span></span> <span> </span><span class="NLM_article-title">Hyperphosphorylation of tau associates with changes in its function beyond microtubule stability</span>. <i>Front. Cell. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">338</span>, <span class="refDoi"> DOI: 10.3389/fncel.2018.00338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.3389%2Ffncel.2018.00338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=30356756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFyjt7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=338&author=A.+D.+Alonsoauthor=L.+S.+Cohenauthor=C.+Corboauthor=V.+Morozovaauthor=A.+ElIdrissiauthor=G.+Phillipsauthor=F.+E.+Kleiman&title=Hyperphosphorylation+of+tau+associates+with+changes+in+its+function+beyond+microtubule+stability&doi=10.3389%2Ffncel.2018.00338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Hyperphosphorylation of tau associates with changes in its function beyond microtubule stability</span></div><div class="casAuthors">Alonso, Alejandra D.; Cohen, Leah S.; Corbo, Christopher; Morozova, Viktoriya; ElIdrissi, Abdeslem; Phillips, Greg; Kleiman, Frida E.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Cellular Neuroscience</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">338</span>CODEN:
                <span class="NLM_cas:coden">FCNRAH</span>;
        ISSN:<span class="NLM_cas:issn">1662-5102</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Tau is a neuronal microtubule assocd. protein whose main biol. functions are to promote microtubule self-assembly by tubulin and to stabilize those already formed.  Tau also plays an important role as an axonal microtubule protein.  Tau is an amazing protein that plays a key role in cognitive processes, however, deposits of abnormal forms of tau are assocd. with several neurodegenerative diseases, including Alzheimer disease (AD), the most prevalent, and Chronic Traumatic Encephalopathy (CTE) and Traumatic Brain Injury (TBI), the most recently assocd. to abnormal tau.  Tau post-translational modifications (PTMs) are responsible for its gain of toxic function.  Alonso et al. were the first to show that the pathol. tau isolated from AD brains has prion-like properties and can transfer its toxic function to the normal mol.  Furthermore, we reported that the pathol. changes are assocd. with tau phosphorylation at Ser199 and 262 and Thr212 and 231.  This pathol. version of tau induces subcellular mislocalization in cultured cells and neurons, and translocates into the nucleus or accumulated in the perinuclear region of cells.  We have generated a transgenic mouse model that expresses pathol. human tau (PH-Tau) in neurons at two different concns. (4% and 14% of the total endogenous tau).  In this model, PH-Tau causes cognitive decline by at least two different mechanisms: one that involves the cytoskeleton with axonal disruption (at high concn.), and another in which the apparent neuronal morphol. is not grossly affected, but the synaptic terminals are altered (at lower concn.).  We will discuss the putative involvement of tau in proteostasis under these conditions.  Understanding tau's biol. activity on and off the microtubules will help shed light to the mechanism of neurodegeneration and of normal neuronal function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPUEgtgX4MvrVg90H21EOLACvtfcHk0lg7gtP1xULkiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFyjt7zK&md5=a898fe9a035a5b9e45afcc2ed5095bff</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.3389%2Ffncel.2018.00338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffncel.2018.00338%26sid%3Dliteratum%253Aachs%26aulast%3DAlonso%26aufirst%3DA.%2BD.%26aulast%3DCohen%26aufirst%3DL.%2BS.%26aulast%3DCorbo%26aufirst%3DC.%26aulast%3DMorozova%26aufirst%3DV.%26aulast%3DElIdrissi%26aufirst%3DA.%26aulast%3DPhillips%26aufirst%3DG.%26aulast%3DKleiman%26aufirst%3DF.%2BE.%26atitle%3DHyperphosphorylation%2520of%2520tau%2520associates%2520with%2520changes%2520in%2520its%2520function%2520beyond%2520microtubule%2520stability%26jtitle%3DFront.%2520Cell.%2520Neurosci.%26date%3D2018%26volume%3D12%26spage%3D338%26doi%3D10.3389%2Ffncel.2018.00338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jicha, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otvos, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, P.</span></span> <span> </span><span class="NLM_article-title">A conformation- and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer’s disease</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">2087</span>– <span class="NLM_lpage">2095</span>, <span class="refDoi"> DOI: 10.1046/j.1471-4159.1997.69052087.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1046%2Fj.1471-4159.1997.69052087.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=9349554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADyaK2sXmvVKktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=1997&pages=2087-2095&author=G.+A.+Jichaauthor=E.+Laneauthor=I.+Vincentauthor=L.+Otvosauthor=R.+Hoffmannauthor=P.+Davies&title=A+conformation-+and+phosphorylation-dependent+antibody+recognizing+the+paired+helical+filaments+of+Alzheimer%E2%80%99s+disease&doi=10.1046%2Fj.1471-4159.1997.69052087.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">A conformation- and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer's disease</span></div><div class="casAuthors">Jicha, Gregory A.; Lane, Eric; Vincent, Inez; Otvos, Laszlo, Jr.; Hoffmann, Ralf; Davies, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2087-2095</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Lippincott-Raven</span>)
        </div><div class="casAbstract">Hyperphosphorylated tau (PHF-tau) is the major constituent of paired helical filaments (PHFs) from Alzheimer's disease (AD) brains.  This conclusion has been based largely on the creation and characterization of monoclonal antibodies raised against PHFs, which can be classified in three categories: (a) those recognizing unmodified primary sequences of tau, (b) those recognizing phosphorylation-dependent epitopes on tau, and (c) those recognizing conformation-dependent epitopes on tau.  Recent studies have suggested that the antibodies recognizing primary sequence and phosphorylation-dependent epitopes on tau are unable to distinguish between normal adult biopsy tau and PHF-tau.  We now present evidence for a new fourth class of monoclonal antibodies recognizing conformation-dependent phosphoepitopes on tau, typified by TG-3, a monoclonal antibody raised to PHFs from AD brain homogenates.  Studies using a series of deletional tau mutants, site-directed tau mutants, and synthetic peptides enable the precise epitope mapping of TG-3.  Addnl. studies demonstrate that TG-3 reacts with neonatal mouse tau and PHF-tau but does not recognize adult mouse tau or tau derived from normal human autopsy or biopsy tissue.  Further investigation reveals that TG-3 recognizes a unique conformation of tau found almost exclusively in PHFs from AD brains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfjT9MtA9FrbVg90H21EOLACvtfcHk0lg7gtP1xULkiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmvVKktrc%253D&md5=6668245383d37d5d5d2272033aa40e4f</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.1997.69052087.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.1997.69052087.x%26sid%3Dliteratum%253Aachs%26aulast%3DJicha%26aufirst%3DG.%2BA.%26aulast%3DLane%26aufirst%3DE.%26aulast%3DVincent%26aufirst%3DI.%26aulast%3DOtvos%26aufirst%3DL.%26aulast%3DHoffmann%26aufirst%3DR.%26aulast%3DDavies%26aufirst%3DP.%26atitle%3DA%2520conformation-%2520and%2520phosphorylation-dependent%2520antibody%2520recognizing%2520the%2520paired%2520helical%2520filaments%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Neurochem.%26date%3D1997%26volume%3D69%26spage%3D2087%26epage%3D2095%26doi%3D10.1046%2Fj.1471-4159.1997.69052087.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gamblin, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zambrano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagalwar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillozet, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Sierra, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaPointe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binder, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cryns, V. L.</span></span> <span> </span><span class="NLM_article-title">Caspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer’s disease</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">10032</span>– <span class="NLM_lpage">10037</span>, <span class="refDoi"> DOI: 10.1073/pnas.1630428100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1073%2Fpnas.1630428100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=12888622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvVeisrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=10032-10037&author=T.+C.+Gamblinauthor=F.+Chenauthor=A.+Zambranoauthor=A.+Abrahaauthor=S.+Lagalwarauthor=A.+L.+Guillozetauthor=M.+Luauthor=Y.+Fuauthor=F.+Garcia-Sierraauthor=N.+LaPointeauthor=R.+Millerauthor=R.+W.+Berryauthor=L.+I.+Binderauthor=V.+L.+Cryns&title=Caspase+cleavage+of+tau%3A+Linking+amyloid+and+neurofibrillary+tangles+in+Alzheimer%E2%80%99s+disease&doi=10.1073%2Fpnas.1630428100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Caspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer's disease</span></div><div class="casAuthors">Gamblin, T. Chris; Chen, Feng; Zambrano, Angara; Abraha, Aida; Lagalwar, Sarita; Guillozet, Angela L.; Lu, Meiling; Fu, Yifan; Garcia-Sierra, Francisco; LaPointe, Nichole; Miller, Richard; Berry, Robert W.; Binder, Lester I.; Cryns, Vincent L.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">10032-10037</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The principal pathol. features of Alzheimer's disease (AD) are extracellular amyloid plaques and intracellular neurofibrillary tangles, the latter composed of the microtubule-binding protein tau assembled into paired helical and straight filaments.  Recent studies suggest that these pathol. entities may be functionally linked, although the mechanisms by which amyloid deposition promotes pathol. tau filament assembly are poorly understood.  Here, we report that tau is proteolyzed by multiple caspases at a highly conserved aspartate residue (Asp421) in its C terminus in vitro and in neurons treated with amyloid-β (Aβ) (1-42) peptide.  Tau is rapidly cleaved at Asp421 in Aβ-treated neurons (within 2 h), and its proteolysis appears to precede the nuclear events of apoptosis.  We also demonstrate that caspase cleavage of tau generates a truncated protein that lacks its C-terminal 20 amino acids and assembles more rapidly and more extensively into tau filaments in vitro than wild-type tau.  Using a monoclonal antibody that specifically recognizes tau truncated at Asp421, we show that tau is proteolytically cleaved at this site in the fibrillar pathologies of AD brain.  Taken together, our results suggest a novel mechanism linking amyloid deposition and neurofibrillary tangles in AD: Aβ peptides promote pathol. tau filament assembly in neurons by triggering caspase cleavage of tau and generating a proteolytic product with enhanced polymn. kinetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTQ2uuzOCOcLVg90H21EOLACvtfcHk0lgw6fOxJXutQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvVeisrc%253D&md5=0b11eb04bfa16794ef3e207e88fd4a35</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1630428100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1630428100%26sid%3Dliteratum%253Aachs%26aulast%3DGamblin%26aufirst%3DT.%2BC.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DZambrano%26aufirst%3DA.%26aulast%3DAbraha%26aufirst%3DA.%26aulast%3DLagalwar%26aufirst%3DS.%26aulast%3DGuillozet%26aufirst%3DA.%2BL.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DFu%26aufirst%3DY.%26aulast%3DGarcia-Sierra%26aufirst%3DF.%26aulast%3DLaPointe%26aufirst%3DN.%26aulast%3DMiller%26aufirst%3DR.%26aulast%3DBerry%26aufirst%3DR.%2BW.%26aulast%3DBinder%26aufirst%3DL.%2BI.%26aulast%3DCryns%26aufirst%3DV.%2BL.%26atitle%3DCaspase%2520cleavage%2520of%2520tau%253A%2520Linking%2520amyloid%2520and%2520neurofibrillary%2520tangles%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2003%26volume%3D100%26spage%3D10032%26epage%3D10037%26doi%3D10.1073%2Fpnas.1630428100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Magi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castaldo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macrì, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiolino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matteucci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastioli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gratteri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amoroso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lariccia, V.</span></span> <span> </span><span class="NLM_article-title">Intracellular calcium dysregulation: Implications for Alzheimer’s disease</span>. <i>BioMed Res. Int.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2016</i></span>,  <span class="NLM_fpage">6701324</span>, <span class="refDoi"> DOI: 10.1155/2016/6701324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1155%2F2016%2F6701324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=27340665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BC2s7js1WltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2016&publication_year=2016&pages=6701324&author=S.+Magiauthor=P.+Castaldoauthor=M.+L.+Macr%C3%ACauthor=M.+Maiolinoauthor=A.+Matteucciauthor=G.+Bastioliauthor=S.+Gratteriauthor=S.+Amorosoauthor=V.+Lariccia&title=Intracellular+calcium+dysregulation%3A+Implications+for+Alzheimer%E2%80%99s+disease&doi=10.1155%2F2016%2F6701324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular Calcium Dysregulation: Implications for Alzheimer's Disease</span></div><div class="casAuthors">Magi Simona; Castaldo Pasqualina; Macri Maria Loredana; Maiolino Marta; Matteucci Alessandra; Bastioli Guendalina; Amoroso Salvatore; Lariccia Vincenzo; Gratteri Santo</div><div class="citationInfo"><span class="NLM_cas:title">BioMed research international</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2016</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6701324</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Alzheimer's Disease (AD) is a neurodegenerative disorder characterized by progressive neuronal loss.  AD is associated with aberrant processing of the amyloid precursor protein, which leads to the deposition of amyloid-β plaques within the brain.  Together with plaques deposition, the hyperphosphorylation of the microtubules associated protein tau and the formation of intraneuronal neurofibrillary tangles are a typical neuropathological feature in AD brains.  Cellular dysfunctions involving specific subcellular compartments, such as mitochondria and endoplasmic reticulum (ER), are emerging as crucial players in the pathogenesis of AD, as well as increased oxidative stress and dysregulation of calcium homeostasis.  Specifically, dysregulation of intracellular calcium homeostasis has been suggested as a common proximal cause of neural dysfunction in AD.  Aberrant calcium signaling has been considered a phenomenon mainly related to the dysfunction of intracellular calcium stores, which can occur in both neuronal and nonneuronal cells.  This review reports the most recent findings on cellular mechanisms involved in the pathogenesis of AD, with main focus on the control of calcium homeostasis at both cytosolic and mitochondrial level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRyi3EPEOXNOUwlCcfExbvbfW6udTcc2eYQETaWICQESLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7js1WltA%253D%253D&md5=962cd2ab1a8d825fe85291003880edf9</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1155%2F2016%2F6701324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2016%252F6701324%26sid%3Dliteratum%253Aachs%26aulast%3DMagi%26aufirst%3DS.%26aulast%3DCastaldo%26aufirst%3DP.%26aulast%3DMacr%25C3%25AC%26aufirst%3DM.%2BL.%26aulast%3DMaiolino%26aufirst%3DM.%26aulast%3DMatteucci%26aufirst%3DA.%26aulast%3DBastioli%26aufirst%3DG.%26aulast%3DGratteri%26aufirst%3DS.%26aulast%3DAmoroso%26aufirst%3DS.%26aulast%3DLariccia%26aufirst%3DV.%26atitle%3DIntracellular%2520calcium%2520dysregulation%253A%2520Implications%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DBioMed%2520Res.%2520Int.%26date%3D2016%26volume%3D2016%26spage%3D6701324%26doi%3D10.1155%2F2016%2F6701324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spires-Jones, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoothoff, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Calignon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, B. T.</span></span> <span> </span><span class="NLM_article-title">Tau pathophysiology in neurodegeneration: A tangled issue</span>. <i>Trends Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">150</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1016/j.tins.2008.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.tins.2008.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=19162340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFOns70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2009&pages=150-159&author=T.+L.+Spires-Jonesauthor=W.+H.+Stoothoffauthor=A.+de+Calignonauthor=P.+B.+Jonesauthor=B.+T.+Hyman&title=Tau+pathophysiology+in+neurodegeneration%3A+A+tangled+issue&doi=10.1016%2Fj.tins.2008.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Tau pathophysiology in neurodegeneration: a tangled issue</span></div><div class="casAuthors">Spires-Jones, Tara L.; Stoothoff, William H.; de Calignon, Alix; Jones, Phillip B.; Hyman, Bradley T.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Neurosciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">150-159</span>CODEN:
                <span class="NLM_cas:coden">TNSCDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-2236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Neurodegenerative tauopathies are marked by their common pathol. feature of aggregates formed of hyperphosphorylated tau protein, which are assocd. with synapse and neuronal loss.  Changes in tau conformation result in both loss of normal function and gain of fibrillogenicity that leads to aggregation.  Here, we discuss the pathophysiol. of tau and emerging evidence of how changes in this protein might ultimately lead to neuronal death.  In particular, based on recent evidence, we propose that a non-apoptotic caspase-assocd. form of death is occurring in tauopathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfJH0otFZPurVg90H21EOLACvtfcHk0lhaoLCeNVMbBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFOns70%253D&md5=2de93205966e73aaa20a2010d55a59f6</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.tins.2008.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tins.2008.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DSpires-Jones%26aufirst%3DT.%2BL.%26aulast%3DStoothoff%26aufirst%3DW.%2BH.%26aulast%3Dde%2BCalignon%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DP.%2BB.%26aulast%3DHyman%26aufirst%3DB.%2BT.%26atitle%3DTau%2520pathophysiology%2520in%2520neurodegeneration%253A%2520A%2520tangled%2520issue%26jtitle%3DTrends%2520Neurosci.%26date%3D2009%26volume%3D32%26spage%3D150%26epage%3D159%26doi%3D10.1016%2Fj.tins.2008.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ash, P. E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maziuk, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballance, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boudeau, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdullatif, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlando, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrucelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikezu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolozin, B.</span></span> <span> </span><span class="NLM_article-title">TIA1 regulates the generation and response to toxic tau oligomers</span>. <i>Acta Neuropathol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">259</span>– <span class="NLM_lpage">277</span>, <span class="refDoi"> DOI: 10.1007/s00401-018-1937-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1007%2Fs00401-018-1937-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=30465259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlCmtLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2019&pages=259-277&author=L.+Jiangauthor=P.+E.+A.+Ashauthor=B.+F.+Maziukauthor=H.+I.+Ballanceauthor=S.+Boudeauauthor=A.+A.+Abdullatifauthor=M.+Orlandoauthor=L.+Petrucelliauthor=T.+Ikezuauthor=B.+Wolozin&title=TIA1+regulates+the+generation+and+response+to+toxic+tau+oligomers&doi=10.1007%2Fs00401-018-1937-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">TIA1 regulates the generation and response to toxic tau oligomers</span></div><div class="casAuthors">Jiang, Lulu; Ash, Peter E. A.; Maziuk, Brandon F.; Ballance, Heather I.; Boudeau, Samantha; Abdullatif, Ali Al; Orlando, Marcello; Petrucelli, Leonard; Ikezu, Tsuneya; Wolozin, Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Neuropathologica</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">259-277</span>CODEN:
                <span class="NLM_cas:coden">ANPTAL</span>;
        ISSN:<span class="NLM_cas:issn">0001-6322</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">RNA binding proteins (RBPs) are strongly linked to the pathophysiol. of motor neuron diseases.  Recent studies show that RBPs, such as TIA1, also contribute to the pathophysiol. of tauopathy.  RBPs co-localize with tau pathol., and redn. of TIA1 protects against tau-mediated neurodegeneration.  The mechanism through which TIA1 redn. protects against tauopathy, and whether TIA1 modulates the propagation of tau, are unknown.  Previous studies indicate that the protective effect of TIA1 depletion correlates with both the redn. of oligomeric tau and the redn. of pathol. TIA1 pos. tau inclusions.  In the current report, we used a novel tau propagation approach to test whether TIA1 is required for producing toxic tau oligomers and whether TIA1 redn. would provide protection against the spread of these oligomers.  The approach used young PS19 P301S tau mice at an age at which neurodegeneration would normally not yet occur and seeding oligomeric or fibrillar tau by injection into hippocampal CA1 region.  We find that propagation of exogenous tau oligomers (but not fibrils) across the brain drives neurodegeneration in this model.  We demonstrate that TIA1 redn. essentially brackets the pathophysiol. of tau, being required for the prodn. of tau oligomers, as well as regulating the response of neurons to propagated toxic tau oligomers.  These results indicate that RNA binding proteins modulate the pathophysiol. of tau at multiple levels and provide insights into possible therapeutic approaches to reduce the spread of neurodegeneration in tauopathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1CgtEBal-g7Vg90H21EOLACvtfcHk0lhaoLCeNVMbBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlCmtLjF&md5=ee7ea3652391188cc212876ecca80c2e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1007%2Fs00401-018-1937-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00401-018-1937-5%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DAsh%26aufirst%3DP.%2BE.%2BA.%26aulast%3DMaziuk%26aufirst%3DB.%2BF.%26aulast%3DBallance%26aufirst%3DH.%2BI.%26aulast%3DBoudeau%26aufirst%3DS.%26aulast%3DAbdullatif%26aufirst%3DA.%2BA.%26aulast%3DOrlando%26aufirst%3DM.%26aulast%3DPetrucelli%26aufirst%3DL.%26aulast%3DIkezu%26aufirst%3DT.%26aulast%3DWolozin%26aufirst%3DB.%26atitle%3DTIA1%2520regulates%2520the%2520generation%2520and%2520response%2520to%2520toxic%2520tau%2520oligomers%26jtitle%3DActa%2520Neuropathol.%26date%3D2019%26volume%3D137%26spage%3D259%26epage%3D277%26doi%3D10.1007%2Fs00401-018-1937-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kopeikina, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spires-Jones, T. L.</span></span> <span> </span><span class="NLM_article-title">Soluble forms of tau are toxic in Alzheimer’s disease</span>. <i>Transl. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.2478/s13380-012-0032-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.2478%2Fs13380-012-0032-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=23029602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BC2sris1Sntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=223-233&author=K.+J.+Kopeikinaauthor=B.+T.+Hymanauthor=T.+L.+Spires-Jones&title=Soluble+forms+of+tau+are+toxic+in+Alzheimer%E2%80%99s+disease&doi=10.2478%2Fs13380-012-0032-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble forms of tau are toxic in Alzheimer's disease</span></div><div class="casAuthors">Kopeikina Katherine J; Hyman Bradley T; Spires-Jones Tara L</div><div class="citationInfo"><span class="NLM_cas:title">Translational neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">223-233</span>
        ISSN:<span class="NLM_cas:issn">2081-3856</span>.
    </div><div class="casAbstract">Accumulation of neurofibrillary tangles (NFT), intracellular inclusions of fibrillar forms of tau, is a hallmark of Alzheimer Disease.  NFT have been considered causative of neuronal death, however, recent evidence challenges this idea.  Other species of tau, such as soluble misfolded, hyperphosphorylated, and mislocalized forms, are now being implicated as toxic.  Here we review the data supporting soluble tau as toxic to neurons and synapses in the brain and the implications of these data for development of therapeutic strategies for Alzheimer's disease and other tauopathies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSGcnTbQFS8PHWEEzDrymxmfW6udTcc2eba_Jp7CrU7a7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sris1Sntw%253D%253D&md5=4536d9d10f37dc659ba09d309a41152c</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.2478%2Fs13380-012-0032-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2478%252Fs13380-012-0032-y%26sid%3Dliteratum%253Aachs%26aulast%3DKopeikina%26aufirst%3DK.%2BJ.%26aulast%3DHyman%26aufirst%3DB.%2BT.%26aulast%3DSpires-Jones%26aufirst%3DT.%2BL.%26atitle%3DSoluble%2520forms%2520of%2520tau%2520are%2520toxic%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DTransl.%2520Neurosci.%26date%3D2012%26volume%3D3%26spage%3D223%26epage%3D233%26doi%3D10.2478%2Fs13380-012-0032-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jaworski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kügler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Leuven, F.</span></span> <span> </span><span class="NLM_article-title">Modeling of tau-mediated synaptic and neuronal degeneration in Alzheimer’s disease</span>. <i>Int. J. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_fpage">573138</span>, <span class="refDoi"> DOI: 10.4061/2010/573138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.4061%2F2010%2F573138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=20862366" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&pages=573138&author=T.+Jaworskiauthor=S.+K%C3%BCglerauthor=F.+Van+Leuven&title=Modeling+of+tau-mediated+synaptic+and+neuronal+degeneration+in+Alzheimer%E2%80%99s+disease&doi=10.4061%2F2010%2F573138"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.4061%2F2010%2F573138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4061%252F2010%252F573138%26sid%3Dliteratum%253Aachs%26aulast%3DJaworski%26aufirst%3DT.%26aulast%3DK%25C3%25BCgler%26aufirst%3DS.%26aulast%3DVan%2BLeuven%26aufirst%3DF.%26atitle%3DModeling%2520of%2520tau-mediated%2520synaptic%2520and%2520neuronal%2520degeneration%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DInt.%2520J.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2010%26spage%3D573138%26doi%3D10.4061%2F2010%2F573138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Twohig, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, H. M.</span></span> <span> </span><span class="NLM_article-title">α-synuclein in the pathophysiology of Alzheimer’s disease</span>. <i>Mol. Neurodegener.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">23</span>, <span class="refDoi"> DOI: 10.1186/s13024-019-0320-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1186%2Fs13024-019-0320-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=31186026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BB3M3lsVGksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=23&author=D.+Twohigauthor=H.+M.+Nielsen&title=%CE%B1-synuclein+in+the+pathophysiology+of+Alzheimer%E2%80%99s+disease&doi=10.1186%2Fs13024-019-0320-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">α-synuclein in the pathophysiology of Alzheimer's disease</span></div><div class="casAuthors">Twohig Daniel; Nielsen Henrietta M</div><div class="citationInfo"><span class="NLM_cas:title">Molecular neurodegeneration</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Alzheimer's disease (AD) afflicted brain is neuropathologically defined by extracellular amyloid-β (Aβ) plaques and intraneuronal neurofibrillary tangles composed of hyperphosphorylated tau protein.  However, accumulating evidence suggests that the presynaptic protein α-synuclein (αSyn), mainly associated with synucleinopathies like Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA), is involved in the pathophysiology of AD.  Lewy-related pathology (LRP), primarily comprised of αSyn, is present in a majority of autopsied AD brains, and higher levels of αSyn in the cerebrospinal fluid (CSF) of patients with mild cognitive impairment (MCI) and AD have been linked to cognitive decline.  Recent studies also suggest that the asymptomatic accumulation of Aβ plaques is associated with higher CSF αSyn levels in subjects at risk of sporadic AD and in individuals carrying autosomal dominant AD mutations.  Experimental evidence has further linked αSyn mainly to tau hyperphosphorylation, but also to the pathological actions of Aβ and the APOEε4 allele, the latter being a major genetic risk factor for both AD and DLB.  In this review, we provide a summary of the current evidence proposing an involvement of αSyn either as an active or passive player in the pathophysiological ensemble of AD, and furthermore describe in detail the current knowledge of αSyn structure and inferred function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJvFbWKSujKyO2kE7krGOBfW6udTcc2ebk9icMDtSdcLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3lsVGksA%253D%253D&md5=3dd826d6335e986ef9f4959ea82c0f64</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1186%2Fs13024-019-0320-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13024-019-0320-x%26sid%3Dliteratum%253Aachs%26aulast%3DTwohig%26aufirst%3DD.%26aulast%3DNielsen%26aufirst%3DH.%2BM.%26atitle%3D%25CE%25B1-synuclein%2520in%2520the%2520pathophysiology%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DMol.%2520Neurodegener.%26date%3D2019%26volume%3D14%26spage%3D23%26doi%3D10.1186%2Fs13024-019-0320-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sengupta, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilson, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayed, R.</span></span> <span> </span><span class="NLM_article-title">The role of amyloid-β oligomers in toxicity, propagation, and immunotherapy</span>. <i>EBioMedicine</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">42</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.1016/j.ebiom.2016.03.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.ebiom.2016.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=27211547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FisVKisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=42-49&author=U.+Senguptaauthor=A.+N.+Nilsonauthor=R.+Kayed&title=The+role+of+amyloid-%CE%B2+oligomers+in+toxicity%2C+propagation%2C+and+immunotherapy&doi=10.1016%2Fj.ebiom.2016.03.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy</span></div><div class="casAuthors">Sengupta Urmi; Nilson Ashley N; Kayed Rakez</div><div class="citationInfo"><span class="NLM_cas:title">EBioMedicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">42-49</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The incidence of Alzheimer's disease (AD) is growing every day and finding an effective treatment is becoming more vital.  Amyloid-β (Aβ) has been the focus of research for several decades.  The recent shift in the Aβ cascade hypothesis from all Aβ to small soluble oligomeric intermediates is directing the search for therapeutics towards the toxic mediators of the disease.  Targeting the most toxic oligomers may prove to be an effective treatment by preventing their spread.  Specific targeting of oligomers has been shown to protect cognition in rodent models.  Additionally, the heterogeneity of research on Aβ oligomers may seem contradictory until size and conformation are taken into account.  In this review, we will discuss Aβ oligomers and their toxicity in relation to size and conformation as well as their influence on inflammation and the potential of Aβ oligomer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmiQSE8_179zslzEEsg76ufW6udTcc2ebk9icMDtSdcLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FisVKisA%253D%253D&md5=5b2a9f3283846038e653cca6731fa90f</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.ebiom.2016.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ebiom.2016.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DSengupta%26aufirst%3DU.%26aulast%3DNilson%26aufirst%3DA.%2BN.%26aulast%3DKayed%26aufirst%3DR.%26atitle%3DThe%2520role%2520of%2520amyloid-%25CE%25B2%2520oligomers%2520in%2520toxicity%252C%2520propagation%252C%2520and%2520immunotherapy%26jtitle%3DEBioMedicine%26date%3D2016%26volume%3D6%26spage%3D42%26epage%3D49%26doi%3D10.1016%2Fj.ebiom.2016.03.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bousset, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otzen, D. E.</span></span> <span> </span><span class="NLM_article-title">α-synuclein oligomers and fibrils: A spectrum of species, a spectrum of toxicities</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">522</span>– <span class="NLM_lpage">534</span>, <span class="refDoi"> DOI: 10.1111/jnc.14808</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1111%2Fjnc.14808" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=31254394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFSgsrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2019&pages=522-534&author=P.+Alamauthor=L.+Boussetauthor=R.+Melkiauthor=D.+E.+Otzen&title=%CE%B1-synuclein+oligomers+and+fibrils%3A+A+spectrum+of+species%2C+a+spectrum+of+toxicities&doi=10.1111%2Fjnc.14808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">α-synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities</span></div><div class="casAuthors">Alam, Parvez; Bousset, Luc; Melki, Ronald; Otzen, Daniel E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">522-534</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  This review article provides an overview of the different species that α-synuclein aggregates can populate.  It also attempts to reconcile conflicting views regarding the cytotoxic roles of oligomers vs. fibrils. α-synuclein, while highly dynamic in the monomeric state, can access a large no. of different assembly states.  Depending on assembly conditions, these states can interconvert over different timescales.  The fibrillar state is the most thermodynamically favored due to the many stabilizing interactions formed between each monomeric unit, but different fibrillar types form at different rates.  The end distribution is likely to reflect kinetic partitioning as much as thermodn. equilibra.  In addn., metastable oligomeric species, some of which are on-pathway and others off-pathway, can be populated for remarkably long periods of time.  Chem. modifications (phosphorylation, oxidn., covalent links to ligands, etc.) perturb these phys. interconversions and invariably destabilize the fibrillar state, leading to small prefibrillar assemblies which can coalesce into amorphous states.  Both oligomeric and fibrillar species have been shown to be cytotoxic although firm conclusions require very careful evaluation of particle concns. and is complicated by the great variety and heterogeneity of different exptl. obsd. states.  The mechanistic relationship between oligomers and fibrils remains to be clarified, both in terms of assembly of oligomers into fibrils and potential dissoln. of fibrils into oligomers.  While oligomers are possibly implicated in the collapse of neuronal homeostasis, the fibrillar state(s) appears to be the most efficient at propagating itself both in vitro and in vivo, pointing to crit. roles for multiple different aggregate species in the progression of Parkinson's disease ().</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq19WdmbXPwT7Vg90H21EOLACvtfcHk0lgXNZGtORM40w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFSgsrnF&md5=8e80c1d5f545bb95f162791356ad7e35</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1111%2Fjnc.14808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjnc.14808%26sid%3Dliteratum%253Aachs%26aulast%3DAlam%26aufirst%3DP.%26aulast%3DBousset%26aufirst%3DL.%26aulast%3DMelki%26aufirst%3DR.%26aulast%3DOtzen%26aufirst%3DD.%2BE.%26atitle%3D%25CE%25B1-synuclein%2520oligomers%2520and%2520fibrils%253A%2520A%2520spectrum%2520of%2520species%252C%2520a%2520spectrum%2520of%2520toxicities%26jtitle%3DJ.%2520Neurochem.%26date%3D2019%26volume%3D150%26spage%3D522%26epage%3D534%26doi%3D10.1111%2Fjnc.14808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thal, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rüb, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Günzel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zedlick, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schober, R.</span></span> <span> </span><span class="NLM_article-title">Alzheimer-related tau-pathology in the perforant path target zone and in the hippocampal stratum oriens and radiatum correlates with onset and degree of dementia</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">98</span>– <span class="NLM_lpage">110</span>, <span class="refDoi"> DOI: 10.1006/exnr.2000.7380</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1006%2Fexnr.2000.7380" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10785448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD3cXislCntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2000&pages=98-110&author=D.+R.+Thalauthor=M.+Holzerauthor=U.+R%C3%BCbauthor=G.+Waldmannauthor=S.+G%C3%BCnzelauthor=D.+Zedlickauthor=R.+Schober&title=Alzheimer-related+tau-pathology+in+the+perforant+path+target+zone+and+in+the+hippocampal+stratum+oriens+and+radiatum+correlates+with+onset+and+degree+of+dementia&doi=10.1006%2Fexnr.2000.7380"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Alzheimer-related τ-pathology in the perforant path target zone and in the hippocampal stratum oriens and radiatum correlates with onset and degree of dementia</span></div><div class="casAuthors">Thal, Dietmar Rudolf; Holzer, Max; Rub, Udo; Waldmann, Guido; Gunzel, Steffen; Zedlick, Dyrk; Schober, Ralf</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">98-110</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Abnormal phosphorylation of the τ-protein is regarded as a crucial step in the formation of neurofibrillary tangles in the neuronal cell body and neuropil threads in dendrites.  The authors studied the effects of τ-pathol. on the clin. expression of dementia in 106 autopsy cases in the entorhinal region, the hippocampal stratum oriens, the stratum radiatum, and the perforant path target zone.  The first cytoskeletal lesions were located in the perikarya and dendrites of the pre-α cells of the transentorhinal and entorhinal region.  Next, abnormally phosphorylated τ-protein (PHF-τ) was found in the neuropil of the CA1-subiculum region.  Thereafter, the stratum radiatum and stratum oriens began to be involved in PHF-τ pathol. in Braak stage II.  In the Braak stages IV and V, the stratum radiatum was completely involved, the stratum oriens increasingly so.  Beginning in Braak stage III, cases having PHF-τ pathol. in the perforant path target zone of the outer mol. layer of the dentate gyrus were noted.  The increase of this pathol. with ever greater involvement on the part of the entorhinohippocampal circuit correlated not only with the Braak stages and with the neurochem. detd. hippocampal content of PHF-τ but also with the degree of dementia as defined by the clin. dementia rating (CDR) scale.  The affection of the stratum oriens in combination with PHF-τ pathol. in the stratum radiatum and in the outer mol. layer of the dentate gyrus was encountered almost exclusively in demented individuals (CDR 1-3).  Thus, axonal PHF-τ pathol. in hippocampal pathways is presumably crit. for the clin. expression of dementia and may constitute an anatomical substrate of clin. verifiable memory dysfunction in Alzheimer's disease.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7MnZIS60L_LVg90H21EOLACvtfcHk0lho22kLwahvpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXislCntr4%253D&md5=d01e074dd528ef1dbcce4f08a9abe7f4</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1006%2Fexnr.2000.7380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fexnr.2000.7380%26sid%3Dliteratum%253Aachs%26aulast%3DThal%26aufirst%3DD.%2BR.%26aulast%3DHolzer%26aufirst%3DM.%26aulast%3DR%25C3%25BCb%26aufirst%3DU.%26aulast%3DWaldmann%26aufirst%3DG.%26aulast%3DG%25C3%25BCnzel%26aufirst%3DS.%26aulast%3DZedlick%26aufirst%3DD.%26aulast%3DSchober%26aufirst%3DR.%26atitle%3DAlzheimer-related%2520tau-pathology%2520in%2520the%2520perforant%2520path%2520target%2520zone%2520and%2520in%2520the%2520hippocampal%2520stratum%2520oriens%2520and%2520radiatum%2520correlates%2520with%2520onset%2520and%2520degree%2520of%2520dementia%26jtitle%3DExp.%2520Neurol.%26date%3D2000%26volume%3D163%26spage%3D98%26epage%3D110%26doi%3D10.1006%2Fexnr.2000.7380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goedert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klug, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowther, R. A.</span></span> <span> </span><span class="NLM_article-title">Tau protein, the paired helical filament and Alzheimer’s disease</span>. <i>J. Alzheimer's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">207</span>, <span class="refDoi"> DOI: 10.3233/JAD-2006-9S323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.3233%2FJAD-2006-9S323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=16914859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD28XotFKktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2006&pages=195-207&author=M.+Goedertauthor=A.+Klugauthor=R.+A.+Crowther&title=Tau+protein%2C+the+paired+helical+filament+and+Alzheimer%E2%80%99s+disease&doi=10.3233%2FJAD-2006-9S323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Tau protein, the paired helical filament and Alzheimer's disease</span></div><div class="casAuthors">Goedert, Michel; Klug, Aaron; Crowther, R. Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">Suppl. 3</span>),
    <span class="NLM_cas:pages">195-207</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">A review.  In 1906, Alzheimer described the clin. and neuropathol. characteristics of the disease that was subsequently named after him.  Although the paired helical filament was identified as the major component of the neurofibrillary pathol. of Alzheimer's disease in 1963, its mol. compn. was only uncovered in the 1980s.  In 1988, work at the MRC Lab. of Mol. Biol. in Cambridge (UK) provided direct proof that tau protein is an integral component of the paired helical filament.  The paper highlighted here [Goedert M., Wischik C.M., Crowther R.A., Walker J.E. and Klug A. (1988) Cloning and sequencing of a core protein of the paired helical filament of Alzheimer disease: Identification as the microtubule-assocd. protein tau. Proc. Natl. Acad. Sci. USA 85, 4051-4055] also reported the first sequence of a human tau isoform and paved the way for the identification of the six brain tau isoforms that are expressed by alternative mRNA splicing from a single gene.  By the early 1990s, it was clear that tau protein is the major component of the paired helical filament and that the latter is made of all six tau isoforms, each full-length and hyperphosphorylated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGray90MZn-vsrVg90H21EOLACvtfcHk0lho22kLwahvpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotFKktb8%253D&md5=771b173ae0abf27ecca786094c932931</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.3233%2FJAD-2006-9S323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-2006-9S323%26sid%3Dliteratum%253Aachs%26aulast%3DGoedert%26aufirst%3DM.%26aulast%3DKlug%26aufirst%3DA.%26aulast%3DCrowther%26aufirst%3DR.%2BA.%26atitle%3DTau%2520protein%252C%2520the%2520paired%2520helical%2520filament%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Alzheimer%2527s%2520Dis.%26date%3D2006%26volume%3D9%26spage%3D195%26epage%3D207%26doi%3D10.3233%2FJAD-2006-9S323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knowles, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vendruscolo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobson, C. M.</span></span> <span> </span><span class="NLM_article-title">The amyloid state and its association with protein misfolding diseases</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">384</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.1038/nrm3810</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2Fnrm3810" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=24854788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosV2lurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=384-396&author=T.+P.+Knowlesauthor=M.+Vendruscoloauthor=C.+M.+Dobson&title=The+amyloid+state+and+its+association+with+protein+misfolding+diseases&doi=10.1038%2Fnrm3810"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">The amyloid state and its association with protein misfolding diseases</span></div><div class="casAuthors">Knowles, Tuomas P. J.; Vendruscolo, Michele; Dobson, Christopher M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">384-396</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The phenomenon of protein aggregation and amyloid formation has become the subject of rapidly increasing research activities across a wide range of scientific disciplines.  Such activities have been stimulated by the assocn. of amyloid deposition with a range of debilitating medical disorders, from Alzheimer's disease to type II diabetes, many of which are major threats to human health and welfare in the modern world.  It has become clear, however, that the ability to form the amyloid state is more general than previously imagined, and that its study can provide unique insights into the nature of the functional forms of peptides and proteins, as well as understanding the means by which protein homeostasis can be maintained and protein metastasis avoided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryuIN_Qt8Fa7Vg90H21EOLACvtfcHk0lho22kLwahvpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosV2lurk%253D&md5=68e2e4d963646f1daca50ab3288f5a37</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnrm3810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3810%26sid%3Dliteratum%253Aachs%26aulast%3DKnowles%26aufirst%3DT.%2BP.%26aulast%3DVendruscolo%26aufirst%3DM.%26aulast%3DDobson%26aufirst%3DC.%2BM.%26atitle%3DThe%2520amyloid%2520state%2520and%2520its%2520association%2520with%2520protein%2520misfolding%2520diseases%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2014%26volume%3D15%26spage%3D384%26epage%3D396%26doi%3D10.1038%2Fnrm3810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajasekhar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakrabarti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindaraju, T.</span></span> <span> </span><span class="NLM_article-title">Function and toxicity of amyloid beta and recent therapeutic interventions targeting amyloid beta in Alzheimer’s disease</span>. <i>Chem. Commun. (Cambridge, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">13434</span>– <span class="NLM_lpage">13450</span>, <span class="refDoi"> DOI: 10.1039/C5CC05264E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1039%2FC5CC05264E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=26247608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1KmtbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=13434-13450&author=K.+Rajasekharauthor=M.+Chakrabartiauthor=T.+Govindaraju&title=Function+and+toxicity+of+amyloid+beta+and+recent+therapeutic+interventions+targeting+amyloid+beta+in+Alzheimer%E2%80%99s+disease&doi=10.1039%2FC5CC05264E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Function and toxicity of amyloid beta and recent therapeutic interventions targeting amyloid beta in Alzheimer's disease</span></div><div class="casAuthors">Rajasekhar, K.; Chakrabarti, Malabika; Govindaraju, T.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">70</span>),
    <span class="NLM_cas:pages">13434-13450</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Amyloidogenesis has been implicated in a broad spectrum of diseases in which amyloid protein is invariably misfolded and deposited in cells and organs.  Alzheimer's disease is one of the most devastating ailments among amyloidogenesis induced dementia.  The amyloid beta (Aβ) peptide derived from amyloid precursor protein (APP) is misfolded and deposited as plaques in the brain, which are said to be the hallmark of Alzheimer's disease.  In normal brains physiol. concn. of the Aβ peptide has been indicated to be involved in modulating neurogenesis and synaptic plasticity.  However, excess Aβ prodn., its aggregation and deposition deleteriously affect a large no. of biol. important pathways leading to neuronal cell death.  Targeting Aβ prodn., Aβ aggregation or its clearance from the brain has been an active area of research for preventing or curing AD.  Our Feature Article intends to detail the aggregation mechanism, the physiol. role of the Aβ peptide, elaborate its toxic effects, and outline the different classes of mols. designed in the last two years to inhibit amyloidogenic APP processing, Aβ oligomerization or fibrillogenesis and to modulate different pathways for active clearance of Aβ from the brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTO9UD6e6Hh7Vg90H21EOLACvtfcHk0lho22kLwahvpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1KmtbzP&md5=8a7b765f1d2f7bdda5c3f8bbba831452</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1039%2FC5CC05264E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5CC05264E%26sid%3Dliteratum%253Aachs%26aulast%3DRajasekhar%26aufirst%3DK.%26aulast%3DChakrabarti%26aufirst%3DM.%26aulast%3DGovindaraju%26aufirst%3DT.%26atitle%3DFunction%2520and%2520toxicity%2520of%2520amyloid%2520beta%2520and%2520recent%2520therapeutic%2520interventions%2520targeting%2520amyloid%2520beta%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DChem.%2520Commun.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D2015%26volume%3D51%26spage%3D13434%26epage%3D13450%26doi%3D10.1039%2FC5CC05264E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Canter, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, L. H.</span></span> <span> </span><span class="NLM_article-title">The road to restoring neural circuits for the treatment of Alzheimer’s disease</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>539</i></span>,  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1038/nature20412</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2Fnature20412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=27830780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BC2snkslKhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=539&publication_year=2016&pages=187-196&author=R.+G.+Canterauthor=J.+Penneyauthor=L.+H.+Tsai&title=The+road+to+restoring+neural+circuits+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1038%2Fnature20412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The road to restoring neural circuits for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Canter Rebecca G; Penney Jay; Tsai Li-Huei; Tsai Li-Huei</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">539</span>
        (<span class="NLM_cas:issue">7628</span>),
    <span class="NLM_cas:pages">187-196</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Alzheimer's disease is a progressive loss of memory and cognition, for which there is no cure.  Although genetic studies initially suggested a primary role for amyloid-in Alzheimer's disease, treatment strategies targeted at reducing amyloid-have failed to reverse cognitive symptoms.  These clinical findings suggest that cognitive decline is the result of a complex pathophysiology and that targeting amyloid-alone may not be sufficient to treat Alzheimer's disease.  Instead, a broad outlook on neural-circuit-damaging processes may yield insights into new therapeutic strategies for curing memory loss in the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHFxchnTOjw90Q2ypr7jHkfW6udTcc2eYUtkJ_2zZvgLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2snkslKhtg%253D%253D&md5=508cffcf1281908d3f030c7a14468109</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fnature20412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature20412%26sid%3Dliteratum%253Aachs%26aulast%3DCanter%26aufirst%3DR.%2BG.%26aulast%3DPenney%26aufirst%3DJ.%26aulast%3DTsai%26aufirst%3DL.%2BH.%26atitle%3DThe%2520road%2520to%2520restoring%2520neural%2520circuits%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNature%26date%3D2016%26volume%3D539%26spage%3D187%26epage%3D196%26doi%3D10.1038%2Fnature20412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheignon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefont-Rousselot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hureau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collin, F.</span></span> <span> </span><span class="NLM_article-title">Oxidative stress and the amyloid beta peptide in Alzheimer’s disease</span>. <i>Redox Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">450</span>– <span class="NLM_lpage">464</span>, <span class="refDoi"> DOI: 10.1016/j.redox.2017.10.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.redox.2017.10.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=29080524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslans73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=450-464&author=C.+Cheignonauthor=M.+Tomasauthor=D.+Bonnefont-Rousselotauthor=P.+Fallerauthor=C.+Hureauauthor=F.+Collin&title=Oxidative+stress+and+the+amyloid+beta+peptide+in+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.redox.2017.10.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative stress and the amyloid beta peptide in Alzheimer's disease</span></div><div class="casAuthors">Cheignon, C.; Tomas, M.; Bonnefont-Rousselot, D.; Faller, P.; Hureau, C.; Collin, F.</div><div class="citationInfo"><span class="NLM_cas:title">Redox Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">450-464</span>CODEN:
                <span class="NLM_cas:coden">RBEIB3</span>;
        ISSN:<span class="NLM_cas:issn">2213-2317</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Oxidative stress is known to play an important role in the pathogenesis of a no. of diseases.  In particular, it is linked to the etiol. of Alzheimer's disease (AD), an age-related neurodegenerative disease and the most common cause of dementia in the elderly.  Histopathol. hallmarks of AD are intracellular neurofibrillary tangles and extracellular formation of senile plaques composed of the amyloid-beta peptide (Aβ) in aggregated form along with metal-ions such as copper, iron or zinc.  Redox active metal ions, as for example copper, can catalyze the prodn. of Reactive Oxygen Species (ROS) when bound to the amyloid-β (Aβ).  The ROS thus produced, in particular the hydroxyl radical which is the most reactive one, may contribute to oxidative damage on both the Aβ peptide itself and on surrounding mol. (proteins, lipids, ...).  This review highlights the existing link between oxidative stress and AD, and the consequences towards the Aβ peptide and surrounding mols. in terms of oxidative damage.  In addn., the implication of metal ions in AD, their interaction with the Aβ peptide and redox properties leading to ROS prodn. are discussed, along with both in vitro and in vivo oxidn. of the Aβ peptide, at the mol. level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAsJM-PSPjNrVg90H21EOLACvtfcHk0ljAkZdHnYA_jA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslans73L&md5=f61600ab9e355cd49838961d26de5c4f</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.redox.2017.10.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.redox.2017.10.014%26sid%3Dliteratum%253Aachs%26aulast%3DCheignon%26aufirst%3DC.%26aulast%3DTomas%26aufirst%3DM.%26aulast%3DBonnefont-Rousselot%26aufirst%3DD.%26aulast%3DFaller%26aufirst%3DP.%26aulast%3DHureau%26aufirst%3DC.%26aulast%3DCollin%26aufirst%3DF.%26atitle%3DOxidative%2520stress%2520and%2520the%2520amyloid%2520beta%2520peptide%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DRedox%2520Biol.%26date%3D2018%26volume%3D14%26spage%3D450%26epage%3D464%26doi%3D10.1016%2Fj.redox.2017.10.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, X.</span></span> <span> </span><span class="NLM_article-title">New insights in amyloid beta interactions with human telomerase</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">1213</span>– <span class="NLM_lpage">1219</span>, <span class="refDoi"> DOI: 10.1021/ja511030s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja511030s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltVWrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=1213-1219&author=J.+Wangauthor=C.+Zhaoauthor=A.+Zhaoauthor=M.+Liauthor=J.+Renauthor=X.+Qu&title=New+insights+in+amyloid+beta+interactions+with+human+telomerase&doi=10.1021%2Fja511030s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">New Insights in Amyloid Beta Interactions with Human Telomerase</span></div><div class="casAuthors">Wang, Jiasi; Zhao, Chuanqi; Zhao, Andong; Li, Meng; Ren, Jinsong; Qu, Xiaogang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1213-1219</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">It is well-known that aging is the most risk factor for Alzheimer's disease (AD).  Recent studies have demonstrated that human telomerase is assocd. with pathol. mechanisms of AD.  In view of the central role of telomere and telomerase in the aging process, herein we found that the aggregated form Aβ (Aβ1-40 and Aβ1-42), not Aβ monomer, could inhibit telomerase activity both in vitro and in living cells.  The β-sheet structures were essential for Aβ-induced telomerase inhibition.  Further studies indicated Aβ oligomers inhibited telomerase activity through binding to DNA·RNA hybrid formed by telomeric DNA and the RNA template of telomerase, then blocking telomerase elongation of telomeric DNA.  We also identified that intracellular Aβ localized at telomere, and induced cell senescence and telomere shortening.  These results indicate that Aβ oligomers can be potential natural inhibitors of telomerase and that inhibition of telomerase activity may be one of the factors for Aβ-induced cytotoxicity.  Our work may offer a new clue to a better understanding of aging and AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpotcUOPckUfLVg90H21EOLACvtfcHk0ljAkZdHnYA_jA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltVWrtg%253D%253D&md5=1d867014e443b42d27ae739137909ecc</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fja511030s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja511030s%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DQu%26aufirst%3DX.%26atitle%3DNew%2520insights%2520in%2520amyloid%2520beta%2520interactions%2520with%2520human%2520telomerase%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26spage%3D1213%26epage%3D1219%26doi%3D10.1021%2Fja511030s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brunden, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojanowski, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, V. M.</span></span> <span> </span><span class="NLM_article-title">Advances in tau-focused drug discovery for Alzheimer’s disease and related tauopathies</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">783</span>– <span class="NLM_lpage">793</span>, <span class="refDoi"> DOI: 10.1038/nrd2959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2Fnrd2959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=19794442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2kurrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=783-793&author=K.+R.+Brundenauthor=J.+Q.+Trojanowskiauthor=V.+M.+Lee&title=Advances+in+tau-focused+drug+discovery+for+Alzheimer%E2%80%99s+disease+and+related+tauopathies&doi=10.1038%2Fnrd2959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies</span></div><div class="casAuthors">Brunden, Kurt R.; Trojanowski, John Q.; Lee, Virginia M.-Y.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">783-793</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Neuronal inclusions comprised of the microtubule-assocd. protein tau are found in numerous neurodegenerative diseases, commonly known as tauopathies.  In Alzheimer's disease - the most prevalent tauopathy - misfolded tau is probably a key pathol. agent.  The recent failure of amyloid-β-targeted therapeutics in Phase III clin. trials suggests that it is timely and prudent to consider alternative drug discovery strategies for Alzheimer's disease.  Here, we focus on strategies directed at reducing misfolded tau and compensating for the loss of normal tau function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeWhB7oau9ALVg90H21EOLACvtfcHk0li0_OPZsz8NQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2kurrN&md5=6178c6f0e9a83c31a0e7f9dd8dae79d8</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fnrd2959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2959%26sid%3Dliteratum%253Aachs%26aulast%3DBrunden%26aufirst%3DK.%2BR.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26aulast%3DLee%26aufirst%3DV.%2BM.%26atitle%3DAdvances%2520in%2520tau-focused%2520drug%2520discovery%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%2520and%2520related%2520tauopathies%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D783%26epage%3D793%26doi%3D10.1038%2Fnrd2959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hutton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lendon, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froelich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houlden, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickering-Brown, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraverty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grover, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lincoln, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Graaff, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wauters, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Baren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillebrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joosse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowotny, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojanowski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lannfelt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neystat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dark, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tannenberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodd, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schofield, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreadis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snowden, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craufurd, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neary, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oostra, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goate, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Swieten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heutink, P.</span></span> <span> </span><span class="NLM_article-title">Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>393</i></span>,  <span class="NLM_fpage">702</span>– <span class="NLM_lpage">705</span>, <span class="refDoi"> DOI: 10.1038/31508</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2F31508" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=9641683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADyaK1cXktVyqsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=393&publication_year=1998&pages=702-705&author=M.+Huttonauthor=C.+L.+Lendonauthor=P.+Rizzuauthor=M.+Bakerauthor=S.+Froelichauthor=H.+Houldenauthor=S.+Pickering-Brownauthor=S.+Chakravertyauthor=A.+Isaacsauthor=A.+Groverauthor=J.+Hackettauthor=J.+Adamsonauthor=S.+Lincolnauthor=D.+Dicksonauthor=P.+Daviesauthor=R.+C.+Petersenauthor=M.+Stevensauthor=E.+de+Graaffauthor=E.+Wautersauthor=J.+van+Barenauthor=M.+Hillebrandauthor=M.+Joosseauthor=J.+M.+Kwonauthor=P.+Nowotnyauthor=L.+K.+Cheauthor=J.+Nortonauthor=J.+C.+Morrisauthor=L.+A.+Reedauthor=J.+Trojanowskiauthor=H.+Basunauthor=L.+Lannfeltauthor=M.+Neystatauthor=S.+Fahnauthor=F.+Darkauthor=T.+Tannenbergauthor=P.+R.+Doddauthor=N.+Haywardauthor=J.+B.+Kwokauthor=P.+R.+Schofieldauthor=A.+Andreadisauthor=J.+Snowdenauthor=D.+Craufurdauthor=D.+Nearyauthor=F.+Owenauthor=B.+A.+Oostraauthor=J.+Hardyauthor=A.+Goateauthor=J.+van+Swietenauthor=D.+Mannauthor=T.+Lynchauthor=P.+Heutink&title=Association+of+missense+and+5%E2%80%B2-splice-site+mutations+in+tau+with+the+inherited+dementia+FTDP-17&doi=10.1038%2F31508"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17</span></div><div class="casAuthors">Hutton, Mike; Lendon, Corinne L.; Rizzu, Patrizia; Baker, Matt; Froelich, Susanne; Houlden, Henry; Pickering-Brown, Stuart; Chakraverty, Sumi; Isaacs, Adrian; Grover, Andrew; Hackett, Jennifer; Adamson, Jennifer; Lincoln, Sarah; Dickson, Dennis; Davies, Peter; Petersen, Ronald C.; Stevens, Martijn; de Graaff, Esther; Wauters, Erwin; van Baren, Jeltje; Hillebrand, Marcel; Joosse, Marijke; Kwon, Jennifer M.; Nowotny, Petra; Che, Lien Kuei; Norton, Joanne; Morris, John C.; Reed, Lee A.; Trojanowski, John; Basun, Hans; Lannfelt, Lars; Neystat, Michael; Fahn, Stanley; Dark, Francis; Tannenberg, Tony; Dodd, Peter R.; Hayward, Nick; Kwok, John B. J.; Schofield, Peter R.; Andreadis, Athena; Snowden, Julie; Craufurd, David; Neary, David; Owen, Frank; Oostra, Ben A.; Hardy, John; Goate, Alison; van Swieten, John; Mann, David; Lynch, Timothy; Heutink, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">393</span>
        (<span class="NLM_cas:issue">6686</span>),
    <span class="NLM_cas:pages">702-705</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Thirteen families have been described with an autosomal dominantly inherited dementia named frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), historically termed Pick's disease.  Most FTDP-17 cases show neuronal and/or glial inclusions that stain pos. with antibodies raised against the microtubule-assocd. protein Tau, although the Tau pathol. varies considerably in both its quantity (or severity) and characteristics.  Previous studies have mapped the FTDP-17 locus to a 2-centimorgan region on chromosome 17q21.11; the tau gene also lies within this region.  We have now sequenced tau in FTDP-17 families and identified three missense mutations (G272V, P301L and R406W) and three mutations in the 5' splice site of exon 10.  The splice-site mutations all destabilize a potential stem-loop structure which is probably involved in regulating the alternative splicing of exon 10.  This causes more frequent usage of the 5' splice site an increased proportion of tau transcripts that include exon 10.  The increase in exon 10+ mRNA will increase the proportion of Tau contg. four microtubule-binding repeats, which is consistent with the neuropathol. described in several families with FTDP-17.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmDAkDTiFru7Vg90H21EOLACvtfcHk0li0_OPZsz8NQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXktVyqsr0%253D&md5=8ec0725fa99708a52022b404dc97a72f</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2F31508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F31508%26sid%3Dliteratum%253Aachs%26aulast%3DHutton%26aufirst%3DM.%26aulast%3DLendon%26aufirst%3DC.%2BL.%26aulast%3DRizzu%26aufirst%3DP.%26aulast%3DBaker%26aufirst%3DM.%26aulast%3DFroelich%26aufirst%3DS.%26aulast%3DHoulden%26aufirst%3DH.%26aulast%3DPickering-Brown%26aufirst%3DS.%26aulast%3DChakraverty%26aufirst%3DS.%26aulast%3DIsaacs%26aufirst%3DA.%26aulast%3DGrover%26aufirst%3DA.%26aulast%3DHackett%26aufirst%3DJ.%26aulast%3DAdamson%26aufirst%3DJ.%26aulast%3DLincoln%26aufirst%3DS.%26aulast%3DDickson%26aufirst%3DD.%26aulast%3DDavies%26aufirst%3DP.%26aulast%3DPetersen%26aufirst%3DR.%2BC.%26aulast%3DStevens%26aufirst%3DM.%26aulast%3Dde%2BGraaff%26aufirst%3DE.%26aulast%3DWauters%26aufirst%3DE.%26aulast%3Dvan%2BBaren%26aufirst%3DJ.%26aulast%3DHillebrand%26aufirst%3DM.%26aulast%3DJoosse%26aufirst%3DM.%26aulast%3DKwon%26aufirst%3DJ.%2BM.%26aulast%3DNowotny%26aufirst%3DP.%26aulast%3DChe%26aufirst%3DL.%2BK.%26aulast%3DNorton%26aufirst%3DJ.%26aulast%3DMorris%26aufirst%3DJ.%2BC.%26aulast%3DReed%26aufirst%3DL.%2BA.%26aulast%3DTrojanowski%26aufirst%3DJ.%26aulast%3DBasun%26aufirst%3DH.%26aulast%3DLannfelt%26aufirst%3DL.%26aulast%3DNeystat%26aufirst%3DM.%26aulast%3DFahn%26aufirst%3DS.%26aulast%3DDark%26aufirst%3DF.%26aulast%3DTannenberg%26aufirst%3DT.%26aulast%3DDodd%26aufirst%3DP.%2BR.%26aulast%3DHayward%26aufirst%3DN.%26aulast%3DKwok%26aufirst%3DJ.%2BB.%26aulast%3DSchofield%26aufirst%3DP.%2BR.%26aulast%3DAndreadis%26aufirst%3DA.%26aulast%3DSnowden%26aufirst%3DJ.%26aulast%3DCraufurd%26aufirst%3DD.%26aulast%3DNeary%26aufirst%3DD.%26aulast%3DOwen%26aufirst%3DF.%26aulast%3DOostra%26aufirst%3DB.%2BA.%26aulast%3DHardy%26aufirst%3DJ.%26aulast%3DGoate%26aufirst%3DA.%26aulast%3Dvan%2BSwieten%26aufirst%3DJ.%26aulast%3DMann%26aufirst%3DD.%26aulast%3DLynch%26aufirst%3DT.%26aulast%3DHeutink%26aufirst%3DP.%26atitle%3DAssociation%2520of%2520missense%2520and%25205%25E2%2580%25B2-splice-site%2520mutations%2520in%2520tau%2520with%2520the%2520inherited%2520dementia%2520FTDP-17%26jtitle%3DNature%26date%3D1998%26volume%3D393%26spage%3D702%26epage%3D705%26doi%3D10.1038%2F31508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brion, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heraud, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, K.</span></span> <span> </span><span class="NLM_article-title">Modulation of tau pathology in tau transgenic models</span>. <i>Biochem. Soc. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">996</span>– <span class="NLM_lpage">1000</span>, <span class="refDoi"> DOI: 10.1042/BST0380996</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1042%2FBST0380996" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=20658992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlyls7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=996-1000&author=J.+P.+Brionauthor=K.+Andoauthor=C.+Heraudauthor=K.+Leroy&title=Modulation+of+tau+pathology+in+tau+transgenic+models&doi=10.1042%2FBST0380996"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of tau pathology in tau transgenic models</span></div><div class="casAuthors">Brion, Jean-Pierre; Ando, Kunie; Heraud, Celine; Leroy, Karelle</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">996-1000</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  NFTs (neurofibrillary tangles) in Alzheimer's disease and in tauopathies are hallmark neuropathol. lesions whose relationship with neuronal dysfunction, neuronal death and with other lesions [such as Aβ (amyloid β-peptide) pathol.] are still imperfectly understood.  Many transgenic mice overexpressing wild-type or mutant tau proteins have been generated to investigate the physiopathol. of tauopathies.  Most of the mice overexpressing wild-type tau do not develop NFTs, but can develop a severe axonopathy, whereas overexpression of mutant tau leads to NFT formation, synaptic loss and neuronal death in several models.  The assocn. between neuronal death and NFTs has, however, been challenged in some models showing a dissocn. between tau aggregation and tau toxicity.  Cross-breeding of mice developing NFTs with mice developing Aβ deposits increases NFT pathol., highlighting the relationship between tau and amyloid pathol.  On the other hand, tau expression seems to be necessary for expression of a pathol. phenotype assocd. with amyloid pathol.  These findings suggest that there is a bilateral cross-talk between Aβ and tau pathol.  These observations are discussed by the presentation of some relevant models developed recently.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrl_dl5emyJlLVg90H21EOLACvtfcHk0lgqyFQc1Zqwzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlyls7s%253D&md5=62f579a4e36ca8169802eb415ddf54a7</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1042%2FBST0380996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST0380996%26sid%3Dliteratum%253Aachs%26aulast%3DBrion%26aufirst%3DJ.%2BP.%26aulast%3DAndo%26aufirst%3DK.%26aulast%3DHeraud%26aufirst%3DC.%26aulast%3DLeroy%26aufirst%3DK.%26atitle%3DModulation%2520of%2520tau%2520pathology%2520in%2520tau%2520transgenic%2520models%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2010%26volume%3D38%26spage%3D996%26epage%3D1000%26doi%3D10.1042%2FBST0380996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Congdon, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigurdsson, E. M.</span></span> <span> </span><span class="NLM_article-title">Tau-targeting therapies for Alzheimer disease</span>. <i>Nat. Rev. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">399</span>– <span class="NLM_lpage">415</span>, <span class="refDoi"> DOI: 10.1038/s41582-018-0013-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2Fs41582-018-0013-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=29895964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFaks73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=399-415&author=E.+E.+Congdonauthor=E.+M.+Sigurdsson&title=Tau-targeting+therapies+for+Alzheimer+disease&doi=10.1038%2Fs41582-018-0013-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Tau-targeting therapies for Alzheimer disease</span></div><div class="casAuthors">Congdon, Erin E.; Sigurdsson, Einar M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neurology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">399-415</span>CODEN:
                <span class="NLM_cas:coden">NRNACP</span>;
        ISSN:<span class="NLM_cas:issn">1759-4758</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Alzheimer disease (AD) is the most common form of dementia.  Pathol., AD is characterized by amyloid plaques and neurofibrillary tangles in the brain, with assocd. loss of synapses and neurons, resulting in cognitive deficits and eventually dementia.  Amyloid-β (Aβ) peptide and tau protein are the primary components of the plaques and tangles, resp.  In the decades since Aβ and tau were identified, development of therapies for AD has primarily focused on Aβ, but tau has received more attention in recent years, in part because of the failure of various Aβ-targeting treatments in clin. trials.  In this article, we review the current status of tau-targeting therapies for AD.  Initially, potential anti-tau therapies were based mainly on inhibition of kinases or tau aggregation, or on stabilization of microtubules, but most of these approaches have been discontinued because of toxicity and/or lack of efficacy.  Currently, the majority of tau-targeting therapies in clin. trials are immunotherapies, which have shown promise in numerous preclin. studies.  Given that tau pathol. correlates better with cognitive impairments than do Aβ lesions, targeting of tau is expected to be more effective than Aβ clearance once the clin. symptoms are evident.  With future improvements in diagnostics, these two hallmarks of the disease might be targeted prophylactically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT0IYIr5ElmbVg90H21EOLACvtfcHk0lgqyFQc1Zqwzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFaks73M&md5=d26350964814206ce4860b7256c9d6a0</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fs41582-018-0013-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41582-018-0013-z%26sid%3Dliteratum%253Aachs%26aulast%3DCongdon%26aufirst%3DE.%2BE.%26aulast%3DSigurdsson%26aufirst%3DE.%2BM.%26atitle%3DTau-targeting%2520therapies%2520for%2520Alzheimer%2520disease%26jtitle%3DNat.%2520Rev.%2520Neurol.%26date%3D2018%26volume%3D14%26spage%3D399%26epage%3D415%26doi%3D10.1038%2Fs41582-018-0013-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bulic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickhardt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandelkow, E.</span></span> <span> </span><span class="NLM_article-title">Progress and developments in tau aggregation inhibitors for Alzheimer disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4135</span>– <span class="NLM_lpage">4155</span>, <span class="refDoi"> DOI: 10.1021/jm3017317</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3017317" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktVCks7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4135-4155&author=B.+Bulicauthor=M.+Pickhardtauthor=E.+Mandelkow&title=Progress+and+developments+in+tau+aggregation+inhibitors+for+Alzheimer+disease&doi=10.1021%2Fjm3017317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Progress and Developments in Tau Aggregation Inhibitors for Alzheimer Disease</span></div><div class="casAuthors">Bulic, Bruno; Pickhardt, Marcus; Mandelkow, Eckhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4135-4155</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pharmacol. approaches directed toward Alzheimer disease are diversifying in parallel with a growing no. of promising targets.  Investigations on the microtubule-assocd. protein tau yielded innovative targets backed by recent findings about the central role of tau in numerous neurodegenerative diseases.  In this review, we summarize the recent evolution in the development of nonpeptidic small mols. tau aggregation inhibitors (TAGIs) and their advancement toward clin. trials.  The compds. are classified according to their chem. structures, providing correlative insights into their pharmacol.  Overall, shared structure-activity traits are emerging, as well as specific binding modes related to their ability to engage in hydrogen bonding.  Medicinal chem. efforts on TAGIs together with encouraging in vivo data argue for successful translation to the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-MCCWng61lLVg90H21EOLACvtfcHk0lgqyFQc1Zqwzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktVCks7w%253D&md5=35aa968d078ff044e0d353fca4f13e42</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fjm3017317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3017317%26sid%3Dliteratum%253Aachs%26aulast%3DBulic%26aufirst%3DB.%26aulast%3DPickhardt%26aufirst%3DM.%26aulast%3DMandelkow%26aufirst%3DE.%26atitle%3DProgress%2520and%2520developments%2520in%2520tau%2520aggregation%2520inhibitors%2520for%2520Alzheimer%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4135%26epage%3D4155%26doi%3D10.1021%2Fjm3017317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ballatore, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunden, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojanowski, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huryn, D. M.</span></span> <span> </span><span class="NLM_article-title">Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">317</span>– <span class="NLM_lpage">330</span>, <span class="refDoi"> DOI: 10.2174/156802611794072605</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.2174%2F156802611794072605" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=21320060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslahsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=317-330&author=C.+Ballatoreauthor=K.+R.+Brundenauthor=J.+Q.+Trojanowskiauthor=V.+M.+Leeauthor=A.+B.+Smithauthor=D.+M.+Huryn&title=Modulation+of+protein-protein+interactions+as+a+therapeutic+strategy+for+the+treatment+of+neurodegenerative+tauopathies&doi=10.2174%2F156802611794072605"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies</span></div><div class="casAuthors">Ballatore, C.; Brunden, K. R.; Trojanowski, J. Q.; Lee, V. M.-Y.; Smith, A. B., III; Huryn, D. M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">317-330</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The recognition that malfunction of the microtubule (MT) assocd. protein tau is likely to play a defining role in the onset and/or progression of a no. of neurodegenerative diseases, including Alzheimer's disease, has resulted in the initiation of drug discovery programs that target this protein.  Tau is an endogenous MT-stabilizing agent that is highly expressed in the axons of neurons.  The MT-stabilizing function of tau is essential for the axonal transport of proteins, neurotransmitters and other cellular constituents.  Under pathol. conditions, tau misfolding and aggregation results in axonal transport deficits that appear to have deleterious consequences for the affected neurons, leading to synapse dysfunction and, ultimately, neuronal loss.  This review focuses on both progress and unresolved issues surrounding the development of novel therapeutics for the treatment of neurodegenerative tauopathies, which are based on (A) MT-stabilizing agents to compensate for the loss of normal tau function and (B) small mol. inhibitors of tau aggregation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRv3v9WR9uIrVg90H21EOLACvtfcHk0lgqyFQc1Zqwzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslahsLk%253D&md5=b35d6ff9dac27b56e59f1e2fd5b8fafd</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.2174%2F156802611794072605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611794072605%26sid%3Dliteratum%253Aachs%26aulast%3DBallatore%26aufirst%3DC.%26aulast%3DBrunden%26aufirst%3DK.%2BR.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26aulast%3DLee%26aufirst%3DV.%2BM.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DHuryn%26aufirst%3DD.%2BM.%26atitle%3DModulation%2520of%2520protein-protein%2520interactions%2520as%2520a%2520therapeutic%2520strategy%2520for%2520the%2520treatment%2520of%2520neurodegenerative%2520tauopathies%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D317%26epage%3D330%26doi%3D10.2174%2F156802611794072605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mabonga, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kappo, A. P.</span></span> <span> </span><span class="NLM_article-title">Protein-protein interaction modulators: Advances, successes and remaining challenges</span>. <i>Biophys. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">559</span>– <span class="NLM_lpage">581</span>, <span class="refDoi"> DOI: 10.1007/s12551-019-00570-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1007%2Fs12551-019-00570-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=31301019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtl2rsb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=559-581&author=L.+Mabongaauthor=A.+P.+Kappo&title=Protein-protein+interaction+modulators%3A+Advances%2C+successes+and+remaining+challenges&doi=10.1007%2Fs12551-019-00570-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Protein-protein interaction modulators: advances, successes and remaining challenges</span></div><div class="casAuthors">Mabonga, Lloyd; Kappo, Abidemi Paul</div><div class="citationInfo"><span class="NLM_cas:title">Biophysical Reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">559-581</span>CODEN:
                <span class="NLM_cas:coden">BRIECG</span>;
        ISSN:<span class="NLM_cas:issn">1867-2450</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Modulating disease-relevant protein-protein interactions (PPIs) using small-mol. inhibitors is a quite indispensable diagnostic and therapeutic strategy in averting pathophysiol. cues and disease progression.  Over the years, targeting intracellular PPIs as drug design targets has been a challenging task owing to their highly dynamic and expansive interfacial areas (flat, featureless and relatively large).  However, advances in PPI-focused drug discovery technol. have been reported and a few drugs are already on the market, with some potential drug-like candidates already in clin. trials.  In this article, we review the advances, successes and remaining challenges in the application of small mols. as valuable PPI modulators in disease diagnosis and therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKCN2e4SrXuLVg90H21EOLACvtfcHk0lgBbQRuXVZu9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtl2rsb3J&md5=02c2c9b4b9d1ccb279c76c21776bb2ec</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1007%2Fs12551-019-00570-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12551-019-00570-x%26sid%3Dliteratum%253Aachs%26aulast%3DMabonga%26aufirst%3DL.%26aulast%3DKappo%26aufirst%3DA.%2BP.%26atitle%3DProtein-protein%2520interaction%2520modulators%253A%2520Advances%252C%2520successes%2520and%2520remaining%2520challenges%26jtitle%3DBiophys.%2520Rev.%26date%3D2019%26volume%3D11%26spage%3D559%26epage%3D581%26doi%3D10.1007%2Fs12551-019-00570-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsuo, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billingsley, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van deVoorde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojanowski, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, V. M.</span></span> <span> </span><span class="NLM_article-title">Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer’s disease paired helical filament tau</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">989</span>– <span class="NLM_lpage">1002</span>, <span class="refDoi"> DOI: 10.1016/0896-6273(94)90264-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2F0896-6273%2894%2990264-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=7946342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADyaK2MXitVOgt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1994&pages=989-1002&author=E.+S.+Matsuoauthor=R.+W.+Shinauthor=M.+L.+Billingsleyauthor=A.+Van+deVoordeauthor=M.+O%E2%80%99Connorauthor=J.+Q.+Trojanowskiauthor=V.+M.+Lee&title=Biopsy-derived+adult+human+brain+tau+is+phosphorylated+at+many+of+the+same+sites+as+Alzheimer%E2%80%99s+disease+paired+helical+filament+tau&doi=10.1016%2F0896-6273%2894%2990264-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau</span></div><div class="casAuthors">Matsuo, Eriko S.; Shin, Ryong-Woon; Billingsley, Melvin L.; Van deVoorde, Andre; O'Connor, Michael; Trojanowski, John Q.; Lee, Virginia M.-Y.</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">989-1002</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Tau from Alzheimer's disease (AD) paired helical filaments (PHF-tau) is phosphorylated at sites not found in autopsy-derived adult tau from normal human brains, and this suggested that PHF-tau is abnormally phosphorylated.  To explore this hypothesis, the authors examd. human adult tau from brain biopsies and demonstrated that biopsy-derived tau is phosphorylated at most sites thought to be abnormally phosphorylated in PHF-tau.  These sites also were phosphorylated in autopsy-derived human fetal tau and rapidly processed rat tau.  The hypophosphorylation of autopsy-derived adult human tau is due to rapid dephosphorylation postmortem, and protein phosphatases 2A (PP2A) and 2B (PP2B) in human brain biopsies dephosphorylate tau in a site-specific manner.  The down-regulation of phosphatases (i.e, PP2A and PP2B) in the AD brain could lead to the generation of maximally phosphorylated PHF-tau that does not bind microtubules and aggregates as PHFs in neurofibrillary tangles and dystrophic neurites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryVEroJQtKMbVg90H21EOLACvtfcHk0lgBbQRuXVZu9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXitVOgt7o%253D&md5=9316d037d89f85f75008bef2789dde77</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2F0896-6273%2894%2990264-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0896-6273%252894%252990264-X%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuo%26aufirst%3DE.%2BS.%26aulast%3DShin%26aufirst%3DR.%2BW.%26aulast%3DBillingsley%26aufirst%3DM.%2BL.%26aulast%3DVan%2BdeVoorde%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26aulast%3DLee%26aufirst%3DV.%2BM.%26atitle%3DBiopsy-derived%2520adult%2520human%2520brain%2520tau%2520is%2520phosphorylated%2520at%2520many%2520of%2520the%2520same%2520sites%2520as%2520Alzheimer%25E2%2580%2599s%2520disease%2520paired%2520helical%2520filament%2520tau%26jtitle%3DNeuron%26date%3D1994%26volume%3D13%26spage%3D989%26epage%3D1002%26doi%3D10.1016%2F0896-6273%2894%2990264-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundke-Iqbal, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, K.</span></span> <span> </span><span class="NLM_article-title">Alzheimer’s disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">783</span>– <span class="NLM_lpage">787</span>, <span class="refDoi"> DOI: 10.1038/nm0796-783</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2Fnm0796-783" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=8673924" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADyaK28XjvF2isr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1996&pages=783-787&author=A.+C.+Alonsoauthor=I.+Grundke-Iqbalauthor=K.+Iqbal&title=Alzheimer%E2%80%99s+disease+hyperphosphorylated+tau+sequesters+normal+tau+into+tangles+of+filaments+and+disassembles+microtubules&doi=10.1038%2Fnm0796-783"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules</span></div><div class="casAuthors">Alonso, Alejandra delC.; Grundke-Iqbal, Inge; Iqbal, Khalid</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">783-787</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">Microtubule-assocd. protein tau becomes abnormally hyperphosphorylated in Alzheimer's disease (AD) and accumulates as tangles of paired helical filaments in neurons undergoing degeneration.  The authors now show that in soln., normal tau assocs. with the AD hyperphosphorylated tau (AD P-tau) in a nonsaturable fashion, forming large tangles of filaments 3.3 nm in diam.  These tangles, which are not detected in identically treated normal tau or AD P-tau alone, are made up of filaments several microns in length and are labeled with tau antibodies.  Dephosphorylation with alk. phosphatase abolishes the ability of AD P-tau to aggregate with normal tau and prevents tangle formation.  AD P-tau disassembles microtubules assembled from normal tau and tubulin.  These data provide insight into how the hyperphosphorylation of tau might lead to the formation of the neurofibrillary tangles and the degeneration of the affected neurons in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoubdLxKdTTmLVg90H21EOLACvtfcHk0lgBbQRuXVZu9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjvF2isr0%253D&md5=c49e7b62bcb15f24084cedbd86ef438c</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fnm0796-783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0796-783%26sid%3Dliteratum%253Aachs%26aulast%3DAlonso%26aufirst%3DA.%2BC.%26aulast%3DGrundke-Iqbal%26aufirst%3DI.%26aulast%3DIqbal%26aufirst%3DK.%26atitle%3DAlzheimer%25E2%2580%2599s%2520disease%2520hyperphosphorylated%2520tau%2520sequesters%2520normal%2520tau%2520into%2520tangles%2520of%2520filaments%2520and%2520disassembles%2520microtubules%26jtitle%3DNat.%2520Med.%26date%3D1996%26volume%3D2%26spage%3D783%26epage%3D787%26doi%3D10.1038%2Fnm0796-783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sengupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundke-Iqbal, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, K.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of tau at both thr 231 and Ser. 262 is required for maximal inhibition of its binding to microtubules</span>. <i>Arch. Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>357</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1006/abbi.1998.0813</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1006%2Fabbi.1998.0813" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=9735171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADyaK1cXmtFyjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=1998&pages=299-309&author=A.+Senguptaauthor=J.+Kabatauthor=M.+Novakauthor=Q.+Wuauthor=I.+Grundke-Iqbalauthor=K.+Iqbal&title=Phosphorylation+of+tau+at+both+thr+231+and+Ser.+262+is+required+for+maximal+inhibition+of+its+binding+to+microtubules&doi=10.1006%2Fabbi.1998.0813"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules</span></div><div class="casAuthors">Sengupta, Amitabha; Kabat, Juraj; Novak, Michal; Wu, Qiongli; Grundke-Iqbal, Inge; Iqbal, Khalid</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">299-309</span>CODEN:
                <span class="NLM_cas:coden">ABBIA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-9861</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The paired helical filaments (PHFs) found in Alzheimer's disease (AD) brains are composed primarily of the microtubule-assocd. protein tau.  PHF-tau is in a hyperphosphorylated state and is unable to promote microtubule assembly.  We investigated whether the inhibition of tau is binding to microtubules is increased when tau is phosphorylated by different kinases in combination with GSK-3.  We found that when tau was first phosphorylated by A-kinase, C-kinase, cdk5, or CaM kinase II and then by GSK-3, its binding to microtubules was inhibited by 45, 61, 78, and 79%, resp.  Further, the kinase combinations cdk5/GSK-3 and CaM kinase II/GSK-3 rapidly phosphorylated the sites Thr 231 and Ser 235.  When these sites were individually replaced by Ala and the phosphorylation expts. repeated, tau binding to microtubules was inhibited by 54 and 71%, resp.  By comparison, when Ser 262 was replaced by Ala, tau binding to microtubules was inhibited by only 8% after phosphorylation by CaM kinase II.  From these observations we est. that the phosphorylation of Thr 231, Ser 235, and Ser 262 contributes ∼26, ∼9, and ∼33%, resp., of the overall inhibition of tau binding to microtubules.  Together, our results indicate that the binding of tau to microtubules is controlled by the phosphorylation of several sites, among which are Thr 231, Ser 235, and Ser 262.  (c) 1998 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwvML27B25WbVg90H21EOLACvtfcHk0lgrL5jm9drI_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmtFyjtbo%253D&md5=e807d59160bb4455368978560e5f3561</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1006%2Fabbi.1998.0813&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fabbi.1998.0813%26sid%3Dliteratum%253Aachs%26aulast%3DSengupta%26aufirst%3DA.%26aulast%3DKabat%26aufirst%3DJ.%26aulast%3DNovak%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DQ.%26aulast%3DGrundke-Iqbal%26aufirst%3DI.%26aulast%3DIqbal%26aufirst%3DK.%26atitle%3DPhosphorylation%2520of%2520tau%2520at%2520both%2520thr%2520231%2520and%2520Ser.%2520262%2520is%2520required%2520for%2520maximal%2520inhibition%2520of%2520its%2520binding%2520to%2520microtubules%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D1998%26volume%3D357%26spage%3D299%26epage%3D309%26doi%3D10.1006%2Fabbi.1998.0813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biernat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Bergen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandelkow, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandelkow, E. M.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">3549</span>– <span class="NLM_lpage">3558</span>, <span class="refDoi"> DOI: 10.1021/bi981874p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi981874p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADyaK1MXhsVyhsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1999&pages=3549-3558&author=A.+Schneiderauthor=J.+Biernatauthor=M.+von+Bergenauthor=E.+Mandelkowauthor=E.+M.+Mandelkow&title=Phosphorylation+that+detaches+tau+protein+from+microtubules+%28Ser262%2C+Ser214%29+also+protects+it+against+aggregation+into+Alzheimer+paired+helical+filaments&doi=10.1021%2Fbi981874p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments</span></div><div class="casAuthors">Schneider, A.; Biernat, J.; von Bergen, M.; Mandelkow, E.; Mandelkow, E.-M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3549-3558</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">One of the hallmarks of Alzheimer's disease is the abnormal state of the microtubule-assocd. protein tau in neurons.  It is both highly phosphorylated and aggregated into paired helical filaments, and it is commonly assumed that the hyperphosphorylation of tau causes its detachment from microtubules and promotes its assembly into PHFs.  The authors have studied the relation between the phosphorylation of tau by several kinases (MARK, PKA, MAPK, GSK3) and its assembly into PHFs.  The proline-directed kinases MAPK and GSK3 are known to phosphorylate most Ser-Pro or Thr-Pro motifs in the regions flanking the repeat domain of tau: they induce the reaction with several antibodies diagnostic of Alzheimer PHFs, but this type of phosphorylation has only a weak effect on tau-microtubule interactions and on PHF assembly.  By contrast, MARK and PKA phosphorylate several sites within the repeats (notably the KXGS motifs including Ser262, Ser324, and Ser356, plus Ser320); in addn. PKA phosphorylates some sites in the flanking domains, notably Ser214.  This type of phosphorylation strongly reduces tau's affinity for microtubules, and at the same time inhibits tau's assembly into PHFs.  Thus, contrary to expectations, the phosphorylation that detaches tau from microtubules does not prime it for PHF assembly, but rather inhibits it.  Likewise, although the phosphorylation sites on Ser-Pro or Thr-Pro motifs are the most prominent ones on Alzheimer PHFs (by antibody labeling), they are only weakly inhibitory to PHF assembly.  This implies that the hyperphosphorylation of tau in Alzheimer's disease is not directly responsible for the pathol. aggregation into PHFs; on the contrary, phosphorylation protects tau against aggregation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpR_mr0wtSK4bVg90H21EOLACvtfcHk0lgrL5jm9drI_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhsVyhsbk%253D&md5=3403b22fdd0e690bae38d7262c016e96</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fbi981874p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi981874p%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DA.%26aulast%3DBiernat%26aufirst%3DJ.%26aulast%3Dvon%2BBergen%26aufirst%3DM.%26aulast%3DMandelkow%26aufirst%3DE.%26aulast%3DMandelkow%26aufirst%3DE.%2BM.%26atitle%3DPhosphorylation%2520that%2520detaches%2520tau%2520protein%2520from%2520microtubules%2520%2528Ser262%252C%2520Ser214%2529%2520also%2520protects%2520it%2520against%2520aggregation%2520into%2520Alzheimer%2520paired%2520helical%2520filaments%26jtitle%3DBiochemistry%26date%3D1999%26volume%3D38%26spage%3D3549%26epage%3D3558%26doi%3D10.1021%2Fbi981874p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanger, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, W.</span></span> <span> </span><span class="NLM_article-title">Tau phosphorylation: The therapeutic challenge for neurodegenerative disease</span>. <i>Trends Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">119</span>, <span class="refDoi"> DOI: 10.1016/j.molmed.2009.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.molmed.2009.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=19246243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjt1ahu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=112-119&author=D.+P.+Hangerauthor=B.+H.+Andertonauthor=W.+Noble&title=Tau+phosphorylation%3A+The+therapeutic+challenge+for+neurodegenerative+disease&doi=10.1016%2Fj.molmed.2009.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Tau phosphorylation: the therapeutic challenge for neurodegenerative disease</span></div><div class="casAuthors">Hanger, Diane P.; Anderton, Brian H.; Noble, Wendy</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">112-119</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The microtubule-assocd. protein tau is integral to the pathogenesis of Alzheimer's disease (AD), as well as several related disorders, termed tauopathies, in which tau is deposited in affected brain regions.  In the tauopathies, pathol. tau is in an elevated state of phosphorylation and is aberrantly cleaved.  It also exhibits abnormal conformations and becomes aggregated, resulting in neurofibrillary tau pathol.  Recent evidence suggests that relatively early disease-assocd. changes in sol. tau proteins, including phosphorylation, are involved in the induction of neuronal death.  Here, we summarize recent developments that suggest new therapeutic strategies to prevent or reduce the progression of pathol. in the tauopathies.  A list of tau phosphorylation sites identified in the tauopathies and in controls accompanies this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8l3EQ3bznVLVg90H21EOLACvtfcHk0lgrL5jm9drI_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjt1ahu7w%253D&md5=116159eeaae25800a22b687f36df70e2</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2009.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2009.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DHanger%26aufirst%3DD.%2BP.%26aulast%3DAnderton%26aufirst%3DB.%2BH.%26aulast%3DNoble%26aufirst%3DW.%26atitle%3DTau%2520phosphorylation%253A%2520The%2520therapeutic%2520challenge%2520for%2520neurodegenerative%2520disease%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2009%26volume%3D15%26spage%3D112%26epage%3D119%26doi%3D10.1016%2Fj.molmed.2009.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Kinase inhibitors: The road ahead</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1038/nrd.2018.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2Fnrd.2018.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=29545548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1cXks12ktbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=353-377&author=F.+M.+Fergusonauthor=N.+S.+Gray&title=Kinase+inhibitors%3A+The+road+ahead&doi=10.1038%2Fnrd.2018.21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase inhibitors: the road ahead</span></div><div class="casAuthors">Ferguson, Fleur M.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">353-377</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinase signaling pathways have been successfully targeted to inhibit proliferation and angiogenesis for cancer therapy.  However, kinase deregulation has been firmly demonstrated to play an essential role in virtually all major disease areas.  Kinase inhibitor drug discovery programs have recently broadened their focus to include an expanded range of kinase targets and therapeutic areas.  In this Review, we provide an overview of the novel targets, biol. processes and disease areas that kinase-targeting small mols. are being developed against, highlight the assocd. challenges and assess the strategies and technologies that are enabling efficient generation of highly optimized kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZPospb1TP7Vg90H21EOLACvtfcHk0lgrL5jm9drI_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXks12ktbg%253D&md5=34e42911d8a70301905460c3507e737a</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.21%26sid%3Dliteratum%253Aachs%26aulast%3DFerguson%26aufirst%3DF.%2BM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DKinase%2520inhibitors%253A%2520The%2520road%2520ahead%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26spage%3D353%26epage%3D377%26doi%3D10.1038%2Fnrd.2018.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghoreschi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">Selectivity and therapeutic inhibition of kinases: To be or not to be?</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">356</span>– <span class="NLM_lpage">360</span>, <span class="refDoi"> DOI: 10.1038/ni.1701</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2Fni.1701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=19295632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtlyms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=356-360&author=K.+Ghoreschiauthor=A.+Laurenceauthor=J.+J.+O%E2%80%99Shea&title=Selectivity+and+therapeutic+inhibition+of+kinases%3A+To+be+or+not+to+be%3F&doi=10.1038%2Fni.1701"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Selectivity and therapeutic inhibition of kinases: to be or not to be?</span></div><div class="casAuthors">Ghoreschi, Kamran; Laurence, Arian; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">356-360</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Protein kinases, which serve crit. functions in signaling pathways in all cells, are popular therapeutic targets.  At present, eight kinase inhibitors have been approved in the United States, each of which shows nanomolar potency.  Although the initial goal was to generate inhibitors with a high degree of selectivity, recent experience has revealed that many of these approved compds. target more than one kinase.  Surprisingly, this promiscuity is less problematic than one would have imagined; indeed, it opens new therapeutic opportunities.  In this Perspective, we discuss the present status of Janus kinase inhibitors-a new class of immunosuppressive drugs-and the advantages and disadvantages of selectively inhibiting this class of kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrU0w6t4jgqirVg90H21EOLACvtfcHk0lhOyf-awEqneg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtlyms78%253D&md5=64dd47e897181d00e5dce6be3bc5db6e</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fni.1701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.1701%26sid%3Dliteratum%253Aachs%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DSelectivity%2520and%2520therapeutic%2520inhibition%2520of%2520kinases%253A%2520To%2520be%2520or%2520not%2520to%2520be%253F%26jtitle%3DNat.%2520Immunol.%26date%3D2009%26volume%3D10%26spage%3D356%26epage%3D360%26doi%3D10.1038%2Fni.1701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. G.</span></span> <span> </span><span class="NLM_article-title">Recent advances in designing substrate-competitive protein kinase inhibitors</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2875</span>– <span class="NLM_lpage">2882</span>, <span class="refDoi"> DOI: 10.2174/138161212800672697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.2174%2F138161212800672697" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=22571656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFaltr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=2875-2882&author=K.+C.+Hanauthor=S.+Y.+Kimauthor=E.+G.+Yang&title=Recent+advances+in+designing+substrate-competitive+protein+kinase+inhibitors&doi=10.2174%2F138161212800672697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in designing substrate-competitive protein kinase inhibitors</span></div><div class="casAuthors">Han, Ki-Cheol; Kim, So Yeon; Yang, Eun Gyeong</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2875-2882</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases play central roles in cellular signaling pathways and their abnormal phosphorylation activity is inseparably linked with various human diseases.  Therefore, modulation of kinase activity using potent inhibitors is an attractive strategy for the treatment of human disease.  While most protein kinase inhibitors in clin. development are mainly targeted to the highly conserved ATP-binding sites and thus likely promiscuously inhibit multiple kinases, including kinases unrelated to diseases, protein substrate-competitive inhibitors are more selective and expected to be promising therapeutic agents.  Most substrate-competitive inhibitors mimic peptides derived from substrate proteins, or from inhibitory domains within kinases or inhibitor proteins.  In addn., bisubstrate inhibitors are generated by conjugating substrate-competitive peptide inhibitors to ATP-competitive inhibitors to improve affinity and selectivity.  Although structural information on protein kinases provides invaluable guidance in designing substrate-competitive inhibitors, other strategies including bioinformatics, computational modeling, and high-throughput screening are often employed for developing specific substrate-competitive kinase inhibitors.  Here, the authors focus on recent advances in the design and discovery of substrate-competitive inhibitors of protein kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGAqU2Rh64l7Vg90H21EOLACvtfcHk0lhOyf-awEqneg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFaltr8%253D&md5=841afc2c63bb0d956ba9d5c4caef3cb6</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.2174%2F138161212800672697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161212800672697%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DK.%2BC.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DYang%26aufirst%3DE.%2BG.%26atitle%3DRecent%2520advances%2520in%2520designing%2520substrate-competitive%2520protein%2520kinase%2520inhibitors%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2012%26volume%3D18%26spage%3D2875%26epage%3D2882%26doi%3D10.2174%2F138161212800672697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">New promise and opportunities for allosteric kinase inhibitors</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">13764</span>– <span class="NLM_lpage">13776</span>, <span class="refDoi"> DOI: 10.1002/anie.201914525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1002%2Fanie.201914525" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmt1Giurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2020&pages=13764-13776&author=X.+Luauthor=J.+B.+Smaillauthor=K.+Ding&title=New+promise+and+opportunities+for+allosteric+kinase+inhibitors&doi=10.1002%2Fanie.201914525"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">New Promise and Opportunities for Allosteric Kinase Inhibitors</span></div><div class="casAuthors">Lu, Xiaoyun; Smaill, Jeff B.; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">13764-13776</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Drugs that function through allosteric inhibition of kinase signaling represent a promising approach for the targeted discovery of therapeutics.  The majority of developed allosteric kinase inhibitors are characterized as type III and IV inhibitors that show good kinome selectivity but generally lack the subtype selectivity of same kinase family.  Recently allosteric inhibitors have been developed that bind outside the catalytic kinase domain with high selectivity for specific kinase subtypes.  Allosteric inhibitors that bind to the pseudokinase domain of pseudokinase or the extracellular domain of receptor tyrosine kinases are reviewed.  We also review recent developments in the field of allosteric kinase inhibitors including examples of proteolysis targeting chimeras, and highlight the unique binding modes for each type of inhibitors and address future opportunities in this area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIeFGyjfBKrLVg90H21EOLACvtfcHk0lhOyf-awEqneg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmt1Giurw%253D&md5=27959fdb1a96202db7ca65b2a8e19bc7</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1002%2Fanie.201914525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201914525%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DNew%2520promise%2520and%2520opportunities%2520for%2520allosteric%2520kinase%2520inhibitors%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2020%26volume%3D59%26spage%3D13764%26epage%3D13776%26doi%3D10.1002%2Fanie.201914525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chico, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eldik, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span> <span> </span><span class="NLM_article-title">Targeting protein kinases in central nervous system disorders</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">892</span>– <span class="NLM_lpage">909</span>, <span class="refDoi"> DOI: 10.1038/nrd2999</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2Fnrd2999" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=19876042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCjtrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=892-909&author=L.+K.+Chicoauthor=L.+J.+Van+Eldikauthor=D.+M.+Watterson&title=Targeting+protein+kinases+in+central+nervous+system+disorders&doi=10.1038%2Fnrd2999"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting protein kinases in central nervous system disorders</span></div><div class="casAuthors">Chico, Laura K.; Van Eldik, Linda J.; Watterson, D. Martin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">892-909</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Protein kinases are a growing drug target class in disorders in peripheral tissues, but the development of kinase-targeted therapies for central nervous system (CNS) diseases remains a challenge, largely owing to issues assocd. specifically with CNS drug discovery.  However, several candidate therapeutics that target CNS protein kinases are now in various stages of preclin. and clin. development.  We review candidate compds. and discuss selected CNS protein kinases that are emerging as important therapeutic targets.  In addn., we analyze trends in small-mol. properties that correlate with key challenges in CNS drug discovery, such as blood-brain barrier penetrance and cytochrome P 450-mediated metab., and discuss the potential of future approaches that will integrate mol.-fragment expansion with pharmacoinformatics to address these challenges.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzQo2JmuPNlrVg90H21EOLACvtfcHk0liLtJKAG0xkUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCjtrzO&md5=4dc1f6b7542e59c99f91525d37c49973</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fnrd2999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2999%26sid%3Dliteratum%253Aachs%26aulast%3DChico%26aufirst%3DL.%2BK.%26aulast%3DVan%2BEldik%26aufirst%3DL.%2BJ.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26atitle%3DTargeting%2520protein%2520kinases%2520in%2520central%2520nervous%2520system%2520disorders%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D892%26epage%3D909%26doi%3D10.1038%2Fnrd2999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wen, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yung, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamborn, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahia, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrey, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raizer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cloughesy, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junck, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiff, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieberman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fine, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robins, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeAngelis, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groves, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puduvalli, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrad, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldape, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letvak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egorin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capdeville, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murgo, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiles, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prados, M. D.</span></span> <span> </span><span class="NLM_article-title">Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American brain tumor consortium study 99–08</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">4899</span>– <span class="NLM_lpage">4907</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-06-0773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1158%2F1078-0432.CCR-06-0773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=16914578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD28XotFKgt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=4899-4907&author=P.+Y.+Wenauthor=W.+K.+Yungauthor=K.+R.+Lambornauthor=P.+L.+Dahiaauthor=Y.+Wangauthor=B.+Pengauthor=L.+E.+Abreyauthor=J.+Raizerauthor=T.+F.+Cloughesyauthor=K.+Finkauthor=M.+Gilbertauthor=S.+Changauthor=L.+Junckauthor=D.+Schiffauthor=F.+Liebermanauthor=H.+A.+Fineauthor=M.+Mehtaauthor=H.+I.+Robinsauthor=L.+M.+DeAngelisauthor=M.+D.+Grovesauthor=V.+K.+Puduvalliauthor=V.+Levinauthor=C.+Conradauthor=E.+A.+Maherauthor=K.+Aldapeauthor=M.+Hayesauthor=L.+Letvakauthor=M.+J.+Egorinauthor=R.+Capdevilleauthor=R.+Kaplanauthor=A.+J.+Murgoauthor=C.+Stilesauthor=M.+D.+Prados&title=Phase+I%2FII+study+of+imatinib+mesylate+for+recurrent+malignant+gliomas%3A+North+American+brain+tumor+consortium+study+99%E2%80%9308&doi=10.1158%2F1078-0432.CCR-06-0773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08</span></div><div class="casAuthors">Wen, Patrick Y.; Yung, W. K. Alfred; Lamborn, Kathleen R.; Dahia, Patricia L.; Wang, Yanfeng; Peng, Bin; Abrey, Lauren E.; Raizer, Jeffrey; Cloughesy, Timothy F.; Fink, Karen; Gilbert, Mark; Chang, Susan; Junck, Larry; Schiff, David; Lieberman, Frank; Fine, Howard A.; Mehta, Minesh; Robins, H. Ian; DeAngelis, Lisa M.; Groves, Morris D.; Puduvalli, Vinay K.; Levin, Victor; Conrad, Charles; Maher, Elizabeth A.; Aldape, Kenneth; Hayes, Michael; Letvak, Laurie; Egorin, Merrill J.; Capdeville, Renaud; Kaplan, Richard; Murgo, Anthony J.; Stiles, Charles; Prados, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4899-4907</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Phase I: To det. the max. tolerated doses, toxicities, and pharmacokinetics of imatinib mesylate (Gleevec) in patients with malignant gliomas taking enzyme-inducing antiepileptic drugs (EIAED) or not taking EIAED.  Phase II: To det. the therapeutic efficacy of imatinib.  Exptl. Design: Phase I component used an inter-patient dose escalation scheme.  End points of the phase II component were 6-mo progression-free survival and response.  RESULTS: Fifty patients enrolled in the phase I component (27 EIAED and 23 non-EIAED).  The max. tolerated dose for non-EIAED patients was 800 mg/d.  Dose-limiting toxicities were neutropenia, rash, and elevated alanine aminotransferase.  EIAED patients received up to 1200 mg/d imatinib without developing dose-limiting toxicity.  Plasma exposure of imatinib was reduced by ∼68% in EIAED patients compared with non-EIAED patients.  Fifty-five non-EIAED patients (34 glioblastoma multiforme and 21 anaplastic glioma) enrolled in the phase II component.  Patients initially received 800 mg/d imatinib; 15 anaplastic glioma patients received 600 mg/d after hemorrhages were obsd.  There were 2 partial response and 6 stable disease among glioblastoma multiforme patients and 0 partial response and 5 stable disease among anaplastic glioma patients.  Six-month progression-free survival was 3% for glioblastoma multiforme and 10% for anaplastic glioma patients.  Five phase II patients developed intratumoral hemorrhages.  CONCLUSIONS: Single-agent imatinib has minimal activity in malignant gliomas.  CYP3A4 inducers, such as EIAEDs, substantially decreased plasma exposure of imatinib and should be avoided in patients receiving imatinib for chronic myelogenous leukemia and gastrointestinal stromal tumors.  The evaluation of the activity of combination regimens incorporating imatinib is under way in phase II trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAxZrLJjINsLVg90H21EOLACvtfcHk0liLtJKAG0xkUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotFKgt70%253D&md5=6776f269d0c46042919c98b17db03214</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-0773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-0773%26sid%3Dliteratum%253Aachs%26aulast%3DWen%26aufirst%3DP.%2BY.%26aulast%3DYung%26aufirst%3DW.%2BK.%26aulast%3DLamborn%26aufirst%3DK.%2BR.%26aulast%3DDahia%26aufirst%3DP.%2BL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DAbrey%26aufirst%3DL.%2BE.%26aulast%3DRaizer%26aufirst%3DJ.%26aulast%3DCloughesy%26aufirst%3DT.%2BF.%26aulast%3DFink%26aufirst%3DK.%26aulast%3DGilbert%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DS.%26aulast%3DJunck%26aufirst%3DL.%26aulast%3DSchiff%26aufirst%3DD.%26aulast%3DLieberman%26aufirst%3DF.%26aulast%3DFine%26aufirst%3DH.%2BA.%26aulast%3DMehta%26aufirst%3DM.%26aulast%3DRobins%26aufirst%3DH.%2BI.%26aulast%3DDeAngelis%26aufirst%3DL.%2BM.%26aulast%3DGroves%26aufirst%3DM.%2BD.%26aulast%3DPuduvalli%26aufirst%3DV.%2BK.%26aulast%3DLevin%26aufirst%3DV.%26aulast%3DConrad%26aufirst%3DC.%26aulast%3DMaher%26aufirst%3DE.%2BA.%26aulast%3DAldape%26aufirst%3DK.%26aulast%3DHayes%26aufirst%3DM.%26aulast%3DLetvak%26aufirst%3DL.%26aulast%3DEgorin%26aufirst%3DM.%2BJ.%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DKaplan%26aufirst%3DR.%26aulast%3DMurgo%26aufirst%3DA.%2BJ.%26aulast%3DStiles%26aufirst%3DC.%26aulast%3DPrados%26aufirst%3DM.%2BD.%26atitle%3DPhase%2520I%252FII%2520study%2520of%2520imatinib%2520mesylate%2520for%2520recurrent%2520malignant%2520gliomas%253A%2520North%2520American%2520brain%2520tumor%2520consortium%2520study%252099%25E2%2580%259308%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D4899%26epage%3D4907%26doi%3D10.1158%2F1078-0432.CCR-06-0773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marbach, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemaire, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmquist, W. F.</span></span> <span> </span><span class="NLM_article-title">Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>304</i></span>,  <span class="NLM_fpage">1085</span>– <span class="NLM_lpage">1092</span>, <span class="refDoi"> DOI: 10.1124/jpet.102.045260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1124%2Fjpet.102.045260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=12604685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit1eisrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2003&pages=1085-1092&author=H.+Daiauthor=P.+Marbachauthor=M.+Lemaireauthor=M.+Hayesauthor=W.+F.+Elmquist&title=Distribution+of+STI-571+to+the+brain+is+limited+by+P-glycoprotein-mediated+efflux&doi=10.1124%2Fjpet.102.045260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux</span></div><div class="casAuthors">Dai, Haiqing; Marbach, Peter; Lemaire, Michel; Hayes, Michael; Elmquist, William F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1085-1092</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The adequate distribution of STI-571 (Gleevec) to the central nervous system (CNS) is crit. for its effective use in CNS tumors.  P-glycoprotein-mediated efflux in the blood-brain barrier may play a role in the CNS delivery of this drug.  Whether STI-571 is a substrate of P-glycoprotein was detd. by examg. the directional flux of [14C]STI-571 in parental and MDR1-transfected Madin-Darby canine kidney (MDCK) II epithelial cell monolayers.  The basolateral-to-apical flux of STI-571 was 39-fold greater than the apical-to-basolateral flux in the MDR1-transfected cells and 8-fold greater in the parental cell monolayers.  This difference in directional flux was significantly reduced by a specific P-glycoprotein inhibitor (2R)-anti-5-{3-[4-(10,11-difluoromethanodibenzo- suber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline trihydrochloride (LY335979).  The role of P-glycoprotein in the CNS distribution of STI-571 was examd. in vivo, using wild-type and mdr1a/b (-/-) knockout mice that were orally administered 25 mg/kg [14C]STI-571.  In the wild-type mice, the brain-to-plasma STI-571 concn. ratio at all time points was low (1-3%); however, there was an 11-fold greater brain partitioning of STI-571 at 1 h postdose in the mdr1a/b (-/-) mice compared with the wild-type mice.  When 12.5 mg/kg STI-571 was given i.v., the brain-to-plasma ratio of STI-571 in the mdr1a/b (-/-) mice was approx. 7-fold greater than that of wild-type mice up to 120 min postdose.  These data indicate that STI-571 is a substrate of P-glycoprotein, and that the inhibition of P-glycoprotein affects the transport of STI-571 across MDCKII monolayers.  Moreover, P-glycoprotein plays an important role in limiting the distribution of STI-571 to the CNS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF6vLgl-LGObVg90H21EOLACvtfcHk0liLtJKAG0xkUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit1eisrs%253D&md5=c4f1082f27454e16635d768ce337ce7f</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1124%2Fjpet.102.045260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.102.045260%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DH.%26aulast%3DMarbach%26aufirst%3DP.%26aulast%3DLemaire%26aufirst%3DM.%26aulast%3DHayes%26aufirst%3DM.%26aulast%3DElmquist%26aufirst%3DW.%2BF.%26atitle%3DDistribution%2520of%2520STI-571%2520to%2520the%2520brain%2520is%2520limited%2520by%2520P-glycoprotein-mediated%2520efflux%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2003%26volume%3D304%26spage%3D1085%26epage%3D1092%26doi%3D10.1124%2Fjpet.102.045260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porkka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koskenvesa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundán, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimpiläinen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustjoki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smykla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brethon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccersley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hjorth-Hansen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Höglund, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klamova, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knutsen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffoux, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruber, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brito-Babapulle, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dombret, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duarte, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elonen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paquette, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwaan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F. Y.</span></span> <span> </span><span class="NLM_article-title">Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">1005</span>– <span class="NLM_lpage">1012</span>, <span class="refDoi"> DOI: 10.1182/blood-2008-02-140665</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1182%2Fblood-2008-02-140665" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=18477770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpvVOksL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2008&pages=1005-1012&author=K.+Porkkaauthor=P.+Koskenvesaauthor=T.+Lund%C3%A1nauthor=J.+Rimpil%C3%A4inenauthor=S.+Mustjokiauthor=R.+Smyklaauthor=R.+Wildauthor=R.+Luoauthor=M.+Arnanauthor=B.+Brethonauthor=L.+Eccersleyauthor=H.+Hjorth-Hansenauthor=M.+H%C3%B6glundauthor=H.+Klamovaauthor=H.+Knutsenauthor=S.+Parikhauthor=E.+Raffouxauthor=F.+Gruberauthor=F.+Brito-Babapulleauthor=H.+Dombretauthor=R.+F.+Duarteauthor=E.+Elonenauthor=R.+Paquetteauthor=C.+M.+Zwaanauthor=F.+Y.+Lee&title=Dasatinib+crosses+the+blood-brain+barrier+and+is+an+efficient+therapy+for+central+nervous+system+Philadelphia+chromosome-positive+leukemia&doi=10.1182%2Fblood-2008-02-140665"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system philadelphia chromosome-positive leukemia</span></div><div class="casAuthors">Porkka, Kimmo; Koskenvesa, Perttu; Lundan, Tuija; Rimpilainen, Johanna; Mustjoki, Satu; Smykla, Richard; Wild, Robert; Luo, Roger; Arnan, Montserrat; Brethon, Benoit; Eccersley, Lydia; Hjorth-Hansen, Henrik; Hoglund, Martin; Klamova, Hana; Knutsen, Havar; Parikh, Suhag; Raffoux, Emmanuel; Gruber, Franz; Brito-Babapulle, Finella; Dombret, Herve; Duarte, Rafael F.; Elonen, Erkki; Paquette, Ron; Zwaan, C. Michel; Lee, Francis Y. F.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1005-1012</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Although imatinib, a BCR-ABL tyrosine kinase inhibitor, is used to treat acute Philadelphia chromosome-pos. (Ph+) leukemia, it does not prevent central nervous system (CNS) relapses resulting from poor drug penetration through the blood-brain barrier.  Imatinib and dasatinib (a dual-specific SRC/BCR-ABL kinase inhibitor) were compared in a preclin. mouse model of intracranial Ph+ leukemia.  Clin. dasatinib treatment in patients with CNS Ph+ leukemia was assessed.  In preclin. studies, dasatinib increased survival, whereas imatinib failed to inhibit intracranial tumor growth.  Stabilization and regression of CNS disease were achieved with continued dasatinib administration.  The drug also demonstrated substantial activity in 11 adult and pediatric patients with CNS Ph+ leukemia.  Eleven evaluable patients had clin. significant, long-lasting responses, which were complete in 7 patients.  In 3 addnl. patients, isolated CNS relapse occurred during dasatinib therapy; and in 2 of them, it was caused by expansion of a BCR-ABL-mutated dasatinib-resistant clone, implying selection pressure exerted by the compd. in the CNS.  Dasatinib has promising therapeutic potential in managing intracranial leukemic disease and substantial clin. activity in patients who experience CNS relapse while on imatinib therapy.  This study is registered at ClinicalTrials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc65cpne9-fbVg90H21EOLACvtfcHk0lioUGhmvZy31w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpvVOksL0%253D&md5=2edc2781403f7d921ec732db2e9cd560</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-02-140665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-02-140665%26sid%3Dliteratum%253Aachs%26aulast%3DPorkka%26aufirst%3DK.%26aulast%3DKoskenvesa%26aufirst%3DP.%26aulast%3DLund%25C3%25A1n%26aufirst%3DT.%26aulast%3DRimpil%25C3%25A4inen%26aufirst%3DJ.%26aulast%3DMustjoki%26aufirst%3DS.%26aulast%3DSmykla%26aufirst%3DR.%26aulast%3DWild%26aufirst%3DR.%26aulast%3DLuo%26aufirst%3DR.%26aulast%3DArnan%26aufirst%3DM.%26aulast%3DBrethon%26aufirst%3DB.%26aulast%3DEccersley%26aufirst%3DL.%26aulast%3DHjorth-Hansen%26aufirst%3DH.%26aulast%3DH%25C3%25B6glund%26aufirst%3DM.%26aulast%3DKlamova%26aufirst%3DH.%26aulast%3DKnutsen%26aufirst%3DH.%26aulast%3DParikh%26aufirst%3DS.%26aulast%3DRaffoux%26aufirst%3DE.%26aulast%3DGruber%26aufirst%3DF.%26aulast%3DBrito-Babapulle%26aufirst%3DF.%26aulast%3DDombret%26aufirst%3DH.%26aulast%3DDuarte%26aufirst%3DR.%2BF.%26aulast%3DElonen%26aufirst%3DE.%26aulast%3DPaquette%26aufirst%3DR.%26aulast%3DZwaan%26aufirst%3DC.%2BM.%26aulast%3DLee%26aufirst%3DF.%2BY.%26atitle%3DDasatinib%2520crosses%2520the%2520blood-brain%2520barrier%2520and%2520is%2520an%2520efficient%2520therapy%2520for%2520central%2520nervous%2520system%2520Philadelphia%2520chromosome-positive%2520leukemia%26jtitle%3DBlood%26date%3D2008%26volume%3D112%26spage%3D1005%26epage%3D1012%26doi%3D10.1182%2Fblood-2008-02-140665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, P. S.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3 and alternative splicing</span>. <i>Wiley Interdiscip Rev. RNA</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e1501</span> <span class="refDoi"> DOI: 10.1002/wrna.1501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1002%2Fwrna.1501" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=30118183" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&author=X.+Liuauthor=P.+S.+Klein&title=Glycogen+synthase+kinase-3+and+alternative+splicing&doi=10.1002%2Fwrna.1501"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1002%2Fwrna.1501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fwrna.1501%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DKlein%26aufirst%3DP.%2BS.%26atitle%3DGlycogen%2520synthase%2520kinase-3%2520and%2520alternative%2520splicing%26jtitle%3DWiley%2520Interdiscip%2520Rev.%2520RNA%26date%3D2018%26volume%3D9%26doi%3D10.1002%2Fwrna.1501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arden, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viars, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vestergaard, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Møller, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodgett, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, O.</span></span> <span> </span><span class="NLM_article-title">Chromosomal mapping and mutational analysis of the coding region of the glycogen synthase kinase-3alpha and beta isoforms in patients with NIDDM</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">940</span>– <span class="NLM_lpage">946</span>, <span class="refDoi"> DOI: 10.1007/s001250050771</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1007%2Fs001250050771" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=9267989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADyaK2sXltV2kt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=940-946&author=L.+Hansenauthor=K.+C.+Ardenauthor=S.+B.+Rasmussenauthor=C.+S.+Viarsauthor=H.+Vestergaardauthor=T.+Hansenauthor=A.+M.+M%C3%B8llerauthor=J.+R.+Woodgettauthor=O.+Pedersen&title=Chromosomal+mapping+and+mutational+analysis+of+the+coding+region+of+the+glycogen+synthase+kinase-3alpha+and+beta+isoforms+in+patients+with+NIDDM&doi=10.1007%2Fs001250050771"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Chromosomal mapping and mutational analysis of the coding region of the glycogen synthase kinase-3α and β isoforms in patients with NIDDM</span></div><div class="casAuthors">Hansen, L.; Arden, K. C.; Rasmussen, S. B.; Viars, C. S.; Vestergaard, H.; Hansen, T.; Moller, A. M.; Woodgett, J. R.; Pedersen, O.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetologia</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">940-946</span>CODEN:
                <span class="NLM_cas:coden">DBTGAJ</span>;
        ISSN:<span class="NLM_cas:issn">0012-186X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Activation of glycogen synthesis in skeletal muscle in response to insulin results from the combined inactivation of glycogen synthase kinase-3 (GSK-3) and activation of the protein phosphatase-1, changing the ratio between the inactive phosphorylated state of the glycogen synthase to the active dephosphorylated state.  In a search for genetic defects responsible for the decreased insulin stimulated glycogen synthesis seen in patients with non-insulin-dependent diabetes mellitus (NIDDM) and their glucose-tolerant first-degree relatives the authors performed mutational anal. of the coding region of the 2 isoforms of GSK-3α and GSK-3β in 72 NIDDM patients and 12 control subjects.  No structural changes were detected apart from a few silent mutations.  Mapping of the GSK-3α to chromosome 19q13.1-13.2 and the GSK-3β to chromosome 3q13.3-q21 outside known genetic loci linked to NIDDM further makes it unlikely that these genes are involved in the pathogenesis of common forms of NIDDM [Diabetologia (1997), 40: 940-946].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaPb_ulal5Z7Vg90H21EOLACvtfcHk0lioUGhmvZy31w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXltV2kt7g%253D&md5=c6a2aa87dba5e73148b16a6999ca5e3d</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1007%2Fs001250050771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs001250050771%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DL.%26aulast%3DArden%26aufirst%3DK.%2BC.%26aulast%3DRasmussen%26aufirst%3DS.%2BB.%26aulast%3DViars%26aufirst%3DC.%2BS.%26aulast%3DVestergaard%26aufirst%3DH.%26aulast%3DHansen%26aufirst%3DT.%26aulast%3DM%25C3%25B8ller%26aufirst%3DA.%2BM.%26aulast%3DWoodgett%26aufirst%3DJ.%2BR.%26aulast%3DPedersen%26aufirst%3DO.%26atitle%3DChromosomal%2520mapping%2520and%2520mutational%2520analysis%2520of%2520the%2520coding%2520region%2520of%2520the%2520glycogen%2520synthase%2520kinase-3alpha%2520and%2520beta%2520isoforms%2520in%2520patients%2520with%2520NIDDM%26jtitle%3DDiabetologia%26date%3D1997%26volume%3D40%26spage%3D940%26epage%3D946%26doi%3D10.1007%2Fs001250050771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benajiba, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weïwer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacher, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gale, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puissant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Back, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pikman, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galinsky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeAngelo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robers, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machleidt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermine, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakshminarasimhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemann, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scolnick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegmaier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holson, E. B.</span></span> <span> </span><span class="NLM_article-title">Exploiting an Asp-Glu “switch” in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">eaam8460</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aam8460</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1126%2Fscitranslmed.aam8460" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=29515000" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=eaam8460&author=F.+F.+Wagnerauthor=L.+Benajibaauthor=A.+J.+Campbellauthor=M.+We%C3%AFwerauthor=J.+R.+Sacherauthor=J.+P.+Galeauthor=L.+Rossauthor=A.+Puissantauthor=G.+Alexeauthor=A.+Conwayauthor=M.+Backauthor=Y.+Pikmanauthor=I.+Galinskyauthor=D.+J.+DeAngeloauthor=R.+M.+Stoneauthor=T.+Kayaauthor=X.+Shiauthor=M.+B.+Robersauthor=T.+Machleidtauthor=J.+Wilkinsonauthor=O.+Hermineauthor=A.+Kungauthor=A.+J.+Steinauthor=D.+Lakshminarasimhanauthor=M.+T.+Hemannauthor=E.+Scolnickauthor=Y.+L.+Zhangauthor=J.+Q.+Panauthor=K.+Stegmaierauthor=E.+B.+Holson&title=Exploiting+an+Asp-Glu+%E2%80%9Cswitch%E2%80%9D+in+glycogen+synthase+kinase+3+to+design+paralog-selective+inhibitors+for+use+in+acute+myeloid+leukemia&doi=10.1126%2Fscitranslmed.aam8460"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aam8460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aam8460%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DF.%2BF.%26aulast%3DBenajiba%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DA.%2BJ.%26aulast%3DWe%25C3%25AFwer%26aufirst%3DM.%26aulast%3DSacher%26aufirst%3DJ.%2BR.%26aulast%3DGale%26aufirst%3DJ.%2BP.%26aulast%3DRoss%26aufirst%3DL.%26aulast%3DPuissant%26aufirst%3DA.%26aulast%3DAlexe%26aufirst%3DG.%26aulast%3DConway%26aufirst%3DA.%26aulast%3DBack%26aufirst%3DM.%26aulast%3DPikman%26aufirst%3DY.%26aulast%3DGalinsky%26aufirst%3DI.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DKaya%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DRobers%26aufirst%3DM.%2BB.%26aulast%3DMachleidt%26aufirst%3DT.%26aulast%3DWilkinson%26aufirst%3DJ.%26aulast%3DHermine%26aufirst%3DO.%26aulast%3DKung%26aufirst%3DA.%26aulast%3DStein%26aufirst%3DA.%2BJ.%26aulast%3DLakshminarasimhan%26aufirst%3DD.%26aulast%3DHemann%26aufirst%3DM.%2BT.%26aulast%3DScolnick%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DY.%2BL.%26aulast%3DPan%26aufirst%3DJ.%2BQ.%26aulast%3DStegmaier%26aufirst%3DK.%26aulast%3DHolson%26aufirst%3DE.%2BB.%26atitle%3DExploiting%2520an%2520Asp-Glu%2520%25E2%2580%259Cswitch%25E2%2580%259D%2520in%2520glycogen%2520synthase%2520kinase%25203%2520to%2520design%2520paralog-selective%2520inhibitors%2520for%2520use%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2018%26volume%3D10%26spage%3Deaam8460%26doi%3D10.1126%2Fscitranslmed.aam8460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doble, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodgett, J. R.</span></span> <span> </span><span class="NLM_article-title">GSK-3: Tricks of the trade for a multi-tasking kinase</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">1175</span>– <span class="NLM_lpage">1186</span>, <span class="refDoi"> DOI: 10.1242/jcs.00384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1242%2Fjcs.00384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=12615961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD3sXivFWhtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2003&pages=1175-1186&author=B.+W.+Dobleauthor=J.+R.+Woodgett&title=GSK-3%3A+Tricks+of+the+trade+for+a+multi-tasking+kinase&doi=10.1242%2Fjcs.00384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">GSK-3: Tricks of the trade for a multi-tasking kinase</span></div><div class="casAuthors">Doble, Bradley W.; Woodgett, James R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1175-1186</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  Glycogen synthase kinase-3 (GSK-3) is a multifunctional serine/threonine kinase found in all eukaryotes.  The enzyme is a key regulator of numerous signaling pathways, including cellular responses to Wnt, receptor tyrosine kinases, and G-protein-coupled receptors and is involved in a wide range of cellular processes, ranging from glycogen metab. to cell cycle regulation and proliferation.  GSK-3 is unusual in that it is normally active in cells and is primarily regulated through inhibition of its activity.  Another peculiarity compared with other protein kinases is its preference for primed substrates, i.e., substrates previously phosphorylated by another kinase.  Several recent advances have improved the understanding of GSK-3 regulation in multiple pathways.  These include the soln. of the crystal structure of GSK-3, which has provided insight into GSK-3's penchant for primed substrates and the regulation of GSK-3 by serine phosphorylation, and findings related to the involvement of GSK-3 in the Wnt/β-catenin and Hedgehog pathways.  Finally, since increased GSK-3 activity may be linked to pathol. in diseases such as Alzheimer's disease and non-insulin-dependent diabetes mellitus, several new GSK-3 inhibitors, such as the aloisines, the paullones and the maleimides, have been developed.  Although they are just starting to be characterized in cell culture expts., these new inhibitors hold promise as therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7SGJVebXiRLVg90H21EOLACvtfcHk0ljINY_u-pGTTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXivFWhtbc%253D&md5=fb267e44a019d584b6cac5881e8ed1a9</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1242%2Fjcs.00384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.00384%26sid%3Dliteratum%253Aachs%26aulast%3DDoble%26aufirst%3DB.%2BW.%26aulast%3DWoodgett%26aufirst%3DJ.%2BR.%26atitle%3DGSK-3%253A%2520Tricks%2520of%2520the%2520trade%2520for%2520a%2520multi-tasking%2520kinase%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2003%26volume%3D116%26spage%3D1175%26epage%3D1186%26doi%3D10.1242%2Fjcs.00384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frame, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biondi, R. M.</span></span> <span> </span><span class="NLM_article-title">A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1321</span>– <span class="NLM_lpage">1327</span>, <span class="refDoi"> DOI: 10.1016/S1097-2765(01)00253-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2FS1097-2765%2801%2900253-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=11430833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkvVejsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=1321-1327&author=S.+Frameauthor=P.+Cohenauthor=R.+M.+Biondi&title=A+common+phosphate+binding+site+explains+the+unique+substrate+specificity+of+GSK3+and+its+inactivation+by+phosphorylation&doi=10.1016%2FS1097-2765%2801%2900253-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation</span></div><div class="casAuthors">Frame, Sheelagh; Cohen, Philip; Biondi, Ricardo M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1321-1327</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The inhibition of GSK3 is required for the stimulation of glycogen and protein synthesis by insulin and the specification of cell fate during development.  Here, we demonstrate that the insulin-induced inhibition of GSK3 and its unique substrate specificity are explained by the existence of a phosphate binding site in which Arg-96 is crit.  Thus, mutation of Arg-96 abolishes the phosphorylation of "primed" glycogen synthase as well as inhibition by PKB-mediated phosphorylation of Ser-9.  Hence, the phosphorylated N terminus acts as a pseudosubstrate, occupying the same phosphate binding site used by primed substrates.  Significantly, this mutation does not affect phosphorylation of "non-primed" substrates in the Wnt-signaling pathway (Axin and β-catenin), suggesting new approaches to design more selective GSK3 inhibitors for the treatment of diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp8FVqjCg77LVg90H21EOLACvtfcHk0ljINY_u-pGTTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkvVejsr4%253D&md5=994d36975d1db73b52ab8a01be39175a</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2801%2900253-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252801%252900253-2%26sid%3Dliteratum%253Aachs%26aulast%3DFrame%26aufirst%3DS.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DBiondi%26aufirst%3DR.%2BM.%26atitle%3DA%2520common%2520phosphate%2520binding%2520site%2520explains%2520the%2520unique%2520substrate%2520specificity%2520of%2520GSK3%2520and%2520its%2520inactivation%2520by%2520phosphorylation%26jtitle%3DMol.%2520Cell%26date%3D2001%26volume%3D7%26spage%3D1321%26epage%3D1327%26doi%3D10.1016%2FS1097-2765%2801%2900253-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gumbiner, B. M.</span></span> <span> </span><span class="NLM_article-title">Regulation of protein stability by GSK3 mediated phosphorylation</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">4032</span>– <span class="NLM_lpage">4039</span>, <span class="refDoi"> DOI: 10.4161/cc.8.24.10111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.4161%2Fcc.8.24.10111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=19923896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC3cXotlWru7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=4032-4039&author=C.+Xuauthor=N.+G.+Kimauthor=B.+M.+Gumbiner&title=Regulation+of+protein+stability+by+GSK3+mediated+phosphorylation&doi=10.4161%2Fcc.8.24.10111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of protein stability by GSK3 mediated phosphorylation</span></div><div class="casAuthors">Xu, Chong; Kim, Nam-Gyun; Gumbiner, Barry M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4032-4039</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  Glycogen synthase kinase-3 (GSK3) plays important roles in numerous signaling pathways that regulate a variety of cellular processes including cell proliferation, differentiation, apoptosis and embryonic development.  In the canonical Wnt signaling pathway, GSK3 phosphorylation mediates proteasomal targeting and degrdn. of β-catenin via the destruction complex.  We recently reported a biochem. screen that discovered multiple addnl. protein substrates whose stability is regulated by Wnt signaling and/or GSK3 and these have important implications for Wnt/GSK3 regulation of different cellular processes.  In this article, we also present a bio-informatics based screen for proteins whose stability may be controlled by GSK3 and β-Trcp, the SCF E3 ubiquitin ligase that is responsible for β-catenin degrdn. in the Wnt signaling pathway.  Furthermore, we review various GSK3 regulated proteolysis substrates described in the literature.  We propose that GSK3 phosphorylation dependent proteolysis is a widespread mechanism that the cell employs to regulate a variety of cell processes in response to signals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLdvp6WfBWKrVg90H21EOLACvtfcHk0ljINY_u-pGTTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXotlWru7g%253D&md5=8d89a41f58e318bf45ede52d6ecba030</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.4161%2Fcc.8.24.10111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.8.24.10111%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DN.%2BG.%26aulast%3DGumbiner%26aufirst%3DB.%2BM.%26atitle%3DRegulation%2520of%2520protein%2520stability%2520by%2520GSK3%2520mediated%2520phosphorylation%26jtitle%3DCell%2520Cycle%26date%3D2009%26volume%3D8%26spage%3D4032%26epage%3D4039%26doi%3D10.4161%2Fcc.8.24.10111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beurel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grieco, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jope, R. S.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2014.11.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.pharmthera.2014.11.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=25435019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVeisr7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2015&pages=114-131&author=E.+Beurelauthor=S.+F.+Griecoauthor=R.+S.+Jope&title=Glycogen+synthase+kinase-3+%28GSK3%29%3A+Regulation%2C+actions%2C+and+diseases&doi=10.1016%2Fj.pharmthera.2014.11.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases</span></div><div class="casAuthors">Beurel, Eleonore; Grieco, Steven F.; Jope, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">114-131</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Glycogen synthase kinase-3 (GSK3) may be the busiest kinase in most cells, with over 100 known substrates to deal with.  How does GSK3 maintain control to selectively phosphorylate each substrate, and why was it evolutionarily favorable for GSK3 to assume such a large responsibility.  GSK3 must be particularly adaptable for incorporating new substrates into its repertoire, and we discuss the distinct properties of GSK3 that may contribute to its capacity to fulfill its roles in multiple signaling pathways.  The mechanisms regulating GSK3 (predominantly post-translational modifications, substrate priming, cellular trafficking, protein complexes) have been reviewed previously, so here we focus on newly identified complexities in these mechanisms, how each of these regulatory mechanism contributes to the ability of GSK3 to select which substrates to phosphorylate, and how these mechanisms may have contributed to its adaptability as new substrates evolved.  The current understanding of the mechanisms regulating GSK3 is reviewed, as are emerging topics in the actions of GSK3, particularly its interactions with receptors and receptor-coupled signal transduction events, and differential actions and regulation of the two GSK3 isoforms, GSK3α and GSK3β.  Another remarkable characteristic of GSK3 is its involvement in many prevalent disorders, including psychiatric and neurol. diseases, inflammatory diseases, cancer, and others.  We address the feasibility of targeting GSK3 therapeutically, and provide an update of its involvement in the etiol. and treatment of several disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonota4sOu8PbVg90H21EOLACvtfcHk0lhZeGb2H5F7cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVeisr7J&md5=a6c54e0331492b0b61a9d67b1f07575d</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2014.11.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2014.11.016%26sid%3Dliteratum%253Aachs%26aulast%3DBeurel%26aufirst%3DE.%26aulast%3DGrieco%26aufirst%3DS.%2BF.%26aulast%3DJope%26aufirst%3DR.%2BS.%26atitle%3DGlycogen%2520synthase%2520kinase-3%2520%2528GSK3%2529%253A%2520Regulation%252C%2520actions%252C%2520and%2520diseases%26jtitle%3DPharmacol.%2520Ther.%26date%3D2015%26volume%3D148%26spage%3D114%26epage%3D131%26doi%3D10.1016%2Fj.pharmthera.2014.11.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alessi, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andjelkovich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemmings, B. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">785</span>– <span class="NLM_lpage">789</span>, <span class="refDoi"> DOI: 10.1038/378785a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2F378785a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=8524413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADyaK28XltFWj" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=1995&pages=785-789&author=D.+A.+Crossauthor=D.+R.+Alessiauthor=P.+Cohenauthor=M.+Andjelkovichauthor=B.+A.+Hemmings&title=Inhibition+of+glycogen+synthase+kinase-3+by+insulin+mediated+by+protein+kinase+B&doi=10.1038%2F378785a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B</span></div><div class="casAuthors">Cross, Darren A. E.; Alessi, Dario R.; Cohen, Philip; Andjelkovich, Mirjana; Hemmings, Brian A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">6559</span>),
    <span class="NLM_cas:pages">785-9</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Agents which prevent the activation of both MAP kinase-activated protein kinase-1 and p70S6k by insulin in vivo do not block the phosphorylation and inhibition of glycogen synthase kinase-3 (GSK3) in L6 myotubes.  Another insulin-stimulated protein kinase inactivates GSK3 under these conditions, and the authors demonstrate that it is the product of the proto-oncogene protein kinase B (PKB, also known as Akt/RAC).  Like the inhibition of GSK3, the activation of PKB is prevented by inhibitors of phosphatidylinositol 3-kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKh6GNVgGhFbVg90H21EOLACvtfcHk0lhZeGb2H5F7cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XltFWj&md5=56723cab1f5412b4e55aca875989d1fa</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1038%2F378785a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F378785a0%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DAndjelkovich%26aufirst%3DM.%26aulast%3DHemmings%26aufirst%3DB.%2BA.%26atitle%3DInhibition%2520of%2520glycogen%2520synthase%2520kinase-3%2520by%2520insulin%2520mediated%2520by%2520protein%2520kinase%2520B%26jtitle%3DNature%26date%3D1995%26volume%3D378%26spage%3D785%26epage%3D789%26doi%3D10.1038%2F378785a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span> <span> </span><span class="NLM_article-title">Wnt/beta-catenin signaling: Components, mechanisms, and diseases</span>. <i>Dev. Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/j.devcel.2009.06.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.devcel.2009.06.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=19619488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsV2msb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=9-26&author=B.+T.+MacDonaldauthor=K.+Tamaiauthor=X.+He&title=Wnt%2Fbeta-catenin+signaling%3A+Components%2C+mechanisms%2C+and+diseases&doi=10.1016%2Fj.devcel.2009.06.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Wnt/β-catenin signaling: components, mechanisms, and diseases</span></div><div class="casAuthors">MacDonald, Bryan T.; Tamai, Keiko; He, Xi</div><div class="citationInfo"><span class="NLM_cas:title">Developmental Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-26</span>CODEN:
                <span class="NLM_cas:coden">DCEEBE</span>;
        ISSN:<span class="NLM_cas:issn">1534-5807</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Signaling by the Wnt family of secreted glycolipoproteins via the transcriptional coactivator β-catenin controls embryonic development and adult homeostasis.  Here we review recent progress in this so-called canonical Wnt signaling pathway.  We discuss Wnt ligands, agonists, and antagonists, and their interactions with Wnt receptors.  We also dissect crit. events that regulate β-catenin stability, from Wnt receptors to the cytoplasmic β-catenin destruction complex, and nuclear machinery that mediates β-catenin-dependent transcription.  Finally, we highlight some key aspects of Wnt/β-catenin signaling in human diseases including congenital malformations, cancer, and osteoporosis, and discuss potential therapeutic implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNap4TpxXFWbVg90H21EOLACvtfcHk0lhZeGb2H5F7cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsV2msb8%253D&md5=25e1a7dd5c3aca54a1cfc7993fd5bb43</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.devcel.2009.06.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.devcel.2009.06.016%26sid%3Dliteratum%253Aachs%26aulast%3DMacDonald%26aufirst%3DB.%2BT.%26aulast%3DTamai%26aufirst%3DK.%26aulast%3DHe%26aufirst%3DX.%26atitle%3DWnt%252Fbeta-catenin%2520signaling%253A%2520Components%252C%2520mechanisms%252C%2520and%2520diseases%26jtitle%3DDev.%2520Cell%26date%3D2009%26volume%3D17%26spage%3D9%26epage%3D26%26doi%3D10.1016%2Fj.devcel.2009.06.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Metcalfe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bienz, M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of GSK3 by wnt signalling--two contrasting models</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">3537</span>– <span class="NLM_lpage">3544</span>, <span class="refDoi"> DOI: 10.1242/jcs.091991</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1242%2Fjcs.091991" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=22083140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1OrtrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2011&pages=3537-3544&author=C.+Metcalfeauthor=M.+Bienz&title=Inhibition+of+GSK3+by+wnt+signalling%2D%2Dtwo+contrasting+models&doi=10.1242%2Fjcs.091991"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of GSK3 by Wnt signaling - two contrasting models</span></div><div class="casAuthors">Metcalfe, Ciara; Bienz, Mariann</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3537-3544</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  The key read-out of Wnt signaling is a change in the transcriptional profile of the cell, which is driven by β-catenin.  β-Catenin levels are normally kept low by a phosphorylation event that is mediated by glycogen synthase kinase-3 (GSK3, α- and β-isoforms), which targets β-catenin for ubiquitination and proteasomal degrdn.  Wnt blocks this phosphorylation event, thereby allowing β-catenin to accumulate and to co-activate transcription in the nucleus.  Exactly how Wnt inhibits GSK3 activity toward β-catenin is unclear and has been the focus of intensive research.  Recent studies on the role of conserved PPPSPxS motifs in the cytoplasmic tail of low-d. lipoprotein receptor-related protein (LRP, isoforms 5 and 6) culminated in a biochem. model: Wnt induces the phosphorylation of LRP6 PPPSPxS motifs, which consequently access the catalytic pocket of GSK3 as pseudo-substrates, thus directly blocking its activity against β-catenin.  A distinct cell-biol. model was proposed more recently: Wnt proteins induce the uptake of GSK3 into multivesicular bodies (MVBs), an event that sequesters the enzyme away from newly synthesized β-catenin substrate in the cytoplasm, thus blocking its phosphorylation.  This new model is based on intriguing observations, but also challenges a body of existing evidence, so will require further exptl. consolidation.  The authors discuss whether the 2 models apply to different modes of Wnt signaling: acute vs. chronic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq7IOjo03EtrVg90H21EOLACvtfcHk0liUJ68OY8MZKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1OrtrrL&md5=5ee874619c533fe30b143204d0c77437</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1242%2Fjcs.091991&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.091991%26sid%3Dliteratum%253Aachs%26aulast%3DMetcalfe%26aufirst%3DC.%26aulast%3DBienz%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520GSK3%2520by%2520wnt%2520signalling--two%2520contrasting%2520models%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2011%26volume%3D124%26spage%3D3537%26epage%3D3544%26doi%3D10.1242%2Fjcs.091991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valvezan, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, P. S.</span></span> <span> </span><span class="NLM_article-title">GSK-3 and wnt signaling in neurogenesis and bipolar disorder</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2012.00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.3389%2Ffnmol.2012.00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=22319467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Kks7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2012&pages=1&author=A.+J.+Valvezanauthor=P.+S.+Klein&title=GSK-3+and+wnt+signaling+in+neurogenesis+and+bipolar+disorder&doi=10.3389%2Ffnmol.2012.00001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">GSK-3 and Wnt signaling in neurogenesis and bipolar disorder</span></div><div class="casAuthors">Valvezan, Alexander J.; Klein, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">Jan.</span>),
    <span class="NLM_cas:pages">1</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  The canonical Wnt signaling pathway is crit. for development of the mammalian central nervous system and regulates diverse processes throughout adulthood, including adult neurogenesis.  Glycogen synthase kinase-3 (GSK-3) antagonizes the canonical Wnt pathway and therefore also plays a central role in neural development and adult neurogenesis.  Lithium, the first line of therapy for bipolar disorder, inhibits GSK-3, activates Wnt signaling and stimulates adult neurogenesis, which may be important for its therapeutic effects.  GSK-3 also regulates other crit. signaling pathways which may contribute to the therapeutic effects of lithium, including growth factor/neurotrophin signaling downstream of Akt.  Here we will review the roles of GSK-3 in CNS development and adult neurogenesis, with a focus on the canonical Wnt pathway.  We will also discuss the validation of GSK-3 as the relevant target of lithium and the mechanisms downstream of GSK-3 that influence mammalian behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrye-OzONjfJbVg90H21EOLACvtfcHk0liUJ68OY8MZKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Kks7g%253D&md5=126a406fd1623765a65f8d0ab5d9df84</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2012.00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2012.00001%26sid%3Dliteratum%253Aachs%26aulast%3DValvezan%26aufirst%3DA.%2BJ.%26aulast%3DKlein%26aufirst%3DP.%2BS.%26atitle%3DGSK-3%2520and%2520wnt%2520signaling%2520in%2520neurogenesis%2520and%2520bipolar%2520disorder%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2012%26volume%3D5%26spage%3D1%26doi%3D10.3389%2Ffnmol.2012.00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salcedo-Tello, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz-Matamoros, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arias, C.</span></span> <span> </span><span class="NLM_article-title">GSK3 function in the brain during development, neuronal plasticity, and neurodegeneration</span>. <i>Int. J. Alzheimer's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2011</i></span>,  <span class="NLM_fpage">189728</span>, <span class="refDoi"> DOI: 10.4061/2011/189728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.4061%2F2011%2F189728" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=21660241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BC3Mrpt1alsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=189728&author=P.+Salcedo-Telloauthor=A.+Ortiz-Matamorosauthor=C.+Arias&title=GSK3+function+in+the+brain+during+development%2C+neuronal+plasticity%2C+and+neurodegeneration&doi=10.4061%2F2011%2F189728"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">GSK3 Function in the Brain during Development, Neuronal Plasticity, and Neurodegeneration</span></div><div class="casAuthors">Salcedo-Tello Pamela; Ortiz-Matamoros Abril; Arias Clorinda</div><div class="citationInfo"><span class="NLM_cas:title">International journal of Alzheimer's disease</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2011</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">189728</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">GSK3 has diverse functions, including an important role in brain pathology.  In this paper, we address the primary functions of GSK3 in development and neuroplasticity, which appear to be interrelated and to mediate age-associated neurological diseases.  Specifically, GSK3 plays a pivotal role in controlling neuronal progenitor proliferation and establishment of neuronal polarity during development, and the upstream and downstream signals modulating neuronal GSK3 function affect cytoskeletal reorganization and neuroplasticity throughout the lifespan.  Modulation of GSK3 in brain areas subserving cognitive function has become a major focus for treating neuropsychiatric and neurodegenerative diseases.  As a crucial node that mediates a variety of neuronal processes, GSK3 is proposed to be a therapeutic target for restoration of synaptic functioning and cognition, particularly in Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTSWpsFFc4A4BKDYG3bNImrfW6udTcc2eYWh7kC4DyxXbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mrpt1alsQ%253D%253D&md5=817cf22bd2735fe4d1c6249959a690ef</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.4061%2F2011%2F189728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4061%252F2011%252F189728%26sid%3Dliteratum%253Aachs%26aulast%3DSalcedo-Tello%26aufirst%3DP.%26aulast%3DOrtiz-Matamoros%26aufirst%3DA.%26aulast%3DArias%26aufirst%3DC.%26atitle%3DGSK3%2520function%2520in%2520the%2520brain%2520during%2520development%252C%2520neuronal%2520plasticity%252C%2520and%2520neurodegeneration%26jtitle%3DInt.%2520J.%2520Alzheimer%2527s%2520Dis.%26date%3D2011%26volume%3D2011%26spage%3D189728%26doi%3D10.4061%2F2011%2F189728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joo, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cha, C. I.</span></span> <span> </span><span class="NLM_article-title">Age-related changes in glycogen synthase kinase 3beta (GSK3beta) immunoreactivity in the central nervous system of rats</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>409</i></span>,  <span class="NLM_fpage">134</span>– <span class="NLM_lpage">139</span>, <span class="refDoi"> DOI: 10.1016/j.neulet.2006.09.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.neulet.2006.09.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=17046157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFerurjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=409&publication_year=2006&pages=134-139&author=S.+J.+Leeauthor=Y.+H.+Chungauthor=K.+M.+Jooauthor=H.+C.+Limauthor=G.+S.+Jeonauthor=D.+Kimauthor=W.+B.+Leeauthor=Y.+S.+Kimauthor=C.+I.+Cha&title=Age-related+changes+in+glycogen+synthase+kinase+3beta+%28GSK3beta%29+immunoreactivity+in+the+central+nervous+system+of+rats&doi=10.1016%2Fj.neulet.2006.09.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Age-related changes in glycogen synthase kinase 3β (GSK3β) immunoreactivity in the central nervous system of rats</span></div><div class="casAuthors">Lee, Soo Joo; Chung, Yoon Hee; Joo, Kyeung Min; Lim, Heon Chang; Jeon, Gye Sun; Kim, Daejin; Lee, Won Bok; Kim, Yong Sik; Cha, Choong Ik</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">409</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">134-139</span>CODEN:
                <span class="NLM_cas:coden">NELED5</span>;
        ISSN:<span class="NLM_cas:issn">0304-3940</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Although glycogen synthase kinase 3β (GSK3β) is emerging as a prominent drug target in the treatment of neurodegenerative diseases such as Alzheimer's disease (AD) and stroke, very little is known about age-related changes in GSK3β expression and GSK3β phosphorylation.  Therefore, we examd. age-related changes in immunoreactivities for GSK3β and phosphorylated GSK3β (pGSK3β) in the central nervous system.  In aged rats, there were significant increases in GSK3β immunoreactivity in the cell bodies and processes of pyramidal cells in most cortical regions.  GSK3β immunoreactivity was also significantly increased in the pyramidal layer of CA1-3 regions, and the granule cell layer of dentate gyrus.  Age-related increases were prominent in lateral septal nuclei, compared to the medial septal nuclei.  Interestingly, both GSK3β and pGSK3β was increased in the prefrontal cortex, while GSK3β and pGSK3β was differentially localized in the cerebellar cortex.  The first demonstration of age-related alterations in immunoreactivities for GSK3β and pGSK3β in the basal forebrain area and cholinergic projection targets may provide useful data for investigating the pathogenesis of age-related neurodegenerative diseases including AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCfWv5OuCta7Vg90H21EOLACvtfcHk0liUJ68OY8MZKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFerurjO&md5=3593884bff31c615b4a0bccb9299600e</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.neulet.2006.09.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neulet.2006.09.026%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DChung%26aufirst%3DY.%2BH.%26aulast%3DJoo%26aufirst%3DK.%2BM.%26aulast%3DLim%26aufirst%3DH.%2BC.%26aulast%3DJeon%26aufirst%3DG.%2BS.%26aulast%3DKim%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DW.%2BB.%26aulast%3DKim%26aufirst%3DY.%2BS.%26aulast%3DCha%26aufirst%3DC.%2BI.%26atitle%3DAge-related%2520changes%2520in%2520glycogen%2520synthase%2520kinase%25203beta%2520%2528GSK3beta%2529%2520immunoreactivity%2520in%2520the%2520central%2520nervous%2520system%2520of%2520rats%26jtitle%3DNeurosci.%2520Lett.%26date%3D2006%26volume%3D409%26spage%3D134%26epage%3D139%26doi%3D10.1016%2Fj.neulet.2006.09.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span> <span> </span><span class="NLM_article-title">The role of GSK3beta in the development of the central nervous system</span>. <i>Front. Biol. (Beijing, China)</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">212</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1007/s11515-012-1222-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1007%2Fs11515-012-1222-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=25688261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsFGit7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=212-220&author=J.+Luo&title=The+role+of+GSK3beta+in+the+development+of+the+central+nervous+system&doi=10.1007%2Fs11515-012-1222-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">The role of GSK3beta in the development of the central nervous system</span></div><div class="casAuthors">Luo, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Biology (Beijing, China)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">212-220</span>CODEN:
                <span class="NLM_cas:coden">FBRIA3</span>;
        ISSN:<span class="NLM_cas:issn">1674-7984</span>.
    
            (<span class="NLM_cas:orgname">Higher Education Press</span>)
        </div><div class="casAbstract">A review.  Glycogen synthase kinase 3β (GSK3β) is a multifunctional serine/threonine kinase.  It is particularly abundant in the developing central nervous system (CNS).  Since GSK3β has diverse substrates ranging from metabolic/signaling proteins and structural proteins to transcription factors, it is involved in many developmental events in the immature brain, such as neurogenesis, neuronal migration, differentiation and survival.  The activity of GSK3β is developmentally regulated and is affected by various environmental/cellular insults, such as deprivation of nutrients/trophic factors, oxidative stress and endoplasmic reticulum stress.  Abnormalities in GSK3β activity may disrupt CNS development.  Therefore, GSK3β is a crit. signaling protein that regulates brain development.  It may also det. neuronal susceptibility to damages caused by various environmental insults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDh9aAoCAcXbVg90H21EOLACvtfcHk0lgvyIGL8UMgtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsFGit7o%253D&md5=e508714d47c9f85da04c30c8a74c33d9</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1007%2Fs11515-012-1222-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11515-012-1222-2%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DJ.%26atitle%3DThe%2520role%2520of%2520GSK3beta%2520in%2520the%2520development%2520of%2520the%2520central%2520nervous%2520system%26jtitle%3DFront.%2520Biol.%2520%2528Beijing%252C%2520China%2529%26date%3D2012%26volume%3D7%26spage%3D212%26epage%3D220%26doi%3D10.1007%2Fs11515-012-1222-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hur, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F. Q.</span></span> <span> </span><span class="NLM_article-title">GSK3 signalling in neural development</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">539</span>– <span class="NLM_lpage">551</span>, <span class="refDoi"> DOI: 10.1038/nrn2870</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2Fnrn2870" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=20648061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptVGisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=539-551&author=E.+M.+Hurauthor=F.+Q.+Zhou&title=GSK3+signalling+in+neural+development&doi=10.1038%2Fnrn2870"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">GSK3 signaling in neural development</span></div><div class="casAuthors">Hur, Eun-Mi; Zhou, Feng-Quan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">539-551</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Recent evidence suggests that glycogen synthase kinase-3 (GSK3) proteins and their upstream and downstream regulators have key roles in many fundamental processes during neurodevelopment.  Disruption of GSK3 signaling adversely affects brain development and is assocd. with several neurodevelopmental disorders.  Here, the authors discuss the mechanisms by which GSK3 activity is regulated in the nervous system and provide an overview of the recent advances in the understanding of how GSK3 signaling controls neurogenesis, neuronal polarization, and axon growth during brain development.  These recent advances suggest that GSK3 is a crucial node that mediates various cellular processes that are controlled by multiple signaling mols., e.g., disrupted in schizophrenia 1 (DISC1), partitioning defective homolog 3 (PAR3), PAR6, and Wnt proteins, that regulate neurodevelopment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiOzmiQawg1rVg90H21EOLACvtfcHk0lgvyIGL8UMgtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptVGisro%253D&md5=7ad4651b8fd5a97028df1a57be2c4b38</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2Fnrn2870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn2870%26sid%3Dliteratum%253Aachs%26aulast%3DHur%26aufirst%3DE.%2BM.%26aulast%3DZhou%26aufirst%3DF.%2BQ.%26atitle%3DGSK3%2520signalling%2520in%2520neural%2520development%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2010%26volume%3D11%26spage%3D539%26epage%3D551%26doi%3D10.1038%2Fnrn2870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jaworski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banach-Kasper, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gralec, K.</span></span> <span> </span><span class="NLM_article-title">GSK-3 at the intersection of neuronal plasticity and neurodegeneration</span>. <i>Neural Plast.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>2019</i></span>,  <span class="NLM_fpage">4209475</span>, <span class="refDoi"> DOI: 10.1155/2019/4209475</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1155%2F2019%2F4209475" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=31191636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BB3M3mtVWmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2019&publication_year=2019&pages=4209475&author=T.+Jaworskiauthor=E.+Banach-Kasperauthor=K.+Gralec&title=GSK-3+at+the+intersection+of+neuronal+plasticity+and+neurodegeneration&doi=10.1155%2F2019%2F4209475"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">GSK-3β at the Intersection of Neuronal Plasticity and Neurodegeneration</span></div><div class="casAuthors">Jaworski Tomasz; Banach-Kasper Ewa; Gralec Katarzyna</div><div class="citationInfo"><span class="NLM_cas:title">Neural plasticity</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">2019</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4209475</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In neurons, Glycogen Synthase Kinase-3β (GSK-3β) has been shown to regulate various critical processes underlying structural and functional synaptic plasticity.  Mouse models with neuron-selective expression or deletion of GSK-3β present behavioral and cognitive abnormalities, positioning this protein kinase as a key signaling molecule in normal brain functioning.  Furthermore, mouse models with defective GSK-3β activity display distinct structural and behavioral abnormalities, which model some aspects of different neurological and neuropsychiatric disorders.  Equalizing GSK-3β activity in these mouse models by genetic or pharmacological interventions is able to rescue some of these abnormalities.  Thus, GSK-3β is a relevant therapeutic target for the treatment of many brain disorders.  Here, we provide an overview of how GSK-3β is regulated in physiological synaptic plasticity and how aberrant GSK-3β activity contributes to the development of dysfunctional synaptic plasticity in neuropsychiatric and neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQMWTmz72EpP7ZpSb_XWfMrfW6udTcc2eYCVTSspQ3agLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3mtVWmtg%253D%253D&md5=0b0c558757f5d282532f9b894d51910a</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1155%2F2019%2F4209475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2019%252F4209475%26sid%3Dliteratum%253Aachs%26aulast%3DJaworski%26aufirst%3DT.%26aulast%3DBanach-Kasper%26aufirst%3DE.%26aulast%3DGralec%26aufirst%3DK.%26atitle%3DGSK-3%2520at%2520the%2520intersection%2520of%2520neuronal%2520plasticity%2520and%2520neurodegeneration%26jtitle%3DNeural%2520Plast.%26date%3D2019%26volume%3D2019%26spage%3D4209475%26doi%3D10.1155%2F2019%2F4209475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giese, K. P.</span></span> <span> </span><span class="NLM_article-title">GSK-3: A key player in neurodegeneration and memory</span>. <i>IUBMB Life</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">516</span>– <span class="NLM_lpage">521</span>, <span class="refDoi"> DOI: 10.1002/iub.187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1002%2Fiub.187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=19391164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFCgsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2009&pages=516-521&author=K.+P.+Giese&title=GSK-3%3A+A+key+player+in+neurodegeneration+and+memory&doi=10.1002%2Fiub.187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">GSK-3: a key player in neurodegeneration and memory</span></div><div class="casAuthors">Giese, Karl Peter</div><div class="citationInfo"><span class="NLM_cas:title">IUBMB Life</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">516-521</span>CODEN:
                <span class="NLM_cas:coden">IULIF8</span>;
        ISSN:<span class="NLM_cas:issn">1521-6543</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Inc.</span>)
        </div><div class="casAbstract">A review.  Abnormalities in mol. signalling have been implicated in neurodegeneration.  It is emerging that glycogen synthase kinase-3 (GSK-3) is a key signalling mol. that induces neurodegeneration and deficits in memory formation related to Alzheimer's disease (AD).  Early stages of AD are assocd. with deficits in memory formation before neuronal cell death is detectable.  Recent studies in rodents have suggested that these impairments in memory formation might result from increased GSK-3 signalling, because enhanced GSK-3 activity impairs hippocampal memory formation.  GSK-3 activity blocks synaptic long-term potentiation and induces long-term depression.  Furthermore, increased GSK-3 signalling is likely to be a key contributor to the formation of the pathol. hallmarks in AD, neurofibrillary tangles (NFTs) and amyloid plaques.  Recent studies with mouse models have indicated that GSK-3, but not cyclin-dependent kinase 5, is crit. for hyperphosphorylation of the cytoskeletal protein tau, which is the prerequisite for NFT formation in AD.  Furthermore, increased GSK-3 signalling in AD mice causes abnormal processing of the amyloid precursor protein so that amyloid peptide prodn. augments and neurotoxicity is induced.  Taken together, the current evidences suggest that increased GSK-3 signalling may be responsible for the deficits in memory formation in early stages of AD and neurodegeneration in later stages of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfGAuMfcOC_bVg90H21EOLACvtfcHk0ljfAQUHI3HBWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFCgsLk%253D&md5=eb868c3ad7371c3a7a07ccbf1648fe98</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1002%2Fiub.187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fiub.187%26sid%3Dliteratum%253Aachs%26aulast%3DGiese%26aufirst%3DK.%2BP.%26atitle%3DGSK-3%253A%2520A%2520key%2520player%2520in%2520neurodegeneration%2520and%2520memory%26jtitle%3DIUBMB%2520Life%26date%3D2009%26volume%3D61%26spage%3D516%26epage%3D521%26doi%3D10.1002%2Fiub.187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Llorens-Martín, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurado, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernández, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avila, J.</span></span> <span> </span><span class="NLM_article-title">GSK-3β, a pivotal kinase in Alzheimer disease</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">46</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2014.00046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.3389%2Ffnmol.2014.00046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=24904272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVaqs7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=46&author=M.+Llorens-Mart%C3%ADnauthor=J.+Juradoauthor=F.+Hern%C3%A1ndezauthor=J.+Avila&title=GSK-3%CE%B2%2C+a+pivotal+kinase+in+Alzheimer+disease&doi=10.3389%2Ffnmol.2014.00046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">GSK-3β, a pivotal kinase in Alzheimer disease</span></div><div class="casAuthors">Llorens-Martin, Maria; Jurado, Jeronimo; Hernandez, Felix; Avila, Jesus</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46/1-46/11, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Alzheimer disease (AD) is the most common form of age-related dementia.  The etiol. of AD is considered to be multifactorial as only a negligible percentage of cases have a familial or genetic origin.  Glycogen synthase kinase-3 (GSK-3) is regarded as a crit. mol. link between the two histopathol. hallmarks of the disease, namely senile plaques and neurofibrillary tangles.  In this review, we summarize current data regarding the involvement of this kinase in several aspects of AD development and progression, as well as key observations highlighting GSK-3 as one of the most relevant targets for AD treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-u6YWBRA8XLVg90H21EOLACvtfcHk0ljfAQUHI3HBWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVaqs7fM&md5=7ea2969c4a89644aebb73701cf7b7d60</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2014.00046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2014.00046%26sid%3Dliteratum%253Aachs%26aulast%3DLlorens-Mart%25C3%25ADn%26aufirst%3DM.%26aulast%3DJurado%26aufirst%3DJ.%26aulast%3DHern%25C3%25A1ndez%26aufirst%3DF.%26aulast%3DAvila%26aufirst%3DJ.%26atitle%3DGSK-3%25CE%25B2%252C%2520a%2520pivotal%2520kinase%2520in%2520Alzheimer%2520disease%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2014%26volume%3D7%26spage%3D46%26doi%3D10.3389%2Ffnmol.2014.00046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanger, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodgett, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brion, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, B. H.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3 induces Alzheimer’s disease-like phosphorylation of tau: Generation of paired helical filament epitopes and neuronal localisation of the kinase</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">62</span>, <span class="refDoi"> DOI: 10.1016/0304-3940(92)90774-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2F0304-3940%2892%2990774-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1336152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADyaK3sXpvFGksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=1992&pages=58-62&author=D.+P.+Hangerauthor=K.+Hughesauthor=J.+R.+Woodgettauthor=J.+P.+Brionauthor=B.+H.+Anderton&title=Glycogen+synthase+kinase-3+induces+Alzheimer%E2%80%99s+disease-like+phosphorylation+of+tau%3A+Generation+of+paired+helical+filament+epitopes+and+neuronal+localisation+of+the+kinase&doi=10.1016%2F0304-3940%2892%2990774-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau:  generation of paired helical filament epitopes and neuronal localization of the kinase</span></div><div class="casAuthors">Hanger, Diane P.; Hughes, Kenneth; Woodgett, James R.; Brion, Jean Pierre; Anderton, Brian H.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience Letters</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-62</span>CODEN:
                <span class="NLM_cas:coden">NELED5</span>;
        ISSN:<span class="NLM_cas:issn">0304-3940</span>.
    </div><div class="casAbstract">Glycogen synthase kinase-3 (GSK-3) reduced the mobility of human tau on SDS-PAGE, prevented binding of the monoclonal antibody (mAb) Tau. 1, and induced binding of the mAb 8D8.  Recombinant tau phosphorylated by GSK-3 aligned on SDS-PAGE with the abnormally phosphorylated tau (PHF-tau) assocd. with the paired helical filaments in Alzheimer's disease brain.  Phosphorylated serine396 (numbering of the largest human brain tau isoform) was identified as a binding site on tau for mAb 8D8.  The localization of GSK-3 within granular structures in pyramidal cells indicates that GSK-3α and GSK-3β may have a role in the prodn. of PHF-tau in Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOM1_KaxlV9LVg90H21EOLACvtfcHk0ljfAQUHI3HBWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXpvFGksg%253D%253D&md5=88d0a3271ce167362ce8b363bae5dbf4</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2F0304-3940%2892%2990774-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0304-3940%252892%252990774-2%26sid%3Dliteratum%253Aachs%26aulast%3DHanger%26aufirst%3DD.%2BP.%26aulast%3DHughes%26aufirst%3DK.%26aulast%3DWoodgett%26aufirst%3DJ.%2BR.%26aulast%3DBrion%26aufirst%3DJ.%2BP.%26aulast%3DAnderton%26aufirst%3DB.%2BH.%26atitle%3DGlycogen%2520synthase%2520kinase-3%2520induces%2520Alzheimer%25E2%2580%2599s%2520disease-like%2520phosphorylation%2520of%2520tau%253A%2520Generation%2520of%2520paired%2520helical%2520filament%2520epitopes%2520and%2520neuronal%2520localisation%2520of%2520the%2520kinase%26jtitle%3DNeurosci.%2520Lett.%26date%3D1992%26volume%3D147%26spage%3D58%26epage%3D62%26doi%3D10.1016%2F0304-3940%2892%2990774-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Medina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wandosell, F. G.</span></span> <span> </span><span class="NLM_article-title">Modulation of GSK-3 as a therapeutic strategy on tau pathologies</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">24</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2011.00024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.3389%2Ffnmol.2011.00024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=22007157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC38XovVOr" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=24&author=M.+Medinaauthor=J.+J.+Garridoauthor=F.+G.+Wandosell&title=Modulation+of+GSK-3+as+a+therapeutic+strategy+on+tau+pathologies&doi=10.3389%2Ffnmol.2011.00024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of GSK-3 as a therapeutic strategy on tau pathologies</span></div><div class="casAuthors">Medina, Miguel; Garrido, Juan Jose; Wandosell, Francisco G.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">Oct.</span>),
    <span class="NLM_cas:pages">24</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Glycogen synthase kinase-3 (GSK-3) is ubiquitously expressed and unusually active in resting, non-stimulated cells.  In mammals, at least three proteins (α, β1, and β2), generated from two different genes, gsk-3α and gsk-3β, are widely expressed at both the RNA and protein levels although some tissues show preferential expression of some of the three proteins.  Control of GSK-3 activity occurs by complex mechanisms that depend on specific signaling pathways, often controlling the inhibition of the kinase activity.  GSK-3 appears to integrate different signaling pathways from a wide selection of cellular stimuli.  The unique position of GSK-3 in modulating the function of a diverse series of proteins and its assocn. with a wide variety of human disorders has attracted significant attention as a therapeutic target and as a means to understand the mol. basis of brain disorders.  Different neurodegenerative diseases including frontotemporal dementia, progressive supranuclear palsy, and Alzheimer's disease, present prominent tau pathol. such as tau hyperphosphorylation and aggregation and are collectively referred to as tauopathies.  GSK-3 has also been assocd. to different neuropsychiatric disorders, like schizophrenia and bipolar disorder.  GSK-3β is the major kinase to phosphorylate tau both in vitro and in vivo and has been proposed as a target for therapeutic intervention.  The first therapeutic strategy to modulate GSK-3 activity was the direct inhibition of its kinase activity.  This review will focus on the signaling pathways involved in the control of GSK-3 activity and its pathol. deregulation.  We will highlight different alternatives of GSK-3 modulation including the direct pharmacol. inhibition as compared to the modulation by upstream regulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozOpI-IGncc7Vg90H21EOLACvtfcHk0ljfAQUHI3HBWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovVOr&md5=ba4d1b446707beabb6db326ec3d6b951</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2011.00024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2011.00024%26sid%3Dliteratum%253Aachs%26aulast%3DMedina%26aufirst%3DM.%26aulast%3DGarrido%26aufirst%3DJ.%2BJ.%26aulast%3DWandosell%26aufirst%3DF.%2BG.%26atitle%3DModulation%2520of%2520GSK-3%2520as%2520a%2520therapeutic%2520strategy%2520on%2520tau%2520pathologies%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2011%26volume%3D4%26spage%3D24%26doi%3D10.3389%2Ffnmol.2011.00024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaworski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Leuven, F.</span></span> <span> </span><span class="NLM_article-title">GSK3 and Alzheimer’s disease: Facts and fiction...</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">17</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2011.00017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.3389%2Ffnmol.2011.00017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=21904524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC38XovVKr" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=17&author=A.+Kremerauthor=J.+V.+Louisauthor=T.+Jaworskiauthor=F.+Van+Leuven&title=GSK3+and+Alzheimer%E2%80%99s+disease%3A+Facts+and+fiction...&doi=10.3389%2Ffnmol.2011.00017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">GSK3 and Alzheimer's disease: facts and fiction</span></div><div class="casAuthors">Kremer, Anna; Louis, Justin V.; Jaworski, Tomasz; Van Leuven, Fred</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">Aug.</span>),
    <span class="NLM_cas:pages">17</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  The physiol. functions and pathol. roles of the Glycogen synthase kinase-type 3 (GSK3) kinases in peripheral and central systems are diverse and complex, and therefore hard to unravel in mol. detail in vivo.  Our assignment to review and discuss available data to clarify the actual position of these kinases in the pathol. of Alzheimer's dementia (AD) was both ambitious and easy.  On the one hand, numerous studies are available in isolated, recombinant, or cell-based systems, which have resulted in very diverse data-sets that are hardly informative for the brain in vivo.  At the other extreme, reliable, and relevant models for the role of GSK3 in CNS are rare, if not lacking.  Moreover, (too) many in vivo studies used Li+ as "specific" inhibitor of GSK3, which is factually not valid because lithium ions are neither specific nor potent inhibitors of GSK3 in vivo.  More specific pharmacol. inhibitors of GSK3 have met with considerable problems, and are reviewed by others in this issue or elsewhere.  We conc. here on AD-related aspects of GSK3 in brain in vivo, mainly studied in transgenic mice and highlight some of the more important issues, among many remaining: activation of GSK3 by amyloid, phosphorylation of protein tau, effects on or interference with synaptic activity, differentiation between both GSK3 isoforms.  These relate directly to brain function, and brain dysfunction in AD, and are to be resolved if we want to understand the mol. pathol. of this dreadful disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkyOq4ZInd37Vg90H21EOLACvtfcHk0liSxPerwL9-NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovVKr&md5=ca9888444963da083e23df3c17a51521</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2011.00017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2011.00017%26sid%3Dliteratum%253Aachs%26aulast%3DKremer%26aufirst%3DA.%26aulast%3DLouis%26aufirst%3DJ.%2BV.%26aulast%3DJaworski%26aufirst%3DT.%26aulast%3DVan%2BLeuven%26aufirst%3DF.%26atitle%3DGSK3%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520Facts%2520and%2520fiction...%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2011%26volume%3D4%26spage%3D17%26doi%3D10.3389%2Ffnmol.2011.00017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melcher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H. E.</span></span> <span> </span><span class="NLM_article-title">Amyloid beta: Structure, biology and structure-based therapeutic development</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1205</span>– <span class="NLM_lpage">1235</span>, <span class="refDoi"> DOI: 10.1038/aps.2017.28</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2Faps.2017.28" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=28713158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVektLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2017&pages=1205-1235&author=G.+F.+Chenauthor=T.+H.+Xuauthor=Y.+Yanauthor=Y.+R.+Zhouauthor=Y.+Jiangauthor=K.+Melcherauthor=H.+E.+Xu&title=Amyloid+beta%3A+Structure%2C+biology+and+structure-based+therapeutic+development&doi=10.1038%2Faps.2017.28"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Amyloid beta: structure, biology and structure-based therapeutic development</span></div><div class="casAuthors">Chen, Guo-fang; Xu, Ting-hai; Yan, Yan; Zhou, Yu-ren; Jiang, Yi; Melcher, Karsten; Xu, H. Eric</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1205-1235</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Amyloid beta peptide (Aβ) is produced through the proteolytic processing of a transmembrane protein, amyloid precursor protein (APP), by β- and γ-secretases.  Aβ accumulation in the brain is proposed to be an early toxic event in the pathogenesis of Alzheimer's disease, which is the most common form of dementia assocd. with plaques and tangles in the brain.  Currently, it is unclear what the physiol. and pathol. forms of Aβ are and by what mechanism Aβ causes dementia.  Moreover, there are no efficient drugs to stop or reverse the progression of Alzheimer's disease.  In this paper, we review the structures, biol. functions, and neurotoxicity role of Aβ.  We also discuss the potential receptors that interact with Aβ and mediate Aβ intake, clearance, and metab.  Addnl., we summarize the therapeutic developments and recent advances of different strategies for treating Alzheimer's disease.  Finally, we will report on the progress in searching for novel, potentially effective agents as well as selected promising strategies for the treatment of Alzheimer's disease.  These prospects include agents acting on Aβ, its receptors and tau protein, such as small mols., vaccines and antibodies against Aβ; inhibitors or modulators of β- and γ-secretase; Aβ-degrading proteases; tau protein inhibitors and vaccines; amyloid dyes and microRNAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC9Hw1Lo4LXbVg90H21EOLACvtfcHk0liSxPerwL9-NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVektLbM&md5=b29b9899f56ebeecf5bce2cd80b04d2a</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1038%2Faps.2017.28&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2017.28%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DG.%2BF.%26aulast%3DXu%26aufirst%3DT.%2BH.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.%2BR.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DMelcher%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DH.%2BE.%26atitle%3DAmyloid%2520beta%253A%2520Structure%252C%2520biology%2520and%2520structure-based%2520therapeutic%2520development%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2017%26volume%3D38%26spage%3D1205%26epage%3D1235%26doi%3D10.1038%2Faps.2017.28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uemura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuzuya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimozono, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoyagi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimohama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, A.</span></span> <span> </span><span class="NLM_article-title">GSK3beta activity modifies the localization and function of presenilin 1</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>282</i></span>,  <span class="NLM_fpage">15823</span>– <span class="NLM_lpage">15832</span>, <span class="refDoi"> DOI: 10.1074/jbc.M610708200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1074%2Fjbc.M610708200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=17389597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltl2ns7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=15823-15832&author=K.+Uemuraauthor=A.+Kuzuyaauthor=Y.+Shimozonoauthor=N.+Aoyagiauthor=K.+Andoauthor=S.+Shimohamaauthor=A.+Kinoshita&title=GSK3beta+activity+modifies+the+localization+and+function+of+presenilin+1&doi=10.1074%2Fjbc.M610708200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">GSK3β Activity Modifies the Localization and Function of Presenilin 1</span></div><div class="casAuthors">Uemura, Kengo; Kuzuya, Akira; Shimozono, Yoshiharu; Aoyagi, Nobuhisa; Ando, Koichi; Shimohama, Shun; Kinoshita, Ayae</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">15823-15832</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Presenilin 1, a causative gene product of familial Alzheimer disease, has been reported to be localized mainly in the endoplasmic reticulum and Golgi membranes.  However, endogenous Presenilin 1 also localizes at the plasma membrane as a biol. active mol.  Presenilin 1 interacts with N-cadherin/β-catenin to form a trimeric complex at the synaptic site through its loop domain, whose serine residues (serine 353 and 357) can be phosphorylated by glycogen synthase kinase 3β.  Here, we demonstrate that cell-surface expression of Presenilin 1/γ-secretase is enhanced by N-cadherin-based cell-cell contact.  Phys. interaction between Presenilin 1 and N-cadherin/β-catenin plays an important role in this process.  Glycogen synthase kinase 3β-mediated phosphorylation of Presenilin 1 reduces its binding to N-cadherin, thereby down-regulating its cell-surface expression.  Moreover, redn. of the Presenilin 1·N-cadherin·β-catenin complex formation leads to an impaired activation of contact-mediated phosphatidylinositol 3-kinase/Akt cell survival signaling.  Furthermore, phosphorylation of Presenilin 1 hinders ε-cleavage of N-cadherin, whereas ε-cleavage of APP remained unchanged.  This is the first report that clarifies the regulatory mechanism of Presenilin 1/γ-secretase with respect to its subcellular distribution and its differential substrate cleavage.  Because the cleavage of various membrane proteins by Presenilin 1/γ-cleavage is involved in cellular signaling, glycogen synthase kinase 3β-mediated phosphorylation of Presenilin 1 should be deeply assocd. with signaling functions.  Our findings indicate that the abnormal activation of glycogen synthase kinase 3β can reduce neuronal viability and synaptic plasticity via modulating Presenilin 1/N-cadherin/β-catenin interaction and thus have important implications in the pathophysiol. of Alzheimer disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvgbs5a8_hL7Vg90H21EOLACvtfcHk0liSxPerwL9-NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltl2ns7Y%253D&md5=196ac5747507f94a668eec0766e763d1</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M610708200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M610708200%26sid%3Dliteratum%253Aachs%26aulast%3DUemura%26aufirst%3DK.%26aulast%3DKuzuya%26aufirst%3DA.%26aulast%3DShimozono%26aufirst%3DY.%26aulast%3DAoyagi%26aufirst%3DN.%26aulast%3DAndo%26aufirst%3DK.%26aulast%3DShimohama%26aufirst%3DS.%26aulast%3DKinoshita%26aufirst%3DA.%26atitle%3DGSK3beta%2520activity%2520modifies%2520the%2520localization%2520and%2520function%2520of%2520presenilin%25201%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D15823%26epage%3D15832%26doi%3D10.1074%2Fjbc.M610708200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ly, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodgett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, W.</span></span> <span> </span><span class="NLM_article-title">Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">224</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.1172/JCI64516</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1172%2FJCI64516" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=23202730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsFGntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2013&pages=224-235&author=P.+T.+Lyauthor=Y.+Wuauthor=H.+Zouauthor=R.+Wangauthor=W.+Zhouauthor=A.+Kinoshitaauthor=M.+Zhangauthor=Y.+Yangauthor=F.+Caiauthor=J.+Woodgettauthor=W.+Song&title=Inhibition+of+GSK3%CE%B2-mediated+BACE1+expression+reduces+Alzheimer-associated+phenotypes&doi=10.1172%2FJCI64516"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes</span></div><div class="casAuthors">Ly, Philip T. T.; Wu, Yili; Zou, Haiyan; Wang, Ruitao; Zhou, Weihui; Kinoshita, Ayae; Zhang, Mingming; Yang, Yi; Cai, Fang; Woodgett, James; Song, Weihong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">224-235</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Deposition of amyloid β protein (Aβ) to form neuritic plaques in the brain is the pathol. hallmark of Alzheimer's disease (AD).  Aβ is generated from sequential cleavages of the β-amyloid precursor protein (APP) by the β- and γ-secretases, and β-site APP-cleaving enzyme 1 (BACE1) is the β-secretase essential for Aβ generation.  Previous studies have indicated that glycogen synthase kinase 3 (GSK3) may play a role in APP processing by modulating γ-secretase activity, thereby facilitating Aβ prodn.  There are 2 highly conserved isoforms of GSK3: GSK3α and GSK3β.  We now report that specific inhibition of GSK3β, but not GSK3α, reduced BACE1-mediated cleavage of APP and Aβ prodn. by decreasing BACE1 gene transcription and expression.  The regulation of BACE1 gene expression by GSK3β was dependent on NF-κB signaling.  Inhibition of GSK3 signaling markedly reduced Aβ deposition and neuritic plaque formation, and rescued memory deficits in the double transgenic AD model mice.  These data provide evidence for regulation of BACE1 expression and AD pathogenesis by GSK3β and that inhibition of GSK3 signaling can reduce Aβ neuropathol. and alleviate memory deficits in AD model mice.  Our study suggests that interventions that specifically target the β-isoform of GSK3 may be a safe and effective approach for treating AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpvC5m1dwxRLVg90H21EOLACvtfcHk0lhCHZO4tWpEMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsFGntw%253D%253D&md5=560fdf1e8199e9f7bc15294d1f8cc712</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1172%2FJCI64516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI64516%26sid%3Dliteratum%253Aachs%26aulast%3DLy%26aufirst%3DP.%2BT.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DKinoshita%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DF.%26aulast%3DWoodgett%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DW.%26atitle%3DInhibition%2520of%2520GSK3%25CE%25B2-mediated%2520BACE1%2520expression%2520reduces%2520Alzheimer-associated%2520phenotypes%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2013%26volume%3D123%26spage%3D224%26epage%3D235%26doi%3D10.1172%2FJCI64516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tone, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, W.</span></span> <span> </span><span class="NLM_article-title">Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer’s disease</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1017/S1461145711000149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1017%2FS1461145711000149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=21329555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC38XksValsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2012&pages=77-90&author=C.+H.+Chenauthor=W.+Zhouauthor=S.+Liuauthor=Y.+Dengauthor=F.+Caiauthor=M.+Toneauthor=Y.+Toneauthor=Y.+Tongauthor=W.+Song&title=Increased+NF-%CE%BAB+signalling+up-regulates+BACE1+expression+and+its+therapeutic+potential+in+Alzheimer%E2%80%99s+disease&doi=10.1017%2FS1461145711000149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease</span></div><div class="casAuthors">Chen, Chia-Hsiung; Zhou, Weihui; Liu, Shengchun; Deng, Yu; Cai, Fang; Tone, Masahide; Tone, Yukiko; Tong, Yigang; Song, Weihong</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-90</span>CODEN:
                <span class="NLM_cas:coden">IJNUFB</span>;
        ISSN:<span class="NLM_cas:issn">1461-1457</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">Elevated levels of β-site APP cleaving enzyme 1 (BACE1) were found in the brain of some sporadic Alzheimer's disease (AD) patients; however, the underlying mechanism is unknown.  BACE1 cleaves β-amyloid precursor protein (APP) to generate amyloid β protein (Aβ), a central component of neuritic plaques in AD brains.  Nuclear factor-kappa B (NF-κB) signalling plays an important role in gene regulation and is implicated in inflammation, oxidative stress and apoptosis.  In this report we found that both BACE1 and NF-κB p65 levels were significantly increased in the brains of AD patients.  Two functional NF-κB-binding elements were identified in the human BACE1 promoter region.  We found that NF-κB p65 expression resulted in increased BACE1 promoter activity and BACE1 transcription, while disruption of NF-κB p65 decreased BACE1 gene expression in p65 knockout (RelA-knockout) cells.  In addn., NF-κB p65 expression leads to up-regulated β-secretase cleavage and Aβ prodn., while non-steroidal anti-inflammatory drugs (NSAIDs) inhibited BACE1 transcriptional activation induced by strong NF-κB activator tumor necrosis factor-alpha (TNF-α).  Taken together, our results clearly demonstrate that NF-κB signalling facilitates BACE1 gene expression and APP processing, and increased BACE1 expression mediated by NF-κB signalling in the brain could be one of the novel mol. mechanisms underlying the development of AD in some sporadic cases.  Furthermore, NSAIDs could block the inflammation-induced BACE1 transcription and Aβ prodn.  Our study suggests that inhibition of NF-κB-mediated BACE1 expression may be a valuable drug target for AD therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ1hkA7XSgYLVg90H21EOLACvtfcHk0lhCHZO4tWpEMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksValsbk%253D&md5=ccbec29126abde16c207a8960edec470</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1017%2FS1461145711000149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1461145711000149%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DF.%26aulast%3DTone%26aufirst%3DM.%26aulast%3DTone%26aufirst%3DY.%26aulast%3DTong%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DW.%26atitle%3DIncreased%2520NF-%25CE%25BAB%2520signalling%2520up-regulates%2520BACE1%2520expression%2520and%2520its%2520therapeutic%2520potential%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2012%26volume%3D15%26spage%3D77%26epage%3D90%26doi%3D10.1017%2FS1461145711000149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Magdesian, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendes, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saraiva, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juliano, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juliano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Abreu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, S. T.</span></span> <span> </span><span class="NLM_article-title">Amyloid-beta binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt/beta-catenin signaling</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">9359</span>– <span class="NLM_lpage">9368</span>, <span class="refDoi"> DOI: 10.1074/jbc.M707108200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1074%2Fjbc.M707108200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=18234671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjslyqs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=9359-9368&author=M.+H.+Magdesianauthor=M.+M.+Carvalhoauthor=F.+A.+Mendesauthor=L.+M.+Saraivaauthor=M.+A.+Julianoauthor=L.+Julianoauthor=J.+Garcia-Abreuauthor=S.+T.+Ferreira&title=Amyloid-beta+binds+to+the+extracellular+cysteine-rich+domain+of+Frizzled+and+inhibits+Wnt%2Fbeta-catenin+signaling&doi=10.1074%2Fjbc.M707108200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Amyloid-β Binds to the Extracellular Cysteine-rich Domain of Frizzled and Inhibits Wnt/β-Catenin Signaling</span></div><div class="casAuthors">Magdesian, Margaret H.; Carvalho, Milena M. V. F.; Mendes, Fabio A.; Saraiva, Leonardo M.; Juliano, Maria A.; Juliano, Luiz; Garcia-Abreu, Jose; Ferreira, Sergio T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">9359-9368</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The amyloid-β peptide (Aβ) plays a major role in neuronal dysfunction and neurotoxicity in Alzheimer disease.  However, the signal transduction mechanisms involved in Aβ-induced neuronal dysfunction remain to be fully elucidated.  A major current unknown is the identity of the protein receptor(s) involved in neuronal Aβ binding.  Using phage display of peptide libraries, we have identified a no. of peptides that bind Aβ and are homologous to neuronal receptors putatively involved in Aβ interactions.  We report here on a cysteine-linked cyclic heptapeptide (denominated cSP5) that binds Aβ with high affinity and is homologous to the extracellular cysteine-rich domain of several members of the Frizzled (Fz) family of Wnt receptors.  Based on this homol., we investigated the interaction between Aβ and Fz.  The results show that Aβ binds to the Fz cysteine-rich domain at or in close proximity to the Wnt-binding site and inhibits the canonical Wnt signaling pathway.  Interestingly, the cSP5 peptide completely blocks Aβ binding to Fz and prevents inhibition of Wnt signaling.  These results indicate that the Aβ-binding site in Fz is homologous to cSP5 and that this is a relevant target for Aβ-instigated neurotoxicity.  Furthermore, they suggest that blocking the interaction of Aβ with Fz might lead to novel therapeutic approaches to prevent neuronal dysfunction in Alzheimer disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe760qxDg897Vg90H21EOLACvtfcHk0lhCHZO4tWpEMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjslyqs7w%253D&md5=1c65d7e97f51ce92b10d82cfa25073da</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M707108200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M707108200%26sid%3Dliteratum%253Aachs%26aulast%3DMagdesian%26aufirst%3DM.%2BH.%26aulast%3DCarvalho%26aufirst%3DM.%2BM.%26aulast%3DMendes%26aufirst%3DF.%2BA.%26aulast%3DSaraiva%26aufirst%3DL.%2BM.%26aulast%3DJuliano%26aufirst%3DM.%2BA.%26aulast%3DJuliano%26aufirst%3DL.%26aulast%3DGarcia-Abreu%26aufirst%3DJ.%26aulast%3DFerreira%26aufirst%3DS.%2BT.%26atitle%3DAmyloid-beta%2520binds%2520to%2520the%2520extracellular%2520cysteine-rich%2520domain%2520of%2520Frizzled%2520and%2520inhibits%2520Wnt%252Fbeta-catenin%2520signaling%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D9359%26epage%3D9368%26doi%3D10.1074%2Fjbc.M707108200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spangenberg, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, K. N.</span></span> <span> </span><span class="NLM_article-title">Inflammation in Alzheimer’s disease: Lessons learned from microglia-depletion models</span>. <i>Brain, Behav., Immun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1016/j.bbi.2016.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.bbi.2016.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=27395435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFKkur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2017&pages=1-11&author=E.+E.+Spangenbergauthor=K.+N.+Green&title=Inflammation+in+Alzheimer%E2%80%99s+disease%3A+Lessons+learned+from+microglia-depletion+models&doi=10.1016%2Fj.bbi.2016.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammation in Alzheimer's disease: Lessons learned from microglia-depletion models</span></div><div class="casAuthors">Spangenberg, Elizabeth E.; Green, Kim N.</div><div class="citationInfo"><span class="NLM_cas:title">Brain, Behavior, and Immunity</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-11</span>CODEN:
                <span class="NLM_cas:coden">BBIMEW</span>;
        ISSN:<span class="NLM_cas:issn">0889-1591</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Microglia are the primary immune cell of the brain and function to protect the central nervous system (CNS) from injury and invading pathogens.  In the homeostatic brain, microglia serve to support neuronal health through synaptic pruning, promoting normal brain connectivity and development, and through release of neurotrophic factors, providing support for CNS integrity.  However, recent evidence indicates that the homeostatic functioning of these cells is lost in neurodegenerative disease, including Alzheimer's disease (AD), ultimately contributing to a chronic neuroinflammatory environment in the brain.  Importantly, the development of compds. and genetic models to ablate the microglial compartment has emerged as effective tools to further our understanding of microglial function in AD.  Use of these models has identified roles of microglia in several pathol. facets of AD, including tau propagation, synaptic stripping, neuronal loss, and cognitive decline.  Although culminating evidence utilizing these microglial ablation models reports an absence of CNS-endogenous and peripheral myeloid cell involvement in Aβ phagocytosis, recent data indicates that targeting microglia-evoked neuroinflammation in AD may be essential for potential therapeutics.  Therefore, identifying altered signaling pathways in the microglia-devoid brain may assist with the development of effective inflammation-based therapies in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpnkdakB1rHrVg90H21EOLACvtfcHk0lhjHl9E1n7xug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFKkur%252FI&md5=05af777f48592b90bbee6df13e1dcf3f</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2Fj.bbi.2016.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbi.2016.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DSpangenberg%26aufirst%3DE.%2BE.%26aulast%3DGreen%26aufirst%3DK.%2BN.%26atitle%3DInflammation%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520Lessons%2520learned%2520from%2520microglia-depletion%2520models%26jtitle%3DBrain%252C%2520Behav.%252C%2520Immun.%26date%3D2017%26volume%3D61%26spage%3D1%26epage%3D11%26doi%3D10.1016%2Fj.bbi.2016.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Green, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, Y. M.</span></span> <span> </span><span class="NLM_article-title">GSK-3 mediates the release of IL-1β, TNF-α and IL-10 from cortical glia</span>. <i>Neurochem. Int.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">666</span>– <span class="NLM_lpage">671</span>, <span class="refDoi"> DOI: 10.1016/j.neuint.2012.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.neuint.2012.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=22796213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsV2qur%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2012&pages=666-671&author=H.+F.+Greenauthor=Y.+M.+Nolan&title=GSK-3+mediates+the+release+of+IL-1%CE%B2%2C+TNF-%CE%B1+and+IL-10+from+cortical+glia&doi=10.1016%2Fj.neuint.2012.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">GSK-3 mediates the release of IL-1β, TNF-α and IL-10 from cortical glia</span></div><div class="casAuthors">Green, Holly F.; Nolan, Yvonne M.</div><div class="citationInfo"><span class="NLM_cas:title">Neurochemistry International</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">666-671</span>CODEN:
                <span class="NLM_cas:coden">NEUIDS</span>;
        ISSN:<span class="NLM_cas:issn">0197-0186</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Neuroinflammation has been shown to contribute to neurodegenerative and psychiatric disorders such as Alzheimer's disease and major depression due to the inappropriate release of pro-inflammatory cytokines from activated microglia.  The precise mol. events that mediate cytokine release from glia remain unknown but we suggest that the serine/threonine kinase glycogen synthase kinase-3 (GSK-3) may be involved.  The aim of this study therefore was to investigate the effect of lipopolysaccharide (LPS) on expression and activity of the GSK-3β isoform in glia, and to assess if GSK-3 mediates the LPS-induced change in inflammatory cytokine levels in culture medium from rat glial-enriched cortical cultures.  GSK-3β was expressed in microglia and astrocytes, and stimulation of these cultures with LPS induced an increase in GSK-3β expression and activity, and in pro-inflammatory cytokine levels in culture media.  We show that GSK-3 inhibition using a small mol. inhibitor SB216763 or the mood stabilizer lithium chloride reduced the LPS-induced elevated levels of pro-inflammatory cytokines present in culture media from rat glial-enriched cortical cultures.  These results demonstrate a role for GSK-3 as a modulator of inflammatory cytokine levels in the brain, and contribute to a mechanistic insight into neurol. disorders in which neuroinflammation is a characteristic feature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8OgZoGE-b97Vg90H21EOLACvtfcHk0lhjHl9E1n7xug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsV2qur%252FK&md5=3f04cb3cc247a5f779c9a7bb194b8af3</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2Fj.neuint.2012.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuint.2012.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DGreen%26aufirst%3DH.%2BF.%26aulast%3DNolan%26aufirst%3DY.%2BM.%26atitle%3DGSK-3%2520mediates%2520the%2520release%2520of%2520IL-1%25CE%25B2%252C%2520TNF-%25CE%25B1%2520and%2520IL-10%2520from%2520cortical%2520glia%26jtitle%3DNeurochem.%2520Int.%26date%3D2012%26volume%3D61%26spage%3D666%26epage%3D671%26doi%3D10.1016%2Fj.neuint.2012.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinbrecher, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cogswell, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, A. S.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase 3beta functions to specify gene-specific, NF-kappaB-dependent transcription</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">8444</span>– <span class="NLM_lpage">8455</span>, <span class="refDoi"> DOI: 10.1128/MCB.25.19.8444-8455.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1128%2FMCB.25.19.8444-8455.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=16166627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVKqsLnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2005&pages=8444-8455&author=K.+A.+Steinbrecherauthor=W.+Wilsonauthor=P.+C.+Cogswellauthor=A.+S.+Baldwin&title=Glycogen+synthase+kinase+3beta+functions+to+specify+gene-specific%2C+NF-kappaB-dependent+transcription&doi=10.1128%2FMCB.25.19.8444-8455.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase 3β functions to specify gene-specific, NF-κB-dependent transcription</span></div><div class="casAuthors">Steinbrecher, Kris A.; Wilson, Willie, III; Cogswell, Patricia C.; Baldwin, Albert S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8444-8455</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Loss of glycogen synthase kinase 3β (GSK-3β) in mice results in embryonic lethality via hepatocyte apoptosis.  Consistent with this result, cells from these mice have diminished nuclear factor κB (NF-κB) activity, implying a functional role for GSK-3β in regulating NF-κB.  Here, the authors have explored mechanisms by which GSK-3β may control NF-κB function.  Cytokine-induced IκB kinase activity and subsequent phosphorylation of IκBα, p105, and p65 are not affected by the absence of GSK-3β activity.  Furthermore, nuclear accumulation of p65 following tumor necrosis factor treatment is unaffected by the loss of GSK-3β.  However, NF-κB DNA binding activity is reduced in GSK-3β null cells and in cells treated with a pharmacol. inhibitor of GSK-3.  Expression of certain NF-κB-regulated genes, such as IκBα and macrophage inflammatory protein 2, is minimally affected by the absence of GSK-3β.  Conversely, the authors have identified a subset of NF-κB-regulated genes, including those for interleukin-6 and monocyte chemoattractant protein 1, that require GSK-3β for efficient expression.  Efficient localization of p65 to the promoter regions of the interleukin-6 and monocyte chemoattractant protein 1 genes following tumor necrosis factor alpha treatment requires GSK-3β.  Therefore, GSK-3β has profound effects on transcription in a gene-specific manner through a mechanism involving control of promoter-specific recruitment of NF-κB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeCUceQlkidrVg90H21EOLACvtfcHk0lhjHl9E1n7xug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVKqsLnF&md5=f27038f11633983692d6a198f8bc5d98</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1128%2FMCB.25.19.8444-8455.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.25.19.8444-8455.2005%26sid%3Dliteratum%253Aachs%26aulast%3DSteinbrecher%26aufirst%3DK.%2BA.%26aulast%3DWilson%26aufirst%3DW.%26aulast%3DCogswell%26aufirst%3DP.%2BC.%26aulast%3DBaldwin%26aufirst%3DA.%2BS.%26atitle%3DGlycogen%2520synthase%2520kinase%25203beta%2520functions%2520to%2520specify%2520gene-specific%252C%2520NF-kappaB-dependent%2520transcription%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2005%26volume%3D25%26spage%3D8444%26epage%3D8455%26doi%3D10.1128%2FMCB.25.19.8444-8455.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xavier, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercier, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLoughlin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodgett, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ovsenek, N.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase 3beta negatively regulates both DNA-binding and transcriptional activities of heat shock factor 1</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">29147</span>– <span class="NLM_lpage">29152</span>, <span class="refDoi"> DOI: 10.1074/jbc.M002169200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1074%2Fjbc.M002169200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10856293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD3cXms1Cqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=29147-29152&author=I.+J.+Xavierauthor=P.+A.+Mercierauthor=C.+M.+McLoughlinauthor=A.+Aliauthor=J.+R.+Woodgettauthor=N.+Ovsenek&title=Glycogen+synthase+kinase+3beta+negatively+regulates+both+DNA-binding+and+transcriptional+activities+of+heat+shock+factor+1&doi=10.1074%2Fjbc.M002169200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase 3β negatively regulates both DNA-binding and transcriptional activities of heat shock factor 1</span></div><div class="casAuthors">Xavier, Ilungo J.; Mercier, Phillipe A.; McLoughlin, Christine M.; Ali, Adnan; Woodgett, James R.; Ovsenek, Nick</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">29147-29152</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Stress activation of heat shock factor (HSF1) involves the conversion of repressed monomers to DNA-binding homotrimers with increased transcriptional capacity and results in transcriptional up-regulation of the heat shock protein (hsp) gene family.  Cells tightly control the activity of HSF1 through interactions with hsp90 chaperone complexes and through integration into a no. of different signaling cascades.  A no. of studies have shown that HSF1 transcriptional activity is neg. regulated by constitutive phosphorylation in the regulatory domain by glycogen synthase kinase (GSK3) isoforms α/β.  However, previous studies have not examd. the ability of GSK3 to regulate the DNA-binding activity of native HSF1 in vivo under heat shock conditions.  Here we show that GSK3β inhibits both DNA-binding and transcriptional activities of HSF1 in heat-shocked cells.  Specific inhibition of GSK3 increased the levels of DNA binding and transcription after heat shock and delayed the attenuation of HSF1 during recovery.  In contrast, the overexpression of GSK3β resulted in significant redn. in heat-induced HSF1 activities.  These results confirm the role of GSK3β as a neg. regulator of HSF1 transcription in cells during heat shock and demonstrate for the first time that GSK3β functions to repress DNA binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqa4pyU8oLnNrVg90H21EOLACvtfcHk0lhjHl9E1n7xug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXms1Cqtbk%253D&md5=0532574b9c26b7186ed43c25170c3314</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M002169200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M002169200%26sid%3Dliteratum%253Aachs%26aulast%3DXavier%26aufirst%3DI.%2BJ.%26aulast%3DMercier%26aufirst%3DP.%2BA.%26aulast%3DMcLoughlin%26aufirst%3DC.%2BM.%26aulast%3DAli%26aufirst%3DA.%26aulast%3DWoodgett%26aufirst%3DJ.%2BR.%26aulast%3DOvsenek%26aufirst%3DN.%26atitle%3DGlycogen%2520synthase%2520kinase%25203beta%2520negatively%2520regulates%2520both%2520DNA-binding%2520and%2520transcriptional%2520activities%2520of%2520heat%2520shock%2520factor%25201%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D29147%26epage%3D29152%26doi%3D10.1074%2Fjbc.M002169200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hann, S. R.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">51606</span>– <span class="NLM_lpage">51612</span>, <span class="refDoi"> DOI: 10.1074/jbc.M310722200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1074%2Fjbc.M310722200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=14563837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpslOgsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=51606-51612&author=M.+A.+Gregoryauthor=Y.+Qiauthor=S.+R.+Hann&title=Phosphorylation+by+glycogen+synthase+kinase-3+controls+c-myc+proteolysis+and+subnuclear+localization&doi=10.1074%2Fjbc.M310722200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation by Glycogen Synthase Kinase-3 Controls c-Myc Proteolysis and Subnuclear Localization</span></div><div class="casAuthors">Gregory, Mark A.; Qi, Ying; Hann, Stephen R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">51606-51612</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The c-Myc protein is a transcription factor that is a central regulator of cell growth and proliferation.  Thr-58 is a major phosphorylation site in c-Myc and is a mutational hot spot in Burkitt's and other aggressive human lymphomas, indicating that Thr-58 phosphorylation restricts the oncogenic potential of c-Myc.  Mutation of Thr-58 is also assocd. with increased c-Myc protein stability.  Here we show that inhibition of glycogen synthase kinase-3 (GSK-3) activity with lithium increases c-Myc stability and inhibits phosphorylation of c-Myc specifically at Thr-58 in vivo.  Conversely, overexpression of GSK-3α or GSK-3β enhances Thr-58 phosphorylation and ubiquitination of c-Myc.  Together, these observations suggest that phosphorylation of Thr-58 mediated by GSK-3 facilitates c-Myc rapid proteolysis by the ubiquitin pathway.  Furthermore, we demonstrate that GSK-3 binds c-Myc in vivo and in vitro and that GSK-3 colocalizes with c-Myc in the nucleus, strongly arguing that GSK-3 is the c-Myc Thr-58 kinase.  We found that c-MycS, which lacks the N-terminal 100 amino acids of c-Myc, is unable to bind GSK-3; however, mutation of Ser-62, the priming phosphorylation site necessary for Thr-58 phosphorylation, does not disrupt GSK-3 binding.  Finally, we show that Thr-58 phosphorylation alters the subnuclear localization of c-Myc, enhancing its localization to discrete nuclear bodies together with GSK-3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6Dzcw8D5CHrVg90H21EOLACvtfcHk0liuavBhqOyUEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpslOgsrg%253D&md5=f2386608b12050118c5b0594b3468b8a</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M310722200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M310722200%26sid%3Dliteratum%253Aachs%26aulast%3DGregory%26aufirst%3DM.%2BA.%26aulast%3DQi%26aufirst%3DY.%26aulast%3DHann%26aufirst%3DS.%2BR.%26atitle%3DPhosphorylation%2520by%2520glycogen%2520synthase%2520kinase-3%2520controls%2520c-myc%2520proteolysis%2520and%2520subnuclear%2520localization%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D51606%26epage%3D51612%26doi%3D10.1074%2Fjbc.M310722200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grimes, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jope, R. S.</span></span> <span> </span><span class="NLM_article-title">CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1219</span>– <span class="NLM_lpage">1232</span>, <span class="refDoi"> DOI: 10.1046/j.1471-4159.2001.00495.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1046%2Fj.1471-4159.2001.00495.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=11579131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnt12isr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2001&pages=1219-1232&author=C.+A.+Grimesauthor=R.+S.+Jope&title=CREB+DNA+binding+activity+is+inhibited+by+glycogen+synthase+kinase-3+beta+and+facilitated+by+lithium&doi=10.1046%2Fj.1471-4159.2001.00495.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">CREB DNA binding activity is inhibited by glycogen synthase kinase-3β and facilitated by lithium</span></div><div class="casAuthors">Grimes, Carol A.; Jope, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1219-1232</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">The regulatory influences of glycogen synthase kinase-3β (GSK3β) and lithium on the activity of cAMP response element binding protein (CREB) were examd. in human neuroblastoma SH-SY5Y cells.  Activation of Akt (protein kinase B) with serum-increased phospho-serine-9-GSK3β (the inactive form of the enzyme), inhibited GSK3β activity, and increased CREB DNA binding activity.  Inhibition of GSK3β by another paradigm, treatment with the selective inhibitor lithium, also increased CREB DNA binding activity.  The inhibitory regulation of CREB DNA binding activity by GSK3β also was evident in differentiated SH-SY5Y cells, indicating that this regulatory interaction is maintained in nonproliferating cells.  These results demonstrate that inhibition of GSK3β by serine-9 phosphorylation or directly by lithium increases CREB activation.  Conversely, overexpression of active GSK3β to 3.5-fold the normal levels completely blocked increases in CREB DNA binding activity induced by epidermal growth factor, insulin-like growth factor-1, forskolin, and cAMP.  The inhibitory effects due to overexpressed GSK3β were reversed by treatment with lithium and with another GSK3β inhibitor, sodium valproate.  Overall, these results demonstrate that GSK3β inhibits, and lithium enhances, CREB activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHQYoVSZwN7rVg90H21EOLACvtfcHk0liuavBhqOyUEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnt12isr0%253D&md5=e7a16d91216e2b1c7f81fc0d747a9e69</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.2001.00495.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.2001.00495.x%26sid%3Dliteratum%253Aachs%26aulast%3DGrimes%26aufirst%3DC.%2BA.%26aulast%3DJope%26aufirst%3DR.%2BS.%26atitle%3DCREB%2520DNA%2520binding%2520activity%2520is%2520inhibited%2520by%2520glycogen%2520synthase%2520kinase-3%2520beta%2520and%2520facilitated%2520by%2520lithium%26jtitle%3DJ.%2520Neurochem.%26date%3D2001%26volume%3D78%26spage%3D1219%26epage%3D1232%26doi%3D10.1046%2Fj.1471-4159.2001.00495.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hooper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markevich, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plattner, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Killick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schofield, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenblum, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bliss, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avila, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giese, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephenson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovestone, S.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase-3 inhibition is integral to long-term potentiation</span>. <i>Eur. J. Neurosci</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1111/j.1460-9568.2006.05245.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1111%2Fj.1460-9568.2006.05245.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=17241269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BD2s7is1Clsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=81-86&author=C.+Hooperauthor=V.+Markevichauthor=F.+Plattnerauthor=R.+Killickauthor=E.+Schofieldauthor=T.+Engelauthor=F.+Hernandezauthor=B.+Andertonauthor=K.+Rosenblumauthor=T.+Blissauthor=S.+F.+Cookeauthor=J.+Avilaauthor=J.+J.+Lucasauthor=K.+P.+Gieseauthor=J.+Stephensonauthor=S.+Lovestone&title=Glycogen+synthase+kinase-3+inhibition+is+integral+to+long-term+potentiation&doi=10.1111%2Fj.1460-9568.2006.05245.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase-3 inhibition is integral to long-term potentiation</span></div><div class="casAuthors">Hooper Claudie; Markevich Vladimir; Plattner Florian; Killick Richard; Schofield Emma; Engel Tobias; Hernandez Felix; Anderton Brian; Rosenblum Kobi; Bliss Tim; Cooke Sam F; Avila Jesus; Lucas Jose J; Giese Karl Peter; Stephenson John; Lovestone Simon</div><div class="citationInfo"><span class="NLM_cas:title">The European journal of neuroscience</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">81-6</span>
        ISSN:<span class="NLM_cas:issn">0953-816X</span>.
    </div><div class="casAbstract">Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase regulating diverse cellular functions including metabolism, transcription and cell survival.  Numerous intracellular signalling pathways converge on GSK-3 and regulate its activity via inhibitory serine-phosphorylation.  Recently, GSK-3 has been involved in learning and memory and in neurodegeneration.  Here, we present evidence that implicates GSK-3 in synaptic plasticity.  We show that phosphorylation at the inhibitory Ser9 site on GSK-3beta is increased upon induction of long-term potentiation (LTP) in both hippocampal subregions CA1 and the dentate gyrus (DG) in vivo.  The increase in inhibitory GSK-3beta phosphorylation is robust and persists for at least one hour postinduction.  Furthermore, we find that LTP is impaired in transgenic mice conditionally overexpressing GSK-3beta.  The LTP deficits can be attenuated/rescued by chronic treatment with lithium, a GSK-3 inhibitor.  These results suggest that the inhibition of GSK-3 facilitates the induction of LTP and this might explain some of the negative effects of GSK-3 on learning and memory.  It follows that this role of GSK-3beta in LTP might underlie some of the cognitive dysfunction in diseases where GSK-3 dysfunction has been implicated, including Alzheimer's and other dementias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTXsmmxOKDKocScOqQTSkOffW6udTcc2eakLksSDlUdT7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s7is1Clsw%253D%253D&md5=f3ba7589dc57ada4966512aeb9c8279d</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1111%2Fj.1460-9568.2006.05245.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1460-9568.2006.05245.x%26sid%3Dliteratum%253Aachs%26aulast%3DHooper%26aufirst%3DC.%26aulast%3DMarkevich%26aufirst%3DV.%26aulast%3DPlattner%26aufirst%3DF.%26aulast%3DKillick%26aufirst%3DR.%26aulast%3DSchofield%26aufirst%3DE.%26aulast%3DEngel%26aufirst%3DT.%26aulast%3DHernandez%26aufirst%3DF.%26aulast%3DAnderton%26aufirst%3DB.%26aulast%3DRosenblum%26aufirst%3DK.%26aulast%3DBliss%26aufirst%3DT.%26aulast%3DCooke%26aufirst%3DS.%2BF.%26aulast%3DAvila%26aufirst%3DJ.%26aulast%3DLucas%26aufirst%3DJ.%2BJ.%26aulast%3DGiese%26aufirst%3DK.%2BP.%26aulast%3DStephenson%26aufirst%3DJ.%26aulast%3DLovestone%26aufirst%3DS.%26atitle%3DGlycogen%2520synthase%2520kinase-3%2520inhibition%2520is%2520integral%2520to%2520long-term%2520potentiation%26jtitle%3DEur.%2520J.%2520Neurosci%26date%3D2007%26volume%3D25%26spage%3D81%26epage%3D86%26doi%3D10.1111%2Fj.1460-9568.2006.05245.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, G.</span></span> <span> </span><span class="NLM_article-title">Modulation of GSK-3β/β-catenin signaling contributes to learning and memory impairment in a rat model of depression</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">858</span>– <span class="NLM_lpage">870</span>, <span class="refDoi"> DOI: 10.1093/ijnp/pyy040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1093%2Fijnp%2Fpyy040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=29688389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmvVyqur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2018&pages=858-870&author=J.+Huiauthor=J.+Zhangauthor=M.+Puauthor=X.+Zhouauthor=L.+Dongauthor=X.+Maoauthor=G.+Shiauthor=J.+Zouauthor=J.+Wuauthor=D.+Jiangauthor=G.+Xi&title=Modulation+of+GSK-3%CE%B2%2F%CE%B2-catenin+signaling+contributes+to+learning+and+memory+impairment+in+a+rat+model+of+depression&doi=10.1093%2Fijnp%2Fpyy040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of GSK-3β/β-catenin signaling contributes to learning and memory impairment in a rat model of depression</span></div><div class="casAuthors">Hui, Jiaojie; Zhang, Jianping; Pu, Mengjia; Zhou, Xingliang; Dong, Liang; Mao, Xuqiang; Shi, Guofeng; Zou, Jian; Wu, Jingjing; Jiang, Dongmei; Xi, Guangjun</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">858-870</span>CODEN:
                <span class="NLM_cas:coden">IJNUFB</span>;
        ISSN:<span class="NLM_cas:issn">1461-1457</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: It is widely accepted that cognitive processes, such as learning and memory, are affected in depression, but the mol. mechanisms underlying the interactions of these 2 disorders are not clearly understood.  Recently, glycogen synthase kinase-3 beta (GSK-3β)/β-catenin signaling was shown to play an important role in the regulation of learning and memory.  Methods: The present study used a rat model of depression, chronic unpredictable stress, to det. whether hippocampal GSK-3β/β-catenin signaling was involved in learning and memory alterations.  Results: Our results demonstrated that chronic unpredictable stress had a dramatic influence on spatial cognitive performance in the Morris water maze task and reduced the phosphorylation of Ser9 of GSK-3β as well as the total and nuclear levels of β-catenin in the hippocampus.  Inhibition of GSK3β by SB216763 significantly ameliorated the cognitive deficits induced by chronic unpredictable stress, while overexpression of GSK3β by AAV-mediated gene transfer significantly decreased cognitive performance in adult rats.  In addn., chronic unpredictable stress exposure increased the expression of the canonical Wnt antagonist Dkk-1.  Furthermore, chronic administration of corticosterone significantly increased Dkk-1 expression, decreased the phosphorylation of Ser9 of GSK-3β, and resulted in the impairment of hippocampal learning and memory.  Conclusions: Our results indicate that impairment of learning and memory in response to chronic unpredictable stress may be attributed to the dysfunction of GSK-3β/β-catenin signaling mediated by increased glucocorticoid signaling via Dkk-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZTdJOX6mbGbVg90H21EOLACvtfcHk0lgOy3Sorzsxvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmvVyqur0%253D&md5=b66563325561d33206d654c9e5142188</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1093%2Fijnp%2Fpyy040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fijnp%252Fpyy040%26sid%3Dliteratum%253Aachs%26aulast%3DHui%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DPu%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DDong%26aufirst%3DL.%26aulast%3DMao%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DG.%26aulast%3DZou%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DD.%26aulast%3DXi%26aufirst%3DG.%26atitle%3DModulation%2520of%2520GSK-3%25CE%25B2%252F%25CE%25B2-catenin%2520signaling%2520contributes%2520to%2520learning%2520and%2520memory%2520impairment%2520in%2520a%2520rat%2520model%2520of%2520depression%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2018%26volume%3D21%26spage%3D858%26epage%3D870%26doi%3D10.1093%2Fijnp%2Fpyy040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Z.</span></span> <span> </span><span class="NLM_article-title">Glycogen synthase kinase 3 regulates N-methyl-D-aspartate receptor channel trafficking and function in cortical neurons</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1124/mol.107.034942</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1124%2Fmol.107.034942" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=17400762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsVyjs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=40-51&author=P.+Chenauthor=Z.+Guauthor=W.+Liuauthor=Z.+Yan&title=Glycogen+synthase+kinase+3+regulates+N-methyl-D-aspartate+receptor+channel+trafficking+and+function+in+cortical+neurons&doi=10.1124%2Fmol.107.034942"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Glycogen synthase kinase 3 regulates N-methyl-D-aspartate receptor channel trafficking and function in cortical neurons</span></div><div class="casAuthors">Chen, Paul; Gu, Zhenglin; Liu, Wenhua; Yan, Zhen</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">40-51</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Emerging evidence has suggested that glycogen synthase kinase 3 (GSK-3) is a key regulatory kinase involved in a plethora of processes in the nervous system, including neuronal development, mood stabilization, and neurodegeneration.  However, the cellular mechanisms underlying the actions of GSK-3 remain to be identified.  In this study, we examd. the impact of GSK-3 on the N-methyl-D-aspartate (NMDA) receptor channel, a central player involved in cognitive and emotional processes.  We found that application of various structurally different GSK-3 inhibitors caused a long-lasting redn. of NMDA receptor-mediated ionic and synaptic current in cortical pyramidal neurons.  Cellular knockdown of GSK-3β in neuronal cultures with a small interfering RNA led to smaller NMDA receptor current and loss of its regulation by GSK-3 inhibitors.  The NR2B subunit-contg. NMDA receptor was the primary target of GSK-3, but the GSK-3 modulation of NMDAR current did not involve the motor protein kinesin superfamily member 17-based transport of NR2B-contg. vesicles along microtubules.  Combined electrophysiol., immunocytochem., and biochem. evidence indicated that GSK-3 inhibitors induced the down-regulation of NMDAR current through increasing the Rab5-mediated and PSD-95-regulated NMDAR internalization in a clathrin/dynamin-dependent manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAsbFOh2O_vbVg90H21EOLACvtfcHk0lgOy3Sorzsxvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsVyjs7c%253D&md5=40421b2ca753a3e573909d432e18e3ea</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1124%2Fmol.107.034942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.107.034942%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DP.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DYan%26aufirst%3DZ.%26atitle%3DGlycogen%2520synthase%2520kinase%25203%2520regulates%2520N-methyl-D-aspartate%2520receptor%2520channel%2520trafficking%2520and%2520function%2520in%2520cortical%2520neurons%26jtitle%3DMol.%2520Pharmacol.%26date%3D2007%26volume%3D72%26spage%3D40%26epage%3D51%26doi%3D10.1124%2Fmol.107.034942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.</span></span> <span> </span><span class="NLM_article-title">Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>152</i></span>,  <span class="NLM_fpage">104609</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2019.104609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.phrs.2019.104609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=31862477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisV2ktbrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2020&pages=104609&author=R.+Roskoski&title=Properties+of+FDA-approved+small+molecule+protein+kinase+inhibitors%3A+A+2020+update&doi=10.1016%2Fj.phrs.2019.104609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update</span></div><div class="casAuthors">Roskoski, Robert Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104609</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Because genetic alterations including mutations, overexpression, translocations, and dysregulation of protein kinases are involved in the pathogenesis of many illnesses, this enzyme family is currently the subject of many drug discovery programs in the pharmaceutical industry.  The US FDA approved four small mol. protein kinase antagonists in 2019; these include entrectinib, erdafitinib, pexidartinib, and fedratinib.  Entrectinib binds to TRKA/B/C and ROS1 and is prescribed for the treatment of solid tumors with NTRK fusion proteins and for ROS1-postive non-small cell lung cancers.  Erdafitinib inhibits fibroblast growth factor receptors 1-4 and is used in the treatment of urothelial bladder cancers.  Pexidartinib is a CSF1R antagonist that is prescribed for the treatment of tenosynovial giant cell tumors.  Fedratinib blocks JAK2 and is used in the treatment of myelofibrosis.  Overall, the US FDA has approved 52 small mol. protein kinase inhibitors, nearly all of which are orally effective with the exceptions of temsirolimus (which is given i.v.) and netarsudil (an eye drop).  Of the 52 approved drugs, eleven inhibit protein-serine/threonine protein kinases, two are directed against dual specificity protein kinases, eleven target non-receptor protein-tyrosine kinases, and 28 block receptor protein-tyrosine kinases.  The data indicate that 46 of these drugs are used in the treatment of neoplastic diseases (eight against non-solid tumors such as leukemias and 41 against solid tumors including breast and lung cancers; some drugs are used against both tumor types).  Eight drugs are employed in the treatment of non-malignancies: fedratinib, myelofibrosis; ruxolitinib, myelofibrosis and polycythemia vera; fostamatinib, chronic immune thrombocytopenia; baricitinib, rheumatoid arthritis; sirolimus, renal graft vs. host disease; nintedanib, idiopathic pulmonary fibrosis; netarsudil, glaucoma; and tofacitinib, rheumatoid arthritis, Crohn disease, and ulcerative colitis.  Moreover, sirolimus and ibrutinib are used for the treatment of both neoplastic and non-neoplastic diseases.  Entrectinib and larotrectinib are tissue-agnostic anti-cancer small mol. protein kinase inhibitors.  These drugs are prescribed for the treatment of any solid cancer harboring NTRK1/2/3 fusion proteins regardless of the organ, tissue, anatomical location, or histol. type.  Of the 52 approved drugs, seventeen are used in the treatment of more than one disease.  Imatinib, for example, is approved for the treatment of eight disparate disorders.  The most common drug targets of the approved pharmaceuticals include BCR-Abl, B-Raf, vascular endothelial growth factor receptors (VEGFR), epidermal growth factor receptors (EGFR), and ALK.  Most of the approved small mol. protein kinase antagonists (49) bind to the protein kinase domain and six of them bind covalently.  In contrast, everolimus, temsirolimus, and sirolimus are larger mols. (MW ≈ 1000) that bind to FK506 binding protein-12 (FKBP-12) to generate a complex that inhibits the mammalian target of rapamycin (mTOR) protein kinase complex.  This review presents the physicochem. properties of all of the FDA-approved small mol. protein kinase inhibitors.  Twenty-two of the 52 drugs have mol. wts. greater than 500, exceeding a Lipinski rule of five criterion.  Excluding the macrolides (everolimus, sirolimus, temsirolimus), the av. mol. wt. of the approved drugs is 480 with a range of 306 (ruxolitinib) to 615 (trametinib).  More than half of the antagonists (29) have lipophilic efficiency values of less than five while the recommended optima range from 5 to 10.  One of the troublesome problems with both targeted and cytotoxic drugs in the treatment of malignant diseases is the near universal development of resistance to every therapeutic modality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRgMvsJqanSLVg90H21EOLACvtfcHk0lgOy3Sorzsxvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisV2ktbrE&md5=7753f0e8c04a145e15b09b3e55e09cde</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2019.104609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2019.104609%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DProperties%2520of%2520FDA-approved%2520small%2520molecule%2520protein%2520kinase%2520inhibitors%253A%2520A%25202020%2520update%26jtitle%3DPharmacol.%2520Res.%26date%3D2020%26volume%3D152%26spage%3D104609%26doi%3D10.1016%2Fj.phrs.2019.104609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, J. P.</span></span> <span> </span><span class="NLM_article-title">DAPK1: A novel pathology and treatment target for Alzheimer’s disease</span>. <i>Mol. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2838</span>– <span class="NLM_lpage">2844</span>, <span class="refDoi"> DOI: 10.1007/s12035-018-1242-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1007%2Fs12035-018-1242-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=30062675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVWrurnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2019&pages=2838-2844&author=L.+Z.+Xuauthor=B.+Q.+Liauthor=J.+P.+Jia&title=DAPK1%3A+A+novel+pathology+and+treatment+target+for+Alzheimer%E2%80%99s+disease&doi=10.1007%2Fs12035-018-1242-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">DAPK1: a Novel Pathology and Treatment Target for Alzheimer's Disease</span></div><div class="casAuthors">Xu, Ling-zhi; Li, Bing-qiu; Jia, Jian-ping</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Neurobiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2838-2844</span>CODEN:
                <span class="NLM_cas:coden">MONBEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-7648</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) is the most common neurodegenerative disease and seriously damages the health of elderly population.  Clin. drug research targeting at classic pathol. hallmarks, such as amyloid-β (Aβ) and tau protein, failed to achieve effective cognitive improvement, suggesting that the pathogenesis of AD is much complicated, and there are still other unknown and undetd. important factors.  Death-assocd. protein kinase 1 (DAPK1) is a calcium/calmodulin-dependent serine/threonine kinase that plays an important role in various neuronal injury models.  Mounting evidence has demonstrated that DAPK1 variants are assocd. with AD risk.  The activation of DAPK1 is also involved in AD-related neurodegeneration in the brain.  Exploring the roles of DAPK1 in AD might help us understand the pathogenic mechanisms and find a novel promising therapeutic target in AD.  Therefore, in this review, we comprehensively summary the main progress of DAPK1 in the AD studies from genetic risk, neuropathol. process, and clin. potential implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovHMU9i6Hha7Vg90H21EOLACvtfcHk0lhEaexuKRUHwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVWrurnI&md5=59f867741be4079125dc272a7e1e76fd</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1007%2Fs12035-018-1242-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12035-018-1242-2%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DL.%2BZ.%26aulast%3DLi%26aufirst%3DB.%2BQ.%26aulast%3DJia%26aufirst%3DJ.%2BP.%26atitle%3DDAPK1%253A%2520A%2520novel%2520pathology%2520and%2520treatment%2520target%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DMol.%2520Neurobiol.%26date%3D2019%26volume%3D56%26spage%3D2838%26epage%3D2844%26doi%3D10.1007%2Fs12035-018-1242-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N. J.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the inhibition of p38 MAPK as a potential strategy for the treatment of Alzheimer’s disease</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1287</span>, <span class="refDoi"> DOI: 10.3390/molecules22081287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.3390%2Fmolecules22081287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=28767069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Cls77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=1287&author=J.+K.+Leeauthor=N.+J.+Kim&title=Recent+advances+in+the+inhibition+of+p38+MAPK+as+a+potential+strategy+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.3390%2Fmolecules22081287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the inhibition of p38 MAPK as a potential strategy for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Lee, Jong Kil; Kim, Nam-Jung</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1287/1-1287/23</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">P38 mitogen-activated protein kinase (MAPK) is a crucial target for chronic inflammatory diseases.  Alzheimer's disease (AD) is characterized by the presence of amyloid plaques and neurofibrillary tangles in the brain, as well as neurodegeneration, and there is no known cure.  Recent studies on the underlying biol. of AD in cellular and animal models have indicated that p38 MAPK is capable of orchestrating diverse events related to AD, such as tau phosphorylation, neurotoxicity, neuroinflammation and synaptic dysfunction.  Thus, the inhibition of p38 MAPK is considered a promising strategy for the treatment of AD.  In this review, we summarize recent advances in the targeting of p38 MAPK as a potential strategy for the treatment of AD and envision possibilities of p38 MAPK inhibitors as a fundamental therapeutics for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1NNXguBzPobVg90H21EOLACvtfcHk0lhEaexuKRUHwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Cls77P&md5=9aa70ca6361ea8e5e3bf789fd5df58be</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.3390%2Fmolecules22081287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules22081287%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BK.%26aulast%3DKim%26aufirst%3DN.%2BJ.%26atitle%3DRecent%2520advances%2520in%2520the%2520inhibition%2520of%2520p38%2520MAPK%2520as%2520a%2520potential%2520strategy%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DMolecules%26date%3D2017%26volume%3D22%26spage%3D1287%26doi%3D10.3390%2Fmolecules22081287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentry, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rush, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troncoso, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thambisetty, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montine, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herskowitz, J. H.</span></span> <span> </span><span class="NLM_article-title">Rho-associated protein kinase 1 (ROCK1) is increased in Alzheimer’s disease and ROCK1 depletion reduces amyloid-β levels in brain</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">531</span>, <span class="refDoi"> DOI: 10.1111/jnc.13688</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1111%2Fjnc.13688" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=27246255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVyntLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2016&pages=525-531&author=B.+W.+Hendersonauthor=E.+G.+Gentryauthor=T.+Rushauthor=J.+C.+Troncosoauthor=M.+Thambisettyauthor=T.+J.+Montineauthor=J.+H.+Herskowitz&title=Rho-associated+protein+kinase+1+%28ROCK1%29+is+increased+in+Alzheimer%E2%80%99s+disease+and+ROCK1+depletion+reduces+amyloid-%CE%B2+levels+in+brain&doi=10.1111%2Fjnc.13688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Rho-associated protein kinase 1 (ROCK1) is increased in Alzheimer's disease and ROCK1 depletion reduces amyloid-β levels in brain</span></div><div class="casAuthors">Henderson, Benjamin W.; Gentry, Erik G.; Rush, Travis; Troncoso, Juan C.; Thambisetty, Madhav; Montine, Thomas J.; Herskowitz, Jeremy H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">525-531</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is the leading cause of dementia and mitigating amyloid-β (Aβ) levels may serve as a rational therapeutic avenue to slow AD progression.  Pharmacol. inhibition of the Rho-assocd. protein kinases (ROCK1 and ROCK2) is proposed to curb Aβ levels, and mechanisms that underlie ROCK2's effects on Aβ prodn. are defined.  How ROCK1 affects Aβ generation remains a crit. barrier.  Here, we report that ROCK1 protein levels were elevated in mild cognitive impairment due to AD (MCI) and AD brains compared to controls.  Aβ42 oligomers marginally increased ROCK1 and ROCK2 protein levels in neurons but strongly induced phosphorylation of Lim kinase 1 (LIMK1), suggesting that Aβ42 activates ROCKs.  RNAi depletion of ROCK1 or ROCK2 suppressed endogenous Aβ40 prodn. in neurons, and Aβ40 levels were reduced in brains of ROCK1 heterozygous knock-out mice compared to wild-type littermate controls.  ROCK1 knockdown decreased amyloid precursor protein (APP), and treatment with bafilomycin accumulated APP levels in neurons depleted of ROCK1.  These observations suggest that redn. of ROCK1 diminishes Aβ levels by enhancing APP protein degrdn.  Collectively, these findings support the hypothesis that both ROCK1 and ROCK2 are therapeutic targets to combat Aβ prodn. in AD.  Mitigating amyloid-β (Aβ) levels is a rational strategy for Alzheimer's disease (AD) treatment, however, therapeutic targets with clin. available drugs are lacking.  We hypothesize that Aβ accumulation in mild cognitive impairment because of AD (MCI) and AD activates the RhoA/ROCK pathway which in turn fuels prodn. of Aβ.  Escalation of this cycle over the course of many years may contribute to the buildup of amyloid pathol. in MCI and/or AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqojJcfZXda27Vg90H21EOLACvtfcHk0lhEaexuKRUHwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVyntLvN&md5=07493d821f9384878f455b62d7836778</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1111%2Fjnc.13688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjnc.13688%26sid%3Dliteratum%253Aachs%26aulast%3DHenderson%26aufirst%3DB.%2BW.%26aulast%3DGentry%26aufirst%3DE.%2BG.%26aulast%3DRush%26aufirst%3DT.%26aulast%3DTroncoso%26aufirst%3DJ.%2BC.%26aulast%3DThambisetty%26aufirst%3DM.%26aulast%3DMontine%26aufirst%3DT.%2BJ.%26aulast%3DHerskowitz%26aufirst%3DJ.%2BH.%26atitle%3DRho-associated%2520protein%2520kinase%25201%2520%2528ROCK1%2529%2520is%2520increased%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520and%2520ROCK1%2520depletion%2520reduces%2520amyloid-%25CE%25B2%2520levels%2520in%2520brain%26jtitle%3DJ.%2520Neurochem.%26date%3D2016%26volume%3D138%26spage%3D525%26epage%3D531%26doi%3D10.1111%2Fjnc.13688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nygaard, H. B.</span></span> <span> </span><span class="NLM_article-title">Targeting Fyn kinase in Alzheimer’s disease</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">369</span>– <span class="NLM_lpage">376</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2017.06.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.biopsych.2017.06.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=28709498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFGmt7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2018&pages=369-376&author=H.+B.+Nygaard&title=Targeting+Fyn+kinase+in+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.biopsych.2017.06.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Fyn Kinase in Alzheimer's Disease</span></div><div class="casAuthors">Nygaard, Haakon B.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">369-376</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The past decade has brought tremendous progress in unraveling the pathophysiol. of Alzheimer's disease (AD).  While increasingly sophisticated immunotherapy targeting sol. and aggregated brain amyloid-beta (Aβ) continues to dominate clin. research in AD, a deeper understanding of Aβ physiol. has led to the recognition of distinct neuronal signaling pathways linking Aβ to synaptotoxicity and neurodegeneration and to new targets for therapeutic intervention.  Identifying specific signaling pathways involving Aβ has allowed for the development of more precise therapeutic interventions targeting the most relevant mol. mechanisms leading to AD.  In this review, I highlight the discovery of cellular prion protein as a high-affinity receptor for Aβ oligomers, and the downstream signaling pathway elucidated to date, converging on nonreceptor tyrosine kinase Fyn.  I discuss preclin. studies targeting Fyn as a therapeutic intervention in AD and our recent experience with the safety, tolerability, and cerebrospinal fluid penetration of the Src family kinase inhibitor saracatinib in patients with AD.  Fyn is an attractive target for AD therapeutics, not only based on its activation by Aβ via cellular prion protein but also due to its known interaction with tau, uniquely linking the two key pathologies in AD.  Fyn is also a challenging target, with broad expression throughout the body and significant homol. with other members of the Src family kinases, which may lead to unintended off-target effects.  A phase 2a proof-of-concept clin. trial in patients with AD is currently under way, providing crit. first data on the potential effectiveness of targeting Fyn in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDCIJXCt9gzbVg90H21EOLACvtfcHk0lhEaexuKRUHwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFGmt7jF&md5=55d32bcf85535a8bc303114a8f42e42d</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2017.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2017.06.004%26sid%3Dliteratum%253Aachs%26aulast%3DNygaard%26aufirst%3DH.%2BB.%26atitle%3DTargeting%2520Fyn%2520kinase%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DBiol.%2520Psychiatry%26date%3D2018%26volume%3D83%26spage%3D369%26epage%3D376%26doi%3D10.1016%2Fj.biopsych.2017.06.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tondo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergink, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grof, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewitka, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Licht, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manchia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller-Oerlinghausen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simhandl, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldessarini, R. J.</span></span> <span> </span><span class="NLM_article-title">Clinical use of lithium salts: Guide for users and prescribers</span>. <i>Int. J. Bipolar Disord.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">16</span>, <span class="refDoi"> DOI: 10.1186/s40345-019-0151-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1186%2Fs40345-019-0151-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=31328245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BB3MzpsF2hsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=16&author=L.+Tondoauthor=M.+Aldaauthor=M.+Bauerauthor=V.+Berginkauthor=P.+Grofauthor=T.+Hajekauthor=U.+Lewitkaauthor=R.+W.+Lichtauthor=M.+Manchiaauthor=B.+M%C3%BCller-Oerlinghausenauthor=R.+E.+Nielsenauthor=M.+Seloauthor=C.+Simhandlauthor=R.+J.+Baldessarini&title=Clinical+use+of+lithium+salts%3A+Guide+for+users+and+prescribers&doi=10.1186%2Fs40345-019-0151-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical use of lithium salts: guide for users and prescribers</span></div><div class="casAuthors">Tondo Leonardo; Baldessarini Ross J; Tondo Leonardo; Baldessarini Ross J; Tondo Leonardo; Alda Martin; Hajek Tomas; Bauer Michael; Lewitka Ute; Bergink Veerle; Bergink Veerle; Grof Paul; Licht Rasmus W; Nielsen Rene E; Licht Rasmus W; Nielsen Rene E; Manchia Mirko; Manchia Mirko; Muller-Oerlinghausen Bruno; Selo Marylou; Simhandl Christian</div><div class="citationInfo"><span class="NLM_cas:title">International journal of bipolar disorders</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16</span>
        ISSN:<span class="NLM_cas:issn">2194-7511</span>.
    </div><div class="casAbstract">BACKGROUND:  Lithium has been used clinically for 70 years, mainly to treat bipolar disorder.  Competing treatments and exaggerated impressions about complexity and risks of lithium treatment have led to its declining use in some countries, encouraging this update about its safe clinical use.  We conducted a nonsystematic review of recent research reports and developed consensus among international experts on the use of lithium to treat major mood disorders, aiming for a simple but authoritative guide for patients and prescribers.  MAIN TEXT:  We summarized recommendations concerning safe clinical use of lithium salts to treat major mood disorders, including indications, dosing, clinical monitoring, adverse effects and use in specific circumstances including during pregnancy and for the elderly.  CONCLUSIONS:  Lithium continues as the standard and most extensively evaluated treatment for bipolar disorder, especially for long-term prophylaxis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRrqOwhPXN7GUH3Rlp_k91zfW6udTcc2eZh-dia9dmNVbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MzpsF2hsA%253D%253D&md5=02de55b07286d06c5e5bee44e1a9fdfe</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1186%2Fs40345-019-0151-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40345-019-0151-2%26sid%3Dliteratum%253Aachs%26aulast%3DTondo%26aufirst%3DL.%26aulast%3DAlda%26aufirst%3DM.%26aulast%3DBauer%26aufirst%3DM.%26aulast%3DBergink%26aufirst%3DV.%26aulast%3DGrof%26aufirst%3DP.%26aulast%3DHajek%26aufirst%3DT.%26aulast%3DLewitka%26aufirst%3DU.%26aulast%3DLicht%26aufirst%3DR.%2BW.%26aulast%3DManchia%26aufirst%3DM.%26aulast%3DM%25C3%25BCller-Oerlinghausen%26aufirst%3DB.%26aulast%3DNielsen%26aufirst%3DR.%2BE.%26aulast%3DSelo%26aufirst%3DM.%26aulast%3DSimhandl%26aufirst%3DC.%26aulast%3DBaldessarini%26aufirst%3DR.%2BJ.%26atitle%3DClinical%2520use%2520of%2520lithium%2520salts%253A%2520Guide%2520for%2520users%2520and%2520prescribers%26jtitle%3DInt.%2520J.%2520Bipolar%2520Disord.%26date%3D2019%26volume%3D7%26spage%3D16%26doi%3D10.1186%2Fs40345-019-0151-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Forlenza, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De-Paula, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diniz, B. S.</span></span> <span> </span><span class="NLM_article-title">Neuroprotective effects of lithium: Implications for the treatment of Alzheimer’s disease and related neurodegenerative disorders</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1021/cn5000309</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn5000309" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmvF2nur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=443-450&author=O.+V.+Forlenzaauthor=V.+J.+De-Paulaauthor=B.+S.+Diniz&title=Neuroprotective+effects+of+lithium%3A+Implications+for+the+treatment+of+Alzheimer%E2%80%99s+disease+and+related+neurodegenerative+disorders&doi=10.1021%2Fcn5000309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroprotective Effects of Lithium: Implications for the Treatment of Alzheimer's Disease and Related Neurodegenerative Disorders</span></div><div class="casAuthors">Forlenza, O. V.; De-Paula, V. J. R.; Diniz, B. S. O.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">443-450</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Lithium is a well-established therapeutic option for the acute and long-term management of bipolar disorder and major depression.  More recently, based on findings from translational research, lithium has also been regarded as a neuroprotective agent and a candidate drug for disease-modification in certain neurodegenerative disorders, namely, Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and, more recently, Parkinson's disease (PD).  The putative neuroprotective effects of lithium rely on the fact that it modulates several homeostatic mechanisms involved in neurotrophic response, autophagy, oxidative stress, inflammation, and mitochondrial function.  Such a wide range of intracellular responses may be secondary to two key effects, i.e., the inhibition of glycogen synthase kinase-3 beta (GSK-3β) and inositol monophosphatase (IMP) by lithium.  In the present review, we revisit the neurobiol. properties of lithium in light of the available evidence of its neurotrophic and neuroprotective properties, and discuss the rationale for its use in the treatment and prevention of neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZTodicRKytrVg90H21EOLACvtfcHk0lhVbulDMT-6iA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmvF2nur4%253D&md5=d9920f0dda84aa3bcfc5bb8666a52448</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1021%2Fcn5000309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn5000309%26sid%3Dliteratum%253Aachs%26aulast%3DForlenza%26aufirst%3DO.%2BV.%26aulast%3DDe-Paula%26aufirst%3DV.%2BJ.%26aulast%3DDiniz%26aufirst%3DB.%2BS.%26atitle%3DNeuroprotective%2520effects%2520of%2520lithium%253A%2520Implications%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%2520and%2520related%2520neurodegenerative%2520disorders%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2014%26volume%3D5%26spage%3D443%26epage%3D450%26doi%3D10.1021%2Fcn5000309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nunes, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viel, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buck, H. S.</span></span> <span> </span><span class="NLM_article-title">Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer’s disease</span>. <i>Curr. Alzheimer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">104</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.2174/1567205011310010014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.2174%2F1567205011310010014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=22746245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFelsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=104-107&author=M.+A.+Nunesauthor=T.+A.+Vielauthor=H.+S.+Buck&title=Microdose+lithium+treatment+stabilized+cognitive+impairment+in+patients+with+Alzheimer%E2%80%99s+disease&doi=10.2174%2F1567205011310010014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease</span></div><div class="casAuthors">Nunes, Marielza Andrade; Viel, Tania Araujo; Buck, Hudson Sousa</div><div class="citationInfo"><span class="NLM_cas:title">Current Alzheimer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">104-107</span>CODEN:
                <span class="NLM_cas:coden">CARUBY</span>;
        ISSN:<span class="NLM_cas:issn">1567-2050</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A lower incidence of dementia in bipolar patients treated with lithium has been described.  This metal inhibits the phosphorylation of glycogen-synthase-kinase 3-α and β, which are related to amyloid precursor protein processing and tau hyperphosphorylation in pathol. conditions, resp.  Following the same rationale, a group just found that lithium has disease-modifying properties in amnestic mild cognitive impairment with potential clin. implications for the prevention of Alzheimer's Disease (AD) when a dose ranging from 150 to 600 mg is used.  As lithium is highly toxic in regular doses, our group evaluated the effect of a microdose of 300μg, administered once daily on AD patients for 15 mo.  In the evaluation phase, the treated group showed no decreased performance in the mini-mental state examn. test, in opposition to the lower scores obsd. for the control group during the treatment, with significant differences starting three months after the beginning of the treatment, and increasing progressively.  This data suggests the efficacy of a microdose lithium treatment in preventing cognitive loss, reinforcing its therapeutic potential to treat AD using very low doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouXJgwK8Wwu7Vg90H21EOLACvtfcHk0lhVbulDMT-6iA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFelsrY%253D&md5=a4892edfba3411511adea4e09cd27d32</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.2174%2F1567205011310010014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1567205011310010014%26sid%3Dliteratum%253Aachs%26aulast%3DNunes%26aufirst%3DM.%2BA.%26aulast%3DViel%26aufirst%3DT.%2BA.%26aulast%3DBuck%26aufirst%3DH.%2BS.%26atitle%3DMicrodose%2520lithium%2520treatment%2520stabilized%2520cognitive%2520impairment%2520in%2520patients%2520with%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DCurr.%2520Alzheimer%2520Res.%26date%3D2013%26volume%3D10%26spage%3D104%26epage%3D107%26doi%3D10.2174%2F1567205011310010014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo Monte, F.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibitors of GSK-3: Structural insights and their application to Alzheimer’s disease models</span>. <i>Int. J. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2012</i></span>,  <span class="NLM_fpage">381029</span>, <span class="refDoi"> DOI: 10.1155/2012/381029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1155%2F2012%2F381029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=22888461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BC38fpvVKmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2012&publication_year=2012&pages=381029&author=T.+Kramerauthor=B.+Schmidtauthor=F.+Lo+Monte&title=Small-molecule+inhibitors+of+GSK-3%3A+Structural+insights+and+their+application+to+Alzheimer%E2%80%99s+disease+models&doi=10.1155%2F2012%2F381029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Inhibitors of GSK-3: Structural Insights and Their Application to Alzheimer's Disease Models</span></div><div class="casAuthors">Kramer Thomas; Schmidt Boris; Lo Monte Fabio</div><div class="citationInfo"><span class="NLM_cas:title">International journal of Alzheimer's disease</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2012</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">381029</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The world health organization (WHO) estimated that 18 million people are struck by Alzheimer's disease (AD).  The USA, France, Germany, and other countries launched major programmes targeting the identification of risk factors, the improvement of caretaking, and fundamental research aiming to postpone the onset of AD.  The glycogen synthase kinase 3 (GSK-3) is implicated in multiple cellular processes and has been linked to the pathogenesis of several diseases including diabetes mellitus, cancer, and AD.  Inhibition of GSK-3 leads to neuroprotective effects, decreased β-amyloid production, and a reduction in tau hyperphosphorylation, which are all associated with AD.  Various classes of small molecule GSK-3 inhibitors have been published in patents and original publications.  Herein, we present a comprehensive summary of small molecules reported to interact with GSK-3.  We illustrate the interactions of the inhibitors with the active site.  Furthermore, we refer to the biological characterisation in terms of activity and selectivity for GSK-3, elucidate in vivo studies and pre-/clinical trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRgN9KQeV4e1yA3UY9EwTNrfW6udTcc2eZjxTJCuf2B2bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38fpvVKmug%253D%253D&md5=100844ec1c85bbf465eeecb27559066d</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1155%2F2012%2F381029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2012%252F381029%26sid%3Dliteratum%253Aachs%26aulast%3DKramer%26aufirst%3DT.%26aulast%3DSchmidt%26aufirst%3DB.%26aulast%3DLo%2BMonte%26aufirst%3DF.%26atitle%3DSmall-molecule%2520inhibitors%2520of%2520GSK-3%253A%2520Structural%2520insights%2520and%2520their%2520application%2520to%2520Alzheimer%25E2%2580%2599s%2520disease%2520models%26jtitle%3DInt.%2520J.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2012%26volume%3D2012%26spage%3D381029%26doi%3D10.1155%2F2012%2F381029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakesh, K. P.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship (SAR) studies of synthetic glycogen synthase kinase-3β inhibitors: A critical review</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">448</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.12.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.ejmech.2018.12.073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=30616053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkvVGgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2019&pages=448-470&author=M.+Xuauthor=S.+L.+Wangauthor=L.+Zhuauthor=P.+Y.+Wuauthor=W.+B.+Daiauthor=K.+P.+Rakesh&title=Structure-activity+relationship+%28SAR%29+studies+of+synthetic+glycogen+synthase+kinase-3%CE%B2+inhibitors%3A+A+critical+review&doi=10.1016%2Fj.ejmech.2018.12.073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationship (SAR) studies of synthetic glycogen synthase kinase-3β inhibitors: A critical review</span></div><div class="casAuthors">Xu, M.; Wang, S. L.; Zhu, L.; Wu, P. Y.; Dai, W. B.; Rakesh, K. P.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">448-470</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Glycogen Synthase Kinase-3 (GSK-3) is a constitutively dynamic, omnipresent serine/threonine protein kinase regularly called as a "multi-tasking kinase" due to its pliable function in diverse signaling pathways.  It exists in two isoforms i.e., GSK-3α and GSK-3β.  Inhibition of GSK-3 may be useful in curing various diseases such as Alzheimer's disease, type II diabetes, mood disorders, cancers, chronic inflammatory agents, stroke, bipolar disorders and so on, but the approach poses significant challenges.  Lithium was the first GSK-3β inhibitor to be used for therapeutic outcome and has been effectively used for many years.  In recent years, a large no. of structurally diverse potent GSK-3β inhibitors are reported.  The present review focuses on the recent developments in the area of medicinal chem. to explore the diverse chem. structures of potent GSK-3β inhibitors and also describes its structure-activity relationships (SAR) and mol. binding interactions of favorable applicability in various diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp72bJHjANYA7Vg90H21EOLACvtfcHk0ljjtPew7FFXrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkvVGgug%253D%253D&md5=3ee6633bf8aea71b4eec73979f2f39c9</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.12.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.12.073%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DS.%2BL.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DP.%2BY.%26aulast%3DDai%26aufirst%3DW.%2BB.%26aulast%3DRakesh%26aufirst%3DK.%2BP.%26atitle%3DStructure-activity%2520relationship%2520%2528SAR%2529%2520studies%2520of%2520synthetic%2520glycogen%2520synthase%2520kinase-3%25CE%25B2%2520inhibitors%253A%2520A%2520critical%2520review%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D164%26spage%3D448%26epage%3D470%26doi%3D10.1016%2Fj.ejmech.2018.12.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thieffine, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristiani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valsasina, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalisz, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flocco, M.</span></span> <span> </span><span class="NLM_article-title">Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>333</i></span>,  <span class="NLM_fpage">393</span>– <span class="NLM_lpage">407</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2003.08.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.jmb.2003.08.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=14529625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD3sXns1KrtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=333&publication_year=2003&pages=393-407&author=J.+A.+Bertrandauthor=S.+Thieffineauthor=A.+Vulpettiauthor=C.+Cristianiauthor=B.+Valsasinaauthor=S.+Knappauthor=H.+M.+Kaliszauthor=M.+Flocco&title=Structural+characterization+of+the+GSK-3beta+active+site+using+selective+and+non-selective+ATP-mimetic+inhibitors&doi=10.1016%2Fj.jmb.2003.08.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Characterization of the GSK-3β Active Site Using Selective and Non-selective ATP-mimetic Inhibitors</span></div><div class="casAuthors">Bertrand, J. A.; Thieffine, S.; Vulpetti, A.; Cristiani, C.; Valsasina, B.; Knapp, S.; Kalisz, H. M.; Flocco, M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">333</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">393-407</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">GSK-3β is a regulatory serine/threonine kinase with a plethora of cellular targets.  Consequently, selective small mol. inhibitors of GSK-3β may have a variety of therapeutic uses including the treatment of neurodegenerative diseases, type II diabetes and cancer.  In order to characterize the active site of GSK-3β, we detd. crystal structures of unphosphorylated GSK-3β in complex with selective and non-selective ATP-mimetic inhibitors.  Anal. of the inhibitors' interactions with GSK-3β in the structures reveals how the enzyme can accommodate a no. of diverse mol. scaffolds.  In addn., a conserved water mol. near Thr138 is identified that can serve a functional role in inhibitor binding.  Finally, a comparison of the interactions made by selective and non-selective inhibitors highlights residues on the edge of the ATP binding-site that can be used to obtain inhibitor selectivity.  Information gained from these structures provides a promising route for the design of second-generation GSK-3β inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1bMYOQCSrdrVg90H21EOLACvtfcHk0ljjtPew7FFXrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXns1KrtLY%253D&md5=788fcb4dfa754e16e529c468014f44ab</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2003.08.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2003.08.031%26sid%3Dliteratum%253Aachs%26aulast%3DBertrand%26aufirst%3DJ.%2BA.%26aulast%3DThieffine%26aufirst%3DS.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DCristiani%26aufirst%3DC.%26aulast%3DValsasina%26aufirst%3DB.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DKalisz%26aufirst%3DH.%2BM.%26aulast%3DFlocco%26aufirst%3DM.%26atitle%3DStructural%2520characterization%2520of%2520the%2520GSK-3beta%2520active%2520site%2520using%2520selective%2520and%2520non-selective%2520ATP-mimetic%2520inhibitors%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2003%26volume%3D333%26spage%3D393%26epage%3D407%26doi%3D10.1016%2Fj.jmb.2003.08.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ormö, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radesäter, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jerning, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markgren, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgegård, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nylöf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giménez-Cassina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernández, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Díaz-Nido, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avila, J.</span></span> <span> </span><span class="NLM_article-title">Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">45937</span>– <span class="NLM_lpage">45945</span>, <span class="refDoi"> DOI: 10.1074/jbc.M306268200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1074%2Fjbc.M306268200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=12928438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosl2itL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=45937-45945&author=R.+Bhatauthor=Y.+Xueauthor=S.+Bergauthor=S.+Hellbergauthor=M.+Orm%C3%B6author=Y.+Nilssonauthor=A.+C.+Rades%C3%A4terauthor=E.+Jerningauthor=P.+O.+Markgrenauthor=T.+Borgeg%C3%A5rdauthor=M.+Nyl%C3%B6fauthor=A.+Gim%C3%A9nez-Cassinaauthor=F.+Hern%C3%A1ndezauthor=J.+J.+Lucasauthor=J.+D%C3%ADaz-Nidoauthor=J.+Avila&title=Structural+insights+and+biological+effects+of+glycogen+synthase+kinase+3-specific+inhibitor+AR-A014418&doi=10.1074%2Fjbc.M306268200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Insights and Biological Effects of Glycogen Synthase Kinase 3-specific Inhibitor AR-A014418</span></div><div class="casAuthors">Bhat, Ratan; Xue, Yafeng; Berg, Stefan; Hellberg, Sven; Ormoe, Mats; Nilsson, Yvonne; Radesaeter, Ann-Cathrin; Jerning, Eva; Markgren, Per-Olof; Borgegard, Thomas; Nyloef, Martin; Gimenez-Cassina, Alfredo; Hernandez, Felix; Lucas, Jose J.; Diaz-Nido, Javier; Avila, Jesus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">45937-45945</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Glycogen synthase kinase 3 (GSK3) is a serine/threonine kinase that has been implicated in pathol. conditions such as diabetes and Alzheimer's disease.  We report the characterization of a GSK3 inhibitor, AR-A014418, which inhibits GSK3 (IC50 = 104±27 nM), in an ATP-competitive manner (Ki = 38 nM).  AR-A014418 does not significantly inhibit cdk2 or cdk5 (IC50 > 100 μM) or 26 other kinases demonstrating high specificity for GSK3.  We report the co-crystn. of AR-A014418 with the GSK3β protein and provide a description of the interactions within the ATP pocket, as well as an understanding of the structural basis for the selectivity of AR-A014418.  AR-A014418 inhibits tau phosphorylation at a GSK3-specific site (Ser-396) in cells stably expressing human four-repeat tau protein.  AR-A014418 protects N2A neuroblastoma cells against cell death mediated by inhibition of the phosphatidylinositol 3-kinase/protein kinase B survival pathway.  Furthermore, AR-A014418 inhibits neurodegeneration mediated by β-amyloid peptide in hippocampal slices.  AR-A014418 may thus have important applications as a tool to elucidate the role of GSK3 in cellular signaling and possibly in Alzheimer's disease.  AR-A014418 is the first compd. of a family of specific inhibitors of GSK3 that does not significantly inhibit closely related kinases such as cdk2 or cdk5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVw7LgEHct0LVg90H21EOLACvtfcHk0ljNDtsG9XGKBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosl2itL0%253D&md5=c52e13ab3dfdcef165620714c3181860</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M306268200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M306268200%26sid%3Dliteratum%253Aachs%26aulast%3DBhat%26aufirst%3DR.%26aulast%3DXue%26aufirst%3DY.%26aulast%3DBerg%26aufirst%3DS.%26aulast%3DHellberg%26aufirst%3DS.%26aulast%3DOrm%25C3%25B6%26aufirst%3DM.%26aulast%3DNilsson%26aufirst%3DY.%26aulast%3DRades%25C3%25A4ter%26aufirst%3DA.%2BC.%26aulast%3DJerning%26aufirst%3DE.%26aulast%3DMarkgren%26aufirst%3DP.%2BO.%26aulast%3DBorgeg%25C3%25A5rd%26aufirst%3DT.%26aulast%3DNyl%25C3%25B6f%26aufirst%3DM.%26aulast%3DGim%25C3%25A9nez-Cassina%26aufirst%3DA.%26aulast%3DHern%25C3%25A1ndez%26aufirst%3DF.%26aulast%3DLucas%26aufirst%3DJ.%2BJ.%26aulast%3DD%25C3%25ADaz-Nido%26aufirst%3DJ.%26aulast%3DAvila%26aufirst%3DJ.%26atitle%3DStructural%2520insights%2520and%2520biological%2520effects%2520of%2520glycogen%2520synthase%2520kinase%25203-specific%2520inhibitor%2520AR-A014418%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D45937%26epage%3D45945%26doi%3D10.1074%2Fjbc.M306268200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leost, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Link, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biernat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandelkow, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bibb, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greengard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaharevitz, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gussio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senderowicz, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sausville, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunick, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span> <span> </span><span class="NLM_article-title">Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25</span>. <i>Eur. J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>267</i></span>,  <span class="NLM_fpage">5983</span>– <span class="NLM_lpage">5994</span>, <span class="refDoi"> DOI: 10.1046/j.1432-1327.2000.01673.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1046%2Fj.1432-1327.2000.01673.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10998059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnt1Smtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=2000&pages=5983-5994&author=M.+Leostauthor=C.+Schultzauthor=A.+Linkauthor=Y.+Z.+Wuauthor=J.+Biernatauthor=E.+M.+Mandelkowauthor=J.+A.+Bibbauthor=G.+L.+Snyderauthor=P.+Greengardauthor=D.+W.+Zaharevitzauthor=R.+Gussioauthor=A.+M.+Senderowiczauthor=E.+A.+Sausvilleauthor=C.+Kunickauthor=L.+Meijer&title=Paullones+are+potent+inhibitors+of+glycogen+synthase+kinase-3beta+and+cyclin-dependent+kinase+5%2Fp25&doi=10.1046%2Fj.1432-1327.2000.01673.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Paullones are potent inhibitors of glycogen synthase kinase-3β and cyclin-dependent kinase 5/p25</span></div><div class="casAuthors">Leost, Maryse; Schultz, Christiane; Link, Andreas; Wu, Yong-Zhong; Biernat, Jacek; Mandelkow, Eva-Maria; Bibb, James A.; Snyder, Gretchen L.; Greengard, Paul; Zaharevitz, Daniel W.; Gussio, Rick; Senderowicz, Adrian M.; Sausville, Edward A.; Kunick, Conrad; Meijer, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5983-5994</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">Paullones constitute a new family of benzazepinones with promising antitumor properties.  They were recently described as potent, ATP-competitive, inhibitors of the cell cycle regulating cyclin-dependent kinases (CDKs).  We here report that paullones also act as very potent inhibitors of glycogen synthase kinase-3β u(GSuK-3β) (IC50·4-80 nm) and the neuronal CDK5/p25 (IC50:20-200 nM).  These two enzymes are responsible for most of the hyperphosphorylation of the microtubule-binding protein lau, a feature obsd. in the brains of patients with Alzheimer's disease and other neurodegenerative 'taupathies'.  Alsterpaullone, the most active paullone, was demonstrated to act by competing with ATP for binding to GSK-3β.  Alsterpaullone inhibits the phosphorylation of tau in vivo at sites which are typically phosphorylated by GSK-3β in Alzheimer's disease.  Alsterpaullone also inhibits the CDK5/p25-dependent phosphorylation of DARPP-32 in mouse striatum slices in vitro.  This dual specificity of paullones may turn these compds. into very useful tools for the study and possibly treatment of neurodegenerative and proliferative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkzLsn0FFzNLVg90H21EOLACvtfcHk0ljNDtsG9XGKBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnt1Smtro%253D&md5=7a9ab4b55ac18653eb74246ace20754a</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1046%2Fj.1432-1327.2000.01673.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1432-1327.2000.01673.x%26sid%3Dliteratum%253Aachs%26aulast%3DLeost%26aufirst%3DM.%26aulast%3DSchultz%26aufirst%3DC.%26aulast%3DLink%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DY.%2BZ.%26aulast%3DBiernat%26aufirst%3DJ.%26aulast%3DMandelkow%26aufirst%3DE.%2BM.%26aulast%3DBibb%26aufirst%3DJ.%2BA.%26aulast%3DSnyder%26aufirst%3DG.%2BL.%26aulast%3DGreengard%26aufirst%3DP.%26aulast%3DZaharevitz%26aufirst%3DD.%2BW.%26aulast%3DGussio%26aufirst%3DR.%26aulast%3DSenderowicz%26aufirst%3DA.%2BM.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DKunick%26aufirst%3DC.%26aulast%3DMeijer%26aufirst%3DL.%26atitle%3DPaullones%2520are%2520potent%2520inhibitors%2520of%2520glycogen%2520synthase%2520kinase-3beta%2520and%2520cyclin-dependent%2520kinase%25205%252Fp25%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D2000%26volume%3D267%26spage%3D5983%26epage%3D5994%26doi%3D10.1046%2Fj.1432-1327.2000.01673.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, F. J.</span></span> <span> </span><span class="NLM_article-title">First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1292</span>– <span class="NLM_lpage">1299</span>, <span class="refDoi"> DOI: 10.1021/jm011020u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm011020u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtFCgu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=1292-1299&author=A.+Martinezauthor=M.+Alonsoauthor=A.+Castroauthor=C.+P%C3%A9rezauthor=F.+J.+Moreno&title=First+non-ATP+competitive+glycogen+synthase+kinase+3+beta+%28GSK-3beta%29+inhibitors%3A+Thiadiazolidinones+%28TDZD%29+as+potential+drugs+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1021%2Fjm011020u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">First Non-ATP Competitive Glycogen Synthase Kinase 3β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease</span></div><div class="casAuthors">Martinez, Ana; Alonso, Mercedes; Castro, Ana; Perez, Concepcion; Moreno, Francisco J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1292-1299</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glycogen synthase kinase 3β (GSK-3β) has a central role in Alzheimer's disease (AD).  Selective inhibitors which avoid τ hyperphosphorylation may represent an effective therapeutic approach to the pharmacotherapy of AD and other neurodegenerative disorders.  The synthesis, biol. evaluation, and SAR of some thiadiazolidinones (TDZD) as the first non-ATP competitive inhibitor of GSK-3β.  Their synthesis is based on the reactivity of sulfenyl chlorides.  In GSK-3β assays, TDZD derivs. showed IC50 values in the micromolar range, whereas in other protein kinase assays they were devoid of any inhibitory activity.  SAR studies allowed the identification of the key structural features.  Finally, a possible enzymic binding mode is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofQZkRe2BHh7Vg90H21EOLACvtfcHk0ljNDtsG9XGKBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtFCgu70%253D&md5=a364133d1035bee183c58ad30ac140f8</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Fjm011020u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm011020u%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DAlonso%26aufirst%3DM.%26aulast%3DCastro%26aufirst%3DA.%26aulast%3DP%25C3%25A9rez%26aufirst%3DC.%26aulast%3DMoreno%26aufirst%3DF.%2BJ.%26atitle%3DFirst%2520non-ATP%2520competitive%2520glycogen%2520synthase%2520kinase%25203%2520beta%2520%2528GSK-3beta%2529%2520inhibitors%253A%2520Thiadiazolidinones%2520%2528TDZD%2529%2520as%2520potential%2520drugs%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D1292%26epage%3D1299%26doi%3D10.1021%2Fjm011020u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bidon-Chanal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuertes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luque, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, M.</span></span> <span> </span><span class="NLM_article-title">Evidence for a new binding mode to GSK-3: Allosteric regulation by the marine compound palinurin</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">479</span>– <span class="NLM_lpage">489</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2012.12.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.ejmech.2012.12.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=23354070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtVelsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2013&pages=479-489&author=A.+Bidon-Chanalauthor=A.+Fuertesauthor=D.+Alonsoauthor=D.+I.+P%C3%A9rezauthor=A.+Mart%C3%ADnezauthor=F.+J.+Luqueauthor=M.+Medina&title=Evidence+for+a+new+binding+mode+to+GSK-3%3A+Allosteric+regulation+by+the+marine+compound+palinurin&doi=10.1016%2Fj.ejmech.2012.12.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for a new binding mode to GSK-3: Allosteric regulation by the marine compound palinurin</span></div><div class="casAuthors">Bidon-Chanal, Axel; Fuertes, Ana; Alonso, Diana; Perez, Daniel I.; Martinez, Ana; Luque, F. Javier; Medina, Miguel</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">479-489</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Glycogen synthase kinase 3β (GSK-3β) is widely recognized as a relevant player in the pathogenesis of several highly prevalent disorders such as Alzheimer's disease, mood disorders, diabetes and cancer.  Therefore, this enzyme constitutes a highly attractive therapeutic target for the development of selective inhibitors as new promising drugs for the treatment of these pathologies.  The authors describe here the isolation and biochem. characterization of the marine natural sesquiterpene palinurin as a GSK-3β inhibitor.  Exptl. studies performed for characterizing the inhibitory mechanism indicate that GSK-3β inhibition by palinurin cannot be competed out by ATP nor peptide substrate.  Mol. modeling techniques have enabled the authors to propose an unconventional binding mode to GSK-3β.  Moreover, mol. dynamics simulations have identified an allosteric mechanism by which binding of palinurin leads to GSK-3β inhibition.  The inhibitory activities detd. for a series of structurally related analogs support the proposed binding mode of palinurin, which is the first compd. described to target this allosteric site.  The results offer new opportunities for designing and developing selective inhibitors with novel mechanisms of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpXmrBhA5ub7Vg90H21EOLACvtfcHk0lg5bHURoH7dIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtVelsrY%253D&md5=e9005c12a4f6897a91c3ee56e83b5f2d</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.12.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.12.014%26sid%3Dliteratum%253Aachs%26aulast%3DBidon-Chanal%26aufirst%3DA.%26aulast%3DFuertes%26aufirst%3DA.%26aulast%3DAlonso%26aufirst%3DD.%26aulast%3DP%25C3%25A9rez%26aufirst%3DD.%2BI.%26aulast%3DMart%25C3%25ADnez%26aufirst%3DA.%26aulast%3DLuque%26aufirst%3DF.%2BJ.%26aulast%3DMedina%26aufirst%3DM.%26atitle%3DEvidence%2520for%2520a%2520new%2520binding%2520mode%2520to%2520GSK-3%253A%2520Allosteric%2520regulation%2520by%2520the%2520marine%2520compound%2520palinurin%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D60%26spage%3D479%26epage%3D489%26doi%3D10.1016%2Fj.ejmech.2012.12.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">del Ser, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinwachs, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gertz, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrés, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gómez-Carrillo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vericat, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redondo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">León, T.</span></span> <span> </span><span class="NLM_article-title">Treatment of Alzheimer’s disease with the GSK-3 inhibitor tideglusib: A pilot study</span>. <i>J. Alzheimer's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">215</span>, <span class="refDoi"> DOI: 10.3233/JAD-2012-120805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.3233%2FJAD-2012-120805" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=205-215&author=T.+del+Serauthor=K.+C.+Steinwachsauthor=H.+J.+Gertzauthor=M.+V.+Andr%C3%A9sauthor=B.+G%C3%B3mez-Carrilloauthor=M.+Medinaauthor=J.+A.+Vericatauthor=P.+Redondoauthor=D.+Fleetauthor=T.+Le%C3%B3n&title=Treatment+of+Alzheimer%E2%80%99s+disease+with+the+GSK-3+inhibitor+tideglusib%3A+A+pilot+study&doi=10.3233%2FJAD-2012-120805"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.3233%2FJAD-2012-120805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-2012-120805%26sid%3Dliteratum%253Aachs%26aulast%3Ddel%2BSer%26aufirst%3DT.%26aulast%3DSteinwachs%26aufirst%3DK.%2BC.%26aulast%3DGertz%26aufirst%3DH.%2BJ.%26aulast%3DAndr%25C3%25A9s%26aufirst%3DM.%2BV.%26aulast%3DG%25C3%25B3mez-Carrillo%26aufirst%3DB.%26aulast%3DMedina%26aufirst%3DM.%26aulast%3DVericat%26aufirst%3DJ.%2BA.%26aulast%3DRedondo%26aufirst%3DP.%26aulast%3DFleet%26aufirst%3DD.%26aulast%3DLe%25C3%25B3n%26aufirst%3DT.%26atitle%3DTreatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%2520with%2520the%2520GSK-3%2520inhibitor%2520tideglusib%253A%2520A%2520pilot%2520study%26jtitle%3DJ.%2520Alzheimer%2527s%2520Dis.%26date%3D2012%26volume%3D33%26spage%3D205%26epage%3D215%26doi%3D10.3233%2FJAD-2012-120805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovestone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hüll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinne, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huppertz, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrés, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gómez-Carrillo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">León, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">del Ser, T.</span></span> <span> </span><span class="NLM_article-title">A phase II trial of tideglusib in Alzheimer’s disease</span>. <i>J. Alzheimer's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.3233/JAD-141959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.3233%2FJAD-141959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=25537011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjslOltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2015&pages=75-88&author=S.+Lovestoneauthor=M.+Boadaauthor=B.+Duboisauthor=M.+H%C3%BCllauthor=J.+O.+Rinneauthor=H.+J.+Huppertzauthor=M.+Caleroauthor=M.+V.+Andr%C3%A9sauthor=B.+G%C3%B3mez-Carrilloauthor=T.+Le%C3%B3nauthor=T.+del+Ser&title=A+phase+II+trial+of+tideglusib+in+Alzheimer%E2%80%99s+disease&doi=10.3233%2FJAD-141959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase II Trial of Tideglusib in Alzheimer's Disease</span></div><div class="casAuthors">Lovestone, Simon; Boada, Merce; Dubois, Bruno; Huell, Michael; Rinne, Juha O.; Huppertz, Hans-Juergen; Calero, Miguel; Andres, Maria V.; Gomez-Carrillo, Belen; Leon, Teresa; del Ser, Teodoro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-88</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">Background: The ARGO study was a phase II, double-blind, placebo controlled, four parallel arm trial of tideglusib in Alzheimer's disease (AD).  Objective: To prove the clin. efficacy of an inhibitor of glycogen synthase kinase-3 (GSK-3), in AD.  Methods: Mild to moderate (Mini-Mental State Examn. (MMSE) score, 14-26) AD patients on cholinesterase inhibitor and/or memantine treatment were administered tideglusib or placebo for 26 wk.  The ADAS-cog15 was the primary efficacy measure; function, cognition, behavior, and quality of life were assessed as secondary measures; cerebral atrophy in MRI and the levels of tau, amyloid-β, and BACE1 in cerebrospinal fluid (CSF) were exploratory endpoints.  Results: 306 AD patients were randomized to active (1000 mg QD: n = 86, 1000 mg QOD: n = 90, and 500 mg QD: n = 50) or placebo (n = 85) in 55 sites in four European countries.  There were no statistically significant differences between either active and placebo arms in the efficacy variables.  However, BACE1 in CSF significantly decreased with treatment in a small subgroup of patients.  Participants with mild AD in the 500 mg QD group showed significant responses on ADAS-cog15, MMSE, and word fluency.  Diarrhea (14-18% in active, 11% placebo) and dose-dependent, mild to moderate, and fully reversible transaminase increase (9-16% in active, 3.5% placebo) were the most frequent adverse events.  Conclusions: Short term (26 wk) tideglusib was acceptably safe but produced no clin. benefit in this trial.  However, given the non-linear dose response, esp. in mildly affected patients, further dose finding studies in early disease stages and for longer duration are warranted to examine GSK-3 inhibition in AD patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGru-ZlfznWkUbVg90H21EOLACvtfcHk0lg5bHURoH7dIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjslOltb8%253D&md5=7a342ad28ad2cfbbc3dc768849fb73ef</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.3233%2FJAD-141959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-141959%26sid%3Dliteratum%253Aachs%26aulast%3DLovestone%26aufirst%3DS.%26aulast%3DBoada%26aufirst%3DM.%26aulast%3DDubois%26aufirst%3DB.%26aulast%3DH%25C3%25BCll%26aufirst%3DM.%26aulast%3DRinne%26aufirst%3DJ.%2BO.%26aulast%3DHuppertz%26aufirst%3DH.%2BJ.%26aulast%3DCalero%26aufirst%3DM.%26aulast%3DAndr%25C3%25A9s%26aufirst%3DM.%2BV.%26aulast%3DG%25C3%25B3mez-Carrillo%26aufirst%3DB.%26aulast%3DLe%25C3%25B3n%26aufirst%3DT.%26aulast%3Ddel%2BSer%26aufirst%3DT.%26atitle%3DA%2520phase%2520II%2520trial%2520of%2520tideglusib%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Alzheimer%2527s%2520Dis.%26date%3D2015%26volume%3D45%26spage%3D75%26epage%3D88%26doi%3D10.3233%2FJAD-141959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><a href="https://clinicaltrials.gov/ct2/show/NCT03692312" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03692312</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03692312."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><a href="https://clinicaltrials.gov/ct2/show/NCT02586935?term=tideglusib’draw=2&amp;rank=2&amp;rank=2" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02586935?term=tideglusib'draw=2&rank=2&rank=2</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02586935%3Fterm%3Dtideglusib%27draw%3D2%26rank%3D2%26rank%3D2."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tolosa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litvan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Höglinger, G. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrés, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gómez-Carrillo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">León, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Ser, T.</span></span> <span> </span><span class="NLM_article-title">A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy</span>. <i>Mov. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">470</span>– <span class="NLM_lpage">478</span>, <span class="refDoi"> DOI: 10.1002/mds.25824</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1002%2Fmds.25824" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=24532007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvFSmtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2014&pages=470-478&author=E.+Tolosaauthor=I.+Litvanauthor=G.+U.+H%C3%B6glingerauthor=D.+Burnauthor=A.+Leesauthor=M.+V.+Andr%C3%A9sauthor=B.+G%C3%B3mez-Carrilloauthor=T.+Le%C3%B3nauthor=T.+Del+Ser&title=A+phase+2+trial+of+the+GSK-3+inhibitor+tideglusib+in+progressive+supranuclear+palsy&doi=10.1002%2Fmds.25824"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy</span></div><div class="casAuthors">Tolosa, Eduardo; Litvan, Irene; Hoeglinger, Guenter U.; Burn, David; Lees, Andrew; Andres, Maria V.; Gomez-Carrillo, Belen; Leon, Teresa; del Ser, Teodoro</div><div class="citationInfo"><span class="NLM_cas:title">Movement Disorders</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">470-478</span>CODEN:
                <span class="NLM_cas:coden">MOVDEA</span>;
        ISSN:<span class="NLM_cas:issn">0885-3185</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">It is believed that glycogen synthase kinase-3 (GSK-3) hyperphosphorylates tau protein in progressive supranuclear palsy (PSP).  The Tau Restoration on PSP (TAUROS) study was a double-blind, placebo-controlled, randomized trial to assess the efficacy, safety, and tolerability of tideglusib, a GSK-3 inhibitor, as potential treatment for PSP.  The study enrolled 146 PSP patients with mild-to-moderate disease who were randomized to receive once-daily 600 mg tideglusib, 800 mg tideglusib, or placebo (ratio, 2:2:1) administered orally over 52 wk.  The primary endpoint was the change from baseline to week 52 on the PSP rating scale.  Secondary endpoints were safety and tolerability of tideglusib, changes in motor function (the Timed Up and Go Test), cognition (Dementia Rating Scale-2, Frontal Assessment Battery, verbal fluency), apathy (Starkstein scale), activities of daily living (Schwab and England scale; Unified Parkinson's Disease Rating Scale, part II), quality of life (EuroQol), and Global Clin. Assessment.  Brain atrophy on magnetic resonance imaging and several biomarkers in plasma and cerebrospinal fluid also were examd.  No significant differences were detected in the primary or secondary endpoints at week 52 between placebo and either dose of tideglusib.  Tideglusib was safe, with the exception of some asymptomatic, transient, and reversible transaminase elevations (mainly alanine aminotransferase) in 9% of patients, and diarrhea in 13% of patients.  Tideglusib was generally well tolerated but it did not show clin. efficacy in patients with mild-to-moderate PSP. © 2014 International Parkinson and Movement Disorder Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgJLeCmPA9ULVg90H21EOLACvtfcHk0liAPeNxBnNeeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvFSmtL8%253D&md5=4b7899d99427a60b8edae580355a740d</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1002%2Fmds.25824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.25824%26sid%3Dliteratum%253Aachs%26aulast%3DTolosa%26aufirst%3DE.%26aulast%3DLitvan%26aufirst%3DI.%26aulast%3DH%25C3%25B6glinger%26aufirst%3DG.%2BU.%26aulast%3DBurn%26aufirst%3DD.%26aulast%3DLees%26aufirst%3DA.%26aulast%3DAndr%25C3%25A9s%26aufirst%3DM.%2BV.%26aulast%3DG%25C3%25B3mez-Carrillo%26aufirst%3DB.%26aulast%3DLe%25C3%25B3n%26aufirst%3DT.%26aulast%3DDel%2BSer%26aufirst%3DT.%26atitle%3DA%2520phase%25202%2520trial%2520of%2520the%2520GSK-3%2520inhibitor%2520tideglusib%2520in%2520progressive%2520supranuclear%2520palsy%26jtitle%3DMov.%2520Disord.%26date%3D2014%26volume%3D29%26spage%3D470%26epage%3D478%26doi%3D10.1002%2Fmds.25824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horrigan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snape, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolenko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMorn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaroshinsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Della Pasqua, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oosterholt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lochmüller, H.</span></span> <span> </span><span class="NLM_article-title">A phase 2 study of AMO-02 (Tideglusib) in congenital and childhood-onset myotonic dystrophy type 1 (DM1)</span>. <i>Pediatr Neurol</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1016/j.pediatrneurol.2020.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.pediatrneurol.2020.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=32942085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BB3s%252FgtVyisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2020&pages=84-93&author=J.+Horriganauthor=T.+B.+Gomesauthor=M.+Snapeauthor=N.+Nikolenkoauthor=A.+McMornauthor=S.+Evansauthor=A.+Yaroshinskyauthor=O.+Della+Pasquaauthor=S.+Oosterholtauthor=H.+Lochm%C3%BCller&title=A+phase+2+study+of+AMO-02+%28Tideglusib%29+in+congenital+and+childhood-onset+myotonic+dystrophy+type+1+%28DM1%29&doi=10.1016%2Fj.pediatrneurol.2020.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase 2 Study of AMO-02 (Tideglusib) in Congenital and Childhood-Onset Myotonic Dystrophy Type 1 (DM1)</span></div><div class="casAuthors">Horrigan Joseph; Gomes Tiago Bernardino; Snape Mike; McMorn Alison; Evans Stuart; Nikolenko Nikoletta; Yaroshinsky Alex; Della Pasqua Oscar; Oosterholt Sean; Lochmuller Hanns</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric neurology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">84-93</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  GSK3β is an intracellular regulatory kinase that is dysregulated in multiple tissues in type 1 myotonic dystrophy, a rare neuromuscular disorder that manifests at any age.  AMO-02 (tideglusib) inhibits GSK3β activity in preclinical models of type 1 myotonic dystrophy and promotes cellular maturation as well as normalizes aberrant molecular and behavioral phenotypes.  This phase 2 study assessed the pharmacokinetics, safety and tolerability, and preliminary efficacy of AMO-02 in adolescents and adults with congenital and childhood-onset type 1 myotonic dystrophy.  METHODS:  Sixteen subjects (aged 13 to 34 years) with congenital and childhood-onset type 1 myotonic dystrophy received 12 weeks of single-blind fixed-dose oral treatment with either 400 mg (n = 8) or 1000 mg (n = 8) AMO-02 (NCT02858908).  Blood samples were obtained for pharmacokinetic assessment.  Safety assessments, such as laboratory tests and electrocardiograms, as well as efficacy assessments of syndromal, cognitive, and muscular functioning, were obtained.  RESULTS:  AMO-02 plasma concentrations conformed to a two-compartment model with first-order absorption and elimination, and dose-dependent increases in exposure (area under the curve) were observed.  AMO-02 was generally safe and well-tolerated.  No early discontinuations due to adverse events or dose adjustments of AMO-02 occurred.  The majority of subjects manifested clinical improvement in their central nervous system and neuromuscular symptoms after 12 weeks of treatment compared with the placebo baseline, with a larger response noted at the 1000 mg/day dose level.  AMO-02 exposure (cumulative area under the curve) was significantly correlated (P < 0.01) with change from baseline on several key efficacy assessments.  CONCLUSION:  AMO-02 has favorable pharmacokinetic and clinical risk/benefit profiles meriting further study as a potential treatment for congenital and childhood-onset type 1 myotonic dystrophy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRo1-Ytzv0sx-Lt9HypzAgQfW6udTcc2ebGxWoo8XVS47ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3s%252FgtVyisQ%253D%253D&md5=74db89ffb71eb1fc21a6989770b194ef</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.pediatrneurol.2020.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pediatrneurol.2020.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DHorrigan%26aufirst%3DJ.%26aulast%3DGomes%26aufirst%3DT.%2BB.%26aulast%3DSnape%26aufirst%3DM.%26aulast%3DNikolenko%26aufirst%3DN.%26aulast%3DMcMorn%26aufirst%3DA.%26aulast%3DEvans%26aufirst%3DS.%26aulast%3DYaroshinsky%26aufirst%3DA.%26aulast%3DDella%2BPasqua%26aufirst%3DO.%26aulast%3DOosterholt%26aufirst%3DS.%26aulast%3DLochm%25C3%25BCller%26aufirst%3DH.%26atitle%3DA%2520phase%25202%2520study%2520of%2520AMO-02%2520%2528Tideglusib%2529%2520in%2520congenital%2520and%2520childhood-onset%2520myotonic%2520dystrophy%2520type%25201%2520%2528DM1%2529%26jtitle%3DPediatr%2520Neurol%26date%3D2020%26volume%3D112%26spage%3D84%26epage%3D93%26doi%3D10.1016%2Fj.pediatrneurol.2020.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palomo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soteras, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campillo, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span> <span> </span><span class="NLM_article-title">Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">8461</span>– <span class="NLM_lpage">8470</span>, <span class="refDoi"> DOI: 10.1021/jm200996g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200996g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVWms7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8461-8470&author=V.+Palomoauthor=I.+Soterasauthor=D.+I.+Perezauthor=C.+Perezauthor=C.+Gilauthor=N.+E.+Campilloauthor=A.+Martinez&title=Exploring+the+binding+sites+of+glycogen+synthase+kinase+3.+Identification+and+characterization+of+allosteric+modulation+cavities&doi=10.1021%2Fjm200996g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring the Binding Sites of Glycogen Synthase Kinase 3. Identification and Characterization of Allosteric Modulation Cavities</span></div><div class="casAuthors">Palomo, Valle; Soteras, Ignacio; Perez, Daniel I.; Perez, Concepcion; Gil, Carmen; Campillo, Nuria Eugenia; Martinez, Ana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8461-8470</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glycogen synthase kinase 3 (GSK-3) is an important drug target for human severe unmet diseases.  Discovery and/or design of allosteric kinase modulators are gaining importance in this field not only for the increased selectivity of this kind of compds. but also for the subtle modulation of the target.  This last point is of utmost importance for the GSK-3 inhibition as a therapeutic approach.  GSK-3 activity is completely necessary for life, and only the aberrant overactivity found in the pathologies should be inhibited with its inhibitors treatment.  We performed here a search for the druggable sites on the enzyme using the fpocket algorithm with the aim to provide allosteric potential binding sites on it and new clues for further drug discoveries.  Moreover, our results allowed us to det. the binding sites of different GSK-3 ATP noncompetitive inhibitors, such as manzamine A and the new small mol. VP 0.7, providing evidence for potential allosteric inhibition of GSK-3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9YWCNrZPfb7Vg90H21EOLACvtfcHk0liAPeNxBnNeeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVWms7zI&md5=087cfee46fb46b531abcacb46317d122</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1021%2Fjm200996g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200996g%26sid%3Dliteratum%253Aachs%26aulast%3DPalomo%26aufirst%3DV.%26aulast%3DSoteras%26aufirst%3DI.%26aulast%3DPerez%26aufirst%3DD.%2BI.%26aulast%3DPerez%26aufirst%3DC.%26aulast%3DGil%26aufirst%3DC.%26aulast%3DCampillo%26aufirst%3DN.%2BE.%26aulast%3DMartinez%26aufirst%3DA.%26atitle%3DExploring%2520the%2520binding%2520sites%2520of%2520glycogen%2520synthase%2520kinase%25203.%2520Identification%2520and%2520characterization%2520of%2520allosteric%2520modulation%2520cavities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8461%26epage%3D8470%26doi%3D10.1021%2Fjm200996g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duda, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akula, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steelman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martelli, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocco, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Candido, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Libra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montalto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gizak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakus, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCubrey, J. A.</span></span> <span> </span><span class="NLM_article-title">Targeting GSK3 and associated signaling pathways involved in cancer</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1110</span>, <span class="refDoi"> DOI: 10.3390/cells9051110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.3390%2Fcells9051110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BB3cXis1Sku7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=1110&author=P.+Dudaauthor=S.+M.+Akulaauthor=S.+L.+Abramsauthor=L.+S.+Steelmanauthor=A.+M.+Martelliauthor=L.+Coccoauthor=S.+Rattiauthor=S.+Candidoauthor=M.+Libraauthor=G.+Montaltoauthor=M.+Cervelloauthor=A.+Gizakauthor=D.+Rakusauthor=J.+A.+McCubrey&title=Targeting+GSK3+and+associated+signaling+pathways+involved+in+cancer&doi=10.3390%2Fcells9051110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting GSK3 and associated signaling pathways involved in cancer</span></div><div class="casAuthors">Duda, Przemyslaw; Akula, Shaw M.; Abrams, Stephen L.; Steelman, Linda S.; Martelli, Alberto M.; Cocco, Lucio; Ratti, Stefano; Candido, Saverio; Libra, Massimo; Montalto, Giuseppe; Cervello, Melchiorre; Gizak, Agnieszka; Rakus, Dariusz; McCubrey, James A.</div><div class="citationInfo"><span class="NLM_cas:title">Cells</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1110</span>CODEN:
                <span class="NLM_cas:coden">CELLC6</span>;
        ISSN:<span class="NLM_cas:issn">2073-4409</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Glycogen synthase kinase 3 (GSK-3) is a serine/threonine (S/T) protein kinase.  Although GSK-3 originally was identified to have functions in regulation of glycogen synthase, it was subsequently detd. to have roles in multiple normal biochem. processes as well as various disease conditions.  GSK-3 is sometimes referred to as a moonlighting protein due to the multiple substrates and processes which it controls.  Frequently, when GSK-3 phosphorylates proteins, they are targeted for degrdn.  GSK-3 is often considered a component of the PI3K/PTEN/AKT/GSK-3/mTORC1 pathway as GSK-3 is frequently phosphorylated by AKT which regulates its inactivation.  AKT is often active in human cancer and hence, GSK-3 is often inactivated.  Moreover, GSK-3 also interacts with WNT/β-catenin signaling and β-catenin and other proteins in this pathway are targets of GSK-3.  GSK-3 can modify NF-κB activity which is often expressed at high levels in cancer cells.  Multiple pharmaceutical companies developed small mol. inhibitors to suppress GSK-3 activity.  In addn., various natural products will modify GSK-3 activity.  This review will focus on the effects of small mol. inhibitors and natural products on GSK-3 activity and provide examples where these compds. were effective in suppressing cancer growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmtCdaBstHubVg90H21EOLACvtfcHk0lhZ6BAdCDefwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXis1Sku7jK&md5=52d9fc10c3720bf3bbd37ba51511754d</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.3390%2Fcells9051110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells9051110%26sid%3Dliteratum%253Aachs%26aulast%3DDuda%26aufirst%3DP.%26aulast%3DAkula%26aufirst%3DS.%2BM.%26aulast%3DAbrams%26aufirst%3DS.%2BL.%26aulast%3DSteelman%26aufirst%3DL.%2BS.%26aulast%3DMartelli%26aufirst%3DA.%2BM.%26aulast%3DCocco%26aufirst%3DL.%26aulast%3DRatti%26aufirst%3DS.%26aulast%3DCandido%26aufirst%3DS.%26aulast%3DLibra%26aufirst%3DM.%26aulast%3DMontalto%26aufirst%3DG.%26aulast%3DCervello%26aufirst%3DM.%26aulast%3DGizak%26aufirst%3DA.%26aulast%3DRakus%26aufirst%3DD.%26aulast%3DMcCubrey%26aufirst%3DJ.%2BA.%26atitle%3DTargeting%2520GSK3%2520and%2520associated%2520signaling%2520pathways%2520involved%2520in%2520cancer%26jtitle%3DCells%26date%3D2020%26volume%3D9%26spage%3D1110%26doi%3D10.3390%2Fcells9051110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Makin, S.</span></span> <span> </span><span class="NLM_article-title">The amyloid hypothesis on trial</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>559</i></span>,  <span class="NLM_fpage">S4</span>– <span class="NLM_lpage">S7</span>, <span class="refDoi"> DOI: 10.1038/d41586-018-05719-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2Fd41586-018-05719-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=30046080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtl2jt7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=559&publication_year=2018&pages=S4-S7&author=S.+Makin&title=The+amyloid+hypothesis+on+trial&doi=10.1038%2Fd41586-018-05719-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">The amyloid hypothesis on trial</span></div><div class="casAuthors">Makin, Simon</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">559</span>
        (<span class="NLM_cas:issue">7715</span>),
    <span class="NLM_cas:pages">S4-S7</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">As the development of treatments for Alzheimer's disease continues to stumble, is it time for researchers to broaden their list of the condition's potential causes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYpIAatE5SYbVg90H21EOLACvtfcHk0lhZ6BAdCDefwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtl2jt7zI&md5=83ae788246ed27a5a8b93b6bc20d8803</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1038%2Fd41586-018-05719-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fd41586-018-05719-4%26sid%3Dliteratum%253Aachs%26aulast%3DMakin%26aufirst%3DS.%26atitle%3DThe%2520amyloid%2520hypothesis%2520on%2520trial%26jtitle%3DNature%26date%3D2018%26volume%3D559%26spage%3DS4%26epage%3DS7%26doi%3D10.1038%2Fd41586-018-05719-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hargreaves, R. J.</span></span> <span> </span><span class="NLM_article-title">“It ain't over 'til it's over” (a) -the search for treatments and cures for Alzheimer’s disease</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">862</span>– <span class="NLM_lpage">866</span>, <span class="refDoi"> DOI: 10.1021/ml300359g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300359g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFygtLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=862-866&author=R.+J.+Hargreaves&title=%E2%80%9CIt+ain%27t+over+%27til+it%27s+over%E2%80%9D+%28a%29+-the+search+for+treatments+and+cures+for+Alzheimer%E2%80%99s+disease&doi=10.1021%2Fml300359g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">"It Ain't Over 'til It's Over"a-The Search for Treatments and Cures for Alzheimer's Disease</span></div><div class="casAuthors">Hargreaves, Richard J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">862-866</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In the neuro-science landscape, there is no condition with higher unmet medical and societal need than Alzheimer's disease (AD).  There are significant opportunities to improve upon symptomatic treatments in AD, and as yet, there are no treatments to modify (slow, stop, or prevent) underlying disease progression.  Our goals are to discover new symptomatic AD therapies with improved efficacy and longevity; to complete definitive studies that refute or prove the amyloid hypothesis, potentially opening multiple avenues to new therapeutic modalities; and to initiate tests of novel mechanisms that can prevent tau pathol. and neurodegeneration.  It's a crit. time in the testing of novel AD therapeutics-let's hope we succeed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ6SVDrZ3RkrVg90H21EOLACvtfcHk0lhZ6BAdCDefwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFygtLnM&md5=0062f7f6ff1c79cbef8b013bda0425e5</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1021%2Fml300359g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300359g%26sid%3Dliteratum%253Aachs%26aulast%3DHargreaves%26aufirst%3DR.%2BJ.%26atitle%3D%25E2%2580%259CIt%2520ain%2527t%2520over%2520%2527til%2520it%2527s%2520over%25E2%2580%259D%2520%2528a%2529%2520-the%2520search%2520for%2520treatments%2520and%2520cures%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D862%26epage%3D866%26doi%3D10.1021%2Fml300359g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottegoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span> <span> </span><span class="NLM_article-title">BACE-1 inhibitors: From recent single-target molecules to multitarget compounds for Alzheimer’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">619</span>– <span class="NLM_lpage">637</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00393</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00393" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1eks7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=619-637&author=F.+Pratiauthor=G.+Bottegoniauthor=M.+L.+Bolognesiauthor=A.+Cavalli&title=BACE-1+inhibitors%3A+From+recent+single-target+molecules+to+multitarget+compounds+for+Alzheimer%E2%80%99s+disease&doi=10.1021%2Facs.jmedchem.7b00393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">BACE-1 Inhibitors: From Recent Single-Target Molecules to Multitarget Compounds for Alzheimer's Disease</span></div><div class="casAuthors">Prati, Federica; Bottegoni, Giovanni; Bolognesi, Maria Laura; Cavalli, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">619-637</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The amyloid hypothesis has long been the central dogma in drug discovery for Alzheimer's disease (AD), leading to many small-mol. and biol. drug candidates.  One major target has been the β-site amyloid-precursor-protein-cleaving enzyme 1 (BACE-1), with many big pharma companies expending great resources in the search for BACE-1 inhibitors.  The lack of efficacy of verubecestat in mild-to-moderate AD raises important questions about the timing of intervention with BACE-1 inhibitors, and anti-amyloid therapies in general, in AD treatment.  It also suggests new possibilities for discovering BACE-1-targeted compds. with more complex mechanisms of actions and improved efficacy.  Herein, the authors review the major advances in BACE-1 drug discovery, from single-target small mol. inhibitors to multitarget compds.  The authors discuss these compds. as innovative tools for better understanding the complexity of AD and for identifying efficacious drug candidates to treat this devastating disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqIKti01PzWrVg90H21EOLACvtfcHk0liONTa6VLJjWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1eks7nO&md5=a30fe7a54f34206355c6380eb9eacbe4</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00393%26sid%3Dliteratum%253Aachs%26aulast%3DPrati%26aufirst%3DF.%26aulast%3DBottegoni%26aufirst%3DG.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DCavalli%26aufirst%3DA.%26atitle%3DBACE-1%2520inhibitors%253A%2520From%2520recent%2520single-target%2520molecules%2520to%2520multitarget%2520compounds%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D619%26epage%3D637%26doi%3D10.1021%2Facs.jmedchem.7b00393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mullard, A.</span></span> <span> </span><span class="NLM_article-title">BACE inhibitor bust in Alzheimer trial</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">155</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.43</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2Fnrd.2017.43" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlslentL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=155&author=A.+Mullard&title=BACE+inhibitor+bust+in+Alzheimer+trial&doi=10.1038%2Fnrd.2017.43"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">New plaque psoriasis approval carries suicide warning</span></div><div class="casAuthors">Mullard, Asher</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">155</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorrFVcqAa99rVg90H21EOLACvtfcHk0liONTa6VLJjWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlslentL4%253D&md5=057ed2ef8ae29db922708b84a51482f2</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.43&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.43%26sid%3Dliteratum%253Aachs%26aulast%3DMullard%26aufirst%3DA.%26atitle%3DBACE%2520inhibitor%2520bust%2520in%2520Alzheimer%2520trial%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D155%26doi%3D10.1038%2Fnrd.2017.43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ittner, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Götz, J.</span></span> <span> </span><span class="NLM_article-title">Amyloid-β and tau--a toxic pas de deux in Alzheimer’s disease</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1038/nrn2967</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1038%2Fnrn2967" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=67-72&author=L.+M.+Ittnerauthor=J.+G%C3%B6tz&title=Amyloid-%CE%B2+and+tau%2D%2Da+toxic+pas+de+deux+in+Alzheimer%E2%80%99s+disease&doi=10.1038%2Fnrn2967"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1038%2Fnrn2967&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn2967%26sid%3Dliteratum%253Aachs%26aulast%3DIttner%26aufirst%3DL.%2BM.%26aulast%3DG%25C3%25B6tz%26aufirst%3DJ.%26atitle%3DAmyloid-%25CE%25B2%2520and%2520tau--a%2520toxic%2520pas%2520de%2520deux%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2011%26volume%3D12%26spage%3D67%26epage%3D72%26doi%3D10.1038%2Fnrn2967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Terwel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muyllaert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewachter, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borghgraef, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devijver, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Leuven, F.</span></span> <span> </span><span class="NLM_article-title">Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">786</span>– <span class="NLM_lpage">798</span>, <span class="refDoi"> DOI: 10.2353/ajpath.2008.070904</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.2353%2Fajpath.2008.070904" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=18258852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktVKgsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2008&pages=786-798&author=D.+Terwelauthor=D.+Muyllaertauthor=I.+Dewachterauthor=P.+Borghgraefauthor=S.+Croesauthor=H.+Devijverauthor=F.+Van+Leuven&title=Amyloid+activates+GSK-3beta+to+aggravate+neuronal+tauopathy+in+bigenic+mice&doi=10.2353%2Fajpath.2008.070904"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Amyloid activates GSK-3β to aggravate neuronal tauopathy in bigenic mice</span></div><div class="casAuthors">Terwel, Dick; Muyllaert, David; Dewachter, Ilse; Borghgraef, Peter; Croes, Sophie; Devijver, Herman; Van Leuven, Fred</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">786-798</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">The hypothesis that amyloid pathol. precedes and induces the tau pathol. of Alzheimer's disease is exptl. supported here through the identification of GSK-3 isoenzymes as a major link in the signaling pathway from amyloid to tau pathol.  This study compares two novel bigenic mouse models: APP-V717I × Tau-P301L mice with combined amyloid and tau pathol. and GSK-3β × Tau-P301L mice with tauopathy only.  Extensive and remarkable parallels were obsd. between these strains including (1) aggravation of tauopathy with highly fibrillar tangles in the hippocampus and cortex; (2) prolonged survival correlated to alleviated brainstem tauopathy; (3) development of severe cognitive and behavioral defects in young adults before the onset of amyloid deposition or tauopathy; and (4) presence of pathol. phospho-epitopes of tau, including the characteristic GSK-3β motif at S396/S404.  Both GSK-3 isoenzymes were activated in the brain of parental APP-V717I amyloid mice, even at a young age when cognitive and behavioral defects are evident but before amyloid deposition.  The data indicate that amyloid induces tauopathy through activation of GSK-3 and suggest a role for the kinase in maintaining the functional integrity of adult neurons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0Q4WlwJ0AZrVg90H21EOLACvtfcHk0liONTa6VLJjWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktVKgsrk%253D&md5=734b1ec316392574d4624734bb80a2e3</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.2353%2Fajpath.2008.070904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2353%252Fajpath.2008.070904%26sid%3Dliteratum%253Aachs%26aulast%3DTerwel%26aufirst%3DD.%26aulast%3DMuyllaert%26aufirst%3DD.%26aulast%3DDewachter%26aufirst%3DI.%26aulast%3DBorghgraef%26aufirst%3DP.%26aulast%3DCroes%26aufirst%3DS.%26aulast%3DDevijver%26aufirst%3DH.%26aulast%3DVan%2BLeuven%26aufirst%3DF.%26atitle%3DAmyloid%2520activates%2520GSK-3beta%2520to%2520aggravate%2520neuronal%2520tauopathy%2520in%2520bigenic%2520mice%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2008%26volume%3D172%26spage%3D786%26epage%3D798%26doi%3D10.2353%2Fajpath.2008.070904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gandini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedesco, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Gonzalez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campillo, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaldivar-Diez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccheri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petralla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moda, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legname, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">Tau-centric multitarget approach for Alzheimer’s disease: Development of first-in-class dual Glycogen synthase kinase 3β and Tau-aggregation inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7640</span>– <span class="NLM_lpage">7656</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00610</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00610" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVChu7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7640-7656&author=A.+Gandiniauthor=M.+Bartoliniauthor=D.+Tedescoauthor=L.+Martinez-Gonzalezauthor=C.+Rocaauthor=N.+E.+Campilloauthor=J.+Zaldivar-Diezauthor=C.+Perezauthor=G.+Zuccheriauthor=A.+Mitiauthor=A.+Feoliauthor=S.+Castellanoauthor=S.+Petrallaauthor=B.+Montiauthor=M.+Rossiauthor=F.+Modaauthor=G.+Legnameauthor=A.+Martinezauthor=M.+L.+Bolognesi&title=Tau-centric+multitarget+approach+for+Alzheimer%E2%80%99s+disease%3A+Development+of+first-in-class+dual+Glycogen+synthase+kinase+3%CE%B2+and+Tau-aggregation+inhibitors&doi=10.1021%2Facs.jmedchem.8b00610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Tau-Centric Multitarget Approach for Alzheimer's Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors</span></div><div class="casAuthors">Gandini, Annachiara; Bartolini, Manuela; Tedesco, Daniele; Martinez-Gonzalez, Loreto; Roca, Carlos; Campillo, Nuria E.; Zaldivar-Diez, Josefa; Perez, Concepcion; Zuccheri, Giampaolo; Miti, Andrea; Feoli, Alessandra; Castellano, Sabrina; Petralla, Sabrina; Monti, Barbara; Rossi, Martina; Moda, Fabio; Legname, Giuseppe; Martinez, Ana; Bolognesi, Maria Laura</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7640-7656</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several findings propose the altered tau protein network as an important target for Alzheimer's disease (AD).  Particularly, two points of pharmacol. intervention can be envisaged: inhibition of phosphorylating tau kinase GSK-3β and tau aggregation process.  On the basis of this consideration and on the authors' interest in multitarget paradigms in AD, the authors report on the discovery of 2,4-thiazolidinedione derivs. endowed with such a profile. 28 and 30 displayed micromolar IC50 values toward GSK-3β, together with the capacity of inhibiting AcPHF6 aggregation of 60% and 80% at 10 μM, resp.  In addn., they showed PAMPA-BBB permeability, together with a suitable cellular safety profile. 30 also displayed inhibition of both K18 and full-length tau aggregations.  Finally, both compds. were able to improve cell viability in an okadaic acid-induced neurodegeneration cell model.  To the best of the authors' knowledge, 28 and 30 are the first balanced, nontoxic, dual-acting compds. hitting tau cascade at two different hubs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6bQV6XoAhyrVg90H21EOLACvtfcHk0ljsoa_WYCzEpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVChu7%252FL&md5=34b7e2f2556f3e96c768dd87fb3f0e6d</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00610%26sid%3Dliteratum%253Aachs%26aulast%3DGandini%26aufirst%3DA.%26aulast%3DBartolini%26aufirst%3DM.%26aulast%3DTedesco%26aufirst%3DD.%26aulast%3DMartinez-Gonzalez%26aufirst%3DL.%26aulast%3DRoca%26aufirst%3DC.%26aulast%3DCampillo%26aufirst%3DN.%2BE.%26aulast%3DZaldivar-Diez%26aufirst%3DJ.%26aulast%3DPerez%26aufirst%3DC.%26aulast%3DZuccheri%26aufirst%3DG.%26aulast%3DMiti%26aufirst%3DA.%26aulast%3DFeoli%26aufirst%3DA.%26aulast%3DCastellano%26aufirst%3DS.%26aulast%3DPetralla%26aufirst%3DS.%26aulast%3DMonti%26aufirst%3DB.%26aulast%3DRossi%26aufirst%3DM.%26aulast%3DModa%26aufirst%3DF.%26aulast%3DLegname%26aufirst%3DG.%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DTau-centric%2520multitarget%2520approach%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520Development%2520of%2520first-in-class%2520dual%2520Glycogen%2520synthase%2520kinase%25203%25CE%25B2%2520and%2520Tau-aggregation%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7640%26epage%3D7656%26doi%3D10.1021%2Facs.jmedchem.8b00610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bulic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickhardt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khlistunova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biernat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandelkow, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandelkow, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldmann, H.</span></span> <span> </span><span class="NLM_article-title">Rhodanine-based tau aggregation inhibitors in cell models of tauopathy</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">9215</span>– <span class="NLM_lpage">9219</span>, <span class="refDoi"> DOI: 10.1002/anie.200704051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1002%2Fanie.200704051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BD2sjjtlSltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=9215-9219&author=B.+Bulicauthor=M.+Pickhardtauthor=I.+Khlistunovaauthor=J.+Biernatauthor=E.+M.+Mandelkowauthor=E.+Mandelkowauthor=H.+Waldmann&title=Rhodanine-based+tau+aggregation+inhibitors+in+cell+models+of+tauopathy&doi=10.1002%2Fanie.200704051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Rhodanine-based tau aggregation inhibitors in cell models of tauopathy</span></div><div class="casAuthors">Bulic Bruno; Pickhardt Marcus; Khlistunova Inna; Biernat Jacek; Mandelkow Eva-Maria; Mandelkow Eckhard; Waldmann Herbert</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie (International ed. in English)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">9215-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcScsfK7C2PCgf6xYuD7tu2XfW6udTcc2eauHAyWoj3ZPLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sjjtlSltg%253D%253D&md5=9948b3054bae5ce9e52d0ce3d4635788</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1002%2Fanie.200704051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200704051%26sid%3Dliteratum%253Aachs%26aulast%3DBulic%26aufirst%3DB.%26aulast%3DPickhardt%26aufirst%3DM.%26aulast%3DKhlistunova%26aufirst%3DI.%26aulast%3DBiernat%26aufirst%3DJ.%26aulast%3DMandelkow%26aufirst%3DE.%2BM.%26aulast%3DMandelkow%26aufirst%3DE.%26aulast%3DWaldmann%26aufirst%3DH.%26atitle%3DRhodanine-based%2520tau%2520aggregation%2520inhibitors%2520in%2520cell%2520models%2520of%2520tauopathy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2007%26volume%3D46%26spage%3D9215%26epage%3D9219%26doi%3D10.1002%2Fanie.200704051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arfeen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborti, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharatam, P. V.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of 5-benzylidene-2-iminothiazolidin-4-ones as selective GSK-3β inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">736</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.04.075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.ejmech.2016.04.075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=27423119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtF2hs7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2016&pages=727-736&author=M.+Arfeenauthor=S.+Bhagatauthor=R.+Patelauthor=S.+Prasadauthor=I.+Royauthor=A.+K.+Chakrabortiauthor=P.+V.+Bharatam&title=Design%2C+synthesis+and+biological+evaluation+of+5-benzylidene-2-iminothiazolidin-4-ones+as+selective+GSK-3%CE%B2+inhibitors&doi=10.1016%2Fj.ejmech.2016.04.075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of 5-benzylidene-2-iminothiazolidin-4-ones as selective GSK-3β inhibitors</span></div><div class="casAuthors">Arfeen, Minhajul; Bhagat, Shweta; Patel, Rahul; Prasad, Shivcharan; Roy, Ipsita; Chakraborti, Asit K.; Bharatam, Prasad V.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">727-736</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In this work, iminothiazolidin-4-one derivs. were explored as selective GSK-3β inhibitors.  Mol. docking anal. was carried to design a series of compds., which were synthesized using substituted thioureas, Et chloroacetate and benzaldehydes.  Out of the twenty five compds. synthesized during this work, the in vitro evaluation against GSK-3 led to the identification of nine compds. with activity in lower nano-molar range (2-85 nM).  Further, in vitro evaluation against CDK-2 showed five compds. to be selective towards GSK-3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquv-FRHRtwRbVg90H21EOLACvtfcHk0lj6rCvTPQYV-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtF2hs7vJ&md5=fae12d7afdb57bf8512a0f8fbe481056</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.04.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.04.075%26sid%3Dliteratum%253Aachs%26aulast%3DArfeen%26aufirst%3DM.%26aulast%3DBhagat%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DR.%26aulast%3DPrasad%26aufirst%3DS.%26aulast%3DRoy%26aufirst%3DI.%26aulast%3DChakraborti%26aufirst%3DA.%2BK.%26aulast%3DBharatam%26aufirst%3DP.%2BV.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%25205-benzylidene-2-iminothiazolidin-4-ones%2520as%2520selective%2520GSK-3%25CE%25B2%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D121%26spage%3D727%26epage%3D736%26doi%3D10.1016%2Fj.ejmech.2016.04.075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaisina, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petukhov, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blond, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidhu, A.</span></span> <span> </span><span class="NLM_article-title">Highly potent and specific GSK-3beta inhibitors that block tau phosphorylation and decrease alpha-synuclein protein expression in a cellular model of Parkinson’s disease</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">256</span>– <span class="NLM_lpage">266</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200500039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1002%2Fcmdc.200500039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=16892358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvFyjur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=256-266&author=A.+P.+Kozikowskiauthor=I.+N.+Gaisinaauthor=P.+A.+Petukhovauthor=J.+Sridharauthor=L.+T.+Kingauthor=S.+Y.+Blondauthor=T.+Dukaauthor=M.+Rusnakauthor=A.+Sidhu&title=Highly+potent+and+specific+GSK-3beta+inhibitors+that+block+tau+phosphorylation+and+decrease+alpha-synuclein+protein+expression+in+a+cellular+model+of+Parkinson%E2%80%99s+disease&doi=10.1002%2Fcmdc.200500039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Highly potent and specific GSK-3β inhibitors that block tau phosphorylation and decrease α-synuclein protein expression in a cellular model of Parkinson's disease</span></div><div class="casAuthors">Kozikowski, Alan P.; Gaisina, Irina N.; Petukhov, Pavel A.; Sridhar, Jayalakshmi; King, LaShaunda T.; Blond, Sylvie Y.; Duka, Tetyana; Rusnak, Milan; Sidhu, Anita</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">256-266</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Research by Klein and co-workers suggests that the inhibition of GSK-3β by small mols. may offer an important strategy in the treatment of a no. of central nervous system (CNS) disorders including Alzheimer's disease, Parkinson's disease, and bipolar disorders.  Based on results from kinase-screening assays that identified a staurosporine analog as a modest inhibitor of GSK-3β, a series of 3-indolyl-4-indazolylmaleimides was prepd. for study in both enzymic and cell-based assays.  Most strikingly, whereas we identified ligands having poor to high potency for GSK-3β inhibition, only ligands with a Ki value of less than 8 nM, namely maleimides 18 and 22, were found to inhibit Tau phosphorylation at a GSK-3β-specific site (Ser 396/404).  Accordingly, maleimides 18 and 22 may protect neuronal cells against cell death by decreasing the level of α-Syn protein expression.  We conclude that the GSK-3β inhibitors described herein offer promise in defending cells against MPP+-induced neurotoxicity and that such compds. will be valuable to explore in animal models of Parkinson's disease as well as in other Tau-related neurodegenerative disease states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX5jA9WqgoU7Vg90H21EOLACvtfcHk0lj6rCvTPQYV-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvFyjur4%253D&md5=8fbe6e281c054141c7e85aaa31eeac7b</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200500039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200500039%26sid%3Dliteratum%253Aachs%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DGaisina%26aufirst%3DI.%2BN.%26aulast%3DPetukhov%26aufirst%3DP.%2BA.%26aulast%3DSridhar%26aufirst%3DJ.%26aulast%3DKing%26aufirst%3DL.%2BT.%26aulast%3DBlond%26aufirst%3DS.%2BY.%26aulast%3DDuka%26aufirst%3DT.%26aulast%3DRusnak%26aufirst%3DM.%26aulast%3DSidhu%26aufirst%3DA.%26atitle%3DHighly%2520potent%2520and%2520specific%2520GSK-3beta%2520inhibitors%2520that%2520block%2520tau%2520phosphorylation%2520and%2520decrease%2520alpha-synuclein%2520protein%2520expression%2520in%2520a%2520cellular%2520model%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DChemMedChem%26date%3D2006%26volume%3D1%26spage%3D256%26epage%3D266%26doi%3D10.1002%2Fcmdc.200500039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Northfield, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craik, D. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of tau aggregation using a naturally-occurring cyclic peptide scaffold</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">342</span>– <span class="NLM_lpage">349</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.01.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.ejmech.2016.01.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=26807864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtl2ntLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2016&pages=342-349&author=C.+K.+Wangauthor=S.+E.+Northfieldauthor=Y.+H.+Huangauthor=M.+C.+Ramosauthor=D.+J.+Craik&title=Inhibition+of+tau+aggregation+using+a+naturally-occurring+cyclic+peptide+scaffold&doi=10.1016%2Fj.ejmech.2016.01.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of tau aggregation using a naturally-occurring cyclic peptide scaffold</span></div><div class="casAuthors">Wang, Conan K.; Northfield, Susan E.; Huang, Yen-Hua; Ramos, Mariana C.; Craik, David J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">342-349</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Disulfide-rich macrocyclic peptides are emerging as versatile scaffolds for the development of stable biochem. tools.  This potential is due to the combination of their structural stability and range of bioactivities.  Here, we explored the activity of these peptides on fibril growth of the hexapeptide Ac-VQIVYK-NH2 (AcPHF6), which is a tau-derived peptide that has been widely used to understand the pathol. mechanism of numerous tauopathies, including Alzheimer's disease.  Of the cyclic peptides tested, SFTI-1 and kB1 showed an inherent ability to inhibit AcPHF6 fibril formation.  Using an end-capping strategy and combining it with a mol. grafting approach, we demonstrated that SFTI-1 could be used as a starting point to design more potent fibril inhibitors.  We further identified chem. and structural features of SFTI-1 and its analogs that underpin their inhibitory activity.  The ability to inhibit fibril growth using the strategy employed herein supports the 'steric zipper' model of AcPHF6 fibril formation and shows that naturally-occurring cyclic peptides have potential as drug leads or mol. probes for understanding fibril formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8EceNHBR-sbVg90H21EOLACvtfcHk0licZJU8AMnaxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtl2ntLk%253D&md5=3e649c3437e072ab206fc739d3d95bd2</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.01.006%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%2BK.%26aulast%3DNorthfield%26aufirst%3DS.%2BE.%26aulast%3DHuang%26aufirst%3DY.%2BH.%26aulast%3DRamos%26aufirst%3DM.%2BC.%26aulast%3DCraik%26aufirst%3DD.%2BJ.%26atitle%3DInhibition%2520of%2520tau%2520aggregation%2520using%2520a%2520naturally-occurring%2520cyclic%2520peptide%2520scaffold%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D109%26spage%3D342%26epage%3D349%26doi%3D10.1016%2Fj.ejmech.2016.01.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Inestrosa, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderón, F.</span></span> <span> </span><span class="NLM_article-title">Acetylcholinesterase is a senile plaque component that promotes assembly of amyloid beta-peptide into Alzheimer’s filaments</span>. <i>Mol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">359</span>– <span class="NLM_lpage">361</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=9154226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADyaK2s3pvVyisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1996&pages=359-361&author=N.+C.+Inestrosaauthor=A.+Alvarezauthor=F.+Calder%C3%B3n&title=Acetylcholinesterase+is+a+senile+plaque+component+that+promotes+assembly+of+amyloid+beta-peptide+into+Alzheimer%E2%80%99s+filaments"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Acetylcholinesterase is a senile plaque component that promotes assembly of amyloid beta-peptide into Alzheimer's filaments</span></div><div class="casAuthors">Inestrosa N C; Alvarez A; Calderon F</div><div class="citationInfo"><span class="NLM_cas:title">Molecular psychiatry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">359-61</span>
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTv6bPd99LAEbZpSb_XWfMrfW6udTcc2ebv9UoFwhm9grntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s3pvVyisg%253D%253D&md5=dfddb14f33e0950f8b5a8d0719ef79a5</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DInestrosa%26aufirst%3DN.%2BC.%26aulast%3DAlvarez%26aufirst%3DA.%26aulast%3DCalder%25C3%25B3n%26aufirst%3DF.%26atitle%3DAcetylcholinesterase%2520is%2520a%2520senile%2520plaque%2520component%2520that%2520promotes%2520assembly%2520of%2520amyloid%2520beta-peptide%2520into%2520Alzheimer%25E2%2580%2599s%2520filaments%26jtitle%3DMol.%2520Psychiatry%26date%3D1996%26volume%3D1%26spage%3D359%26epage%3D361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Simone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ticchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrisano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumiatti, V.</span></span> <span> </span><span class="NLM_article-title">Tacrine-based multifunctional agents in Alzheimer’s disease: An old story in continuous development</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3522</span>– <span class="NLM_lpage">3546</span>, <span class="refDoi"> DOI: 10.2174/0929867324666170309123920</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.2174%2F0929867324666170309123920" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=28294041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGgtrnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=3522-3546&author=A.+Milelliauthor=A.+De+Simoneauthor=N.+Ticchiauthor=H.+H.+Chenauthor=N.+Betariauthor=V.+Andrisanoauthor=V.+Tumiatti&title=Tacrine-based+multifunctional+agents+in+Alzheimer%E2%80%99s+disease%3A+An+old+story+in+continuous+development&doi=10.2174%2F0929867324666170309123920"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Tacrine-based Multifunctional Agents in Alzheimer's Disease: An Old Story in Continuous Development.bdintg.</span></div><div class="casAuthors">Milelli, Andrea; De Simone, Angela; Ticchi, Nicole; Chen, Huan H.; Betari, Nibal; Andrisano, Vincenza; Tumiatti, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">3522-3546</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: The design of multifunctional agents represents one of the most active research field in medicinal chem.  In particular, tacrine, a well known Acetylcholinesterase inhibitor, is one of the most used starting point to develop multifunctional ligands and hundreds of papers report about these new agents.  This is the third review of a series concerning tacrine based multifunctional ligands; in particular, in the present, we will summarize and discuss the most intriguing examples of tacrine-based multifunctional agents published since 2013 until 2016. </P><P> Methods: We analyzed the bibliog. databases for peer-reviewed publications concerning tacrine-based multifunctional agents possessing biol. actions that go beyond the simple "cholinergic" blockage.  These papers have been subdivided according to their biol. activities.  Since this is the third review of a series, we took into considerations only the papers appeared since 2013 until 2016.  Results: In this review, we have analyzed more than 33 papers.  All the reported compds. retain good inhibitory activity towards acetyl- and butyryl-cholinesterase.  The other biol. activities concern mostly inhibition of a. β-amyloid aggregation, b. β-secretase, c. monoamino oxidases, modulation of β; and ROS and metal chelation.  Conclusion: The anal. of the current literature reported in this review confirm the importance of tacrine as scaffold to develop multifunctional agents potentially usefull to contrast Alzheimer's disease.  Furthermore, the compds. herein reported showed very intriguing biol. activities that could be used as starting point to develop new compds. even more interesting and, hopefully, clin. usefull to contrast Alzheimer's Disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZimowwL4q_7Vg90H21EOLACvtfcHk0licZJU8AMnaxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGgtrnM&md5=2a6f856526a08139bca151c647733f95</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.2174%2F0929867324666170309123920&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867324666170309123920%26sid%3Dliteratum%253Aachs%26aulast%3DMilelli%26aufirst%3DA.%26aulast%3DDe%2BSimone%26aufirst%3DA.%26aulast%3DTicchi%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DH.%2BH.%26aulast%3DBetari%26aufirst%3DN.%26aulast%3DAndrisano%26aufirst%3DV.%26aulast%3DTumiatti%26aufirst%3DV.%26atitle%3DTacrine-based%2520multifunctional%2520agents%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520An%2520old%2520story%2520in%2520continuous%2520development%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2017%26volume%3D24%26spage%3D3522%26epage%3D3546%26doi%3D10.2174%2F0929867324666170309123920" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. P.</span></span> <span> </span><span class="NLM_article-title">Dual GSK-3β/AChE inhibitors as a new strategy for multitargeting anti-Alzheimer’s disease drug discovery</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisF2gtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=171-176&author=X.+Y.+Jiangauthor=T.+K.+Chenauthor=J.+T.+Zhouauthor=S.+Y.+Heauthor=H.+Y.+Yangauthor=Y.+Chenauthor=W.+Quauthor=F.+Fengauthor=H.+P.+Sun&title=Dual+GSK-3%CE%B2%2FAChE+inhibitors+as+a+new+strategy+for+multitargeting+anti-Alzheimer%E2%80%99s+disease+drug+discovery&doi=10.1021%2Facsmedchemlett.7b00463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Dual GSK-3β/AChE Inhibitors as a New Strategy for Multitargeting Anti-Alzheimer's Disease Drug Discovery</span></div><div class="casAuthors">Jiang, Xue-Yang; Chen, Ting-Kai; Zhou, Jun-Ting; He, Si-Yu; Yang, Hong-Yu; Chen, Yao; Qu, Wei; Feng, Feng; Sun, Hao-Peng</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">171-176</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Designing multitarget-directed ligands (MTDLs) is considered to be a promising approach to address complex and multifactorial maladies such as Alzheimer's disease (AD).  The concurrent inhibition of the two crucial AD targets, glycogen synthase kinase-3β (GSK-3β) and human acetylcholinesterase (hAChE), might represent a breakthrough in the quest for clin. efficacy.  Thus, a novel family of GSK-3β/AChE dual-target inhibitors was designed and synthesized.  Among these hybrids, I showed the most promising profile as a nanomolar inhibitor on both hAChE (IC50 = 6.5 nM) and hGSK-3β kinase activity (IC50 = 66 nM).  It also showed good inhibitory effect on β-amyloid self-aggregation (inhibitory rate = 46%) at 20 μM.  Western blot anal. revealed that compd. I inhibited hyperphosphorylation of tau protein in mouse neuroblastoma N2a-Tau cells.  In vivo studies confirmed that I significantly ameliorated the cognitive disorders in scopolamine-treated ICR mice and less hepatotoxicity than tacrine.  This study provides new leads for assessment of GSK-3β and AChE pathway dual inhibition as a promising strategy for AD treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq103h9q_6uaLVg90H21EOLACvtfcHk0licZJU8AMnaxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisF2gtrY%253D&md5=8858bb4cbc503c79896ccbc00fb23153</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00463%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DX.%2BY.%26aulast%3DChen%26aufirst%3DT.%2BK.%26aulast%3DZhou%26aufirst%3DJ.%2BT.%26aulast%3DHe%26aufirst%3DS.%2BY.%26aulast%3DYang%26aufirst%3DH.%2BY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DQu%26aufirst%3DW.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DH.%2BP.%26atitle%3DDual%2520GSK-3%25CE%25B2%252FAChE%2520inhibitors%2520as%2520a%2520new%2520strategy%2520for%2520multitargeting%2520anti-Alzheimer%25E2%2580%2599s%2520disease%2520drug%2520discovery%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D171%26epage%3D176%26doi%3D10.1021%2Facsmedchemlett.7b00463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sivaprakasam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civiello, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacutin-Porte, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kish, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pokross, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szapiel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newitt, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nophsker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubowchik, G. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of new acylaminopyridines as GSK-3 inhibitors by a structure guided in-depth exploration of chemical space around a pyrrolopyridinone core</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1856</span>– <span class="NLM_lpage">1863</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.03.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.bmcl.2015.03.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=25845281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVKrsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1856-1863&author=P.+Sivaprakasamauthor=X.+Hanauthor=R.+L.+Civielloauthor=S.+Jacutin-Porteauthor=K.+Kishauthor=M.+Pokrossauthor=H.+A.+Lewisauthor=N.+Ahmedauthor=N.+Szapielauthor=J.+A.+Newittauthor=E.+T.+Baldwinauthor=H.+Xiaoauthor=C.+M.+Krauseauthor=H.+Parkauthor=M.+Nophskerauthor=J.+S.+Lippyauthor=C.+R.+Burtonauthor=D.+R.+Langleyauthor=J.+E.+Macorauthor=G.+M.+Dubowchik&title=Discovery+of+new+acylaminopyridines+as+GSK-3+inhibitors+by+a+structure+guided+in-depth+exploration+of+chemical+space+around+a+pyrrolopyridinone+core&doi=10.1016%2Fj.bmcl.2015.03.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of new acylaminopyridines as GSK-3 inhibitors by a structure guided in-depth exploration of chemical space around a pyrrolopyridinone core</span></div><div class="casAuthors">Sivaprakasam, Prasanna; Han, Xiaojun; Civiello, Rita L.; Jacutin-Porte, Swanee; Kish, Kevin; Pokross, Matt; Lewis, Hal A.; Ahmed, Nazia; Szapiel, Nicolas; Newitt, John A.; Baldwin, Eric T.; Xiao, Hong; Krause, Carol M.; Park, Hyunsoo; Nophsker, Michelle; Lippy, Jonathan S.; Burton, Catherine R.; Langley, David R.; Macor, John E.; Dubowchik, Gene M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1856-1863</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Glycogen synthase kinase-3 (GSK-3) has been proposed to play a crucial role in the pathogenesis of many diseases including cancer, stroke, bipolar disorders, diabetes and neurodegenerative diseases.  GSK-3 inhibition has been a major area of pharmaceutical interest over the last two decades.  A plethora of reports appeared recently on selective inhibitors and their co-crystal structures in GSK-3β.  We identified several series of promising new GSK-3β inhibitors from a coherent design around a pyrrolopyridinone core structure.  A systematic exploration of the chem. space around the central spacer led to potent single digit and sub-nanomolar GSK-3β inhibitors.  When dosed orally in a transgenic mouse model of Alzheimer's disease (AD), an exemplary compd. showed significant lowering of Tau phosphorylation at one of the GSK-3 phosphorylating sites, Ser396.  X-ray crystallog. greatly aided in validating the binding hypotheses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTULEgiCtJ_bVg90H21EOLACvtfcHk0li6gyzgHtqu9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVKrsro%253D&md5=207523726b69167ee5318f90b2822af0</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.03.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.03.046%26sid%3Dliteratum%253Aachs%26aulast%3DSivaprakasam%26aufirst%3DP.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DCiviello%26aufirst%3DR.%2BL.%26aulast%3DJacutin-Porte%26aufirst%3DS.%26aulast%3DKish%26aufirst%3DK.%26aulast%3DPokross%26aufirst%3DM.%26aulast%3DLewis%26aufirst%3DH.%2BA.%26aulast%3DAhmed%26aufirst%3DN.%26aulast%3DSzapiel%26aufirst%3DN.%26aulast%3DNewitt%26aufirst%3DJ.%2BA.%26aulast%3DBaldwin%26aufirst%3DE.%2BT.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DKrause%26aufirst%3DC.%2BM.%26aulast%3DPark%26aufirst%3DH.%26aulast%3DNophsker%26aufirst%3DM.%26aulast%3DLippy%26aufirst%3DJ.%2BS.%26aulast%3DBurton%26aufirst%3DC.%2BR.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DDubowchik%26aufirst%3DG.%2BM.%26atitle%3DDiscovery%2520of%2520new%2520acylaminopyridines%2520as%2520GSK-3%2520inhibitors%2520by%2520a%2520structure%2520guided%2520in-depth%2520exploration%2520of%2520chemical%2520space%2520around%2520a%2520pyrrolopyridinone%2520core%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D1856%26epage%3D1863%26doi%3D10.1016%2Fj.bmcl.2015.03.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oukoloff, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coquelle, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naldi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Guevel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bach, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josselin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruchaud, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denora, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacobazzi, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sussman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buron, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colletier, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Routier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renard, P. Y.</span></span> <span> </span><span class="NLM_article-title">Design, biological evaluation and X-ray crystallography of nanomolar multifunctional ligands targeting simultaneously acetylcholinesterase and glycogen synthase kinase-3</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.12.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.ejmech.2018.12.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=30798053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjs1Ghsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2019&pages=58-77&author=K.+Oukoloffauthor=N.+Coquelleauthor=M.+Bartoliniauthor=M.+Naldiauthor=R.+Le+Guevelauthor=S.+Bachauthor=B.+Josselinauthor=S.+Ruchaudauthor=M.+Cattoauthor=L.+Pisaniauthor=N.+Denoraauthor=R.+M.+Iacobazziauthor=I.+Silmanauthor=J.+L.+Sussmanauthor=F.+Buronauthor=J.+P.+Colletierauthor=L.+Jeanauthor=S.+Routierauthor=P.+Y.+Renard&title=Design%2C+biological+evaluation+and+X-ray+crystallography+of+nanomolar+multifunctional+ligands+targeting+simultaneously+acetylcholinesterase+and+glycogen+synthase+kinase-3&doi=10.1016%2Fj.ejmech.2018.12.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Design, biological evaluation and X-ray crystallography of nanomolar multifunctional ligands targeting simultaneously acetylcholinesterase and glycogen synthase kinase-3</span></div><div class="casAuthors">Oukoloff, Killian; Coquelle, Nicolas; Bartolini, Manuela; Naldi, Marina; Le Guevel, Remy; Bach, Stephane; Josselin, Beatrice; Ruchaud, Sandrine; Catto, Marco; Pisani, Leonardo; Denora, Nunzio; Iacobazzi, Rosa Maria; Silman, Israel; Sussman, Joel L.; Buron, Frederic; Colletier, Jacques-Philippe; Jean, Ludovic; Routier, Sylvain; Renard, Pierre-Yves</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">58-77</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Two scaffolds, targeting AChE (tacrine) and GSK-3α/β (valmerin) simultaneously, were assembled, using copper(I)-catalyzed azide alkyne cycloaddn. (CuAAC), to generate a new series of multifunctional ligands.  A series of eight multi-target directed ligands (MTDLs) was synthesized and evaluated in-vitro and in cell cultures.  Mol. docking studies, together with the crystal structures of three MTDL/TcAChE complexes, with three tacrine-valmerin hybrids allowed designing an appropriate linker contg. a 1,2,3-triazole moiety whose incorporation preserved and even increased, the original inhibitory potencies of the two selected pharmacophores toward the two targets.  Most of the new derivs. exhibited nanomolar affinity for both targets and the most potent compd. of the series displayed inhibitory potencies of 9.5 nM for human acetylcholinesterase (hAChE) and 7 nM for GSK-3α/β.  These novel dual MTDLs was served as suitable leads for further development, since, in the micromolar range, they exhibited low cytotoxicity on a panel of representative human cell lines including the human neuroblastoma cell line SH-SY5Y.  Moreover, these tacrine-valmerin hybrids displayed a good ability to penetrate the blood-brain barrier (BBB) without interacting with efflux pumps such as P-gp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAKk4Uw7lCIbVg90H21EOLACvtfcHk0li6gyzgHtqu9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjs1Ghsrw%253D&md5=50fe860fee4331dde495b905772f5ad8</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.12.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.12.063%26sid%3Dliteratum%253Aachs%26aulast%3DOukoloff%26aufirst%3DK.%26aulast%3DCoquelle%26aufirst%3DN.%26aulast%3DBartolini%26aufirst%3DM.%26aulast%3DNaldi%26aufirst%3DM.%26aulast%3DLe%2BGuevel%26aufirst%3DR.%26aulast%3DBach%26aufirst%3DS.%26aulast%3DJosselin%26aufirst%3DB.%26aulast%3DRuchaud%26aufirst%3DS.%26aulast%3DCatto%26aufirst%3DM.%26aulast%3DPisani%26aufirst%3DL.%26aulast%3DDenora%26aufirst%3DN.%26aulast%3DIacobazzi%26aufirst%3DR.%2BM.%26aulast%3DSilman%26aufirst%3DI.%26aulast%3DSussman%26aufirst%3DJ.%2BL.%26aulast%3DBuron%26aufirst%3DF.%26aulast%3DColletier%26aufirst%3DJ.%2BP.%26aulast%3DJean%26aufirst%3DL.%26aulast%3DRoutier%26aufirst%3DS.%26aulast%3DRenard%26aufirst%3DP.%2BY.%26atitle%3DDesign%252C%2520biological%2520evaluation%2520and%2520X-ray%2520crystallography%2520of%2520nanomolar%2520multifunctional%2520ligands%2520targeting%2520simultaneously%2520acetylcholinesterase%2520and%2520glycogen%2520synthase%2520kinase-3%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D168%26spage%3D58%26epage%3D77%26doi%3D10.1016%2Fj.ejmech.2018.12.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boulahjar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozach, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guguen-Guillouzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Guevel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akssira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillaumet, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Routier, S.</span></span> <span> </span><span class="NLM_article-title">Advances in tetrahydropyrido[1,2-a]isoindolone (valmerins) series: Potent glycogen synthase kinase 3 and cyclin dependent kinase 5 inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">274</span>– <span class="NLM_lpage">287</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.06.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.ejmech.2015.06.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=26142492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlCqsbrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2015&pages=274-287&author=R.+Boulahjarauthor=A.+Ouachauthor=S.+Bourgauthor=P.+Bonnetauthor=O.+Lozachauthor=L.+Meijerauthor=C.+Guguen-Guillouzoauthor=R.+Le+Guevelauthor=S.+Lazarauthor=M.+Akssiraauthor=Y.+Troinauthor=G.+Guillaumetauthor=S.+Routier&title=Advances+in+tetrahydropyrido%5B1%2C2-a%5Disoindolone+%28valmerins%29+series%3A+Potent+glycogen+synthase+kinase+3+and+cyclin+dependent+kinase+5+inhibitors&doi=10.1016%2Fj.ejmech.2015.06.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in tetrahydropyrido[1,2-a]isoindolone (valmerins) series: Potent glycogen synthase kinase 3 and cyclin dependent kinase 5 inhibitors</span></div><div class="casAuthors">Boulahjar, Rajaa; Ouach, Aziz; Bourg, Stephane; Bonnet, Pascal; Lozach, Olivier; Meijer, Laurent; Guguen-Guillouzo, Christiane; Le Guevel, Remy; Lazar, Said; Akssira, Mohamed; Troin, Yves; Guillaumet, Gerald; Routier, Sylvain</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">274-287</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">An efficient synthetic strategy was developed to modulate the structure of the tetrahydropyridine isoindolone (Valmerin) skeleton.  A library of more than 30 novel final structures was generated.  Biol. activities on CDK5 and GSK3 as well as cellular effects on cancer cell lines were measured for each novel compd.  Addnl. docking studies were performed to support medicinal chem. efforts.  A strong GSK3/CDK5 dual inhibitor (I, IC50 GSK3/CDK5 32/84 nM) was obtained.  A set of highly selective GSK3 inhibitors was synthesized by fine-tuning structural modifications (II, IC50 GSK3/CDK5 32/320 nM).  Antiproliferative effects on cells were correlated with the in vitro kinase activities and the best effects were obtained with lung and colon cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNKc6ssVA1k7Vg90H21EOLACvtfcHk0ljRbZrTBzjIrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlCqsbrK&md5=5385782f450d6914ddc149004d5facce</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.06.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.06.046%26sid%3Dliteratum%253Aachs%26aulast%3DBoulahjar%26aufirst%3DR.%26aulast%3DOuach%26aufirst%3DA.%26aulast%3DBourg%26aufirst%3DS.%26aulast%3DBonnet%26aufirst%3DP.%26aulast%3DLozach%26aufirst%3DO.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DGuguen-Guillouzo%26aufirst%3DC.%26aulast%3DLe%2BGuevel%26aufirst%3DR.%26aulast%3DLazar%26aufirst%3DS.%26aulast%3DAkssira%26aufirst%3DM.%26aulast%3DTroin%26aufirst%3DY.%26aulast%3DGuillaumet%26aufirst%3DG.%26aulast%3DRoutier%26aufirst%3DS.%26atitle%3DAdvances%2520in%2520tetrahydropyrido%255B1%252C2-a%255Disoindolone%2520%2528valmerins%2529%2520series%253A%2520Potent%2520glycogen%2520synthase%2520kinase%25203%2520and%2520cyclin%2520dependent%2520kinase%25205%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D101%26spage%3D274%26epage%3D287%26doi%3D10.1016%2Fj.ejmech.2015.06.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brogi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramunno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chemi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecorelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pambianchi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galatello, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compagnoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Focher, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biamonti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valacchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campiani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brindisi, M.</span></span> <span> </span><span class="NLM_article-title">First dual AK/GSK-3β inhibitors endowed with antioxidant properties as multifunctional, potential neuroprotective agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">438</span>– <span class="NLM_lpage">457</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.06.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.ejmech.2017.06.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=28689095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFChurvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2017&pages=438-457&author=S.+Brogiauthor=A.+Ramunnoauthor=L.+Saviauthor=G.+Chemiauthor=G.+Alfanoauthor=A.+Pecorelliauthor=E.+Pambianchiauthor=P.+Galatelloauthor=G.+Compagnoniauthor=F.+Focherauthor=G.+Biamontiauthor=G.+Valacchiauthor=S.+Butiniauthor=S.+Gemmaauthor=G.+Campianiauthor=M.+Brindisi&title=First+dual+AK%2FGSK-3%CE%B2+inhibitors+endowed+with+antioxidant+properties+as+multifunctional%2C+potential+neuroprotective+agents&doi=10.1016%2Fj.ejmech.2017.06.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">First dual AK/GSK-3β inhibitors endowed with antioxidant properties as multifunctional, potential neuroprotective agents</span></div><div class="casAuthors">Brogi, Simone; Ramunno, Anna; Savi, Lida; Chemi, Giulia; Alfano, Gloria; Pecorelli, Alessandra; Pambianchi, Erika; Galatello, Paola; Compagnoni, Giulia; Focher, Federico; Biamonti, Giuseppe; Valacchi, Giuseppe; Butini, Stefania; Gemma, Sandra; Campiani, Giuseppe; Brindisi, Margherita</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">438-457</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The manuscript deals with the design, synthesis and biol. evaluation of novel benzoxazinone- and indole-based compds. as multifunctional neuroprotective agents.  These compds. inhibit human adenosine kinase (hAK) and human glycogen synthase kinase 3 beta (hGSK-3β) enzymes.  In silico hints drove the synthesis of appropriately decorated benzoxazinones I (R1 = Ph, 1-naphthyl, 2-naphthyl; R2 = CH2C6H5, 4-ClC6H4CH2, 4-O2NC6H4CH2, etc.; X = H, F, morpholin-1-yl; Y = H; XY = OCH2O; Z = H, O) and indoles II (R1 = 4-H3CC6H4, 1-naphthyl; R2 = CH3, N(Et)2) and biochem. anal. revealed their behavior as allosteric inhibitors of hGSK-3β.  For hit III and compds. I (R1 = 1-naphthyl; R2 = 4-FC6H4CH2; X = Y = H; Z = O), I (R1 = 1-naphthyl; R2 = CH2C6H5; XY = OCH2O; Z = O) and II (R1 = 1-naphthyl; R2 = CH3) the potential antioxidant profile was assessed in human neuroblastoma cell lines (IMR 32), by evaluating the protective effect of selected compds. against H2O2 cytotoxicity and reactive oxygen species (ROS) prodn.  Results showed a strong efficacy of the tested compds., even at the lower doses, in counteracting the induced oxidative stress (50 μM of H2O2) and in preventing ROS formation.  In addn., the tested compds. did not show any cytotoxic effect detd. by the LDH release, at the concn. range analyzed (from 0.1 to 50 μM).  This study allowed the identification of compd. I (R1 = 1-naphthyl; R2 = CH2C6H5; XY = OCH2O; Z = O), as the first dual hAK/hGSK-3β inhibitor reported to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrno6lxql7c_7Vg90H21EOLACvtfcHk0ljRbZrTBzjIrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFChurvO&md5=1ea9d5251ac6d10f173c170e7c749b4b</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.06.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.06.017%26sid%3Dliteratum%253Aachs%26aulast%3DBrogi%26aufirst%3DS.%26aulast%3DRamunno%26aufirst%3DA.%26aulast%3DSavi%26aufirst%3DL.%26aulast%3DChemi%26aufirst%3DG.%26aulast%3DAlfano%26aufirst%3DG.%26aulast%3DPecorelli%26aufirst%3DA.%26aulast%3DPambianchi%26aufirst%3DE.%26aulast%3DGalatello%26aufirst%3DP.%26aulast%3DCompagnoni%26aufirst%3DG.%26aulast%3DFocher%26aufirst%3DF.%26aulast%3DBiamonti%26aufirst%3DG.%26aulast%3DValacchi%26aufirst%3DG.%26aulast%3DButini%26aufirst%3DS.%26aulast%3DGemma%26aufirst%3DS.%26aulast%3DCampiani%26aufirst%3DG.%26aulast%3DBrindisi%26aufirst%3DM.%26atitle%3DFirst%2520dual%2520AK%252FGSK-3%25CE%25B2%2520inhibitors%2520endowed%2520with%2520antioxidant%2520properties%2520as%2520multifunctional%252C%2520potential%2520neuroprotective%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D138%26spage%3D438%26epage%3D457%26doi%3D10.1016%2Fj.ejmech.2017.06.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Savi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brindisi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Pietra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novellino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lossani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Focher, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavella, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campiani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, S.</span></span> <span> </span><span class="NLM_article-title">Site-directed mutagenesis of key residues unveiled a novel allosteric site on human adenosine kinase for Pyrrolobenzoxa(thia)zepinone non-nucleoside inhibitors</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.1111/cbdd.12630</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1111%2Fcbdd.12630" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=26242695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFWlsLfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2016&pages=112-120&author=L.+Saviauthor=M.+Brindisiauthor=G.+Alfanoauthor=S.+Butiniauthor=V.+La+Pietraauthor=E.+Novellinoauthor=L.+Marinelliauthor=A.+Lossaniauthor=F.+Focherauthor=C.+Cavellaauthor=G.+Campianiauthor=S.+Gemma&title=Site-directed+mutagenesis+of+key+residues+unveiled+a+novel+allosteric+site+on+human+adenosine+kinase+for+Pyrrolobenzoxa%28thia%29zepinone+non-nucleoside+inhibitors&doi=10.1111%2Fcbdd.12630"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Site-directed Mutagenesis of Key Residues Unveiled a Novel Allosteric Site on Human Adenosine Kinase for Pyrrolobenzoxa(thia)zepinone Non-Nucleoside Inhibitors</span></div><div class="casAuthors">Savi, Lida; Brindisi, Margherita; Alfano, Gloria; Butini, Stefania; La Pietra, Valeria; Novellino, Ettore; Marinelli, Luciana; Lossani, Andrea; Focher, Federico; Cavella, Caterina; Campiani, Giuseppe; Gemma, Sandra</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">112-120</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Most nucleoside kinases, besides the catalytic domain, feature an allosteric domain which modulates their activity.  Generally, non-substrate analogs, interacting with allosteric sites, represent a major opportunity for developing more selective and safer therapeutics.  We recently developed a series of non-nucleoside non-competitive inhibitors of human adenosine kinase (hAK), based on a pyrrolobenzoxa(thia)zepinone scaffold.  Based on computational anal., we hypothesized the existence of a novel allosteric site on hAK, topog. distinct from the catalytic site.  In this study, we have adopted a multidisciplinary approach including mol. modeling, biochem. studies, and site-directed mutagenesis to validate our hypothesis.  Based on a three-dimensional model of interaction between hAK and our mols., we designed, cloned, and expressed specific, single and double point mutants of hAK (Q74A, Q78A, H107A, K341A, F338A, and Q74A-F338A).  Kinetic characterization of recombinant enzymes indicated that these mutations did not affect enzyme functioning; conversely, mutated enzymes are endowed with reduced susceptibility to our non-nucleoside inhibitors, while maintaining comparable affinity for nucleoside inhibitors to the wild-type enzyme.  This study represents the first characterization and validation of a novel allosteric site in hAK and may pave the way to the development of novel selective and potent non-nucleoside inhibitors of hAK endowed with therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxKNxAhKk_jrVg90H21EOLACvtfcHk0ljRbZrTBzjIrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFWlsLfM&md5=b2ef5d8ee0a05b6c29b69d1df321df02</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.12630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.12630%26sid%3Dliteratum%253Aachs%26aulast%3DSavi%26aufirst%3DL.%26aulast%3DBrindisi%26aufirst%3DM.%26aulast%3DAlfano%26aufirst%3DG.%26aulast%3DButini%26aufirst%3DS.%26aulast%3DLa%2BPietra%26aufirst%3DV.%26aulast%3DNovellino%26aufirst%3DE.%26aulast%3DMarinelli%26aufirst%3DL.%26aulast%3DLossani%26aufirst%3DA.%26aulast%3DFocher%26aufirst%3DF.%26aulast%3DCavella%26aufirst%3DC.%26aulast%3DCampiani%26aufirst%3DG.%26aulast%3DGemma%26aufirst%3DS.%26atitle%3DSite-directed%2520mutagenesis%2520of%2520key%2520residues%2520unveiled%2520a%2520novel%2520allosteric%2520site%2520on%2520human%2520adenosine%2520kinase%2520for%2520Pyrrolobenzoxa%2528thia%2529zepinone%2520non-nucleoside%2520inhibitors%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2016%26volume%3D87%26spage%3D112%26epage%3D120%26doi%3D10.1111%2Fcbdd.12630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brindisi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borrelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lossani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponte, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maga, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Pietra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorini, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamponi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campiani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zisterer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathwani, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sartini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Motta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Da Settimo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novellino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Focher, F.</span></span> <span> </span><span class="NLM_article-title">Non-nucleoside inhibitors of human adenosine kinase: Synthesis, molecular modeling, and biological studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1401</span>– <span class="NLM_lpage">1420</span>, <span class="refDoi"> DOI: 10.1021/jm101438u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101438u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFeisLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1401-1420&author=S.+Butiniauthor=S.+Gemmaauthor=M.+Brindisiauthor=G.+Borrelliauthor=A.+Lossaniauthor=A.+M.+Ponteauthor=A.+Tortiauthor=G.+Magaauthor=L.+Marinelliauthor=V.+La+Pietraauthor=I.+Fioriniauthor=S.+Lamponiauthor=G.+Campianiauthor=D.+M.+Zistererauthor=S.+M.+Nathwaniauthor=S.+Sartiniauthor=C.+La+Mottaauthor=F.+Da+Settimoauthor=E.+Novellinoauthor=F.+Focher&title=Non-nucleoside+inhibitors+of+human+adenosine+kinase%3A+Synthesis%2C+molecular+modeling%2C+and+biological+studies&doi=10.1021%2Fjm101438u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Non-nucleoside inhibitors of human adenosine kinase: synthesis, molecular modeling, and biological studies</span></div><div class="casAuthors">Butini, Stefania; Gemma, Sandra; Brindisi, Margherita; Borrelli, Giuseppe; Lossani, Andrea; Ponte, Anna Maria; Torti, Andrea; Maga, Giovanni; Marinelli, Luciana; La Pietra, Valeria; Fiorini, Isabella; Lamponi, Stefania; Campiani, Giuseppe; Zisterer, Daniela M.; Nathwani, Seema-Maria; Sartini, Stefania; La Motta, Concettina; Da Settimo, Federico; Novellino, Ettore; Focher, Federico</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1401-1420</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Adenosine kinase (AK) catalyzes the phosphorylation of adenosine (Ado) to AMP by means of a kinetic mechanism in which the two substrates Ado and ATP bind the enzyme in a binary and/or ternary complex, with distinct protein conformations.  Most of the described inhibitors have Ado-like structural motifs and are nonselective, and some of them (e.g., the tubercidine-like ligands) are characterized by a toxic profile.  Here, human AK (hAK) was cloned and expressed, and a search for novel non-substrate-like inhibitors was carried out.  The efforts to widen the structural diversity of AK inhibitors led to the identification of novel non-nucleoside, noncompetitive allosteric modulators I (X, Y = O, S; R1 = H, Et; R2 = Ph, 2-ClC6H4, 4-Me3SiC≡CC6H4, 2,6-Cl2C6H3, 2-pyridyl, 2-pyrimidyl, 2-imidazolyl, etc.) characterized by a unique mol. scaffold.  Among the pyrrolobenzoxa(thia)zepinones developed, I (X = O; Y = S; R1 = Et; R2 = Ph) was identified as a non-nucleoside prototype hAK inhibitor.  This compd. has proapoptotic efficacy, slight inhibition of short-term RNA synthesis, and cytostatic activity on tumor cell lines while showing low cytotoxicity and no significant adverse effects on short-term DNA synthesis in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprrF751kg487Vg90H21EOLACvtfcHk0lgex6aKZ05sOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFeisLg%253D&md5=ef3868f031a50a451dd7ea1cd8505361</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1021%2Fjm101438u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101438u%26sid%3Dliteratum%253Aachs%26aulast%3DButini%26aufirst%3DS.%26aulast%3DGemma%26aufirst%3DS.%26aulast%3DBrindisi%26aufirst%3DM.%26aulast%3DBorrelli%26aufirst%3DG.%26aulast%3DLossani%26aufirst%3DA.%26aulast%3DPonte%26aufirst%3DA.%2BM.%26aulast%3DTorti%26aufirst%3DA.%26aulast%3DMaga%26aufirst%3DG.%26aulast%3DMarinelli%26aufirst%3DL.%26aulast%3DLa%2BPietra%26aufirst%3DV.%26aulast%3DFiorini%26aufirst%3DI.%26aulast%3DLamponi%26aufirst%3DS.%26aulast%3DCampiani%26aufirst%3DG.%26aulast%3DZisterer%26aufirst%3DD.%2BM.%26aulast%3DNathwani%26aufirst%3DS.%2BM.%26aulast%3DSartini%26aufirst%3DS.%26aulast%3DLa%2BMotta%26aufirst%3DC.%26aulast%3DDa%2BSettimo%26aufirst%3DF.%26aulast%3DNovellino%26aufirst%3DE.%26aulast%3DFocher%26aufirst%3DF.%26atitle%3DNon-nucleoside%2520inhibitors%2520of%2520human%2520adenosine%2520kinase%253A%2520Synthesis%252C%2520molecular%2520modeling%252C%2520and%2520biological%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1401%26epage%3D1420%26doi%3D10.1021%2Fjm101438u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, Y.</span></span> <span> </span><span class="NLM_article-title">Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">5639</span>– <span class="NLM_lpage">5643</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.10.078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.bmcl.2014.10.078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=25467150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVylu7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=5639-5643&author=P.+Zhangauthor=S.+Liauthor=Y.+Gaoauthor=W.+Luauthor=K.+Huangauthor=D.+Yeauthor=X.+Liauthor=Y.+Chu&title=Novel+benzothiazinones+%28BTOs%29+as+allosteric+modulator+or+substrate+competitive+inhibitor+of+glycogen+synthase+kinase+3%CE%B2+%28GSK-3%CE%B2%29+with+cellular+activity+of+promoting+glucose+uptake&doi=10.1016%2Fj.bmcl.2014.10.078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake</span></div><div class="casAuthors">Zhang, Peng; Li, Shufen; Gao, Yang; Lu, Wenbo; Huang, Ke; Ye, Deyong; Li, Xi; Chu, Yong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5639-5643</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Glycogen synthase kinase 3β (GSK-3β) plays a key role in insulin metabolizing pathway and therefore inhibition of the enzyme might provide an important therapeutic approach for treatment of insulin resistance and type 2 diabetes.  Recently, discovery of ATP noncompetitive inhibitors is gaining importance not only due to their generally increased selectivity but also for the potentially subtle modulation of the target.  These kinds of compds. include allosteric modulators and substrate competitive inhibitors.  Here we reported two benzothiazinone compds. (BTO), named BTO-5h (IC50 = 8 μM) and BTO-5s (IC50 = 10 μM) as novel allosteric modulator and substrate competitive inhibitor of GSK-3β, resp.  Their different action modes were proved by kinetic expts.  Furthermore, BTO-5s was selected to check the kinases profile and showed little or even no activity to a panel of ten protein kinases at 100 μM, indicating it has good selectivity.  Docking studies were performed to give suggesting binding modes which can well explain their impacts on the enzyme.  Moreover, cell expts. displayed both compds. reduced the phosphorylation level of glycogen synthase in an intact cell, and greatly enhanced the glucose uptake in both HpG2 and 3T3-L1 cells.  All of these results suggested BTO-5s and BTO-5h maybe have potentially therapeutic value for anti-diabetes.  The results also offer a new scaffold for designing and developing selective inhibitors with novel mechanisms of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV3DIlOnazo7Vg90H21EOLACvtfcHk0lgex6aKZ05sOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVylu7%252FL&md5=9dbd90f264f80c8aabae85c5237c01bd</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.10.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.10.078%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DK.%26aulast%3DYe%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DChu%26aufirst%3DY.%26atitle%3DNovel%2520benzothiazinones%2520%2528BTOs%2529%2520as%2520allosteric%2520modulator%2520or%2520substrate%2520competitive%2520inhibitor%2520of%2520glycogen%2520synthase%2520kinase%25203%25CE%25B2%2520%2528GSK-3%25CE%25B2%2529%2520with%2520cellular%2520activity%2520of%2520promoting%2520glucose%2520uptake%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D5639%26epage%3D5643%26doi%3D10.1016%2Fj.bmcl.2014.10.078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of novel GSK-3β inhibitors as multifunctional agents against Alzheimer’s disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">211</span>– <span class="NLM_lpage">225</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1016%2Fj.ejmech.2019.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=30772605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjt1Wit7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2019&pages=211-225&author=X.+L.+Shiauthor=J.+D.+Wuauthor=P.+Liuauthor=Z.+P.+Liu&title=Synthesis+and+evaluation+of+novel+GSK-3%CE%B2+inhibitors+as+multifunctional+agents+against+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.ejmech.2019.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of novel GSK-3β inhibitors as multifunctional agents against Alzheimer's disease</span></div><div class="casAuthors">Shi, Xiao-Long; Wu, Jing-De; Liu, Ping; Liu, Zhao-Peng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">211-225</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">To target the multi-facets of Alzheimer's disease (AD), a series of novel GSK-3β inhibitors contg. the 2,3-diaminopyridine moiety I [R = H, Ph, 4-Me-2-thienyl, etc.], II [R = H, 4-Ph, 4-(4-ClC6H4), etc.] and III [R = H, Ph, 4-MeC6H4, 4-Me-2-thienyl, 4-pyridinyl] were designed and synthesized.  The amide derivs. I [R = H, Ph, 4-Me-2-thienyl, etc.] showed moderate potency against GSK-3β with weak Cu2+, Zn2+ and Al3+ chelating ability.  The imine derivs. II [R = H, 5-Ph, 5-(4-pyridinyl)] were potent GSK-3β inhibitors and selective Cu2+and Al3+ chelators.  The 1,2-diamine derivs. III [R = H, Ph, 4-MeC6H4, 4-Me-2-thienyl, 4-pyridinyl] were strong metal-chelators, but decreased or lost their GSK-3β inhibitory potency.  In-vitro, compds. II [R = H, 5-Ph, 5-(4-pyridinyl)] esp. compd. II [R = 5-Ph] exhibited good Cu2+-induced Aβ aggregation inhibition, Cu2+-Aβ complex disaggregation, ROS formation inhibition and antioxidant activities.  In cells, compds. II [R = H, 5-Ph, 5-(4-pyridinyl)] inhibited tau protein phosphorylation and protect neuro cells against Cu2+-Aβ1-42 and H2O2-induced cell damage.  Furthermore, compd. II [R = 5-Ph] was predicted to have the ability to pass the BBB with drug likeness properties.  Therefore, compd. II [R = 5-Ph] might be a good lead for the development of novel GSK-3β inhibitors targeting multi-facets of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_ELITXD4x-bVg90H21EOLACvtfcHk0lgex6aKZ05sOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjt1Wit7s%253D&md5=e3bfb7dd073058e731546b83774696f1</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DX.%2BL.%26aulast%3DWu%26aufirst%3DJ.%2BD.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DZ.%2BP.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520novel%2520GSK-3%25CE%25B2%2520inhibitors%2520as%2520multifunctional%2520agents%2520against%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D167%26spage%3D211%26epage%3D225%26doi%3D10.1016%2Fj.ejmech.2019.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. Z.</span></span> <span> </span><span class="NLM_article-title">Current understanding of metal ions in the pathogenesis of Alzheimer’s disease</span>. <i>Transl. Neurodegener.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">10</span>, <span class="refDoi"> DOI: 10.1186/s40035-020-00189-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1186%2Fs40035-020-00189-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=32266063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BB38zivVSrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=10&author=L.+Wangauthor=Y.+L.+Yinauthor=X.+Z.+Liuauthor=P.+Shenauthor=Y.+G.+Zhengauthor=X.+R.+Lanauthor=C.+B.+Luauthor=J.+Z.+Wang&title=Current+understanding+of+metal+ions+in+the+pathogenesis+of+Alzheimer%E2%80%99s+disease&doi=10.1186%2Fs40035-020-00189-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Current understanding of metal ions in the pathogenesis of Alzheimer's disease</span></div><div class="casAuthors">Wang Lu; Yin Ya-Ling; Liu Xin-Zi; Shen Peng; Zheng Yan-Ge; Lan Xin-Rui; Lu Cheng-Biao; Wang Jian-Zhi</div><div class="citationInfo"><span class="NLM_cas:title">Translational neurodegeneration</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10</span>
        ISSN:<span class="NLM_cas:issn">2047-9158</span>.
    </div><div class="casAbstract">Background:  The homeostasis of metal ions, such as iron, copper, zinc and calcium, in the brain is crucial for maintaining normal physiological functions.  Studies have shown that imbalance of these metal ions in the brain is closely related to the onset and progression of Alzheimer's disease (AD), the most common neurodegenerative disorder in the elderly.  Main body:  Erroneous deposition/distribution of the metal ions in different brain regions induces oxidative stress.  The metal ions imbalance and oxidative stress together or independently promote amyloid-β (Aβ) overproduction by activating β- or γ-secretases and inhibiting α-secretase, it also causes tau hyperphosphorylation by activating protein kinases, such as glycogen synthase kinase-3β (GSK-3β), cyclin-dependent protein kinase-5 (CDK5), mitogen-activated protein kinases (MAPKs), etc., and inhibiting protein phosphatase 2A (PP2A).  The metal ions imbalances can also directly or indirectly disrupt organelles, causing endoplasmic reticulum (ER) stress; mitochondrial and autophagic dysfunctions, which can cause or aggravate Aβ and tau aggregation/accumulation, and impair synaptic functions.  Even worse, the metal ions imbalance-induced alterations can reversely exacerbate metal ions misdistribution and deposition.  The vicious cycles between metal ions imbalances and Aβ/tau abnormalities will eventually lead to a chronic neurodegeneration and cognitive deficits, such as seen in AD patients.  Conclusion:  The metal ions imbalance induces Aβ and tau pathologies by directly or indirectly affecting multiple cellular/subcellular pathways, and the disrupted homeostasis can reversely aggravate the abnormalities of metal ions transportation/deposition.  Therefore, adjusting metal balance by supplementing or chelating the metal ions may be potential in ameliorating AD pathologies, which provides new research directions for AD treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSz7VnJ4vRr7b7NkxioyDXTfW6udTcc2eYZqqN1e5SvELntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38zivVSrsQ%253D%253D&md5=5e609526d780b09dd908be0390148907</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1186%2Fs40035-020-00189-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40035-020-00189-z%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYin%26aufirst%3DY.%2BL.%26aulast%3DLiu%26aufirst%3DX.%2BZ.%26aulast%3DShen%26aufirst%3DP.%26aulast%3DZheng%26aufirst%3DY.%2BG.%26aulast%3DLan%26aufirst%3DX.%2BR.%26aulast%3DLu%26aufirst%3DC.%2BB.%26aulast%3DWang%26aufirst%3DJ.%2BZ.%26atitle%3DCurrent%2520understanding%2520of%2520metal%2520ions%2520in%2520the%2520pathogenesis%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DTransl.%2520Neurodegener.%26date%3D2020%26volume%3D9%26spage%3D10%26doi%3D10.1186%2Fs40035-020-00189-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cristóvão, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, C. M.</span></span> <span> </span><span class="NLM_article-title">Metals and neuronal metal binding proteins implicated in Alzheimer’s disease</span>. <i>Oxid. Med. Cell. Longevity</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2016</i></span>,  <span class="NLM_fpage">9812178</span>, <span class="refDoi"> DOI: 10.1155/2016/9812178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1155%2F2016%2F9812178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=26881049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BC28jhtVOksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2016&publication_year=2016&pages=9812178&author=J.+S.+Crist%C3%B3v%C3%A3oauthor=R.+Santosauthor=C.+M.+Gomes&title=Metals+and+neuronal+metal+binding+proteins+implicated+in+Alzheimer%E2%80%99s+disease&doi=10.1155%2F2016%2F9812178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Metals and Neuronal Metal Binding Proteins Implicated in Alzheimer's Disease</span></div><div class="casAuthors">Cristovao Joana S; Gomes Claudio M; Santos Renata</div><div class="citationInfo"><span class="NLM_cas:title">Oxidative medicine and cellular longevity</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2016</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9812178</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Alzheimer's disease (AD) is the most prevalent age-related dementia affecting millions of people worldwide.  Its main pathological hallmark feature is the formation of insoluble protein deposits of amyloid-β and hyperphosphorylated tau protein into extracellular plaques and intracellular neurofibrillary tangles, respectively.  Many of the mechanistic details of this process remain unknown, but a well-established consequence of protein aggregation is synapse dysfunction and neuronal loss in the AD brain.  Different pathways including mitochondrial dysfunction, oxidative stress, inflammation, and metal metabolism have been suggested to be implicated in this process.  In particular, a body of evidence suggests that neuronal metal ions such as copper, zinc, and iron play important roles in brain function in health and disease states and altered homeostasis and distribution as a common feature across different neurodegenerative diseases and aging.  In this focused review, we overview neuronal proteins that are involved in AD and whose metal binding properties may underlie important biochemical and regulatory processes occurring in the brain during the AD pathophysiological process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRRFS7HBs9MUudfST00W0BcfW6udTcc2eYZqqN1e5SvELntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jhtVOksg%253D%253D&md5=cb60acf31e00254b550a419d450f97e9</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1155%2F2016%2F9812178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2016%252F9812178%26sid%3Dliteratum%253Aachs%26aulast%3DCrist%25C3%25B3v%25C3%25A3o%26aufirst%3DJ.%2BS.%26aulast%3DSantos%26aufirst%3DR.%26aulast%3DGomes%26aufirst%3DC.%2BM.%26atitle%3DMetals%2520and%2520neuronal%2520metal%2520binding%2520proteins%2520implicated%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DOxid.%2520Med.%2520Cell.%2520Longevity%26date%3D2016%26volume%3D2016%26spage%3D9812178%26doi%3D10.1155%2F2016%2F9812178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuajungco, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atwood, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartshorn, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyndall, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokes, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopold, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Multhaup, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpa, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moir, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glabe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowden, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masters, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlie, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanzi, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bush, A. I.</span></span> <span> </span><span class="NLM_article-title">Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>274</i></span>,  <span class="NLM_fpage">37111</span>– <span class="NLM_lpage">37116</span>, <span class="refDoi"> DOI: 10.1074/jbc.274.52.37111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1074%2Fjbc.274.52.37111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10601271" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BD3cXpsFSi" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=37111-37116&author=X.+Huangauthor=M.+P.+Cuajungcoauthor=C.+S.+Atwoodauthor=M.+A.+Hartshornauthor=J.+D.+Tyndallauthor=G.+R.+Hansonauthor=K.+C.+Stokesauthor=M.+Leopoldauthor=G.+Multhaupauthor=L.+E.+Goldsteinauthor=R.+C.+Scarpaauthor=A.+J.+Saundersauthor=J.+Limauthor=R.+D.+Moirauthor=C.+Glabeauthor=E.+F.+Bowdenauthor=C.+L.+Mastersauthor=D.+P.+Fairlieauthor=R.+E.+Tanziauthor=A.+I.+Bush&title=Cu%28II%29+potentiation+of+alzheimer+abeta+neurotoxicity.+Correlation+with+cell-free+hydrogen+peroxide+production+and+metal+reduction&doi=10.1074%2Fjbc.274.52.37111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Cu(II) potentiation of Alzheimer Aβ neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction</span></div><div class="casAuthors">Huang, Xudong; Cuajungco, Math P.; Atwood, Craig S.; Hartshorn, Mariana A.; Tyndall, Joel D. A.; Hanson, Graeme R.; Stokes, Karen C.; Leopold, Michael; Multhaup, Gerd; Goldstein, Lee E.; Scarpa, Richard C.; Saunders, Aleister J.; Lim, James; Moir, Robert D.; Glahe, Charles; Bowden, Edmond F.; Masters, Colin L.; Fairlie, David P.; Tanzi, Rudolph E.; Bush, Ashley I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">274</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">37111-37116</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Oxidative stress markers as well as high concns. of copper are found in the vicinity of Aβ amyloid deposits in Alzheimer's disease.  The neurotoxicity of Aβ in cell culture has been linked to H2O2 generation by an unknown mechanism.  We now report that Cu(II) markedly potentiates the neurotoxicity exhibited by Aβ in cell culture.  The potentiation of toxicity is greatest for Aβ1-42 > Aβ1-40 » mouse/rat Aβ1-40, corresponding to their relative capacities to reduce Cu(II) to Cu(I), form H2O2 in cell-free assays and to exhibit amyloid pathol.  The copper complex of Aβ1-42 has a highly pos. formal redn. potential (≈+500-550 mV vs. Ag/AgCl) characteristic of strongly reducing cuproproteins.  These findings suggest that certain redox active metal ions may be important in exacerbating and perhaps facilitating Aβ-mediated oxidative damage in Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB0QS7aV67c7Vg90H21EOLACvtfcHk0ljMTJaSRPoKsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXpsFSi&md5=dcd0d9e8ebf8fc3550a356111e07eee7</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1074%2Fjbc.274.52.37111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.274.52.37111%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DCuajungco%26aufirst%3DM.%2BP.%26aulast%3DAtwood%26aufirst%3DC.%2BS.%26aulast%3DHartshorn%26aufirst%3DM.%2BA.%26aulast%3DTyndall%26aufirst%3DJ.%2BD.%26aulast%3DHanson%26aufirst%3DG.%2BR.%26aulast%3DStokes%26aufirst%3DK.%2BC.%26aulast%3DLeopold%26aufirst%3DM.%26aulast%3DMulthaup%26aufirst%3DG.%26aulast%3DGoldstein%26aufirst%3DL.%2BE.%26aulast%3DScarpa%26aufirst%3DR.%2BC.%26aulast%3DSaunders%26aufirst%3DA.%2BJ.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DMoir%26aufirst%3DR.%2BD.%26aulast%3DGlabe%26aufirst%3DC.%26aulast%3DBowden%26aufirst%3DE.%2BF.%26aulast%3DMasters%26aufirst%3DC.%2BL.%26aulast%3DFairlie%26aufirst%3DD.%2BP.%26aulast%3DTanzi%26aufirst%3DR.%2BE.%26aulast%3DBush%26aufirst%3DA.%2BI.%26atitle%3DCu%2528II%2529%2520potentiation%2520of%2520alzheimer%2520abeta%2520neurotoxicity.%2520Correlation%2520with%2520cell-free%2520hydrogen%2520peroxide%2520production%2520and%2520metal%2520reduction%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D37111%26epage%3D37116%26doi%3D10.1074%2Fjbc.274.52.37111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alavi Naini, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soussi-Yanicostas, N.</span></span> <span> </span><span class="NLM_article-title">Tau hyperphosphorylation and oxidative stress, a critical vicious circle in neurodegenerative tauopathies?</span>. <i>Oxid. Med. Cell. Longevity</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>,  <span class="NLM_fpage">151979</span>, <span class="refDoi"> DOI: 10.1155/2015/151979</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1155%2F2015%2F151979" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=26576216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BC28vjvVantA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=151979&author=S.+M.+Alavi+Nainiauthor=N.+Soussi-Yanicostas&title=Tau+hyperphosphorylation+and+oxidative+stress%2C+a+critical+vicious+circle+in+neurodegenerative+tauopathies%3F&doi=10.1155%2F2015%2F151979"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Tau Hyperphosphorylation and Oxidative Stress, a Critical Vicious Circle in Neurodegenerative Tauopathies?</span></div><div class="casAuthors">Alavi Naini Seyedeh Maryam; Soussi-Yanicostas Nadia</div><div class="citationInfo"><span class="NLM_cas:title">Oxidative medicine and cellular longevity</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2015</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">151979</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Hyperphosphorylation and aggregation of the microtubule-associated protein tau in brain, are pathological hallmarks of a large family of neurodegenerative disorders, named tauopathies, which include Alzheimer's disease.  It has been shown that increased phosphorylation of tau destabilizes tau-microtubule interactions, leading to microtubule instability, transport defects along microtubules, and ultimately neuronal death.  However, although mutations of the MAPT gene have been detected in familial early-onset tauopathies, causative events in the more frequent sporadic late-onset forms and relationships between tau hyperphosphorylation and neurodegeneration remain largely elusive.  Oxidative stress is a further pathological hallmark of tauopathies, but its precise role in the disease process is poorly understood.  Another open question is the source of reactive oxygen species, which induce oxidative stress in brain neurons.  Mitochondria have been classically viewed as a major source for oxidative stress, but microglial cells were recently identified as reactive oxygen species producers in tauopathies.  Here we review the complex relationships between tau pathology and oxidative stress, placing emphasis on (i) tau protein function, (ii) origin and consequences of reactive oxygen species production, and (iii) links between tau phosphorylation and oxidative stress.  Further, we go on to discuss the hypothesis that tau hyperphosphorylation and oxidative stress are two key components of a vicious circle, crucial in neurodegenerative tauopathies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcROas30ElPsHlMGsG_HTXYFfW6udTcc2eZyIXFVdhUV1bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28vjvVantA%253D%253D&md5=ba6fa445008d606ebb146fad41bbe68d</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1155%2F2015%2F151979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F151979%26sid%3Dliteratum%253Aachs%26aulast%3DAlavi%2BNaini%26aufirst%3DS.%2BM.%26aulast%3DSoussi-Yanicostas%26aufirst%3DN.%26atitle%3DTau%2520hyperphosphorylation%2520and%2520oxidative%2520stress%252C%2520a%2520critical%2520vicious%2520circle%2520in%2520neurodegenerative%2520tauopathies%253F%26jtitle%3DOxid.%2520Med.%2520Cell.%2520Longevity%26date%3D2015%26volume%3D2015%26spage%3D151979%26doi%3D10.1155%2F2015%2F151979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Simone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Pietra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petragnani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniele, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietrobono, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petralla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casadei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frabetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russomanno, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novellino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montanari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumiatti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballerini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebbioso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altucci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrisano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milelli, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of the first-in-class GSK-3β/HDAC dual inhibitor as disease-modifying agent to combat Alzheimer’s disease</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">469</span>– <span class="NLM_lpage">474</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00507</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00507" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVSqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=469-474&author=A.+De+Simoneauthor=V.+La+Pietraauthor=N.+Betariauthor=N.+Petragnaniauthor=M.+Conteauthor=S.+Danieleauthor=D.+Pietrobonoauthor=C.+Martiniauthor=S.+Petrallaauthor=R.+Casadeiauthor=L.+Davaniauthor=F.+Frabettiauthor=P.+Russomannoauthor=E.+Novellinoauthor=S.+Montanariauthor=V.+Tumiattiauthor=P.+Balleriniauthor=F.+Sarnoauthor=A.+Nebbiosoauthor=L.+Altucciauthor=B.+Montiauthor=V.+Andrisanoauthor=A.+Milelli&title=Discovery+of+the+first-in-class+GSK-3%CE%B2%2FHDAC+dual+inhibitor+as+disease-modifying+agent+to+combat+Alzheimer%E2%80%99s+disease&doi=10.1021%2Facsmedchemlett.8b00507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease</span></div><div class="casAuthors">De Simone, Angela; La Pietra, Valeria; Betari, Nibal; Petragnani, Nicola; Conte, Mariarosaria; Daniele, Simona; Pietrobono, Deborah; Martini, Claudia; Petralla, Sabrina; Casadei, Raffaella; Davani, Lara; Frabetti, Flavia; Russomanno, Pasquale; Novellino, Ettore; Montanari, Serena; Tumiatti, Vincenzo; Ballerini, Patrizia; Sarno, Federica; Nebbioso, Angela; Altucci, Lucia; Monti, Barbara; Andrisano, Vincenza; Milelli, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">469-474</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several evidence pointed out the role of epigenetics in Alzheimer's disease (AD) revealing strictly relationships between epigenetic and "classical" AD targets.  Based on the reported connection among histone deacetylases (HDACs) and glycogen synthase kinase 3β (GSK-3β), herein we present the discovery and the biochem. characterization of the first-in-class hit compd. able to exert promising anti-AD effects by modulating the targeted proteins in the low micromolar range of concn.  Compd. 11 induces an increase in histone acetylation and a redn. of tau phosphorylation.  It is nontoxic and protective against H2O2 and 6-OHDA stimuli in SH-SY5Y and in CGN cell lines, resp.  Moreover, it promotes neurogenesis and displays immunomodulatory effects.  Compd. 11 shows no lethality in a wt-zebrafish model (<100 μM) and high water soly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFpd6rQuX3jrVg90H21EOLACvtfcHk0liPIVVqheAn1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVSqtbs%253D&md5=c57168700a73c70eafa747add137cac1</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00507%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSimone%26aufirst%3DA.%26aulast%3DLa%2BPietra%26aufirst%3DV.%26aulast%3DBetari%26aufirst%3DN.%26aulast%3DPetragnani%26aufirst%3DN.%26aulast%3DConte%26aufirst%3DM.%26aulast%3DDaniele%26aufirst%3DS.%26aulast%3DPietrobono%26aufirst%3DD.%26aulast%3DMartini%26aufirst%3DC.%26aulast%3DPetralla%26aufirst%3DS.%26aulast%3DCasadei%26aufirst%3DR.%26aulast%3DDavani%26aufirst%3DL.%26aulast%3DFrabetti%26aufirst%3DF.%26aulast%3DRussomanno%26aufirst%3DP.%26aulast%3DNovellino%26aufirst%3DE.%26aulast%3DMontanari%26aufirst%3DS.%26aulast%3DTumiatti%26aufirst%3DV.%26aulast%3DBallerini%26aufirst%3DP.%26aulast%3DSarno%26aufirst%3DF.%26aulast%3DNebbioso%26aufirst%3DA.%26aulast%3DAltucci%26aufirst%3DL.%26aulast%3DMonti%26aufirst%3DB.%26aulast%3DAndrisano%26aufirst%3DV.%26aulast%3DMilelli%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520the%2520first-in-class%2520GSK-3%25CE%25B2%252FHDAC%2520dual%2520inhibitor%2520as%2520disease-modifying%2520agent%2520to%2520combat%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D469%26epage%3D474%26doi%3D10.1021%2Facsmedchemlett.8b00507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z. F.</span></span> <span> </span><span class="NLM_article-title">Targeting HDACs: A promising therapy for Alzheimer’s disease</span>. <i>Oxid. Med. Cell. Longevity</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2011</i></span>,  <span class="NLM_fpage">143269</span>, <span class="refDoi"> DOI: 10.1155/2011/143269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1155%2F2011%2F143269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=21941604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A280%3ADC%252BC3MflvVWitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=143269&author=K.+Xuauthor=X.+L.+Daiauthor=H.+C.+Huangauthor=Z.+F.+Jiang&title=Targeting+HDACs%3A+A+promising+therapy+for+Alzheimer%E2%80%99s+disease&doi=10.1155%2F2011%2F143269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting HDACs: a promising therapy for Alzheimer's disease</span></div><div class="casAuthors">Xu Ke; Dai Xue-Ling; Huang Han-Chang; Jiang Zhao-Feng</div><div class="citationInfo"><span class="NLM_cas:title">Oxidative medicine and cellular longevity</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2011</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">143269</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Epigenetic modifications like DNA methylation and histone acetylation play an important role in a wide range of brain disorders.  Histone deacetylases (HDACs) regulate the homeostasis of histone acetylation.  Histone deacetylase inhibitors, which initially were used as anticancer drugs, are recently suggested to act as neuroprotectors by enhancing synaptic plasticity and learning and memory in a wide range of neurodegenerative and psychiatric disorders, such as Alzheimer's disease (AD) and Parkinson's disease (PD).  To reveal the physiological roles of HDACs may provide us with a new perspective to understand the mechanism of AD and to develop selective HDAC inhibitors.  This paper focuses on the recent research progresses of HDAC proteins and their inhibitors on the roles of the treatment for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTRVYQlbx4kqny-c-E1v-fmfW6udTcc2eZyIXFVdhUV1bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MflvVWitA%253D%253D&md5=0f0bed71a4778db8838e676d9e2e81f7</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1155%2F2011%2F143269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2011%252F143269%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DK.%26aulast%3DDai%26aufirst%3DX.%2BL.%26aulast%3DHuang%26aufirst%3DH.%2BC.%26aulast%3DJiang%26aufirst%3DZ.%2BF.%26atitle%3DTargeting%2520HDACs%253A%2520A%2520promising%2520therapy%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DOxid.%2520Med.%2520Cell.%2520Longevity%26date%3D2011%26volume%3D2011%26spage%3D143269%26doi%3D10.1155%2F2011%2F143269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Simone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milelli, A.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase inhibitors as multitarget ligands: New players in Alzheimer’s disease drug discovery?</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1067</span>– <span class="NLM_lpage">1073</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201900174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.1002%2Fcmdc.201900174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=30958639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC1MXos1Wiurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=1067-1073&author=A.+De+Simoneauthor=A.+Milelli&title=Histone+Deacetylase+inhibitors+as+multitarget+ligands%3A+New+players+in+Alzheimer%E2%80%99s+disease+drug+discovery%3F&doi=10.1002%2Fcmdc.201900174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors as multitarget ligands: new players in Alzheimer's disease drug discovery?</span></div><div class="casAuthors">De Simone, Angela; Milelli, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1067-1073</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase inhibitors (HDACIs) are responsible for controlling gene expression by modulating the acetylation status of histone proteins.  Furthermore, they modulate the activity of cytoplasmic non-histone proteins.  Due to the involvement of HDACs in neurodevelopment, memory formation, and cognitive processes, HDACIs have been suggested as innovative agents for the treatment of neurodegenerative disorders such as Alzheimer's disease (AD).  Given their mechanisms of action and the complex nature of AD, HDACIs have been proposed for the design of novel multitarget ligands (MTLs).  To this aim, the fragment responsible for HDAC inhibition has been coupled with other structures that are able to provide addnl. biol. actions, such as antioxidant activity or the inhibition of phosphodiesterase 5, transglutaminase 2, and glycogen synthase kinase 3β.  Herein we discuss recent efforts to design HDACI-based MTLs as potential disease-modifying entities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotgFDwLEiUt7Vg90H21EOLACvtfcHk0lifzybQ05k_0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXos1Wiurc%253D&md5=191fca2c9334551a52be5c13bf71cf90</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201900174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201900174%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSimone%26aufirst%3DA.%26aulast%3DMilelli%26aufirst%3DA.%26atitle%3DHistone%2520Deacetylase%2520inhibitors%2520as%2520multitarget%2520ligands%253A%2520New%2520players%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520drug%2520discovery%253F%26jtitle%3DChemMedChem%26date%3D2019%26volume%3D14%26spage%3D1067%26epage%3D1073%26doi%3D10.1002%2Fcmdc.201900174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eldar-Finkelman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span> <span> </span><span class="NLM_article-title">GSK-3 inhibitors: Preclinical and clinical focus on CNS</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">32</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2011.00032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=10.3389%2Ffnmol.2011.00032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=22065134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;key=1%3ACAS%3A528%3ADC%252BC38XovVyg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=32&author=H.+Eldar-Finkelmanauthor=A.+Martinez&title=GSK-3+inhibitors%3A+Preclinical+and+clinical+focus+on+CNS&doi=10.3389%2Ffnmol.2011.00032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">GSK-3 inhibitors: preclinical and clinical focus on CNS</span></div><div class="casAuthors">Eldar-Finkelman, Hagit; Martinez, Ana</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">Oct.</span>),
    <span class="NLM_cas:pages">32</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Inhibiting glycogen synthase kinase-3 (GSK-3) activity via pharmacol. intervention has become an important strategy for treating neurodegenerative and psychiatric disorders.  The known GSK-3 inhibitors are of diverse chemotypes and mechanisms of action and include compds. isolated from natural sources, cations, synthetic small-mol. ATP-competitive inhibitors, non-ATP-competitive inhibitors, and substrate-competitive inhibitors.  Here we describe the variety of GSK-3 inhibitors with a specific emphasis on their biol. activities in neurons and neurol. disorders.  We further highlight our current progress in the development of non-ATP-competitive inhibitors of GSK-3.  The available data raise the hope that one or more of these drug design approaches will prove successful at stabilizing or even reversing the aberrant neuropathol. and cognitive deficits of certain central nervous system disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh6s366QUVnLVg90H21EOLACvtfcHk0lifzybQ05k_0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovVyg&md5=d497efe2ec600fc16f10260cd53d7103</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2011.00032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2011.00032%26sid%3Dliteratum%253Aachs%26aulast%3DEldar-Finkelman%26aufirst%3DH.%26aulast%3DMartinez%26aufirst%3DA.%26atitle%3DGSK-3%2520inhibitors%253A%2520Preclinical%2520and%2520clinical%2520focus%2520on%2520CNS%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2011%26volume%3D4%26spage%3D32%26doi%3D10.3389%2Ffnmol.2011.00032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1Q4L" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1Q4L','PDB','1Q4L'); return false;">PDB: 1Q4L</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1Q5K" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1Q5K','PDB','1Q5K'); return false;">PDB: 1Q5K</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00931&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00931%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-1%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00931" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799b3026d55d18b","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
